<SEC-DOCUMENT>0001213900-19-018314.txt : 20190917
<SEC-HEADER>0001213900-19-018314.hdr.sgml : 20190917
<ACCEPTANCE-DATETIME>20190917171909
ACCESSION NUMBER:		0001213900-19-018314
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20190917
DATE AS OF CHANGE:		20190917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences plc
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233020
		FILM NUMBER:		191097746

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ff12019a1_tizianalife.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM F-1
<TEXT>
<HTML>
<HEAD><TITLE></TITLE></HEAD>
<BODY STYLE="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><DIV STYLE="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;text-align:center;margin-top:8pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As filed with the U.S. Securities and Exchange Commission on </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> </FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, 2019.</FONT> </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:2pt;text-align:right;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Registration Statement No. 333</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-</FONT></FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">233020</FONT></FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:2pt;text-align:center;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_______________</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:4pt;text-align:center;margin-top:4pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amendment No. 1 to <BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Form F</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><BR>REGISTRATION STATEMENT<BR>UNDER<BR>THE SECURITIES ACT OF 1933</FONT> </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_______________</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">Tiziana Life Sciences plc</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;">(Exact name of Registrant as specified in its charter)</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_______________</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Not Applicable<BR></FONT>(Translation of Registrant&#x2019;s name into English)</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales<BR></FONT>(Jurisdiction of incorporation or organization)<BR>(Address, including zip code, and telephone number, including area code, of Registrant&#x2019;s principal executive offices)</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 31.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2836</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.85%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Not Applicable</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 31.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(State or other Jurisdiction of <BR>Incorporation or Organization)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 31.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(Primary Standard Industrial <BR>Classification Code Number)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(I.R.S. Employer <BR>Identification Number)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">3</FONT><FONT CLASS="Bold---Super" STYLE="font-style:normal;font-weight:bold;vertical-align:super;font-size:6pt;">rd </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Floor,<BR>11</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">-12</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"> St James&#x2019;s Square<BR>London SW1Y 4LB<BR>United Kingdom<BR>+44 20 7495 2379<BR></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">_______________</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">Copies to:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 31.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Jeffrey Fessler, Esq.<BR>Justin Anslow, Esq.<BR>Sheppard, Mullin, Richter &amp;<BR>Hampton LLP<BR>30 Rockefeller Plaza<BR>New York, NY 10112</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">-0015</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"><BR>(212) 653</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">-8700</FONT></FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 31.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Edward Dyson<BR>Cooley (UK) LLP<BR>Dashwood<BR>69 Old Broad Street<BR>London EC2M 1QS<BR>United Kingdom<BR>+44 20 7785 9355</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Leslie Marlow, Esq.<BR>Hank Gracin, Esq.<BR>Patrick J. Egan, Esq.<BR>Gracin &amp; Marlow, LLP<BR>The Chrysler Building<BR>405 Lexington Avenue, 26</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;vertical-align:super;">th</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"> Floor<BR>New York, NY 10174<BR>(212) 907</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">-6457</FONT></FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_______________</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box. </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">S</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#x00a3;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">If this Form is a post</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-effective</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;"> amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#x00a3;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">If this Form is a post</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-effective</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;"> amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#x00a3;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act:</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:3pt;text-align:right;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">Emerging growth company </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">S</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:3pt;margin-top:2.5pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section 7(a)(2)(B) of the Securities Act. </FONT><FONT CLASS="CharOverride-6" STYLE="font-family:'Wingdings 2', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#x00a3;</FONT></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;margin-top:8pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;">&#x2020;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;The term &#x201c;new or revised financial accounting standard&#x201d; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:4pt;margin-top:4pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.</FONT> </P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>


	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="CharOverride-7" STYLE="color:#d2232a;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</FONT></P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">PRELIMINARY PROSPECTUS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">SUBJECT TO COMPLETION</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;"> <FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">DATED </FONT><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">SEPTEMBER</FONT><FONT CLASS="nobreak" STYLE="color:#d2232a;font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">17</FONT><FONT CLASS="CharOverride-8" STYLE="color:#d2232a;font-style:normal;font-weight:bold;">, 2019</FONT> </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:10pt;text-align:left;margin-top:10pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">1,383,125</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> American Depositary Shares<BR>Representing </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">13,831,250</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> Ordinary Shares</FONT> </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tiziana_logo.jpg" STYLE="height:56.32px;width:245.76px;max-width:100%;"></FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">Tiziana Life Sciences PLC</FONT></P>
		<DIV STYLE="border: none; border-top: windowtext 1pt none; border-top-style: solid; padding: 0in 0in 2.0pt 0in;"></DIV>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:9pt;margin-top:9pt;"> <FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"></FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">We are offering </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">1,383,125</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> American Depositary Shares, or ADSs. Each ADS represents 10 ordinary shares. The ADSs may be evidenced by American Depositary Receipts, or ADRs.</FONT> </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"> <FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"></FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">The assumed public offering price is $</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">7.23</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> per ADS, which was the last reported sale price of our ADSs on the Nasdaq Global Market on </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">September</FONT><FONT CLASS="nobreak" STYLE="font-size:11pt;"> </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">13</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">, 2019. Our ADSs are listed on the Nasdaq Global Market under the symbol &#x201c;TLSA.&#x201d; Our Ordinary Shares are listed on AIM, a market of London Stock Exchange plc under the symbol &#x201c;TLS.&#x201d;</FONT> </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">Investing in our ADSs involves a high degree of risk. Before buying any ADSs, you should carefully read the discussion of material risks of investing in our ADSs in &#x201c;Risk factors&#x201d; beginning on page 11 of this prospectus.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">We are an &#x201c;emerging growth company&#x201d; as that term is used in the Jumpstart Our Business Startups Act of 2012 and a &#x201c;foreign private issuer&#x201d; under applicable U.S. federal securities laws. As such, we have elected to comply with certain reduced public company reporting requirements. See &#x201c;Prospectus summary &#x2014; implications of being an emerging growth company and a foreign private issuer&#x201d; for additional information.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-12" STYLE="font-size:10pt;font-style:normal;font-weight:bold;">Per ADS</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-12" STYLE="font-size:10pt;font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-top:4pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">Public offering price</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-top:4pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">Underwriting discounts and commissions</FONT><FONT CLASS="Super" STYLE="vertical-align:super;font-size:6pt;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-top:4pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">Proceeds, before expenses, to us</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;"><FONT CLASS="CharOverride-14" STYLE="font-size:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;The underwriters will receive compensation in addition to the discounts and commissions. See &#x201c;Underwriting&#x201d; for a description of compensation payable to the underwriters.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"> <FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"></FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">We have granted the representative of the underwriters an over</FONT><FONT CLASS="nobreak" STYLE="font-size:11pt;">-allotment</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> option to purchase up to an additional </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">207,468</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> ADSs from us at the public offering price, less the underwriting discounts and commissions, within 45 days from the date of this prospectus to cover over</FONT><FONT CLASS="nobreak" STYLE="font-size:11pt;">-allotments</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">, if any. If the representative of the underwriters exercises their over</FONT><FONT CLASS="nobreak" STYLE="font-size:11pt;">-allotment</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"> option in full, the total underwriting discounts and commissions payable will be $&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;, and the total proceeds to us, before expenses, will be $&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;.</FONT> </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">The underwriters expect to deliver our ADSs to purchasers in this offering on or about&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;&#x00a0;, 2019.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">ThinkEquity</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:11pt;">a division of Fordham Financial Management, Inc.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;text-align:center;margin-top:12pt;"> <FONT CLASS="CharOverride-10" STYLE="font-size:11pt;"></FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">The date of this prospectus is </FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">September</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">&#x00a0;</FONT><FONT CLASS="CharOverride-10" STYLE="font-size:11pt;">, 2019</FONT> </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>


	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="image_01.jpg" STYLE="height:407.04px;width:601.6px;max-width:100%;"></FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="image_02.jpg" STYLE="height:339.2px;width:610.56px;max-width:100%;"></FONT></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>


	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> Page </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T01"> About This Prospectus </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> ii </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T02"> Presentation of Financial Information </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> ii </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T03"> Prospectus Summary </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 1 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T04"> Risk Factors </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 11 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T05"> Cautionary Statement Regarding Forward-Looking Statements </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 54 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T06"> Market and Industry Data </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 55 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T07"> Trademarks, Service Marks and Tradenames </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 55 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T08"> Use of Proceeds </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 56 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T09"> Dividend Policy </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 57 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T10"> Capitalization </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 58 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T11"> Dilution </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 59 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T12"> Selected Consolidated Financial Data </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 60 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T13"> Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 61 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T14"> Business </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 70 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T15"> Management </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 108 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T16"> Certain Relationships and Related Party Transactions </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 118 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T17"> Principal Shareholders </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 119 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T18"> Description of Share Capital and Articles of Association </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 120 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T19"> Material Tax Considerations </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 146 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T20"> Underwriting </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 153 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T21"> Expenses of This Offering </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 159 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T22"> Legal Matters </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 160 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T23"> Experts </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 160 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T24"> Service of Process and Enforcement of Liabilities </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 161 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T25"> Where You Can Find Additional Information </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> 163 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T26"> Index to Consolidated Financial Statements </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> F-1 </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are responsible for the information contained in this prospectus and any free</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-writing</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> prospectus we prepare or authorize. We have not, and the underwriters have not, authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell our ADSs in any jurisdiction where the offer or sale is not permitted. For the avoidance of doubt, we are not, and the underwriters are not, making an offer to sell our ordinary shares in any jurisdiction. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or the sale of any ADSs.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For investors outside the United States, neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering and the distribution of this prospectus outside the United States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a public limited company incorporated under the laws of England and Wales and a majority of our outstanding securities are owned by non<FONT CLASS="nobreak">-U</FONT>.S. residents. Under the rules of the SEC, we are currently eligible for treatment as a &#x201c;foreign private issuer,&#x201d; or FPI. As an FPI, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, or Exchange Act.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;text-indent:0pt;">i</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T01"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">About This Prospectus</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Unless otherwise indicated or the context otherwise requires, all references in this registration statement to the terms &#x201c;Tiziana,&#x201d; &#x201c;Tiziana Life Sciences plc,&#x201d; &#x201c;the company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Tiziana Life Sciences plc and its wholly owned subsidiaries, Tiziana Therapeutics, Inc., Tiziana Pharma Limited and Longevia Genomics S.r.l.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Solely for convenience, the trademarks, service marks and trade names in this registration statement may be referred to without the &#x00ae; and &#x2122; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. This registration statement contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. We do not intend to use or display other companies&#x2019; trademarks, service marks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In this registration statement, unless otherwise stated, all references to &#x201c;U.S. dollars&#x201d; or &#x201c;US$&#x201d; or &#x201c;$&#x201d; or &#x201c;cents&#x201d; are to the currency of the United States of America, and all references to &#x201c;Pounds Sterling&#x201d; or &#x201c;Sterling&#x201d; or &#x201c;&#x00a3;&#x201d; or &#x201c;pence&#x201d; are to the currency of the United Kingdom.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In this registration statement, any reference to any provision of any legislation shall include any amendment, modification, re<FONT CLASS="nobreak">-enactment</FONT> or extension thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include the feminine or neutral gender.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T02"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Presentation of Financial Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This prospectus includes our audited consolidated financial statements as of and for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, which are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our financial information is presented in U.S. dollars. Solely for the convenience of the reader, in this prospectus, unless otherwise indicated, translations from Pounds Sterling into U.S. dollars were made at the rate of &#x00a3;1.00 to $1.2387, which was the noon buying rate of the Federal Reserve Bank of New York on July<FONT CLASS="nobreak"> </FONT>26, 2019. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could actually have been purchased upon exchange of Pounds Sterling at the dates indicated.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;text-indent:0pt;">ii</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T03"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PROSPECTUS SUMMARY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our ADSs or ordinary shares, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes and the information set forth under the sections titled &#x201c;Risk Factors,&#x201d; &#x201c;Special Note Regarding Forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Statements,&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; in each case included elsewhere in this prospectus. Unless the context otherwise requires, we use the terms &#x201c;Tiziana,&#x201d; &#x201c;company,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; and &#x201c;we&#x201d; in this prospectus to refer to Tiziana Life Sciences plc and, where appropriate, our consolidated subsidiaries.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a biotechnology company that is focused on the discovery and development of novel molecules and related diagnostics to treat high unmet medical needs in oncology and immunology. Our mission is to design and deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical development expertise. We employ a lean and virtual research and development, or R&amp;D, model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in immunology is Foralumab (TZLS<FONT CLASS="nobreak">-401</FONT>), which we believe is the only fully human anti<FONT CLASS="nobreak">-cluster</FONT> of differentiation<FONT CLASS="nobreak"> </FONT>3, or anti<FONT CLASS="nobreak">-CD3</FONT>, monoclonal antibody, or mAb, in clinical development. We believe that based on the concepts of mucosal tolerance, oral or intranasal administration of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects. We believe the switch from intravenous administration to oral and nasal administration is a &#x2018;game changer&#x2019; for treatment with mAbs as it could improve patient&#x2019;s compliance and safety. MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers and autoimmune diseases. The global market opportunity for mAb therapeutics is greater than $86<FONT CLASS="nobreak"> </FONT>billion. Generation of antibodies for use in humans developed in animals, lead to strong, immune responses limiting their effectiveness and potentially leading to severe side effects. A process known as &#x201c;humanization&#x201d; removes most of the animal components of the antibody thereby lowering the immune response from the human immune system. The entire omission of other animal material, as in fully human antibodies, is the optimal goal to avoid incompatibility with the human immune system.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in oncology is Milciclib (TZLS<FONT CLASS="nobreak">-201</FONT>), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin<FONT CLASS="nobreak">-dependent</FONT> kinases, or CDKs, and Sarcoma, or Src, family kinases. CDKs are a highly conserved family of enzymes that phosphorylate a specific group of proteins that are involved in regulating the cell cycle. The cell cycle is a series of events that takes place in cells leading to division and duplication of its DNA to produce two daughter cells. Src family kinases are non<FONT CLASS="nobreak">-receptor</FONT> tyrosine kinase proteins encoded by the Src gene also involved in regulating cell growth and potential transformation of normal cells to cancer cells. We have a drug discovery pipeline of small molecule new chemical entities, or NCEs, and biologics. Milciclib has Orphan Drug Designation (ODD) in the U.S. and EU for thymic cancer (thymic epithelial tumor or TET) such as thymic carcinoma dn thymoma.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We are developing Foralumab, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Novimmune SA, or Novimmune, in December 2014, as a potential treatment for non<FONT CLASS="nobreak">-alcoholic</FONT> steatohepatitis, or NASH, and Crohn&#x2019;s disease as well as neurodegenerative diseases such as multiple sclerosis, or MS. We have developed and filed patent applications with respect to oral and nasal administration formulation of Foralumab for treatment of human diseases. These patent applications may be applicable to all mAbs for nasal and oral administration. To date, Foralumab has been studied in one Phase 1 and two Phase 2a clinical trials conducted by Novimmune in 68 patients dosed by the intravenous route of administration. In these trials, Foralumab was observed to be well<FONT CLASS="nobreak">-tolerated</FONT> with a maximum tolerated dose (MTD) of 1 mg/dose and produced immunologic effects consistent with potential clinical benefit while demonstrating mild to moderate infusion related reactions, or IRR. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We planned to first investigate orally and nasally administered Foralumab for its safety and immunomodulatory activity in healthy volunteers in separate Phase 1 clinical trials. A Phase I single site, double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT>, dose<FONT CLASS="nobreak">-ranging</FONT> clinical study dosed intranasally in healthy volunteers was initiated in November 2018 to evaluate safety and biomarkers of immunomodulation of clinical responses planned in healthy volunteers to dose Foralumab intranasally. in collaboration with Brigham and Women&#x2019;s Hospital, Harvard Medical School, Boston, MA. This clinical </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;"> trial was recently completed in July 2019 in which 18 subjects received Foralumab treatment and 9 patients received placebo. All nasal doses were well tolerated, and no drug related safety issues were reported at any of the doses. Biomarker analysis showed significant positive immune effects, that were most prominent in the 50 &#x00b5;g cohort with minimal immunomodulatory effects at the 10 &#x00b5;g and 250 &#x00b5;g doses. In addition, we submitted an IND on March<FONT CLASS="nobreak"> </FONT>18, 2019 for the oral formulation, to the FDA. The FDA requested safety data from the phase 1 trial with nasal administration of Foralumab to justify the proposed dose<FONT CLASS="nobreak">-range</FONT> for the phase 1 trial with oral administration of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. We withdrew the IND on April<FONT CLASS="nobreak"> </FONT>17, 2019. A third IND was submitted to the FDA on July<FONT CLASS="nobreak"> </FONT>23, 2019 for a Phase I trial in healthy volunteers using orally administered Foralumab with an intent to treat progressive multiple sclerosis, or pMS. On September<FONT CLASS="nobreak"> </FONT>9, 2019, the FDA granted approval to initiate the Phase I clinical trials to evaluate the safety and pharmacokinetics of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. Based on successful Phase 1 data, we intend to conduct a Phase 2 study using Crohn&#x2019;s Disease patients starting in the second half of 2020 and file an IND for a Phase 2 trial using NASH patients. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:6.9pt;">We are developing Milciclib, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Nerviano Medical Sciences S.r.l., or Nerviano, in January 2015, as a potential treatment for hepatocellular carcinoma, or HCC. A novel feature of Milciclib is its ability to reduce levels of microRNAs, miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT>. MicroRNAs are small RNA molecules that play a significant role in the regulation of gene expression. miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT> are believed to be linked to the development of blood supply (angiogenesis) in cancer tumors. Levels of these microRNAs are consistently elevated in HCC patients and may contribute towards resistance to treatment with Sorafenib, a multikinase inhibitor (a drug which may inhibit the cellular division and proliferation associated with certain cancers) often prescribed to HCC patients as the Standard of Care (SOC). To date, Milciclib has been studied in a total of eight Phase 1 and Phase 2 clinical trials in 316 patients. In these trials, Milciclib was well<FONT CLASS="nobreak">-tolerated</FONT> with minimal adverse events. We initiated a Phase 2a trial for Milciclib as a monotherapy in patients with HCC in the third quarter of 2017. This trial is a single<FONT CLASS="nobreak">-arm</FONT>, repeated<FONT CLASS="nobreak">-dose</FONT> (100 mg once daily; 4 days on/3 days off every 4 weeks defining each cycle), 6<FONT CLASS="nobreak">-month</FONT> duration study to evaluate the safety, tolerability and anti<FONT CLASS="nobreak">-tumor</FONT> activity of Milciclib in Sorafenib<FONT CLASS="nobreak">-refractory</FONT> or intolerant patients with unresectable or metastatic advanced HCC, the most common form of liver cancer. Enrollment of 31 patients in Italy, Greece, and Israel was completed in November 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6.9pt;"> In March 2019, the Independent Monitoring Committee, or IDMC, reviewed safety data from patients as of February<FONT CLASS="nobreak"> </FONT>26, 2019 and concluded that the administration of Milciclib to patients with advanced HCC was not associated with unexpected signs or signals of toxicity. 28 out of 31 treated patients were evaluable, 14 completed the 6<FONT CLASS="nobreak">-month</FONT> duration study. The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable. No drug<FONT CLASS="nobreak">-related</FONT> deaths were recorded. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>9 out of 14 patients (64.2%) were approved by their respective ethical committees to continue the treatment. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5 of the 9 patients on compassionate use had received Milciclib for a total of<FONT CLASS="nobreak"> </FONT>9,<FONT CLASS="nobreak"> </FONT>9,<FONT CLASS="nobreak"> </FONT>11, 13 and 16<FONT CLASS="nobreak"> </FONT>months. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>As of  September<FONT CLASS="nobreak"> </FONT>1, 2019, the remaining 4 patients continuing the treatment are in their 10<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> and 12<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> months. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Both median TTP and PFS were 5.9<FONT CLASS="nobreak"> </FONT>months (95% Confidence Interval (&#x201c;CI&#x201d;) 1.5<FONT CLASS="nobreak">-6</FONT>.7<FONT CLASS="nobreak"> </FONT>months) out of the 6<FONT CLASS="nobreak">-months</FONT> duration of the trial. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>17 of 28 (60.7%) evaluable patients showed &#x2018;Stable Disease&#x2019; (SD; met at least once in an 8<FONT CLASS="nobreak">-week</FONT> interval). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>One patient (3.6%) showed &#x2018;Partial Response&#x2019; (PR, unconfirmed). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:6.9pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18 of 28 (64.3%) evaluable patients showed &#x2018;Clinical Benefit Rate&#x2019; defined as CBR=CR+PR+SD (with CR representing Complete Remission). </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:6.9pt;">Since overexpression of CDKs and dysregulation in pRB pathway (regulates transcription factors critical for cell cycle progression) are prominently associated with tumor cell resistance to certain chemotherapeutic drugs, inhibition of multiple CDKs is an appealing approach to improve clinical responses in cancer patient&#x2019;s refractory to existing treatment options. A Phase 1 dose<FONT CLASS="nobreak">-escalation</FONT> study of Milciclib in combination with gemcitabine in patients with refractory solid tumors exhibited clinical activity in patients including those refractory to gemcitabine. We plan to explore a combination approach in patients with HCC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:6.9pt;">A Phase 2b trial for Milciclib in combination with a tyrosine kinase inhibitor (TKI) such as Sorafenib (Nexavar<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT>) or regorafenib (Stivarga<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT>), used to treat some types of kidney, liver and thyroid cancers in patients with HCC is expected to be initiated in the second half of 2019.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we are developing a fully human mAb targeting the IL<FONT CLASS="nobreak">-6R</FONT> (TZLS<FONT CLASS="nobreak">-501</FONT>) for the treatment of inflammatory and autoimmune diseases. We licensed the intellectual property from Novimmune in January 2017. This fully human mAb has a novel mechanism of action, binding to both the membrane<FONT CLASS="nobreak">-bound</FONT> and soluble forms of the IL<FONT CLASS="nobreak">-6R</FONT> as well as depleting circulating levels of the IL<FONT CLASS="nobreak">-6</FONT> in the blood. Excessive production of IL<FONT CLASS="nobreak">-6</FONT> is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications and rheumatoid arthritis, and we believe that TZLS<FONT CLASS="nobreak">-501</FONT> may have potential therapeutic value for these indications.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In preclinical studies, TZLS<FONT CLASS="nobreak">-501</FONT> demonstrated the potential for overcoming the limitations of other IL<FONT CLASS="nobreak">-6</FONT> blocking pathway drugs. Compared to tocilizumab and sarilumab, while binding to the membrane<FONT CLASS="nobreak">-bound</FONT> IL<FONT CLASS="nobreak">-6R</FONT> complex, TZLS<FONT CLASS="nobreak">-501</FONT> has been observed to have a higher affinity for the soluble IL<FONT CLASS="nobreak">-6</FONT> receptor from antibody binding studies conducted in cell culture. TZLS<FONT CLASS="nobreak">-501</FONT> also demonstrated the potential to block or reduce IL<FONT CLASS="nobreak">-6</FONT> signaling in mouse models of inflammation. The soluble form of IL<FONT CLASS="nobreak">-6</FONT> has been implicated to have a larger role in disease progression compared to the membrane- bound form (Kallen, K.J. (2002). &#x201c;The role of trans<FONT CLASS="nobreak">-signaling</FONT> via the agonistic soluble IL<FONT CLASS="nobreak">-6</FONT> receptor in human diseases.&#x201d; Biochimica et Biophysica Acta. 1592 (3): 323&#x2013;343.)</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Competitive Strengths</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our mission is to design and deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical development expertise. We believe the following strengths will allow us to continue to pursue this mission:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Advanced, novel pipeline.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We have an advanced pipeline of novel and proprietary drug candidates, including antibodies and small molecules, to address high unmet medical needs in the inflammation, autoimmune and oncology markets with significant commercial potential.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Proprietary technology</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">.</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our proprietary technology enables the development of alternative routes of administration of antibodies, including oral delivery. We believe that oral and nasal routes of delivery will alleviate the significant time and cost burden associated with other routes of administration, including intravenous delivery.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Broad and engaged network of experts</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">.</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our strong relationships with key opinion leaders contribute to our clinical development efforts and position us well to support our products, if approved. Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Kevan Herold, and Dr. Howard Weiner are among the thought leaders on our scientific advisory committee.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Specialized expertise and focus on oncology and inflammation</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">.</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our management team, including Dr. Kunwar Shailubhai, Jules Jacob, Dr. Priya Eddy and Dr. Vaseem Palejwala, has considerable experience translating technologies from bench to market, and managing the global administration of clinical trials.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Strong intellectual property and know</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">-how</FONT></FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">.</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We believe our proprietary intellectual property portfolio, in<FONT CLASS="nobreak">-licensed</FONT> from Nerviano and Novimmune, provides us with a substantial competitive advantage for the commercial development of small molecule NCEs, and biologics, as well as expanded possibilities for new development programs in the future. We have retained the worldwide development and commercialization rights to all of our product candidates. We have submitted additional patent applications to further strengthen our intellectual property.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Lean research and development model, designed to maximize value.</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We employ a lean and virtual R&amp;D model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Strategy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our goal is to become a leading biotechnology company focused on developing and delivering therapies and related diagnostics in both oncology and immunology. The key elements of our strategy to achieve this goal are to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Advance the clinical development of orally administered Foralumab for the treatment of NASH and Crohn&#x2019;s disease using a novel and proprietary oral formulation by initiating a Phase 1 trial in the second half of 2019 and a Phase 2 trial in the second half of 2020. In addition, a Phase 1 trial for the first<FONT CLASS="nobreak">-in-human</FONT> evaluation of the nasal administration of Foralumab in healthy volunteers, for neurodegenerative disease </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;text-indent:0pt;">indications such as MS, was initiated in November 2018. Topline results from this study are expected in the second half of 2019.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue to advance the clinical development and obtain regulatory approval for our lead oncology product candidate, Milciclib, as a monotherapy in HCC and as a combination therapy for the treatment of refractory solid tumors (being cancers which are non<FONT CLASS="nobreak">-responsive</FONT> or become resistant to treatment) and HCC by continuing to enroll the ongoing Phase 2a trial as a monotherapy and initiating a planned Phase 2b trial in combination with a TKI (Sorafenib or Regorafenib).</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue to leverage relationships with key opinion leaders to promote clinical trial success and enhance future commercialization.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue preclinical studies and non<FONT CLASS="nobreak">-clinical</FONT> development of our product candidate, TZLS<FONT CLASS="nobreak">-501</FONT>, a fully human mAb targeting the IL<FONT CLASS="nobreak">-6R</FONT> (a biological mAb which may control the proteins involved in cell signaling relevant to many inflammatory diseases and cancers), for treatment of inflammatory and oncology indications.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Opportunistically identify and acquire or in<FONT CLASS="nobreak">-license</FONT> complimentary product and technology candidates.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Seek orphan drug, fast track or breakthrough designation for our product candidates where warranted.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Product Candidates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our product candidate pipeline is set forth below:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="image_011.jpg" STYLE="height:371.2px;width:549.12px;max-width:100%;"></FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Selected Risks Affecting Our Business</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth in the section titled &#x201c;Risk Factors&#x201d; before deciding whether to invest in our ADSs. These important risks include, but are not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>If we encounter substantial delays in clinical trials of our product candidates, we may be unable to obtain required regulatory approvals, and therefore will be unable to commercialize our product candidates on a timely basis or at all.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We may fail to demonstrate the safety and therapeutic utility of our product candidates to the satisfaction of applicable regulatory authorities, which would prevent or delay regulatory approval and commercialization.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We depend on enrollment of patients in our clinical trials for our product candidates and may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates and could materially adversely affect our R&amp;D efforts and business, financial condition and results of operations.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We need substantial additional funding to complete the development of our product candidates, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development, research operations or future commercialization efforts, if any.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our 10% or more stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our limited operating history and no history of commercializing pharmaceutical products may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We utilize, and expect to continue to utilize, third parties to conduct our product manufacturing for the foreseeable future, and these third parties may not perform satisfactorily.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The future commercial success of our product candidates will depend upon the degree of each product candidates&#x2019; market acceptance by physicians, patients, third<FONT CLASS="nobreak">-party</FONT> payors and others in the medical community.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We may not be able to protect our intellectual property rights throughout the world.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Even if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our product candidates in other major markets.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We do not know whether an active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will be. As a result, it may be difficult for shareholders to sell their ADSs.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We may lose our FPI status, which would then require us to comply with the Exchange Act&#x2019;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Corporate Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We were originally incorporated under the laws of England and Wales on February<FONT CLASS="nobreak"> </FONT>11, 1998 with the goal of leveraging the expertise of our management team as well as Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Howard Weiner and Dr. Kevan Herold, and to acquire and exploit certain intellectual property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition of Tiziana Pharma Limited in April 2014.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our registered office is located at 3<FONT CLASS="CharOverride-16" STYLE="font-size:58%;vertical-align:super;">rd</FONT> Floor, 11<FONT CLASS="nobreak">-12</FONT> St James&#x2019;s Square, London SW1Y 4LB and our telephone number is +44 20 7495 2379. Our website address is www.tizianalifesciences.com. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website is not a part of this registration statement. Our agent for service of process in the United States is Tiziana Therapeutics, Inc.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">&#x201c;Tiziana,&#x201d; the Tiziana logo and other trademarks or service marks of Tiziana Life Sciences plc appearing in this prospectus are the property of Tiziana or our subsidiaries. This prospectus contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the &#x00ae; or <FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">TM</FONT> symbols.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Implications of Being an Emerging Growth Company</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are an EGC as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not EGCs. These exemptions include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the option to present only two years of audited financial statements and related discussion in the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in this prospectus;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act of 2002, or Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>not being required to submit certain executive compensation matters to stockholder advisory votes, such as &#x201c;say<FONT CLASS="nobreak">-on-pay</FONT>,&#x201d; &#x201c;say<FONT CLASS="nobreak">-on-frequency</FONT>,&#x201d; and &#x201c;say<FONT CLASS="nobreak">-on-golden</FONT> parachutes;&#x201d; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>not being required to disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#x2019;s compensation to median employee compensation.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a result, we do not know if some investors will find our ADSs or ordinary shares less attractive. The result may be a less active trading market for our ADSs and/or ordinary shares, and the price of ADSs and/or ordinary shares may become more volatile.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Section 107 of the JOBS Act also provides that an EGC can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act, for complying with new or revised accounting standards. As a result, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to opt out of this extended transition period and will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non<FONT CLASS="nobreak">-EGCs</FONT>. Under federal securities laws, our decision to opt out of the extended transition period is irrevocable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We will remain an EGC until the earliest of: (1) the last day of the first fiscal year in which our annual gross revenues exceed $1.07<FONT CLASS="nobreak"> </FONT>billion; (2) the last day of 2023; (3) the date that we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b<FONT CLASS="nobreak">-2</FONT> under the Exchange Act, which would occur on the last day of any fiscal year that the aggregate worldwide market value of our common equity held by non<FONT CLASS="nobreak">-affiliates</FONT> exceeds $700<FONT CLASS="nobreak"> </FONT>million as of the last business day of our most recently completed second fiscal quarter; or (iv) the date on which we have issued more than $1.0<FONT CLASS="nobreak"> </FONT>billion in non<FONT CLASS="nobreak">-convertible</FONT> debt securities during any three<FONT CLASS="nobreak">-year</FONT> period.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Implications of Being a Foreign Private Issuer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We report under the Exchange Act as a non<FONT CLASS="nobreak">-U</FONT>.S. company with FPI status. Even after we no longer qualify as an EGC, as long as we qualify as an FPI under the Exchange Act we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10<FONT CLASS="nobreak">-Q</FONT> containing unaudited financial and other specific information, and current reports on Form 8<FONT CLASS="nobreak">-K</FONT> upon the occurrence of specified significant events.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">FPIs are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an EGC, but remain an FPI, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an EGC nor an FPI.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">The Offering</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;text-indent:-10pt;">ADSs offered by us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 1,383,125 ADSs. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Ordinary&#x00a0;shares&#x00a0;to&#x00a0;be&#x00a0;outstanding after this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;"> <BR>150,295,067 ordinary shares, including 13,831,249 ordinary shares in the form of ADSs (or 152,646,372 ordinary shares if the underwriters exercise in full their over<FONT CLASS="nobreak">-allotment</FONT> option to purchase 2,074,680 ordinary shares in the form of ADSs). </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Over<FONT CLASS="nobreak">-allotment</FONT> option</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;"> 207,468 ADSs. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">ADSs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Each ADS represents 10 ordinary shares, nominal value &#x00a3;0.03 per ordinary share. The depositary will hold the ordinary shares underlying your ADSs and you will have rights as provided in the deposit agreement among us, the depositary, and holders and beneficial owners of ADSs from time to time. To better understand the terms of our ADSs, see &#x201c;Description of the American Depositary Shares.&#x201d; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Depositary</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">JPMorgan Chase Bank, N.A.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Use of proceeds</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;"> We estimate that the net proceeds from our sale of ADSs in this offering will be approximately $8.8<FONT CLASS="nobreak"> </FONT>million (or approximately $10.2<FONT CLASS="nobreak"> </FONT>million if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full), assuming a public offering price of $7.23 per ADS, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September<FONT CLASS="nobreak"> </FONT>13, 2019, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">We intend to use the net proceeds we receive from this offering to advance the clinical development of Foralumab and Milciclib, and our other research and development programs, working capital and other general corporate purposes.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">See &#x201c;Use of Proceeds&#x201d; for additional information.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Risk factors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">See &#x201c;Risk Factors&#x201d; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ADSs.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Representative&#x2019;s Warrants</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;"> The registration statement of which this prospectus is a part also registers warrants to purchase 27,663 ADSs to ThinkEquity, a division of Fordham Financial Management, Inc., the representative of the underwriters, or the Representative, as a portion of the underwriting compensation payable to the underwriters in connection with this offering. The warrants, or the Representative&#x2019;s Warrants, will be exercisable for a four and a half<FONT CLASS="nobreak">-year</FONT> period commencing 180 days following the effective date of the registration statement related to this offering at an exercise price equal to 125% of the public offering price of the ADSs. Please see &#x201c;Underwriting &#x2014; Representative&#x2019;s Warrants&#x201d; for a description of these warrants. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:10pt;margin-top:8pt;text-indent:-10pt;">Nasdaq Global Market symbol</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">&#x201c;TLSA.&#x201d;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The number of shares of our ordinary shares that will be outstanding after this offering is based on 136,463,818  ordinary shares outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018, and excludes:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5,236,166 ordinary shares issuable upon the exercise of share options outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.19 and $2.30 per ordinary share;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18,617,403 ordinary shares that may be issued under our existing share option plans, as described in &#x201c;Management &#x2014; The Tiziana Life Sciences plc Employee Share Plan with Non<FONT CLASS="nobreak">-Employee</FONT> Sub<FONT CLASS="nobreak">-Plan</FONT> and US Sub<FONT CLASS="nobreak">-Plan</FONT>,&#x201d; as of December<FONT CLASS="nobreak"> </FONT>31, 2018; and</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>3,617,905 ordinary shares that may be issued upon the exercise of warrants to purchase ordinary shares outstanding as at December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.62 and $3.10 per ordinary share.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Unless otherwise indicated, this prospectus reflects and assumes the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>no exercise of outstanding share options after December<FONT CLASS="nobreak"> </FONT>31, 2018;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>no exercise of the underwriters&#x2019; over<FONT CLASS="nobreak">-allotment</FONT> option; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>no exercise of the Representative&#x2019;s Warrants.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border-style:solid;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Summary Consolidated Financial Data</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following tables set forth our summary consolidated financial data for the periods indicated. We have derived the consolidated statement of comprehensive income for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017 and the consolidated balance sheet data as of December<FONT CLASS="nobreak"> </FONT>31, 2018 from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be expected for any future period. You should read the following summary consolidated financial data together with the audited consolidated financial statements included elsewhere in this prospectus and the sections entitled &#x201c;Exchange Rate Information&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial results in U.S. dollars.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statement of Operations Data:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Years Ended <BR>December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands, except per share data)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,510</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,015</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,417</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,602</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,617</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,617</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax provision</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to ordinary shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,716</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive loss:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total comprehensive loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,646</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted net loss per ordinary share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Balance Sheet Data:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December 31, 2018</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Actual</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">As <BR>Adjusted</FONT><FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,304</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,150</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Working capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">514</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,360</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,920</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,767</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; equity (deficit)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">519</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,365</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;"> (1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;On an as adjusted basis to give effect to the sale of 1,383,125 ADSs in this offering at the assumed public price of $7.23  per ADS in this offering, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September 13, 2019, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T04"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">RISK FACTORS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">You should carefully consider the risks described below, together with all of the other information in this registration statement. The risks and uncertainties below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could be seriously harmed and potential future investors in our ADSs could lose all or part of their investment. Further, if we fail to meet the expectations of the public market in any given period, the potential market price of our ADSs could decline. We operate in a highly competitive environment that involves significant risks and uncertainties, some of which are outside of our control. If any of these risks actually occurs, our business and financial condition could suffer and the potential market price of our ADSs could decline.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to the Development of our Product Candidates</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we encounter substantial delays in clinical trials of our product candidates, we may be unable to obtain required regulatory approvals, and therefore will be unable to commercialize our product candidates on a timely basis or at all.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and utility of the product candidates. Clinical testing is expensive, time<FONT CLASS="nobreak">-consuming</FONT> and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all, as a failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in reaching a consensus with the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or other regulatory authorities on trial design;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in opening clinical trial sites or obtaining required institutional review board or independent ethics committee approval at each clinical trial site;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in recruiting suitable patients to participate in our future clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or clinical trial sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>failure to perform in accordance with good clinical practice, or GCP, or applicable regulatory guidelines in Europe and other international markets;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical trial sites, including delays by third parties with whom we have contracted to perform certain of those functions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delays in having patients complete participation in a clinical trial or return for post<FONT CLASS="nobreak">-treatment</FONT> follow<FONT CLASS="nobreak">-up</FONT>;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>clinical trial sites or patients dropping out of a clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>occurrence of serious adverse events in clinical trials of the same class of agents conducted by other sponsors; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may fail to demonstrate the safety and therapeutic utility of our product candidates to the satisfaction of applicable regulatory authorities, which would prevent or delay regulatory approval and commercialization.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved as products. If the results of our registrational trial or future pivotal trials for our other product candidates do not demonstrate therapeutic utility of our product candidates, or if there are safety concerns or serious adverse events associated with our product candidates, we may:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be delayed in obtaining marketing approval for our product candidates, if at all;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>obtain approval for indications or patient populations that are not as broad as intended or desired;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be subject to additional post<FONT CLASS="nobreak">-marketing</FONT> testing requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be subject to changes in the way the product is administered;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be required to perform additional clinical trials to support approval or be subject to additional post<FONT CLASS="nobreak">-marketing</FONT> testing requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be subject to the addition of labeling statements, such as warnings or contraindications; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be sued or experience damage to our reputation.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the effectiveness and safety of our product candidate. Frequently, product candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. To date, some of our clinical trials have involved small patient populations and because of the small sample size in such trials, the interim results of these clinical trials may be subject to substantial variability and may not be indicative of either future interim results or final results. In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, there is a high failure rate for drugs and biologic products proceeding through clinical trials. In fact, many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late<FONT CLASS="nobreak">-stage</FONT> clinical trials even after achieving promising results in preclinical testing and earlier<FONT CLASS="nobreak">-stage</FONT> clinical trials. Moreover, data obtained from preclinical and clinical activities is subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We depend on enrollment of patients in our clinical trials for our product candidates and may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates and could materially adversely affect our R&amp;D efforts and business, financial condition and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate, and to see those patients through the completion of required follow<FONT CLASS="nobreak">-up</FONT> periods. If, for any reason, patients are unwilling to enroll in our clinical trials, then the timeline for recruiting patients, conducting studies and obtaining regulatory approvals for our product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our current product candidates are being developed to treat oncology and immune diseases of high unmet medical need. However, we may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA, EMA or other regulatory authorities. As a result, we may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment can be affected by many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>size of the patient population and process for identifying patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>eligibility and exclusion criteria for our clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>perceived risks and benefits of our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>severity of the disease under investigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>proximity and availability of clinical trial sites for prospective patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>competition with other clinical trials for product candidates competing in the same therapeutic areas as our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ability to obtain and maintain patient consent;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>patient drop<FONT CLASS="nobreak">-outs</FONT> prior to completion of clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>patient referral practices of physicians; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ability to monitor patients adequately during and after treatment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our ability to successfully initiate, enroll and complete clinical trials in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>difficulty in establishing or managing relationships with CROs and physicians;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>different standards for the conduct of clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>absence in some countries of established groups with sufficient regulatory expertise for review of certain treatment protocols;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>inability to locate qualified local consultants, physicians and partners; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we have difficulty enrolling a sufficient number of patients or finding additional clinical trial sites to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which could have an adverse effect on our business, financial condition, results of operations and prospects.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations. For Milciclib, the most frequent drug<FONT CLASS="nobreak">-related</FONT> side effects reported across studies, at all doses tested, were gastrointestinal, or GI, adverse events (nausea and diarrhea, followed by less frequent vomiting), neurological effects (mainly tremor, then ataxia, dizziness and dysgeusia), skin disorders and asthenia, fatigue, headache and anorexia. For Foralumab, the most frequent drug<FONT CLASS="nobreak">-related</FONT> side effects reported following intravenous administration were infusion related reactions, or IRR, including fever, headaches, chills, nausea, vomiting diarrhea and hypotension considered the result of cytokine release also known as cytokine release syndrome, or CRS. Other adverse events included reactivation of Epstein<FONT CLASS="nobreak">-Barr</FONT> virus (clinically silent); moderate lymphocytopenia, abnormalities in liver function tests. Since most of these changes are related to the infusion route of administration and dosage level, such systemic toxicities are not anticipated when administered orally or nasally due to what we assume will be minimal systemic absorption and induction of anti<FONT CLASS="nobreak">-inflammatory</FONT> T regulatory T cells.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large<FONT CLASS="nobreak">-scale</FONT>, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that our product candidates cause serious or life<FONT CLASS="nobreak">-threatening</FONT> side effects, the development of our product candidates may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If in the future we are unable to demonstrate that such adverse events were caused by the administration process or related procedures, the FDA, EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that any serious adverse events are not product<FONT CLASS="nobreak">-related</FONT>, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the clinical trial. Moreover, if we elect or are required to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidate may be harmed and our ability to generate product revenues from such product candidate may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, if we or others later identify undesirable side effects caused by any of our product candidates, several potentially significant negative consequences could result, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>regulatory authorities may suspend or withdraw approvals of such product candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>regulatory authorities may require additional warnings on the label;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we may be required to change the way a product candidate is administered or conduct additional clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we could be sued and held liable for harm caused to patients; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our reputation may suffer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Given the nature of biologics and NCE manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">of operations and cause reputational damage. In addition, some of the raw materials required in our manufacturing process are derived from biologic sources and are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Financial Position and Need For Capital</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Mazars LLP, our independent registered public accounting firm for the fiscal year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, has included an explanatory paragraph in their opinion that accompanies our audited consolidated financial statements as of and for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, indicating that our current liquidity position raises substantial doubt about our ability to continue as a going concern. If we are unable to improve our liquidity position, we may not be able to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result if we are unable to continue as a going concern and, therefore, be required to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We have incurred net losses in every year since our inception. We anticipate that we will continue to incur losses for the foreseeable future and may never achieve or maintain profitability.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a clinical stage biotechnology company with a limited operating history. Since our inception in May 2013, we have incurred significant net losses. Our net losses were $8.0<FONT CLASS="nobreak"> </FONT>million and $8.7<FONT CLASS="nobreak"> </FONT>million for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, respectively. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, we had an accumulated loss of $50.6<FONT CLASS="nobreak"> </FONT>million. We have devoted substantially all of our efforts to research and development of our product candidates, including clinical development of our lead product candidates, Foralumab and Milciclib, as well as to building out our management team and infrastructure. We expect that it could be several years, if ever, before we have a commercialized product candidate. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. These net losses will adversely impact our shareholders&#x2019; equity and net assets and may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>continue research and development of Foralumab, including the initiation of our orally administered Phase 1 trials in normal healthy volunteers with an intent to treat patients with NASH, Crohn&#x2019;s disease and MS;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>complete our Phase 2 program for Milciclib as a monotherpay in HCC patients and initiate a Phase 2b trial for Milciclib in combination with Sorafenib in HCC patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>initiate clinical trials and preclinical studies for any additional product candidates that we may pursue in the future;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>manufacture our product candidates in accordance with current good manufacturing practices, or cGMP, for clinical trials or potential commercial sales;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>develop, maintain, expand and protect our intellectual property portfolio;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>identify, assess, and acquire or in<FONT CLASS="nobreak">-license</FONT> other product candidates and technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>secure, maintain or obtain freedom to operate for any in<FONT CLASS="nobreak">-licensed</FONT> technologies and products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>address any competing technological and market developments; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>expand our operations in the United States and Europe.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our R&amp;D efforts, expand our business or continue our operations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We need substantial additional funding to complete the development of our product candidates, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development, research operations or future commercialization efforts, if any.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the R&amp;D of, initiate further clinical trials of and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company listed on both AIM in the United Kingdom and Nasdaq in the United States. Our future capital requirements will depend on many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the scope, progress, results and costs of laboratory testing, manufacturing, preclinical and clinical development for our current and future product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs, timing and outcome of regulatory review of our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the extent to which we acquire or in<FONT CLASS="nobreak">-license</FONT> and develop other product candidates and technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our ability to establish and maintain collaborations and license agreements on favorable terms, if at all;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales and distribution for our product candidates for which we receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs of developing, maintaining and enforcing our intellectual property rights and defending intellectual property<FONT CLASS="nobreak">-related</FONT> claims; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the sales price and availability of adequate third<FONT CLASS="nobreak">-party</FONT> coverage and reimbursement for our product candidates, if and when approved.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Developing product candidates and conducting preclinical studies and clinical trials is a time<FONT CLASS="nobreak">-consuming</FONT>, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, will be derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, if at all. To the extent that additional capital is raised through the issuance of equity or equity<FONT CLASS="nobreak">-linked</FONT> securities, the issuance of those securities could result in substantial dilution for our current shareholders and the terms of any future issuance may include liquidation or other preferences that adversely affect the rights of our current shareholders. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or additional equity financing that we raise may contain terms that are not favorable to us or our shareholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that are not favorable to us. Furthermore, the potential issuance of additional securities in the future, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our American Depositary Shares, or ADSs, to decline and existing shareholders may not agree with our financing plans or the terms of such financings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are unable to obtain adequate funding on a timely basis, we may be required to significantly curtail, delay or discontinue our R&amp;D programs of our product candidates or any future commercialization efforts, be unable to expand our operations or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our limited operating history and no history of commercializing pharmaceutical products may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since our inception, we have devoted substantially all of our resources to developing Foralumab and Milciclib, and our other product candidates, building our intellectual property portfolio and providing general and administrative support for these operations. Although our R&amp;D efforts to date have resulted in a pipeline of product candidates, we have not yet demonstrated our ability to successfully complete Phase 3 or other pivotal clinical trials, obtain regulatory approvals, or commercialize any of our product candidates. In addition, given our limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors in achieving our business objectives.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, we are not profitable and have incurred losses in each year since our inception, and we expect that our financial condition and operating results may continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Reliance on Third Parties</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third<FONT CLASS="nobreak">-party</FONT> CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. In engaging these third parties, we typically have to, and expect to have to, negotiate budgets and contracts, which may result in delays to our development timelines and increases costs. Additionally, there is a limited number of qualified third<FONT CLASS="nobreak">-party</FONT> service providers that specialize or have the expertise required to achieve our business objectives, and so it may be challenging to find alternative investigators or CROs, or do so on commercially reasonable terms. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third<FONT CLASS="nobreak">-party</FONT> contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon a regulatory inspection of us or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of our product candidates. These investigators and CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. In addition, the use of third<FONT CLASS="nobreak">-party</FONT> service providers requires us to disclose our proprietary information to these parties, which increases the risk that a competitor will discover them or that this information will be misappropriated or disclosed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If any of our relationships with these third<FONT CLASS="nobreak">-party</FONT> CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and commercial prospects would be harmed, our costs could increase and our ability to generate revenues could be delayed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Repeating clinical trials or switching or engaging additional CROs involves additional cost and requires our management&#x2019;s time and focus. In addition, there is a natural transition period when a clinical trial has to be repeated or when a new CRO commences work. As a result, delays could occur, which could materially impact our ability to meet our desired clinical development timelines.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have engaged contract manufacturing organizations, or CMOs, to manufacture Foralumab and Milciclib and to perform quality testing, and because we collaborate with various organizations and academic institutions for the advancement of our platforms, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know<FONT CLASS="nobreak">-how</FONT> and trade secrets, a competitor&#x2019;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure of such technology or information would impair our competitive position and may have an adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets by third parties. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We utilize, and expect to continue to utilize, third parties to conduct our product manufacturing for the foreseeable future, and these third parties may not perform satisfactorily.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We currently rely on CMOs for the manufacturing of clinical batches and intend to continue to rely on third parties to manufacture our preclinical study and clinical trial product supplies. If our current CMOs, or any future third<FONT CLASS="nobreak">-party</FONT> manufacturers, do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, or if there are disagreements between us and our CMOs or any future third<FONT CLASS="nobreak">-party</FONT> manufacturers, we will not be able to complete, or may be delayed in completing, the preclinical studies required to support future investigational new drug, or IND, submissions and the clinical trials required for approval of our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition to our current CMOs, we may rely on additional third parties to manufacture ingredients of our product candidates in the future and to perform quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>reduced control for certain aspects of manufacturing activities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>disruptions to the operations of our third<FONT CLASS="nobreak">-party</FONT> manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize any of our product candidates. Some of these events could be the basis for FDA, EMA or other regulatory authority action, including injunction, recall, seizure or total or partial suspension of product manufacture.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">To the extent we rely on a third-party manufacturing facility for commercial supply, that third party will be subject to significant regulatory oversight with respect to manufacturing our product candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The preparation of therapeutics for clinical trials or commercial sale is subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late<FONT CLASS="nobreak">-stage</FONT> clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of outside agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. To the extent that we utilize third<FONT CLASS="nobreak">-party</FONT> facilities for commercial supply, the third party&#x2019;s facilities and quality systems must pass an inspection for compliance with the applicable regulations as a condition of regulatory approval. In addition, the regulatory authorities may, at any time, audit or inspect the third<FONT CLASS="nobreak">-party</FONT> manufacturing facility or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If, for example, these facilities do not pass a plant inspection, the FDA will not approve the applicable NDA or biologics license application, or BLA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We do not directly control the manufacturing of, and are completely dependent on, our CMOs for compliance with cGMP requirements. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our CMOs are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory clearance of our CMOs&#x2019; facilities. Our failure, or the failure of third parties, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our potential future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Commercialization of Our Product Candidates</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We currently have no marketing and sales force. If we are unable to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties to market, sell and distribute our product candidates that may be approved, we may not be successful in commercializing our product candidates if and when approved, and we may be unable to generate any product revenue.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates. In order to commercialize any of our product candidates that may be approved, we intend to build, on a territory<FONT CLASS="nobreak">-by-territory</FONT> basis, marketing, sales, distribution, managerial and other non<FONT CLASS="nobreak">-technical</FONT> capabilities or make arrangements with third parties to perform these services. These efforts will require significant capital expenditures, management resources and time, and we face competition in search for qualified personnel or third parties to assist with marketing, sales and distribution of any of our product candidates. We may not be successful in building these capabilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There are risks involved with both establishing our own sales, marketing and distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">for which we recruit a sales force and establish marketing and/or distribution capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future product that we may develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>unforeseen costs and expenses associated with creating an independent sales and marketing organization.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability to us from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger R&amp;D, clinical, sales and marketing and manufacturing organizations. These third parties also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, the development of our products. In addition, mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidate that we may develop. Competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#x2019; products. The availability of our competitors&#x2019; products could limit the demand, and the price we are able to charge, for any product candidate that we may develop and commercialize.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be smaller than we anticipate.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We focus our R&amp;D efforts on treatments for cancer and autoimmune disease. Our understanding of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, is based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Further, there are several factors that could contribute to making the actual number of patients who receive our potential products, if and when approved, less than the potentially addressable market. These include, for example, the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The future commercial success of our product candidates will depend upon the degree of each product candidates&#x2019; market acceptance by physicians, patients, third-party payors and others in the medical community.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our product candidates are at varying stages of development, and we may never have a product that is commercially successful. To date, we have no product authorized for marketing. Due to the inherent risk in the development of pharmaceutical products, we may never successfully complete development and commercialization of any of our product candidates. Even with the requisite approvals from the FDA, EMA and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients and third<FONT CLASS="nobreak">-party</FONT> payors of our product candidates as medically necessary, cost<FONT CLASS="nobreak">-effective</FONT> and safe. Any product that we commercialize may not gain acceptance by physicians, patients, third<FONT CLASS="nobreak">-party</FONT> payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. Even if some product candidates achieve market acceptance, the market may not prove to be large enough to allow us to generate significant revenues. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the effectiveness and safety of our product candidates as demonstrated in clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the potential and perceived advantages of our product candidates over alternative treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the availability and cost of treatment relative to alternative treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>changes in the SOC for the targeted indications for any product candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the willingness of physicians to prescribe, and the target patient population to try, new therapies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the prevalence and severity of any side effects;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#x2019;s approved labeling;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the timing of market introduction of competitive products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>sales, distribution and marketing support;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>publicity concerning our product candidates or competing products and treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>potential product liability claims;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>any restrictions on the use of our products together with other medications; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>favorable third<FONT CLASS="nobreak">-party</FONT> payor coverage and adequate reimbursement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if a potential product displays favorable clinical properties and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect that coverage and adequate reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third<FONT CLASS="nobreak">-party</FONT> payors. Coverage and reimbursement by a third<FONT CLASS="nobreak">-party</FONT> payor may depend upon several factors, including the third<FONT CLASS="nobreak">-party</FONT> payor&#x2019;s determination that use of a product is:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a covered benefit under our health plan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>safe, effective and medically necessary;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>appropriate for the specific patient;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>cost<FONT CLASS="nobreak">-effective</FONT>; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>neither experimental nor investigational.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Obtaining coverage and reimbursement for a product from third<FONT CLASS="nobreak">-party</FONT> payors is a time<FONT CLASS="nobreak">-consuming</FONT> and costly process that could require us to provide to the payor supporting scientific, clinical and cost<FONT CLASS="nobreak">-effectiveness</FONT> data. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There is significant uncertainty related to third<FONT CLASS="nobreak">-party</FONT> coverage and reimbursement of newly approved products. In the United States, third<FONT CLASS="nobreak">-party</FONT> payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors develop their coverage and reimbursement policies. However, no uniform policy of coverage and reimbursement exists among third<FONT CLASS="nobreak">-party</FONT> payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. One payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement. It is difficult to predict what the Centers for Medicare and Medicaid Services, or CMS will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these types of products. Moreover, reimbursement agencies in the European Union may be more conservative than the CMS. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European Union, or EU, member states, or Member States. It is difficult to predict what third<FONT CLASS="nobreak">-party</FONT> payors will decide with respect to the coverage and reimbursement for our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost<FONT CLASS="nobreak">-containment</FONT> programs to limit the growth of government<FONT CLASS="nobreak">-paid</FONT> healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, in the United States, the Patient Protection and Affordable Care Act of 2010 (as amended by the Health Care and Education Reconciliation Act of 2010), or the PPACA, contains provisions that may reduce the profitability of products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, contain the cost of drugs, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Outside the United States, international operations generally are subject to extensive government price controls and other market regulations and increasing emphasis on cost<FONT CLASS="nobreak">-containment</FONT> initiatives in the European Union, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenues.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various Member States and parallel distribution, or arbitrage between low<FONT CLASS="nobreak">-priced</FONT> and high<FONT CLASS="nobreak">-priced</FONT> Member States, can further reduce prices. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost<FONT CLASS="nobreak">-effectiveness</FONT> of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Moreover, increasing efforts by government and third<FONT CLASS="nobreak">-party</FONT> payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Payors increasingly are considering new metrics as the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. Therefore, it may be difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover product candidates that we or our partners are able to commercialize. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as ours.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Intellectual Property</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our rights to develop and commercialize our product candidates are subject to the terms and conditions of licenses granted to us by others. If we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to the business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We do not currently own any patents; however, we are heavily reliant upon licenses and sublicenses from Nerviano and Novimmune to certain patent rights and proprietary technology that are important or necessary to the development of our technology and product candidates, including the patents and know<FONT CLASS="nobreak">-how</FONT> relating to manufacture. These and other licenses may not provide exclusive rights to use such intellectual property and technology or may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products, including in territories covered by our licenses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. If our licensors fail to maintain such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Licenses to additional third<FONT CLASS="nobreak">-party</FONT> technology and materials that may be required for our development programs, including additional technology and materials owned by any of our current licensors, may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have an adverse effect on our business and financial condition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our current product candidates, any future product candidates we may develop and our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our success depends, in large part, on our ability to seek, obtain and maintain patent protection in the United States and other countries with respect to our product candidates and to future innovation related to our manufacturing technology. Our licensors have sought, and we intend to seek to protect our proprietary position by filing patent applications in the United States, the United Kingdom and elsewhere, related to certain technologies and our product candidates that are important to our business. Our current patent portfolio contains a limited number of patent applications, all of which are in<FONT CLASS="nobreak">-licensed</FONT> from third parties and relate to either composition of matter, formulation, method of use or process of manufacturing Foralumab, Milciclib and a fully human anti<FONT CLASS="nobreak">-interleukin-6</FONT> receptor, or IL<FONT CLASS="nobreak">-6r</FONT>, mAb. However, the risks associated with patent rights generally apply to patent rights that we in<FONT CLASS="nobreak">-license</FONT> now or in the future, as well as patent rights that we may own in the future. Moreover, the risks apply with respect to patent rights and other intellectual property applicable to our product candidates, as well as to any intellectual property rights that we may acquire in the future related to future product candidates, if any. We have filed a new patent application covering the composition of matter of Foralumab. However, this application is pending and there is no guarantee that the U.S. Patent and Trademark Office, or USPTO, will grant this application.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The patent prosecution process is expensive, time<FONT CLASS="nobreak">-consuming</FONT> and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In some cases, the work of certain academic researchers in the oncology and immunology fields has entered the public domain, which we believe precludes our ability to obtain patent protection for certain inventions relating to such work.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Consequently, we will not be able to assert any such patents to prevent others from using our technology for, and developing and marketing competing products to treat, these indications. It is also possible that we will fail to identify patentable aspects of our R&amp;D output before it is too late to obtain patent protection.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our existing license agreements impose, and we expect that future license agreements will impose, various due diligence, development and commercialization timelines, insurance, milestone payments, royalties and other obligations on us. See the description in the section titled &#x201c;Business<FONT CLASS="nobreak">-Collaboration</FONT> and License Agreements&#x201d; herein. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, or, in some cases, under other circumstances, the licensor may have the right to terminate the license, in which event we would not be able to market product candidates covered by the license. In addition, certain of these license agreements are not assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. Our licensed patent applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product candidates or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even assuming patents issue from patent applications in which we have rights, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Other parties have developed technologies that may be related or competitive to our own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents. We may not be aware of all third<FONT CLASS="nobreak">-party</FONT> intellectual property rights potentially relating to our current and future product candidates.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18<FONT CLASS="nobreak"> </FONT>months after filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our licensed patents have, or that any of our pending licensed patent applications that mature into issued patents will include, claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our product candidates, including &#x201c;highly similar,&#x201d; or biosimilar, versions of such products. In addition, the intellectual property portfolio licensed to us by Nerviano and Novimmune may be used by them or licensed to third parties, and such third parties may have certain enforcement rights. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if we acquire patent protection that we expect should enable us to maintain some competitive advantage, third parties, including competitors, may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and our licensed patents may be challenged in courts or patent offices in the United States and abroad. For example, we may be subject to a third<FONT CLASS="nobreak">-party</FONT> submission of prior art to the USPTO challenging the validity of one or more claims of our licensed patents. Such submissions may also be made prior to a patent&#x2019;s issuance, precluding the granting of a patent based on one of our pending licensed patent applications. We may become involved in opposition, derivation, re<FONT CLASS="nobreak">-examination</FONT>, inter partes review, post<FONT CLASS="nobreak">-grant</FONT> review or interference proceedings challenging the patent rights of others from whom we have obtained licenses to such rights. Competitors may claim that they invented the inventions claimed in our licensed issued patents or patent applications prior to the inventors of such patents or applications. A competitor who can establish an earlier filing or invention date may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed under our licensed patents, if issued. Competitors may also contest our licensed patents, if issued, by showing that the invention was not patent<FONT CLASS="nobreak">-eligible</FONT>, was not novel, was obvious or that the patent claims failed any other requirement for patentability.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An adverse determination by former employees or consultants asserting ownership rights to our patents may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third<FONT CLASS="nobreak">-party</FONT> patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if they are unchallenged, our licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our licensed patents by developing similar or alternative technologies or therapeutics in a non<FONT CLASS="nobreak">-infringing</FONT> manner. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">For example, a third party may develop a competitive therapeutic that provides benefits similar to one or more of our product candidates but that uses a different antibody or molecular active ingredient that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We currently depend, and will continue to depend, on our license agreements whereby we obtain rights in certain patents and patent applications owned by them. Further development and commercialization of our current product candidates may, and development of any future product candidates will, require us to enter into additional license or collaboration agreements. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have an adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If any of our licenses or material relationships or any in<FONT CLASS="nobreak">-licenses</FONT> upon which our licenses are based are terminated or breached, we may:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>lose our rights to develop and market our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>lose patent protection for our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>experience significant delays in the development or commercialization of our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>not be able to obtain any other licenses on acceptable terms, if at all; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>incur liability for damages.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, a third party may in the future bring claims that our performance under our license agreements, including our sponsoring of clinical trials, interferes with such third party&#x2019;s rights under its agreement with one of our licensors. If any such claim were successful, it may adversely affect our rights and ability to advance our product candidates as clinical candidates or subject us to liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">These risks apply to any agreements that we may enter into in the future for our current or any future product candidates. If we experience any of the foregoing, it could have a negative impact on our business, financial condition, results or operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have entered into license agreements with third parties and may need to obtain additional licenses from one or more of these same third parties or from others to advance our research or allow commercialization of our product candidates. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize our product candidates, which would harm our business. We cannot provide any assurances that third<FONT CLASS="nobreak">-party</FONT> patents or other intellectual property rights do not exist which might be enforced against our current product candidates or future product candidates, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In each of our existing license agreements, and we expect in our future agreements, patent prosecution of our licensed technology is controlled solely by the licensor, and we may be required to reimburse the licensor for their costs of patent prosecution. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property, or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. Our license agreements with Nerviano and Novimmune also require us to meet development thresholds to maintain each license, including establishing a set timeline for developing and commercializing product candidates. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the scope of rights granted under the license agreement and other interpretation<FONT CLASS="nobreak">-related</FONT> issues;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the sublicensing of patent and other rights pursuant to our collaborative development relationships;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our diligence obligations under the license agreements and what activities satisfy those diligence obligations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the inventorship or ownership of inventions and know<FONT CLASS="nobreak">-how</FONT> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the priority of invention of patented technology.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our product candidates.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We currently have certain rights to the intellectual property, through licenses from third parties, to develop our product candidates. Because our programs may require the use of additional proprietary rights held by these or other third parties, the growth of our business likely will depend, in part, on our ability to acquire, in<FONT CLASS="nobreak">-license</FONT> or use these proprietary rights. We may be unable to acquire or in<FONT CLASS="nobreak">-license</FONT> any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing or acquisition of third<FONT CLASS="nobreak">-party</FONT> intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third<FONT CLASS="nobreak">-party</FONT> intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third<FONT CLASS="nobreak">-party</FONT> intellectual property rights on terms that would allow us to make an appropriate return on our investment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may collaborate with non<FONT CLASS="nobreak">-profit</FONT> and academic institutions to accelerate our preclinical R&amp;D under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are unable to successfully obtain rights to required third<FONT CLASS="nobreak">-party</FONT> intellectual property or maintain the existing intellectual property rights we have, we may have to abandon development of our product candidates and our business, financial condition, results of operations and prospects could suffer. Moreover, to the extent that we seek to develop other product candidates in the future, we will likely require acquisition or in<FONT CLASS="nobreak">-license</FONT> of additional proprietary rights held by third parties.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of non-compliance with these requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we may own in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non<FONT CLASS="nobreak">-U</FONT>.S. patent agencies. The USPTO and various non<FONT CLASS="nobreak">-U</FONT>.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non<FONT CLASS="nobreak">-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have an adverse effect on our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Moreover, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business and results of operations may be adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may not be able to protect our trade secrets in court.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know<FONT CLASS="nobreak">-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know<FONT CLASS="nobreak">-how</FONT>, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. However, we may not be able to prevent the unauthorized disclosure or use of our technical know<FONT CLASS="nobreak">-how</FONT> or other trade secrets by the parties to these agreements, despite the existence generally of confidentiality agreements and other contractual restrictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements and security measures, they may still be breached, and we may not have adequate remedies for any breach.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#x2019; therapeutics, our competitive position could be adversely affected, as could our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain or guarantee that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional R&amp;D programs expected in the future. Furthermore, because patent applications can take many years to issue, may be confidential for 18<FONT CLASS="nobreak"> </FONT>months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates and we may or may not be aware of such patents. If a patent holder believes the manufacture, use, sale or importation of one of our product candidates infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our technology. Moreover, we may face patent infringement claims from non<FONT CLASS="nobreak">-practicing</FONT> entities that have no relevant product revenue and against whom our licensed patent portfolio may therefore have no deterrent effect.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">It is also possible that we have failed to identify relevant third<FONT CLASS="nobreak">-party</FONT> patents or applications. For example, applications filed before November<FONT CLASS="nobreak"> </FONT>29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third<FONT CLASS="nobreak">-party</FONT> patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third<FONT CLASS="nobreak">-party</FONT> patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent or other intellectual property rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third<FONT CLASS="nobreak">-party</FONT> patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Similarly, there is no assurance that a court of competent jurisdiction would find that product candidates or our technology did not infringe a third<FONT CLASS="nobreak">-party</FONT> patent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found or believe there is a risk that we may be found, to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required or may choose to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non<FONT CLASS="nobreak">-exclusive</FONT>, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some or all of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time<FONT CLASS="nobreak">-consuming</FONT>. Competitors may infringe our patents or the patents of our licensing partners, should such patents issue, or we may be required to defend against claims of infringement. To counter infringement or unauthorized use claims or to defend against claims of infringement can be expensive and time consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on us. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know<FONT CLASS="nobreak">-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm our business and may prevent us from successfully obtaining necessary regulatory approvals and commercializing our product candidates. In addition, we may lose personnel as a result of such claims, and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to obtain necessary regulatory approvals and commercialize our product candidates, which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self<FONT CLASS="nobreak">-executing</FONT> or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre<FONT CLASS="nobreak">-existing</FONT> or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we may own may have an adverse effect on our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September<FONT CLASS="nobreak"> </FONT>16, 2011, the Leahy<FONT CLASS="nobreak">-Smith</FONT> America Invents Act, or the Leahy<FONT CLASS="nobreak">-Smith</FONT> Act, was signed into law. The Leahy<FONT CLASS="nobreak">-Smith</FONT> Act includes several significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a &#x201c;first<FONT CLASS="nobreak">-to-invent</FONT>&#x201d; system to a &#x201c;first<FONT CLASS="nobreak">-to-file</FONT>&#x201d; system, allow third<FONT CLASS="nobreak">-party</FONT> submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent through various post<FONT CLASS="nobreak">-grant</FONT> proceedings administered by the USPTO. Under a first<FONT CLASS="nobreak">-to-file</FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy<FONT CLASS="nobreak">-Smith</FONT> Act, and many of the substantive changes to patent law associated with the Leahy<FONT CLASS="nobreak">-Smith</FONT> Act, and in particular, the first<FONT CLASS="nobreak">-to-file</FONT> provisions, only became effective on March<FONT CLASS="nobreak"> </FONT>16, 2013.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Accordingly, it is not clear what, if any, impact the Leahy<FONT CLASS="nobreak">-Smith</FONT> Act will have on the operation of our business. However, the Leahy<FONT CLASS="nobreak">-Smith</FONT> Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a negative impact effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the combination of new federal legislation, federal court decisions, and guidance from the USPTO has created uncertainty with respect to the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">value of patents, once obtained. Depending on the decisions by the U.S. Congress, federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or enforce our existing patents and patents we might obtain in the future.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We do not currently have any registered trademarks and we have not filed any trademark applications to date. Any trademark applications in the United States, Europe and in other foreign jurisdictions where we may file may not be allowed or may subsequently be opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time<FONT CLASS="nobreak">-consuming</FONT>, particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license or may own in the future;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we, or our license partners or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we, or our license partners or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>others may circumvent our regulatory exclusivities, such as by pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical data, rather than relying on the abbreviated pathway provided for biosimilar applicants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>issued patents that we hold rights to now or in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>others may have access to the same intellectual property rights licensed to us on a non<FONT CLASS="nobreak">-exclusive</FONT> basis;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our competitors might conduct R&amp;D activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we may not develop additional proprietary technologies that are patentable;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the patents or other intellectual property rights of others may have an adverse effect on our business; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we may choose not to file a patent for certain trade secrets or know<FONT CLASS="nobreak">-how</FONT>, and a third party may subsequently file a patent covering such intellectual property.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates and the approval may be for a narrower indication than we seek.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. The FDA must review and approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed labeling, as well as the evaluation of the manufacturing process and manufacturers&#x2019; facilities, all of which is lengthy, expensive and uncertain. To obtain approval, we must, among other things, demonstrate with substantial evidence from well<FONT CLASS="nobreak">-controlled</FONT> clinical trials that the product candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet the FDA&#x2019;s safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse to file our application for substantive review or may determine after review of our data that our application is insufficient to allow approval of our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing validation studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non<FONT CLASS="nobreak">-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The FDA, EMA or other regulatory authorities also may approve a product candidate for more limited indications than requested or may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require precautions or contraindications with respect to conditions of use or may grant approval subject to the performance of costly post<FONT CLASS="nobreak">-marketing</FONT> clinical trials. In addition, the FDA, EMA or other regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could harm the commercial prospects for our product candidates and negatively impact our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Delays in obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We do not currently operate manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin to commercially manufacture our product candidates, whether in a third<FONT CLASS="nobreak">-party</FONT> facility or in our own facility, if and when established, we must obtain regulatory approval from the FDA for our manufacturing process and facility. A manufacturing authorization must also be obtained from the appropriate European Union regulatory authorities and from other foreign regulatory authorities, as applicable. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers are found to be non<FONT CLASS="nobreak">-compliant</FONT> with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality assurance to confirm that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we or our third<FONT CLASS="nobreak">-party</FONT> manufacturers fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre<FONT CLASS="nobreak">-existing</FONT> approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be harmed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, if the supply of our products from our third<FONT CLASS="nobreak">-party</FONT> manufacturers to us is interrupted for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contamination, business interruptions or labor shortages or disputes, there could be a significant disruption in commercial supply of our products. We do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial sale. An alternative manufacturer would need to be qualified through a supplement to its regulatory filing, which could result in further delays. The regulatory authorities also may require additional clinical trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user<FONT CLASS="nobreak">-fee</FONT> waivers. In the European Union, the EMA&#x2019;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life<FONT CLASS="nobreak">-threatening</FONT> or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended for the diagnosis, prevention or treatment of a life<FONT CLASS="nobreak">-threatening</FONT>, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biologic product. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The designation as an orphan product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if we obtain regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record<FONT CLASS="nobreak">-keeping</FONT> and submission of safety and other post<FONT CLASS="nobreak">-market</FONT> information. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post<FONT CLASS="nobreak">-marketing</FONT> testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Some of our product candidates are classified as biologics in the United States, and therefore, can only be sold if we obtain a BLA from the FDA. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. In addition, the holder of a BLA must comply with the FDA&#x2019;s advertising and promotion requirements, such as those related to the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off<FONT CLASS="nobreak">-label</FONT> use&#x201d;). Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that product (in addition to our being obligated as holder of a BLA to monitor and report adverse events and any failure of a product to meet the BLA specifications), a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority may:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>issue a warning letter asserting that we are in violation of the law;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>suspend or withdraw regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>suspend any ongoing clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>restrict the marketing or manufacturing of the product;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>seize or detain the product or otherwise require the withdrawal of the product from the market;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>refuse to permit the import or export of the product; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>refuse to allow us to enter into supply contracts, including government contracts.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, the FDA&#x2019;s policies, and those of the EMA and other regulatory authorities, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would negatively impact our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Even if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our product candidates in other major markets.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. For example, in many jurisdictions outside of the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products would also be subject to approval. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the United States, Europe or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be compromised.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may seek a conditional marketing authorization in Europe for some or all of our current product candidates, but we may not be able to obtain or maintain such designation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As part of its marketing authorization process, the EMA may grant marketing authorizations for certain categories of medicinal products on the basis of less complete data than is normally required, when doing so may meet unmet medical needs of patients and serve the interest of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention, or the medical diagnosis of seriously debilitating or life<FONT CLASS="nobreak">-threatening</FONT> diseases and those designated as orphan medicinal products.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and therapeutic utility of the medicinal product have not been supplied, all the following requirements are met:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the risk<FONT CLASS="nobreak">-benefit</FONT> balance of the medicinal product is positive;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it is likely that the applicant will be in a position to provide the comprehensive clinical data;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>unmet medical needs will be fulfilled; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data is still required.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency situations in response to public health threats. Conditional marketing authorizations are valid for one year, on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that the benefit<FONT CLASS="nobreak">-risk</FONT> balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Granting a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the case and will ensure that additional data on a product is generated, submitted, assessed and acted upon.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post<FONT CLASS="nobreak">-approval</FONT> activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part D program and introduced a new reimbursement methodology based on average sales prices for Medicare Part B physician<FONT CLASS="nobreak">-administered</FONT> drugs. In addition, the MMA authorized Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic class in their formularies. The MMA&#x2019;s cost reduction initiatives and other provisions could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies may be enacted in international markets, which could similarly impact our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">More recently, in March 2010, the PPACA (as amended by the Health Care and Education Reconciliation Act of 2010) was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point<FONT CLASS="nobreak">-of-sale</FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D. Additionally, in the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biologic products that are demonstrated to be biosimilar or &#x201c;interchangeable&#x201d; with an FDA<FONT CLASS="nobreak">-approved</FONT> biologic product. This new pathway could allow competitors to reference data from biologic products already approved after 12 years from the time of approval. This could expose us to potential competition by lower<FONT CLASS="nobreak">-cost</FONT> biosimilars even if we commercialize a product candidate faster than our competitors. Moreover, the creation of this abbreviated approval pathway does not preclude or delay a third party from pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical trial data.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additional changes that may affect our business include those governing enrollments in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the PPACA and the passage of additional laws and </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For each state that does not choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact the sales, business and financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage under any of the new options made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting drug utilization. The U.S. federal government also has announced delays in the implementation of key provisions of the PPACA. The implications of these delays for our and our potential partners&#x2019; business and financial condition, if any, are not yet clear.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, there have been judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration and Congress will likely continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions of the PPACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. More recently, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017, and Senate Republicans have released a draft bill known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects of the PPACA if ultimately enacted. The prospects for enactment of these legislative initiatives remain uncertain. Further, Congress also could consider other legislation to replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or any future healthcare reform legislation will impact our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We are subject to governmental regulation and other legal obligations related to privacy, data protection and data security. Our actual or perceived failure to comply with such obligations could harm our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are subject to diverse laws and regulations relating to data privacy and security in the EU, and shortly in the European Economic Area, including the GDPR. New global privacy rules are being enacted and existing ones are being updated and strengthened. We are likely to be required to expend capital and other resources to ensure ongoing compliance with these laws and regulations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The GDPR applies extraterritorially and implements stringent operational requirements for controllers and processors of personal data. For example, the GDPR: (i) requires detailed disclosures to data subjects; (ii) requires disclosure of the legal basis on which personal data is processed; (iii) makes it harder to obtain valid consent for processing; (iv) requires the appointment of a data protection officers where sensitive personal data (i.e. health data) is processed on a large scale; (v) provides more robust rights for data subjects; (vi) introduces mandatory data breach notification through the EU; (vii) imposes additional obligations when contracting with service providers; and (viii) requires an appropriate privacy governance framework to be implemented including policies, procedures, training and data audit. The GDPR permits Member State derogations for certain issues and, accordingly, we are also subject to EU national laws relating to the processing of certain data such as genetic data, biometric data and data concerning health. Complying with these numerous, complex and often changing regulations is expensive and difficult. Failure by us, or our partners or service providers, to comply with the GDPR could result in regulatory investigations, enforcement notices and/ or fines of up to the higher of 20,000,000 Euros or up to 4% of our total worldwide annual turnover. In addition to </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">the foregoing, any breach of privacy laws or data security laws, particularly those resulting in any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, could have a material adverse effect on our business, reputation and financial condition.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a data controller, we are accountable for any third party data service providers we engage to process personal data on our behalf. We attempt to address the associated risks by performing security assessments, detailed due diligence and regularly performing privacy and security reviews of its vendors and requiring all such third<FONT CLASS="nobreak">-party</FONT> providers with data access to sign agreements, including business associate agreements, and where required under EU law, obligating them to only process data according to our instructions and to take sufficient security measures to protect such data. There is no assurance that these contractual measures and our own privacy and security<FONT CLASS="nobreak">-related</FONT> safeguards will protect us from the risks associated with the third<FONT CLASS="nobreak">-party</FONT> processing, storage and transmission of such information. Any violation of data or security laws by our third party processors could have a material adverse effect on our business and result in the fines and penalties outlined above. We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e<FONT CLASS="nobreak">-Privacy</FONT> Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each Member State. The draft e<FONT CLASS="nobreak">-Privacy</FONT> Regulation imposes strict opt<FONT CLASS="nobreak">-in</FONT> marketing rules with limited exceptions for business<FONT CLASS="nobreak">-to-business</FONT> communications, alters rules on third<FONT CLASS="nobreak">-party</FONT> cookies, web beacons and similar technology and significantly increases fining powers to the same levels as GDPR (i.e. the greater of 20,000,000 Euros or 4% of total global annual revenue). While the e<FONT CLASS="nobreak">-Privacy</FONT> Regulation was originally intended to be adopted on May<FONT CLASS="nobreak"> </FONT>25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators now expect it to be adopted during the second half of 2020 or during 2021 following a transition period.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our operations are subject to anti<FONT CLASS="nobreak">-corruption</FONT> laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977, or the FCPA, the U.S. domestic bribery statute contained in 18 &#x00a7;201, the U.S. Travel Act, and other anti<FONT CLASS="nobreak">-corruption</FONT> laws that apply in countries where we do business. The U.K. Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the U.K. Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential U.K. Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the U.K. Bribery Act, FCPA or local anti<FONT CLASS="nobreak">-corruption</FONT> laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti<FONT CLASS="nobreak">-money</FONT> laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti<FONT CLASS="nobreak">-corruption</FONT> laws, including the U.K. Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery Act, the FCPA and other anti<FONT CLASS="nobreak">-corruption</FONT> laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti<FONT CLASS="nobreak">-corruption</FONT> laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our relationships with customers, physicians and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are found in violation of these laws and regulations, we may be required to pay a penalty or be suspended from participation in federal or state healthcare programs, which may adversely affect our business, financial condition and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we obtain FDA approval for our product candidates and begin commercializing them in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, the federal civil and criminal laws and Physician Payments Sunshine Act of 2010 and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the U.S. federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the purchase, lease or order of a good, facility, item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>federal civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support the view that federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute violations and certain marketing practices, including off<FONT CLASS="nobreak">-label</FONT> promotion, may implicate the False Claims Act of 1863;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>HIPAA (as amended by the Health Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers, and their respective business associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>federal transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the CMS information related to: (i) payments or other &#x201c;transfers of value&#x201d; made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family members;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>state and foreign law equivalents of each of the above federal laws, state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non<FONT CLASS="nobreak">-compliance</FONT> with these laws, reputational harm, and we may be required to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur substantial costs.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. We contract with third parties that conduct operations on our behalf that involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors also produce and dispose of hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our contractors&#x2019; use of hazardous materials, we could be held liable for any resulting damages and any liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We also could incur significant costs associated with civil or criminal fines and penalties. Our third<FONT CLASS="nobreak">-party</FONT> contractors may not carry specific biological or hazardous waste insurance coverage, and their property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Although we maintain workers&#x2019; compensation insurance for certain costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work<FONT CLASS="nobreak">-related</FONT> injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could adversely affect our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to our Business Operations</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The success of our business depends upon our ability to identify, develop and commercialize product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources. Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">approval of our product candidates, a key element of our long<FONT CLASS="nobreak">-term</FONT> growth strategy is to develop and market additional products and product candidates. However, we may fail to identify other potential product candidates for clinical development for several reasons. For example, our research may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects, may be commercially impracticable to manufacture or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our spending on current and future R&amp;D programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our long<FONT CLASS="nobreak">-term</FONT> growth strategy to develop and market additional products and product candidates is heavily dependent on precise, accurate and reliable scientific data to identify, select and develop promising pharmaceutical product candidates and products. Our business decisions may therefore be adversely influenced by improper or fraudulent scientific data sourced from third parties. Any irregularities in the scientific data used by us to determine our focus in R&amp;D of product candidates and products could have a material adverse effect on our business, prospects, financial condition and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate, which could have a negative impact on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key employees, consultants and advisors and to recruit, retain and motivate qualified personnel.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time. We currently do not have &#x201c;key person&#x201d; insurance on any of our employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical studies or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have an adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">At December<FONT CLASS="nobreak"> </FONT>31, 2018, we had 5 full<FONT CLASS="nobreak">-time</FONT> employees who were engaged in R&amp;D activities. If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our R&amp;D activities and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. Future growth would impose significant added responsibilities on members of management and, to a potentially significant extent, divert our management and business development resources away from their current uses. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and any future product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas, to attract and retain sufficient numbers of talented employees and to expand the group of contractors we use.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have a material adverse impact on our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to: comply with FDA or EMA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA, EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self<FONT CLASS="nobreak">-dealing</FONT> and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Additionally, we are subject to the risk that a person could allege fraud or other misconduct, even in none occurred. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant criminal, civil and administrative sanctions, such as monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non<FONT CLASS="nobreak">-compliance</FONT> with these laws, reputational harm, and we may be required to curtail or restructure our operations. We are also subject to the data privacy regime in the EU, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU and includes the General Data Protection Regulation, or the GDPR, and any national laws implementing or supplementing the GDPR. If we do not comply with our obligations under the EU privacy regime, we could be exposed to significant fines and we may be the subject of litigation and/or adverse publicity, which could have a material adverse effect on our reputation and business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We face an inherent risk of product liability exposure related to the testing of our current and future product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. For example, we may be sued if our current or future product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>decreased demand for any product candidate that we may develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>loss of revenue;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>substantial monetary awards to trial participants or patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>significant time and costs to defend the related litigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>withdrawal of clinical trial participants;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the inability to commercialize any product candidates that we may develop; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>injury to our reputation and significant negative media attention.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Legal, political and economic uncertainty surrounding the planned exit of the United Kingdom or the U.K., from the European Union, or EU, may be a source of instability in international markets, create significant currency fluctuations, adversely affect our operations in the U.K. and pose additional risks to our business, revenue, financial condition, and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. to leave the EU. The U.K&#x2019;s withdrawal from the EU is commonly referred to as Brexit. Pursuant to Article 50 of the Treaty on European Union, the U.K. will cease to be an EU Member State either on the effective date of a withdrawal agreement (entry into such a withdrawal agreement will require U.K. parliamentary approval) or, failing that, two years following the U.K.&#x2019;s notification of its intention to leave the EU (the &#x201c;Brexit Date&#x201d;), unless the European Council (together with the U.K.) unanimously decides to extend the two year period. On March<FONT CLASS="nobreak"> </FONT>29, 2017, the U.K. formally notified the European Council of its intention to leave the EU. It is unclear how long it will take to negotiate a withdrawal agreement, but it appears likely that Brexit will continue to involve a process of lengthy negotiations between the U.K. and EU Member States to determine the future terms of the U.K&#x2019;s relationship with the EU. For example, in March 2018, the U.K. reached a provisional agreement (the &#x201c;Withdrawal Agreement&#x201d;) with the EU on transitional arrangements following the U.K&#x2019;s exit (which are intended to enable the U.K. to remain within the EU single market and customs union for a transitional period through 2020), but this Withdrawal Agreement needs to be formally agreed as part of the withdrawal arrangements currently under negotiation. The U.K. and the European Council had agreed an extension of the Brexit Date until May<FONT CLASS="nobreak"> </FONT>22, 2019, which was conditional upon endorsement of the Withdrawal Agreement by the U.K. House of Commons by March<FONT CLASS="nobreak"> </FONT>29, 2019. The Withdrawal Agreement was not so endorsed, therefore the Brexit Date is unconditionally extended until October<FONT CLASS="nobreak"> </FONT>31, 2019 instead.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The lack of clarity over which EU laws and regulations will continue to be implemented in the U.K. after Brexit (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data protection laws, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws) may negatively impact foreign direct investment in the U.K., increase costs, depress economic activity and restrict access to capital.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The uncertainty concerning the U.K&#x2019;s legal, political and economic relationship with the EU after Brexit may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross<FONT CLASS="nobreak">-border</FONT> co<FONT CLASS="nobreak">-operation</FONT> arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">These developments, or the perception that any of them could occur, have had, and may continue to have, a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be subject to increased market volatility.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If the U.K. and the EU are unable to negotiate acceptable withdrawal terms or if other EU Member States pursue withdrawal, barrier<FONT CLASS="nobreak">-free</FONT> access between the U.K. and other EU Member States or among the European Economic Area overall could be diminished or eliminated. The long<FONT CLASS="nobreak">-term</FONT> effects of Brexit will depend on any agreements (or lack thereof) between the U.K. and the EU and, in particular, any arrangements for the U.K. to retain access to EU markets either during a transitional period or more permanently.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Such a withdrawal from the EU is unprecedented, and it is unclear how the U.K&#x2019;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our U.K. operations and customers. Our U.K. operations service customers in the U.K. as well as in other countries in the EU and European Economic Area, or EEA, and these operations could be disrupted by Brexit, particularly if there is a change in the U.K&#x2019;s relationship to the single market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may also face new regulatory costs and challenges that could have an adverse effect on our operations. Depending on the terms of the U.K&#x2019;s withdrawal from the EU, the U.K. could lose the benefits of global trade agreements negotiated by the EU on behalf of its members, which may result in increased trade barriers that could make our doing business in the EU and the EEA more difficult. Furthermore, at present, there are no indications of the effect Brexit will have on the pathway to obtaining marketing approval for any of our product candidates in the U.K., or what, if any, role the EMA may have in the approval process. Even prior to any change to the U.K&#x2019;s relationship with the EU, the announcement of Brexit has created economic uncertainty surrounding the terms of Brexit and its consequences could adversely impact customer confidence resulting in customers reducing their spending budgets on our solutions, which could adversely affect our business, revenue, financial condition, results of operations and could adversely affect the market price of our ADSs and our ordinary shares.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Exchange rate fluctuations may materially affect our results of operations and financial condition.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between Pounds Sterling and the U.S. dollar, may adversely affect us. Although we are based in the United Kingdom, we may source R&amp;D, manufacturing, consulting and other services from the United States and the European Union. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the potential value of our ADSs may be affected by fluctuations in foreign exchange rates not only between the Pounds Sterling and the U.S. dollar, but also the euro, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to the Ownership of Our Securities</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If you purchase ADSs in this offering, you will suffer immediate dilution of your investment.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> The public offering price of our ADSs is substantially higher than the pro forma as adjusted net tangible book value per ADS. Therefore, if you purchase ADSs in this offering, you will pay a price per ADS that substantially exceeds our pro forma as adjusted net tangible book value per ADS after this offering. Based on an assumed public offering price of $7.23 per ADS in this offering, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September<FONT CLASS="nobreak"> </FONT>13, 2019, you will experience immediate dilution of $0.66 per ordinary share (equal to $6.61 per ADS), representing the difference between our as adjusted net tangible book value per ADS after this offering and the public offering price per ADS. After this offering, we may have outstanding options to purchase ordinary shares with exercise prices lower than the public offering price. To the extent these outstanding options are exercised, there will be further dilution to investors in this offering. For further information regarding the dilution resulting from this offering, see the section titled &#x201c;Dilution&#x201d; in this prospectus. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The prices of the ADSs and our ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for holders of the ADSs and our ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The market prices of the ADSs on the Nasdaq Global Market and of our ordinary shares on AIM may be volatile and fluctuate substantially. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, holders of the ADSs and our ordinary shares may not be able to sell their ADSs or ordinary shares at or above the price at which they were purchased. The market price for the ADSs and ordinary shares may be influenced by many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the success of competitive products or technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>results of clinical trials of Miciclib and Foralumab and any other future product candidate that we develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>results of clinical trials of product candidates of our competitors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>changes or developments in laws or regulations applicable to Miciclib and Foralumab and any other future product candidates that we develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our entry into, and the success of, any collaboration agreements with third parties;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>developments or disputes concerning patent applications, issued patents or other proprietary rights;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the recruitment or departure of key personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the level of expenses related to any of our product candidates or clinical development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the results of our efforts to discover, develop, acquire or in<FONT CLASS="nobreak">-license</FONT> additional product candidates, products or technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>variations in our financial results or those of companies that are perceived to be similar to us;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>market conditions in the biotechnology and pharmaceutical sectors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>general economic, industry and market conditions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the trading volume of ADSs on the Nasdaq Global Market and of our ordinary shares on AIM; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the other factors described in this &#x201c;Risk Factors&#x201d; section.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The ADSs are traded on the Nasdaq Global Market, and our ordinary shares are listed on AIM. The dual listing of our ordinary shares and the ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect the maintenance of an active trading market for the ADSs in the United States. The price of the ADSs could also be adversely affected by trading in our ordinary shares on AIM. Although our ordinary shares are currently listed on AIM, we may decide at some point in the future to delist our ordinary shares from AIM, and our ordinary shareholders may approve such delisting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In this circumstance, shareholders on the AIM market, either because they are not permitted to hold such securities or for other reasons, may seek to convert their shares into ADSs and sell them on NASDAQ as the date for de<FONT CLASS="nobreak">-listing</FONT> from the AIM market draws near, which could cause the trading price of our ADSs on NASDAQ to decline. We are also contemplating eliminating our ADS facility, with the intent of having common shares traded on NASDAQ, which would then be our only publicly<FONT CLASS="nobreak">-traded</FONT> security. Terminating the facility may obligate us to pay fees to our Depositary. There can be no assurance that the liquidity of the our shares or ADS would not be&#x00a0;impaired.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Securities traded on AIM may carry a higher risk than shares traded on other exchanges that may impact the value of your investment.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our ordinary shares are currently traded on AIM. Investment in equities traded on AIM is perceived by some to carry a higher risk than an investment in equities quoted on exchanges with more stringent listing requirements, such as the London Stock Exchange, New York Stock Exchange or the Nasdaq Stock Market. This is because AIM imposes less stringent corporate governance and ongoing reporting requirements than those other exchanges. In addition, AIM requires only semi<FONT CLASS="nobreak">-annual</FONT>, rather than quarterly, financial reporting. You should be aware that the value of our ordinary shares may be influenced by many factors, some of which may be specific to us and some of which may affect AIM<FONT CLASS="nobreak">-listed</FONT> companies generally, including the depth and liquidity of the market, our performance, a large or small volume of trading in our ordinary shares, legislative changes and general economic, political or regulatory conditions, and that the prices may be volatile and subject to extensive fluctuations. Therefore, the market price of our ordinary shares underlying the ADSs may not reflect the underlying value of our company.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Holders of our ADSs do not have the same rights as our shareholders and may only exercise their voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee as their representative to exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting is convened, if you hold ADSs, you may not receive sufficient notice of a shareholders&#x2019; meeting to permit you to withdraw the ordinary shares underlying your ADSs to allow you to vote with respect to any specific matter. We will make all commercially reasonable efforts to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#x2019; meeting.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of any potential future holders of ADSs, are governed by English law, including the provisions of the U.K. Companies Act 2006, or the Companies Act, and by our Articles of Association, or Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See &#x201c;Description of Share Capital and Articles of Association<FONT CLASS="nobreak">-Differences</FONT> in Corporate Law&#x201d; in this report for a description of the principal differences between the provisions of the Companies Act applicable to us and, for example, the Delaware General Corporation Law relating to stockholders&#x2019; rights and protections.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may re-incorporate in another jurisdiction, and the laws of such jurisdiction will likely govern all of our material agreements and we may not be able to enforce our legal rights.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may relocate the home jurisdiction of our business from the United Kingdom to another jurisdiction. If we determine to do this, the laws of such jurisdiction would likely govern all of our material agreements. In this circumstance, the rights of shareholders could be substantially different under the corporate law of the jurisdiction to which we might migrate than they are under English law. Moreover, the system of laws and the enforcement of existing laws in such jurisdiction may not be as certain in implementation and interpretation as in the United States or the United Kingdom. The inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business, business opportunities or capital.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our AIM shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We intend to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>increased operating expenses and cash requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the assumption of additional indebtedness or contingent liabilities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the diversion of our management&#x2019;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">As an FPI, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than U.S. public companies</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are an FPI, as defined in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#x201c;short<FONT CLASS="nobreak">-swing</FONT>&#x201d; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As an FPI, we will file an annual report on Form 20<FONT CLASS="nobreak">-F</FONT> within four months of the close of each fiscal year ended December 31 and reports on Form 6<FONT CLASS="nobreak">-K</FONT> relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions for FPIs, our ADS holders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">While we are an FPI, we are not subject to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are entitled to rely on a provision in Nasdaq&#x2019;s corporate governance rules that allows us to follow English corporate law and the Companies Act with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For example, we are exempt from Nasdaq regulations that require a listed U.S. company to (i) have a majority of the board of directors consist of independent directors, (ii) require non<FONT CLASS="nobreak">-management</FONT> directors to meet on a regular basis without management present and (iii) promptly disclose any waivers of the code for directors or executive officers that should address certain specified items.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In accordance with our Nasdaq listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act and Rule 10A<FONT CLASS="nobreak">-3</FONT> of the Exchange Act, both of which are also applicable to Nasdaq<FONT CLASS="nobreak">-listed</FONT> U.S. companies. Because we are an FPI, however, our audit committee is not subject to additional </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">Nasdaq requirements applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &#x201c;independent,&#x201d; using more stringent criteria than those applicable to us as an FPI. Furthermore, Nasdaq&#x2019;s corporate governance rules require listed U.S. companies to, among other things, seek shareholder approval for the implementation of certain equity compensation plans and issuances of ordinary shares, which we are not required to follow as an FPI.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may lose our FPI status, which would then require us to comply with the Exchange Act&#x2019;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As an FPI, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be an FPI as early as June<FONT CLASS="nobreak"> </FONT>30, 2019 (the end of our second fiscal quarter in the fiscal year following this Nasdaq listing), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January<FONT CLASS="nobreak"> </FONT>1, 2019. In order to maintain our current status as an FPI, either (a) a majority of our ADSs must be either directly or indirectly owned of record by non<FONT CLASS="nobreak">-residents</FONT> of the United States or (b)(i) a majority of our executive officers or directors cannot be U.S. citizens or residents, (ii) more than 50% of our assets must be located outside the United States and (iii) our business must be administered principally outside the United States. If we lose our status as an FPI, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for FPIs. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as an FPI. As a result, we expect that a loss of FPI status would increase our legal and financial compliance costs and is likely to make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We are an emerging growth company within the meaning of the Securities Act of 1933 and will take advantage of certain reduced reporting requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are an EGC, as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, or Section 404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an EGC, we are required to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We may take advantage of these exemptions until we are no longer an EGC. We could be an EGC for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ADSs held by non<FONT CLASS="nobreak">-affiliates</FONT> exceeds $700<FONT CLASS="nobreak"> </FONT>million as of any June 30 (the end of our second fiscal quarter) before that time, in which case we would no longer be an EGC as of the following December 31 (our fiscal year<FONT CLASS="nobreak">-end</FONT>). We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile in the event that we decide to make an offering of our ADSs following our Nasdaq listing.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Section 404(a) of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, or Section 404(a), requires that beginning with our second annual report following our initial public offering, management assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses in our internal control over financial reporting. Although Section 404(b) of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, or Section 404(b), requires our independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over financial reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section 404(b) until such time as we are no longer an EGC.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect our first Section 404(a) assessment will take place for our annual report for the fiscal year ending December<FONT CLASS="nobreak"> </FONT>31, 2019. The presence of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports, delays in our financial reporting, which could require us to restate our operating results or our auditors may be required to issue a qualified audit report. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section 404 (a). In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we will need to expend significant resources and provide significant management oversight.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Implementing any appropriate changes to our internal control may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&#x2019;s attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If either we are unable to conclude that we have effective internal control over financial reporting or, at the appropriate time, our independent auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal control over financial reporting as required by Section 404(b), then in the event we have decided to make an offering of our ADSs following our Nasdaq listing, investors may lose confidence in our operating results, the price of our ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404, we may not be able to remain listed on Nasdaq.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Pursuant to Section 404, we will be required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify as an EGC, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Our 10% or more stockholders and management own a significant percentage of our stock and are able to exercise significant influence over matters subject to stockholder approval.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> As of the date of this prospectus, our executive officers, directors and 10% or more stockholders, together with their respective affiliates, owned approximately 49% of our outstanding securities. Accordingly, this group of security holders will be able to exert a significant degree of influence over our management and affairs and over matters requiring security holder approval, including the election of our Board of Directors, future issuances of our securities, declaration of dividends and approval of other significant corporate transactions. As a result, if these shareholders were to choose to act together, they would be able to exert significant influence over matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would exercise sufficient voting power to influence the election of directors and approve any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>delay, defer or prevent a change in control;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>entrench our management and board of directors; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>impede a merger, consolidation, takeover or other business combination involving us that other shareholders may desire.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Panetta Partners Limited, Planwise Group Limited and Gabriele Cerrone, together the Cerrone Concert Party, are considered to be a &#x201c;concert party&#x201d; for the purposes of the Takeover Code. Following this offering, the Cerrone Concert Party holds shares carrying voting rights equal to approximately 42.6%. Accordingly, the Cerrone Concert Party will not, save in limited circumstances, be able to acquire further interests in shares carrying voting rights </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">without being obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non<FONT CLASS="nobreak">-voting</FONT>, and also to the holders of any other class of transferable securities carrying voting rights.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less favorable results to the plaintiff(s) in any such action.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The deposit agreement governing the ADSs representing our ordinary shares provides that holders and beneficial owners of ADSs irrevocably waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non<FONT CLASS="nobreak">-exclusive</FONT> jurisdiction over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based upon a creditor&#x2019;s negligence in failing to liquidate collateral upon a guarantor&#x2019;s demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought against us and / or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may augur different results than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Claims of U.S. civil liabilities may not be enforceable against us.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are incorporated under English law. Certain members of our board of directors and senior management are non<FONT CLASS="nobreak">-residents</FONT> of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Internal Revenue Code of 1986, or the Internal Revenue Code, we will be a PFIC for any taxable year in which either (1) 75% or more of our gross income consists of &#x201c;passive income&#x201d; or (2) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non<FONT CLASS="nobreak">-U</FONT>.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year during which a U.S. Holder (as defined below under &#x201c;Material Tax Considerations<FONT CLASS="nobreak">-Material</FONT> U.S. Federal Income Tax Considerations for U.S. Holders&#x201d;) holds our shares, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We believe that we were a PFIC for our taxable year ended December<FONT CLASS="nobreak"> </FONT>31, 2018 but cannot provide any assurances regarding our PFIC status for any past, current or future taxable years. The determination of whether we are a PFIC is a fact<FONT CLASS="nobreak">-intensive</FONT> determination made on an annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise in any offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In certain circumstances, a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making a qualified electing fund, or QEF, election to include in income its pro rata share of the corporation&#x2019;s income on a current basis. However, a U.S. Holder may make a QEF election with respect to our ordinary shares or ADSs only if we agree to furnish such U.S. Holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury Regulations. We currently do not intend to prepare or provide the information that would enable U.S. Holders to make a QEF election if we are treated as a PFIC for any taxable year, and prospective investors should assume that a QEF election will not be available.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this report entitled &#x201c;Material Tax Considerations<FONT CLASS="nobreak">-Material</FONT> U.S. Federal Income Tax Considerations for U.S. Holders.&#x201d;</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U.K. tax legislation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a U.K. resident trading entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, we had cumulative carryforward tax losses of $19.6<FONT CLASS="nobreak"> </FONT>million. Subject to any relevant restrictions, we expect these to be available to carry forward and offset against future operating profits. As a company that carries out extensive research and development activities, we benefit from the U.K. research and development tax credit regime for small and medium<FONT CLASS="nobreak">-sized</FONT> companies, whereby we are able to surrender the trading losses that arise from our qualifying research and development activities for a payable tax credit of up to 33.35% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects. Certain subcontracted qualifying research expenditures are eligible for a cash rebate of up to 21.67%. The majority of our pipeline research, clinical trials management and manufacturing development </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">activities are eligible for inclusion within these tax credit cash rebate claims. Our ability to continue to claim payable research and development tax credits in the future may be limited because we may no longer qualify as a small or medium<FONT CLASS="nobreak">-sized</FONT> company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may benefit in the future from the United Kingdom&#x2019;s &#x201c;patent box&#x201d; regime, which allows certain profits attributable to revenues from patented products to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long<FONT CLASS="nobreak">-term</FONT> lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the U.K. research and development tax credit regime or the &#x201c;patent box&#x201d; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Changes and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being affected by certain changes currently proposed by the Organization for Economic Co<FONT CLASS="nobreak">-operation</FONT> and Development and their action plan on Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities; (4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5) changes in the taxation of share<FONT CLASS="nobreak">-based</FONT> compensation; (6) changes in tax laws or the interpretation of such tax laws, and changes in generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&#x2019;s Revenue &amp; Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including methodologies for valuing developed technology and amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#x201c;permanent establishment&#x201d; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High<FONT CLASS="nobreak">-profile</FONT> companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</P>




	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T05"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This prospectus contains statements that constitute forward<FONT CLASS="nobreak">-looking</FONT> statements. Many of the forward<FONT CLASS="nobreak">-looking</FONT> statements contained in this prospectus can be identified by the use of forward<FONT CLASS="nobreak">-looking</FONT> words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential&#x201d; and &#x201c;should,&#x201d; among others.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Forward<FONT CLASS="nobreak">-looking</FONT> statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief, or current expectations. Forward<FONT CLASS="nobreak">-looking</FONT> statements are based on our management&#x2019;s beliefs and assumptions and on information currently available to our management. Such statements are subject to substantial risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward<FONT CLASS="nobreak">-looking</FONT> statements due to various important factors, including, but not limited to, those identified under &#x201c;Risk Factors.&#x201d; In light of the significant uncertainties in these forward<FONT CLASS="nobreak">-looking</FONT> statements, you should not regard these statements as a guarantee by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Forward<FONT CLASS="nobreak">-looking</FONT> statements include, but are not limited to, statements about:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the development of Milciclib, Foralumab and any of our other product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our ability to obtain and maintain regulatory approval of our product candidates, including Milciclib and Foralumab, in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our plans to research, develop, manufacture and commercialize our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the timing of our regulatory filings for our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the size and growth potential of the markets for our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our ability to raise additional capital;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our commercialization, marketing and manufacturing capabilities and strategy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our expectations regarding our ability to obtain and maintain intellectual property protection;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our ability to attract and retain qualified employees and key personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our ability to contract with third party suppliers and manufacturers and their ability to perform adequately;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our estimates regarding future revenue, expenses and needs for additional financing; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>regulatory developments in the United States, European Union and other jurisdictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Forward<FONT CLASS="nobreak">-looking</FONT> statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward<FONT CLASS="nobreak">-looking</FONT> statements by these cautionary statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T06"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MARKET and industry DATA</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Certain industry data and market data included in this prospectus were obtained from independent third<FONT CLASS="nobreak">-party</FONT> surveys, market research, publicly available information, reports of governmental agencies, and industry publications and surveys. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#x201c;Risk Factors.&#x201d; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T07"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TRADEMARKS, SERVICE MARKS AND TRADENAMES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &#x00ae; and &#x2122; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names. For the avoidance of doubt, &#x201c;Tiziana,&#x201d; the Tiziana logo and other trademarks or service marks of Tiziana Life Sciences plc appearing in this prospectus are the property of Tiziana or our subsidiaries. This prospectus contains additional trademarks, service marks, and trade names of others, which are the property of their respective owners. All trademarks, service marks, and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#x2019; trademarks, service marks, copyrights, or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T08"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">USE OF PROCEEDS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We estimate that the net proceeds from this offering will be approximately $8.8<FONT CLASS="nobreak"> </FONT>million, or approximately $10.2<FONT CLASS="nobreak"> </FONT>million if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full, assuming a public offering price of $7.23&#x00a0;per ADS, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September<FONT CLASS="nobreak"> </FONT>13, 2019, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> Each $1.00 increase (decrease) in the public offering price per ADS would increase (decrease) our net proceeds, after deducting estimated underwriting discounts and commissions and offering expenses, by approximately $1.3<FONT CLASS="nobreak"> </FONT>million (assuming no exercise of the over<FONT CLASS="nobreak">-allotment</FONT> option by the underwriters). </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We intend to use the net proceeds from the offering to fund our planned clinical trials, manufacturing and process development, analytical testing, regulatory expenses and for general corporate purposes, including working capital, as follows:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>approximately $4.0<FONT CLASS="nobreak"> </FONT>million to advance the clinical development of Milciclib, which we expect will be sufficient to commence a Phase 2b clinical trial for the combination of Milciclib with a Tyrosine Kinase Inhibitor or TKI (Sorafenib or Regorafenib) in na&#x00ef;ve HCC patients (which would exclude costs associated with protocol development, which have already been paid, but include the cost of purchasing sufficient quantities of TKI drug supply and the cost of activation of clinical sites);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>approximately $3.0<FONT CLASS="nobreak"> </FONT>million to advance the clinical development of Foralumab, which we expect will be sufficient to complete a Phase 1 trial evaluating oral administration of Foralumab in healthy subjects ($1.0<FONT CLASS="nobreak"> </FONT>million) and to commence a Phase 2 trial for nasal administration of Foralumab for treatment of progressive MS patients ($2.0<FONT CLASS="nobreak"> </FONT>million)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>and the remainder ($1.8<FONT CLASS="nobreak"> </FONT>million) to fund our other research and development programs, working capital and other general corporate purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. We may also use a portion of the net proceeds to in<FONT CLASS="nobreak">-license</FONT>, acquire, or invest in additional products or assets, businesses, or technologies, although currently we have no specific agreements, commitments, or understandings in this regard. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. Predicting the costs necessary to develop product candidates can be difficult. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We anticipate that our existing cash resources, together with the net proceeds from the offering, will enable us to fully fund our operating expenses for the planned trials outlined above and our planned capital expenditure requirements for at least the 12<FONT CLASS="nobreak"> </FONT>months following the date of this prospectus. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Pending their use, we plan to invest the net proceeds from the offering in short- and intermediate<FONT CLASS="nobreak">-term</FONT> interest<FONT CLASS="nobreak">-bearing</FONT> obligations and certificates of deposit. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are readily available to fund our operations.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T09"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DIVIDEND POLICY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Under English law, among other things, we may only pay dividends if we have sufficient distributable reserves (on a non<FONT CLASS="nobreak">-consolidated</FONT> basis), which are our accumulated realized profits that have not been previously distributed or capitalized less our accumulated realized losses, so far as such losses have not been previously written off in a reduction or reorganization of capital.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T10"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CAPITALIZATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">You should read the information in this &#x201c;Capitalization&#x201d; section together with &#x201c;Selected Consolidated Financial Data,&#x201d; &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and our consolidated financial statements and the related notes appearing elsewhere in this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The table below sets forth our cash and short<FONT CLASS="nobreak">-term</FONT> deposits and short<FONT CLASS="nobreak">-term</FONT> investments and capitalization as of December<FONT CLASS="nobreak"> </FONT>31, 2018 derived from our audited consolidated financial statements included elsewhere in this prospectus:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>on an actual basis;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>on an as adjusted basis to give effect to the sale of 1,383,125 ADS in this offering at the assumed public price of $7.23 per ADS in this offering, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September<FONT CLASS="nobreak"> </FONT>13, 2019, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December 31, 2018</FONT> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(in thousands)</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Actual</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As Adjusted</FONT><FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(1)</FONT> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Cash and short-term deposits and short-term investments </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 5,304 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 14,150 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Equity: </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Issued capital </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 8,592 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 9,145 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Share premium </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 40,862 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 49,154 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Other reserves </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 1,695 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 1,695 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Accumulated loss </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"> (50,630 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"> ) </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"> (50,630 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"> ) </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Total equity (deficit) </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 519 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 9,364 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Total capitalization </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 519 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 9,364 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;"> (1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Each $1.00 increase or decrease in the assumed public offering price of $7.23 per ADS in this offering, would increase or decrease the as adjusted total equity and total capitalization by approximately $1.3<FONT CLASS="nobreak"> </FONT>million after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The table above excludes:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5,236,166 ordinary shares issuable upon the exercise of share options outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.19 and $2.30 per ordinary share;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18,617,403 ordinary shares that may be issued under our existing share option plans, as described in &#x201c;Management &#x2014; The Tiziana Life Sciences plc Employee Share Plan with Non<FONT CLASS="nobreak">-Employee</FONT> Sub<FONT CLASS="nobreak">-Plan</FONT> and US Sub<FONT CLASS="nobreak">-Plan</FONT>,&#x201d; as of December<FONT CLASS="nobreak"> </FONT>31, 2018; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>3,617,905 ordinary shares that may be issued upon the exercise of warrants to purchase ordinary shares outstanding as at December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.62 and $3.10 per ordinary share.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T11"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DILUTION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If you invest in our ADSs in this offering, your interest will be diluted to the extent of the difference between the public offering price per ADS paid by purchasers in this offering and our pro forma as adjusted net tangible book value per ADS after completion of this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">At December<FONT CLASS="nobreak"> </FONT>31, 2018, we had a historical net tangible book value of $0.004 per ordinary share (equal to $0.04 per ADS). Net tangible book value per ordinary share represents the amount of our total assets less our total liabilities, excluding goodwill and other intangible assets, divided by the total number of our ordinary shares outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> After giving effect to the sale by us of 1,383,125 ADS in this offering at the assumed public price of $7.23 per ADS in this offering, which was the last reported sale price of our ADSs on the Nasdaq Global Market on September<FONT CLASS="nobreak"> </FONT>13, 2019, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value per ordinary share as of December<FONT CLASS="nobreak"> </FONT>31, 2018 would have been $0.062 (equal to $0.62 per ADS). This represents an immediate increase in net tangible book value of $0.06 per ordinary share (equal to $0.59 ADS) to existing shareholders and an immediate dilution of $0.66 per ordinary share (equal to $6.61 per ADS) to new investors purchasing ADSs in this offering. Dilution per ADS or ordinary share to new investors is determined by subtracting the as adjusted net tangible book value per ADS or ordinary share after this offering from the assumed public offering price per ADS paid by new investors. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table illustrates this dilution to new investors purchasing ADSs in this offering.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Assumed public offering price per ADS </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 7.23 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Net tangible book value per ADS </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 0.04 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Increase in net tangible book value per ADS attributable to this offering </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 0.58 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> As adjusted net tangible book value per ADS after this offering </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 0.62 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Dilution per ADS to new investors in this offering </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"> &#x00a0; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> $ </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 6.61 </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> If the underwriters exercise in full their over<FONT CLASS="nobreak">-allotment</FONT> option to purchase an additional 207,468 ADSs, our as adjusted net tangible book value after this offering would be $0.07 per ordinary share (equal to $0.70 per ADS), representing an immediate increase in as adjusted net tangible book value of $0.07 per ordinary share (equal to $0.67&#x00a0;per ADS) to existing shareholders and immediate dilution of $0.65 per ordinary share (equal to $6.53 per ADS). </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> Each $1.00 increase (decrease) in the assumed public offering price of $7.23 per ADS in this offering, would increase (decrease) the as adjusted net tangible book value after this offering by $0.09 per ADS and the dilution to new investors in this offering by $0.92 per ADS, assuming that the number of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The tables above are based on 136,463,818 ordinary shares outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018. The tables above exclude:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5,236,166 ordinary shares issuable upon the exercise of share options outstanding as of December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.19 and $2.30 per ordinary share;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18,617,403 ordinary shares that may be issued under our existing share option plans, as described in &#x201c;Management &#x2014; The Tiziana Life Sciences plc Employee Share Plan with Non<FONT CLASS="nobreak">-Employee</FONT> Sub<FONT CLASS="nobreak">-Plan</FONT> and US Sub<FONT CLASS="nobreak">-Plan</FONT>,&#x201d; as of December<FONT CLASS="nobreak"> </FONT>31, 2018; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>3,617,905 ordinary shares that may be issued upon the exercise of warrants to purchase ordinary shares outstanding as at December<FONT CLASS="nobreak"> </FONT>31, 2018 at exercise prices of between $0.62 and $3.10 per ordinary share.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">To the extent that share options or warrants are exercised, or we issue additional ADSs or ordinary shares in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T12"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">SELECTED CONSOLIDATED FINANCIAL DATA</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following tables set forth our selected consolidated financial data for the periods indicated.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial results in U.S. dollars.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statement of Operations and Comprehensive Loss Data:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="19" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years Ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2015</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2014</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="19" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands except share and per share data)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,510</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,015</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,007</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,609</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,309</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,417</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,602</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,872</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(3,557</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,189</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,617</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(13,166</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,497</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,617</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(13,166</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,497</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(86</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax provision</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">99</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to ordinary shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,716</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,770</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(13,193</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,484</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive loss:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">650</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,063</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(942</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total comprehensive loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,646</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,120</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,130</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,426</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted net loss per ordinary share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.24</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Balance Sheet Data:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="15" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2015</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2014</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="15" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands except share and per share data)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,304</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,802</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,128</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,530</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Working capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">514</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,302</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,054</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,540</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,768</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,920</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,231</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,640</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,832</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; equity/(deficit)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">519</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,278</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,088</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,540</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,768</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T13"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>AND RESULTS OF OPERATIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of our financial condition and results of operations together with &#x201c;Selected Consolidated Financial Data&#x201d; and our consolidated financial statements and the related notes thereto appearing in this prospectus. We present our consolidated financial statements in U.S. dollars and in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Some information included in this discussion and analysis, including statements regarding industry outlook, our expectations regarding our future performance, liquidity and capital resources and other statements regarding our plans and strategy for our business and related financing, are forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements. These forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements are subject to numerous risks and uncertainties. You should read the &#x201c;Risk Factors&#x201d; section of this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements contained in the following discussion and analysis.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">We maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial results in U.S. dollars.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Introduction to Tiziana</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a biotechnology company that is focused on the discovery and development of novel molecules and related diagnostics to treat high unmet medical needs in oncology and immunology. Our mission is to design and deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical development expertise. We employ a lean and virtual research and development, or R&amp;D, model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in immunology is Foralumab (TZLS<FONT CLASS="nobreak">-401</FONT>), which we believe is the only fully human anti<FONT CLASS="nobreak">-CD3</FONT> mAb in clinical development. We believe that based on the concepts of mucosal tolerance, oral or nasal administration of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects. We believe the switch from intravenous inflammation to oral and nasal administration is a &#x2018;game changer&#x201d; for treatment with mAbs as it could improve patient&#x2019;s compliance and safety. MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers and autoimmune diseases. The global market opportunity for mAb therapeutics is greater than $86<FONT CLASS="nobreak"> </FONT>billion. Generation of antibodies for use in humans developed in animals, lead to strong, immune responses limiting their effectiveness and potentially leading to severe side effects. A process known as &#x201c;humanization&#x201d; removes most of the animal components of the antibody thereby lowering the immune response from the human immune system. The entire omission of other animal material, as in fully human antibodies, is the optimal goal to avoid incompatibility with the human immune system.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in oncology is Milciclib (TZLS<FONT CLASS="nobreak">-201</FONT>), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin<FONT CLASS="nobreak">-dependent</FONT> kinases, or CDKs, and Src family kinases. CDKs are a highly conserved family of enzymes that phosphorylate a specific group of proteins that are involved in regulating the cell cycle. The cell cycle is a series of events that takes place in cells leading to division and duplication of its DNA to produce two daughter cells. Src family kinases are non<FONT CLASS="nobreak">-receptor</FONT> tyrosine kinase proteins encoded by the Src gene also involved in regulating cell growth and potential transformation of normal cells to cancer cells. We also have a drug discovery pipeline of small molecule NCEs, and biologics. Milciclib has Orphan Drug Designation (ODD) in the U.S. and EU for thymic cancer (thymic epithelial tumor or TET) such as thymic carcinoma and thymoma.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We are developing Foralumab, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Novimmune, in December 2014, as a potential treatment for NASH, and Crohn&#x2019;s disease as well as neurodegenerative diseases such as MS. To date, Foralumab has been studied in one Phase 1 and two Phase 2a clinical trials conducted by Novimmune in 68 patients dosed by the intravenous route of administration. In the Novimmune intravenous trails, Foralumab was observed to be well<FONT CLASS="nobreak">-tolerated</FONT> and immunologic findings are ongoing. In the Novimmune intravenous trials Foralumab was well tolerated and produced immunologic effects consistent with clinical benefits while demonstrating mild to moderate IRRs. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;"> We planned to first investigate orally and nasally administered Foralumab for its safety and immunomodulatory activity in healthy volunteers in separate Phase 1 clinical trials. A Phase I single site, double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT>, dose<FONT CLASS="nobreak">-ranging</FONT> clinical study dosed intranasally in healthy volunteers was initiated in November 2018 to evaluate safety and biomarkers of immunomodulation of clinical responses planned in healthy volunteers to dose Foralumab intranasally. in collaboration with Brigham and Women&#x2019;s Hospital, Harvard Medical School, Boston, MA. This clinical trial was recently completed in July 2019 in which 18 subjects received Foralumab treatment and 9 patients received placebo. All nasal doses were well tolerated, and no drug related safety issues were reported at any of the doses. Biomarker analysis showed significant positive immune effects, that were most prominent in the 50 &#x00b5;g cohort with minimal immunomodulatory effects at the 10 &#x00b5;g and 250 &#x00b5;g doses. In addition, we submitted an IND on March<FONT CLASS="nobreak"> </FONT>18, 2019 for the oral formulation, to the FDA. The FDA requested safety data from the phase 1 trial with nasal administration of Foralumab to justify the proposed dose<FONT CLASS="nobreak">-range</FONT> for the phase 1 trial with oral administration of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. We withdrew the IND on April<FONT CLASS="nobreak"> </FONT>17, 2019. A third IND was submitted to the FDA on July<FONT CLASS="nobreak"> </FONT>23, 2019 for a Phase I trial in healthy volunteers using orally administered Foralumab with an intent to treat pMS. On September<FONT CLASS="nobreak"> </FONT>9, 2019, the FDA granted approval to initiate the Phase I clinical trials to evaluate the safety and pharmacokinetics of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. Based on successful Phase 1 data, we intend to conduct a Phase 2 study using Crohn&#x2019;s Disease patients starting in the second half of 2020 and file an IND for a Phase 2 trial using NASH patients. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">We are developing Milciclib, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Nerviano, in January 2015, as a potential treatment for HCC. A novel feature of Milciclib is its ability to reduce levels of microRNAs, miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT>. MicroRNAs are small RNA molecules that play a significant role in the regulation of gene expression. miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT> are believed to be linked to the development of blood supply in cancer tumors. Levels of these microRNAs are consistently elevated in HCC patients and may contribute towards resistance to treatment with Sorafenib, a multikinase inhibitor (a drug which may inhibit the cellular division and proliferation associated with certain cancers) often prescribed to HCC patients as the SOC. To date, Milciclib has been studied in a total of eight Phase 1 and Phase 2 clinical trials in a total of 316 patients conducted by Nerviano. In these trials, Milciclib was well<FONT CLASS="nobreak">-tolerated</FONT> with minimal adverse events. We initiated a Phase 2a trial for Milciclib as a monotherapy in patients with HCC in the third quarter of 2017. This trial is a single<FONT CLASS="nobreak">-arm</FONT>, repeated<FONT CLASS="nobreak">-dose</FONT> (100 mg once daily; 4 days on/3 days off every 4 weeks defining each cycle), 6<FONT CLASS="nobreak">-month</FONT> duration study to evaluate the safety, tolerability and anti<FONT CLASS="nobreak">-tumor</FONT> activity of Milciclib in Sorafenib<FONT CLASS="nobreak">-refractory</FONT> or intolerant patients with unresectable or metastatic advanced HCC, the most common form of liver cancer. Enrollment of 31 patients in Italy, Greece, and Israel was completed in November 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;"> In March 2019, the IDMC reviewed safety data from patients as of February<FONT CLASS="nobreak"> </FONT>26, 2019 and concluded that the administration of Milciclib to patients with advanced HCC was not associated with unexpected signs or signals of toxicity. 28 out of 31 treated patients were evaluable, 14 completed the 6<FONT CLASS="nobreak">-month</FONT> duration study. The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable. No drug<FONT CLASS="nobreak">-related</FONT> deaths were recorded. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">Cumulative Patient Exposure in Milciclib Clinical Studies:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Clinical Study</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Drug</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Indication</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number of <BR>Patients Treated</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-001 Phase 1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Solid tumors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-002 Phase 1 / Phase 2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Malignant glioma (Phase 1) Glioblastoma (Phase 2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-003 Phase 1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Solid tumors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-004 Phase 1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib + gemcitabine</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Solid tumors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-005/-006/-007 Phase 2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Malignant Pleural Mesothelioma (-005) Thymic carcinoma and malignant thymoma (-006 and -007)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">CDKO-125a-010 Phase 2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">HCC monotherapy</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total Patients Exposed</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">316</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">Source: Development Safety Update Report No.<FONT CLASS="nobreak"> </FONT>8, February<FONT CLASS="nobreak"> </FONT>28, 2019, Tiziana Life Sciences plc; Investigator Brochure, Version<FONT CLASS="nobreak"> </FONT>14, 2019.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since our inception in March 2014, we have devoted substantially all our resources to conducting preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the sale of ordinary shares. Through December<FONT CLASS="nobreak"> </FONT>31, 2018, we had received net cash proceeds of $39.7<FONT CLASS="nobreak"> </FONT>million from sales of our ordinary shares, issuance of convertible loans, short term loans and warrants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since our inception, we have incurred operating losses. Our net loss after taxation was $8.0<FONT CLASS="nobreak"> </FONT>million for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, $8.7m for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2017 and $9.8m for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2016 respectively. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, we had cash and cash equivalents of $5.3<FONT CLASS="nobreak"> </FONT>million.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect to continue to incur significant expenses for the foreseeable future as we advance our product candidates through preclinical and clinical development and seek regulatory approval and pursue commercialization of any approved product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Trend information</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Recent developments</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> In March 2019, we announced the submission of an IND to the FDA (Liver Division) to initiate a Phase 1 clinical trial of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. This single<FONT CLASS="nobreak">-site</FONT> clinical study is expected to enroll 36 subjects and it will be conducted at the BWH, Harvard Medical School. The primary objective of this study is to evaluate safety, tolerability and immunomodulatory effects of orally administered Foralumab in healthy volunteers with a dose<FONT CLASS="nobreak">-escalating</FONT> regimen comprising of placebo, 1.25, 2.50 and 5.0 mg/day for 5 consecutive days. The trial will also investigate the established biomarkers with anti<FONT CLASS="nobreak">-inflammatory</FONT> effects and stimulation of T regulatory cells. The FDA requested safety data from the phase 1 trial with nasal administration of Foralumab to justify the proposed dose<FONT CLASS="nobreak">-range</FONT> for the phase 1 trial with oral administration of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. We withdrew the current IND on April<FONT CLASS="nobreak"> </FONT>17, 2019. A Type B pre<FONT CLASS="nobreak">-IND</FONT> meeting was held with the FDA (GI division, Crohn&#x2019;s Disease) on July<FONT CLASS="nobreak"> </FONT>24, 2019. The FDA provided clear guidance on design of the clinical trials in healthy subjects. A revised IND will be submitted following FDA review of safety data from the nasal trial. The FDA (Neurology Division) approved initiation of a Phase I trial of orally administered enteric<FONT CLASS="nobreak">-coated</FONT> capsule formulation of Foralumab in healthy subjects in the second half of 2019 following submission of an IND on July<FONT CLASS="nobreak"> </FONT>23, 2019 with an intent to treat pMS patients. We expect to initiate a Phase 1 trial of the oral, enteric capsule formulation of Foralumab in healthy subjects in the second half of 2019. Based on successful Phase 1 data, we intend to conduct a Phase 2 study using Crohn&#x2019;s Disease patients starting in the second half of 2020 and file an IND for a Phase 2 trial using NASH patients. </P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Legal proceedings</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material legal proceedings.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign currency translations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year<FONT CLASS="nobreak">-end</FONT> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The financial statements of overseas subsidiary undertakings are translated into U.S. dollars on the following basis:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Assets and liabilities at the rate of exchange ruling at the year<FONT CLASS="nobreak">-end</FONT> date.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Profit and loss account items at the average rate of exchange for the year.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Components of Our Results of Operations</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Revenues</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Operating Expenses</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">R&amp;D expenses consist primarily of costs incurred in connection with the R&amp;D of our product candidates and are expensed as incurred. These expenses consist of:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>manufacturing scale<FONT CLASS="nobreak">-up</FONT> expenses and the cost of acquiring and manufacturing materials for preclinical studies and clinical trial materials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>employee<FONT CLASS="nobreak">-related</FONT> expenses, including salaries, related benefits, travel and share<FONT CLASS="nobreak">-based</FONT> compensation expense for employees engaged in R&amp;D functions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>costs related to compliance with regulatory requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>facilities costs, depreciation and other expenses, which include rent and utilities; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>fees for maintaining our third<FONT CLASS="nobreak">-party</FONT> licensing agreements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Our direct R&amp;D expenses are tracked on a program<FONT CLASS="nobreak">-by-program</FONT> basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development activities. Our direct R&amp;D expenses by program also include fees incurred under our license agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the R&amp;D as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">The table below summarizes our R&amp;D expenses incurred by program:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Direct research and development expense by program:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foralumab</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,261</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,202</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Milciclib</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,581</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,625</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">BCL-3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">347</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">TZLS-0501</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">StemPrintER</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">166</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,201</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total direct research and development expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,008</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,375</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Indirect research and development expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">640</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total research and development expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,510</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,015</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">R&amp;D activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later<FONT CLASS="nobreak">-stage</FONT> clinical trials and related product manufacturing expenses. As a result, we expect that our R&amp;D expenses will increase substantially over the next several years as we increase personnel costs and prepare for regulatory filings related to our product candidates. We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements to acquire the rights related to our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with development and commercialization, including the uncertainty of:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>establishing an appropriate safety profile with IND- and CTA<FONT CLASS="nobreak">-enabling</FONT> studies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>successful patient enrollment in, and the initiation and completion of, clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>establishing commercial manufacturing capabilities or making arrangements with third<FONT CLASS="nobreak">-party</FONT> manufacturers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>development and timely delivery of commercial<FONT CLASS="nobreak">-grade</FONT> drug formulations that can be used in our clinical trials and for commercial launch;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>significant and changing government regulation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>maintaining a continued acceptable safety profile of the product candidates following approval.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">General and Administrative Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">General and administrative expenses consist primarily of salaries, related benefits, travel and share<FONT CLASS="nobreak">-based</FONT> compensation expense for personnel in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting and audit services.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Other Income (Expense)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Other expense consists of interest on a convertible loan note.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Taxation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under UK tax legislation, small and medium entity R&amp;D relief allows us to claim back up to 14.5% of our surrenderable losses as a tax cash credit.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Results of Operations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The results of operations that follow reflect the historic periods under review and should not be taken as indicative of future performance.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Comparison of Years Ended December 31, 2018 and 2017</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following tables summarizes our results of operations for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="11" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year Ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="11" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousands)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating Expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,510</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,015</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">505</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,417</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,601</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">184</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Operating Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,616</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">689</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Income/ (Expense)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax provision</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss for the year</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,716</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">722</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive loss:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Currency translation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(90</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive (Loss)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,646</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">632</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Research and development activities were $5.5<FONT CLASS="nobreak"> </FONT>million for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018 compared to $6<FONT CLASS="nobreak"> </FONT>million for the year ended December<FONT CLASS="nobreak"> </FONT>30, 2017. In the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018 the research and development activities were focused on the Milciclib and Foralumab projects. The slowdown in activities for StemPrinER enabled an extra $1<FONT CLASS="nobreak"> </FONT>million to be used for the continuation of Phase 2 clinical trials in Foralumab.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">General and Administrative Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">General and administrative expenses were $4.4<FONT CLASS="nobreak"> </FONT>million and $4.6<FONT CLASS="nobreak"> </FONT>million for the years ended December<FONT CLASS="nobreak"> </FONT>30, 2018 and 2017, respectively. Within general and administrative expenses, there were decreases in consultancy fees of $0.2<FONT CLASS="nobreak"> </FONT>million.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Income Tax Credit</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Income tax credits of $1.9<FONT CLASS="nobreak"> </FONT>million and $1.9<FONT CLASS="nobreak"> </FONT>million are recognized for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, respectively. The credits are obtained at a rate of 14.5% of 230% of our qualifying research and development expenditure, and the increase in the credit amount was primarily attributable to a true up on the amount claimed for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2017, 2016, and 2015.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since our inception, we have not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have funded our operations to date primarily with proceeds from the sale of ordinary shares, American Depository Shares, or ADSs, and convertible loan notes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As of December<FONT CLASS="nobreak"> </FONT>31, 2018, we had cash and cash equivalents of $5.3<FONT CLASS="nobreak"> </FONT>million.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Through December<FONT CLASS="nobreak"> </FONT>31, 2018, we had received net cash proceeds of $39.7<FONT CLASS="nobreak"> </FONT>million from sales of our ordinary shares, issuance of convertible loan notes, conversion of warrants and long term loan agreements In November 2018, in our initial public offering in the United States, we received net proceeds of $2.8<FONT CLASS="nobreak"> </FONT>million from the issuance and sale of 442,910 American Depositary Shares which represent 4,429,100 ordinary shares.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Cash Flows</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table summarizes our cash flows for each of the periods presented:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,551</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,533</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in investing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,041</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,542</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of exchange rate changes on cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(249</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">254</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net decrease in cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,241</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,738</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Net Cash Used in Operating Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our use of cash in each of the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, resulted primarily from our net losses, adjusted for non<FONT CLASS="nobreak">-cash</FONT> charges and changes in components of working capital. Net cash used in operating activities of $4.6<FONT CLASS="nobreak"> </FONT>million during the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018 decreased by $3.0<FONT CLASS="nobreak"> </FONT>million compared to the year ended December<FONT CLASS="nobreak"> </FONT>31, 2017. The decrease in net cash used in operating activities was primarily due to the cash inflow from the R&amp;D taxation credit.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Net Cash Used in Investing Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">During the year ended December<FONT CLASS="nobreak"> </FONT>31, 2017, we used $0.1<FONT CLASS="nobreak"> </FONT>million of cash in investing activities for the purchases of property and equipment and the acquisition of SharDNA Srl.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Net Cash Provided by Financing Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">During the years ended December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, net cash provided by financing activities was $10<FONT CLASS="nobreak"> </FONT>million and $1.5<FONT CLASS="nobreak"> </FONT>million, respectively, consisting of net cash proceeds from our sale and issuance of ordinary shares and convertible loan notes.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Funding Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities, manufacturing and clinical trials of our product candidates and as we:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>seek regulatory approvals for any product candidates that successfully complete clinical trials;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>hire additional clinical, medical and development personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>expand our infrastructure and facilities to accommodate our growing employee base; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>maintain, expand and protect our intellectual property portfolio.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We believe that our existing cash along with the proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements for at least the 12<FONT CLASS="nobreak"> </FONT>months following the date of this prospectus. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we receive regulatory approval for our other product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs and timing of hiring new employees to support our continued growth;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property<FONT CLASS="nobreak">-related</FONT> claims; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the extent to which we acquire technologies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings. To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted. If we raise additional funds through other third<FONT CLASS="nobreak">-party</FONT> funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Borrowings</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On May 15 2018, we entered into a fixed term unsecured loan agreement with an existing shareholder for $127,369 at an interest rate of 8% per annum to be repaid no later than 24<FONT CLASS="nobreak"> </FONT>months after the date of the agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>22, 2018, we entered into a fixed term unsecured loan agreement with an existing shareholder for $382,107 at an interest rate of 20% per annum to be repaid no later than 24<FONT CLASS="nobreak"> </FONT>months after the date of the agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The May 2018 and June 2018 loans were converted into ordinary shares in November 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>16, 2017, we completed a conversion of all of our outstanding convertible loan notes through the issuance of 28,455,214 ordinary shares.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We did not have during the periods presented, and we do not currently have, any off<FONT CLASS="nobreak">-balance</FONT> sheet arrangements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Tabular Disclosure of Contractual Obligations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table summarizes our contractual commitments and obligations as of December<FONT CLASS="nobreak"> </FONT>31, 2018.</P>
		<P CLASS="H5" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">As at December 31, 2018</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="8" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Payments Due by Period</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(in thousands)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Less than<BR>1 Year</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Between 1 and<BR>5&#x00a0;Years</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Borrowings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease obligations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,114</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">691</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,114</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">691</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T14"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Business</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a biotechnology company that is focused on the discovery and development of novel molecules and related diagnostics to treat high unmet medical needs in oncology and immunology. Our mission is to design and deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical development expertise. We employ a lean and virtual research and development, or R&amp;D, model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in immunology is Foralumab (TZLS<FONT CLASS="nobreak">-401</FONT>), which we believe is the only fully human anti<FONT CLASS="nobreak">-CD3</FONT> monoclonal antibody, or mAb, in clinical development. We believe that based on the concepts of mucosal tolerance, oral or intranasal administration of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects. We believe the switch from intravenous administration to oral and nasal administration is a &#x201c;game changer&#x201d; for treatment with mAbs as it could improve patient&#x2019;s compliance and safety. MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers and autoimmune diseases. The global market opportunity for mAb therapeutics is greater than $86<FONT CLASS="nobreak"> </FONT>billion. Generation of antibodies for use in humans developed in animals, leads to strong, immune responses limiting their effectiveness and potentially leading to severe side effects. A process known as &#x201c;humanization&#x201d; removes most of the animal components of the antibody thereby lowering the immune response from the human immune system. The entire omission of other animal material, as in fully human antibodies, is the optimal goal to avoid incompatibility with the human immune system.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our lead product candidate in oncology is Milciclib (TZLS<FONT CLASS="nobreak">-201</FONT>), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin<FONT CLASS="nobreak">-dependent</FONT> kinases, or CDKs, and Src family kinases. CDKs are a highly conserved family of enzymes that phosphorylate a specific group of proteins that are involved in regulating the cell cycle. The cell cycle is a series of events that takes place in cells leading to division and duplication of its DNA to produce two daughter cells. Src family kinases are non<FONT CLASS="nobreak">-receptor</FONT> tyrosine kinase proteins encoded by the Src gene also involved in regulating cell growth and potential transformation of normal cells to cancer cells. We have a drug discovery pipeline of small molecule new chemical entities, or NCEs, and biologics. Milciclib has Orphan Drug Designation (ODD) in the U.S. and EU for thymic cancer (thymic epithelial tumor or TET) such as thymic carcinoma and thymoma.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are developing Foralumab, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Novimmune SA, or Novimmune, in December 2014, as a potential treatment for non<FONT CLASS="nobreak">-alcoholic</FONT> steatohepatitis, or NASH, and Crohn&#x2019;s disease as well as neurodegenerative diseases such as MS. To date, Foralumab has been studied in one Phase 1 and two Phase 2a clinical trials conducted by Novimmune in 68 patients dosed by the intravenous route of administration. In these trials, Foralumab had a favorable safety profile and was well<FONT CLASS="nobreak">-tolerated</FONT> with an MTD of 1 mg/dose and produced immunologic effects consistent with potential clinical benefit while demonstrating mild to moderate infusion related reactions, or IRR. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We planned to first investigate orally and nasally administered Foralumab for its safety and immunomodulatory activity in healthy volunteers in separate Phase 1 clinical trials. A Phase I single site, double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT>, dose<FONT CLASS="nobreak">-ranging</FONT> clinical study dosed intranasally in healthy volunteers was initiated in November 2018 to evaluate safety and biomarkers of immunomodulation of clinical responses planned in healthy volunteers to dose Foralumab intranasally. in collaboration with Brigham and Women&#x2019;s Hospital, Harvard Medical School, Boston, MA. This clinical trial was recently completed in July 2019 in which 18 subjects received Foralumab treatment and 9 patients received placebo. All nasal doses were well tolerated, and no drug related safety issues were reported at any of the doses. Biomarker analysis showed significant positive immune effects, that were most prominent in the 50 &#x00b5;g cohort with minimal immunomodulatory effects at the 10 &#x00b5;g and 250 &#x00b5;g doses. In addition, we submitted an IND on March<FONT CLASS="nobreak"> </FONT>18, 2019 for the oral formulation, to the FDA. The FDA requested safety data from the phase 1 trial with nasal administration of Foralumab to justify the proposed dose<FONT CLASS="nobreak">-range</FONT> for the phase 1 trial with oral administration of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. We withdrew the IND on April<FONT CLASS="nobreak"> </FONT>17, 2019. A third IND was submitted to the FDA on July<FONT CLASS="nobreak"> </FONT>23, 2019 for a Phase I trial in healthy volunteers using orally administered Foralumab with an intent to treat pMS.  On September<FONT CLASS="nobreak"> </FONT>9, 2019, the FDA granted approval to initiate the Phase&#x00a0;I clinical trials to evaluate the safety and pharmacokinetics of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. Based on successful Phase 1 data, we intend to conduct a Phase 2 study using Crohn&#x2019;s Disease patients starting in the second half of 2020 and file an IND for a Phase 2 trial using NASH patients. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are developing Milciclib, for which we in<FONT CLASS="nobreak">-licensed</FONT> the intellectual property from Nerviano Medical Sciences S.r.l., or Nerviano, in January 2015, as a potential treatment for hepatocellular carcinoma, or HCC. A novel feature of Milciclib is its ability to reduce levels of microRNAs, miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT>. MicroRNAs are small RNA molecules that play a significant role in the regulation of gene expression. miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT> are believed to be linked to the development of blood supply (angiogenesis) in cancer tumors. Levels of these microRNAs are consistently elevated in HCC patients and may contribute towards resistance to treatment with Sorafenib, a multikinase inhibitor (a drug which may inhibit the cellular division and proliferation associated with certain cancers) often prescribed to HCC patients as the SOC. To date, Milciclib has been studied in a total of eight Phase 1 and Phase 2 clinical trials in 316 patients. In these trials, Milciclib was well<FONT CLASS="nobreak">-tolerated</FONT> with minimal adverse events. We initiated a Phase 2a trial for Milciclib as a monotherapy in patients with HCC in the third quarter of 2017. This trial is a single<FONT CLASS="nobreak">-arm</FONT>, repeated<FONT CLASS="nobreak">-dose</FONT> (100 mg once daily; 4 days on/3 days off every 4 weeks defining each cycle), 6<FONT CLASS="nobreak">-month</FONT> duration study to evaluate the safety, tolerability and anti<FONT CLASS="nobreak">-tumor</FONT> activity of Milciclib in Sorafenib<FONT CLASS="nobreak">-refractory</FONT> or intolerant patients with unresectable or metastatic advanced HCC, the most common form of liver cancer. Enrollment of 31 patients in Italy, Greece, and Israel was completed in November 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> In March 2019, the IDMC reviewed safety data from patients as of February<FONT CLASS="nobreak"> </FONT>26, 2019 and concluded that the administration of Milciclib to patients with advanced HCC was not associated with unexpected signs or signals of toxicity. 28 out of 31 treated patients were evaluable, 14 completed the 6<FONT CLASS="nobreak">-month</FONT> duration study. The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable. No drug<FONT CLASS="nobreak">-related</FONT> deaths were recorded. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> As per the study protocol, data collection was limited to 6<FONT CLASS="nobreak">-months</FONT>. Thus, clinical data were not collected from patients under compassionate use treatment. The clinical activity assessment in evaluable patients was based on the investigators&#x2019; review using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>9 out of 14 patients (64.2%) were approved by their respective ethical committees to continue the treatment. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5 of the 9 patients on compassionate use had received Milciclib for a total of<FONT CLASS="nobreak"> </FONT>9,<FONT CLASS="nobreak"> </FONT>9,<FONT CLASS="nobreak"> </FONT>11, 13 and 16<FONT CLASS="nobreak"> </FONT>months. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>As of 1 September 2019, the remaining 4 patients continuing the treatment are in their 10<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> and 12<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> months. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Both median TTP and PFS were 5.9<FONT CLASS="nobreak"> </FONT>months (95% Confidence Interval (&#x201c;CI&#x201d;) 1.5<FONT CLASS="nobreak">-6</FONT>.7<FONT CLASS="nobreak"> </FONT>months) out of the 6<FONT CLASS="nobreak">-months</FONT> duration of the trial. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>17 of 28 (60.7%) evaluable patients showed &#x2018;Stable Disease&#x2019; (SD; met at least once in an 8<FONT CLASS="nobreak">-week</FONT> interval). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>One patient (3.6%) showed &#x2018;Partial Response&#x2019; (PR, unconfirmed). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18 of 28 (64.3%) evaluable patients showed &#x2018;Clinical Benefit Rate&#x2019; defined as CBR=CR+PR+SD (with CR representing Complete Remission). </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since overexpression of CDKs and dysregulation in pRB pathway (regulates transcription factors critical for cell cycle progression) are prominently associated with tumor cell resistance to certain chemotherapeutic drugs, inhibition of multiple CDKs is an appealing approach to improve clinical responses in cancer patient&#x2019;s refractory to existing treatment options. A Phase 1 dose<FONT CLASS="nobreak">-escalation</FONT> study of Milciclib in combination with gemcitabine in patients with refractory solid tumors exhibited clinical activity in patients including those refractory to gemcitabine. We plan to explore combination approach in patients with HCC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A Phase 2b trial for Milciclib in combination with a tyrosine kinase inhibitor (TKI) such as Sorafenib (Nexavar<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT>) or regorafenib (Stivarga<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">&#x00ae; </FONT>), used to treat some types of kidney, liver and thyroid cancers) in patients with HCC is expected to be initiated in the second half of 2019.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we are developing a fully human mAb targeting the IL<FONT CLASS="nobreak">-6R</FONT> (TZLS<FONT CLASS="nobreak">-501</FONT>) for the treatment of inflammatory and autoimmune diseases. We licensed the intellectual property from Novimmune in January 2017. This fully human mAb has a novel mechanism of action, binding to both the membrane<FONT CLASS="nobreak">-bound</FONT> and soluble forms of the IL<FONT CLASS="nobreak">-6R</FONT> as well as depleting circulating levels of the IL<FONT CLASS="nobreak">-6</FONT> in the blood. Excessive production of IL<FONT CLASS="nobreak">-6</FONT> is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications and rheumatoid arthritis, and we believe that TZLS<FONT CLASS="nobreak">-501</FONT> may have potential therapeutic value for these indications.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In preclinical studies, TZLS<FONT CLASS="nobreak">-501</FONT> demonstrated the potential for overcoming the limitations of other IL<FONT CLASS="nobreak">-6</FONT> blocking pathway drugs. Compared to tocilizumab and sarilumab, while binding to the membrane<FONT CLASS="nobreak">-bound</FONT> IL<FONT CLASS="nobreak">-6R</FONT> complex, TZLS<FONT CLASS="nobreak">-501</FONT> has been observed to have a higher affinity for the soluble IL<FONT CLASS="nobreak">-6</FONT> receptor from antibody binding studies conducted in cell culture. TZLS<FONT CLASS="nobreak">-501</FONT> also demonstrated the potential to block or reduce IL<FONT CLASS="nobreak">-6</FONT> signaling in mouse models of inflammation. The soluble form of IL<FONT CLASS="nobreak">-6</FONT> has been implicated to have a larger role in disease progression compared to the membrane- bound form (Kallen, K.J. (2002). &#x201c;The role of trans<FONT CLASS="nobreak">-signaling</FONT> via the agonistic soluble IL<FONT CLASS="nobreak">-6</FONT> receptor in human diseases.&#x201d; Biochimica et Biophysica Acta. 1592 (3): 323&#x2013;343).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Competitive Strengths</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our mission is to design and deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical development expertise. We believe the following strengths will allow us to continue to pursue this mission:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Advanced, novel pipeline</FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;We have an advanced pipeline of novel and proprietary drug candidates, including antibodies and small molecules, to address high unmet medical needs in the inflammation, autoimmune and oncology markets with significant commercial potential.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Proprietary technology</FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;Our proprietary technology enables the development of alternative routes of administration of antibodies, including oral delivery. We believe that oral and nasal routes of delivery will alleviate the significant time and cost burden associated with other routes of administration, including intravenous delivery.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Broad and engaged network of experts.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Our strong relationships with key opinion leaders contribute to our clinical development efforts and position us well to support our products, if approved. Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Kevan Herold, and Dr. Howard Weiner are among   the thought leaders on our scientific advisory committee.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Specialized expertise and focus on oncology and inflammation</FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;Our management team, including Dr.&#x00a0;Kunwar Shailubhai, Jules Jacob, Dr. Priya Eddy and Dr. Vaseem Palejwala, has considerable experience translating technologies from bench to market, and managing the global administration of clinical trials.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Strong intellectual property and know</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">-how</FONT></FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;We believe our proprietary intellectual property portfolio, in<FONT CLASS="nobreak">-licensed</FONT> from Nerviano and Novimmune, provides us with a substantial competitive advantage for the commercial development of small molecule NCEs, and biologics, as well as expanded possibilities for new development programs in the future. We have retained the worldwide development and commercialization rights to all of our product candidates. We have submitted additional patent applications to further strengthen our intellectual property.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Lean research and development model, designed to maximize value</FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;We employ a lean and virtual R&amp;D model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Strategy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our goal is to become a leading biotechnology company focused on developing and delivering therapies and related diagnostics in both oncology and immunology. The key elements of our strategy to achieve this goal are to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Advance the clinical development of orally administered Foralumab for the treatment of NASH and Crohn&#x2019;s disease using a novel and proprietary oral formulation by initiating a Phase 1 trial in the second half of 2019 and a Phase 2 trial in the second half of 2020. In addition, a Phase 1 trial for the first<FONT CLASS="nobreak">-in-human</FONT> evaluation of the intranasal administration of Foralumab in healthy volunteers, for neurodegenerative disease indications such as MS, was initiated in November 2018. Topline results from this study are expected in the second half of 2019.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue to advance the clinical development and obtain regulatory approval for our lead oncology product candidate, Milciclib, as a monotherapy in HCC and as a combination therapy for the treatment of refractory solid tumors (being cancers which are non<FONT CLASS="nobreak">-responsive</FONT> or become resistant to treatment) and HCC by completing the ongoing Phase 2a trial as a monotherapy and initiating a planned Phase 2b trial in combination with a TKI ( Sorafenib or Regorafenib).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue to leverage relationships with key opinion leaders to promote clinical trial success and enhance future commercialization.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Continue preclinical studies and non<FONT CLASS="nobreak">-clinical</FONT> development of our product candidate, TZLS<FONT CLASS="nobreak">-501</FONT>, a fully human mAb targeting the IL<FONT CLASS="nobreak">-6R</FONT> (a biological mAb which may control the proteins involved in cell signaling relevant to many inflammatory diseases and cancers), for treatment of inflammatory and oncology indications.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Opportunistically identify and acquire or in<FONT CLASS="nobreak">-license</FONT> complimentary product and technology candidates.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Seek orphan drug, fast track or breakthrough designation for our product candidates where warranted.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Product Candidates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our product candidate pipeline is set forth below:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="image_01.jpg" STYLE="height:385.28px;width:569.6px;max-width:100%;"></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foralumab (TZLS-401 formerly known as NI-0401)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> We believe Foralumab is the only fully human anti<FONT CLASS="nobreak">-CD3</FONT> mAb in clinical development, in contrast to the previous non<FONT CLASS="nobreak">-human</FONT> or humanized anti<FONT CLASS="nobreak">-CD3</FONT> mAbs. Foralumab targets the CD3 epsilon (CD3<FONT CLASS="CharOverride-4" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b5;</FONT>) receptor, which is a recognized approach for modulating T<FONT CLASS="nobreak">-Cell</FONT> response and achieving immunosuppression. We believe Foralumab could have broad application to autoimmune and inflammatory diseases, such as NASH, Crohn&#x2019;s disease, MS, type<FONT CLASS="nobreak">-1</FONT> diabetes, or T1D, inflammatory bowel disease, psoriasis and rheumatoid arthritis, where modulation of a T<FONT CLASS="nobreak">-cell</FONT> response is desirable. In July 2017, we announced publication of a research article in, Clinical Immunology, entitled: &#x201c;Oral treatment with Foralumab, a fully human anti<FONT CLASS="nobreak">-CD3</FONT> mAb, prevents skin xenograft rejection in humanized mice.&#x201d; We believe this is the first<FONT CLASS="nobreak">-ever</FONT> published report demonstrating the potential of oral therapy with Foralumab for inflammatory diseases and is based on the landmark discovery by Prof. Howard Weiner of Harvard University, one of our Scientific Advisory Committee members. We planned to first investigate orally and nasally administered Foralumab for its safety and immunomodulatory activity in healthy volunteers in separate Phase 1 clinical trials. A Phase I single site, double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT>, dose<FONT CLASS="nobreak">-ranging</FONT> clinical study dosed intranasally in healthy volunteers was initiated in November 2018 to evaluate safety and biomarkers of immunomodulation of clinical responses planned in healthy volunteers to dose Foralumab intranasally. in collaboration with Brigham and Women&#x2019;s Hospital, Harvard Medical School, Boston, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;"> MA. This clinical trial was recently completed in July 2019 in which 18 subjects received Foralumab treatment and 9 patients received placebo. All nasal doses were well tolerated, and no drug related safety issues were reported at any of the doses. Biomarker analysis showed significant positive immune effects, that were most prominent in the 50 &#x00b5;g cohort with minimal immunomodulatory effects at the 10 &#x00b5;g and 250 &#x00b5;g doses. In addition, we submitted an IND on March<FONT CLASS="nobreak"> </FONT>18, 2019 for the oral formulation, to the FDA. The FDA requested safety data from the phase 1 trial with nasal administration of Foralumab to justify the proposed dose<FONT CLASS="nobreak">-range</FONT> for the phase 1 trial with oral administration of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. We withdrew the IND on April<FONT CLASS="nobreak"> </FONT>17, 2019. A third IND was submitted to the FDA on July<FONT CLASS="nobreak"> </FONT>23, 2019 for a Phase I trial in healthy volunteers using orally administered Foralumab with an intent to treat pMS. On September<FONT CLASS="nobreak"> </FONT>9, 2019, the FDA granted approval to initiate the Phase I clinical trials to evaluate the safety and pharmacokinetics of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. Based on successful Phase 1 data, we intend to conduct a Phase 2 study using Crohn&#x2019;s Disease patients starting in the second half of 2020 and file an IND for a Phase 2 trial using NASH patients. </P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Non-alcoholic steatohepatitis</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Non<FONT CLASS="nobreak">-alcoholic</FONT> fatty liver disease, or NAFLD, comprises a spectrum of progressive liver diseases, which currently affects approximately one<FONT CLASS="nobreak">-third</FONT> of the western world. It is associated with liver<FONT CLASS="nobreak">-related</FONT> morbidity and mortality and with increased risk of cardiovascular disease, type 2 diabetes mellitus, or T2DM, hyperlipidemia (acquired or genetic disorders resulting in elevated levels of lipids circulating in the blood) and abdominal obesity. NASH, one of the manifestations of NAFLD, leads to inflammation and fat and fibrous tissue buildup in the liver, and elevated liver enzymes levels, and can lead to liver cirrhosis, end<FONT CLASS="nobreak">-stage</FONT> liver disease and primary liver cancer, or HCC (as shown in the graphic on page 82 under &#x201c;&#x2014; Milciclib &#x2014; Hepatocellular Cancer.&#x201d; NASH is predicted to become the leading cause of liver transplantation in the U.S. by 2020. Drug companies and liver organizations have signaled that NASH medicines represent a $35<FONT CLASS="nobreak"> </FONT>billion market. Both genetic predisposition and environmental factors have been implicated in its onset, and inflammation and associated fibrogenesis contribute to its perpetuation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Chronic inflammatory processes involve an imbalance in pro<FONT CLASS="nobreak">-versus</FONT> anti<FONT CLASS="nobreak">-inflammatory</FONT> cytokines (small proteins which are secreted by certain cells of the immune system and have an effect on other cells), altered insulin responses due to inflammation and fat and fibrous tissue buildup. Therapeutic avenues must provide for multifactorial effects, with focus on reduced insulin resistance and inflammatory processes. Mild inflammation imparts a hepatoprotective effect (preventing damage to the liver), while excessive inflammation triggers hepatocyte damage (damage to cell membranes and tissue death) and irreversible liver damage, fibrosis and carcinogenesis. Such detrimental effects are associated with overexpression of inflammatory genes and increased activity of Kupffer cells, natural killer T<FONT CLASS="nobreak">-cells</FONT>, hepatic stellate cells, sinusoidal endothelial cells, dendritic cells, monocytes and lymphocytes, which secrete a range of proinflammatory factors, including cytokines, chemokines, lipid messengers and reactive oxygen species.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">While several drugs, such as pioglitazone (Actos<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT>), have proven effective in improving NASH<FONT CLASS="nobreak">-related</FONT> features, side effects, including weight gain, adipose tissue insulin resistance, increased risk of bone fracture in women, congestive heart failure, heightened risk of bladder cancer, increased mortality, risk of hemorrhage stroke, prostate cancer in men over 50 years of age, pruritus and increased low<FONT CLASS="nobreak">-density</FONT> lipoprotein cholesterol have been measured following their chronic use.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Crohn&#x2019;s Disease</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Crohn&#x2019;s disease is a relapsing, transmural inflammatory disease of the gastrointestinal mucosa that can affect all parts of the intestinal tract as well as extra<FONT CLASS="nobreak">-intestinal</FONT> organs. Crohn&#x2019;s disease affects between 400,000 and 600,000 people in North America. Prevalence estimates for Northern Europe have ranged from 27&#x2013;48 per 100,000. Although the incidence and prevalence of Crohn&#x2019;s disease are beginning to stabilize in high<FONT CLASS="nobreak">-incidence</FONT> areas such as northern Europe and North America, they continue to rise in low<FONT CLASS="nobreak">-incidence</FONT> areas such as southern Europe, Asia, and much of the developing world. Differences in incidence across age, time, and geographic region suggest that environmental factors significantly modify the expression of Crohn&#x2019;s disease. The strongest environmental factors identified are cigarette smoking and appendectomy. The disease affects slightly more females than males and is most commonly diagnosed in young adults, e.g. late adolescence to the third decade of life (Kim, S.C. and G.D. Ferry. Gastroenterology (June 2004) 126 (6): 1550<FONT CLASS="nobreak">-1560</FONT>). It is expected that the Crohn&#x2019;s disease treatment market will exceed $10<FONT CLASS="nobreak"> </FONT>billion by 2025. Although the exact etiology remains unknown, the occurrence of Crohn&#x2019;s disease is strongly associated with mutations of a receptor for microbial pathogens, or NOD2, that lead to increased activation of antigen presenting cells </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">and a defect in the release of antimicrobial defensins. It is now widely accepted that as a result of this altered balance of immune homeostasis, exposure to commensal bacterial antigens causes increased stimulation and proliferation of mucosal T<FONT CLASS="nobreak">-lymphocytes</FONT>, leading to immune inflammation. Additional pathogenic mechanisms may include a defect in T<FONT CLASS="nobreak">-cell</FONT> programmed death, or apoptosis, and possibly a defect in regulatory T<FONT CLASS="nobreak">-cell</FONT> function.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Crohn&#x2019;s disease usually presents as acute or chronic bowel inflammation then the inflammatory process evolves toward one of two patterns of the disease: a fibrostenotic<FONT CLASS="nobreak">-obstructing</FONT> pattern or a penetrating<FONT CLASS="nobreak">-fistulous</FONT> pattern, each with different treatments and prognoses. The site of disease influences the clinical manifestations and can include diarrhea, abdominal pain, fever, clinical signs of bowel obstruction, as well as passage of blood or mucus or both.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Up to 25% of patients with Crohn&#x2019;s disease will develop extraintestinal disease manifestations which usually respond to treatment of the underlying disease (e.g. arthritis, uveitis, primary sclerosing cholangitis) (Harrison&#x2019;s Principles of Internal Medicine 2008).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Crohn&#x2019;s disease is histologically characterized by a discontinuous transmural granulomatous inflammation of the intestinal wall, but typical granulomas are found on mucosal biopsies in a minority of subjects. Surgical resection reveals granulomas in about half of cases (Harrison&#x2019;s 17<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">th</FONT> edition).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The pharmacological management of Crohn&#x2019;s disease is based on the control of the inflammatory process. Current treatment regimens include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>anti<FONT CLASS="nobreak">-inflammatory</FONT> drugs (e.g. corticosteroids, aminosalicylates), which are the first<FONT CLASS="nobreak">-line</FONT> treatment to induce remission in acute active disease;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>immunosuppressants such as azathioprine, 6<FONT CLASS="nobreak">-mercaptopurine</FONT> and methotrexate (Feagan, 2000) which are used to maintain remission or treating chronic active disease; biologic immunotherapies (e.g. anti<FONT CLASS="nobreak">-TNF</FONT> mAbs including infliximab and adalimumab) which are used to induce and maintain remission.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All of these treatments have limited long<FONT CLASS="nobreak">-term</FONT> efficacy and potential for serious adverse effects (Targan, 1997; Present, 1999).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Previously reported studies using anti<FONT CLASS="nobreak">-cluster</FONT> definition<FONT CLASS="nobreak"> </FONT>4, or anti<FONT CLASS="nobreak">-CD4</FONT>, and tumor necrosis factor, or TNF, binding mAbs provide a strong rationale for targeting T<FONT CLASS="nobreak">-cells</FONT> in Crohn&#x2019;s disease (van Deventer et. al. Intl. J. Clin. Pharm. (1997) 19(2): 55<FONT CLASS="nobreak">-9</FONT>). It is now known that TNF targeting mAbs in Crohn&#x2019;s disease and IBD are effective because of the bringing about of programmed cell death (apoptosis) of activated T<FONT CLASS="nobreak">-lymphocytes</FONT> rather than neutralization of soluble TNF (Chowers et.al., Current Drug Targets (2010) 11: 138<FONT CLASS="nobreak">-142</FONT>; Atreya et. al. Gastroenterology (2011) 14<FONT CLASS="nobreak">1 (6</FONT>): 2026<FONT CLASS="nobreak">-2038</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, there are few published clinical data on the use of anti<FONT CLASS="nobreak">-CD3</FONT> mAbs in subjects with Crohn&#x2019;s disease. One product in development, visilizumab (Nuvion&#x00ae;, PDL Biopharma) is a humanized IgG2 anti<FONT CLASS="nobreak">-CD3</FONT> monoclonal antibody has been tested in the clinical setting. Two studies with visilizumab in patients with severe Crohn&#x2019;s disease have been performed: An open<FONT CLASS="nobreak">-label</FONT> study (ClinicalTrials.gov Identifier: NCT00267709) in patients with Crohn&#x2019;s disease having peri<FONT CLASS="nobreak">-anal</FONT> fistulas and an open<FONT CLASS="nobreak">-label</FONT> study (ClinicalTrials.gov Identifier: NCT00267722) in patients with moderate<FONT CLASS="nobreak">-to-severe</FONT> inflammatory, non<FONT CLASS="nobreak">-structuring</FONT>, non<FONT CLASS="nobreak">-penetrating</FONT> Crohn&#x2019;s disease. Eighteen patients were expected to be enrolled in each study. Results form this study suggested that 10 &#x00b5;g/kg visilizumab administered by IV bolus injection appeared to have promising clinical activity as determined by a drop in the Crohn&#x2019;s Disease Activity Index (CDAI) scores of 100 points.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Preliminary results from the second study suggested that two 10 &#x03bc;g/kg doses of visilizumab administered by IV bolus injection on consecutive days appeared to have clinical activity. Ten of the 14 patients reported a clinical response by day<FONT CLASS="nobreak"> </FONT>59, as determined by a drop in the Crohn&#x2019;s disease Activity Index, or CDAI score, of 100 points. Five patients achieved a complete remission, as defined by a CDAI score of &lt;150 during the 59 days. Of note, two patients who never responded to infliximab, as well as seven patients who lost their response to infliximab, responded to visilizumab.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Multiple Sclerosis</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">MS is an inflammatory<FONT CLASS="nobreak">-mediated</FONT> demyelinating disease of the human central nervous system. The disease develops in young adults with a complex predisposing genetic trait and most likely involves an environmental insult </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">such as a viral infection to trigger the disease. The activation of CD4+ autoreactive T cells and their differentiation are crucial initial steps in the progression of this disease. The therapeutic use of monoclonal antibodies was initially viewed with great skepticism owing to the high rates of sensitization against mouse proteins, their pharmacokinetic properties, and the difficulties in their production. However, most of these problems have been overcome, and monoclonal antibodies are now among the most promising therapies for MS.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Autoimmune and Inflammatory Diseases</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Autoimmune diseases are primarily due to a malfunction when the immune system attacks certain cells in the body as foreign invaders. This can result in irreparable damage to critical organs and tissues eventually resulting in autoimmune diseases.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In humans, CD3<FONT CLASS="nobreak">-epsilon</FONT> is encoded by the CD3<FONT CLASS="CharOverride-4" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b5;</FONT> gene on Chromosome 11. The CD3<FONT CLASS="CharOverride-4" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b5;</FONT> molecule, along with four other membrane<FONT CLASS="nobreak">-bound</FONT> polypeptides (CD3<FONT CLASS="nobreak">-gamma</FONT>, <FONT CLASS="nobreak">-delta</FONT>, <FONT CLASS="nobreak">-zeta</FONT>, and <FONT CLASS="nobreak">-eta</FONT>) form the CD3 complex, which is associated with the T<FONT CLASS="nobreak">-cell</FONT> receptor. Upon antigen bindings, the CD3 complex sends signals through the cell membrane to the cytoplasm inside the T<FONT CLASS="nobreak">-cell</FONT>. This leads to activation of the T<FONT CLASS="nobreak">-cell</FONT> that rapidly divides to produce new T<FONT CLASS="nobreak">-cells</FONT> sensitized to fight the particular antigen to which the TCR was exposed. While T<FONT CLASS="nobreak">-cell</FONT> activation is critical for the human immune system to properly fight bacterial, viral or parasitic infections, abnormal T<FONT CLASS="nobreak">-cell</FONT> induction can cause and worsen numerous human diseases, including T<FONT CLASS="nobreak">-cell</FONT> lymphoma and leukemia, human malignancies, autoimmune disorders, cardiovascular disease and transplant rejection.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Our Solution</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We believe Foralumab is the only fully human anti<FONT CLASS="nobreak">-CD3</FONT> mAb in clinical development. Since the discovery of the hybridoma technology, a method to generate large quantities of a single (monoclonal) antibody, the production and manufacture of mAbs has become widely available showing promise in several autoimmune and inflammatory disease clinical trials and therapeutic utility in animal models. The first murine anti<FONT CLASS="nobreak">-CD3</FONT> mAb (IgG2a) was developed and approved by the FDA in 1985 under the name of muromonab, OKT3, (Ortho Kung T3; Orthoclone&#x00ae;) to treat allograft rejection in kidney, liver and heart transplantation by exerting its potent immunosuppressive effects, mainly due to depletion of T<FONT CLASS="nobreak">-cells</FONT> in tissues and thereby preventing rejection of the allografts. Subsequently, OKT3 was administered in clinical trials to patients with MS, T1D, inflammatory bowel disease, rheumatoid arthritis and NASH. Although showing promise to alleviate the disease process, the mAb being of murine origin and extremely immunogenic in humans, was associated with a wide range of side effects that included the typical Cytokine Release Syndrom (CRS) or flu<FONT CLASS="nobreak">-like</FONT> syndrome, limiting its clinical development. The side effect profile of OKT3 is a consequence of T<FONT CLASS="nobreak">-cell</FONT> activation resulting in the release of numerous cytokines into the systemic circulation. These shortcomings of the murine OKT3 led to the development of a new generation of anti<FONT CLASS="nobreak">-CD3</FONT> mAbs using genetic engineering of the mAb structure, as depicted below.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="image_03.jpg" STYLE="height:266.24px;width:569.6px;max-width:100%;"></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Foralumab dosed intravenously has been observed to alter T<FONT CLASS="nobreak">-cell</FONT> function via antigenic modulation, that is, removal of the CD3/TCR complex from the T<FONT CLASS="nobreak">-cell</FONT> surface. Modulation has two therapeutic benefits:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>It transiently renders the T<FONT CLASS="nobreak">-cells</FONT> incapable of recognizing an antigen and thus unable to orchestrate an immune response such as an allograft rejection; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>It has a favorable long<FONT CLASS="nobreak">-term</FONT> effect on generation and maintenance of regulatory T<FONT CLASS="nobreak">-cells</FONT>, or Tregs, a specialized subset of T<FONT CLASS="nobreak">-cells</FONT> that promote immunological tolerance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In comparison with the two other anti<FONT CLASS="nobreak">-CD3</FONT> mAbs evaluated in patients with T1D (otelixizumab and teplizumab), Foralumab, being fully human, was less mitogenic (capable of causing cell division), therefore allowing re<FONT CLASS="nobreak">-treatment</FONT>, and to have a better risk/benefit profile. As such, Foralumab was previously developed by Novimmune as an intravenous formulation for the treatment of autoimmune indications: Crohn&#x2019;s disease and in renal allograft recipients.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Further, recent data from studies conducted in the laboratories of our Scientific Advisory Committee members, Prof. Howard Weiner of Harvard University and Prof. Kevan Herold of Yale University, suggest that oral administration of Foralumab has the potential for therapeutic utility while minimizing toxicity associated with intravenous administration, such as CRS.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The mechanism of action of orally administered enteric<FONT CLASS="nobreak">-coated</FONT> Foralumab capsules is indicated below:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="image_04.jpg" STYLE="height:313.6px;width:522.24px;max-width:100%;"></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Importantly, recent clinical studies conducted by Prof. Yaron Ilan with oral administration of anti<FONT CLASS="nobreak">-CD3</FONT> (OKT3; murine mAb) in HCV infected patients (non<FONT CLASS="nobreak">-respondents</FONT>) and in NASH patients suggested that the treatment was well<FONT CLASS="nobreak">-tolerated</FONT> and produced immunologic effects consistent with potential clinical benefits.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, increasing appreciation for the gut<FONT CLASS="nobreak">-liver</FONT> cross<FONT CLASS="nobreak">-talk</FONT> and of its role in the initiation of NASH<FONT CLASS="nobreak">-associated</FONT> inflammation and fibrogenesis has led to the understanding that systemic inflammatory processes can be alleviated by modulating the gut immune system, without inducing generalized immunosuppression. This has been achieved in multiple approaches, including oral administration of fatty liver<FONT CLASS="nobreak">-derived</FONT> proteins, anti<FONT CLASS="nobreak">-CD3</FONT> antibodies, TNF, fusion protein, anti<FONT CLASS="nobreak">-lipopolysaccharide</FONT> antibodies, glucosylceramide, delayed<FONT CLASS="nobreak">-release</FONT> mercaptopurine and soy<FONT CLASS="nobreak">-derived</FONT> extracts. Several of these compounds were shown to be effective in patients with NASH.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Orally administered OKT3 was evaluated in a Phase 2 trial in 36 patients with NASH and type 2 diabetes and was found to be well tolerated by all patients in all groups with no systemic drug<FONT CLASS="nobreak">-related</FONT> adverse events. Increases in regulatory T<FONT CLASS="nobreak">-cell</FONT> markers consistent with induction of regulatory T<FONT CLASS="nobreak">-cells</FONT> was observed as well as increases in </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">other anti<FONT CLASS="nobreak">-inflammatory</FONT> markers. Although not powered sufficiently to evaluate efficacy endpoints, positive trends were observed including lowering of liver enzymes and lowering of glucose levels (Lalazar et.al, J. Clin. Immunol. (2015) 34 (4):399<FONT CLASS="nobreak">-407</FONT>).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">More recent animal studies conducted separately by Prof. Howard Weiner and Prof. Kevan Herold demonstrated therapeutic utility of orally administered Foralumab for immune<FONT CLASS="nobreak">-inflammatory</FONT> diseases. Our strategy is to build on these findings to develop orally administered Foralumab for the treatment of NASH, Crohn&#x2019;s disease and other autoimmune diseases. We believe Foralumab may also be combined with our other product candidate, TZLS<FONT CLASS="nobreak">-501</FONT>, a fully human anti<FONT CLASS="nobreak">-IL-6R</FONT> mAb, for the treatment of rheumatoid arthritis and other diseases.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Importantly, a recent study conducted by Boden et al., 2019 (Crohn&#x2019;s and Colitis 360) reported that oral treatment with the murine anti<FONT CLASS="nobreak">-human</FONT> anti<FONT CLASS="nobreak">-CD3</FONT> monoclonal antibody OKT3 in moderate<FONT CLASS="nobreak">-to-severe</FONT> ulcerative colitis patiets was well tolerated and no evidence of CRS or development of human anti<FONT CLASS="nobreak">-mouse</FONT> antibodies at 1 mg/dose for 30 days and 3/6 patients showed clinical response and amelioration of gut inflammation and one patient showed clinical remission. It is likely that the OKT3 was not bioavailable and that immunomodulation occurred in the intestinal mucosa with little systemic drug exposure. These results are extremely important and provides promise for oral Foralumab human trials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Kevan Herold et al recently published results of a Phase 2 study (New England Journal of Medicine, June 2019) in subjects at risk to develop Type 1 diabetes (T1D) that were treated with intravenous administration of the humanized anti<FONT CLASS="nobreak">-CD3</FONT> monoclonal antibody, teplizumab. Teplizumab slowed progression to clinical Type 1 diabetes in high risk participants in which only 43% of the subjects who received teplizumab went on to develop T1D indicating 57% of participants slowed progression to develop Type 1 diabetes compared to 72% of the subjects who received placebo. Teplizumab (humanized OKT3), administered intravenously, significantly slowed progression to clinical Type 1 diabetes, with a median delay in the diagnosis of diabetes of 2 years. 20 Grade 3 adverse events were observed, most of which (75%) consisted of lymphopenia that resolved by day 45. The study demonstrates the capacity of anti<FONT CLASS="nobreak">-CD3</FONT> treatment to be effective in treating autoimmune diseases such as T1D.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On April<FONT CLASS="nobreak"> </FONT>16, 2018 we entered into an exclusive license agreement with BWH relating to intranasal administration of Foralumab in a medical device. An IND for the first<FONT CLASS="nobreak">-in-human</FONT> evaluation of Foralumab in healthy human volunteers was filed on June<FONT CLASS="nobreak"> </FONT>1, 2018 and accepted by the FDA on August<FONT CLASS="nobreak"> </FONT>20, 2018. Dosing was initiated in November 2018 for the dose ranging Phase 1 trial to evaluate safety and tolerability as well as biomarkers of immunomodulation resulting in clinical responses. Three doses of Foralumab (10 &#x00b5;g, 50 &#x00b5;g and 250 &#x00b5;g/dose) were administered without any drug<FONT CLASS="nobreak">-related</FONT> safety concerns so far. Topline results from this study are expected in the third quarter of 2019.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Development Plan</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Proposed Phase 1 Clinical Trial for Foralumab in Healthy Volunteers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The proposed Phase 1 clinical trial for Foralumab in healthy volunteers is a single center single arm ascending study in which low doses (0.5, 1.25, 2.5 and 5.0 mg/dose) of Foralumab will be orally administered for 5 consecutive days followed by monitoring for tolerance and adverse events for 5 days. At each dose level, starting with the low dose if the resultant data indicates that the drug is well tolerated and free from significant adverse events, the next higher dose will be administered orally further for 5 consecutive days followed by 5 days of monitoring for tolerance and adverse events. If data from the Phase 1 trials indicate that the drug is well tolerated and free from adverse events, a Phase 2a trial is expected to be initiated in the second quarter of 2020 with the intent to treat patients with NASH and/or Crohn&#x2019;s disease. The primary endpoint of the Phase 1 study is safety and tolerability of Foralumab in humans.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Proposed Phase 2 Clinical Trial for Foralumab for the Treatment of NASH</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The proposed Phase 2 clinical trial for Foralumab is a randomized, placebo<FONT CLASS="nobreak">-controlled</FONT>, four<FONT CLASS="nobreak">-arm</FONT>, double<FONT CLASS="nobreak">-blind</FONT> study. Subjects (48) will be randomized (1:1:1:1) to receive either a once daily oral placebo or Foralumab dose of 1.25 mg, 2.5 mg or 5.0 mg for 30 consecutive days. Patients will record adverse events and daily administration of study medication in a subject diary. This will serve as a measure of compliance and record of adverse events and tolerability. Patients will be followed up for 30 days following completion of treatment. Study visits performed on Days<FONT CLASS="nobreak"> </FONT>14, 30 and 60 of the study, will monitor metabolic parameters (body mass index and waist circumference), serum lipid profiles, immunological markers (C<FONT CLASS="nobreak">-reactive</FONT> protein and an array of cytokines), hepatic enzymes and functions (<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">13</FONT>C<FONT CLASS="nobreak">-methacetin</FONT> breath test and liver steatosis/fibrosis), which will be compared to baseline levels (Day 1).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The safety and tolerability of the treatment regimen is the primary endpoint and will be determined by monitoring vital signs, laboratory values, adverse events and physical findings throughout the study. In addition, efficacy/immunomodulatory activity will be established using the following criteria: (1) reduced Day 30 serum alanine aminotransferase (ALT) levels; (2) reduced hemoglobin A1c; (3) improved homeostasis model assessment (HOMA); (4) HOMA of insulin resistance (HOMA<FONT CLASS="nobreak">-IR</FONT>) scores; as well as (5) levels of T cells and cytokines as compared to baseline (Day 1).</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"> <FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Phase 1 Clinical </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Trials of</FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;"> Foralumab for the Treatment of Multiple Sclerosis</FONT> </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> The Phase 1 clinical trial of nasally<FONT CLASS="nobreak">-administered</FONT> Foralumab in healthy volunteers is a single center single arm ascending study in which low doses (10, 50 and 250 &#x00b5;g/dose) of Foralumab was nasally administered for 5 consecutive days followed by monitoring for tolerance and adverse events for 30 days. At each dose level, starting with the low dose administered nasally for 5 consecutive days followed by 30 days subjects were monitored for tolerance and adverse events and biomarkers for immunomodulation. In September 2019, we announced preliminary data from the Phase 1 trials indicating that the nasally administered drug is well tolerated and free from adverse events. Biomarker analysis showed significant immunomodulatory effects at the 50 &#x00b5;g dose with minimal effects at the 10 and 250 &#x00b5;g doses. Phase 2a trials will be initiated at a later date for the treatment of MS. The primary endpoint of the Phase 1 study was safety and tolerability of Foralumab in humans dosed intranasally using a hand<FONT CLASS="nobreak">-held</FONT> nasal spray device. An IND was submitted to the FDA on July<FONT CLASS="nobreak"> </FONT>23, 2019, to conduct a Phase I clinical trial in healthy volunteers using a newly developed novel enteric<FONT CLASS="nobreak">-coated</FONT> capsule formulation of Foralumab in collaboration with the BWH, Harvard Medical School, Boston, MA with an intent to treat pMS. On September<FONT CLASS="nobreak"> </FONT>9, 2019, the FDA granted approval to initiate Phase I clinical trials to evaluate the safety and pharmacokinetics of the oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Intravenous Foralumab has been studied in a total of one Phase 1 and two Phase 2 clinical trials conducted by Novimmune. A total of 68 patients were exposed to Foralumab:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study NI</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-0401-01</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;a Phase 1/2a randomized, double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT> and dose escalation study NI<FONT CLASS="nobreak">-0401-01</FONT> in subjects with moderate to severe active CD. The study was completed and 33 subjects were exposed to Foralumab. The study NI<FONT CLASS="nobreak">-0401-01</FONT> was designed to assess tolerability of Foralumab and was not powered to evaluate efficacy parameters included the proportion of patients achieving, clinical response and change from baseline of Crohn&#x2019;s Disease Endoscopy Index of Severity. A trend, although not statistically significant, was seen when analyzing the clinical response and endoscopic response. Single and repeat intravenous doses of 0.05, 0.1, 0.5, 1.0, 2.0 and 10.0&#x00a0;mg Foralumab were administered to subjects and serum pharmacokinetics evaluated for up to five days. Limited pharmacokinetic data was collected, however it was observed that at doses over 1.0 mg, severe infusion related reactions (IRRs) were observed that led to discontinuation of the 2 and 10 mg groups. Therefore, the 1.0 mg dose was considered the MTD in this study. CD3 modulation on CD4 positive and CD8 positive T cells was related to Foralumab dose. There was a dose response for the reduction of peripheral T<FONT CLASS="nobreak">-cell</FONT> (CD2 positive) count. The main adverse events were infusion related reactions related to the route of administration of the drug.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study NI</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-0401-02</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;an open<FONT CLASS="nobreak">-label</FONT>, dose titration, multicenter Phase 1 study of Foralumab for the treatment of subjects with biopsy<FONT CLASS="nobreak">-proven</FONT> acute cellular renal allograft rejection (BpACR). The study was completed and 11&#x00a0;subjects were exposed to Foralumab. Patients were dosed with 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg of Foralumab daily for five days and most were pre<FONT CLASS="nobreak">-treated</FONT> with methylprednisolone. The data from study NI<FONT CLASS="nobreak">-0401-02</FONT> has confirmed the dose response in terms of CD3 modulation and reduction of peripheral T<FONT CLASS="nobreak">-cell</FONT> count. A CD3 modulation of up to 90% was achieved at study NI<FONT CLASS="nobreak">-0401-02</FONT> day five with a daily dose of 2.5 mg during the 5 days of treatment period. Although there was no dose<FONT CLASS="nobreak">-response</FONT> relationship, treatment with Foralumab seems to be globally effective to reverse protocol defined acute cellular rejection and in the mormalization of serum creatinine levels, a primary efficacy objective. The main adverse events were infusion related reactions in patients that were not premedication with prednisolone.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study NI</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-0401-03</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;a Phase 2a study with an open label dose escalation phase followed by a double<FONT CLASS="nobreak">-blind</FONT> phase to assess safety and efficacy of Foralumab in subjects with moderate to severe active CD. The study NI<FONT CLASS="nobreak">-0401-03</FONT> was completed and 24 subjects were exposed to Foralumab. 74% of patients had achieved a clinical response at week 2 and 87% of patients at week 4. At weeks<FONT CLASS="nobreak"> </FONT>6, 8 and 12 the proportion of patients with a clinical response decreased to 75%, 70% and 67%, respectively. 30% of patients had achieved clinical remission at week<FONT CLASS="nobreak"> </FONT>2, 42% by weeks<FONT CLASS="nobreak"> </FONT>4, 38% by week<FONT CLASS="nobreak"> </FONT>6, 43% at week 8 and 46% at week 12. Treatment failures were 12.5%. There was a reduction in the mean Crohn&#x2019;s Disease Activity Index (CDAI) scores in all treatment cohorts and an overall improvement in the Crohn&#x2019;s Disease </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">Endoscopic Index of Severity (CDEIS) scores across all treatment groups following 5 daily doses of Foralumab treatment. Pharmacokinetic evaluations were performed, and no dose<FONT CLASS="nobreak">-response</FONT> relationship was established due to variability between patients. The observed half<FONT CLASS="nobreak">-life</FONT> of Foralumab was approximately 180 hours. A rapid and almost complete disappearance of CD45 positive lymphocytes, CD3 positive T<FONT CLASS="nobreak">-cells</FONT>, CD3 positive and CD4 positive helper T<FONT CLASS="nobreak">-cells</FONT> and CD3 positive and CD8 positive cytotoxic T<FONT CLASS="nobreak">-cells</FONT> from the circulation was observed was observed within 24&#x00a0;hours of infusion for all dose cohorts. The lowest unit dose in the study NI<FONT CLASS="nobreak">-0401-03</FONT> was equivalent to the 1 mg daily unit dose that was the maximum tolerated dose in study NI<FONT CLASS="nobreak">-0401-01</FONT>. Pre<FONT CLASS="nobreak">-medication</FONT> with prednisolone reduced the severity and frequency of infusion related reactions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In two Phase 2a trials conducted by Novimmune, patients with Crohn&#x2019;s disease and renal allograft rejection in kidney transplants demonstrated Foralumab&#x2019;s immunomodulatory activity in humans. We have decided not to pursue evaluation of intravenous Foralumab in Crohn&#x2019;s Disease because we believe the market for this disease is saturated by other FDA approved drugs. Further, while intravenous administration of antibodies has been widely used, side effects from the intravenous administration still are prevalent as well as patient compliant issues come into play. We intend to move forward with an oral formulation of Foralumab for treatment of Crohn&#x2019;s disease.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Two of Novimmune&#x2019;s clinical trials were in patients with Crohn&#x2019;s disease and the third clinical trial was conducted in patients undergoing kidney transplantation and suffering with renal allograft rejection. Sixty<FONT CLASS="nobreak">-eight</FONT> subjects with active Crohn&#x2019;s disease and 11 subjects with acute cellular renal allograft rejection were treated with Foralumab. The route of administration of Foralumab in these studies was via intravenous administration.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In these trials, it was observed that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The short<FONT CLASS="nobreak">-term</FONT> tolerability profile of Foralumab was very similar to those reported with other anti CD3 antibodies and no new emerging concerns have been identified.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Total daily doses of up to 1mg (~ 500 &#x00b5;g/m2) per patient were generally well tolerated without corticosteroid premedication. The most common adverse events following exposure to Foralumab were IRRs, which occurred in all patients treated with the compound. In the majority of cases, these symptoms were mild (66%) in intensity and were reported following the first two infusions of the 5<FONT CLASS="nobreak">-infusion</FONT> treatment course. The number of affected patients and the severity of symptoms tended to increase with increasing dose level, or DL.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>A clear reduction of CRS and its associated IRRs were observed with steroid pre<FONT CLASS="nobreak">-medication</FONT>. All patients who received pre<FONT CLASS="nobreak">-medication</FONT> with steroids had mild or no IRRs, and CRS was reduced. Only one patient who did not receive steroid pre<FONT CLASS="nobreak">-medication</FONT> had significant levels of CRS, in particularly IL<FONT CLASS="nobreak">-6</FONT>.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Usage of steroid pre<FONT CLASS="nobreak">-medication</FONT> allows the administration of higher doses.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Both the magnitude and duration of CD3 modulation increased in a dose related manner.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No anti<FONT CLASS="nobreak">-drug</FONT> antibodies were detected.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Prior Clinical Experience</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Oral anti<FONT CLASS="nobreak">-CD3</FONT> antibodies, as opposed to the narrow therapeutic window of its intravenous counterpart, have been shown to impact the gut immune system and mesenteric lymph nodes, thereby promoting regulatory T<FONT CLASS="nobreak">-cells</FONT> activity, without inducing immunosuppression. The treatment alleviated experimental autoimmune encephalitis and T1D mellitus, which was associated with regulatory T<FONT CLASS="nobreak">-cells</FONT> induction. Orally and nasally administered anti<FONT CLASS="nobreak">-CD3</FONT> suppressed autoantibody production in a mouse lupus model. Oral anti<FONT CLASS="nobreak">-CD3</FONT> yielded reduced pancreatic hyperplasia, hepatic fat accumulation and muscle inflammation in a leptin<FONT CLASS="nobreak">-deficient</FONT> model of NASH and diabetes.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacology Summary (In Vitro Studies)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The key conclusions arising from the non<FONT CLASS="nobreak">-clinical</FONT> studies of Foralumab by Novimmune are:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Foralumab is a specific anti<FONT CLASS="nobreak">-CD3</FONT> epsilon mAb, as it binds to human T<FONT CLASS="nobreak">-cells</FONT> and the recombinant human CD3 epsilon chain, and can be displaced by another specific anti<FONT CLASS="nobreak">-CD3</FONT> epsilon mAb, muromonab CD3.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>When bound to its target, Foralumab triggers calcium flux into the cell and modulates the CD3/TCR complex causing its&#x2019; transient removal from the cell surface.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The combination of the two<FONT CLASS="nobreak">-point</FONT> mutations introduced into the Fc portion (the constant region of the antibody that has limited structural variability and is responsible for adverse side effects) of Foralumab, resulting in the abrogation of the binding to Fc gamma receptors, and C1q, consequently eliminates T<FONT CLASS="nobreak">-cell</FONT> proliferation and the release of numerous cytokines including TNF, and interferon gamma, or IFN<FONT CLASS="CharOverride-4" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b3;</FONT> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">in vitro</FONT>.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Foralumab does not cross react with CD3 molecules expressed by T<FONT CLASS="nobreak">-cells</FONT> of other species including baboon, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Rhesus </FONT>monkey, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Cynomolgus </FONT>monkey, rabbit, dog, rat and mouse. As a consequence, options for the most relevant species selection for pharmacology and toxicology assessment of Foralumab are limited. Novimmune addressed this limitation by studying LCD3 transgenic mice. This transgenic mouse line expresses the human as well as the mouse CD3 epsilon chain on the surface of their T<FONT CLASS="nobreak">-cells</FONT>.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Using a transgenic line of mice expressing both human and mouse CD3 molecules (1:1 ratio) at the surface of T<FONT CLASS="nobreak">-cell</FONT> (LCD3<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">), </FONT>following a single intravenous injection, Foralumab dose dependently:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Modifies human CD3 epsilon expression; that is, more than 80% of the cell surface protein was removed within 24 hours when given at a saturating dose. This modulation was transient as receptor expression levels returned to baseline values within 7 days of dosing.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Caused a transient reduction of 70<FONT CLASS="nobreak">-80</FONT>% in the number of circulating T<FONT CLASS="nobreak">-cells</FONT> when given at a saturating dose. The maximal effect was observed at hour 6 post dose. Cell counts returned to baseline levels within 3.5 days.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Demonstrated a half<FONT CLASS="nobreak">-life</FONT> of 1.4 and 1.7 days for doses of 5 and 200 &#x00b5;g per mouse, respectively. This seemingly short half<FONT CLASS="nobreak">-life</FONT> is similar to that observed in vivo for other anti<FONT CLASS="nobreak">-CD3</FONT> mAbs and reflects internalization of Foralumab by the human CD3 molecule on the T<FONT CLASS="nobreak">-cells</FONT> of these transgenic mice. It was therefore expected that Foralumab will be internalized by human T<FONT CLASS="nobreak">-cells</FONT> in patients and consequently have a half<FONT CLASS="nobreak">-life</FONT> comparable to other therapeutic anti<FONT CLASS="nobreak">-CD3</FONT> mAbs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Milciclib (TZLS-201)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> Milciclib is an orally bioavailable, small molecule broad spectrum inhibitor of CDKs (CDKs):<FONT CLASS="nobreak"> </FONT>1,<FONT CLASS="nobreak"> </FONT>2,<FONT CLASS="nobreak"> </FONT>4, 5 and 7 and Src family kinases. CDKs are a family of highly conserved enzymes that are involved in regulating the cell cycle, which is a series of events that takes place in cells leading to division and duplication of its DNA to produce two daughter cells. Src family kinases regulate cell growth and potential transformation of normal cells to cancer cells. A novel feature of Milciclib is its ability to reduce microRNAs, miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT>, that silence gene expression. miR<FONT CLASS="nobreak">-221</FONT> and miR<FONT CLASS="nobreak">-222</FONT> promote the formation of blood vessels (angiogenesis) that are important for spread of cancer cells (metastasis). Levels of these microRNAs are consistently increased in HCC patients and may contribute towards resistance to treatment with Sorafenib. As a result, we are investigating Milciclib both as a monotherapy and plan a combination treatment with Sorafenib. To date, Milciclib has been studied in a total of eight Phase 1 and Phase 2 clinical trials in 316 patients. In these trials, Milciclib was observed to be well<FONT CLASS="nobreak">-tolerated</FONT> and showed initial signals of anti<FONT CLASS="nobreak">-tumor</FONT> action. We have completed a Phase 2a trial (CDKO<FONT CLASS="nobreak">-125a-010</FONT>) for Milciclib as a single therapy in patients with HCC in June 2019 and expect to initiate a Phase 2b trial (TZLS (201)<FONT CLASS="nobreak">-125a-011</FONT>) for Milciclib in combination with a TKI (either Sorafenib for first line treatment or Regorafenib for second line therapy, the standards of care for treatment of HCC) in patients with HCC in the second half of 2019. </P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Hepatocellular Cancer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are initially developing Milciclib for the treatment of HCC. HCC, or liver cancer, is the sixth most common of all malignancies and second most common cause of cancer related deaths in the world. Liver cancer incidence and death rates are steadily rising. As of 2012, rates of new liver cancer cases went up 38% from 2003 to 2012 according to the Centers for Disease Control and Prevention. It is estimated that the liver cancer drug market will be approximately $1.5<FONT CLASS="nobreak"> </FONT>billion by 2022.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Most HCC patients present with advanced disease and do not benefit from transplantation, surgical resection, or locoregional therapies. The SOC, Sorafenib and Lenvatinib, are approved in the United States and EU for advanced HCC patients but have a limited impact on overall survival.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The primary risk factor for HCC is hepatic cirrhosis, with an estimated 78% of HCC cases and 57% of cases of liver cirrhosis caused by chronic infection with hepatitis B virus or HCV. Recently, the combination of insulin resistance, hypertension, dyslipidemia and obesity, termed &#x201c;metabolic syndrome,&#x201d; has also been recognized as a cause of NAFLD, which is the most common liver disease, cirrhosis and HCC. The following graphic represents the progression from a healthy liver to NAFLD, NASH and HCC.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="image_05.jpg" STYLE="height:148.48px;width:556.8px;max-width:100%;"></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Generally, cancer is primarily due to deficiencies in cell cycle control, eventually resulting in transformation of normal cells to rapidly growing cancer cells. Therapeutic intervention to control cell cycle has long been anticipated as effective cancer therapies. CDKs are a family of enzymes first discovered as regulators of the cell cycle. CDKs have been found to be overexpressed in a variety of human diseases with abnormal cell growth such as cancers, viral infections, neurodegenerative disorders and other proliferative diseases. We believe that modulating CDK activity with targeted therapies is an attractive strategy to reinforce cell cycle control and decrease the rate of abnormal proliferation of cancer cells. The first FDA approval in March 2015 of a CDK inhibitor for palbociclib, and more recently in 2017, ribociclib, for a type of breast cancer, has led to great interest in the development of this class of drugs as oncology therapeutics.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Our Solution</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Milciclib is an oral, broad<FONT CLASS="nobreak">-spectrum</FONT> inhibitor of CDKs, as well as several other protein kinases responsible for controlling cell growth and replication. Milciclib has an unusual kinase inhibitory profile making it active against other receptors such as, tyrosine kinase, Src family and splicing kinases, which play a role in cell growth and transformation from normal to cancerous cell types.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In tumor cells exposed to Milciclib, a block in G1 phase (first phase of the growth cycle where the cell synthesizes messenger RNA and proteins before cell division) of the cell cycle was observed, supporting the postulated mechanism of action of the compound as determined in biochemical assays. Additionally, Milciclib was able to modulate the phosphorylation of the Retinoblastoma protein, a substrate of the CDK/cyclin complex as well as to reduce phosphorylation status of proteins of the TRKa signaling pathway in cells expressing the tyrosine kinase receptor. These results supported that Milciclib was active against several families of protein kinases that actively controlled cell growth and transformation from normal to cancerous cell types. This is important because many chemotherapeutic agents are effective at only a single point in the cell cycle, allowing cells to &#x201c;escape&#x201d; the biochemical blockage through alternative biochemical pathways.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Significant anti<FONT CLASS="nobreak">-tumor</FONT> activity was observed in all tested preclinical animal models with different oral treatment schedules of Milciclib. Cancerous cell types were transplanted into immunosuppressed animals and the number and volume of cancerous lesions were evaluated by magnetic resonance imaging after oral administration of Milciclib at different dose levels (DLs) and dose schedules compared to untreated, control animals. In various human xenograft and transgenic models (prostate cancer, lung adenocarcinoma and hepatocarcinoma), consistent tumor growth inhibition, up to 91%, (evaluated by measuring the number and volume of tumors for treated animals versus control animals) was observed <FONT CLASS="nobreak">-with</FONT> repeat daily treatment at tolerated doses. Similar results were obtained in a mammary carcinoma model (stasis and partial remission in 58% and 25% of the primary tumors, respectively) with repeat daily dosing. In an </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">orthotopic mouse model of HCC, statistically significant reduction in tumor growth was observed following five weeks of treatment with Milciclib (<FONT CLASS="nobreak">-20</FONT>% reduction,30mg/kg/day),sorafenib (<FONT CLASS="nobreak">-20</FONT>% reduction, 20 mg/kg/day) vs combination of Milciclib with Sorafenib (<FONT CLASS="nobreak">-38</FONT>% reduction) as compared to vehicle control. The treatment also reduced serum levels of human alpha<FONT CLASS="nobreak">-fetoprotein</FONT>. Preliminary mechanistic and gene expression studies suggest that downregulation of miR<FONT CLASS="nobreak">-221</FONT>, miR<FONT CLASS="nobreak">-222</FONT> by Milciclib results in upregulation of its molecular targets, cyclin dependent kinase inhibitors p27 and p57. Additionally, Milciclib treatment upregulated relative expression of tumor suppressors p21 and p53, which are important regulators of cellular proliferation. Milciclib treatment reduced expression of pAKT, c<FONT CLASS="nobreak">-Myc</FONT> and cyclin&#x00a0;D1, which are known to be overexpressed in HCC tumor tissues. These preclinical data demonstrating the synergistic effect of Milciclib with Sorafenib were presented at the AASLD meeting in November 2018.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Clinical Development Plan</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Phase 2a Clinical Trial (CDKO-125a-010) for Milciclib as a Monotherapy for the Treatment of HCC</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In July 2017, we initiated dosing in a single<FONT CLASS="nobreak">-arm</FONT>, multicenter, Phase 2a clinical trial (CDK<FONT CLASS="nobreak">-125a-010</FONT>) for Milciclib in adult patients with unresectable or metastatic HCC and good liver function. The trial is studying the tolerability and safety of Milciclib in these adult patients. As of 2019, we have enrolled and treated 31 patients at sites in Italy, Greece and Israel. Eligible patients are receiving Milciclib orally, 100 mg/day for four consecutive days a week (four days on followed by three days off) for a total of 12 weeks.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The primary endpoint for the study is the overall safety profile, evaluated based on laboratory findings and adverse events emerging during the trial. The occurrence of adverse events and laboratory tests will be performed weekly during treatment. All the enrolled patients who receive at least one drug administration were evaluated for safety. An interim evaluation of tolerability and adverse events was undertaken when the 10<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">th</FONT> patient had completed the first cycle of treatment. Enrollment of additional patients was allowed after a positive safety evaluation of the first 10 patients by an IDMC. On December<FONT CLASS="nobreak"> </FONT>8, 2017 we announced the results of the first interim review by the IDMC that treatment with Milciclib was well<FONT CLASS="nobreak">-tolerated</FONT> with no drug<FONT CLASS="nobreak">-related</FONT> serious adverse events. The IDMC recommended continuing with the trial. The second IDMC meeting held on January<FONT CLASS="nobreak"> </FONT>25, 2018 recommended that all patients (first cohort) who received at least one dose of Milciclib should be assessed for safety and tolerability at the end of protocol mandated follow up before enrolling the second cohort. The IDMC reconvened on its scheduled date on May<FONT CLASS="nobreak"> </FONT>9, 2018 to evaluate the complete safety data for all 11 patients who completed the study mandated visits. The IDMC concluded that there are no major signals of safety concern that preclude continuation of enrollment of the remaining cohorts as planned. Secondary endpoints include Objective Tumor Response Rate, based on the modified Response Evaluation Criteria in Solid Tumors, or mRECIST, a set of criteria developed to assess tumor response in HCC. In this study, objective response by RECIST will also be evaluated as supportive analysis, along with several secondary parameters. The decrease in alpha<FONT CLASS="nobreak">-fetoprotein</FONT>, or AFP, as compared to baseline in patients with high AFP at baseline will also be considered, based on reports suggesting a better outcome for patients who achieve an AFP response. As an exploratory endpoint, the expression of micro<FONT CLASS="nobreak">-RNAs</FONT> and their possible association with Milciclib treatment will be investigated. Enrollment of 31 patients was completed in November 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> In March 2019, the IDMC reviewed safety data from patients as of February<FONT CLASS="nobreak"> </FONT>26, 2019 and concluded that the administration of Milciclib to patients with advanced HCC was not associated with unexpected signs or signals of toxicity. 28 out of 31 treated patients were evaluable, 14 completed the 6<FONT CLASS="nobreak">-month</FONT> duration study. The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable. No drug<FONT CLASS="nobreak">-related</FONT> deaths were recorded. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> As per the study protocol, data collection was limited to 6<FONT CLASS="nobreak">-months</FONT>. Thus, clinical data were not collected from patients under compassionate use treatment. The clinical activity assessment in evaluable patients was based on the investigators&#x2019; review using the modified Response Evaluation Criteria in Solid Tumors (mRECIST).  </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>9 out of 14 patients (64.2%) were approved by their respective ethical committees to continue the treatment.   </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>5 <FONT CLASS="CharOverride-6" STYLE="">of the </FONT><FONT CLASS="CharOverride-6" STYLE="">9</FONT><FONT CLASS="CharOverride-6" STYLE=""> </FONT><FONT CLASS="CharOverride-6" STYLE="">patients </FONT><FONT CLASS="CharOverride-6" STYLE="">on compassionate use had </FONT><FONT CLASS="CharOverride-6" STYLE="">received Milciclib for a total of</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-6" STYLE="">9</FONT><FONT CLASS="CharOverride-6" STYLE="">,</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-6" STYLE="">9</FONT><FONT CLASS="CharOverride-6" STYLE="">,</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-6" STYLE="">11, 13 and 16</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-6" STYLE="">months.</FONT> </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>As of 1 September 2019, the remaining 4 patients continuing the treatment are in their 10<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>, 11<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> and 12<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> months. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Both median TTP and PFS were 5.9<FONT CLASS="nobreak"> </FONT>months (95% Confidence Interval (&#x201c;CI&#x201d;) 1.5<FONT CLASS="nobreak">-6</FONT>.7<FONT CLASS="nobreak"> </FONT>months) out of the 6<FONT CLASS="nobreak">-months</FONT> duration of the trial. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>17 of 28 (60.7%) evaluable patients showed &#x2018;Stable Disease&#x2019; (SD; met at least once in an 8<FONT CLASS="nobreak">-week</FONT> interval). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>One patient (3.6%) showed &#x2018;Partial Response&#x2019; (PR, unconfirmed). </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"> <FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>18 of 28 (64.3%) evaluable patients showed &#x2018;Clinical Benefit Rate&#x2019; defined as CBR=CR+PR+SD (with CR representing Complete Remission). </P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Phase 2b Clinical Trial (TZLS (201)-125a-011) for Milciclib as a Combination Therapy with a TKI (Sorafenib or Regorafenib) for the Treatment of HCC</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Since overexpression of CDKs and dysregulation in pRB pathway (regulates transcription factors critical for cell cycle progression) are prominently associated with tumor cell resistance to certain chemotherapeutic drugs, inhibition of multiple CDKs is an appealing approach to improve clinical responses in cancer patient&#x2019;s refractory to existing treatment options. A Phase 1 dose<FONT CLASS="nobreak">-escalation</FONT> study of Milciclib in combination with gemcitabine (CDK<FONT CLASS="nobreak">-125a-004</FONT>) in patients with refractory solid tumors exhibited clinical activity in patients including those refractory to gemcitabine. Tiziana plans explore combination approach in patients with HCC. In 2019, we intend to initiate a randomized, multicenter study to explore tolerability and antitumor activity, of Milciclib in combination with a TKI (either Sorafenib or Regorafenib), administered as systemic therapy in adult patients with recurrent, unresectable or metastatic HCC and good liver function.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Sorafenib (Nexavar&#x00ae;) is the SOC for treatment of HCC, yet treatment extends survival probability from&#x00a0;7.9<FONT CLASS="nobreak"> </FONT>months (placebo control) to 10.7<FONT CLASS="nobreak"> </FONT>months (Llovet et al. N Engl J Med (2008) 359:378<FONT CLASS="nobreak">-390</FONT>). There is a need for improvement which may be realized by combination of Milciclib with Sorafenib. Milciclib modulates cell cycle, DNA replication and growth factor receptor cell signaling (Albanese et.al, Mol. Cancer Therap. (2010) 9(8):2243<FONT CLASS="nobreak">-54</FONT>). Sorafenib is a multikinase inhibitor which has demonstrated both anti<FONT CLASS="nobreak">-proliferative</FONT> and anti<FONT CLASS="nobreak">-angiogenic</FONT> properties in vitro and in vivo. The combination of Sorafenib with Milciclib should exert a combined anti<FONT CLASS="nobreak">-proliferative</FONT> effect on tumor cells, involving targets different from the ones modulated by Milciclib, together with antiangiogenesis properties.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;text-align:center;margin-top:12pt;"><IMG ALT="" SRC="linechart.jpg" STYLE="height:183.04px;width:314.88px;max-width:100%;"></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Data</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Milciclib has been studied in a total of eight Phase 1 and Phase 2 clinical trials in approximately 316 patients. Milciclib was observed to be well tolerated by patients with thymoma in Phase 1 and Phase 2 clinical trials.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Phase 1 Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Milciclib has been investigated in each of the below, open<FONT CLASS="nobreak">-label</FONT>, multi<FONT CLASS="nobreak">-center</FONT>, non<FONT CLASS="nobreak">-randomized</FONT>, dose<FONT CLASS="nobreak">-escalation</FONT> Phase 1 clinical trials.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Trial</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Patient Population</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Treatment&#x00a0;Schedule&#x00a0;/&#x00a0;Dosing</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Key Findings</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">CDKO<FONT CLASS="nobreak">-125a-001</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Advanced/metastatic solid tumors</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">37 patients</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">1st Schedule: Orally, once daily for 7 consecutive days every 14 days in a 2<FONT CLASS="nobreak">-week</FONT> cycle at escalating doses of<FONT CLASS="nobreak"> </FONT>50, 100, 150, 200 and 300&#x00a0;mg</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacokinetics:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Comparable plasma pharmacokinetic parameters between the two schedules were observed.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">2<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">nd</FONT> Schedule: Orally, once daily for 4 consecutive days a week for 3 weeks in a 4<FONT CLASS="nobreak">-week</FONT> cycle at escalating doses of 150, 180 and 200&#x00a0;mg</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The exposure to Milciclib increased with the dose and there was a 3<FONT CLASS="nobreak">-fold</FONT> accumulation in the daily systemic exposure after repeated dosing, in good agreement with expectations on the basis of the half<FONT CLASS="nobreak">-life</FONT> of the compound (24<FONT CLASS="nobreak">-43</FONT> h).</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical observations:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">No objective responses were achieved on 1st schedule; Disease stabilizations, defined as cancer disease that is neither increasing nor decreasing in extent or severity, was observed in 6 of 14 evaluable patients (42.9%).</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">A partial response, or PR, was achieved in 2 out of 14 evaluable patients (14.3%) on 2<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">nd</FONT> schedule; Disease stabilization (no change in extent or severity of disease state) was reported in 3 patients (21.4%), all treated at 180 mg/day DL, including a stabilization lasting 31 weeks in a patient with pancreatic cancer and stable disease, or SD, lasting 29 weeks in a patient with carcinoid.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Trial</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Patient Population</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Treatment&#x00a0;Schedule&#x00a0;/&#x00a0;Dosing</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Key Findings</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">CDKO<FONT CLASS="nobreak">-125a-002</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Recurrent malignant glioma 28 patients (Phase&#x00a0;1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Escalating oral doses of<FONT CLASS="nobreak"> </FONT>18,<FONT CLASS="nobreak"> </FONT>36, 54 and 72 mg/m2 once a day for 14 consecutive days followed by 7 days of rest in a 3<FONT CLASS="nobreak">-week</FONT> cycle</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacokinetics:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;">Results indicated that the pharmacokinetics of Milciclib was dose<FONT CLASS="nobreak">-independent</FONT> in the dose range 18 &#x2014; 72 mg/m2.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-30" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">34 patients (Phase&#x00a0;2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">54 mg/m2 (RP2D)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Systemic exposure values of Milciclib maleate accumulated by a factor of 3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical observations:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Phase 1: No evidence of clinical effect was observed in all the 28 treated patients. However 5&#x00a0;patients seemed to have benefitted from therapy with SD observed (no change in extent or severity of cancer).</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Phase 2: One out of 34 patients achieved the primary endpoint. PFS at 6<FONT CLASS="nobreak"> </FONT>months or PFS<FONT CLASS="nobreak">-6</FONT> rate was 2.9%. No complete response, or CR (disappearance of all signs of cancer in response to treatment) or PR (decrease in tumor size or extent of cancer in the body) were reported. 4 patients showed SD as best overall response (11.8%). Prolonged SD (&#x2265; 6<FONT CLASS="nobreak"> </FONT>months) was observed in one patient whose SD lasted for 24.9<FONT CLASS="nobreak"> </FONT>months.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-32" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Safety:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">34 patients were enrolled and treated: 29 patients of non<FONT CLASS="nobreak">-Enzyme</FONT> Inducing Anti<FONT CLASS="nobreak">-Epileptic</FONT> Drugs, or non<FONT CLASS="nobreak">-EIAED</FONT>, population and 5 of EIAEDs population. The primary clinical endpoint was not met. Only one patient (non<FONT CLASS="nobreak">-EIAEDs</FONT>) achieved the study primary endpoint out of 34 treated patients. PFS<FONT CLASS="nobreak">-6</FONT> rate evaluated in the treated patients was 2.9% (95% CI, 0.07<FONT CLASS="nobreak">-15</FONT>.33). No CR or PR was reported; 4 patients in the treated patients showed SD as best overall response on treatment (11.8%). Prolonged SDs (&#x2265;6<FONT CLASS="nobreak"> </FONT>months) was observed in one patient whose SD lasted for 24.9<FONT CLASS="nobreak"> </FONT>months. Median OS in treated patients was 7.03<FONT CLASS="nobreak"> </FONT>months (95% CI, 5.72<FONT CLASS="nobreak">-10</FONT>.58). The exploration of the role play by potential prognostic factors, such as Karnofsky Performance Scale (&#x2265;90 vs. &lt;90), age (&lt;40 vs. &#x2265;40) and interval between initial diagnosis and current recurrence (&#x2265;52&#x00a0;weeks vs. &lt;52 weeks) indicated a better survival outcome for patients whose interval between initial diagnosis and current recurrence was (&#x2265;52&#x00a0;weeks). Given the non<FONT CLASS="nobreak">-comparative</FONT> nature of the study, it cannot be said whether the treatment played any role in this result.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The influence of other factors cannot be excluded but was not apparent in the current sample.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Trial</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Patient Population</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Treatment&#x00a0;Schedule&#x00a0;/&#x00a0;Dosing</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Key Findings</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">CDKO<FONT CLASS="nobreak">-125a-003</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Advanced/metastatic solid tumors</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">30 patients</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">1st Schedule: Orally, once daily for 21 consecutive days followed by 7 days of rest in a 4<FONT CLASS="nobreak">-week</FONT> cycle at escalating doses of 16 and 24 mg/m2</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">2<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">nd</FONT> Schedule: Orally, once daily for 14 consecutive days followed by 7 days of rest in a 3<FONT CLASS="nobreak">-week</FONT> cycle at escalating doses of<FONT CLASS="nobreak"> </FONT>24,<FONT CLASS="nobreak"> </FONT>48, 54 and 72&#x00a0;mg/m2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacokinetics:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;">No differences in the pharmacokinetics were observed between the two schedules after both single and repeated dosing.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The systemic exposure to Milciclib (amount of Milciclib available systemically in the patient) increased with dose in terms of both Cmax (maximum concentration of Milciclib in plasma) and daily Area Under the Plasma Drug Concentration, or AUC, vs Time Curve, a measure of drug bioavailability without deviations from dose<FONT CLASS="nobreak">-proportionality</FONT> (plasma concentration changes in a linear relationship to amount of drug dosed).</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">After repeated administrations, Milciclib Cmax and AUC accumulated by a factor of 2<FONT CLASS="nobreak">-4</FONT>, independent of the dose<FONT CLASS="nobreak">-level</FONT>.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical observations:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">No objective (measurable) responses were achieved. SDs were reported in 5 out of 16 evaluable patients (31.3%), starting from the dose of 48 mg/m2/day. One disease stabilization maintained for 12 cycles (10.5<FONT CLASS="nobreak"> </FONT>months) at 48 mg/m2/day, was achieved in a parotid gland patient.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-36" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">CDKO<FONT CLASS="nobreak">-125a-004</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Advanced/metastatic solid tumors 16 patients</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Orally administered at<FONT CLASS="nobreak"> </FONT>45, 60 and 80 mg/m2 once daily for 7 days on / 7 days off (Days 1 to 7 and 15 to 21) in a 4<FONT CLASS="nobreak">-week</FONT> cycle in combination with fixed dose of IV gemcitabine (1000 mg/m2/day) on Days<FONT CLASS="nobreak"> </FONT>1,<FONT CLASS="nobreak"> </FONT>8, 15 over 30 minutes every 4&#x00a0;weeks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacokinetics:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Pharmacokinetic parameters (Cmax, AUC) of Milciclib after Milciclib maleate/ gemcitabine combination were consistent with those previously observed after Milciclib maleate administration as single agent, suggesting no influence of gemcitabine on the pharmacokinetics of the compound.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical observations:</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">One PR in 14 evaluable patients (7.1%) and one SD in 10 patients (71.4%).</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Disease stabilizations lasting z 6<FONT CLASS="nobreak"> </FONT>months were recorded in 4 cases (28.6%) in thyroid, prostatic, pancreatic carcinoma and peritoneal mesothelioma, in 2 of them lasting 13.4<FONT CLASS="nobreak"> </FONT>months (peritoneal mesothelioma) and 14.3<FONT CLASS="nobreak"> </FONT>months (prostate cancer).</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The PR and 3 of the 4 long lasting disease stabilizations were obtained at the recommended Phase 2 dose (RP2D) of 80 mg/m2/day plus 1000 mg/m2/day gemcitabine, supporting development of combination therapies with Milciclib in advanced cancer patients.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Results of trial CDKO<FONT CLASS="nobreak">-125a-004</FONT> were published: S. Aspeslagh et.al. Cancer Chemother. Pharmacol (2017) 79: 1257<FONT CLASS="nobreak">-1265</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Phase 2 Development</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Trial</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Patient Population</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Treatment&#x00a0;Schedule&#x00a0;/&#x00a0;Dosing</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Key Findings</FONT> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> CDKO<FONT CLASS="nobreak">-125a-005</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> Malignant pleural </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> mesothelioma </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> 38 patients </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> 150 mg/day orally administered for 7 consecutive days every 14 days in 2<FONT CLASS="nobreak">-week</FONT> cycles </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacokinetics:</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Plasma levels of Milciclib were comparable to those previously obtained in the Phase 1 study CDK0<FONT CLASS="nobreak">-125a-001</FONT> at the same dosage and with the same schedule, confirming the reliability of the pharmacokinetic profile of the compound. </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical observations:</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> No objective responses were reported; prolonged SDs were observed in 2 patients, lasting 8.9<FONT CLASS="nobreak"> </FONT>months and 8.7<FONT CLASS="nobreak"> </FONT>months, respectively. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-38" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> CDKO<FONT CLASS="nobreak">-125a-006</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Trial cutoff: 1/9/2017 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Malignant B3 </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> thymoma / thymic </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> carcinoma </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> 72 patients </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Single agent (flat dose) </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> 150 mg once daily </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> 7days on/7days off q2wks </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Observations:</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Treatment with Milciclib met the primary endpoint of PFS at 3<FONT CLASS="nobreak"> </FONT>months (PFS<FONT CLASS="nobreak">-3</FONT>). 56 of 72 treated patients had median PFS of 5.78<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 3.48<FONT CLASS="nobreak"> </FONT>months and 7.89<FONT CLASS="nobreak"> </FONT>months, respectively. The secondary endpoint, OS, was also met in this trial. 36 of 72 patients (50%) had median OS of 24.44<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 22.05 and 54.55<FONT CLASS="nobreak"> </FONT>months, respectively. Five patients from this study are continuing treatment with Milciclib. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> CDKO<FONT CLASS="nobreak">-125a-007</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Trial cutoff: 1/9/2017 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Malignant B3 </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> thymoma / thymic </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> carcinoma </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> 30 patients </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Single agent (flat dose) 150 mg once daily 7days on/7days off q2wks </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Observations:</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Treatment with Milciclib met the primary endpoint of PFS<FONT CLASS="nobreak">-3</FONT>. 18 of 30 patients had median PFS of 5.65<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 3.94<FONT CLASS="nobreak"> </FONT>months and 17.45<FONT CLASS="nobreak"> </FONT>months, respectively. The secondary endpoint, OS, was met in this trial. 3 of 30 treated patients (54.5%) had median OS of 21<FONT CLASS="nobreak"> </FONT>months. Upper 95% confidence limits could not be calculated. </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-40" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> CDKO<FONT CLASS="nobreak">-125a-010</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 17.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Recurrent or </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> metastatic </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> unresectable HCC </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;"> Single agent (flat dose) </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> 100 mg once daily </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> 4days on/3days off x 4 wks q4 wks </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">C</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">linical Observations:</FONT> </P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> 28 out of 31 treated patients were evaluable, 14 completed the 6<FONT CLASS="nobreak">-month</FONT> duration study. The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable. No drug<FONT CLASS="nobreak">-related</FONT> deaths were recorded. </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">Source:&#x00a0;&#x00a0;&#x00a0;&#x00a0;Milciclib Investigators Brochure version 14 and Clinical Study reports for CDKO<FONT CLASS="nobreak">-125a-006-and</FONT> CDKO<FONT CLASS="nobreak">-125a-007</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Safety</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Overall, Milciclib has indicated a similar pattern of toxicity across studies. Consistent with preclinical findings, the safety profile of the compound in humans is characterized by a dose<FONT CLASS="nobreak">-limiting</FONT> neurological toxicity and, to a lesser extent, by GI toxicity. Asthenia (weakness) and fatigue have also been observed, as well as effects on liver, </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">especially with prolonged schedules of administration. Mild/moderate tremors are a common finding, reported also at recommended Phase 2 doses (RP2Ds) (only one case of grade 3), whereas ataxia (loss of muscle control and balance) was observed primarily during the first dose<FONT CLASS="nobreak">-escalation</FONT> study (one case of grade 3 ataxia occurred also at the RP2D in the combination study CDKO<FONT CLASS="nobreak">-125a-004</FONT> and one in CDKO<FONT CLASS="nobreak">-125a-006</FONT> trial). Both tremor and ataxia were generally reversible in all cases in up to 7<FONT CLASS="nobreak">-9</FONT> days, upon drug discontinuation or dose reduction in some cases. Grade&#x00a0;1<FONT CLASS="nobreak">-2</FONT> dizziness was also reported, with only one grade 3 occurrence, overall. Mild dysgeusia (disorder of sense of taste) is another event that was reported across studies, as well as headache and anorexia (loss of appetite). Grade&#x00a0;3 myasthenia (muscle weakness) was also reported in two patients. Nausea and/or vomiting and/or diarrhea were mostly of grade 1<FONT CLASS="nobreak">-2</FONT> in severity and were manageable with appropriate therapy. Diarrhea was occasionally severe, leading to dehydration in several instances. Skin disorders were also reported across studies; the events were mainly of grade&#x00a0;1<FONT CLASS="nobreak">-2</FONT> in severity except for one case of grade 3 rash maculopapular and one case grade 3 of erythema multiforme. Hematological toxicity was mainly represented by lymphocytes (white blood cells) decrease and, to a lesser extent by all the other hematological parameters. Severe thrombocytopenia (decrease in number of platelets in blood) was sporadically observed, especially at the highest doses tested and in combination with gemcitabine. Effects on liver were dose<FONT CLASS="nobreak">-dependent</FONT> and mainly represented by transient transaminase elevation (with bilirubin slightly less affected). ALT/AST (liver enzymes measured to monitor liver damage) elevations were usually mild using the 7 days on / 7&#x00a0;days off schedule (even if prolonged transaminases (liver enzymes) were occasionally observed). The more prolonged administrations were associated with a more frequent and pronounced effect on liver function tests. Asymptomatic grade 3<FONT CLASS="nobreak">-4</FONT> lipase (a pancreatic enzyme that breaks down fats, measured to monitor pancreatic function) elevations were sometimes reported, without clinical manifestation. No important effects on renal function were noted.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">Monitoring of visual function was performed through visual acuity, funduscopy (ophthalmic examination of the back of the eye) and, in a subset of studies, electroretinography examinations, or ERG. Overall, no clinically relevant abnormalities for these parameters emerged during treatment across studies, except for ERG worsening, compared to baseline, observed in three patients, who for this reason discontinued study treatment as per protocol, and one case of retinal detachment reported as a serious event in one patient (CDKO<FONT CLASS="nobreak">-125a-006</FONT> trial) and assessed as probably related to Milciclib maleate.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">Our interim review in trial CDKD<FONT CLASS="nobreak">-125A-010</FONT>, as noted above, found Milciclib to be well<FONT CLASS="nobreak">-tolerated</FONT> with no drug<FONT CLASS="nobreak">-related</FONT> serious adverse events in 6 patients with unresectable or metastatic HCC who had concluded a first cycle of treatment with Milciclib.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase 2 Data in Thymoma and Thymic Carcinoma</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:5pt;margin-top:5pt;">Thymomas and thymic carcinomas are tumors that originate in epithelial cells of the thymus gland. Generally, thymoma does not spread beyond the thymus, while thymic carcinoma, represents an aggressive cancer that metastasizes rapidly and poses treatment challenges. Both cancers are rare, and it is estimated that together they account for ~400 cases per year in the US, or about 1.5 persons per million diagnosed with thymoma/thymic carcinoma. Patients more often present with advanced disease, with a 5<FONT CLASS="nobreak">-year</FONT> survival of 30% to 50%. Standard primary treatment for patients with these types of tumors is surgical resection. Depending on tumor stage, treatment options include the use of radiation therapy and chemotherapy with or without surgery. First line of chemotherapy treatment is the combination of cisplatin, doxorubicin and cyclophosphamide for thymoma. For thymic carcinoma the first line of treatment is the combination of paclitaxel and carboplatin. Milciclib has Orphan Drug Designation (ODD) in the U.S. and EU for thymic cancer (thymic epithelial tumor or TET).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:5pt;margin-top:5pt;">Milciclib met its primary endpoints in two Phase 2 clinical trials in patients with thymic carcinoma and thymoma. Clinical trials, CDKO<FONT CLASS="nobreak">-125A-006</FONT> (72 patients) and CDKO<FONT CLASS="nobreak">-125A-007</FONT> (30 patients) in patients with thymic carcinoma and thymoma, respectively, were conducted in the US, France and Italy. Monotherapy treatment regimen with Milciclib (150mg/day; 7 days on / 7 days off) was well<FONT CLASS="nobreak">-tolerated</FONT>. Seven patients (5 patients in the CDKO<FONT CLASS="nobreak">-125A-006</FONT> study and 2 patients in the CDKO<FONT CLASS="nobreak">-125A-007</FONT>) have been continuing treatment with Milciclib for more than 2 years with excellent tolerance profile. Among these, 2 patients have been treated with Milciclib for approximately 5 years, demonstrating tolerability of the drug for long term treatment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:5pt;margin-top:5pt;">In trial CDKO<FONT CLASS="nobreak">-125A-006</FONT>, 56 of 72 treated patients had median PFS of 5.78<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 3.48 and months, respectively. In trial CDKO<FONT CLASS="nobreak">-125A-007</FONT>, 18 of 30 treated patients had median PFS of 5.65<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 3.94 and 17.45<FONT CLASS="nobreak"> </FONT>months, respectively. These results materially exceeded the median PFS&gt; 10.2 weeks established for monotherapy with pemetrexed. The OS secondary endpoint was also met in both trials. In trial CDKO<FONT CLASS="nobreak">-125A-006</FONT>, 36 of 72 (50%) treated patients had median OS of 24.44<FONT CLASS="nobreak"> </FONT>months with upper and lower 95% confidence limits of 22.05 and 53.55<FONT CLASS="nobreak"> </FONT>months, respectively. In trial CDKO<FONT CLASS="nobreak">-125A-007</FONT>, 18 of 30 patients had an OS (54.5%) of 48<FONT CLASS="nobreak"> </FONT>months. As a median was not reached, the 95% confidence limits could not be calculated.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Both clinical studies demonstrated that treatment with Milciclib met PFS as the primary endpoint and OS as a secondary endpoint.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Preclinical Data</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The pharmacokinetics of Milciclib were investigated in mouse, rat, dog and monkey models after single intravenous and oral administration of the compound. Since the compound is intended for the oral administration route, the pharmacokinetics were further characterized after single and repeated oral administrations. These preclinical studies were performed with Milciclib formulated as maleate or mono/di/tri<FONT CLASS="nobreak">-hydrochloride</FONT> salt. Following intravenous administration, Milciclib was characterized by a moderate clearance in mice, rats and monkeys and a high clearance in dogs. The volume of distribution was higher than the total body water in all tested species, suggesting an extensive tissue distribution. Following oral administration to rats and monkeys, Milciclib crossed the blood<FONT CLASS="nobreak">-brain</FONT> barrier and distributed in the brain. In all species, Milciclib plasma levels increased largely in direct proportion with the dose.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Preclinical toxicology studies conducted with Milciclib have shown that the hemolymphopoietic system, the GI tract and the male reproductive organs are the major target organs considered related to the pharmacological activity of the compound in all species. The effects on the hemolymphopoietic system and GI tract were reversible after drug withdrawal. Reversibility could not be demonstrated in the male reproductive organs at the end of the 2<FONT CLASS="nobreak">-3-week</FONT> recovery period because of the longtime of maturation of the seminiferous epithelium. Additional toxicities, that are considered not related to the mechanism of action of the compound, were Central Nervous System, or CNS, ocular and renal toxicities. In addition, hemorrhages in different organs were observed in dogs and monkeys. Clinical signs of CNS toxicity were observed at high doses given as single or repeated administrations in all species.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Preclinical Programs</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Anti-IL6R Fully Human mAb TZLS-501 (formerly known as NI-1201)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">TZLS<FONT CLASS="nobreak">-501</FONT> is a fully human mAb targeting the IL<FONT CLASS="nobreak">-6R</FONT>. We licensed the intellectual property from Novimmune in January 2017. This fully human mAb has a novel mechanism of action, binding to both the membrane<FONT CLASS="nobreak">-bound</FONT> and soluble forms of the IL<FONT CLASS="nobreak">-6R</FONT> and depleting circulating levels of the IL<FONT CLASS="nobreak">-6</FONT> in the blood. An excessive production of IL<FONT CLASS="nobreak">-6</FONT> is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications and rheumatoid arthritis, and we believe that TZLS<FONT CLASS="nobreak">-501</FONT> may have potential therapeutic value for these indications.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In preclinical studies, TZLS<FONT CLASS="nobreak">-501</FONT> demonstrated the potential for overcoming the limitations of other IL<FONT CLASS="nobreak">-6</FONT> blocking pathway drugs. Compared to tocilizumab and sarilumab, while binding to the membrane<FONT CLASS="nobreak">-bound</FONT> IL<FONT CLASS="nobreak">-6R</FONT> complex, TZLS<FONT CLASS="nobreak">-501</FONT> has been observed to have a higher affinity for the soluble IL<FONT CLASS="nobreak">-6</FONT> receptor from antibody binding studies conducted in cell culture. TZLS<FONT CLASS="nobreak">-501</FONT> also demonstrated the potential to block or reduce IL<FONT CLASS="nobreak">-6</FONT> signaling in mouse models of inflammation. The soluble form of IL<FONT CLASS="nobreak">-6</FONT> has been implicated to have a larger role in disease progression compared to the membrane- bound form (Kallen, K.J. (2002). &#x201c;The role of transsignaling via the agonistic soluble IL<FONT CLASS="nobreak">-6</FONT> receptor in human diseases.&#x201d; Biochimica et Biophysica Acta. 1592 (3): 323&#x2014;343.).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">StemPrintER&#x2122;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">StemPrintER is a multi<FONT CLASS="nobreak">-gene</FONT> signature assay intended for use in patients diagnosed with estrogen<FONT CLASS="nobreak">-receptor</FONT> positive ER+/HER2 negative breast cancers. We believe this in<FONT CLASS="nobreak">-vitro</FONT> prognostic test will be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis. StemPrintER is designed to help physicians distinguish ER+/HER2 negative patients:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>with an elevated risk of early recurrence (&lt;5 years) who could benefit from chemotherapy in addition to hormonal therapy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>with a high risk of late recurrence who could benefit from prolonged endocrine treatment up to 10 years; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>with a low risk of early recurrence who might be spared chemotherapy or be eligible for less aggressive treatments.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our diagnostic has a novel biological basis, being based on the detection of cancer stem cell markers, uses a reliable platform (qRT<FONT CLASS="nobreak">-PCR</FONT>, FFPE), and has been evaluated in an initial retrospective validation study using a consecutive cohort of approximately 2400 patients with breast cancer. Our development team is preparing for a retrospective validation study using an independent cohort and has conducted a pre<FONT CLASS="nobreak">-submission</FONT> meeting with the FDA, and it is our intention to proceed with the study in the event that we are able to procure a collaboration partner or grant funding but it is not a project of primary focus at the current time.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Manufacturing</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We believe our current CMOs will be able to fully meet our current clinical trial needs and anticipated future commercial demand for Foralumab and Milciclib in a cost<FONT CLASS="nobreak">-effective</FONT> manner.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A large<FONT CLASS="nobreak">-scale</FONT> cGMP manufacturing of Foralumab drug substance has been accomplished and we have produced sufficient purified material for completing all clinical studies up to Phase 3. This material was produced by Lonza Group AG using a proprietary cell culture technology. The Foralumab material is highly stable when stored at <FONT CLASS="nobreak">-80</FONT><FONT CLASS="nobreak"><FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">o</FONT></FONT><FONT CLASS="nobreak">C</FONT> for several years. A novel and proprietary formulation suitable for oral administration of Foralumab has been developed. We have completed cGMP manufacturing of formulated drug product for nasal and oral routes of administration for Phase I clinical studies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have also achieved cGMP manufacturing of Milciclib at pilot scale. The chemical scheme for manufacturing is simple with reproducible yields. This method has been used for producing drug substance to supply the ongoing clinical studies. The chemical process is very cost<FONT CLASS="nobreak">-effective</FONT> and can be scaled<FONT CLASS="nobreak">-up</FONT> for much larger scale needed for commercialization.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Competition</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are aware of a number of companies focused on developing therapies in various indications. Any advances made by a competitor may be used to develop therapies that could compete against any of our product candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For our specific product candidates, the main competitors include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Sorafenib and Lenvatinib are currently the standards of use therapy for HCC but the drugs exhibit severe toxicities and patients often develop resistance to the treatment with Sorafenib. As a result, there is an immediate need for improvement in treatment for HCC.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We believe that Foralumab is currently the only fully human anti<FONT CLASS="nobreak">-CD3</FONT> mAb in clinical development for treatment of NASH and Crohn&#x2019;s disease.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger R&amp;D, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Intellectual Property</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As of June<FONT CLASS="nobreak"> </FONT>27, 2019, we have 255 patents and 30 patents pending and our intellectual property portfolio was made up as follows:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="image_06.jpg" STYLE="height:738.56px;width:492.8px;max-width:100%;"></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have rights to a patent family that discloses the Milciclib compound, methods of using the compound, and processes for making the compound under license from Nerviano (which is further described below). This patent family includes six granted U.S. patents, one granted European patent, and one granted Eurasian patent. This patent family also includes granted patents in Africa (African Intellectual Property Organization, African Regional Intellectual Property Organization), Algeria, Argentina, Australia, Barbados, Bosnia &amp; Herzegovina, Canada, Colombia, Costa Rica, Croatia, Cuba, Ecuador, Georgia, Iceland, India, Indonesia, Israel, Japan, Korea, Kosovo, Malaysia, Mexico, Mongolia, Montenegro, New Zealand, Nicaragua, Norway, Pakistan, Philippines, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Tunisia, Ukraine, Uzbekistan, and Vietnam. Several applications are pending in the U.S. and other countries in this family. The patents in this family will expire in April 2024, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We also have rights to a second patent family which covers related entities, such as salts and crystal forms, of Milciclib, and methods of using the salts and crystal forms. This patent family comprises one granted U.S. patent and one granted patent in each of Europe, China, Japan, and Hong Kong. The patents in this family will expire in April 2030, excluding any patent term adjustment and patent term extension in the U.S. and several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we have rights to five patent families which cover methods of using Milciclib in the treatment of multiple indications. These patent families comprise five granted U.S. patents, and granted patents in Europe, China, Hong Kong, and Japan, and one pending patent application in Europe. The patents in these families will expire between February 2027 and March 2030, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Among the above five patent families, two families also cover combination therapies of Milciclib with cytotoxic agents. These families comprise two granted U.S. patents, and granted patents in Europe, China, Hong Kong, and Japan. The patents in these families will expire between November 2029 and March 2030, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">One family of the above five patent families also covers combination therapies of Milciclib with therapeutic antibodies. This patent family includes one granted U.S. patent, and granted patents in Europe, China, and Japan. The patents in this family will expire in February 2027, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we have rights to a patent family which covers methods of using Milciclib together with a second anti<FONT CLASS="nobreak">-cancer</FONT> agent in the treatment of cancer. This patent family includes one pending application in the U.S and one pending international application. The patent applications in this family, if issued as patents, will expire in December 2038, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have rights to a first patent family that disclose methods of using Foralumab, licensed from Novimmune (which is further described below). This patent family includes, one granted European patent, and one granted Eurasian patent. This patent family also includes granted patents in Australia, Canada, China, Hong Kong, Israel, Japan, Mexico, Norway, Singapore, South Africa, Ukraine, and Portugal. The patents in this family will expire in April 2025, excluding any patent term extensions available in several jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We also have rights to a second patent family that discloses the Foralumab compound and methods of using the compound also licensed from Novimmune. This patent family comprises three granted U.S. patent one granted European patent, and one granted Eurasian patent. This patent family also includes granted patents in Australia, Canada, China, Hong Kong, India, Israel, Japan, Mexico, Norway, Republic of Korea, Singapore, South Africa, and Ukraine. Applications are pending in Brazil, Japan, Singapore and U.S. The patents in these families will expire in June 2025, excluding any patent term adjustment in the U.S. and patent term extensions available in the U.S. and several other jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, we have rights to a third patent family that discloses combination therapies of Foralumab with Il<FONT CLASS="nobreak">-6</FONT> or IL<FONT CLASS="nobreak">-6R</FONT> antibodies licensed from Novimmune. This patent family has one pending U.S. application. The patents in these families will expire in January 2032, excluding any patent term adjustment and patent term extensions available in the U.S.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We own and have right to a fourth patent family that discloses formulations of Foralumab and dosing regimens for treating various disorders. This patent family has applications pending in the U.S, Australia, Canada, China, Europe, Israel and Japan. The patents in these families will expire in August 2037, excluding any patent term adjustment and patent term extensions available in the U.S and several other jurisdictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have rights to a patent family that discloses methods of using TZLS<FONT CLASS="nobreak">-501</FONT> to treat various disorders, licensed from Novimmune. This patent family includes, four granted U.S. patents and one granted European patent. This patent family also includes granted patents in Australia, Canada, China, Japan and Mexico. Applications are pending in U.S. and India. The patents in this family will expire in May 2029, excluding any patent term extensions available in several jurisdictions, such as Europe.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non<FONT CLASS="nobreak">-provisional</FONT> filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the USPTO delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory<FONT CLASS="nobreak">-related</FONT> extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Furthermore, we rely upon trade secrets and know<FONT CLASS="nobreak">-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know<FONT CLASS="nobreak">-how</FONT> and inventions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third<FONT CLASS="nobreak">-party</FONT> patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March<FONT CLASS="nobreak"> </FONT>16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, see &#x201c;Risk Factors &#x2014; Risks Related to Our Intellectual Property.&#x201d;</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Material Agreements</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Nerviano Agreement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In January 2015, we entered into an agreement with Nerviano, or the Nerviano Agreement, pursuant to which we obtained a worldwide, exclusive license to patents owned or controlled by Nerviano, or the Nerviano License to develop and commercialize products and services incorporating Milciclib as an active ingredient, and any product or service controlled or owned by Nerviano that is used to diagnose or assess responsiveness to Milciclib therapy or dosage. The Nerviano License confers the right on us grant sub<FONT CLASS="nobreak">-licenses</FONT>, and otherwise to employ third party manufacturers and distributors to produce and sell licensed products and services.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each party to the Nerviano Agreement agreed to a development plan, or the Nerviano Development Plan, approved by a joint development committee, or the JDC. The JDC is comprised of at least two members of each party, meets at least twice a year and endeavors to make decisions by consensus, save that where there is a disagreement with respect to any aspect of the licensed products or services we shall have a deciding vote.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Nerviano Development Plan, we (or, as the case may be, our sub<FONT CLASS="nobreak">-licensee</FONT>(s)) are obliged to use commercially reasonable efforts to develop and commercialize a licensed product or service in at least one therapeutic indication that arises out of the Nerviano Development Plan, and Nerviano is obliged to use commercially reasonable efforts to manufacture such product(s) or service(s). Pursuant to the Nerviano Development Plan, we have sole responsibility for costs for further clinical development and Nerviano is obliged to perform Phase 2 studies of licensed products and services, save that the amounts to be invoiced by Nerviano to us for Phase 2 studies shall be commercially reasonable and not be greater than a low<FONT CLASS="nobreak">-double-digit</FONT> percentage in excess than amounts estimated to be invoiced by another reputable clinical research organization.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">During the term of the Nerviano Development Plan, or the Nerviano Exclusivity Period, we and our affiliates may not, directly or indirectly, develop, make, use, sell, offer for sale or import any small molecule compound or other biological or chemical molecule other than Milciclib that directly binds to, with an affinity indicated by an IC50 of 100nM or less, and modulates the following specified pharmacological targets hit by Milciclib: Cdk<FONT CLASS="nobreak">-2</FONT>, Cdc<FONT CLASS="nobreak">-4</FONT> and Cdc6.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon entry into the Nerviano Agreement, we paid an upfront, non<FONT CLASS="nobreak">-refundable</FONT> initial license fee of $3,500,000 to Nerviano. We issued 4,233,616 of ordinary shares, fully paid with a nominal value of three pence each, or the Consideration Shares, to Nerviano at an issue price of 50.5 pence each (equivalent to an aggregate value of &#x00a3;2,137,976.08).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Nerviano granted us an option, or the Nerviano Option, to buy<FONT CLASS="nobreak">-back</FONT> all the Consideration Shares for a de minimis aggregate consideration exercisable on written notice at any time after the earlier of:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;an unsuccessful Phase 2 trial for HCC or breast cancer with a licensed product or service and the concomitant decision of the company, our affiliates or sub<FONT CLASS="nobreak">-licensees</FONT> to discontinue development of a licensed product or service;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;the fifth anniversary of the Nerviano Agreement, (provided that if on such date a Phase 2 trial has commenced but has not been completed our ability to exercise the Nerviano Option shall be delayed until the outcome of the Phase 2 trial has become clear); or</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iii)&#x00a0;&#x00a0;&#x00a0;our abandonment of any licensed product or service for bona fide scientific reasons.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">The Nerviano Option cannot be exercised if any of the following events (each, a Release Event), occurs:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;a successful completion of a Phase 2 trial for HCC or breast cancer with a licensed product or service, where such successful conclusion renders the licensed product or service eligible for entry into a Phase 3 trial with no further clinical study; or</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;our abandonment of the development of, or failure to exercise commercially reasonable efforts develop any, licensed product or service, save for where we have bona fide scientific reasons.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Nerviano Option effectively allows us to recover the Consideration Shares if it transpires that Milciclib proves to be unsuccessful in the indications for which we licensed it or we fail to see satisfactory results in a period of 5 years from the date of the license agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Prior to a Release Event, Nerviano has agreed to not transfer, dispose of, or grant options or other rights over directly or indirectly any interests in the Consideration Shares nor to derive any financial benefit from the Shares, but is entitled to exercise all voting rights arising from the Consideration Shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Following a Release Event, Nerviano has agreed to a 12<FONT CLASS="nobreak"> </FONT>month lock<FONT CLASS="nobreak">-up</FONT>, or the Nerviano Lock<FONT CLASS="nobreak">-Up</FONT>, in respect of the Consideration Shares, subject to customary exceptions, including the prior written consent of the company and our nominated adviser from time to time (which consent may be approved, provided or provided subject to conditions as each may determine in its absolute discretion), acceptance of takeover bids, share buy<FONT CLASS="nobreak">-backs</FONT> by the company, or where required by law.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Following the lapse of the term of the Nerviano Lock<FONT CLASS="nobreak">-Up</FONT>, Nerviano has agreed to not directly or indirectly, transfer, sell, mortgage, charge or otherwise dispose of more than 10% of the Consideration Shares (i.e. 423,362 ordinary shares) per calendar month, and to utilize the company&#x2019;s broker from time to time to execute those transactions in respect of the legal and or beneficial ownership or any other interest in the Consideration Shares so as to ensure an orderly market.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are obligated to pay Nerviano the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:7pt;margin-top:7pt;">(a)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;$100,000 upon initiation, first patient dosed, or FPD, of the first Phase 3 registration trial in thymic carcinoma.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:7pt;margin-top:7pt;">(b)&#x00a0;&#x00a0;&#x00a0;&#x00a0;$4,000,000 upon FPD of the first Phase 3 registration trial in HCC.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:7pt;margin-top:7pt;">(c)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;$6,000,000 upon FPD of the first Phase 3 registration trial in breast cancer.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:7pt;margin-top:7pt;">(d)&#x00a0;&#x00a0;&#x00a0;&#x00a0;Upon the first NDA equivalent in: thymic carcinoma, $900,000; HCC, $9,000,000; breast cancer, $15,000,000.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">We are obliged to pay Nerviano a low<FONT CLASS="nobreak">-single-digit</FONT> percentage royalty fee of the annual net sales of licensed products or services, subject to certain royalty off<FONT CLASS="nobreak">-sets</FONT> on a country<FONT CLASS="nobreak">-by-country</FONT> basis and, subject to certain exclusions, a low<FONT CLASS="nobreak">-double-digit</FONT> percentage of sub<FONT CLASS="nobreak">-licensing</FONT> revenues from the sale of licensed products or services for the life of the licensed patents.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">During the Nerviano Exclusivity Period, we have the right to terminate activities and funding to Nerviano after 24<FONT CLASS="nobreak"> </FONT>months from the beginning of the Nerviano Exclusivity Period but not prior thereto. If we exercise our termination right, we are obliged to transfer to Nerviano all relevant data, licensed products and services and an exclusive license pertaining to the licensed product or services, and Nerviano shall pay us a low<FONT CLASS="nobreak">-single-digit</FONT> percentage royalty on annual net sales of licensed products and services, subject to certain exceptions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Following the expiry of the Nerviano Exclusivity Period, we may terminate the Nerviano Agreement at any time on 90 days&#x2019; written notice, and either party may terminate the Nerviano Agreement for material breach by the other party of any material obligation or condition of the Nerviano Agreement by written notice, subject to a 45 day cure period for a payment breach, and a 120 day cure period for any other breach.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Absent early termination, the Nerviano Agreement shall remain in force until the later of, in all countries in which licensed products and services are marketed pursuant to the Nerviano Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents, subject to certain exceptions, which covers the sale of such licensed products or services, or (b) five years from the date of first commercial sale of such licensed product or service in such country.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Novimmune CD3 Agreement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">In December 2014, we entered into a license and sublicense agreement with Novimmune, or the Novimmune CD3 Agreement, pursuant to which we obtained a worldwide, exclusive license to certain patents owned or controlled by Novimmune, or the Novimmune CD3 License, together with a sublicense to certain patent licenses from Bristol<FONT CLASS="nobreak">-Myers</FONT> Squibb Company, or BMS, or the BMS CD3 Sublicense, and any associated know<FONT CLASS="nobreak">-how</FONT>, biologic materials, clinical data or other technology relating to CD3 receptor mAbs and their use in order to research, develop and commercialize products and services. The Novimmune CD3 License and BMS CD3 Sublicense both confer the right to us to grant sublicenses, and otherwise to employ third party manufacturers and distributors to produce and sell licensed products and services, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Pursuant to the Novimmune CD3 Agreement, Novimmune granted the BMS CD3 Sub<FONT CLASS="nobreak">-License</FONT> to us. Novimmune effected such grant pursuant to a research and commercialization agreement between Novimmune and BMS dated September<FONT CLASS="nobreak"> </FONT>20, 2014, or the BMS R&amp;C Agreement, and the agreement for the exclusive commercial license for the CD3 licensed product (NI<FONT CLASS="nobreak">-0401</FONT>) between Novimmune and BMS dated February 2005.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Under the Novimmune CD3 Agreement, we have full control and authority over the research, development and commercialization of licensed products and services, and are required to exercise commercially reasonable efforts to commercialize such licensed products and services at all times.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:7pt;margin-top:7pt;">Upon our entry into the Novimmune CD3 Agreement we paid an upfront fee of $750,000 to Novimmune (to&#x00a0;be on paid by Novimmune to BMS pursuant to the terms of the BMS R&amp;C Agreement), and a further upfront fee of $500,000 to Novimmune. We are required to pay Novimmune installments of $250,000 on each of the 14<FONT CLASS="nobreak"> </FONT>month, 26<FONT CLASS="nobreak"> </FONT>month and 38<FONT CLASS="nobreak"> </FONT>month anniversaries of the date of the Novimmune CD3 Agreement. For the term of the Novimmune Agreement, we are obligated to pay to Novimmune a royalty of a low<FONT CLASS="nobreak">-single-digit</FONT> percentage on net sales of licensed products and services, together with any amounts owed to BMS incurred pursuant to the BMS CD3 Sub<FONT CLASS="nobreak">-License</FONT>.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may terminate the Novimmune CD3 Agreement at any time on 90 days&#x2019; written notice, and either party may terminate the Novimmune CD3 Agreement by written notice for a payment breach or any other breach, subject to 45 day and 120 day cure periods, respectively. Absent early termination, the Novimmune CD3 Agreement will continue until the later of, in all countries in which licensed products are marketed pursuant to the Novimmune CD3 Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents or a claim that has not been pending more than five years, subject to certain exceptions, which covers the sale of such licensed product or service, or (b) the end of any market exclusivity period granted by the relevant governmental authority in a country that prevents another party from marketing the same licensed product or service.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Novimmune IL-6r Agreement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In December 2016, we entered into a license and sublicense agreement with Novimmune, or the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement, pursuant to which we obtained a worldwide, exclusive license to certain patents owned or controlled by Novimmune, or the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> License, together with a sub<FONT CLASS="nobreak">-license</FONT> to certain patent licenses from BMS, or the BMS IL<FONT CLASS="nobreak">-6r</FONT> Sub<FONT CLASS="nobreak">-License</FONT>, and any associated know<FONT CLASS="nobreak">-how</FONT>, biologic materials, clinical data or other technology relating to IL<FONT CLASS="nobreak">-6r</FONT> mAbs and their use in order to research, develop, commercialize products and services. The Novimmune IL<FONT CLASS="nobreak">-6r</FONT> License and BMS IL<FONT CLASS="nobreak">-6r</FONT> Sub<FONT CLASS="nobreak">-License</FONT> both confer the right to us to grant sub<FONT CLASS="nobreak">-licenses</FONT>, and otherwise to employ third party manufacturers and distributors to produce and sell licensed products and services, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Pursuant to the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement, Novimmune granted the BMS IL<FONT CLASS="nobreak">-6r</FONT> Sub<FONT CLASS="nobreak">-License</FONT>. Novimmune effected such grant pursuant to the BMS R&amp;C Agreement and the agreement for the IL<FONT CLASS="nobreak">-6r</FONT> exclusive commercial license for the IL<FONT CLASS="nobreak">-6r</FONT> antibody licensed product (NI<FONT CLASS="nobreak">-1201</FONT>) between Novimmune and BMS dated September<FONT CLASS="nobreak"> </FONT>20, 2009, or the IL<FONT CLASS="nobreak">-6r</FONT> Commercial License Agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement, we have full control and authority over the research, development and commercialization of licensed products and services, and are required to exercise commercially reasonable efforts to commercialize such licensed products and services at all times.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon our entry into the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement we paid an upfront fee of $100,000 to Novimmune. For the term of the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement, we are obligated to pay to Novimmune a royalty of a low<FONT CLASS="nobreak">-single-digit</FONT> percentage on net sales of licensed products and services, or low<FONT CLASS="nobreak">-double-digit</FONT> percentage of any sub<FONT CLASS="nobreak">-license</FONT> royalty revenue which we receive that arises from sales of licensed products and services, together with any amounts owed to BMS incurred pursuant to the BMS IL<FONT CLASS="nobreak">-6r</FONT> Sub<FONT CLASS="nobreak">-License</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The BMS R&amp;C Agreement and the IL<FONT CLASS="nobreak">-6r</FONT> Commercial License Agreement were amended pursuant to an agreement between Novimmune and BMS dated December 2016, or the Novimmune Amendment Agreement. Pursuant to the Novimmune Amendment Agreement, in the event that Novimmune (or, as the case may be, a sublicensee) commercializes a combination product comprising NI<FONT CLASS="nobreak">-1201</FONT> and NI<FONT CLASS="nobreak">-0401</FONT>, then such product shall be subject to a single royalty.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may terminate the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement at any time on 90 days&#x2019; written notice, and either party may terminate the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement by written notice for a payment breach or any other breach, subject to 45 day and 120 day cure periods, respectively. Absent early termination, the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement will continue until the later of, in all countries in which licensed products are marketed pursuant to the Novimmune IL<FONT CLASS="nobreak">-6r</FONT> Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents or a claim that has not been pending more than five years, subject to certain exceptions, which covers the sale of such licensed product or service, or (b) the end of any market exclusivity period granted by the relevant governmental authority in a country that prevents another party from marketing the same licensed product or service.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Brigham and Women&#x2019;s Hospital License</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On May<FONT CLASS="nobreak"> </FONT>29, 2018, we entered into a license agreement, or the BWH License, with BWH pursuant to which we obtained a worldwide exclusive license to a patent owned by BWH for a novel technology discovered by Dr. Howard Weiner. The patent relates to a formulation of Foralumab in a medical device developed for nasal administration of Foralumab. The BWH License extends to any associated know<FONT CLASS="nobreak">-how</FONT>, clinical data and use in order to research, develop and commercialize products and services. The BWH License confers on us the right to grant sub<FONT CLASS="nobreak">-licenses</FONT>, and otherwise to employ third party manufacturers and distributors to sell licensed products and services.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the BWH License we have full control and amnesty over the research, development and commercialization of licensed products and services and are required to exercise commercially reasonable efforts to commercialize such licensed products and services at all times.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon our entry into the BWH License we paid an upfront fee of $10,000 to BWH. We are required to pay annual maintenance fees, all ongoing patent maintenance and prosecution costs and a low single<FONT CLASS="nobreak">-digit</FONT> royalty on annual net sales (and a 12% royalty of non<FONT CLASS="nobreak">-royalty</FONT> sub<FONT CLASS="nobreak">-license</FONT> revenues for the life of the intellectual property). We are also obliged to make certain milestone payments of: (a) US$300,000 within 60 days of first patient enrolled in a Phase 1 human clinical trial; (b) US$600,000 within 60 days of first patient enrolled in a Phase 2 human clinical trial; (c) US$1,500,000 within 60 days of first patient enrolled in a Phase 3 clinical trial; and (d) US$3,000,000 within 60 days of first commercial sale of a licensed product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may terminate the BWH License at any time on 90 days&#x2019; written notice, and either party may terminate the BWH License by written notice for payment or other breach, subject to a 60 day cure period. Absent early termination the BWH License will remain in effect until the date on which all patents and filed patent applications have expired or been abandoned.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Organizational Structure</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table sets out details of our significant subsidiaries:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Principal activity</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Registered address</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Percentage shareholding</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Country of incorporation</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-45" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tiziana Pharma Limited</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Clinical stage biotechnology company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">rd </FONT>Floor, 11&#x2013;12 St</P>
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">James&#x2019;s Square,</P>
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">London, SW1Y 4LB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">England &amp; Wales</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-45" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tiziana Therapeutics Inc.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Clinical stage biotechnology company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">420 Lexington Avenue</P>
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Suite 2525</P>
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">New York, NY 10170</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">USA</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Longevia Genomics S.r.l.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biotechnology discovery company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Via&#x00a0;Constantinopli&#x00a0;42</P>
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">09100&#x2013;Cagliria (CA)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="top">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Italy</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Government Regulation</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Government authorities in most jurisdictions extensively regulate the research, development, clinical testing, manufacture, distribution and marketing of pharmaceutical products such as those that the company is developing. Obtaining regulatory approvals and ensuring subsequent compliance with applicable laws and regulations requires the expenditure of substantial time and financial and managerial resources. Regulatory requirements in different jurisdictions vary, and the timing and success of efforts to obtain regulatory approvals can be highly uncertain. Development of a successful drug candidate, from identification of a candidate drug compound, through preclinical and clinical testing, to registration, typically takes more than ten years.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Drug development is a highly structured process divided into two major stages, preclinical and clinical. In the preclinical stage, the toxicology and mode of action of an active compound is evaluated. The clinical stage is designed to prove the safety of any new pharmaceutical, determine dosage requirements and, predominantly in the later phases, prove its therapeutic utility. This stage is carried out in three phases, which, as a developer moves through the phases, require increasingly large, complex, expensive and time<FONT CLASS="nobreak">-consuming</FONT> clinical studies. During Phase<FONT CLASS="nobreak"> </FONT>1, the product candidate is initially given to a small number of healthy human subjects or patients and tested for safety, tolerance, absorption, metabolism, distribution and excretion. During Phase<FONT CLASS="nobreak"> </FONT>2, additional trials are conducted in a larger, but still relatively limited, patient population to verify that the product candidate has the desired effect and to identify optimal dosage levels. Furthermore, possible adverse effects and safety risks are identified. The therapeutic utility of the product candidate for specific targeted diseases is also studied in more depth. During Phase<FONT CLASS="nobreak"> </FONT>3, trials are undertaken to further evaluate dosage, to provide statistically significant evidence of clinical effectiveness and to further study the safety in an expanded patient population at multiple clinical trial sites. Phase 3 trials may require several hundreds or thousands of patients and are therefore the most expensive and time<FONT CLASS="nobreak">-consuming</FONT> to conduct. At any time during one of the phases, a trial may produce a negative result, in which case the developer may choose to end the development project.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Following completion of the Phase 3 trials, the developer submits all the preclinical and clinical trial documentation as well as extensive data characterizing the manufacturing process to the regulator to seek regulatory approval to market the formulation as a pharmaceutical product. The regulator reviews all the information related to the safety of the active compound, and whether the pharmacological effect claimed by the developer on the proposed label can be substantiated by the results of the clinical trials. The regulator has the option to decide to approve the application as requested, ask for changes to the claims made by the developer, ask for more information, require that further clinical trials are undertaken, or refuse to approve the formulation for sale.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even after initial regulatory approval has been obtained, further studies, including Phase 4 post<FONT CLASS="nobreak">-approval</FONT> safety studies, may be required to provide additional data on safety and will be required to gain approval for the use of a product as a treatment for clinical indications other than those for which the product was initially tested. There are also continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. In addition, regulatory authorities require post<FONT CLASS="nobreak">-marketing</FONT> reporting to monitor the adverse effects of the product. Results of post<FONT CLASS="nobreak">-approval</FONT> programs may limit or expand the further marketing of the products. Further, if there are any modifications to the product, including changes in indication, manufacturing process or labeling, or a change in the manufacturing facility, an application seeking approval of such changes or, as the case may be, notification, must be submitted to the relevant regulatory authorities before the modified product can be commercialized. Moreover, an approved drug product may be subject to a REMS, which could impose a number of post<FONT CLASS="nobreak">-approval</FONT> obligations, including (among other things) a communication plan for physicians regarding safe use of the drug, distribution and use restrictions, and/or periodic assessments of the effectiveness of the REMS. Finally, studies may be required as a contingency of regulatory approval (post<FONT CLASS="nobreak">-approval</FONT> commitments), and completion of these studies within a regulator mandated time frame may be required.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">European Union</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The development, marketing and sale of medicinal products in the EU is subject to extensive pre and post marketing regulation by regulatory authorities at both the EU and national levels. The requirements, regulatory approvals and processes governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, although there is some degree of EU wide harmonization.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Trials</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU, it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy and, in most EU countries, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the relevant regulatory authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the regulatory authority in each Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Marketing Approval</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the EU medicinal products can only be commercialized after obtaining an MA. There are three procedures for obtaining marketing approvals: the centralized procedure, the decentralized procedure and the mutual recognition procedure/national procedure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Community marketing authorization, which is issued by the European Commission through the centralized procedure, based on the opinion of the CHMP of the EMA, is valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Marketing approvals obtained using the decentralized procedure are available for products not falling within the mandatory scope of the Centralized Procedure. An identical dossier is submitted to the regulatory authorities of each of the Member States in which the marketing approval is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics and a draft of the labeling and package leaflet, which are sent to the other the concerned Member States, or CMSs, for their approval. A CMS can raise an objection, based on the assessment report, the summary of product characteristics, the labelling and the package leaflet on the grounds of potential serious risk to public health. If no such objections are raised the product will be granted a national marketing authorization in the RMS and all of the selected CMSs. Where a product has already been authorized for marketing in a Member State, this decentralized procedure approval can be recognized in other Member States through the mutual recognition procedure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Marketing approvals obtained using the national procedure are issued by a single regulatory authority of one of the Member States and only apply to the territory covered by the relevant regulatory authority. They are available for products not falling within the mandatory scope of the centralized procedure. Once a product has been authorized for marketing in a Member State through the national procedure, any application in another Member State must be by the mutual recognition procedure whereby the marketing approval can also be recognized in other Member States through the mutual recognition procedure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the procedures described above, before granting the MA, the EMA or the relevant regulatory authority of the Member States of the EU makes an assessment of the risk<FONT CLASS="nobreak">-benefit</FONT> balance of the product on the basis of scientific criteria concerning its quality, safety and therapeutic utility.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The holder of a marketing authorization in any Member State of the EU is subject to various obligations under applicable EU regulations, such as pharmacovigilance obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions, and to submit periodic safety update reports to the regulatory authorities. The holder must also ensure that the manufacturing and batch release of its product is in compliance </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">with the applicable requirements. The marketing approval holder is further obligated to ensure that the advertising and promotion of its products complies with applicable laws, which can differ from Member State to Member State of the EU.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Data Exclusivity</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">MAAs for generic medicinal products in the EU do not need to include the results of preclinical and clinical trials, but instead can refer to the data included in the marketing approval of a reference product for which regulatory data exclusivity has expired. If a marketing approval is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity, during which generic MAAs referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic products may not be placed on the market. The two<FONT CLASS="nobreak">-year</FONT> period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Orphan Medicinal Products</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The EMA&#x2019;s Committee for Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life<FONT CLASS="nobreak">-threatening</FONT> or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life<FONT CLASS="nobreak">-threatening</FONT>, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the product in the EU would be sufficient to justify the necessary investment in developing the medicinal product. The COMP may only recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over existing approved products for the relevant indication. Following a positive opinion by the COMP, the European Commission adopts a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a new product was approved for the indication and no convincing data are available to demonstrate a significant benefit over that product). Orphan medicinal product designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted following marketing authorization. During this period, the competent authorities may not accept or approve any similar medicinal product, unless it offers a significant clinical benefit. This period may be redacted to six years if the orphan medicinal product designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">United States</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Standard Procedure</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>completion of preclinical laboratory studies, animal studies and formulation studies in compliance with the FDA&#x2019;s good laboratory practice regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>submission to the FDA of an IND, which must become effective before human clinical trials may begin;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>approval by the institutional review board, or IRB, at each clinical site before each trial may be initiated;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>performance of adequate and well<FONT CLASS="nobreak">-controlled</FONT> human clinical trials in accordance with applicable IND and other clinical trial<FONT CLASS="nobreak">-related</FONT> regulations, sometimes referred to as GCPs to establish the safety and clinical utility of the proposed product candidate for its proposed indication;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>submission to the FDA of a BLA or NDA;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>satisfactory completion of an FDA pre<FONT CLASS="nobreak">-approval</FONT> inspection of the production facility or facilities where the product is produced to assess compliance with the FDA&#x2019;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality, purity and potency;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>FDA review and approval of the BLA or NDA prior to any commercial marketing or sale of the product in the United States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Other potential consequences include, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>fines, warning letters or holds on post<FONT CLASS="nobreak">-approval</FONT> clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>product seizure or detention, or refusal to permit the import or export of products; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>injunctions or the imposition of civil or criminal penalties.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Clinical Trials</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Clinical trials involve the administration of the IND to human patients under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research patients provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their website. Regulatory authorities, IRBs or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Marketing Approval</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls, or CMC, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a filing decision.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, under the Pediatric Research Equity Act of 2003<FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">, </FONT>certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in<FONT CLASS="nobreak">-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#x2019;s continued safety, quality and purity.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Before approving a BLA or NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a CR letter. A CR letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post<FONT CLASS="nobreak">-approval</FONT> studies, including Phase 4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post<FONT CLASS="nobreak">-marketing</FONT> studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Orphan Drug Designation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Orphan Drug Act of 1983, the FDA may designate a biologic product as an &#x201c;orphan drug&#x201d; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment of the disease or condition will be recovered from sales of the product).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Post-Approval Requirements for the EU and United States</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The FDA and the relevant regulatory authorities in the EU strictly regulate marketing, labeling, advertising and promotion of products that are placed on the market in their respective territories. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off<FONT CLASS="nobreak">-label</FONT> uses, and a company that is found to have improperly promoted off<FONT CLASS="nobreak">-label</FONT> uses may be subject to significant liability.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the relevant regulatory authorities, and are subject to periodic unannounced inspections by them to confirm compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior approval of the relevant regulatory authorities before being implemented. Regulations laid down by the FDA and the regulatory authorities in the EU also require investigation and correction of any deviations from the requirements of cGMP and impose reporting and documentation requirements upon the marketing approval holder and any third party manufacturers that the marketing approval holder may decide to use.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Other Healthcare Laws in the EU and United States</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company will also be subject to healthcare regulation and enforcement by the U.S. federal government and the states and governments in the EU and any other countries in which the company conducts its business, including its research, and the marketing and distribution of its product candidates and products once they have obtained an MA. Failure to comply with these laws, where applicable, can result in the imposition of significant civil penalties, criminal penalties, exclusion from participating in health care programs, additional reporting requirements and oversight if the company becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non<FONT CLASS="nobreak">-compliance</FONT> with these laws and other sanctions. The healthcare laws and regulations that may affect the company&#x2019;s ability to operate in the United States include: the federal fraud and abuse laws, including the federal anti<FONT CLASS="nobreak">-kickback</FONT> and </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals. Many US states have similar laws and regulations that may differ from each other and federal law in significant ways. Moreover, several US states have enacted legislation requiring pharmaceutical manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and prohibiting certain other sales and marketing practices. Rules and legislation covering more or less the same subject matter as those in the United States apply to in countries in the EU and to other countries. These can differ between jurisdictions and can sometimes result in lower or higher exposure in those countries than in the United States. Where a product is sold in a number of countries compliance efforts can therefore be complicated.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Coverage and Reimbursement in the EU and United States</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Sales of products developed from the company&#x2019;s product candidates, if approved, will depend, in part, on the extent to which such products will be covered by third party payors, such as government health care authorities, government health care programs, commercial insurance and managed healthcare organizations. These third party payors are increasingly limiting coverage or reducing reimbursements for medical products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost<FONT CLASS="nobreak">-containment</FONT> programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Governments influence the price of medicinal products in the EU through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost<FONT CLASS="nobreak">-effectiveness</FONT> of a particular product candidate to currently available therapies. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general in the EU governments influence the price of medicinal products through their pricing and reimbursement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The adoption of price controls and cost<FONT CLASS="nobreak">-containment</FONT> measures, and the adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit the company&#x2019;s net revenue and results. Decreases in third party reimbursement for the company&#x2019;s product candidates or a decision by a third party payor to not cover the company&#x2019;s product candidates could reduce physician usage of the company&#x2019;s product candidates, once approved, and have a material adverse effect on the company&#x2019;s sales, results of operations and financial condition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Privacy and Data Protection Laws in Europe</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are subject to European laws relating to our and our suppliers&#x2019;, partners&#x2019; and subcontractors&#x2019; collection, control, processing and other use of personal data (i.e. any data relating to an identifiable living individual, whether that individual can be identified directly or indirectly). We are subject to the supervision of local data protection authorities in those jurisdictions where we are established, where we offer goods or services to EU residents and where we monitor the behavior of individuals in the EU (i.e. undertaking clinical trials). We and our suppliers, partners and subcontractors process personal data including in relation to our employees, employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health and medical information. The data privacy regime in the EU includes the General Data Protection Regulation, or GDPR, the e<FONT CLASS="nobreak">-Privacy</FONT> Directive (2002/58/EC) and the e<FONT CLASS="nobreak">-Privacy</FONT> Regulation (once in force) and the national laws and regulations implementing or supplementing each of them.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the European Economic Area, or EEA, (unless certain steps are taken to ensure an adequate level of protection), and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure the protection of data subject rights, including as required to respond </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">to complaints and requests from data subjects. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e. health data) is processed on a large scale, introduces mandatory data breach notification throughout the EU and imposes additional obligations on us when we are contracting with service providers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, to the extent a company processes, controls or otherwise uses &#x201c;special category&#x201d; personal data (including patients&#x2019; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right for Member State to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating model or standard operating procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We depend on a number of third parties in relation to the provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EU, we do so in compliance with the relevant data export requirements from time to time. We take our data protection obligations seriously, as any improper, unlawful or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal data (i.e. special category), could negatively impact our business and/or our reputation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not considered by the European Commission to offer adequate protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. There is currently ongoing litigation challenging the commonly used transfer mechanisms, the EU Commission approved model clauses. In addition, the U.S. Privacy Shield is currently under review by the European Commission. As such, it is uncertain whether the Privacy Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find alternative bases for the compliant transfer of personal data from the EU to the United States and we are monitoring developments in this area. Invalidation of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The EU is in the process of replacing the e<FONT CLASS="nobreak">-Privacy</FONT> Directive with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each Member State, without the need for further enactment. The draft e<FONT CLASS="nobreak">-Privacy</FONT> Regulation imposes strict opt<FONT CLASS="nobreak">-in</FONT> marketing rules with limited exceptions for business<FONT CLASS="nobreak">-to-business</FONT> communications and alters rules on third<FONT CLASS="nobreak">-party</FONT> cookies, web beacons and similar technology. Regulation of cookies and web beacons may lead to broader restrictions on online research activities, including efforts to understand users&#x2019; internet usage. The current draft also significantly increases fining powers to the same levels as GDPR (i.e. the greater of 20<FONT CLASS="nobreak"> </FONT>million Euros or 4% of total global annual revenue). While no official timeframe has been provided, commentators have stated that the e<FONT CLASS="nobreak">-Privacy</FONT> Regulation is likely to be agreed in 2019 and to come into force during the second half of 2020 or during 2021 following a transition period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&#x2019; national laws and the introduction of the e<FONT CLASS="nobreak">-Privacy</FONT> Regulation once it takes effect. Any failure or perceived failure to comply with global privacy laws carries with it the risk of significant penalties and sanctions of up to &#x20ac;20<FONT CLASS="nobreak"> </FONT>million or 4% of global turnover. These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be expensive and time<FONT CLASS="nobreak">-consuming</FONT> to defend and could result in adverse publicity that could harm our business.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Property, Plant and Equipment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The below table contains information regarding existing or planned material tangible fixed assets owned or leased by us and our subsidiaries. We believe that suitable additional or substitute space will be available as needed to accommodate any future expansion of our operations.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 34.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Location</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Tenure</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Principal Use</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Size</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 34.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">55 Park Lane, Suite 14a,</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">London W1K 1NA, United Kingdom</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Annual Lease</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Principal Office</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">652 square feet</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-45" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 34.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">420 Lexington Avenue</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Suite 2525</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">New York, United States</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Five year lease</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Principal Office</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">3,011 square feet</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-45" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 34.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">3805 Old Easton</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Road, Doylestown,</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">PA, United States</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Annual lease</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Research &amp; Development Centre</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">408 square feet</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</P>




	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T15"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table sets forth information regarding our directors as of June<FONT CLASS="nobreak"> </FONT>30, 2019:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Age</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Gabriele Marco Antonio Cerrone MBA<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">47</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Executive Chairman</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Willy Simon<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(3)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">67</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Non<FONT CLASS="nobreak">-Executive</FONT> Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Dr. Kunwar Shailubhai MBA<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(1)(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">61</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Chief Executive Officer, Chief Scientific Officer and Executive Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Leopoldo Zambeletti<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(1)(2)(3)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Non<FONT CLASS="nobreak">-Executive</FONT> Director</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Remuneration Committee member</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;">(2)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Nominating Committee member</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;">(3)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Audit Committee member</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table sets forth information regarding our senior managers as of June<FONT CLASS="nobreak"> </FONT>30, 2019:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Tiziano Lazzaretti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Chief Financial Officer</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Jules S. Jacob</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Senior Director, CMC &amp; Non<FONT CLASS="nobreak">-Clinical</FONT> Development</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Dr. Evangeline Priya Eddy DABT</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Senior Director, Safety and Toxicology</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Dr. Vaseem A. Palejwala</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Director, Clinical Operations</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Gabriele Marco Antonio Cerrone &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Executive Chairman</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Gabriele Marco Antonio Cerrone, is the Founder of the company and has been its Executive Chairman since April 2014. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has listed six of these companies on Nasdaq and one on AIM. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone co<FONT CLASS="nobreak">-founded</FONT> Trovagene, Inc. a molecular diagnostic company and served as its co<FONT CLASS="nobreak">-chairman</FONT>. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone was a co<FONT CLASS="nobreak">-founder</FONT> and served as chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc., and was a director of and led the restructuring of Siga Technologies, Inc. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone co<FONT CLASS="nobreak">-founded</FONT> FermaVir Pharmaceuticals, Inc. and served as chairman until its merger in September 2007 with Inhibitex, Inc. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myer Squibb in 2012. Mr.<FONT CLASS="nobreak"> </FONT>Cerrone graduated from New York University&#x2019;s Stern School of Business with a master in business administration (MBA).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Willy Simon &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Non-Executive Director</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Willy Jules Simon has served as a Non<FONT CLASS="nobreak">-Executive</FONT> Director of the company since November 2015. Mr.<FONT CLASS="nobreak"> </FONT>Simon has served as non<FONT CLASS="nobreak">-executive</FONT> chairman of Bever Holding B.V. a Dutch listed public company focused on real estate development since August 2007. Mr.<FONT CLASS="nobreak"> </FONT>Simon served as the Chief Executive Officer of Fortis Investment Management from January 2000 to July 2002. Mr.<FONT CLASS="nobreak"> </FONT>Simon worked in banking at Kredietbank N.V. from August 1975 to December 1983 and at Citibank London from January 1984 to December 1996 before serving as an executive member of the board of Generale Bank NL from January 1997 to December 1999. From July 2004 until April 2012, he served as a non<FONT CLASS="nobreak">-executive</FONT> director of Redi &amp; Partners Ltd., a fund of funds. Mr.<FONT CLASS="nobreak"> </FONT>Simon was previously chairman of AIM<FONT CLASS="nobreak">-traded</FONT> Velox3 plc (formerly 24/7 Gaming Group Holdings plc), a company focused on publishing and developing gaming software for the mobile gaming industry, from April 2012 until April 2014. Mr.<FONT CLASS="nobreak"> </FONT>Simon was a director of Playlogic Entertainment Inc., a Nasdaq listed company focused on developing, publishing, and selling interactive software games, from December 2003 to September 2011. Mr.<FONT CLASS="nobreak"> </FONT>Simon acted as chairman of Bank Oyens &amp; van Eeghen from September 2102 to December 2004. Mr.<FONT CLASS="nobreak"> </FONT>Simon holds a law degree from the University of Louvain and a post<FONT CLASS="nobreak">-graduate</FONT> degree in European law and economics from Institut des Hautes Etudes Europ&#x00e9;ennes, Strasbourg.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leopoldo Zambeletti &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Non-Executive Director</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti joined our board of directors on April<FONT CLASS="nobreak"> </FONT>19, 2018. During a 19 year career as an investment banker, Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti led the European Healthcare Investment Banking team at JPMorgan for eight years from April 1999 to April 2007 before taking up the same position at Credit Suisse for a further five years from September 2012 to November 2012. Since 2013 he has been an independent strategic advisor to life science companies on merger </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">and acquisitions, out<FONT CLASS="nobreak">-licensing</FONT> deals and financing strategy. He is a non<FONT CLASS="nobreak">-executive</FONT> director of, Qardio Inc., Summit Therapeutics plc, Nogra Pharma Limited, Faron Pharmaceuticals OY and DS Biopharma Limited. Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti started his career at KPMG as an auditor. Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti received a B.A. in Business from Bocconi University in Milan, Italy. He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St Bartholomew, the Royal London and the London Chest Hospitals. He is the founder of the cultural initiative 5x5 Italy.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dr. Kunwar Shailubhai &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Chief Executive Officer, Chief Scientific Officer and Executive Director</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dr. Kunwar Shalilubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017, Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co<FONT CLASS="nobreak">-founder</FONT> of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008, Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. (&#x201c;Synergy DE&#x201d;). From May 2003 until March 2004, Dr. Shailubhai served as executive vice president, R&amp;D of Synergy DE. From 2001 to April 2003, Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC<FONT CLASS="nobreak">-C</FONT> agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000, he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai is a director of Rasna Therapeutics, Inc. and Okyo Pharma Ltd. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Tiziano Lazzaretti &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Chief Financial Officer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti has served as Chief Financial Officer of the company since March 2016. Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti has extensive experience in the healthcare and pharmaceutical industries and joined the company from Pharmentis Srl, a spin<FONT CLASS="nobreak">-off</FONT> from Teva Ratiopharm, where he served as group finance director from 2011 to 2016. Since 2016, Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti has been the chief financial officer of Rasna Therapeutics, Inc. and since 2017, he has been the chief financial officer of Okyo Pharma Ltd. Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti was executive director at Alliance Boots Healthcare, an international pharmacy<FONT CLASS="nobreak">-led</FONT> health and beauty group. Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti held senior positions at SNIA Spa, Accenture, and Fiat Group. Mr.<FONT CLASS="nobreak"> </FONT>Lazzaretti received his bachelor of science (BSc Hons) in accounting and finance from the University of Turin, Italy, was awarded a master in business administration from Bocconi University, Milan and studied corporate finance at the London Business School.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Jules S. Jacob &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Senior Director, CMC &amp; Non-Clinical Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Jules Jacob has served as Senior Director of CMC and Non<FONT CLASS="nobreak">-Clinical</FONT> Development of the company since July 2017 and has over 25 years of drug development experience. Previously, Mr.<FONT CLASS="nobreak"> </FONT>Jacob was senior director of product development at Aprecia Pharmaceuticals Company, a drug delivery technology platform company, from March 2009 to July 2017, where he led the development of Spritam&#x00ae;, the first FDA<FONT CLASS="nobreak">-approved</FONT> dosage form manufactured using 3<FONT CLASS="nobreak">-dimensional</FONT> printing, and other 505(b)(2) pipeline products. Mr.<FONT CLASS="nobreak"> </FONT>Jacob was director of formulation development at Panacos Pharmaceuticals Inc., a drug company focused on human immunodeficiency virus, or HIV, and other major human viral diseases, from March 2007 to December 2008, where he worked on the development of first<FONT CLASS="nobreak">-in-class</FONT> maturation inhibitors for the treatment of HIV. Mr.<FONT CLASS="nobreak"> </FONT>Jacob was a founding scientist, director of R&amp;D and director of technology development at Spherics, Inc., a pharmaceutical company that engaged in developing and manufacturing oral pharmaceutical products for CNS conditions, GI disorders, and cancer, from February 2000 to February 2007. Mr.<FONT CLASS="nobreak"> </FONT>Jacob worked on the development of bioadhesive dosage forms for treatment of CNS disorders, through the 505(b)(2) regulatory pathway at Spherics Inc. Mr.<FONT CLASS="nobreak"> </FONT>Jacob completed his undergraduate degree and graduate education in biological and medical sciences at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacology, Physiology and Biotechnology at Brown University.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dr. Evangeline Priya Eddy &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Senior Director, Safety &amp; Toxicology</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dr. Eddy has served as Senior Director, Safety &amp; Toxicology of the company and of Rasna Therapeutics, Inc., respectively, since January 2017 and has over 20 years of experience in drug discovery and development. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">Dr. Eddy served as senior director, toxicology and safety pharmacology at Synergy Pharmaceuticals Inc. from September 2013 to January 2017, where she was responsible for toxicology, ADME/PK and safety pharmacology studies. Dr. Eddy contributed to the NDA for Trulance&#x00ae; and her work at Synergy also included the development of a delayed release formulation for dolcanatide, as well as involvement in the supply of API for GLP and feasibility studies. Dr. Eddy worked at Endo Pharmaceuticals as an associate director, toxicology and safety pharmacology from February 2011 to October 2012 and as senior director, preclinical development at Zelos Therapeutics from April 2008 to February 2011. Dr. Eddy worked at Millennium Pharmaceuticals (now a wholly<FONT CLASS="nobreak">-owned</FONT> subsidiary of Takeda Pharmaceutical Company Limited) 2000 to 2003 and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) from August 1992 to February 1999 in the areas of drug discovery and development including early clinical development. Dr. Eddy received her Ph.D. degree in biochemistry from Osmania University, Hyderabad India and is a board<FONT CLASS="nobreak">-certified</FONT> toxicologist of the American Board of Toxicology. Before joining the pharmaceutical industry, Dr. Eddy worked at Case Western Reserve University in Cleveland, OH in the area of chemical carcinogenesis and environmental health sciences.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dr. Vaseem A. Palejwala &#x2014; </FONT><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Director, Clinical Operations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dr. Palejwala is Director, Clinical Operations and has served in this position since January 2019. Between January 2017 to 2019 he served as Director of Non<FONT CLASS="nobreak">-Clinical</FONT> Studies of the company. He has 18 years of experience in drug discovery and development. From January 2015 to January 2017, Dr. Palejwala served as director of discovery and preclinical research, and from December 2012 to December 2014 served as associate director of discovery and preclinical research, at Synergy Pharmaceuticals Inc. where he actively contributed to establishing GI tract<FONT CLASS="nobreak">-related</FONT> preclinical animal models for testing the efficacy and validating the mechanism of action for both plecanatide and dolcanatide. Dr. Palejwala also actively participated in preparation of the nonclinical pharmacology section of the NDA for Trulance&#x00ae;. From 2001 to 2012, Dr. Palejwala served as discovery scientist/manager at Sanofi S.A., <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">a </FONT>multinational pharmaceutical company, where he advanced both small molecule and biologic programs in immunology, inflammation, oncology, CNS and metabolic disorders and also contributed to establishing and managing high<FONT CLASS="nobreak">-throughput</FONT> gene expression profiling platform capabilities. Dr. Palejwala holds a degree in microbiology and chemistry from Bombay University, as well as a master of science degree in microbiology and a Ph.D. in microbiology from the Maharaja Sayajirao University of Baroda.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Family Relationships</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There are no family relationships among any of our executive officers or directors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compensation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Total Compensation for the Chairman and Non<FONT CLASS="nobreak">-Executive</FONT> Directors</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The table below sets out the total remuneration received by the Chairman and the Non<FONT CLASS="nobreak">-Executive</FONT> Directors for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.80%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Fees<BR>earned or<BR>paid in<BR>cash<BR>($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Options<BR>awarded<BR>($)</FONT><FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total<BR>($)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gabriele Cerrone</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Chairman</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">124,008</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">528,036</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">652,044</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Riccardo Dalla-Favera<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Non &#x2013; Executive Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,668</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,668</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Willy Simon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Non &#x2013; Executive Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,670</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,670</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Represents the fair value of incentive stock options granted during the year to December 31, 2018 using the Black<FONT CLASS="nobreak">-Scholes</FONT> model for computing stock<FONT CLASS="nobreak">-based</FONT> compensation expense as of the date of grant.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;">(2)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Dr. Dalla<FONT CLASS="nobreak">-Favera</FONT> resigned from the board of directors on February 7, 2019.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compensation of Executive Directors and Senior Managers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The table below sets the remuneration of each of the Executive Directors and Senior Managers for the financial year ended December<FONT CLASS="nobreak"> </FONT>31, 2018.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Fees<BR>earned or<BR>paid in<BR>cash<BR>($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Options<BR>awarded<BR>($)</FONT><FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total<BR>($)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kunwar Shailubhai</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Executive Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,275,754</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,561,579</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tiziano Lazzaretti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Chief Financial Officer</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141,343</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141,343</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Represents the fair value of incentive stock options granted during the year to December 31, 2018 using the Black<FONT CLASS="nobreak">-Scholes</FONT> model for computing stock<FONT CLASS="nobreak">-based</FONT> compensation expense as of the date of grant.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The Tiziana Life Sciences plc Employee Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Tiziana Life Sciences plc Employee Share Option Plan with Non<FONT CLASS="nobreak">-Employee</FONT> Sub<FONT CLASS="nobreak">-Plan</FONT> and US Sub<FONT CLASS="nobreak">-Plan</FONT>, or the 2016 Plan, was adopted by the Board on March<FONT CLASS="nobreak"> </FONT>23, 2016 and approved by shareholders on June<FONT CLASS="nobreak"> </FONT>30, 2016 and allows for the grant of options to eligible service providers. The material terms of the 2016 Plan are summarized below.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Eligibility and Administration</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our employees, consultants and directors, and employees and consultants of our subsidiaries are eligible to receive options under the 2016 Plan. The 2016 Plan is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to the limitations imposed under the 2016 Plan, stock exchange rules and other applicable laws. The plan administrator has the authority to take all actions and make all determinations under the 2016 Plan, to interpret the 2016 Plan and option agreements and to adopt, amend and repeal rules for the administration of the 2016 Plan as it deems advisable. The plan administrator also has the authority to determine which eligible service providers receive options, to grant options and to set the terms and conditions of all options granted under the 2016 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2016 Plan.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Shares Available for Options</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An aggregate of 10% of the company&#x2019;s ordinary share capital from time to time may be placed under options granted under the 2016 Plan. Shares issued to satisfy the exercise of options granted under the 2016 Plan may be newly issued shares or shares purchased on the open market</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If an option granted under the 2016 Plan, expires, lapses or is terminated, exchanged for cash, surrendered, canceled without having been fully exercised or forfeited, any unused shares subject to the option will, as applicable, become or again be available for new grants under the 2016 Plan.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Options</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The 2016 Plan provides for the grant of options. All options granted under the 2016 Plan will be set forth in option agreements, which will detail the terms and conditions of the options.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Options provide for the purchase of our ordinary shares in the future at an exercise price set on the grant date. The plan administrator will determine the number of shares covered by each option, the exercise price of each option and the conditions and limitations applicable to the exercise of each option</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If a holder of options dies, options may be exercised by the personal representative with 12<FONT CLASS="nobreak"> </FONT>months following death in respect of all or such proportion of the option as the plan administrator may specify to take account of the extent to which any exercise conditions have been achieved at the relevant date. If a holder of options leaves as a good leaver or the plan administrator allows, options may be exercised within 90 days in respect of all or such proportion of the option as the plan administrator may specify to take account of the extent to which any exercise conditions have been achieved at the relevant date</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Exercise Conditions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The plan administrator may specify one or more appropriate exercise conditions that must be satisfied before options may be exercised.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Change of Control and Variation of Share Capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the event of a change of control, the plan administrator may specify whether all or a proportion of options will be exercisable to take account of the extent to which any exercise conditions have been achieved at the relevant date. Alternatively, holders of options may agree to accept an offer to exchange options for options to acquire shares in an acquiring company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If there is a variation of our ordinary shares the plan administrator may adjust the number of shares under options and/or the exercise price.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Plan Amendment and Termination</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our board of directors may amend the 2016 Plan at any time; however, the provisions governing eligibility requirements, equity dilution, the basis for determining the rights of holders of options and the adjustment of options cannot be altered to the advantage of existing or new holders of options without the prior approval of our shareholders in general meeting. No options may be granted under the 2016 Plan after the tenth anniversary of the date of adoption by our board of directors.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Transferability</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Options granted under the 2016 Plan are generally non<FONT CLASS="nobreak">-transferrable</FONT>, except on death. With regard to tax withholding and exercise price obligations arising in connection with the exercise of options under the 2016 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or cheque,</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Non-Employee Sub-Plan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Non<FONT CLASS="nobreak">-Employee</FONT> Sub<FONT CLASS="nobreak">-Plan</FONT>, options may be granted to advisers, consultants and non<FONT CLASS="nobreak">-executive</FONT> directors on terms comparable to those described above.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">US Sub-Plan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The US Sub<FONT CLASS="nobreak">-Plan</FONT> permits the grant of options to employees, directors and consultants who are US residents and US taxpayers, including potentially tax efficient Incentive Stock Options (as defined in Section 422 of the Internal Revenue Code). A maximum of 9,233,392 ordinary shares may be issued under the US Sub<FONT CLASS="nobreak">-Plan</FONT> (which number shall be the maximum number that may be granted as Incentive Stock Options).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table summarizes: (i) the outstanding number of options and awards under the equity incentive plans; and (ii) the number of ordinary shares granted to directors, executive officers, and non<FONT CLASS="nobreak">-executive</FONT> directors, as of April<FONT CLASS="nobreak"> </FONT>1, 2019:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Ordinary <BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Ordinary<BR>Shares <BR>Underlying <BR>Options</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Exercise<BR>Price Per <BR>Ordinary<BR>Share<BR>(&#x00a3;)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Grant Date</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Expiration<BR>Date</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gabriele Cerrone</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,200,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/25/2014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/25/2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,000,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.35</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/25/2014</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/25/2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,259,403</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.50</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/09/2016</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">06/09/2026</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">550,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.8175</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2018</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2028</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Willy Simon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Kunwar Shailubhai</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">300,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">0.50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">06/25/2014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">06/25/2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.595</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">08/30/2017</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">08/30/2027</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.8175</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2018</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2028</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,000,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.8175</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2018</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">04/30/2028</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Leopoldo Zambeletti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">550,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">0.8175</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">04/30/2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">04/30/2028</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Tiziano Lazzaretti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">200,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">1.26</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">03/23/2016</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">03/23/2026</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,000</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.86</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">11/05/2016</P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">11/05/2026</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Fayez Hamzeh</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">600,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">0.8175</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">04/30/2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">04/30/2028</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Jules Jacob</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">50,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">1.595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2027</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Evangeline Priya-Eddy</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">50,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">1.595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2027</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Vaseem Palejwala</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">40,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">1.595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">08/30/2027</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Board Practices</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Corporate Governance Practices</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are a &#x201c;foreign private issuer,&#x201d; as defined by the SEC. As a result, in accordance with Nasdaq listing requirements, we may rely on home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exemption from filing quarterly reports on Form 10<FONT CLASS="nobreak">-Q</FONT> containing unaudited financial and other specified information or current reports on Form 8<FONT CLASS="nobreak">-K</FONT> upon the occurrence of specified significant events.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exemption from Section 16 rules requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades in a short period of time, which will provide less data in this regard than shareholders of U.S. companies that are subject to the Exchange Act.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exemption from the Nasdaq requirement requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exemption from the requirement that our board have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#x2019;s purpose and responsibilities.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exemption from the requirement to have independent director oversight of director nominations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We intend to follow U.K. corporate governance practices in lieu of Nasdaq corporate governance requirements as follows:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We do not intend to follow Nasdaq Rule 5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements are not required under English law. In accordance with generally accepted business practice, our Articles of Association will provide alternative quorum requirements that are generally applicable to meetings of shareholders.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We do not intend to follow Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where only independent directors are present. Our independent directors may choose to meet in executive sessions at their discretion.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Although we may rely on certain home country corporate governance practices, we must comply with Nasdaq&#x2019;s Notification of Noncompliance requirement (Nasdaq Rule 5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies Nasdaq Rule 5605(c)(3), which addresses audit committee responsibilities and authority and requires that the audit committee consist of members who meet the independence requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, the rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. For an overview of our corporate governance principles, see the section titled &#x201c;Description of Share Capital and Articles of Association &#x2014; Differences in Corporate Law.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compliance with the Quoted Companies Alliance Corporate Governance Code</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All companies with securities admitted to trading on AIM are required to include on their website details of a recognized corporate governance code that the board of directors of the company has decided to apply, how the company complies with that code, and where it departs from its chosen corporate governance code an explanation of the reasons for doing so. This information is required to be reviewed annually.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company has decided to apply the Corporate Governance Code published by the Quoted Companies Alliance, or the QCA Code. The QCA Code sets out a standard of minimum best practice for small and midsize quoted companies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Composition of Our Board of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our board of directors is currently composed of four members and the Board has determined that two of the directors, Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti and Mr.<FONT CLASS="nobreak"> </FONT>Simon, are considered to be &#x201c;independent&#x201d; as that term is defined under Nasdaq rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In accordance with our Articles, each of our directors for whom it is the third annual general meeting following the annual general meeting at which they were elected or last re<FONT CLASS="nobreak">-elected</FONT>, or who was appointed by the board since the previous annual general meeting, shall retire from office but shall be eligible to stand for re<FONT CLASS="nobreak">-election</FONT>. See &#x201c;Description of Share Capital and Articles of Association &#x2014; Articles of Association &#x2014; Board of Directors.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The expiration of the current terms of the members of the board of directors and the period each member has served in that term are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year Current<BR>Term Began</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year Current<BR>Term Expires</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gabriele Cerrone</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2020</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kunwar Shailubhai</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2021</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Willy Simon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2016</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2019</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leopoldo Zambeletti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2021</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Committees of Our Board of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our board of directors has three standing committees: an audit committee, a remuneration committee and a nominating committee.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audit Committee</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The audit committee, which consists of, Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti and Mr.<FONT CLASS="nobreak"> </FONT>Simon, assists the board of directors in overseeing our accounting and financial reporting processes. Mr.<FONT CLASS="nobreak"> </FONT>Simon serves as chairman of the audit committee. The audit committee consists exclusively of members of our board who are financially literate, and Mr.<FONT CLASS="nobreak"> </FONT>Simon is considered an &#x201c;audit committee financial expert&#x201d; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our board has determined that all of the members of the audit committee satisfy the &#x201c;independence&#x201d; requirements set forth in Rule 10A<FONT CLASS="nobreak">-3</FONT> under the Exchange Act. The audit committee will be governed by a charter that complies with Nasdaq rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The audit committee&#x2019;s responsibilities include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>recommending the appointment of the independent auditor to the general meeting of shareholders;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>pre<FONT CLASS="nobreak">-approving</FONT> the audit services and non<FONT CLASS="nobreak">-audit</FONT> services to be provided by our independent auditor before the auditor is engaged to render such services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>evaluating the independent auditor&#x2019;s qualifications, performance and independence, and presenting its conclusions to the full board of directors on at least an annual basis;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>reviewing and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting process;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>reviewing, approving or ratifying any related party transactions.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>recommending the appointment of the independent auditor to the general meeting of shareholders; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Remuneration Committee</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The remuneration committee consists of Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti and Mr.<FONT CLASS="nobreak"> </FONT>Simon. Mr.<FONT CLASS="nobreak"> </FONT>Simon serves as chairman of the remuneration committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the remuneration committee, including a prohibition against the receipt of any compensation from us other than standard board member fees.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The remuneration committee&#x2019;s responsibilities include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>identifying, reviewing and proposing policies relevant to the compensation and benefits of our directors and executive officers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>evaluating each executive officer&#x2019;s performance in light of such policies and reporting to the board; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>overseeing and administering our employee share option scheme or equity incentive plans in operation from time to time.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Nominating Committee</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The nominating committee consists of Mr.<FONT CLASS="nobreak"> </FONT>Cerrone, Mr.<FONT CLASS="nobreak"> </FONT>Simon and Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti. Mr.<FONT CLASS="nobreak"> </FONT>Zambeletti serves as chairman of the nominating committee. The nominating committee&#x2019;s responsibilities include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>drawing up selection criteria and appointment procedures for directors;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>recommending nominees for election to our board of directors and its corresponding committees;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>assessing the functioning of individual members of our board of directors and executive officers and reporting the results of such assessment to the board of directors; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>developing corporate governance guidelines.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Code of Business Conduct and Ethics</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our Code of Business Conduct and Ethics is applicable to all of our employees, officers and directors and is available on our website at <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">https://www.tizianalifesciences.com</FONT>. Our Code of Business Conduct and Ethics provides that our directors and officers are expected to avoid any action, position or interest that conflicts with the interests of our company or gives the appearance of a conflict. Our directors and officers have an obligation under our Code of Business Conduct and Ethics to advance our company&#x2019;s interests when the opportunity to do so arises. We expect that any amendment to this code, or any waivers of its requirements, will be disclosed on our website.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compensation of Executive Officers and Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, the aggregate compensation accrued or paid to the members of our board of directors and our executive officers for services in all capacities was $0.5<FONT CLASS="nobreak"> </FONT>million.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Executive Director Service Agreement</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Dr. Kunwar Shailubhai</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We entered into an employment agreement with Dr. Kunwar Shailubhai in May 2017, which was amended by way of a letter agreement in January 2019. The employment agreement requires Dr. Shailubhai to work for the company for 100% of his time and pursuant to it he is entitled to receive an initial annual base salary of $600,000 per year. Dr. Shailubhai is eligible to receive an annual cash bonus of up to 35% of his base salary, such bonus amount to be determined in the company&#x2019;s absolute discretion and subject to such conditions (including, but not limited to, with respect to his performance and that of the company, and related to the timing of payment).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dr. Shailubhai is also entitled to the same fringe benefits as we provide to our other executives from time to time and is eligible to receive employee share incentives. The vesting of any unvested employee share incentives held by Dr. Shailubhai will accelerate in the event his employment is terminated without cause (as such term is defined in his employment agreement), or if he resigns for good reason (as such term is defined in the employment agreement) and, in each case, such termination is upon the consummation of or within 12<FONT CLASS="nobreak"> </FONT>months following a change of control of the company. If Dr. Shailubhai&#x2019;s employment with the company is terminated without cause, or if he resigns for good reason, Dr. Shailubhai will also be entitled to receive severance equal to continuation of his base salary as then currently in effect for 12<FONT CLASS="nobreak"> </FONT>months following his date of termination and will be eligible for reimbursement for medical coverage premiums for up to the same period. Dr. Shailubhai, his spouse and eligible dependents are entitled to stay on our health insurance plans for a period of 12<FONT CLASS="nobreak"> </FONT>months following his termination for any reason. Dr. Shailubhai&#x2019;s severance benefits are conditioned on, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">inter alia</FONT>, his execution of our standard separation agreement and a general release of claims in our favor.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The employment agreement provides that Dr. Shailubhai&#x2019;s employment with us is at<FONT CLASS="nobreak">-will</FONT>. If required by the company, the employment agreement further provides that Dr. Shailubhai will resign from his position on our board of directors effective as of the date of his termination for any reason. The employment agreement further contains a six<FONT CLASS="nobreak">-month</FONT> non<FONT CLASS="nobreak">-competition</FONT> covenant and a 12<FONT CLASS="nobreak">-month</FONT> non<FONT CLASS="nobreak">-solicitation</FONT> covenant by Dr. Shailubhai.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Non-Executive Director Service Contracts</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The remuneration of our non<FONT CLASS="nobreak">-executive</FONT> directors is determined by our board as a whole, based on a review of current practices in other companies. We intend to enter into service contracts with our directors for their services or amend and restate any prior service contracts in place prior to, or as soon as practicable, following the filing of this registration statement.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Employees</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As of December<FONT CLASS="nobreak"> </FONT>31, 2018, 2017 and 2016, we had<FONT CLASS="nobreak"> </FONT>9, 5 and 9 employees, respectively. All of our employees were based in the United Kingdom, except that, as of December<FONT CLASS="nobreak"> </FONT>31, 2017, we had 3 employees based outside of the United Kingdom in the US. All of our employees were engaged in either administrative or R&amp;D functions. None of our employees are covered by a collective bargaining agreement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Insurance and Indemnification</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">To the extent permitted by the Companies Act, we are empowered to indemnify our directors against any liability they incur by reason of their directorship. We maintain directors&#x2019; and officers&#x2019; insurance to insure such persons against certain liabilities. We expect to enter into a deed of indemnity with each of our directors and executive officers prior to, or as soon as practicable, following the filing of this registration statement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition to such indemnification, we provide our directors and executive officers with directors&#x2019; and officers&#x2019; liability insurance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Insofar as indemnification of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T16"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following is a description of related party transactions we have entered into since January<FONT CLASS="nobreak"> </FONT>1, 2018, with the beneficial owners of 5% or more of our ordinary shares, which are our only voting securities, and senior management and members of our board of directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Pharma Limited is a wholly<FONT CLASS="nobreak">-owned</FONT> subsidiary of our company. During the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, we transferred $3.9<FONT CLASS="nobreak"> </FONT>million to Tiziana Pharma Limited.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Therapeutics Inc. is a wholly<FONT CLASS="nobreak">-owned</FONT> subsidiary of our company. During the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018, we transferred $1.5<FONT CLASS="nobreak"> </FONT>million to Tiziana Therapeutics Inc.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Kunwar Shailubhai, a director of our company, is also a director of Rasna Therapeutics, Inc., or Rasna. In addition, Tiziano Lazzaretti, CFO of our company, is also CFO of Rasna. Rasna is a party to a Shared Services Agreement with us whereby we are charged for shared services such as payroll and rent. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, $130,000 was as owed to us by Rasna.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Indemnity Agreements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have entered into deeds of indemnity with each of our directors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related Person Transaction Policy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our board of directors has adopted a written related person transaction policy, effective as of November<FONT CLASS="nobreak"> </FONT>9, 2018. This policy covers, any transaction or proposed transactions between us and a related person that are material to us or the related person, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit and risk committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#x2019;s length transaction and the extent of the related person&#x2019;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T17"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL SHAREHOLDERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> The following table sets forth information relating to the beneficial ownership of our ordinary shares as of September<FONT CLASS="nobreak"> </FONT>13, 2019 by: </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>each member of our board of directors and each of our executive officers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> The number of ordinary shares beneficially owned by each entity, person, board member, or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60 days of September<FONT CLASS="nobreak"> </FONT>13, 2019 through the exercise of any option, warrant or other right. Percentage of ownership is based on 136,463,818 ordinary shares issued as of September<FONT CLASS="nobreak"> </FONT>13, 2019. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person. </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> Number of Ordinary<BR>Shares Beneficially<BR>Owned </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"> Name and address of beneficial owner </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> Shares </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> % </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5% or Greater Shareholders:</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Gabriele Cerrone<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(1)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 67,455,925 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 48.3 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Executive Officers and Directors:</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Gabriele Cerrone<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(1)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 67,455,925 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 48.3 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Willy Simon </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x2014; </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> &#x2014; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Leopoldo Zambeletti<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(4)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 137,500 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> * </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Kunwar Shailubhai<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(2)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 1,505,000 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 1.1 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> Tiziano Lazzaretti<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(3)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 250,000 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> * </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"> All directors and executive officers as a group (5 persons)<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(5)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 69,348,425 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> 49.0 </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">*&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Mr.<FONT CLASS="nobreak"> </FONT>Gabriele Cerrone is the ultimate beneficial owner of ordinary shares through Planwise Group Limited and Panetta Partners Limited.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;"> &#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Includes 3,200,000 stock options which are currently exercisable or exercisable within 60 days of September 13, 2019. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;"> (2)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Includes of 1,500,000 stock options which are currently exercisable or exercisable within 60 days of September 13, 2019. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;"> (3)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Includes of 250,000 stock options which are currently exercisable or exercisable within 60 days of September 13, 2019. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;"> (4)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Includes 137,500 stock options which are currently exercisable or exercisable within 60 days of September 13, 2019. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:0pt;"> (5)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Includes 5,087,500 stock options which are currently exercisable or exercisable within 60 days of September 13, 2019. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T18"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We were originally incorporated under the laws of England and Wales on February<FONT CLASS="nobreak"> </FONT>11, 1998 under the name of Bigboom plc, with the goal of leveraging the expertise of our management team as well as Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Howard Weiner and Dr. Kevan Herold, and to acquire and exploit certain intellectual property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition of Tiziana Pharma Limited in April 2014.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our registered office is located at 3<FONT CLASS="CharOverride-3" STYLE="font-size:58%;vertical-align:super;">rd</FONT> Floor, 11<FONT CLASS="nobreak">-12</FONT> St James&#x2019;s Square, London SW1Y 4LB and our telephone number is +44 20 7495 2379. Our website address is <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.tizianalifesciences.com</FONT>. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website is not a part of this registration statement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current authorized share capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Not applicable.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current issued share capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As of June<FONT CLASS="nobreak"> </FONT>30, 2019, our issued share capital was 136,463,818 ordinary shares with a nominal value of &#x00a3;0.03 per share. Each issued ordinary share is fully paid.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Information about the Ordinary Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In accordance with our Articles to be in effect upon the filing of this registration statement, the following summarizes the rights of holders of our ordinary shares:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Registered Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are required by the Companies Act to keep a register of our shareholders. Under English law, the ordinary shares are deemed to be issued when the name of the shareholder is entered in our share register. The share register therefore is prima facie evidence of the identity of our shareholders, and the shares that they hold. The share register generally provides limited, or no, information regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Link Asset Services.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Potential future holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. Potential future holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see &#x201c;Description of the American Depositary Shares&#x201d; in this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Companies Act, we must enter an allotment of shares in our share register as soon as practicable and in any event within two months of the allotment. We will perform all procedures necessary to update the share register to reflect any ordinary shares being sold in any potential offering, including updating the share register with the number of ordinary shares to be issued to the depositary upon the closing of any such offering in the future. We also are required by the Companies Act to register a transfer of shares (or give the transferee notice of and reasons for refusal as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving notice of the transfer.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We, any of our shareholders, or any other affected person may apply to the court for rectification of the share register if:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the name of any person, without sufficient cause, is entered in or omitted from our register of members; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>default is made or unnecessary delay takes place in entering on the register the fact of any person having ceased to be a member or on which we have a lien, provided that such delay does not prevent dealings in the shares taking place on an open and proper basis.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pre-emptive Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">English law generally provides shareholders with pre<FONT CLASS="nobreak">-emptive</FONT> rights when new shares are issued for cash; however, it is possible for the Articles, or shareholders by special resolution, to exclude pre<FONT CLASS="nobreak">-emptive</FONT> rights. Such an exclusion of pre<FONT CLASS="nobreak">-emptive</FONT> rights may be for a maximum period of up to five years from the date of adoption of the Articles, if the exclusion is contained in the Articles, or from the date of the shareholder resolution, if the exclusion is by shareholder resolution. In either case, this exclusion would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). Typically U.K. public companies renew the disapplication of pre<FONT CLASS="nobreak">-emption</FONT> rights on an annual basis or their annual general meeting. On June<FONT CLASS="nobreak"> </FONT>25, 2018, our shareholders approved the exclusion of pre<FONT CLASS="nobreak">-emptive</FONT> rights for a period of 15<FONT CLASS="nobreak"> </FONT>months or the date of the next annual general meeting, which exclusion is for a number of shares equal to 20% of the issued share capital at the time of passing of the resolution and which will need to be renewed upon expiration (i.e., the earlier of 15<FONT CLASS="nobreak"> </FONT>months from the date of passing the resolution on the date of the next annual general meeting) to remain effective.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Articles of Association</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our Articles were adopted by a special resolution of the founder shareholder passed at a general meeting on June<FONT CLASS="nobreak"> </FONT>30, 2016. A summary of the terms of the Articles is set out below. The summary below is not a complete copy of the terms of the Articles.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Articles contain no specific restrictions on our purpose and therefore, by virtue of section 31(1) of the Companies Act, our purpose is unrestricted.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Articles contain, among other things, provisions to the following effect:</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Share Capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our share capital currently consists of ordinary shares. Subject to the Companies Act and to any rights attached to existing shares, we may issue shares with such rights or restrictions as may be determined by ordinary resolution or if no ordinary resolution has been passed or so far as such ordinary resolution does not make specific provision, as the board may determine. In addition, shares which are to be redeemed, or are liable to be redeemed at our option or the holder of such shares may be issued with the board determining the terms and conditions of such redemption.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Voting</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The shareholders have the right to receive notice of, and to vote at, our general meetings. Each shareholder who is present in person (or, being a corporation, by representative) at a general meeting on a show of hands has one vote and, on a poll, every such holder who is present in person (or, being a corporation, by representative) or by proxy has one vote in respect of every share held by him.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Variation of Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the Companies Act, whenever our share capital is divided into different classes of shares, the special rights attached to any class may be varied or abrogated either with the consent in writing of the holders of three<FONT CLASS="nobreak">-fourths</FONT> in nominal value of the issued shares of that class (excluding any shares held as treasury shares) or with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of that class, held in accordance with the Articles.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Dividends</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may, subject to the provisions of the Companies Act and the Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by our board of directors. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">Subject to the provisions of the Companies Act, in so far as, in the board of directors&#x2019; opinions, our profits justify such payments, the board of directors may pay interim dividends on any class of our shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any dividend unclaimed after a period of 12 years from the date such dividend was declared or became payable shall, if the board of directors resolve, be forfeited and shall cease to remain owing by us. No dividend or other moneys payable on or in respect of a share shall bear interest as against us.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Transfer of Ordinary Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each member may transfer all or any of his shares which are in certificated form by means of an instrument of transfer in any usual form or in any other form which the board of directors may approve. Each member may transfer all or any of his shares which are in uncertificated form by means of a &#x201c;relevant system&#x201d; (i.e., the CREST System) in such manner provided for, and subject as provided in, the CREST Regulations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Board may, in its absolute discretion, refuse to register a transfer of certificated shares unless:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;it is for a share which is fully paid up;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;it is for a share upon which the company has no lien;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iii)&#x00a0;&#x00a0;&#x00a0;it is only for one class of share;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iv)&#x00a0;&#x00a0;&#x00a0;it is in favor of a single transferee or no more than four joint transferees;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(v)&#x00a0;&#x00a0;&#x00a0;&#x00a0;it is duly stamped or is duly certificated or otherwise shown to the satisfaction of the board of directors to be exempt from stamp duty; and</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(vi)&#x00a0;&#x00a0;&#x00a0;it is delivered for registration to the registered office of the company (or such other place as the board of directors may determine), accompanied (except in the case of a transfer by a person to whom the company is not required by law to issue a certificate and to whom a certificate has not been issued or in the case of a renunciation) by the certificate for the shares to which it relates and such other evidence as the board of directors may reasonably require to prove the title of the transferor (or person renouncing) and the due execution of the transfer or renunciation by him or, if the transfer or renunciation is executed by some other person on his behalf, the authority of that person to do so.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The board of directors may refuse to register a transfer of uncertificated shares in any circumstances that are allowed or required by the CREST Regulations and the CREST System.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Allotment of Shares and Pre-emption Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the Companies Act and to any rights attached to existing shares, any share may be issued with or have attached to it such rights and restrictions as the company may by ordinary resolution determine, or if no ordinary resolution has been passed or so far as the resolution does not make specific provision, as the board of directors may determine (including shares which are to be redeemed, or are liable to be redeemed at the option of the company or the holder of such shares).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In accordance with section 551 of the Companies Act, the board of directors may be generally and unconditionally authorized to exercise all the powers of the company to allot shares up to an aggregate nominal amount equal to the amount stated in the relevant ordinary resolution authorizing such allotment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The provisions of section 561 of the Companies Act (which confer on shareholders rights of pre<FONT CLASS="nobreak">-emption</FONT> in respect of the allotment of equity securities which are paid up in cash) apply to the company except to the extent disapplied by special resolution of the company. Such pre<FONT CLASS="nobreak">-emption</FONT> rights have been disapplied, in part, pursuant to the special resolution passed on June<FONT CLASS="nobreak"> </FONT>25, 2018.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Alteration of Share Capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company may by ordinary resolution consolidate or divide all of its share capital into shares of larger nominal value than its existing shares, or cancel any shares which, at the date of the ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of its share capital by the nominal amount of shares so cancelled or sub<FONT CLASS="nobreak">-divide</FONT> its shares, or any of them, into shares of smaller nominal value.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company may, in accordance with the Companies Act, reduce or cancel its share capital or any capital redemption reserve or share premium account in any manner and with and subject to any conditions, authorities and consents required by law.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Board of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Unless otherwise determined by the company by ordinary resolution, the number of directors (other than any alternate directors) shall not be less than two, but there shall be no maximum number of directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the Articles and the Companies Act, the company may by ordinary resolution appoint a person who is willing to act as a director and the board of directors shall have power at any time to appoint any person who is willing to act as a director, in both cases either to fill a vacancy or as an addition to the existing board of directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">At every annual general meeting any director who either (i) has been appointed by the board of directors since the last annual general meeting or (ii) was not elected or re<FONT CLASS="nobreak">-elected</FONT> at one of the preceding two annual general meetings, must retire from office and may offer themselves for re<FONT CLASS="nobreak">-election</FONT> by the shareholders by ordinary resolution.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the provisions of the Articles, the board of directors may regulate their proceedings as they deem appropriate. A director may, and the secretary at the request of a director shall, call a meeting of the directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The quorum for a meeting of the board of directors shall be fixed from time to time by a decision of the board of directors, but it must never be less than two and unless otherwise fixed, it is two.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Questions and matters requiring resolution arising at a meeting shall be decided by a majority of votes of the participating directors, with each director having one vote. In the case of an equality of votes, the chairman will only have a casting vote or second vote (unless he is not entitled to vote on the resolution in question).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Directors shall be entitled to receive such remuneration as the board shall determine for their services to the company as directors, and for any other service which they undertake for the company provided that the aggregate fees payable to the directors must not exceed &#x00a3;250,000 per annum or such higher amount as decided by ordinary resolution. The directors shall also be entitled to be paid all reasonable expenses properly incurred by them in connection with their attendance at meetings of shareholders or class meetings, board of director or committee meetings or otherwise in connection with the exercise of their powers and the discharge of their responsibilities in relation to the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The board of directors may, in accordance with the requirements in the Articles, authorize any matter proposed to them by any director which would, if not authorized, involve a director breaching his duty under the Companies Act, to avoid conflicts of interests.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A director seeking authorization in respect of such conflict shall declare to the board of directors the nature and extent of his interest in a conflict as soon as is reasonably practicable. The director shall provide the board with such details of the matter as are necessary for the board to decide how to address the conflict together with such additional information as may be requested by the board.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any authorization by the board of directors will be effective only if:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;to the extent permitted by the Companies Act, the matter in question shall have been proposed by any director for consideration in the same way that any other matter may be proposed to the directors under the provisions of the Articles;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;any requirement as to the quorum for consideration of the relevant matter is met without counting the conflicted director and any other conflicted director; and</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iii)&#x00a0;&#x00a0;&#x00a0;the matter is agreed to without the conflicted director voting or would be agreed to if the conflicted director&#x2019;s and any other interested director&#x2019;s vote is not counted.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the provisions of the Companies Act, every director, secretary or other officer of the company (other than an auditor) is entitled to be indemnified against all costs, charges, losses, damages and liabilities incurred by him in the actual purported exercise or discharge of his duties or exercise of his powers or otherwise in relation to them.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">General Meetings</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company must convene and hold annual general meetings in accordance with the Companies Act. Under the Companies Act, an annual general meeting must be called by notice of at least 21 days.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No business shall be transacted at any general meeting unless a quorum is present when the meeting proceeds to business, but the absence of a quorum shall not preclude the choice or appointment of a chairman of the meeting which shall not be treated as part of the business of the meeting. Save as otherwise provided by the Articles, two shareholders present in person or by proxy and entitled to vote shall be a quorum for all purposes.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Borrowing Powers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the Articles and the Companies Act, the board of directors may exercise all of the powers of the company to:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(a)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;borrow money;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(b)&#x00a0;&#x00a0;&#x00a0;&#x00a0;indemnify and guarantee;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(c)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;mortgage or charge;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(d)&#x00a0;&#x00a0;&#x00a0;&#x00a0;create and issue debentures and other securities; and</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(e)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;give security either outright or as collateral security for any debt, liability or obligation of the company or of any third party.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The borrowing powers are restricted to the sum of &#x00a3;25,000,000 but this limit may be increased by ordinary resolution of shareholders.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Capitalization of profits</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The directors may, if they are so authorized by an ordinary resolution of the shareholders, decide to capitalize any undivided profits of the company (whether or not they are available for distribution), or any sum standing to the credit of the company&#x2019;s share premium account or capital redemption reserve. The directors may also, subject to the aforementioned ordinary resolution, appropriate any sum which they so decide to capitalize to the persons who would have been entitled to it if it were distributed by way of dividend and in the same proportions.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Uncertificated Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the Companies Act, the board of directors may permit title to shares of any class to be issued or held otherwise than by a certificate and to be transferred by means of a &#x201c;relevant system&#x201d; (i.e., the CREST System) without a certificate.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The board of directors may take such steps as it sees fit in relation to the evidencing of and transfer of title to uncertificated shares, any records relating to the holding of uncertificated shares and the conversion of uncertificated shares to certificated shares, or vice<FONT CLASS="nobreak">-versa</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The board of directors may by notice to the holder of an uncertificated share, require that share to be converted into certificated form.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The board of directors may take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture, re<FONT CLASS="nobreak">-allotment</FONT> or surrender of an uncertified share or otherwise to enforce a lien in respect of it.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Other Relevant Laws and Regulations</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Mandatory Bid</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The U.K. City Code on Takeovers and Mergers, or Takeover Code, applies to the company. Under the Takeover Code, where:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(a)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(b)&#x00a0;&#x00a0;&#x00a0;&#x00a0;any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested, such person shall, except in limited circumstances, be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non<FONT CLASS="nobreak">-voting</FONT>, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the U.K. Panel on Takeovers and Mergers, or Takeover Panel, should be consulted in advance in such cases.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An offer under Rule 9 of the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required to make an offer or any person acting in concert with him during the 12<FONT CLASS="nobreak"> </FONT>months prior to the announcement of the offer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Takeover Code, a &#x201c;concert party&#x201d; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate control of the company. &#x201c;Control&#x201d; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the voting rights of the company, irrespective of whether the holding or holdings give <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">de facto</FONT> control.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Panetta Partners Limited, Planwise Group Limited and Gabriele Cerrone are considered to be a &#x201c;concert party&#x201d; for the purposes of the Takeover Code, or the Cerrone Concert Party. Following the offering the Cerrone Concert Party will hold shares carrying voting rights equal to approximately 42.6%. Accordingly following the offering the Cerrone Concert Party will not, save in limited circumstances, be able to acquire further interests in shares carrying voting rights without being obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non<FONT CLASS="nobreak">-voting</FONT>, and also to the holders of any other class of transferable securities carrying voting rights.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Squeeze-out</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Companies Act, if a takeover offer (as defined in Section 974 of the Companies Act) is made for the shares of a company and the offeror were to acquire, or unconditionally contract to acquire:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;not less than 90% in value of the shares to which the takeover offer relates, or the Takeover Offer Shares; and</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;where those shares are voting shares, not less than 90% of the voting rights attached to the Takeover Offer Shares,</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">the offeror could acquire compulsorily the remaining 10%. It would do so by sending a notice to outstanding shareholders within three months of the last day on which its offer can be accepted telling them that it will acquire compulsorily their shares, or Takeover Offer Shares, and then, six weeks later, it would send a copy of the notice to the company with an executed instrument of transfer of the outstanding Takeover Offer Shares in its favor and pay the consideration to the company, which would hold the consideration on trust for outstanding shareholders. The consideration offered to the shareholders whose Takeover Offer Shares are acquired compulsorily under the Companies Act must, in general, be the same as the consideration that was available under the takeover offer.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Sell-out</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Companies Act also gives minority shareholders a right to be bought out in certain circumstances by an offeror who has made a takeover offer (as defined in Section 974 of the Companies Act). If a takeover offer related to all the shares of a company and, at any time before the end of the period within which the offer could be accepted, the offeror held or had agreed to acquire not less than 90% of the shares to which the offer relates, any holder of the shares to which the offer related who had not accepted the offer could by a written communication to the offeror require it to acquire those shares. The offeror is required to give any shareholder notice of his or her right to be bought out within one month of that right arising. The offeror may impose a time limit on the rights of the minority shareholders to be bought out, but that period cannot end less than three months after the end of the acceptance period. If a shareholder exercises his or her rights, the offeror is bound to acquire those shares on the terms of the offer or on such other terms as may be agreed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholder Notification and Disclosure Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Shareholders are obliged to comply with the shareholding notification and disclosure requirements set out in Chapter 5 of the Disclosure Guidance and Transparency Rules, or DTRs. A shareholder is required pursuant to Rule 5 of the DTRs to notify the company if, as a result of an acquisition or disposal of shares or financial instruments, the shareholder&#x2019;s percentage of voting rights of the company reaches, exceeds or falls below 3% of the nominal value of the company&#x2019;s share capital or any 1% threshold above that.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The DTRs can be accessed and downloaded from the Financial Conduct Authority&#x2019;s website at <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.fshandbook.info/FS/html/FCA/DTR</FONT>. Shareholders are urged to consider their notification and disclosure obligations carefully as a failure to make a required disclosure to the company may result in disenfranchisement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">U.K. City Code on Takeovers and Mergers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a U.K. public company whose shares are traded on a multi<FONT CLASS="nobreak">-lateral</FONT> trading facility in the United Kingdom, we are subject to the Takeover Code, which is issued and administered by the Takeover Panel. The Takeover Code provides a framework within which takeovers are regulated and conducted. Under the Takeover Code, where:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">such person shall, except in limited circumstances, be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non<FONT CLASS="nobreak">-voting</FONT>, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the Takeover Panel should be consulted in advance in such cases.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An offer under Rule 9 of the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required to make an offer or any person acting in concert with him during the 12<FONT CLASS="nobreak"> </FONT>months prior to the announcement of the offer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Takeover Code, a &#x201c;concert party&#x201d; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate control of the company. &#x201c;Control&#x201d; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the voting rights of the company, irrespective of whether the holding or holdings give de facto control.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Panetta Partners Limited, Planwise Group Limited and Gabriele Cerrone, together the Cerrone Concert Party are considered to be a &#x201c;concert party&#x201d; for the purposes of the Takeover Code. Following the offering the Cerrone Concert </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;">Party will hold shares carrying voting rights equal to approximately 42%. Accordingly following the offering the Cerrone Concert Party will not, save in limited circumstances, be able to acquire further interests in shares carrying voting rights without being obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non<FONT CLASS="nobreak">-voting</FONT>, and also to the holders of any other class of transferable securities carrying voting rights.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Differences in Corporate Law</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The applicable provisions of the Companies Act differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act applicable to us and the Delaware General Corporation Law relating to shareholders&#x2019; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English law.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number of Directors</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Under the Companies Act, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#x2019;s Articles.</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-26" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Removal of Directors</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days&#x2019; notice of the resolution has been given to the company and its shareholders. On receipt of notice of an intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act must also be followed, such as allowing the director to make representations against his or her removal either at the meeting or in writing.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause, or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-27" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Vacancies on the Board of<BR>Directors</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under English law, the procedure by which directors, other than a company&#x2019;s initial directors, are appointed is generally set out in a company&#x2019;s Articles, provided that where two or more persons are appointed as directors of a public limited company by a single resolution of the shareholders, such resolution must not be put to shareholders unless a resolution that it should so be made has first been agreed to by the shareholders without any vote being given against it.</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Annual General Meeting</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Under the Companies Act, a public limited company must hold an annual general meeting in each six<FONT CLASS="nobreak">-month</FONT> period beginning with the day following the company&#x2019;s annual accounting reference date.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General Meeting</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, a general meeting of the shareholders of a public limited company may be called by the directors.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-30" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Shareholders holding at least 5% of the paid<FONT CLASS="nobreak">-up</FONT> capital of the company carrying voting rights at general meetings (excluding any paid up capital held as treasury shares) can require the directors to call a general meeting and, if the directors fail to do so within a certain period, may themselves or any of them representing more than one half of the total voting rights of all of them convene a general meeting.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notice of General Meetings</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, at least 21 days&#x2019; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting, subject to a company&#x2019;s Articles providing for a longer period. Subject to a company&#x2019;s Articles providing for a longer period, at least 14 days&#x2019; notice is required for other general meetings of a public limited company which fulfill certain conditions. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 days&#x2019; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#x2019; consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour and purpose or purposes of the meeting.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-32" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Quorum</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Subject to the provisions of a company&#x2019;s Articles, the Companies Act provides that two shareholders present at a meeting (in person, by proxy or authorised under the Companies Act) shall constitute a quorum for companies with more than one shareholder.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one third of the shares entitled to vote at the meeting. In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Proxy</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#x2019;s voting rights as a director.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Issue of New Shares</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, the directors of a company must not exercise any power to allot shares or grant rights to subscribe for, or to convert any security into, shares unless they are authorized to do so by the company&#x2019;s Articles or by an ordinary resolution of the shareholders. Any authorization given must state the maximum amount of shares that may be allotted under it and specify the date on which it will expire, which must be not more than five years from the date the authorization was given. The authority can be renewed by a further resolution of the shareholders.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, if the company&#x2019;s certificate of incorporation so provides, the directors have the power to authorize additional stock. The directors may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the company or any combination thereof.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Pre</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-emptive</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Rights</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:justify;text-align-last:justify;">Under the Companies Act, &#x201c;equity securities,&#x201d; being (i) shares in the company other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution, referred to as &#x201c;ordinary shares,&#x201d; or (ii) rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the company in proportion to the respective nominal value of their holdings, unless the period during which any such offer</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, shareholders have no pre<FONT CLASS="nobreak">-emptive</FONT> rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-36" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">may be accepted has expired or the company has received notice of acceptance or refusal, or an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the Articles provide otherwise in each case in accordance with the provisions of the Companies Act.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Authority to Allot</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, the directors of a company must not allot shares or grant rights to subscribe for or convert any security into shares unless an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the Articles provide otherwise, in each case in accordance with the provisions of the Companies Act.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, if the corporation&#x2019;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. The board of directors may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Liability of Directors and<BR>Officers</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under the Companies Act, any provision, whether contained in a company&#x2019;s Articles or any contract or otherwise, that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company, is void. Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act, which provides exceptions for the company to: (i) purchase and maintain insurance against such liability; (ii) provide a &#x201c;qualifying third party indemnity,&#x201d; or an indemnity against liability incurred by the director to a person other than the company or an associated company; and (iii) provide a &#x201c;qualifying pension scheme indemnity,&#x201d; or an indemnity against liability incurred in connection with the company&#x2019;s activities as trustee of an occupational pension plan.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, a corporation&#x2019;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>any transaction from which the director derives an improper personal benefit.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-38" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Voting Rights</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Under the model articles for public companies, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or the company&#x2019;s Articles, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act, a poll may be demanded by: (i) not fewer than five shareholders having the right to vote on the resolution; (ii) any shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution (excluding any voting rights attaching to treasury shares); or (iii) any shareholder(s) holding shares in the company conferring a right to vote on the resolution (excluding any voting rights attaching to treasury shares) being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company&#x2019;s Articles may provide more extensive rights for shareholders to call a poll.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy, who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholder Vote on Certain Transactions</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The Companies Act provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations or takeovers. These arrangements require:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#x2019;s assets or dissolution requires:</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-40" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="BL_table" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:12pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-12pt;widows:2;text-align:justify;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>the approval at a shareholders&#x2019; or creditors&#x2019; meeting convened by order of the court, of a majority in number of shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="BL_table" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:12pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-12pt;widows:2;list-style-type:none;text-align:justify;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>the approval of the board of directors; and</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-left:12pt;margin-top:0pt;text-indent:0pt;">or creditors or class thereof representing 75% in value, the class of shareholders or creditors, or class thereof present and voting, either in person or by proxy; and</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>the approval of the court.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="BL_table" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:12pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-12pt;widows:2;margin-top:0pt;text-align:justify;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>the approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of the corporation entitled to vote on the matter.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-41" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Standard of Conduct for<BR>Directors</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under English law, a director owes various statutory and fiduciary duties to the company, including:</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to act in the way he considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to act in accordance with the company&#x2019;s constitution and only exercise his powers for the purposes for which they are conferred;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to exercise independent judgment;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to exercise reasonable care, skill and diligence;</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>not to accept benefits from a third party conferred by reason of his being a director or doing, or not doing, anything as a director; and</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>to declare any interest that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self<FONT CLASS="nobreak">-interest</FONT>, on a well<FONT CLASS="nobreak">-informed</FONT> basis and in a manner they reasonably believe to be in the best interest of the stockholders.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:6pt;">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">England and Wales</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Delaware</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-42" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break<FONT CLASS="nobreak">-up</FONT> of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-43" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholder Suits</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an irregularity in the company&#x2019;s internal management. Notwithstanding this general position, the Companies Act provides that (i) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from a director&#x2019;s negligence, default, breach of duty or breach of trust and (ii) a shareholder may bring a claim for a court order where the company&#x2019;s affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#x2019;s failure to obtain the action; or</P>
						<P CLASS="BL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-position:outside;list-style-type:none;margin-left:12pt;text-indent:-12pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;</FONT>state the reasons for not making the effort.</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:6pt;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Other U.K. Law Considerations</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Registered Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are required by the Companies Act to keep a register of our shareholders. Under English law, shares are deemed to be issued when the name of the shareholder is entered in our register of members. The register of members therefore is prima facie evidence of the identity of our shareholders, and the shares that they hold. The register of members generally provides limited, or no, information regarding the ultimate beneficial owners of our shares. Our register of members is maintained by our registrar, LINK Asset Services Limited.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Companies Act, we must enter an allotment of shares in our register of members as soon as practicable and in any event within two months of the allotment. We will perform all procedures necessary to update the register of members to reflect the ordinary shares and the ADSs being allotted and issued in this offering. We also are required by the Companies Act to register a transfer of shares (or give the transferee notice of and reasons for refusal as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving notice of the transfer.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We, any of our shareholders or any other affected person may apply to the court for rectification of the register of members if:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the name of any person, without sufficient cause, is entered in or omitted from our register of members; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>default is made or unnecessary delay takes place in entering on the register the fact of any person having ceased to be a member.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Distributions and Dividends</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the Companies Act, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves, as determined on a non<FONT CLASS="nobreak">-consolidated</FONT> basis. The basic rule is that a company&#x2019;s profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under English law.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As a public company, it is also not sufficient that we have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only make a distribution:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of its net assets to less than that total.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Limitation on Owning Securities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our Articles do not restrict in any way the ownership or voting of our shares by non<FONT CLASS="nobreak">-residents</FONT>.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Purchase of Own Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">English law permits a public limited company to purchase its own shares out of the distributable profits of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, subject to complying with procedural requirements under the Companies Act and provided that its Articles do not prohibit it from doing so. Our Articles, a summary of which is provided above, do not prohibit us from purchasing our own shares. A public limited company must not purchase its own shares if, as a result of the purchase, there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any such purchase will be either a &#x201c;market purchase&#x201d; or &#x201c;off market purchase,&#x201d; each as defined in the Companies Act. A &#x201c;market purchase&#x201d; is a purchase made on a &#x201c;recognized investment exchange&#x201d; (other than an overseas exchange) as defined in the U.K. Financial Services and Markets Act 2000, or FSMA and is not an &#x201c;off<FONT CLASS="nobreak">-market</FONT> purchase.&#x201d; An &#x201c;off market purchase&#x201d; is a purchase that is not made on a &#x201c;recognized investment exchange&#x201d; or purchased on a &#x201c;recognized investment exchange&#x201d; but not subject to a marketing arrangement on such &#x201c;recognized investment exchange.&#x201d; Both &#x201c;market purchases&#x201d; and &#x201c;off market purchases&#x201d; require prior shareholder approval by way of an ordinary resolution. In the case of an &#x201c;off market purchase,&#x201d; a company&#x2019;s shareholders, other than the shareholders from whom the company is purchasing shares, must approve the terms of the contract to purchase shares and in the case of a &#x201c;market purchase,&#x201d; the shareholders must approve the maximum number of shares that can be purchased and the maximum and minimum prices to be paid by the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Nasdaq Global Market is an &#x201c;overseas exchange&#x201d; for the purposes of the Companies Act and does not fall within the definition of a &#x201c;recognized investment exchange&#x201d; for the purposes of FSMA and any purchase made by us would need to comply with the procedural requirements under the Companies Act that regulate &#x201c;off market purchases.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A share buyback by a company of its shares will give rise to U.K. stamp duty at the rate of 0.5% of the amount or value of the consideration payable by the company, and such stamp duty will be paid by the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our Articles do not have conditions governing changes to our capital which are more stringent that those required by law.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholder Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Certain rights granted under the Companies Act, including the right to requisition a general meeting or require a resolution to be put to shareholders at the annual general meeting, are only available to our members. For English law purposes, our members are the persons who are registered as the owners of the legal title to the shares and whose names are recorded in our register of members. In the case of shares held in a settlement system operated by the Depository Trust Company, or DTC, the registered member will be DTC&#x2019;s nominee, Cede &amp; Co. If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Companies Act, they may be required to first take steps to withdraw their ADSs from the settlement system operated by DTC and become the registered holder of the shares in our register of members. A withdrawal of shares from DTC may have tax implications, for additional information on the potential tax implications of withdrawing your shares from the settlement system operated by DTC, see &#x201c;Material Tax Considerations &#x2014; United Kingdom Taxation.&#x201d;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF THE AMERICAN DEPOSITARY SHARES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">JPMorgan Chase Bank, N.A., as depositary will issue the ADSs which you will be entitled to receive in this offering. Each ADS will represent an ownership interest in a designated number of ordinary shares which we will deposit with the custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary and yourself as an ADR holder. In the future, each ADS will also represent any securities, cash or other property deposited with the depositary but which they have not distributed directly to you. Unless certificated ADRs are specifically requested by you, all ADSs will be issued on the books of our depositary in book<FONT CLASS="nobreak">-entry</FONT> form and periodic statements will be mailed to you which reflect your ownership interest in such ADSs. In our description, references to American depositary receipts, or ADRs, shall include the statements you will receive which reflect your ownership of ADSs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary&#x2019;s office is located at 383 Madison Avenue, Floor<FONT CLASS="nobreak"> </FONT>11, New York, NY, 10179.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">You may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having an ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly. If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of such broker or financial institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution to find out what those procedures are.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As an ADR holder, we will not treat you as a shareholder of ours and you will not have any shareholder rights. The law of England and Wales governs shareholder rights. Because the depositary or its nominee will be the shareholder of record for the ordinary shares represented by all outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder. Such rights derive from the terms of the deposit agreement to be entered into among us, the depositary and all registered holders from time to time of ADRs issued under the deposit agreement. The obligations of our company, the depositary and its agents are also set out in the deposit agreement. Because the depositary or its nominee will actually be the registered owner of the ordinary shares, you must rely on it to exercise the rights of a shareholder on your behalf. The deposit agreement and the ADSs are governed by New York law. Under the deposit agreement, as an ADR holder, you agree that any legal suit, action or proceeding against or involving us or the depositary, arising out of or based upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only be instituted in a state or federal court in New York, New York, and you irrevocably waive any objection which you may have to the laying of venue of any such proceeding and irrevocably submit to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary, it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which is filed as an exhibit to the registration statement of which this prospectus forms a part. You may also obtain a copy of the deposit agreement at the SEC&#x2019;s Public Reference Room which is located at 100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1<FONT CLASS="nobreak">-800-732-0330</FONT>. You may also find the registration statement and the attached deposit agreement on the SEC&#x2019;s website at <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov</FONT>.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Share Dividends and Other Distributions</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How will I receive dividends and other distributions on the ordinary shares underlying my ADSs?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it will pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate of JPMorgan Chase Bank, N.A. to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division, branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary. You will receive these distributions in proportion to the number of underlying securities that your ADSs represent.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Except as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Cash.</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable basis, subject to (i) appropriate adjustments for taxes withheld, (ii) such distribution being impermissible or impracticable with respect to certain registered ADR holders, and (iii) deduction of the depositary&#x2019;s and/or its agents&#x2019; expenses in (1) converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable basis, (2) transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4) making any sale by public or private means in any commercially reasonable manner. <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">If exchange rates fluctuate during a time when the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">Ordinary Shares</FONT>.&#x00a0;&#x00a0;&#x00a0;&#x00a0;In the case of a distribution in ordinary shares, the depositary will issue additional ADRs to evidence the number of ADSs representing such ordinary shares. Only whole ADSs will be issued. Any ordinary shares which would result in fractional ADSs will be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Rights to receive additional ordinary shares.</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;In the case of a distribution of rights to subscribe for additional ordinary shares or other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing rights to acquire additional ADRs. However, if we do not timely furnish such evidence, the depositary may:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:72pt;margin-top:8pt;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:72pt;margin-top:8pt;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;if it is not practicable to sell such rights by reason of the non<FONT CLASS="nobreak">-transferability</FONT> of the rights, limited markets therefor, their short duration or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Other Distributions.</FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;In the case of a distribution of securities or property other than those described above, the depositary may either (i) distribute such securities or property in any manner it deems equitable and practicable or (ii) to the extent the depositary deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;font-style:italic;font-weight:normal;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Elective Distributions.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>In the case of a dividend payable at the election of our shareholders in cash or in additional ordinary shares, we will notify the depositary at least 30 days prior to the proposed distribution stating whether or not we wish such elective distribution to be made available to ADR holders. The depositary shall make such elective distribution available to ADR holders only if (i) we shall have timely requested that the elective distribution is available to ADR holders, (ii) the depositary shall have determined that such distribution is reasonably practicable and (iii) the depositary shall have received satisfactory documentation within the terms of the deposit agreement including any legal opinions of counsel that the depositary in its reasonable discretion may request. If the above conditions are not satisfied, the depositary shall, to the extent permitted by law, distribute to the ADR holders, on the basis of the same determination as is made in the local market in respect of the ordinary shares for which no election is made, either (x) cash or (y) additional ADSs representing such additional ordinary shares. If the above conditions are satisfied, the depositary shall establish procedures to enable ADR holders to elect the receipt of the proposed dividend in cash or in additional ADSs. There can be no assurance that ADR holders generally, or any ADR holder in particular, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of the ADR holder as deposited securities, in which case the ADSs will also represent the retained items.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be withheld without liability and dealt with by the depositary in accordance with its then current practices.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">There can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights, shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All purchases and sales of securities will be handled by the Depositary in accordance with its then current policies, which are currently set forth in the &#x201c;Depositary Receipt Sale and Purchase of Security&#x201d; section of www.adr.com/Investors/FindOutAboutDRs, the location and contents of which the Depositary shall be solely responsible for.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Deposit, withdrawal and Cancellation</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How does the depositary issue ADSs?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary will issue ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this prospectus, we will arrange with the underwriters named herein to deposit such ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Ordinary shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such deposit, be registered in the name of the depositary, the custodian or a nominee of either.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The custodian will hold all deposited ordinary shares (including those being deposited by or on our behalf in connection with this offering to which this prospectus relates) for the account and to the order of the depositary for the benefit of registered holders of ADRs, to the extent not prohibited by law. ADR holders thus have no direct ownership interest in the ordinary shares and only have such rights as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in substitution for the deposited ordinary shares. The deposited ordinary shares and any such additional items are referred to as &#x201c;deposited securities.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon each deposit of ordinary shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement, including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled. All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&#x2019;s direct registration system, and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&#x2019;s name. An ADR holder can request that the ADSs not be held through the depositary&#x2019;s direct registration system and that a certificated ADR be issued.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How do ADR holders cancel an ADS and obtain deposited securities?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">When you turn in your ADR certificate at the depositary&#x2019;s office, or when you provide proper instructions and documentation in the case of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying ordinary shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&#x2019;s office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary may only restrict the withdrawal of deposited securities in connection with:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>temporary delays caused by closing our transfer books or those of the depositary or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the payment of fees, taxes and similar charges; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This right of withdrawal may not be limited by any other provision of the deposit agreement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Record Dates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated, as the case may be):</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to receive any distribution on or in respect of deposited securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to give instructions for the exercise of voting rights;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to receive any notice or to act in respect of other matters,</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>all subject to the provisions of the deposit agreement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Voting Rights</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How do I vote?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise the voting rights for the ordinary shares which underlie your ADSs. Subject to the next sentence, as soon as practicable after receipt from us of notice of any meeting at which the holders of ordinary shares are entitled to vote, or of our solicitation of consents or proxies from holders of ordinary shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit agreement in respect of such meeting or solicitation of consent or proxy. The depositary shall, if we request in writing in a timely manner (the depositary having no obligation to take any further action if our request shall not have been received by the depositary at least 30 days prior to the date of such vote or meeting) and at our expense and provided no legal prohibitions exist, distribute to the registered ADR holders a notice stating such information as is contained in the voting materials received by the depositary, stating that that each registered holder of ADRs on the ADS record date will, subject to any applicable provisions of the law of England and Wales, be entitled to instruct the depositary as to the exercise of any voting rights pertaining to ordinary shares underlying such holder&#x2019;s ADSs, and describing how you may instruct the depositary to exercise the voting rights for the ordinary shares which underlie your ADSs, including instructions for giving a discretionary proxy to a person designated by us. For instructions to be valid, the depositary must receive them in the manner and on or before the date specified. The depositary will try, as far as is practical, subject to the provisions of or governing the underlying ordinary shares or other deposited securities, to vote or cause to be voted the ordinary shares or other deposited securities as you instruct. The depositary will only vote or attempt to vote as you instruct. Holders are strongly encouraged to forward their voting instructions to the depositary as soon as possible. Voting instructions will not be deemed to be received until such time as the ADR department responsible for proxies and voting has received such instructions notwithstanding that such instructions may have been physically received by the depositary prior to such time. The depositary will not itself exercise any voting discretion. Furthermore, neither the depositary nor its agents are responsible for any failure to carry out any voting instructions, for the manner in which any vote is cast or for the effect of any vote. Notwithstanding anything contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of deposited securities, distribute to the registered holders of ADRs </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">a notice that provides such holders with, or otherwise publicizes to such holders, instructions on how to retrieve such materials or receive such materials upon request (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">i.e.</FONT>, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Reports and Other Communications</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Will ADR holders be able to view our reports?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement, the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Additionally, if we make any written communications generally available to holders of our ordinary shares, and we furnish copies thereof (or English translations or summaries) to the depositary, it will distribute the same to registered ADR holders.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Fees and Expenses</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">What fees and expenses will I be responsible for paying?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares, issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADSs are cancelled or reduced for any other reason, $5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit to pay such charge.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing ordinary shares or by any party surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a fee of up to U.S.$0.05 per ADS for any cash distribution made pursuant to the deposit agreement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>an aggregate fee of up to U.S.$0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the ordinary shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary&#x2019;s or its custodian&#x2019;s compliance with applicable law, rule or regulation (which fees and charges shall be assessed on a proportionate basis against holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such holders or by deducting such charge from one or more cash dividends or other cash distributions);</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those holders entitled thereto;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>stock transfer or other taxes and other governmental charges;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SWIFT, cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of ordinary shares, ADRs or deposited securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>transfer or registration fees for the registration or transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>in connection with the conversion of foreign currency into U.S. dollars, JPMorgan Chase Bank, N.A. shall deduct out of such foreign currency the fees, expenses and other charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection with such conversion; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">JPMorgan Chase Bank, N.A. and/or its agent may act as principal for such conversion of foreign currency. For further details see <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.adr.com</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us and the depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the termination of the deposit agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the book<FONT CLASS="nobreak">-entry</FONT> system accounts of participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Payment of Taxes</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon, such tax or other governmental charge shall be paid by the holder thereof to the depositary and by holding or having held an ADR the holder and all prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and its agents in respect thereof. If an ADR holder owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof from any cash distributions, or (ii) sell deposited securities by public or private sale (after attempting by reasonable means to notify the ADR holder hereof prior to such sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to effect any registration, registration of transfer, split<FONT CLASS="nobreak">-up</FONT> or combination of deposited securities or withdrawal of deposited securities until such payment is made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required to be withheld from any cash distribution or, in the case of a non<FONT CLASS="nobreak">-cash</FONT> distribution, sell the distributed property or securities (by public or private sale) in such amounts and in such manner as the depositary deems necessary and practicable to pay such taxes and distribute any remaining net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled thereto.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">By holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit obtained.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Reclassifications, Recapitalizations and Mergers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we take certain actions that affect the deposited securities, including (i) any change in nominal value, split<FONT CLASS="nobreak">-up</FONT>, consolidation, cancellation or other reclassification of deposited securities or (ii) any distributions of ordinary shares or other property not made to holders of ADRs or (iii) any recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then the depositary may choose to, and shall if reasonably requested by us:</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;amend the form of ADR;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(2)&#x00a0;&#x00a0;&#x00a0;&#x00a0;distribute additional or amended ADRs;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(3)&#x00a0;&#x00a0;&#x00a0;&#x00a0;distribute cash, securities or other property it has received in connection with such actions;</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(4)&#x00a0;&#x00a0;&#x00a0;&#x00a0;sell any securities or property received and distribute the proceeds as cash; or</P>
		<P CLASS="NL_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(5)&#x00a0;&#x00a0;&#x00a0;&#x00a0;none of the above.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part of the deposited securities and each ADS will then represent a proportionate interest in such property.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amendment and Termination</FONT></P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How may the deposit agreement be amended?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at least 30 days&#x2019; notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise prejudices any substantial existing right of ADR holders. Such notice need not describe in detail the specific amendments effectuated thereby, but must identify to ADR holders a means to access the text of such amendment. If an ADR holder continues to hold an ADR or ADRs after being so notified, such ADR holder is deemed to agree to such amendment and to be bound by the deposit agreement as so amended. Any amendments or supplements which (i) are reasonably necessary (as agreed by us and the depositary) in order for (a) the ADSs to be registered on Form F<FONT CLASS="nobreak">-6</FONT> under the Securities Act or (b) the ADSs or ordinary shares to be traded solely in electronic book<FONT CLASS="nobreak">-entry</FONT> form and (ii) do not in either such case impose or increase any fees or charges to be borne by ADR holders, shall be deemed not to prejudice any substantial rights of ADR holders. Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith, we and the depositary may amend or supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules or regulations, which amendment or supplement may take effect before a notice is given or within any other period of time as required for compliance. No amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">How may the deposit agreement be terminated?</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to the registered holders of ADRs at least 30 days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i) resigned as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered holders unless a successor depositary shall not be operating under the deposit agreement within 60 days of the date of such resignation, and (ii) been removed as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">agreement on the 120<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">th</FONT> day after our notice of removal was first provided to the depositary. After termination, the depositary&#x2019;s only responsibility will be (i) to deliver deposited securities to ADR holders who surrender their ADRs, and (ii) to hold or sell distributions received on deposited securities. As soon as practicable after the expiration of six months from the termination date, the depositary will sell the deposited securities which remain and hold the net proceeds of such sales (as long as it may lawfully do so), without liability for interest, in trust for the ADR holders who have not yet surrendered their ADRs. After making such sale, the depositary shall have no obligations except to account for such proceeds and other cash.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Limitations on Obligations and Liability to ADR holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Limits on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Prior to the issue, registration, registration of transfer, split<FONT CLASS="nobreak">-up</FONT>, combination, or cancellation of any ADRs, or the delivery of any distribution in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian may require:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>payment with respect thereto of (i) any stock transfer or other tax or other governmental charge, (ii) any stock transfer or registration fees in effect for the registration of transfers of ordinary shares or other deposited securities upon any applicable register and (iii) any applicable fees and expenses described in the deposit agreement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the production of proof satisfactory to it of (i) the identity of any signatory and genuineness of any signature and (ii) such other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial ownership of any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>compliance with such regulations as the depositary may establish consistent with the deposit agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The issuance of ADRs, the acceptance of deposits of ordinary shares, the registration, registration of transfer, split<FONT CLASS="nobreak">-up</FONT> or combination of ADRs or the withdrawal of ordinary shares, may be suspended, generally or in particular instances, when the ADR register or any register for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw ordinary shares may only be limited under the following circumstances: (i) temporary delays caused by closing transfer books of the depositary or our transfer books or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends, (ii) the payment of fees, taxes, and similar charges, and (iii) compliance with any laws or governmental regulations relating to ADRs or to the withdrawal of deposited securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The deposit agreement expressly limits the obligations and liability of the depositary, ourselves and each of our and the depositary&#x2019;s respective agents, provided, however, that no disclaimer of liability under the Securities Act or the Exchange Act, to the extent applicable, is intended by any provision of the deposit agreement. In the deposit agreement it provides that neither we nor the depositary nor any such agent will be liable to registered holders or beneficial owners of ADSs if:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>any present or future law, rule, regulation, fiat, order or decree of the United States, England and Wales or any other country or jurisdiction, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism, nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond our, the depositary&#x2019;s or our respective agents&#x2019; direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it exercises or fails to exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution or action may be lawful or reasonably practicable;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it performs its obligations under the deposit agreement and ADRs without gross negligence or willful misconduct; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it takes any action or refrains from taking any action in reliance upon the advice of or information from legal counsel, accountants, any person presenting ordinary shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice or information.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We, the depositary and its agents may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by them to be genuine and to have been signed, presented or given by the proper party or parties.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Neither the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities or the ADRs, which in our opinion may involve us in expense or liability, if indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including without limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary shall not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system. Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of JPMorgan Chase Bank, N.A. Notwithstanding anything to the contrary contained in the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on the part of the custodian except to the extent that any registered holder of ADRs has incurred liability directly as a result of the custodian having (i) committed fraud or willful misconduct in the provision of custodial services to the depositary or (ii) failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance with the standards prevailing in the jurisdiction in which the custodian is located. The depositary shall not have any liability for the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary has no obligation to inform ADR holders or other holders of an interest in any ADSs about the requirements of the law of England and Wales, rules or regulations or any changes therein or thereto.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Neither the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any such vote is cast or for the effect of any such vote. The depositary may rely upon instructions from us or our counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall not incur any liability for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities, for the validity or worth of the deposited securities, for the credit<FONT CLASS="nobreak">-worthiness</FONT> of any third party, for allowing any rights to lapse upon the terms of the deposit agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection with any matter arising wholly after the removal or resignation of the depositary. Neither the depositary nor any of its agents shall be liable to registered holders or beneficial owners of interests in ADSs for any indirect, special, punitive or consequential damages (including, without limitation, legal fees and expenses) or lost profits, in each case of any form incurred by any person or entity, whether or not foreseeable and regardless of the type of action in which such a claim may be brought.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the deposit agreement each party thereto (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests in ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the ordinary shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADSs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Disclosure of Interest in ADSs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">To the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other ownership of deposited securities, other ordinary shares and other securities and may provide for blocking transfer, voting or other rights to enforce such disclosure or limits, you agree to comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you to deliver your ADSs for cancellation and withdrawal of the deposited securities so as to permit us to deal with you directly as a holder of ordinary shares and, by holding an ADS or an interest therein, you will be agreeing to comply with such instructions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Books of Depositary</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary or its agent will maintain a register for the registration, registration of transfer, combination and split<FONT CLASS="nobreak">-up</FONT> of ADRs, which register shall include the depositary&#x2019;s direct registration system. Registered holders of ADRs may inspect such records at the depositary&#x2019;s office at all reasonable times, but solely for the purpose of communicating with other holders in the interest of the business of our company or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time, when deemed expedient by the depositary.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The depositary will maintain facilities for the delivery and receipt of ADRs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Appointment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the deposit agreement, each registered holder of ADRs and each person holding an interest in ADSs, upon acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>appoint the depositary its attorney<FONT CLASS="nobreak">-in-fact</FONT>, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Governing Law</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The deposit agreement and the ADRs shall be governed by and construed in accordance with the laws of the State of New York. In the deposit agreement, we have submitted to the jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Notwithstanding the foregoing, any action based on the deposit agreement or the transactions contemplated thereby may be instituted by the depositary in any competent court in England and Wales.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">By holding an ADS or an interest therein, registered holders of ADRs and owners of ADSs each irrevocably agree that any legal suit, action or proceeding against or involving us or the depositary, arising out of or based upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only be instituted in a state or federal court in New York, New York, and each irrevocably waives any objection which it may have to the laying of venue of any such proceeding, and irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T19"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATERIAL TAX CONSIDERATIONS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Material U.S. Federal Income Tax Considerations for U.S. Holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following discussion describes certain material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs by U.S. Holders. This discussion applies to U.S. Holders that purchase our ADSs pursuant to this offering and hold such ADSs as capital assets for tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, and the income tax treaty between the United Kingdom and the United States, or the Treaty, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, dealers or traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax<FONT CLASS="nobreak">-exempt</FONT> entities or governmental organizations, retirement plans, regulated investment companies, real estate investment trusts, grantor trusts, brokers, dealers or traders in securities, commodities, currencies or notional principal contracts, certain former citizens or long<FONT CLASS="nobreak">-term</FONT> residents of the United States, persons who hold our ADSs as part of a &#x201c;straddle,&#x201d; &#x201c;hedge,&#x201d; &#x201c;conversion transaction,&#x201d; &#x201c;synthetic security&#x201d; or integrated investment, persons that have a &#x201c;functional currency&#x201d; other than the U.S. dollar, persons who are subject to the tax accounting rules of Section 451(b) of the Internal Revenue Code, persons that own directly, indirectly or through attribution 10% or more (by vote or value) of our equity, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass<FONT CLASS="nobreak">-through</FONT> entities, and investors in such pass<FONT CLASS="nobreak">-through</FONT> entities). This discussion does not address any U.S. state or local or non<FONT CLASS="nobreak">-U</FONT>.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As used in this discussion, the term &#x201c;U.S. Holder&#x201d; means a beneficial owner of our ADSs that is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds our ADSs, the U.S. federal income tax consequences relating to an investment in such ADSs will depend upon the status and activities of such entity and the particular partner. Any such entity and a partner in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it (and, as applicable, its partners) of the purchase, ownership and disposition of our ADSs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have not sought, nor will we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that the IRS will not take a different position concerning the tax consequences of the purchase, ownership or disposition of the ADSs or that any such position would not be sustained. Persons considering an investment in our ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase, ownership and disposition of our ADSs, including the applicability of U.S. federal, state and local tax laws and non<FONT CLASS="nobreak">-U</FONT>.S. tax laws.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Passive Foreign Investment Company Rules</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In general, a corporation organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least 75% of its gross income is &#x201c;passive income,&#x201d; or the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, or the PFIC asset test. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that give rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non<FONT CLASS="nobreak">-U</FONT>.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Although PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature of our current and expected income and the current and expected value and composition of our assets, we believe we were a PFIC for our 2018 tax year and we expect to be a PFIC for our current taxable year. There can be no assurance that we will not be a PFIC in future taxable years. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Because of the uncertainties involved in establishing our PFIC status, our U.S. counsel expresses no opinion regarding our PFIC status, and also expresses no opinion with respect to our predictions or past determinations regarding our PFIC status.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are a PFIC in any taxable year during which a U.S. Holder owns our ADSs, the U.S. Holder could be liable for additional taxes and interest charges under the &#x201c;PFIC excess distribution regime&#x201d; upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#x2019;s holding period for our ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a pledge, of our ADSs, whether or not we continue to be a PFIC in the year in which such U.S. Holder disposes of or is deemed to dispose of its ADSs. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#x2019;s holding period for our ADSs. The amount allocated to the current taxable year (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">i.e</FONT>., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are a PFIC for any year during which a U.S. Holder holds our ADSs, we must generally continue to be treated as a PFIC by that U.S. Holder for all succeeding years during which the U.S. Holder holds such ADSs, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#x201c;deemed sale&#x201d; election with respect to our ADSs. If the election is made, the U.S. Holder will be deemed to sell our ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holder&#x2019;s ADSs would not be treated as shares of a PFIC unless we subsequently become a PFIC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs and one of our non<FONT CLASS="nobreak">-United</FONT> States subsidiaries is also a PFIC (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">i.e</FONT>., a lower<FONT CLASS="nobreak">-tier</FONT> PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower<FONT CLASS="nobreak">-tier</FONT> PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower<FONT CLASS="nobreak">-tier</FONT> PFIC and on gain from the disposition of shares of the lower<FONT CLASS="nobreak">-tier</FONT> PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Any of our non<FONT CLASS="nobreak">-United</FONT> States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships for U.S. federal income tax purposes would not be corporations under U.S. federal income tax law and accordingly, cannot be classified as lower<FONT CLASS="nobreak">-tier</FONT> PFICs. However, a non<FONT CLASS="nobreak">-United</FONT> States subsidiary that has not made the election may be classified as a lower<FONT CLASS="nobreak">-tier</FONT> PFIC if we are a PFIC during your holding period and the subsidiary meets the PFIC income test or PFIC asset test.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on our ADSs if a valid &#x201c;mark<FONT CLASS="nobreak">-to-market</FONT>&#x201d; election is made by the U.S. Holder for our ADSs. An electing U.S. Holder generally would take into account as ordinary income each year, the excess of the fair market value of our ADSs held at the end of such taxable year over the adjusted tax basis of such ADSs. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark<FONT CLASS="nobreak">-to-market</FONT> election. The U.S. Holder&#x2019;s tax basis in our ADSs would be adjusted annually to reflect any income or loss recognized as a result of the mark<FONT CLASS="nobreak">-to-market</FONT> election. Any gain from a sale, exchange or other disposition of our ADSs in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark<FONT CLASS="nobreak">-to-market</FONT> gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would not be required to take into account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ADSs would be classified as a capital gain or loss.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A mark<FONT CLASS="nobreak">-to-market</FONT> election is available to a U.S. Holder only for &#x201c;marketable stock.&#x201d; Generally, stock will be considered marketable stock if it is &#x201c;regularly traded&#x201d; on a &#x201c;qualified exchange&#x201d; within the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our ADSs will be marketable stock as long as they remain listed on Nasdaq and are regularly traded. A mark<FONT CLASS="nobreak">-to-market</FONT> election will not apply to the ADSs for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any of our non<FONT CLASS="nobreak">-U</FONT>.S. subsidiaries. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower<FONT CLASS="nobreak">-tier</FONT> PFICs notwithstanding the U.S. Holder&#x2019;s mark<FONT CLASS="nobreak">-to-market</FONT> election for our ADSs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid QEF election. As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election, prospective investors should assume that a QEF election will not be available.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of our ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ADSs of a PFIC.</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Distributions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the discussion above under &#x201c;&#x2014; Passive Foreign Investment Company Rules,&#x201d; a U.S. Holder that receives a distribution with respect to our ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when actually or constructively received by the U.S. Holder to the extent of the U.S. Holder&#x2019;s pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#x2019;s pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax<FONT CLASS="nobreak">-free</FONT> return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#x2019;s ADSs. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#x2019;s ADSs, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. The amount of a dividend will include any amounts withheld by the company in respect of United Kingdom taxes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Distributions on our ADSs that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#x2019;s particular circumstances, any United Kingdom income taxes withheld from dividends on ADSs at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#x2019;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any United Kingdom income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. The amount of any dividend income paid in a currency other than the U.S. dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend amount. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Distributions paid on our ADSs will not be eligible for the &#x201c;dividends received&#x201d; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &#x201c;qualified foreign corporation&#x2019;&#x2019; to non<FONT CLASS="nobreak">-corporate</FONT> U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">the 121<FONT CLASS="nobreak">-day</FONT> period beginning 60 days before the ex<FONT CLASS="nobreak">-dividend</FONT> date) and certain other requirements are met. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends to its particular circumstances. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion above under &#x201c;&#x2014; Passive Foreign Investment Company Rules&#x2019;&#x2019;), we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A non<FONT CLASS="nobreak">-United</FONT> States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays on ADSs that are readily tradable on an established securities market in the United States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The amount of any dividend income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt (actual or constructive).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Sale, Exchange or Other Taxable Disposition of Our ADSs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the discussion above under &#x201c;&#x2014; Passive Foreign Investment Company Rules,&#x201d; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ADSs in an amount equal to the difference, if any, between the amount realized (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">i.e</FONT>., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holder&#x2019;s adjusted tax basis in the ADSs. Such capital gain or loss generally will be long<FONT CLASS="nobreak">-term</FONT> capital gain taxable at a reduced rate for non<FONT CLASS="nobreak">-corporate</FONT> U.S. Holders or long<FONT CLASS="nobreak">-term</FONT> capital loss if, on the date of sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non<FONT CLASS="nobreak">-corporate</FONT> U.S. Holder that is not long<FONT CLASS="nobreak">-term</FONT> capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of our ADSs will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Medicare Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of our ADSs. If you are a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of your investment in our ADSs.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ADSs, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for our ADSs may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties and other adverse circumstances may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dividends on and proceeds from the sale or other disposition of our ADSs generally have to be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S. taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#x2019;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ADSs IN LIGHT OF THE INVESTOR&#x2019;S OWN CIRCUMSTANCES. IN ADDITION, SIGNIFICANT CHANGES IN U.S. FEDERAL INCOME TAX LAWS WERE RECENTLY ENACTED. PROSPECTIVE INVESTORS SHOULD ALSO CONSULT WITH THEIR TAX ADVISORS WITH RESPECT TO SUCH CHANGES IN U.S. TAX LAW AS WELL AS POTENTIAL CONFORMING CHANGES IN STATE TAX LAWS.</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">U.K. Taxation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following is intended as a general guide to current U.K. tax law and HM Revenue and Customs, or HMRC, published practice applying as at the date of this prospectus (both of which are subject to change at any time, possibly with retrospective effect) relating to the holding of ADSs . It does not constitute legal or tax advice and does not purport to be a complete analysis of all U.K. tax considerations relating to the holding of ADSs, or all of the circumstances in which holders of ADSs may benefit from an exemption or relief from U.K. taxation. It is written on the basis that the company does not (and will not) directly or indirectly derive 75% or more of its qualifying asset value form U.K. land, and that the company is and remains solely resident in the U.K. for tax purposes and will therefore be subject to the U.K. tax regime and not the U.S. tax regime save as set out above under &#x201c;U.S. Federal Income Taxation.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Except to the extent that the position of non<FONT CLASS="nobreak">-U</FONT>.K. resident persons is expressly referred to, this guide relates only to persons who are resident (and, in the case of individuals, domiciled or deemed domiciled) for tax purposes solely in the U.K. and do not have a permanent establishment or fixed base in any other jurisdiction with which the holding of the ADSs is connected, or U.K. Holders, who are absolute beneficial owners of the ADSs (where the ADSs are not held through an Individual Savings Account or a Self<FONT CLASS="nobreak">-Invested</FONT> Personal Pension) and who hold the ADSs as investments.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This guide may not relate to certain classes of U.K. Holders, such as (but not limited to):</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>persons who are connected with the company;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>financial institutions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>insurance companies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>charities or tax<FONT CLASS="nobreak">-exempt</FONT> organizations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>collective investment schemes;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>pension schemes;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>market makers, intermediaries, brokers or dealers in securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>persons who have (or are deemed to have) acquired their ADSs by virtue of an office or employment or who are or have been officers or employees of the company or any of its affiliates; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>individuals who are subject to U.K. taxation on a remittance basis.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The decision of the First<FONT CLASS="nobreak">-tier</FONT> Tribunal (Tax Chamber) in <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">HSBC Holdings plc and The Bank of New York Mellon Corporation v HMRC</FONT> (2012) cast some doubt on whether a holder of a depositary receipt is the beneficial owner of the underlying shares. However, based on published HMRC guidance we would expect that HMRC will regard a holder of ADSs as holding the beneficial interest in the underlying shares and therefore these paragraphs assume that a holder of ADSs is the beneficial owner of the underlying ordinary shares and any dividends paid in respect of the underlying ordinary shares (where the dividends are regarded for U.K. purposes as that person&#x2019;s own income) for U.K. direct tax purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">THESE PARAGRAPHS ARE A SUMMARY OF CERTAIN U.K. TAX CONSIDERATIONS AND ARE INTENDED AS A GENERAL GUIDE ONLY. IT IS RECOMMENDED THAT ALL HOLDERS OF ADSs OBTAIN ADVICE AS TO THE CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSAL OF THE ADSs IN THEIR OWN SPECIFIC CIRCUMSTANCES FROM THEIR OWN TAX ADVISORS. IN PARTICULAR, NON</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-U</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.K. RESIDENT OR DOMICILED PERSONS ARE ADVISED TO CONSIDER THE POTENTIAL IMPACT OF ANY RELEVANT DOUBLE TAXATION AGREEMENTS.</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Dividends</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Withholding Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Dividends paid by the company will not be subject to any withholding or deduction for or on account of U.K. tax, irrespective of the residence or particular circumstances of the holders of ADSs.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Income Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An individual U.K. Holder may, depending on his or her particular circumstances, be subject to U.K. tax on dividends received from the company. An individual holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. income tax on dividends received from the company unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in the U.K. through a branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the U.K. through independent agents, such as some brokers and investment managers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All dividends received by an individual U.K. Holder from us or from other sources will form part of that U.K. Holder&#x2019;s total income for income tax purposes and will constitute the top slice of that income. A nil rate of income tax will apply to the first &#x00a3;2,000 of taxable dividend income received by the individual U.K. Holder in a tax year. Income within the nil<FONT CLASS="nobreak">-rate</FONT> band will be taken into account in determining whether income in excess of the &#x00a3;2,000 tax<FONT CLASS="nobreak">-free</FONT> allowance falls within the basic rate, higher rate or additional rate tax bands. Dividend income in excess of the tax<FONT CLASS="nobreak">-free</FONT> allowance will (subject to the availability of any income tax personal allowance) be taxed at 7.5 per cent. to the extent that the excess amount falls within the basic rate tax band, 32.5 per cent. to the extent that the excess amount falls within the higher rate tax band and 38.1 per cent. to the extent that the excess amount falls within the additional rate tax band.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Corporation Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A corporate holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. corporation tax on dividends received from the company unless it carries on (whether solely or in partnership) a trade in the United Kingdom through a permanent establishment to which the ADSs are attributable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Corporate U.K. Holders should not be subject to U.K. corporation tax on any dividend received from the company so long as the dividends qualify for exemption, which should be the case, provided the dividends fall within an exempt class and certain conditions are met. If the conditions for the exemption are not satisfied, or such U.K. Holder elects for an otherwise exempt dividend to be taxable, U.K. corporation tax will be chargeable on the amount of any dividends (at the current rate of 19% reducing to 17% from April<FONT CLASS="nobreak"> </FONT>1, 2020).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Chargeable Gains</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A disposal or deemed disposal of ADSs by a U.K. Holder may, depending on the U.K. Holder&#x2019;s circumstances and subject to any available exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of U.K. capital gains tax and corporation tax on chargeable gains.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If an individual U.K. Holder who is subject to U.K. income tax at either the higher or the additional rate is liable to U.K. capital gains tax on the disposal of ADSs, the current applicable rate will be 20%. For an individual U.K. Holder who is subject to U.K. income tax at the basic rate and liable to capital gains tax on such disposal, the current applicable rate would be 10%, save to the extent that any capital gains when aggregated with the U.K. Holder&#x2019;s other taxable income and gains in the relevant tax year exceed the unused basic rate tax band. In that case, the rate currently applicable to the excess would be 20%.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If a corporate U.K. Holder becomes liable to U.K. corporation tax on the disposal (or deemed disposal) of ADSs, the main rate of U.K. corporation tax (currently 19% reducing to 17% from April<FONT CLASS="nobreak"> </FONT>1, 2020) would apply. Indexation allowance is not available in respect of disposals of ADSs acquired on or after January<FONT CLASS="nobreak"> </FONT>1, 2018 (and only covers the movement in the retail prices index up until 31 December 2017, in respect of assets acquired prior to that date). A holder of ADSs which is not resident for tax purposes in the United Kingdom should not normally be liable to U.K. capital gains tax or corporation tax on chargeable gains on a disposal (or deemed disposal) of ADSs unless the person is carrying on (whether solely or in partnership) a trade, profession or vocation in the United Kingdom through a branch or agency (or, in the case of a corporate holder of ADSs, through a permanent establishment) to which the ADSs are attributable. However, an individual holder of ADSs who is treated as resident outside the United Kingdom </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">for the purposes of a double tax treaty, or who has ceased to be resident for tax purposes in the United Kingdom for a period of less than five years and who disposes of ADSs during that period may be liable on his or her return to the United Kingdom to U.K. tax on any capital gain realized (subject to any available exemption or relief).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Stamp Duty and Stamp Duty Reserve Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Issue of Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No U.K. stamp duty or stamp duty reserve tax, or SDRT, is payable on the issue of the underlying ordinary shares in the company.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Transfers of Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Neither U.K. stamp duty nor SDRT should arise on transfers of the underlying ordinary shares (including instruments transferring ordinary shares and agreements to transfer ordinary shares) on the basis that the ordinary shares are admitted to trading on AIM, provided the following requirements are (and continue to be) met:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the ordinary shares are admitted to trading on AIM, but are not listed on any market (with the term &#x201c;listed&#x201d; being construed in accordance with section 99A of the Finance Act 1986), and this has been certified to Euroclear; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>AIM continues to be accepted as a &#x201c;recognized growth market&#x201d; as construed in accordance with section 99A of the Finance Act 1986).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the event that either of the above requirements is not met, stamp duty or SDRT will generally apply to transfers of, or agreements to transfer, ordinary shares. Where applicable, the purchaser normally pays the stamp duty or SDRT.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Issue and Transfers of ADSs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No U.K. stamp duty or SDRT is payable on the issue or transfer of (including an agreement to transfer) ADSs in the company.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T20"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNDERWRITING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the representative of the underwriters of this offering, or the Representative. We have entered into an underwriting agreement dated &#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;, 2019 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below and each underwriter named below has severally and not jointly agreed to purchase from us, at the public offering price per share less the underwriting discounts set forth on the cover page of this prospectus, the number of ADSs listed next to its name in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Underwriter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number of <BR>ADSs</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ThinkEquity, a division of Fordham Financial Management, Inc.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The underwriters are offering the ADSs subject to their acceptance of the ADSs from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ADSs offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated, severally and not jointly, to take and pay for all of the ADSs offered by this prospectus if any such ADSs are taken, other than the ADSs covered by the underwriters&#x2019; option to purchase additional ADSs described below. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non<FONT CLASS="nobreak">-defaulting</FONT> underwriters may be increased or this offering may be terminated.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The underwriters initially propose to offer part of the ADSs directly to the public at the public offering price listed on the cover page of this prospectus and part of the ADSs to certain dealers at a price that represents a concession not in excess of $         per ADS from the initial public offering price. After the initial offering of the ADSs, this offering price and other selling terms may from time to time be varied by the underwriters.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Option to Purchase Additional ADSs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have granted to the underwriters an option, exercisable for 45 days from the date of this prospectus, to purchase up to additional ADSs at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this over<FONT CLASS="nobreak">-allotment</FONT> option solely for the purpose of covering over<FONT CLASS="nobreak">-allotments</FONT>, if any, made in connection with this offering of the ADSs offered by this prospectus. To the extent the over<FONT CLASS="nobreak">-allotment</FONT> option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional ADSs as the number listed next to the underwriter&#x2019;s name in the preceding table bears to the total number of ADSs listed next to the names of all underwriters in the preceding table.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commissions and Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following table shows the per ADS and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#x2019; over<FONT CLASS="nobreak">-allotment</FONT> option to purchase up to an additional ADSs:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Per ADS</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total<BR>Without<BR>Over-<BR>allotment <BR>Option</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total<BR>With<BR>Over-<BR>allotment<BR>Option</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Public offering price</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Underwriting discounts and commissions (7.0%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-accountable expense allowance (1.0%)<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds, before expenses, to us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;We have agreed to pay a non<FONT CLASS="nobreak">-accountable</FONT> expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have agreed to reimburse the Representative for all reasonable out<FONT CLASS="nobreak">-of-pocket</FONT> accountable fees and costs incurred by the Representative in connection with this offering up to a maximum of $124,500 in the aggregate, consisting of: (a) the cost associated with the use of Ipreo&#x2019;s book<FONT CLASS="nobreak">-building</FONT> prospectus tracking and compliance software </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">for this offering up to a maximum of $29,500; (b) the Representative&#x2019;s actual accountable road show expenses for this offering up to $20,000; and (c) the fees and expenses of the underwriters&#x2019; legal counsel up to $75,000.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We estimate the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately $354,500.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Representatives&#x2019; Warrants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon closing of this offering, we have agreed to issue to the Representative as compensation warrants to purchase a number of ADSs equal to 2% of the aggregate number of ADSs sold in this offering (excluding the over<FONT CLASS="nobreak">-allotment</FONT> option), or the Representative&#x2019;s Warrants. The Representative&#x2019;s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per ADS sold in this offering. The Representative&#x2019;s Warrants are exercisable at any time and from time to time, in whole or in part, during the four and one<FONT CLASS="nobreak">-half</FONT> year period commencing 180 days following the effective date of the registration statement related to this offering. We have registered the ordinary shares comprising the ADSs issuable upon the exercise of the Representative&#x2019;s Warrants in the registration statement of which this prospectus is a part.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Representative&#x2019;s Warrants have been deemed compensation by FINRA and are therefore subject to a 180<FONT CLASS="nobreak">-day</FONT> lock<FONT CLASS="nobreak">-up</FONT> pursuant to Rule 5110(g)(1) of FINRA. The Representative (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in certain cases. The single demand registration right provided will not be greater than five years from the effective date of this offering in compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration right provided will not be greater than seven years from the effective date of this offering in compliance with FINRA Rule 5110(f)(2)(G)(v). We will bear all fees and expenses attendant to registering the securities, including only one demand registration right granted by us to the Representative, issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of securities issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or the underlying securities will not be adjusted for issuances of ADSs at a price below the warrant exercise price.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Right of First Refusal</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Until six months from the closing date of this offering, the Representative will have, subject to certain exceptions, an irrevocable right of first refusal to act as sole investment banker, sole book<FONT CLASS="nobreak">-runner</FONT> and/or sole placement agent, at the Representative&#x2019;s discretion, for each and every future U.S. public and private equity and debt offering, including all equity linked financings, during such six month period for us, or any successor to or any subsidiary of us, on terms customary for the Representative. The Representative will have the sole right to determine whether or not any other broker<FONT CLASS="nobreak">-dealer</FONT> shall have the right to participate in any such offering and the economic terms of any such participation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Lock-Up Agreements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each of our directors and officers have agreed for a period of 180 days after the date of this prospectus, and we and certain of our stockholders have agreed for a period of at least 90 days after the date of this prospectus, without the prior written consent of the Representative, not to directly or indirectly (subject to limited exceptions):</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>issue (in the case of us), offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock, including, but not limited to our ADSs and ordinary shares, or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>file or cause the filing of any registration statement under the Securities Act with respect to any shares of our capital stock, including, but not limited to our ADSs and ordinary shares, or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>in the case of us, complete any offering of our debt securities, other than entering into a line of credit with a traditional bank; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>enter into any swap or other agreement, arrangement, hedge or transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership of our ADSs or ordinary shares or other capital stock or any securities convertible into or exercisable or exchangeable for our ADSs, ordinary shares or other capital stock, whether any transaction described in any of the foregoing bullet points is to be settled by delivery of our ADSs, ordinary shares or other capital stock, other securities, in cash or otherwise, or publicly announce an intention to do any of the foregoing.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Price Stabilization, Short Positions and Penalty Bids</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In connection with this offering, the underwriters may purchase and sell ADSs in the open market. These transactions may include short sales in accordance with Regulation M under the Exchange Act, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of ADSs than they are required to purchase in this offering. &#x201c;Covered&#x201d; short sales are sales made in an amount not greater than the underwriters&#x2019; option to purchase additional ADSs in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional ADSs or purchasing ADSs in the open market. In determining the source of ADSs to close out the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase additional ADSs pursuant to the option granted to them. &#x201c;Naked&#x201d; short sales are any sales in excess of such option. The underwriters must close out any naked short position by purchasing ADSs in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in this offering. Stabilizing transactions consist of various bids for, or purchases of, ADSs made by the underwriters in the open market prior to the completion of this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased ADSs sold by, or for the account of, such underwriter in stabilizing or short covering transactions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the ADSs, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the ADSs. As a result, the price of the ADSs may be higher than the price that otherwise might exist in the open market. If these activities are commenced, they are required to be conducted in accordance with applicable laws and regulations, and they may be discontinued at any time. These transactions may be effected on the Nasdaq, the over<FONT CLASS="nobreak">-the-counter</FONT> market or otherwise.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Passive Market Making</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In connection with this offering, the underwriters and selling group members may engage in passive market making transactions in our ADSs on the Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the ADSs and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#x2019;s bid, that bid must then be lowered when specified purchase limits are exceeded.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Indemnification</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have agreed to indemnify the underwriters against liabilities relating to this offering arising under the Securities Act and the Exchange Act, liabilities arising from breaches of some or all of the representations and warranties contained in the underwriting agreement, and to contribute to payments that the underwriters may be required to make for these liabilities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Discretionary Accounts</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Nasdaq and AIM Listings</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Our ADSs are listed on the Nasdaq Global Market under the symbol &#x201c;TLSA.&#x201d; Our ordinary shares are listed on the AIM market of the London Stock Exchange under the symbol &#x201c;TILS.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Electronic Distribution</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A prospectus in electronic format will be made available on the websites maintained by one or more of the underwriters or one or more securities dealers. One or more of the underwriters may distribute prospectuses electronically. The underwriters may agree to allocate a number of ADSs for sale to their online brokerage account holders. ADSs to be sold pursuant to an Internet distribution will be allocated on the same basis as other allocations. In addition, ADSs may be sold by the underwriters to securities dealers who resell ADSs to online brokerage account holders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other Relationships</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">From time to time, certain of the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees.  In the course of their businesses, the underwriters and their affiliates may actively trade our securities or loans for their own account or for the accounts of customers, and, accordingly, the underwriters and their affiliates may at any time hold long or short positions in such securities or loans.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Selling Restrictions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of our ADSs, or the possession, circulation or distribution of this prospectus supplement, the accompanying prospectus or any other material relating to us or our ADSs in any jurisdiction where action for that purpose is required. Accordingly, our ADSs may not be offered or sold, directly or indirectly, and none of this prospectus or any other offering material or advertisements in connection with our ADSs may be distributed or published, in or from any country or jurisdiction, except in compliance with any applicable rules and regulations of any such country or jurisdiction.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the avoidance of doubt, such prospectus will not constitute a &#x201c;prospectus&#x201d; for the purposes of Regulation (EU) 2017/1129, or Prospectus Regulation, and will not have been reviewed by any competent authority in any member state of the European Economic Area, or EEA Member State.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">European Economic Area</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In relation to each EEA Member State, an offer to the public of any ADSs which are the subject of this offering contemplated by this document may not be made in that EEA Member State except that an offer to the public in that EEA Member State of any ADSs may be made at any time under the following exemptions under the Prospectus Regulation:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to any legal entity which is a &#x201c;qualified investor&#x201d; as defined in the Prospectus Regulation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), as permitted under the Prospectus Regulation, subject to obtaining the prior consent of the underwriters or the underwriters nominated by us for any such offer; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;">provided that no such offer of ADSs or ordinary shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each person located in an EEA Member State to whom any offer of ADSs is made or who receives any communication in respect of an offer of ADSs, or who initially acquires any ADSs will be deemed to have represented, warranted, acknowledged and agreed to and with the underwriter and us that (1) it is a &#x201c;qualified investor&#x201d; as defined in the Prospectus Regulation; and (2) in the case of any ADSs acquired by it as a financial intermediary as that term is used in the Prospectus Regulation, the ADSs acquired by it in the offer have not been acquired on behalf of, nor </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;text-indent:0pt;margin-top:8pt;text-indent:0pt;">have they been acquired with a view to their offer or resale to, persons in any EEA Member State other than qualified investors, as that term is defined in the Prospectus Regulation, or in circumstances in which the prior consent of the underwriters or the underwriters nominated by us has been given to the offer or resale; or where ADSs have been acquired by it on behalf of persons in any EEA Member State other than qualified investors, the offer of those ADSs to it is not treated under the Prospectus Regulation as having been made to such persons.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company, the underwriter and their respective affiliates will rely upon the truth and accuracy of the foregoing representations, warranties, acknowledgments and agreements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This document has been prepared on the basis that any offer of ADSs in any EEA Member State will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities. Accordingly any person making or intending to make an offer in that EEA Member State of ADSs which are the subject of this offering may only do so in circumstances in which no obligation arises for us or the underwriter to publish a prospectus pursuant to Article 23 of the Prospectus Regulation in relation to such offer. Neither we nor the underwriter have authorized or will authorize the making of any offer of ADSs in circumstances in which an obligation arises for the company or the underwriter to publish a prospectus for such offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the purposes of this provision, the expression an &#x201c;offer to the public&#x201d; in relation to any offer of ADSs in any EEA Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for the ADSs and the expression &#x201c;Prospectus Regulation&#x201d; means Regulation (EU) 2017/1129.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Information to Distributors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended, or MiFID II; (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures, (together, the &#x201c;MiFID II Product Governance Requirements&#x201d;), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any &#x201c;manufacturer&#x201d; (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the ADSs have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II, or the Target Market Assessment. Notwithstanding the Target Market Assessment, distributors should note that: the price of the ADSs may decline and investors could lose all or part of their investment; the ADSs offer no guaranteed income and no capital protection; and an investment in the ADSs is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the ADSs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each distributor is responsible for undertaking its own target market assessment in respect of the ADSs and determining appropriate distribution channels.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">United Kingdom</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Each of the underwriters has represented and agreed that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it has not made or will not make an offer of the ADSs to the public in the United Kingdom within the meaning of section 102B of FSMA, except to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities or otherwise in circumstances which do not require the publication by us of a prospectus pursuant to the Prospectus Rules of the U.K. Financial Conduct Authority;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>or inducement to engage in investment activity (within the meaning of section 21 of FSMA) to persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation that also are (i) investment professionals falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated (each such person being referred to as a &#x201c;relevant person&#x201d;); and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>it has complied with and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at, relevant persons. This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. Any investment or investment activity to which this prospectus relates is available only to relevant persons and will be engaged in only with relevant persons.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Canada</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">This offering of our ADSs in Canada is being made on a private placement basis in reliance on exemptions from the prospectus requirements under the securities laws of each applicable Canadian province and territory where our ADSs may be offered and sold, and therein may only be made with investors that are purchasing, or deemed to be purchasing, as principal and that qualify as both an &#x201c;accredited investor&#x201d; as such term is defined in National Instrument 45<FONT CLASS="nobreak">-106</FONT> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Prospectus Exemptions</FONT> or subsection 73.3(1) of the <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Securities Act</FONT> (Ontario) and as a &#x201c;permitted client&#x201d; as such term is defined in National Instrument 31<FONT CLASS="nobreak">-103</FONT> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Registration Requirements, Exemptions and Ongoing Registrant Obligations.</FONT> Any offer and sale of our ADSs in any province or territory of Canada may only be made through a dealer that is properly registered under the securities legislation of the applicable province or territory wherein our ADSs is offered and/or sold or, alternatively, where such registration is not required.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Any resale of our ADSs by an investor resident in Canada must be made in accordance with applicable Canadian securities laws, which require resales to be made in accordance with an exemption from, or in a transaction not subject to, prospectus requirements under applicable Canadian securities laws. These resale restrictions may under certain circumstances apply to resales of the ADSs outside of Canada.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#x2019;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#x2019;s province or territory for particulars of these rights or consult with a legal advisor.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non<FONT CLASS="nobreak">-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument 33<FONT CLASS="nobreak">-105</FONT> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Underwriting Conflicts</FONT> (&#x201c;NI 33<FONT CLASS="nobreak">-105</FONT>&#x201d;), the underwriters are not required to comply with the disclosure requirements of NI 33<FONT CLASS="nobreak">-105</FONT> regarding underwriter conflicts of interest in connection with this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon receipt of this prospectus, each Qu&#x00e9;bec investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Par la r&#x00e9;ception de ce document, chaque investisseur qu&#x00e9;becois confirme par les pr&#x00e9;sentes qu&#x2019;il a express&#x00e9;ment exig&#x00e9; que tous les documents faisant foi ou se rapportant de quelque mani&#x00e8;re que ce soit &#x00e0; la vente des valeurs mobili&#x00e8;res d&#x00e9;crites aux pr&#x00e9;sentes (incluant, pour plus de certitude, toute confirmation d&#x2019;achat ou tout avis) soient r&#x00e9;dig&#x00e9;s en anglais seulement</FONT>.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T21"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Expenses of This Offering</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We estimate that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC registration fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,425</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FINRA filing fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,225</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Printing and engraving expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal fees and expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transfer agent and registrar fees and expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounting fees and expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Miscellaneous costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,350</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">230,000</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All amounts in the table are estimates except the SEC registration fee and the FINRA filing fee. We will pay all of the expenses of this offering.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T22"></A><FONT CLASS="Bold---Caps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The validity of our ordinary shares registered hereby and certain other matters of English law will be passed upon for us by Cooley (UK) LLP and certain matters of U.S. federal law will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, New York. Certain legal matters respect will be passed upon for the underwriters by Gracin &amp; Marlow, LLP.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T23"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXPERTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The consolidated financial statements of Tiziana Pharma Limited as of December<FONT CLASS="nobreak"> </FONT>31, 2017 and 2018, and for each of the years then ended, have been included herein and in the registration statement in reliance on the report of Mazars LLP, an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The registered business address of Mazars LLP is Tower Bridge House, St Katharine&#x2019;s Way, London E1W 1DD.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T24"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SERVICE OF PROCESS AND ENFORCEMENT OF LIABILITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We are incorporated and currently existing under the laws of England and Wales. In addition, certain of our directors and officers reside outside the United States, and most of the assets of our non<FONT CLASS="nobreak">-U</FONT>.S. subsidiaries are located outside the United States. As a result, it may be difficult for investors to effect service of process on us or those persons in the United States or to enforce in the United States judgments obtained in United States courts against us or those persons based on the civil liability or other provisions of the United States securities laws or other laws. In addition, uncertainty exists as to whether the courts of England and Wales would:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liabilities provisions of the securities laws of the United States or any state in the United States; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>entertain original actions brought in England and Wales against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have been advised by Cooley (UK) LLP that there is currently no treaty between (i) the United States and (ii) England and Wales providing for reciprocal recognition and enforcement of judgments of United States courts in civil and commercial matters (although the United States and the United Kingdom are both parties to the New York Convention on the Recognition and Enforcement of Foreign Arbitral Awards) and that a final judgment for the payment of money rendered by any general or state court in the United States based on civil liability, whether predicated solely upon the United States securities laws, would not be automatically enforceable in England and Wales. We have also been advised by Cooley (UK) LLP that any final and conclusive monetary judgment for a definite sum obtained against us in United States courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the relevant U.S. court had jurisdiction over the original proceedings according to English conflicts of laws principles at the time when proceedings were initiated;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>England and Wales courts had jurisdiction over the matter on enforcement and we either submitted to such jurisdiction or were resident or carrying on business within such jurisdiction and were duly served with process;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the U.S. judgment was final and conclusive on the merits in the sense of being final and unalterable in the court that pronounced it and being for a definite sum of money;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the judgment given by the courts was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations (or otherwise based on a U.S. law that an English court considers to relate to a penal, revenue or other public law);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the judgment was not procured by fraud;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>recognition or enforcement of the judgment in England and Wales would not be contrary to public policy or the Human Rights Act 1998;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the proceedings pursuant to which judgment was obtained were not contrary to natural justice;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the U.S. judgment was not arrived at by doubling, trebling or otherwise multiplying a sum assessed as compensation for the loss or damages sustained and not being otherwise in breach of Section 5 of the U.K. Protection of Trading Interests Act 1980, or is a judgment based on measures designated by the Secretary of State under Section 1 of that Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>there is not a prior decision of an English court or the court of another jurisdiction on the issues in question between the same parties; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the English enforcement proceedings were commenced within the limitation period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the United States securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the foregoing, investors may be able to enforce in England and Wales judgments in civil and commercial matters that have been obtained from U.S. federal or state courts. Nevertheless, we cannot assure you that those judgments will be recognized or enforceable in England and Wales.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement. In addition, it may not be possible to obtain an English judgment or to enforce that judgment if the judgment debtor is or becomes subject to any insolvency or similar proceedings, or if the judgment debtor has any set<FONT CLASS="nobreak">-off</FONT> or counterclaim against the judgment creditor. Also note that, in any enforcement proceedings, the judgment debtor may raise any counterclaim that could have been brought if the action had been originally brought in England unless the subject of the counterclaim was in issue and denied in the U.S. proceedings.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T25"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F<FONT CLASS="nobreak">-1</FONT> under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the ADSs offered by this prospectus, we refer you to the registration statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by the filed exhibits.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">You may review a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials at the SEC&#x2019;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1<FONT CLASS="nobreak">-800-SEC-0330</FONT>. The SEC maintains an Internet website (<FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov</FONT>) that contains reports, proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act applicable to FPIs. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form 20<FONT CLASS="nobreak">-F</FONT> and reports on Form 6<FONT CLASS="nobreak">-K</FONT>. Those reports may be inspected without charge at the locations described above. As an FPI, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short<FONT CLASS="nobreak">-swing</FONT> profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">We also maintain a website at <FONT CLASS="italic" STYLE="font-style:italic;font-weight:normal;">www.tizianalifesciences.com</FONT> contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</P>




	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T26"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS<BR><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T27"> Report of Independent Registered Public Accounting Firm </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-2 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T28"> Consolidated Balance Sheets </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-3 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T29"> Consolidated Statements of Comprehensive Income </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-4 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T30"> Consolidated Statements of Changes in Shareholders&#x2019; Equity </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-5 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T31"> Consolidated Statement of Cash Flows </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-7 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 91.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T32"> Notes to Consolidated Financial Statements </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> F-8 </P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T27"></A><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;">The Board of Directors and Shareholders of Tiziana Life Sciences plc</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Opinion on the Consolidated Financial Statements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">We have audited the accompanying consolidated balance sheet of Tiziana Life Sciences plc and its subsidiaries (the Group) as of December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, together with the related consolidated statements of operations and comprehensive loss, changes in shareholders&#x2019; equity, and cash flows for each of the three years in the period ended December<FONT CLASS="nobreak"> </FONT>31, 2018, including the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Group as of December<FONT CLASS="nobreak"> </FONT>31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December<FONT CLASS="nobreak"> </FONT>21, 2018, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Material uncertainty related to going concern</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">We draw attention to note 2 in the financial statements concerning the applicability of the going concern basis of preparation. The Group is pre revenue and its business model requires significant ongoing expenditure on research and development. In the period to December<FONT CLASS="nobreak"> </FONT>31, 2018 the Group incurred losses after taxation of $7,994,000. At December<FONT CLASS="nobreak"> </FONT>31, 2018 the Group had net assets of $519,000 and cash and cash equivalents of $5,304,000. In note 2 the directors explain that to date they have successfully raised funds to finance clinical trials, but that further funding will be required within the foreseeable future to continue their development programmes and to meet liabilities as they fall due. As the directors are confident that the Group will raise the additional funding they have prepared the consolidated financial statements on the going concern basis. However, until the Group secures sufficient investment to fund their clinical trials, and ongoing working capital requirements these events or conditions indicate that a material uncertainty exists that may cast a significant doubt about the Group&#x2019;s ability to continue as a going concern.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;">Our opinion is not modified in respect of this matter.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Basis for Opinion</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">These consolidated financial statements are the responsibility of the company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">Mazars LLP</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;">London, England</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;">April<FONT CLASS="nobreak"> </FONT>3, 2019</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T28"></A><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Balance Sheets<BR></FONT>(In thousands)</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ASSETS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,304</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments and other receivables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,609</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,384</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,913</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,448</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and Equipment, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total non-current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,920</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable and accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,749</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,749</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,749</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shareholders&#x2019; Equity:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Called up share capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,592</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,141</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share premium</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,862</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,284</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share based payment reserve &#x2013; Options</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,854</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,213</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share based payment reserve &#x2013; warrants</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">743</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">579</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan note reserve</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Merger relief reserve</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other reserve</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(46,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(46,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Translation reserve</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,977</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,997</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capital reduction reserve</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41,292</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41,292</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Retained earnings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(50,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(42,613</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">519</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,278</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total liabilities and shareholders&#x2019; equity</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,920</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T29"></A><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss<BR></FONT>(In thousands, except loss per share)</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="11" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of revenue</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross Profit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and Development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,510</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,015</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,007</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,417</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,601</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,872</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,616</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,927</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,616</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income/(expense):</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finance Income/(expense)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations before income taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,939</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,628</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,891</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax provision</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss for the year</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,716</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,770</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Comprehensive loss:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Currency translation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">650</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8,646</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,120</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">Restated</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 62.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted loss per share attributable to common shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(0.11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T30"></A><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statements of Shareholders&#x2019; Equity<BR></FONT>(In thousands)</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Capital</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Premium</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Based <BR>Payment <BR>Reserve <BR>(Options)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Based <BR>Payment <BR>Reserve <BR>(warrants)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Convertible <BR>Loan Note <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Merger <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Other <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Retained <BR>Earnings</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Capital <BR>Redemption <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Translation <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Capital <BR>Reduction <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Total <BR>Equity</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">Balance at 1 January<BR>2016</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">15,563</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">33,496</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">1,503</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">162</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">15,510</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">9,448</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(46,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(19,091</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2,121</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">12,540</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-7" STYLE="font-size:8pt;text-decoration:underline;">Transactions with<BR>owners</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Issue of share capital</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">84</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">546</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (options)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,144</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,144</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (warrants)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">109</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">109</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Convertible loan note  &#x2013; equity component</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,649</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(851</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">798</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Cancellation of deferred shares</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,744</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">8,744</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Capital Reduction</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(25,099</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,448</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,744</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">41,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(1,999</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Prior Year Adjustment</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(14</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(14</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total transactions with owners</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,660</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(24,553</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,144</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">109</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,649</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,448</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(865</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">41,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(669</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-7" STYLE="font-size:8pt;text-decoration:underline;">Comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Loss for the period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,770</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,770</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Translation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">650</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">650</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,770</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">650</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(9,120</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">Balance at 31 December 2016</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">6,903</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">8,943</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2,647</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">271</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">17,158</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(46,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(29,726</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2,771</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">41,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">4,088</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Issue of share capital</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">84</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,464</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,548</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (options)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,324</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,324</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (warrants)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">308</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">308</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Option forfeited in the<BR>year</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(758</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(758</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Options cancelled in the year</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(142</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(142</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Convertible loan note  &#x2013; equity component</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">419</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(419</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Convertible loan note interest</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">3,610</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(3,610</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Convertible Loan Note Conversion</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,154</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">20,877</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(21,188</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(844</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total transactions with owners</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1,237</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">22,341</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">566</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">308</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(17,158</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(4,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(844</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">2,280</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-7" STYLE="font-size:8pt;text-decoration:underline;">Comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Loss for the period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,716</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,716</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Translation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">70</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">70</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,716</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">70</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(8,646</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">Balance at 31 December 2017</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">8,141</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">31,284</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">3,213</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">579</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(46,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(42,613</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">1,997</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">41,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(2,278</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Issue of share capital</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">451</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">9,556</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">10,007</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Convertible loan note interest</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">22</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">(23</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (options)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">641</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">641</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Share based payment (warrants)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">164</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">164</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total transactions with owners</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">452</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">9,578</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">641</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">164</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">(23</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">10,812</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statements of Shareholders&#x2019; Equity &#x2013; (Continued)<BR></FONT>(In thousands)</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Capital</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Premium</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Based <BR>Payment <BR>Reserve <BR>(Options)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Share <BR>Based <BR>Payment <BR>Reserve <BR>(warrants)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Convertible <BR>Loan Note <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Merger <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Other <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Retained <BR>Earnings</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Capital <BR>Redemption <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Translation <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Capital <BR>Reduction <BR>Reserve</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:7pt;">Total <BR>Equity</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:7pt;font-style:normal;font-weight:normal;">$</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-7" STYLE="font-size:8pt;text-decoration:underline;">Comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Loss for the period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">(7,994</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">(7,994</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Translation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(20</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(20</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">Total comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(7,994</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(20</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:8pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(8,014</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 15.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">Balance at 31 December 2018</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">8,592</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">40,862</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">3,854</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">743</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 3.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(46,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">(50,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">1,977</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">41,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">519</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:justify;margin-top:8pt;">The capital reduction reserve includes reserves designated as realized profits available for distribution under section 830(2) of the Companies Act 2006 arising from the court approved capital reduction detailed in notes 16 and 21.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><A NAME="T31"></A><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidated Statements of Cash Flows<BR></FONT>(In thousands)</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="11" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.85%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations before income taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,939</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,628</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,891</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan interest accrued</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan interest paid as equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares issued in lieu of fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share based payment &#x2013; options</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">672</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">539</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,257</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cancellation of options</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(135</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share based payment &#x2013; warrants</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">294</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net (increase)/decrease in operating assets/other receivables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(180</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase/(decrease) in operating liabilities /other liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,123</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,304</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,174</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on foreign exchange</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(296</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash inflow from taxation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,791</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,551</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,533</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6,926</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">PPE</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(48</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Acquisition of other investments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(294</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in investing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(342</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of ordinary shares</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,917</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,542</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">614</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of convertible loan notes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">961</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of warrants</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,509</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fundraising cost</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,385</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,041</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,542</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,575</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase/(decrease) in cash and cash equivalents</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,490</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,992</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,693</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalent, beginning of period</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,802</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,128</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exchange difference</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(249</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">254</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,633</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalent, end of period</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,304</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,802</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T32"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">GENERAL INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Life Sciences PLC is a public limited company incorporated in the United Kingdom under the Companies Act and quoted on AIM, a market of the London Stock Exchange (AIM: TILS). The principal activities of the company and its subsidiaries (the Group) are that of a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">These financial statements are presented in thousands of dollars ($&#x2019;000) which is the presentational currency of the company. The functional currency is Pounds sterling (&#x00a3;) indicative of the primary economic environment in which the company operates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The ultimate parent of the group is Planwise Group Limited, incorporated in the British Virgin Islands. Gabriele Cerrone is the ultimate beneficial owner of the entire issued share capital of Planwise Group Limited.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently to all the years presented unless otherwise stated.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of preparation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board, IFRIC interpretations and the Companies Act 2006 as applicable to companies reporting under IFRS. These accounts have been prepared under the historical cost convention.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Going Concern</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group incurred losses during the year and has net liabilities at the year end.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group is in the early stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and immunology. The directors expect the company to incur further losses and to require significant capital expenditure in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully funded clinical trials to date and is in the process of securing additional investment for purposes of continuing to fund their clinical trials moving forward.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that the company will be able to meet its liabilities as they fall due for the foreseeable future, and therefore that it is appropriate to prepare the financial statements under the going concern basis of preparation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">However, until and unless the company secures sufficient investment to fund their clinical trials, there is a material uncertainty about the company&#x2019;s ability to continue as a going concern, and therefore about the applicability of the going concern basis of preparation. The financial statements do not include the adjustments that would be required if the going concern basis of preparation was considered inappropriate.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of consolidation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor&#x2019;s return.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de<FONT CLASS="nobreak">-consolidated</FONT> from the date at which control ceases.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business combination</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The consolidated position of the Group is as a result of the reverse acquisition of Alexander David Investments plc by Tiziana Pharma Ltd and the subsequent listing of the Company as Tiziana Life Sciences Plc on 24 April 2014. Tiziana Pharma Limited was incorporated on 4 November 2013 and prepared its first set of financial statements to 31 December 2014. Therefore, the parent and subsidiary had the same reporting date but Tiziana Pharma Limited had a long period of account. No adjustment was made in the consolidated financial statements for the difference in length of reporting period because the only transaction in Tiziana Pharma Limited at 31 December 2013 was the issue of ordinary share capital of &#x00a3;1.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Segment reporting</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taxation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign currency translation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Items included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#x2019;s presentation currency.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year<FONT CLASS="nobreak">-end</FONT> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Assets and liabilities at the rate of exchange ruling at the year<FONT CLASS="nobreak">-end</FONT> date.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Profit and loss account items at the average rate of exchange for the year.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">License fees</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Payments related to the acquisition of rights to a product or technology are capitalized as intangible assets if it is probable that future economic benefits from the asset will flow to the entity and the cost of the asset can be reliably measured.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Where fees related to research and development projects are recognized as an expense in the income statement, due to the uncertainty in the length of time that the Group will hold them the expense is recognized fully at the point of recognition.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All on<FONT CLASS="nobreak">-going</FONT> research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group&#x2019;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#x2018;Intangible Assets&#x2019;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no qualifying expenditure.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Financial instruments</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Financial assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(a)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Financial assets, initial recognition and measurement and subsequent measurement</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(b)&#x00a0;&#x00a0;&#x00a0;&#x00a0;Financial liabilities, initial recognition and measurement and subsequent measurement</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Financial liabilities are classified as measured at amortized cost or FVTPL.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group&#x2019;s financial liabilities include trade and other payables.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Share capital</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Ordinary shares of the company are classified as equity.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Property, IT and equipment</FONT></P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:24pt;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(i)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Recognition and measurement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Items of property, IT and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">When parts of an item of property, IT and equipment have different useful lives, they are accounted for as separate items (major components) of property, IT and equipment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Gains and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the revaluation reserve are transferred to retained earnings.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:24pt;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(ii)&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Depreciation</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Depreciation is recognized in profit or loss on a straight<FONT CLASS="nobreak">-line</FONT> basis over the estimated useful life of each part of an item of property, IT and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the company will obtain ownership by the end of the lease term.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The estimated useful lives for the current period and the comparative period are as follows.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">IT and equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3 years</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Fixtures and fittings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5 years</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold-Italic" STYLE="font-style:italic;font-weight:bold;">Impairment</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Impairment of financial assets measured at amortised cost</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">General approach</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12<FONT CLASS="nobreak">-month</FONT> expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Simplified approach</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The simplified approach is applied to the impairment assessment of trade receivables.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Non<FONT CLASS="nobreak">-financial</FONT> assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Non<FONT CLASS="nobreak">-financial</FONT> assets are impaired when its carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Operating leases</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Payments made under operating leases are recognized in profit and loss on a straight<FONT CLASS="nobreak">-line</FONT> basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Share based payments</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The calculation of the fair value of equity<FONT CLASS="nobreak">-settled</FONT> share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the company&#x2019;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of the awards.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Where employees, directors or advisers are rewarded using share based payments, the fair value of the employees&#x2019;, directors&#x2019; or advisers&#x2019; services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share based payment charge is calculated for these too.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In accordance with IFRS<FONT CLASS="nobreak"> </FONT>2, a charge is made to the Statement of Comprehensive Income for all share<FONT CLASS="nobreak">-based</FONT> payments including share options based upon the fair value of the instrument used. A corresponding credit is made to a Share Based Payment Reserve, in the case of options/warrants awarded to employees, directors, advisers, and other consultants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options / warrants expected to vest. Non market vesting conditions are included in assumptions about the number of options / warrants that are expected to become exercisable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Estimates are subsequently revised, if there is any indication that the number of share options / warrants expected to vest differs from previous estimates. No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally estimated. Exercise of share options / warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Where share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services received over the remainder of the vesting period is recognized immediately within the Statement of Comprehensive Income.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">All goods and services received in exchange for the grant of any share based payment are measured at their fair value.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ACCOUNTING POLICIES</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Convertible loan notes</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Under IAS 32 the liability and equity components of convertible loan notes must be presented separately on the Statement of Financial Position. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Where there is no option to repay as cash and the interest rate is fixed</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group considers these to be Convertible Equity Instruments and records the principal of the loan note as an equity in a Convertible loan note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the convertible loan note reserve to share capital and share premium.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Where there is no option to repay as cash and the interest rate is variable</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group considers these to be Convertible Debt Instruments and records the principal of the loan note as a debt liability in the liabilities section of the balance sheet. The accrued interest on the principal amount is recorded in the income statement and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting Standards as adopted by the European Union, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based on historical experience and other factors, including expectations of future events.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">When entering into agreements with third parties which provide the rights to conduct research into specific biological processes the group account for these agreements as an expense if the agreements are &#x2018;milestone&#x2019; in nature and relate to the Group&#x2019;s own research and development costs. Such agreements involve periodic payments and are evaluated as representing payments made to fund research.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The only other critical accounting estimates and judgements in the preparation of the financial statements were fair value estimates used in the calculation of share based payments and warrants which have been detailed above in note<FONT CLASS="nobreak"> </FONT>2, accounting policies, and note<FONT CLASS="nobreak"> </FONT>16, share based payments, to the accounts.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group has also made a judgement on the impact of Brexit during the preparation of the financial statements and considered it to not be significant.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OPERATING LOSS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group and Company&#x2019;s operating loss are stated after charging the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="6" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year Ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2018 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2017 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2016 <BR>$&#x2019;000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">License fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,041</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">662</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">561</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">13</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign exchange (gain)/losses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">(296</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">45</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">215</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">761</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">720</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">788</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SEGMENTAL REPORTING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">During the year under review Management identified the Group&#x2019;s only operating segment as the research and development of biotechnological and pharmaceutical products. This one segment is monitored and strategic decisions are made based upon it and other non<FONT CLASS="nobreak">-financial</FONT> data collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual financial statements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EMPLOYEES</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016 <BR>$&#x2019;000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Group</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Staff costs comprised:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Directors&#x2019; salaries</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">201</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">211</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wages and salaries</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,669</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,107</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">786</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Social security costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">596</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">491</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share based payment charge</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">671</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">539</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,015</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,138</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,348</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,053</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The average monthly number of employees, including directors, employed by<FONT CLASS="nobreak"> </FONT>the group during the year was:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and Development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Corporate and administration</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REMUNERATION OF KEY MANAGEMENT PERSONNEL</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="11" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 66.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Directors <BR>fees</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Salary</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Directors <BR>fees</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Salary</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Directors <BR>fees</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Salary</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">W Simon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">G. Cerrone</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">124</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">86</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">R. Dalla-Favera</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">K. Shailubhai<FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">286</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">201</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">300</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">286</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">214</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:2;margin-top:10pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non<FONT CLASS="nobreak">-executive</FONT> director.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following share options were granted to directors in the following periods:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-47" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2018<BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Number of <BR>options</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2017</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;"><BR>Number of <BR>options</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2016</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;"><BR>Number of <BR>options</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">G. Cerrone</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">550,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,259,403</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">K. Shailubhai</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,500,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">L. Zanbeletti</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">550,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">7,600,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">400,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">3,259,403</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REMUNERATION OF KEY MANAGEMENT PERSONNEL</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The key management personnel of the Group are considered to be represented by the directors and officers of the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No director has yet benefitted from any increase in the value of share capital since issuance of the options.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No director exercised share options in the year.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the year ended December<FONT CLASS="nobreak"> </FONT>31, 2017, the company made $17k (2017: $6k; 2016: $0k) of payments to defined contribution pension schemes on behalf of directors or employees.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FINANCE COSTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016 <BR>$&#x2019;000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-9" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;">Group</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finance charge accrued on convertible loan notes (recognized as debt)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAXATION</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="8" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year Ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017 <BR>$&#x2019;000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016 <BR>$&#x2019;000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-9" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;">Group</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current year tax (credit)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,067</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(489</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments due to prior periods</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,423</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total tax (credit) for the period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as<FONT CLASS="nobreak"> </FONT>follows:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss before taxation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,939</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,628</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,770</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss charged at standard rate of corporation tax 19 % (2017: 19.25%;<BR>2016: 20%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,888</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,046</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,953</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other timing differences</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,104</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,889</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,656</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expenses not deductible for taxation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">176</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">297</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments due to prior periods</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(879</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,423</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development claim</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(459</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,366</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other timing differences</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,945</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,912</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(121</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Research and Development claim has been calculated in accordance with the R&amp;D tax relief available to small and medium sized entities, whereby the entity is able to claim a cash tax credit (if loss making), worth up to 14.5% of the surrenderable losses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The adjustments due to prior periods relates to R&amp;D tax relief claims or the years ended December<FONT CLASS="nobreak"> </FONT>31, 2017, 2016 and 2015. In prior periods there was not enough certainty to recognize an asset for these claims. Under UK tax legislation, a 2 year window is available under which R&amp;D tax relief can be claimed.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAXATION</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The amount of tax losses for which no deferred tax assets has been recognized for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2018 is $3,928 (2017; $4,738; 2016: $3,535).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LOSS PER SHARE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Basic loss per share is calculated by dividing the profit attributable to equity holders of the company by the weighted average number of ordinary shares in issue during the year.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 56.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="8" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 56.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 56.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">(Loss) attributable to equity holders of the company ($000)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(9,135</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(10,622</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 56.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average number of ordinary shares in issue</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">127,553,866</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">106,403,903</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93,592,195</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 56.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basic loss per share (cents per share)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(6.27</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(8.59</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(11.35</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As the Group is reporting a loss from continuing operations for the year then, in accordance with IAS<FONT CLASS="nobreak"> </FONT>33, the share options are not considered dilutive because the exercise of the share options would have an anti<FONT CLASS="nobreak">-dilutive</FONT> effect. The basic and diluted earnings per share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from continuing and total operations and therefore no earnings per share for discontinued operations are presented.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The earnings have been amended to include the interest accrued on Convertible Loan Notes.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PROPERTY, IT AND EQUIPMENT</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Details of the Groups property, IT and equipment are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Furniture and <BR>fixtures</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">IT equipment</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cost</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">At 1 January 2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additions</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disposals</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">At 31 December 2017</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">46</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Depreciation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">At 1 January 2017</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charge in year</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">At 31 December 2017</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net Book Value as at 31 December 2017</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PROPERTY, IT AND EQUIPMENT</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Furniture and <BR>fixtures</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">IT equipment</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cost</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">At 1 January 2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">46</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additions</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disposals</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">At 31 December 2018</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">46</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Depreciation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">At 1 January 2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charge in year</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">At 31 December 2018</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net Book Value as at 31 December 2018</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">12.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OTHER RECEIVABLES</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Group</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other receivables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">246</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">110</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taxation receivable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,019</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,944</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party receivable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">276</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">292</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,609</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,384</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">There are no differences between the carrying amount and fair value of any of the trade and other receivables above.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">13.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OTHER ASSETS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In June 2016, the Board approved the purchase of the Data repository of DNA from SharDNA (an Italian entity in liquidation) for EUR 258,000, approximately $268,000.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Management recognizes that the transaction is not the purchase of a business but the purchase of key assets owned by SharDNA. These assets are to be owned by Tiziana Life Sciences PLC and will be loaned to its subsidiary Longevia SRL for no extra cost.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No research and development work has been carried out to this date, but Management anticipates that this will commence within the next 12<FONT CLASS="nobreak"> </FONT>months.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">As there is current legal action pending against the liquidators as to the validity to the sale of the assets, the company is unable to utilize these assets until the legal action is resolved. For this reason, the investment has been recognized as a current asset until such a time that the company is able to use this asset. In the event the company is unable to use the asset as a result of the legal action denoted above, the company will receive their money back.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">14.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INVESTMENTS IN SUBSIDIARIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company&#x2019;s interest in subsidiary undertakings is as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Principal activity</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Registered Address</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Percentage <BR>shareholding</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Country of <BR>incorporation</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 23.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tiziana Pharma Limited</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 21.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">Clinical stage biotechnology company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">3<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">rd</FONT><FONT CLASS="Super" STYLE="vertical-align:super;font-size:58%;"> </FONT>Floor, 11-12 St&#x00a0;James&#x2019;s Square, <BR>London, SW1Y 4LB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">100%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">England &amp; Wales</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-54" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 23.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Tiziana Therapeutics, Inc.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 21.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Clinical stage biotechnology company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 20.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">420 Lexington Avenue Suite 2525 <BR>New York, NY 10170</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 11.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">100%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 17.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;">USA</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-55" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 23.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Longevia Genomics SRL</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 21.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Biotech Discovery Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 20.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Via Constantinpoli 42 09100-Cagliari (CA)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 11.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">100%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 17.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;">Italy</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Therapeutics, Inc. was incorporated on 28 October 2015. This entity was set up to house the company&#x2019;s US operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Longevia Genomics SRL was incorporated on 4 July 2016. This entity was established to enable the company to carry out R&amp;D activities in Sardinia.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHARE CAPITAL</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Company and Group</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Ordinary Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Deferred Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">&#x00a3;000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">In issue at 1 January</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,054,805</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94,393,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,752</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,832</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issued for cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,742,167</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,301,250</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">66</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Convertible Loan notes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">700,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">854</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of warrants</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,454,644</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Loan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,137,625</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">In lieu of commission</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">74,577</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">In issue at 31 December</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">136,463,818</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,054,805</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,094</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,752</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Ordinary Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Ordinary shares have a par value of &#x00a3;0.03. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. The company does not have a limited amount of authorized capital.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:6pt;margin-top:6pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Issuance of ordinary shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In March 2017, a notification was received from warrant holders to exercise warrants over 1,789,524 ordinary shares in the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In August 2017, the Board passed a resolution to convert all outstanding Convertible Loan Notes effective from 26 July 2017. It also resolved that the Convertible loan note holders be offered an additional bonus coupon of three years of interest at the relevant applicable rate of return for agreeing to the immediate conversion of the Convertible loan note&#x2019;s into ordinary shares. The company has issued 28,455,214 new ordinary shares in respect of this conversion. All of the new shares are subject to a restriction on disposal for a period of 12&#x00a0;months.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In November 2017, 283,333 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHARE CAPITAL</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An additional 133,333 new ordinary shares were issued in December 17 by way of a further placing of ordinary shares to raise finance.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Share issues since 1 January 2018</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In January 2018, 166,667 new ordinary shares were issued by way of a placing of ordinary shares to raise finance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In March 2018, 600,000 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">An additional 1,031,250 new ordinary shares were issued in April 2018 by way of a further placing of ordinary shares to raise finance. In addition, 51,563 new ordinary shares were issued to intermediaries in lieu of commissions on the funds raised.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Also in April 2018, 23,014 new ordinary shares were issued in relation to a shortfall in capitalized interest due to a former holder of the Company&#x2019;s Class C Convertible Loan Notes which was discovered during the annual audit process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In October 2018, 1,515,150 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In November 2018, 4,429,100 new ordinary shares were issued as part of the initial public offering of American Depositary Shares on the Nasdaq Global Market. In addition to the IPO, 2,137,625 new ordinary shares were issued to extinguish &#x00a3;1.3<FONT CLASS="nobreak"> </FONT>million in debt.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In November 2018, notification was also received from warrant holders to exercise warrants over 1,400,644 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In conjunction with the IPO, the Company resolved to allow the holders of its warrants to exercise at reduced exercise prices in the period ending on 30 November 2018. Notification was also received from warrant holders to exercise warrants over 54,000 ordinary shares in connection with this offer.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHARE BASED PAYMENTS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Group and Company Options</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company operates share<FONT CLASS="nobreak">-based</FONT> payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option is normally equal to the market price of an ordinary share in the company at the date of grant.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-60" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Weighted <BR>Average <BR>exercise price <BR>(cents)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Options <BR>(&#x2019;000)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Weighted <BR>Average <BR>exercise price <BR>(cents)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Options <BR>(&#x2019;000)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Weighted <BR>Average <BR>exercise price <BR>(cents)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Options <BR>(&#x2019;000)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding at 1 January</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,717</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,449</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,985</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">104</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">216</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">668</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">190</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,464</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(219</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,600</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding at 31 December</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,617</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,717</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,449</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercisable at 31 December</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,236</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">57</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,011</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,152</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">No options were exercised during the years ended 31<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">st</FONT> December 2018, 2017 and 2016.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHARE BASED PAYMENTS</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The total outstanding fair value of the share option instruments is deemed to be approximately $6,591 as at December<FONT CLASS="nobreak"> </FONT>31, 2018 (2017: $6,217k; 2016: $2,305k).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Directors have used the Black<FONT CLASS="nobreak">-Scholes</FONT> option pricing model to estimate the fair value of most of the options applying the assumptions below.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Historical volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable to the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company has estimated a forfeiture rate of zero.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">10 March <BR>2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">30 August <BR>2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">30 April <BR>2018</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Grant date share price</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;1.725&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;1.595&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;0.8175&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise share price</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;1.725&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;1.595&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">&#x00a0;&#x00a3;0.8175&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vesting periods</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Yr1, Yr 2, Yr 3, Yr4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Yr 1, Yr 2, Yr 3, Yr4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Yr1, Yr 2, Yr 3, Yr4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk free rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.38% to 1.09%&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.69% to 1.09%&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.69% to 1.03%&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">80% to 167%&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">58% to 60%&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">58% to 60%&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Option life</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10 years</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10 years</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10 years</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the options issued with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options, the company uses the following methods to determine its underlying assumptions:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>expected volatilities are based on the historical volatilities of the market</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>the expected term of the awards is 15 years based on managements&#x2019; assessment of when the market condition is likely to be achieved</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;margin-top:12pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Warrants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Directors have estimated the fair value of the warrants in services provided using the Black<FONT CLASS="nobreak">-Scholes</FONT> valuation model. The total fair value of the warrant instruments is deemed to be approximately $340,501 as at 31 December 2017. For each set of warrants, the charge has been expensed over the vesting period. A share based payment charge for the year to December<FONT CLASS="nobreak"> </FONT>31, 2017 of $120,441 (2016: $156,424) has been expensed in the statement of comprehensive income.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The directors estimate the total fair value of warrant instruments at 30 June 2018 is $1,397,662 (unaudited), and the share based payments charge taken to the statement of comprehensive income for the six month period to June<FONT CLASS="nobreak"> </FONT>30, 2018 is $89,431 (unaudited).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONVERTIBLE LOAN NOTES</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;margin-top:12pt;"><FONT CLASS="CharOverride-8" STYLE="text-decoration:underline;">Group and Company</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Planwise Convertible Loan Notes 2016</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company&#x2019;s on<FONT CLASS="nobreak">-going</FONT> working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of &#x00a3;0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014. The company considers this to be a Convertible Debt Instrument as detailed in the policy described at note 2.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accounting for the convertible debt instrument</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The net proceeds received from the issue of the Planwise Convertible Loan Note has been recorded as a debt liability in the balance sheet and the accrued interest charged to the income statement and the debt liability. The liability for the convertible debt instrument is;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Planwise Convertible Loan Note</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan notes issued</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">290</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">247</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">302</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">290</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">18.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RESERVES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The share based payment reserve for warrants represent the value of equity shares which could be issued in future accounting periods if the warrants in issue are exercised.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The share based payment reserve for options represents the value of equity shares which could be issued in future accounting periods if the share based payment options in issue are exercised.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The other reserve was created as a result of the reverse acquisition of Alexander David Investments plc in the year and the accounting treatment required, which is described in Note 2. The reserve is required due to the fact that the reverse acquisition accounting requires the legal parent&#x2019;s equity structure to be shown.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Retained earnings represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The capital reduction reserve is credited with $41.3m of reserves arising from the court approved capital reduction detailed below. These reserves are designated as realized profits available for distribution under section&#x00a0;830&#x00a0;(2) of the Companies Act 2006.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On September<FONT CLASS="nobreak"> </FONT>14, 2016, the High court granted the company permission to cancel its share premium account and its capital redemption reserve. The order had previously been ratified at the AGM held on June<FONT CLASS="nobreak"> </FONT>30, 2016.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The company also decided to cancel its merger relief reserve as part of the capital reduction exercise.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">19.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FINANCIAL INSTRUMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The main risks arising from the Group&#x2019;s financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and agree policies for managing each of these risks which are summarized below.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Market risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled &#x201c;interest rate risk&#x201d; below. The directors do not consider the Group&#x2019;s exposure to price risk to be significant. The Group&#x2019;s risk management is coordinated by the directors, and focuses on actively securing the Group&#x2019;s short to medium term cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative purposes nor does it write options.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Credit risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Credit risk is managed on a group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure to customers including committed transactions and outstanding receivables. The group reviews its banking arrangements carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the group as part of their internal reporting and assess outstanding receivables for ability to be repaid.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Liquidity risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The group&#x2019;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated from operating activities and private and public offerings of equity and debt securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The table below summarizes the maturity profile of the Group&#x2019;s financial liabilities based on contractual undiscounted payments.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$000</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Less than <BR>3&#x00a0;months</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">3 to 12 months</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade and other payables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,631</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,010</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,641</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan notes (debt)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">307</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">310</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party payables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,774</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,317</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,091</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign currency risks</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The group operates internationally although the majority of its operations are based in the United Kingdom and the majority of assets and liabilities denominated in British Pounds. It therefore is exposed to foreign exchange risk arising from exposure to various currencies primarily the Euro and US Dollar.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Due to the majority of assets being denominated in British Pounds the group has no formal policies for managing foreign currency risks.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Interest rate risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group has limited exposure to interest<FONT CLASS="nobreak">-rate</FONT> risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Allied Irish Bank base rate.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">19.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FINANCIAL INSTRUMENTS</FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity position at the year<FONT CLASS="nobreak">-end</FONT> for the years ended 31 December 2018, 2017 or 2016.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">20.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CAPITAL RISK MANAGEMENT</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">For the purpose of the Group&#x2019;s capital management, capital includes called up share capital, share premium, share based payment reserve for options, convertible loan note reserve, share based payment reserve for warrants, capital reduction reserve and all other equity reserves attributable to the equity holders of the parent as reflected in the statement of financial position.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group adjusts its capital structure in light of changes in economic conditions and expected business demands on capital. In order to maintain or adjust its capital structure, the Group considers whether or not to pay dividends and adjusts the amount of any dividend payments to shareholders. The Group may also return capital to shareholders or issue additional shares.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">21.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TRADE AND OTHER PAYABLES</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Group</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade payables</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,641</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,738</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,496</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accruals</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,310</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">683</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible loan note liability</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">310</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">316</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,749</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,143</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">22.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RELATED PARTY TRANSACTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Pharma Limited is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $3,922k (2017: $5,146k; 2016:$3,604k) 2017: &#x00a3;2,566k) in total to Tiziana Pharma Limited.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Tiziana Therapeutics Inc. is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $1,534k (2017: $1,182k; 2016: $1,182k) to Tiziana Therapeutics Inc.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Longevia Genomics SRL. is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $23k (2017: $0) to Longevia Genomics SRL.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Rasna Therapeutics Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Rasna. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Rasna. Rasna is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, $130k was owed to Tiziana Life Sciences PLC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">OKYO Pharma Ltd is a related party as Kunwar Shailubhai, director of our Company, is also a director of OKYO. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of OKYO. OKYO is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, $9k was owed to Tiziana Life Sciences PLC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Gensignia Life Sciences Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Gensignia. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Gensignia. As of December<FONT CLASS="nobreak"> </FONT>31, 2018, $55k was owed to Tiziana Life Sciences PLC.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Notes to Consolidated Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">23.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OPERATING LEASES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group leases number of office premises under operating lease. The future minimum rentals payable under non<FONT CLASS="nobreak">-cancellable</FONT> operating leases are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Year ended December 31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2018</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2017</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2016</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">$000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less than one year</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">266</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Between one and five years</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">691</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">575</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">612</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,113</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">853</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">878</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Lease expenses during year ended December<FONT CLASS="nobreak"> </FONT>30, 2018 amounted to $153k (2017: $142k; 2016: $146k).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">24.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">POST BALANCE SHEET EVENTS &#x2014; POST 31 DECEMBER 2018</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On February<FONT CLASS="nobreak"> </FONT>7, 2019, the company announced that Riccardo Dalla<FONT CLASS="nobreak">-Favera</FONT> MD had resigned from his role as Non<FONT CLASS="nobreak">-Executive</FONT> Director of the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On March<FONT CLASS="nobreak"> </FONT>20, 2019, the Company announced that it had submitted an Investigational New Drug application (&#x201c;IND&#x201d;) to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of enteric<FONT CLASS="nobreak">-coated</FONT> capsules of Foralumab in healthy volunteers. This single<FONT CLASS="nobreak">-site</FONT> clinical study is expected to enroll 36 subjects and it will be conducted at the Brigham and Women&#x2019;s Hospital (BWH), Harvard Medical School</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">25.</FONT> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FINANCIAL COMMITMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The Group&#x2019;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research and development and the length of time required to reach commercialization of the products of this research and development, preclinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Milciclib project research funding of approximately &#x00a3;1m has been committed to for 2019 and beyond. Diligence obligations are payable to BMS / Medarex should the project continue. Other payments relate to the achievement of clinical milestones or the payment of royalties.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:2;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Foralumab project &#x2014; Future payments relate to the achievement of clinical milestones or the payment of royalties.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:80pt;margin-top:80pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">1,383,125</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> American Depositary Shares</FONT> </P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">Representing </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">13,831,250</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> Ordinary Shares</FONT> </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:48pt;text-align:center;margin-top:48pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tiziana_logo.jpg" STYLE="height:55.04px;width:245.76px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:60pt;margin-top:60pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">___________________</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">PROSPECTUS</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">___________________</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:84pt;text-align:center;margin-top:84pt;">, 2019</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:48pt;text-align:center;margin-top:48pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">ThinkEquity</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-bottom:80pt;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">a division of Fordham Financial Management, Inc.</FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>


	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PART II</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Unless otherwise indicated, all references to &#x201c;Tiziana&#x201d; or the &#x201c;company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or similar terms refer to Tiziana Life Sciences plc and its subsidiaries.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item 6. Indemnification of Directors and Officers.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Subject to the U.K. Companies Act 2006, members of the registrant&#x2019;s board of directors and its officers (excluding auditors) have the benefit of the following indemnification provisions in the registrant&#x2019;s Articles:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">Current and former members of the registrant&#x2019;s board of directors or officers shall be reimbursed for:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iii)&#x00a0;&#x00a0;&#x00a0;all costs, charges, losses, expenses and liabilities sustained or incurred in relation to his or her actual or purported execution of his or her duties in relation to the registrant, including any liability incurred in defending any criminal or civil proceedings; and</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(iv)&#x00a0;&#x00a0;&#x00a0;expenses incurred or to be incurred in defending any criminal or civil proceedings, in an investigation by a regulatory authority or against a proposed action to be taken by a regulatory authority, or in connection with any application for relief under the statutes of the United Kingdom and any other statutes that concern and affect the registrant as a company, or collectively the Statutes, arising in relation to the registrant or an associated company, by virtue of the actual or purposed execution of the duties of his or her office or the exercise of his or her powers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In the case of current or former members of the registrant&#x2019;s board of directors, there shall be no entitlement to reimbursement as referred to above for (i) any liability incurred to the registrant or any associated company, (ii) the payment of a fine imposed in any criminal proceeding or a penalty imposed by a regulatory authority for non<FONT CLASS="nobreak">-compliance</FONT> with any requirement of a regulatory nature, (iii) the defense of any criminal proceeding if the member of the registrant&#x2019;s board of directors is convicted, (iv) the defense of any civil proceeding brought by the registrant or an associated company in which judgment is given against the director, and (v) any application for relief under the statutes of the United Kingdom and any other statutes that concern and affect the registrant as a company in which the court refuses to grant relief to the director.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">In addition, members of the registrant&#x2019;s board of directors and its officers who have received payment from the registrant under these indemnification provisions must repay the amount they received in accordance with the Statutes or in any other circumstances that the registrant may prescribe or where the registrant has reserved the right to require repayment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The underwriting agreement the registrant will enter into in connection with this offering of ADSs being registered hereby provides that the underwriters will indemnify, under certain conditions, the registrant&#x2019;s board of directors and its officers against certain liabilities arising in connection with this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item 7. Recent Sales of Unregistered Securities.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">The following list sets forth information regarding all unregistered securities sold by us since January<FONT CLASS="nobreak"> </FONT>1, 2016 through the date of the prospectus that is a part of this registration statement:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On March<FONT CLASS="nobreak"> </FONT>23, 2016, we issued options to purchase 200,000 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>9, 2016, we issued options to purchase 3,264,403 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>28, 2016, we issued 700,000 new ordinary shares upon conversion, with noteholder consent, $222,466 (&#x00a3;168,000) of convertible loan notes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On November<FONT CLASS="nobreak"> </FONT>11, 2016, we issued options to purchase 100,000 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>16, 2017 we issued 27,645,013 new ordinary shares upon conversion, with noteholder consent, $16,733,146 (&#x00a3;12,969,219) of convertible loan notes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>30, 2017, we issued options to purchase 548,000 ordinary shares.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">From November 2017 to March 2018, we sold 1,183,333 new ordinary shares for cash to purchasers adding $1,954,312 (&#x00a3;1,475,000) to our share capital. In connection with these sales, we issued warrants to purchase an aggregate 763,001 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On January<FONT CLASS="nobreak"> </FONT>16, 2018 we issued 810,201 new ordinary shares to our former noteholders in respect of accrued interest (in respect of the convertible loan conversion on August<FONT CLASS="nobreak"> </FONT>16, 2017).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On April<FONT CLASS="nobreak"> </FONT>19, 2018 we issued 1,031,250 new ordinary shares adding $1,100,000 (&#x00a3;825,000) to our share capital and simultaneously issued 51,563 new ordinary shares, credited as fully paid to intermediaries in lieu of commissions on the fundraise. In connection with this sale, we issued warrants to purchase 51,563 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On April<FONT CLASS="nobreak"> </FONT>27, 2018 we issued 23,014 new ordinary shares to our former noteholders in respect of final accrued interest (in respect of the convertible loan conversion on August<FONT CLASS="nobreak"> </FONT>16, 2017).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On April<FONT CLASS="nobreak"> </FONT>30, 2018, we issued options to purchase 9,500,000 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">On October<FONT CLASS="nobreak"> </FONT>26, 2018, we sold 1,515,150 new ordinary shares credited as fully paid at a price of $0.99 (75p) per share at a fixed exchange rate of GBP1:US$1.32 to raise deferred cash proceeds of $1,500,000. In connection with this sale, we issued warrants to purchase 335,000 ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act (and Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item 8. Exhibits and Financial Statement Schedules.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITEM 19: EXHIBITS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exhibit No.</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Description</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 1.1* </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex1-1_tiziana.htm">Form of Underwriting Agreement.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">3.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex3-1_tiziana.htm">Memorandum and Articles of Association of Tiziana Life Sciences plc (incorporated by reference to Exhibit 3.1 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">4.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018012939/ff12018a2ex4-1_tiziana.htm">Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to Form F-1 filed on September 25, 2018).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">4.2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018012939/ff12018a2ex4-1_tiziana.htm">Form of American Depositary Receipt (included in Exhibit 4.1).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 4.3* </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390019014612/ff12019ex4-3_tiziana.htm">Form of Representative&#x2019;s Warrant.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 5.1 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="ff12019a1ex5-1_tiziana.htm">Opinion of Cooley (UK) LLP.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">10.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-1_tiziana.htm">License Agreement relating to Milciclib between Nerviano Medical Services S.r.l. and Tiziana Life Sciences plc, dated January 2015 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">10.2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-2_tiziana.htm">License and Sublicense Agreement relating to CD3 (NI-0401) between Novimmune SA and Tiziana Life Sciences plc, dated December 2014(incorporated by reference to Exhibit 10.2 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">10.3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-3_tiziana.htm">License and Sublicense Agreement relating to IL-6r (NI-1201) between Novimmune SA and Tiziana&#x00a0;Life Sciences plc, dated December 2016 (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-68" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">10.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"><A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-4_tiziana.htm">License Agreement relating to a novel formulation of Foralumab in a medical device for nasal administration between The Brigham and Women&#x2019;s Hospital, Inc. and Tiziana Life Sciences plc, dated April 2018 (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">

						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exhibit No.</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Description</FONT> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.5 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-5_tiziana.htm">Annual Lease for 55 Park Lane, Suite 14a, London W1K 1NA, United Kingdom, dated June 29,&#x00a0;2018 (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.6 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-6_tiziana.htm">Five-Year Lease for 420 Lexington Avenue, Suite 2525, New York, United States, dated August 2,&#x00a0;2016 (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.7 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390019005736/f20f2018ex4-7_tizianalife.htm">Amendment to Lease Agreement for 3705 Old Easton Road, Doylestown, Pennsylvania, United States, dated October 1, 2018 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-48" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.8 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-8_tiziana.htm">Tiziana Life Sciences plc Employee Share Option Plan, with Non-Employee Sub-Plan and US&#x00a0;Sub-Plan, adopted by the Board on 23 March 2016 and approved by shareholders on June 30, 2016 (incorporated by reference to Exhibit 4.7 to Form 20-F filed on April 4, 2019).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.9 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390019014612/ff12019ex10-9_tiziana.htm">Amended and Restated Service Agreement dated July 11, 2019, between the Registrant and Dr. Kunwar Shailubhai</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 10.10 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-10_tiziana.htm">Form of Deed of Indemnity for board members (incorporated by reference to Exhibit 10.10 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 21.1 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex21-1_tiziana.htm">List of subsidiaries (incorporated by reference to Exhibit 21.1 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 23.1 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="ff12019a1ex23-1_tiziana.htm">Consent of Mazars LLP, independent registered public accounting firm, regarding the financial statements of Tiziana Life Sciences plc as of December 31, 2018 and 2017 and for each of the years then ended.</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 23.2 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="ff12019a1ex5-1_tiziana.htm">Consent of Cooley (UK) LLP (included in Exhibit 5.1).</A> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> 24.1* </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;"> <A HREF="http://www.sec.gov/Archives/edgar/data/1723069/000121390018009705/ff12018_tizianalife.htm#sig">Power of Attorney (included on signature page).</A> </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: .0001pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:2;margin-top:10pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT>* Previously Filed </P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Financial Statement Schedules.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:6pt;margin-top:6pt;">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or the notes thereto.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:2;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item 9. Undertakings.</FONT></P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:8pt;">(a)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:6pt;margin-top:6pt;">(b)&#x00a0;&#x00a0;&#x00a0;&#x00a0;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-top:6pt;margin-top:6pt;">(c)&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;The undersigned registrant hereby undertakes that:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:72pt;margin-top:6pt;margin-top:6pt;">(1)&#x00a0;&#x00a0;&#x00a0;&#x00a0;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-left:72pt;margin-top:6pt;margin-top:6pt;">(2)&#x00a0;&#x00a0;&#x00a0;&#x00a0;For the purpose of determining any liability under the Securities Act, each post<FONT CLASS="nobreak">-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;border-style:solid;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SIGNATURES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on the 17<FONT CLASS="superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> day of September, 2019. </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="3" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TIZIANA LIFE SCIENCES PLC</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-39" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Kunwar Shailubhai</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Kunwar Shailubhai</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Chief Executive Officer and Director</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"> Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">

						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Signature</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Title</FONT> </P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Date</FONT> </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-73" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"> /s/ Kunwar Shailubhai </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Chief Executive Officer and Director </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;"> September<FONT CLASS="nobreak"> </FONT>17, 2019 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Kunwar Shailubhai </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(Principal Executive Officer)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-73" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"> * </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Chief Financial Officer </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;"> September<FONT CLASS="nobreak"> </FONT>17, 2019 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Tiziano Lazzaretti </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(Principal Financial Officer and</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Principal Accounting Officer)</FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-73" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"> * </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Executive Chairman </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;"> September<FONT CLASS="nobreak"> </FONT>17, 2019 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Gabriele Cerrone </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-73" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"> * </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Director </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;"> September<FONT CLASS="nobreak"> </FONT>17, 2019 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Willy Simon </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-73" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:9pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"> * </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> Director </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:9pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;"> September<FONT CLASS="nobreak"> </FONT>17, 2019 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 30.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"> Leopoldo Zambeletti </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-77" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"> *By: </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 25.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Kunwar Shailubhai</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 46.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-31" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;"> Kunwar Shailubhai, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Attorney</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-In-Fact</FONT></FONT> </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</P>



</DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ff12019a1ex5-1_tiziana.htm
<DESCRIPTION>OPINION OF COOLEY (UK) LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 17, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tiziana Life Sciences plc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3rd Floor,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11-12 St James&rsquo;s Square</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">London SW1 4LB</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana Life Sciences plc &ndash; Registration Statement on Form&nbsp;F-1 &ndash; Exhibit&nbsp;5.1</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as English legal advisers
to Tiziana Life Sciences plc, a public limited company incorporated in England and Wales (the &ldquo; <B>Company</B> &rdquo;) in
connection with the proposed offering of American Depositary Shares (&ldquo;<B>ADSs</B>&rdquo;), each representing ordinary shares
of nominal value &pound;0.03 each in the issued share capital of the Company (&ldquo;<B>Ordinary Shares</B>&rdquo;) (the &ldquo;<B>Offering</B>&rdquo;
and the Ordinary Shares allotted and issued in connection therewith, including those being issued to JPMorgan Chase Bank, N.A.)
as the custodian and represented by ADSs, being the &ldquo;<B>Shares</B>&rdquo;). Each ADS represents 10 Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTRODUCTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the preparation and filing of a registration statement on Form&nbsp;F-1 (File No. 333 &ndash; 233020) (such registration statement, as amended through the date hereof, the &ldquo; <B>Registration Statement</B> &rdquo;), to which this letter is attached as an exhibit, with the U.S. Securities and Exchange Commission (the &ldquo; <B>SEC</B> &rdquo;) pursuant to the U.S. Securities Act of 1933, as amended (the &ldquo; <B>Securities Act</B> &rdquo;), we have been asked to provide opinions on certain matters, as set out below. We have taken instruction in this regard solely from the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defined terms and headings</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In this letter:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">capitalised terms used without definition in this letter or the schedules hereto have the meanings assigned to them in the Registration Statement unless a contrary indication appears;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">headings are for ease of reference only and shall not affect interpretation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the term &ldquo; <B>Shares</B> &rdquo; shall include any additional Ordinary Shares registered by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offering contemplated by the Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;|&nbsp;Dashwood &nbsp;|&nbsp;69
Old Broad Street |&nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 |&nbsp;f: +44 (0) 20 7785 9355 |&nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal review</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of issuing this letter, we have examined such matters of fact and questions of law as we have considered appropriate. We have reviewed only the following documents and conducted only the following enquiries and searches:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an online search at Companies House in respect of information available for inspection on the Company&rsquo;s file conducted on September 17, 2019 at 09:00 a.m.&nbsp;(London time);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an enquiry by telephone at the Central Index of Winding Up Petitions, London on September 17, 2019 at 10:00 a.m.&nbsp;(London time) ((a)&nbsp;and (b)&nbsp;together, the &ldquo; <B>Searches</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certified PDF executed copy of the minutes of the annual general meeting of the Company (the &ldquo; <B>AGM Minutes</B> &rdquo;), which was held on 31 May 2019 (the &ldquo; <B>AGM</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certified PDF copy of the resolutions passed at the AGM (the &ldquo; <B>AGM Resolutions</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a PDF copy of the executed written resolutions of the board of directors of the Company (the &ldquo; <B>Board</B> &rdquo;) dated August 5, 2019 regarding, <I>inter alia</I> , the appointment of a pricing committee of the Board (the &ldquo; <B>Pricing Committee</B> &rdquo;) and the Registration Statement (together, the &ldquo; <B>Written Resolutions</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a draft copy of minutes of a meeting of the Pricing Committee to be held resolving,&nbsp; <I>inter alia</I> , to allot the Shares (the &ldquo; <B>Allotment Resolutions</B> &rdquo; and together with the Written Resolutions, the AGM Minutes and the AGM Resolutions, the &ldquo; <B>Corporate Approvals</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a PDF copy of the certificate of incorporation of the Company dated 11 February 1998, and PDF copies of the certificates of incorporation on change of name of the Company dated 6 August 1998, 18 February 2011 and 23 April 2014, respectively;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a PDF copy of the current articles of association of the Company dated 30 June 2016 (the &ldquo; <B>Articles</B> &rdquo;); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a draft copy of the Registration Statement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicable law</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This letter, the opinions given in it, and any non-contractual obligations arising out of or in connection with this letter and/or the opinions given in it, are governed by, and to be construed in accordance with, English law and relate only to English law as applied by the English courts, including the laws of the European Union to the extent having the force of law in England, as at today&rsquo;s date. In particular:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have not investigated the laws of any country other than England and we assume that no foreign law affects any of the opinions stated below;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we do not undertake or accept any obligation to update this letter and/or the opinions given in it to reflect subsequent changes in English law or factual matters, except where an amendment to the Registration Statement is filed with the SEC; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we express no opinion in this letter on the laws of any jurisdiction other than England. It is assumed that no foreign law which may apply to the matters contemplated by the Registration Statement, the Company, any document or any other matter contemplated by any document would or might affect this letter and/or the opinions given in it.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assumptions and reservations</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The opinions given in this letter are given on the basis of each of the assumptions set out in schedule&nbsp;1 ( <I>Assumptions</I> ) and are subject to each of the reservations set out in schedule 2 ( <I>Reservations</I> ) to this letter. The opinions given in this letter are strictly limited to the matters stated in paragraph 2 ( <I>Opinions</I> ) below and do not extend, and should not be read as extending, by implication or otherwise, to any other matters.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPINION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to paragraph 1 ( <I>Introduction</I> ) and the other matters set out in this letter and its schedules, and subject further to the following:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Registration Statement, as finally amended, becoming effective under the Securities Act;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of Shares to be allotted and issued in connection with the Offering not being greater than the aggregate nominal value specified in the Written Resolutions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the Corporate Approvals were or will be (as appropriate) each passed at a meeting which was or will be duly convened and held in accordance with all applicable laws and regulations; that in particular, but without limitation, a duly qualified quorum of directors or, as the case may be, shareholders was or will be present in each case throughout the meeting and voted in favour of the resolutions; and that in relation to each meeting of the Board and of the Pricing Committee, each provision contained in the UK Companies Act 2006, as amended (the &ldquo; <B>Act</B> &rdquo;) or the Articles relating to the declaration of the directors&rsquo; interests or the power of the interested directors to vote and to count in the quorum was or will be duly observed;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt in full of payment for the Shares in an amount of &ldquo;cash consideration&rdquo; (as defined in section 583(3)&nbsp;of the Act) of not less than the aggregate nominal value for such Shares; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">valid entries having been made in relation to the allotment and issue of the Shares in the books and registers of the Company, it is our opinion that, as at today&rsquo;s date, the Shares, if and when allotted and issued, registered in the name of the recipient in the register of members of the Company and delivered as described in the Registration Statement, will be duly and validly authorised and issued, fully paid or credited as fully paid (subject to the receipt of valid consideration by the Company for the issue thereof in connection with the Offering) and will not be subject to any call for payment of further capital.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXTENT OF OPINIONS</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We express no opinion as to any agreement, instrument or other document other than as specified in this letter or as to any liability to tax or duty which may arise or be suffered as a result of or in connection with the Offering or the transactions contemplated thereby.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This letter only applies to those facts and circumstances which exist as at today&rsquo;s date and we assume no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our attention, any changes in laws which may occur after today, or to inform the addressee of any change in circumstances happening after the date of this letter which would alter our opinion.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE AND RELIANCE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This letter is addressed to you in connection with the Registration Statement. We consent to the filing of this letter as an exhibit to the Registration Statement. We further consent to the incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act with respect to the Shares. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations thereunder.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than for the purpose set out in the prior paragraph, this letter may not be relied upon, or assigned, for any purpose, without our prior written consent, which may be granted or withheld in our discretion.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Edward J. Lukins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cooley (UK) LLP</B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSUMPTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions in this letter have been given
on the basis of the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the genuineness of all signatures, stamps and seals on all documents, the authenticity and completeness of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as copies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, where a document has been examined by us in draft or specimen form, it will be or has been duly executed in the form of that draft or specimen, and that each of the signed documents examined by us has been duly executed and, where applicable, delivered on behalf of the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the Articles remain in full force and effect, and no alteration has been made or will be made to such articles of association, in each case prior to the date of allotment and issue of the Shares (the &ldquo; <B>Allotment Date</B> &rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the Allotment Date the Company will comply with all applicable laws to allot and issue the Shares and the Company will receive such amounts as are necessary to fully pay the nominal value of the Shares and any applicable share premium;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that all documents, forms and notices which should have been delivered to the Registrar of Companies in respect of the Company have been so delivered, that information revealed by the Searches was complete and accurate in all respects and has not, since the time of the Searches, been altered and that the results of the Searches will remain complete and accurate as at the Allotment Date;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the Company has not taken any corporate or other action nor have any steps been taken or legal proceedings been started against the Company for the liquidation, winding up, dissolution, reorganisation or bankruptcy of, or for the appointment of a liquidator, receiver, trustee, administrator, administrative receiver or similar officer of, the Company or all or any of its assets (or any analogous proceedings in any jurisdiction) and the Company is not unable to pay its debts as they fall due within the meaning of section 123 of the Insolvency Act 1986, as amended (the &ldquo; <B>Insolvency Act</B> &rdquo;), and will not become unable to pay its debts within the meaning of that section as a result of any of the transactions contemplated herein, is not insolvent and has not been dissolved or declared bankrupt (although the Searches gave no indication that any winding-up, dissolution or administration order or appointment of a receiver, administrator, administrative receiver or similar officer has been made with respect to the Company);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the minutes of the meeting of the Pricing Committee provided to us in connection with the giving of the opinions in this letter reflect a true record of the proceedings described in them in duly convened, constituted and quorate meetings in which all constitutional, statutory and other formalities were duly observed, and the resolutions set out in the minutes were validly passed and have not been and will not be revoked or varied and remain in full force and effect and will remain so as at the Allotment Date;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the resolutions set out in the Corporate Approvals were validly passed and have not been and will not be revoked or varied and remain in full force and effect and will remain so as at the Allotment Date;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that in relation to the allotment and issue of the Shares, the directors of the Company have acted and will act in the manner required by section 172 of the Act ( <I>Duty to promote the success of the Company</I> ), and there has not been and will not be any bad faith, breach of trust, fraud, coercion, duress or undue influence on the part of any of the directors of the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">following the date of this letter and prior to the issue of the Ordinary Shares, the Company will validly enter into an underwriting agreement on substantially the terms and conditions described in Exhibit 1.1 of the Registration Statement; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that no Shares or rights to subscribe for Shares have been or shall be offered to the public in the United Kingdom in breach of the Financial Services and Markets Act 2000, as amended (&ldquo; <B>FSMA</B> &rdquo;) or of any other United Kingdom laws or regulations concerning offers of securities to the public, and no communication has been or shall be made in relation to the Shares in breach of section 21 of FSMA or any other United Kingdom laws or regulations relating to offers or invitations to subscribe for, or to acquire rights to subscribe for or otherwise acquire, shares or other securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RESERVATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions in this letter are subject
to the following reservations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Searches are not capable of revealing conclusively whether or not a winding-up or administration petition or order has been presented or made, a receiver appointed, a company voluntary arrangement proposed or approved or any other insolvency proceeding commenced, and the available records may not be complete or up-to-date.&nbsp;&nbsp;In particular, the Central Registry of Winding-Up Petitions in England may not contain details of administration applications filed, or appointments recorded in or orders made by, district registries and county courts outside London. Searches at Companies House and at the Central Registry of Winding Up Petitions in England are not capable of revealing whether or not a winding up petition or a petition for the making of an administration order has been presented and, further, notice of a winding up order or resolution, notice of an administration order and notice of the appointment of a receiver may not be filed at Companies House immediately and there may be a delay in the relevant notice appearing on the file of the company concerned.&nbsp;&nbsp;Further, not all security interests are registrable, such security interests have not in fact been registered or such security interests have been created by an individual or an entity which is not registered in England. We have not made enquiries of any District Registry or County Court in England;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the opinions set out in this letter are subject to: (i)&nbsp;any limitations arising from applicable laws relating to insolvency, bankruptcy, administration, reorganisation, liquidation, moratoria, schemes or analogous circumstances; and (ii)&nbsp;an English court exercising its discretion under section 426 of the Insolvency Act ( <I>co-operation between courts exercising jurisdiction in relation to insolvency</I> ) to assist the courts having the corresponding jurisdiction in any part of the United Kingdom or any relevant country or territory;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we express no opinion as to matters of fact;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have only reviewed the documents listed in paragraph 2 above;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have made no enquiries of any individual connected with the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certificate, documentation, notification, opinion or the like might be held by the English courts not to be conclusive if it can be shown to have an unreasonable or arbitrary basis or in the event of a manifest error; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it should be understood that we have not been responsible for investigating or verifying the accuracy of the facts, including statements of foreign law, or the reasonableness of any statements of opinion, contained in the Registration Statement, or that no material facts have been omitted from it.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP &nbsp;&nbsp;Dashwood &nbsp;&nbsp;69
Old Broad Street &nbsp;&nbsp;London EC2M 1QS, UK<BR>
t: +44 (0) 20 7583 4055 &nbsp;f: +44 (0) 20 7785 9355 &nbsp;cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooley (UK) LLP is a limited liability partnership
and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK)
LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK)
LLP and their professional qualifications is open to inspection at its registered office. The word &lsquo;partner,&rsquo; used
in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated
firm) of equivalent standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ff12019a1ex23-1_tiziana.htm
<DESCRIPTION>CONSENT OF MAZARS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the reference to our firm under
the caption &ldquo;Experts&rdquo; and to the use of our audit report dated April 3, 2019 on the financial statements as of December
31, 2018 and 2017, and for each of the years then ended, included by reference in the Registration Statement (Form F-1) and related
Prospectus of Tiziana Life Sciences plc dated September 17, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ Mazars LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">London, United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">September 17, 2019</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W *H# 2(  A$! Q$!_\0
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M2BO\8_C1O&,^$=-!'_<3M/3KQS^&,5^^O_!327=^PM^T4$_Z$'4CWR/WMO\
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M'WX0_':POM4^$?C[PYXZL=(NVL-3&@:A:7W]GZ@%^T_9;L*2+2]P1\KX..<
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M0*_2C_@X>'B"[\&?LZ7]I\WA@:_XOBOI[>;-E,+W2K+^R<X)&-V>O<&OO/\
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M]U:G(88Z9!'&<$@ <AX,^$GPW\ 3S7?@SP5X?\,SWD8CN;C1-,M+ SP#YO\
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tiziana_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tiziana_logo.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
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M0F(%X5*2(Q0P\'*"HK+20,(S4_$50V,D!A,!  $# P(& @,! 0$      1$
M(3%!46$0<2#P@9&AL6#!,-'A0/%0_]H # ,!  (0 Q    "?P #'U2AQYS\&
MY'Y^$<X\Q%-,,E'\'7&/PM=XOP_5/Z^A>YQM[_8FQS6Q=IE=IK'-[-668V.L
M\OF.UR>0:-UO]BY%O)8Y8                                      #
M!ES8<')5K#A)*M8<BI)KGT5>P\_[2\O[2\KU3_;[\_3SY/G\>O?X_/OC?/?B
M>:O@_*OKO-;U/FX]3YN.VL4VK8$:LZ2R!3K
M              :,9..1\IGIR/\ SK0^$<E%/9^K7V'JW\WU1\K[2_?U3_K[
MY'\_/7X_/?B_*OA>:_@>:_K/%UZGS<R#X#T'-2U=TY[7YZ   &EQ"=)"1(A
M                                  /G_='A/.="QL-K<?X$S$#\WW;^
M7ZI?N\?HIC^%3\'OQ/%7P?-?UWBY]9XO)+&J.Q)1>LNI/[ ,*W%CEJA>^P^?
M0!&O*E<EKEI" #U1 4->R?Z;#@      TS($)T0)S!_0
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M5R#8ML?ME%=JY3MLB!ZRK:<5]R<(Z0S70W^'XJ7AUK;WU"][P:-_0[:Z*;E
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MH>R!&O-%28H>W//  !7F$I0ZWGU)^X(8AS9+#8\,^U/Z!5<%J. 5/1;  _4
MJWS_ $M'2 *2USI*"&(<WBPR/"/M3^@51!:HG]GT8!47EN&?*'W   !IW?8B
MM%W#RM@W)P[=:WK6C6A>ZP(?NQ^=XDT_T;)J@&^)N.N.@@    .5Q$N+"( $
M7<P42_01VR+P26SKH;N C7D4 [V'?\Z2   C(D2$GO'6X J5"U0,M@ %5P6H
MX!4]$E(^])>P!62'6@VO.8Y+7.DH*E$M5S*X !4:DJ<S<2M0"K1.RQ,R,S
M  T>O\-6S[?Y9PODHG;C: [I]W\]#@])]=0B]C:%M$]+=<9"IUP    .5Q$N
M+"( $7<P42_01VR-02?3J2;:@C7G& E/&ZYGH   T+*Y<G%'=(%266K9ED
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MR<]/-P0N<9H>N/7!RZ1/(J5FJY^")J7+PBII,F$?*6$PF$0Z&^JM\&LRGSA
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MK4.E--?%IP[*EO/29+YJX_(D.&\^\X7G&ZZXI&X9>^JKKQXOV.%.BN[BF,G
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M*,4D8:]MWG^+UP7_ *#*^9R*NO,;.:W7O6=58>CJ:6C]5,DQVY;+D9!#O+1
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M:IS3FOS:ZW2W'FR(]'5*U$AP*]D9-QD-Y,%WT9C])%-QEM^SL"9+3M#;9:;
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ML]X?T?<?ES_JSWA_1]PQ"8WUBMO27$;;.=@.Z=9$$E]]^?98/$@16_\ /=<
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M?$ZR8^':L5YSFHD^;/L39T,F(<:2ZTV0FX@"8*397WM'T];*5K5YFHVOFW;
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MT:]>BU;\B.CHFUV[+4I2#J11ZDYIQF&P6ZDXH^!7V4I@^8./N&U6U=J#G_\
M2=RH<=.](Q!LH,UE7_*#6MG(XZI%&;'A"%4(21%1475%1>:*BIR5%3CV7?\
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M]$DI];S<SW(8J\RM&-8F$,B4&,[%)!0H6#*TN,AXS2U#J$R@O /^ B'@< !
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M/VFI#-CH_0C6EZ< A>0!PM"4$L&??,U5T1(0J(\"O5)4FY#+.&)@IJ#OR*$
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MYO:]2#.^'$VU&3JUES98A$\0#KQ4E9%6"*(NW"O8M!I66;,CK87BR'H@_P"
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M%^J0?F1M!T4FS-+H>DL\TRPU8K,QWC2UB-M:4530O8\>!M!0Q)SZDGE82R,
ME!/7[16E&E:X+1+>(K0C'15K9&C";X?QG+HJJ" Y'TL*R @ !-H*)BY[Q""#
MX=VOUI>6'YYL$6L%R/:1+7L)-=9-"D6EP14"AU,,_4%"MB1,"&#40C'15K9&
MC";X>(4,$W8N/5<R!*/"%7@-31C'<(CJ@^I@ 8_C*$1&EA^82'K(,,B!4UA+
M!$ @+/G/\.<"(0[(4$L3BP:RU,A3 LZE=@6S.T""#'-D ;]4+77F[X:** B$
M#R)/G)1&P A_,/.8@V2DAG0M)B2<]*3LM2*N@40BQ I_,&6=KB1!_0'G=(Y
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006LA<SA?XCV[T!'!$\K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  J     $  0"H
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
M$0@"YP1+ P$1  (1 0,1 ?_$ 7@  0 ! P4! 0             ! @<( P0&
M"0H%"P$! 0 " P$! 0            $" P0%!@<("1    4# @((! 4# P,#
M! ,!  ,$!08! @<1"!460"$2$Q07&!D04"()(# Q-#9!,C5@,SAP(S=")"6
M0R8GD"@Y*1$   4!! ,'"0P3"@@*" 4% 0(#! 4& !$2!R$B$S%!,A05U3=
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M    ]_             .)2<MM        '$XY90        XE'+:
M'$I.6V@       #B9RP        T3C&+EN0                    6FQ79
MR        "UB734        6I2ZR@       "U4MU;        !:DNL
M   ;-;=)=$                    %I9E=JX@       "UB734        6
MJ2ZJ@       "U:W40        6I+K        &S6W,72L
M      %I2[0        +6)=-0       !:FXW6F0        M:72
M!:DNL        ;-;=)=$                    %I<5VL@  Z@V./DO9;9U
M=QQU<U*[9%  %K$NFH        M6EU%        %K,;=/*        "U)=8
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M        VA;B6Z5@                    M+BNUD        %K$NFH
M    M7<+J3,        6M+I         M276        -H6XENE8
M            +3Q=B@       !:Q+IJ        +5)=50       !:TND
M     "U)=8        V:VYBZ5@                    M-BNSD
M%K$NFH        M4EU5        %K,;=/*        "U)=8        VA;@N
MD                    "TV*[.0        6J2ZJ@       "U2754
M   6LQMT\H        +4EU@       #9K;E+I         %*34R@      "(
MF@!:;%=G(        +5)=50       !:I+JJ        +68VZ>4        %
MJ2ZP       !L\L;<XY72        !@"GY/B>N0]SK(  ?EII^FM%UK0  .E
M>/.,>^&@!:;%=G(        +6)=-0       !:I+JJ        +5EU
M   6I+K        &S6W271        !U\'Y4,Q]V:^9!.9K?&S):7%.N6)U[
MKWU)RN7$"WKJ2W)$OIJN/1I+V\GG(L[$E_2"4"TN*[60        6L2Z:@
M     "U2754        6LQMT\H        +4EU@       #9K;I+H@
M  Z^#\V)C[]I?&@N(#'F=OZ&^+PW9.O.R\,O:U;R/%@Q5R#KBCGMG=&G61+D
M19EDO18?K.J!:;%=G(        +6)=-0       !:I+JJ        +5K=1
M      !:DNL        ;-;<I=(        &&">,J/>]7YJL7A+KV>PJ7PIG-
MZNR=OJ>>1>PJ7GEQPEEY;9?S&XT5F =>1DQ9[_V0%IXNQ0        M8ETU
M       %JDNJH        M5C;JY0        6I+K        &SRQMSAG=*P
M       :)T&S')9><G'C33)"VVB9I2\3LX%+D/E+('TL;,;6SXQ3;=R:?/9]
M=_'W91X?[9V3>9^N5Y!:697:N(        M8ETU        %JDNJH
M M6MU$        %J"ZX       !LUMRET@        #IPN-B)>>R8]+W IU
MKF@F9B_ KA"9OKUZX+]Y3B"VSDYQ7'US1TY='OU/\PYY^0^L=A_0?1-?*BT\
M78H        6L2Z:@       "U*764        6LENG8        +4%UP
M    #9K;E+I            TY-*8[G+,       6GB[%        "U>*ZF0
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M51%(4"I HI!,02=M_AOM'O.^"_O/YFKFW6        -FMN4ND
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MCX?VT>.^RVXYO3;O1ORLZKV.&_=>%Y1Q>=R3#L>?ZN1YU_IGYSZ[/5_)4%E
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M_H5=#B>ENL        ;-;<I=(            Z>?;_&? +^@?Y_$ @D@$@@
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M^G4>E]_?YX_H)V,=%[ZT^,NQE0      B,9.=%J2ZP       !M"W!=(
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MFQJU3NV)C.$G/CH@J!!*@@@D*002I!!*@$BA&.WM)\?]>_0W_._]!:J
M   M276        -H6XENE8           !YUOH?YZ\5'W7\. I"D I*@
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M$))!) "R%,2PDJ!!)!FWT7OOT#?SE_0?)?@^AM%,KNW$        6I+K
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MT/ED^M?D?6N"20 0143;&6-Y>N[[WG_G?^@7:AY[Z*        +4EU@
M  #:%N);I6            >=;Z'^>O%1]U_#H)"DE820%A) 4A2 %( !%47<
MQJ(RRY+HY.]QRX=OT49\*K(T[ZL[&1JSKQV:>[C3KVS(LG+7%QJ83*0 %)!)
M 4@$@@D!004U)1KV>@KYW^C/;U\._;         M276        -FMN8NE8
M          !YUOH7YY\5'W;\.@02 I() "D  A9002 I-/7MSMZ3Z1=7@=G\
M;/3?G@^@P%]#\]S8Z/VWR:V5XVZFSY>7&WDSYEQ^TQA[SQUQNK[/(WK_ &&)
M7<^)Y/=F!O?^'MWRNFJFF LH4E)(%3+!*"DDD@E822"0"#NW\/\ ?/:C^?\
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M=&?',Z9KU\.9H;>),J8ZF/*J936AEPZL=VMJY&IGA[&/A_[+],?S7]*U9
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MR1IW3\NOL8[5R(1&FPRXZ;W'M"^)?LOGG&YE>T   -H6XENE8
M         +2XKM9        !:Q+IJ        +5)=50       !:TND
M   "U)=8        VA;@ND                    "TN*[60        6L2
MZ:@       "U2754        6K6ZB        "U)=8        VA;@ND
M     ;.JXKC9Y3>RZ9IF] - DU@4&W2#<+MTWB@"TN*[60        6L2Z:@
M       "U475H        6M+I         M475        -FMNHNC8
M  !^5@ERT[[)?S^K/U^C!9?&8?IULKJ(.C5C>.7MGM'7/'B4L]!$G:4O@3K]
M1U0!:>+L4        +5)=50       !:I+JJ        +68VZ>4        %
MJBZH       !LUMRET@        #\GV+(7'/.7JB/T;%Z9CH2K]$R3\^0RZ.
MWJS+(\H!J+[F#QHRWM3U(6_G(29''ZR*U4+2XKM9        !:I+JJ
M  +4I=90       !:M;J(        +4EU@       #9K;E+I         'Y0
M#',)</I,::_0(QRZ1\G2>>X)/.HG>DN!*Y?6>,K%[PTOK+XT;>05ZRL7B;RQ
ML2?K+3+<4+2XKM9        !:Q+IJ        +4W&ZTR        %JUNH@
M      M276        -FMN8NE8        !Y1).R9,?3!3)W\XW"B3"BWTPI
MX\:[!9EE[9=PZKI,5%]3]G29+]+*=JNK+RX9:N5;L?:/AEO9M%IL5V<@
M    M8ETU        %JRZ@        +5K=1        !:DNL        ;0MP
M72         .E22T-68DR?7%\REK'J/156$<?;29E]2S<66+7<QR(Y,?6QV8
M)_0?SCUQ>Y^#^K'X/^_>87<+3Q=B@       !:Q+IJ        +5)=50
M   !:R6Z=@        M276        -FMN4ND         < 2R=<"C[-QYG+
M<C5<2\[V"U99+E1PQ-P:-M,N^8_'F6H;VMMOZ_'CL?/9N=3["I1:7%=K(
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M2QBZ^,'*L-M&>M+-HB9)92G+"6-":LV191,>_#YQ^B>QSI/=#9K;E+I
M       '3U[;XSX _P!!_P _0 ( )!, 4U)%3BE5D&G-^@PELU<,=2[HRQIR
MP8Y:4U:MJ9Z>6S6QL./+93BH:JMN:2MG-S:\Z<^,NRF-"::L\HPU[C+DM<IV
M<>=>ZJ[J;HJRE,RKFR<L8<68 %-50!%3  F4D6Q9,02 020*15%-*F $2M-D
M@$ DF(J%))3=UY.N[O\ 0#_.']"NQGI?>;;*6YPSNE8           !T\^W^
M,^ 7] _S]$  E825(4A2 %) MIU[O0'\W_1=Z>'Z#ZFGD=,_N_AE\^!Z"Z'7
M]SCEVGF\U>D]QASW'B^>Z.1D;T_J\/N]\/O<\_IZ>9RGC\B]?'[_  Y[KPM[
M^M]':KG=#=+A]SCMVOF[N=?W?5#['Y#V[^)^NVQ[+K^WGPOV+D^KLNE?WWP?
MB67%S4\Y[RR'<=!;OD]=RK3R[S<#N\=^?YNZO#[7JT]K\BXMOZT@  *0  %A
M)"D *2"0  %(  () 4A2 "*HPVU3.\W%[CW_ /YO_H3V)]'[^VZW2L
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MY7.X/:>^K\]?OWM!\O\ 4+<V72            .GKV_QGP!?H+^?JIQ*+"2
M "%E )B!4Q3.?RKC[:INNAQ.=:_G];O=.VC=..9<+G^GMN$Y]5]_5S;P<3O+
M:<GIJ=E^/EQZM>SG^KM/K:\+/<WI_M:MW&=_%Y!CSOAY\3;QKX9;';IY#IY.
MZ;/G9Z]*3<8X+R-GGQ.=<3L;>\KKN2X\VWO*Z&"0 "9:+C4H$!2"$J6"2E*E
M @$B%3%-23        %-4WE7/X/;>^G\]?OGM#\I].IV6W$MTK
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M%^*^V>K[Y/\ J:JK5)=50     -/7:Y)VAM"W!=(            Z>O;_&?
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M6?-+K\/M/N</G<I<OR6_9_QD" %(    "DA5E$W>J'Y'^L/49\C_ %E=<
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M6<C'9+ R8VJXP,Y7CJ! (64$$J00202 02:>6WG7%YWNR_/7[^[E_)?5IRH
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M?%-E4M%D@BJ\;395**;%DS+4U;>S7R7UCM+\W]*%J8NM0 &G<6%U,E.-JR
M #9K;F+I6           ",)U,^O^4>&?[U^%JKE&2K'*<5&6%;/3N-<RBXF5
M&.NO+- JF6RRT;J[(DF1<JI:6,VJC%6RB2&,W*J9:5PKQSC/&J79,-XRHDFI
MLG"TY64"9$BV2AIJ;)EJMIEB8:&6.Y9T3&O+)C:<L)M8&0"<<HJ9(LFJ)*KE
M##:QO&=*$FU%,QG*K8DFJL<Z9C3G*L)&6-6.R,L$RVMPW,RISU):EA)PVY3=
M+ZWWE_GS][9'<;O0   -FMN4ND            =//N/C/@$_0/\ /V8BA,14
MQ%   (44@$Q%"**F,K"Z4W]T'C?M>A@N#U?:\4YO$OMU_H.B+Z%\#RBZ3T?Q
M=ML?V'F.7:^SO5UO>XY]IY2ZG']!V1^9^C<1PX/6#[+Y;]R9[O5E]#7SKAZN
M=:OD]-PG?P[-]AY^NZH) A4RD%.28$ 7*9B !,12%(D@4B,B)B*E9DBH$DK)
M2E2@"%E*3.OS_P!#_0._.?\ 0?(CB=[$E3(  ;0MQ+=*P           #IY]
MO\9\ OZ!_G\00LH*4J4  I!"R@  @$@$5&KE>HOY1^H>6[>9;7;J^[PN9PSE
M<#H%^B?G?TN_,?TQE=TGJ<..X\KQYQLV.O\ 6X^<SJ,;.Q\ME+P_5WJX'=8M
M\SH+@<7G8Q]MY7)3IN_YKAS.%<O@8;=YXOSP?2OSIJ9<8I!!(!!("D$$@ @D
M $$@*00I)!!(   4@ BFODYL])[C]!?\W_T&R1XWH$H  VA;DNB
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MZ"]5_P K_3]4,C8TL95;70    V:VY2Z0           !YU?H?YZ\5/W7\.
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M')*B1)7<L^J!V+6UD53:UJ:9:RK5%Z1D9-4BYR-U=B2SBD21P)HUQ^^XQO\
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MOJMNJ7XS06K;>TE/\39;32[I3DX%(+%2@Y2=\_C?[WI5*Z ]/4\6I:>/X?\
M_'\-[NBY'WX\!V3"D'8L+0=BT]#WM:HZ=\6AT+HVUTHCTJH;N\"A#VP:BUN)
M1=D(4]4UE.N[I'76KBO*0%JU9BDS_0$:_>=*TU&O9%*#6HI]8U^'744^J[7J
MI76ZW]!UC2HZ]=*U%.H5NI4?ITE>XV("5*@U4:/[O] )$9BLW@#@.7UXX O'
M ' < 7C@"\< <!P!>. . X X"C"O'+[@. KQP%P' 7 <!<!P!<. KQR^O' '
M < 7C@"\< 7C@#@. KQP%>. +QP!>. . X O' %XX X#@"\< 7C@*\58%PX
MO' %XX"O' ' < <!P!P' %XY=<!P%P' 7 48%XJP. X"X#@+@. KAP!>*,#@
M.7G$58%PX O' %XX O' %XX O' ' < 7C@#@. +QP!P'+Z\< 7C@#@.7UXX
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M56F*5':N67W&):FN&EM5]4Q1RB](>I7FDW*351155M;+TJVIMB&^ZY&0IO\
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M.9R!246THXN1JZ[IE>JUH2VJU_ V\<#;AP1N' VX<#;AP-N' VX<";AP-N'
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MP\SSQYFG#S-.'F:</,TX>9QP\SU \S3AYFG#S-4Z^9IX\S3AYGJ!3)QX\SE
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MD YND I+I!0<W2 <W2 <WR#7FZ0#FZ0#FZ0#FZ0#G!_'-\@TYND YND YND
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M2M?HK72P:V]JWM7W5MMN%4IU2K*]@=DVE?[AU:ZZ&ZZ#70:UJ.S=6E:T&O\
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MG:KO=<'1VI6E:"$_QC\VG:U^)_\ L0G^)=)WW_\ &C\NHP=B^W,N2]R&W,[
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M>I[/X]3V?QZGL_#U.Y^'J=S^/4[G\>I[/X]3V?P5N6ST13U.Y^'J=S\/4_N
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M_P IK]&3ZXD^NE^K5^DK_')_2$OU6G_]JN5$$5>A4#/UE<97C"HA6".?E/\
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MZHZ21#*P92J&UB(Q'/N\%H*]B4+"V^ /HL,BD0U^]O!KK""&1,Q'&BK/>4'
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MX04+8144(9S7 MBWZ!I+!6?1]%.M5;AW*+OU<S>=^4_YIJ/F8<T4K[22Z($
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M4:O.ZHR,[J#5YW4&KSNJ,C.Z@R,[J#(SNH-7G%T1D9W4&KSNJ,C.Z@EAWRZ
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MMH"TTB;K9AL**U:4W!=PBM%6<5\$B,O6G4U-#*T/<E2MFJ;TA@X;<1"D.?\
MZB$>%XN:&U*+2I3RV6GO"C#);W+OBBPD2V?V#3'*3<*3+=#:DS%I'.<LA%:-
M+OVAM4J+C.B1TS1TIVI53?*?B!E'Q3,BD])+RC21)+4QAU6KQHU%LW3L&5H0
M/#W;/6#Q'6R:TC=)27CX)A%\,@.D:A%(1%DM<>Z\@T1FAM*7AE*V-'%DM3'P
M_:#AP[%FWNW&-#10K+E*219@XDF3=.&0ZQ)I*:<!&=AWV#05:5TI%<ME+<Y
ML2>S,MX$;9S*6:23?&2IML^A4!T25"MI:N@S<5\EX@:P\4DLML[K 0BR?/,'
M59TY)P%YPRK0VXSCDR9,X-J'B#DA6R6:BM@UGD$7Y26"U$<DO"1RS[_$&UI[
M9'R3W>$->;<2=9);-C #AF<LB3<.XQ6/GI-$33;G6C(5:/ BZ:,ZG3Q7-]:2
M>3<HI)1:<TV&PMD:2'DE]EOS#W9232)+PR":>P22HAVQI72-9>60K/F#CH33
M[RWPD*4]_#]!*K/+_&=8M3J<QGP H\ U:Z8+]6QM^'^=O\O&%5-TQN=>B1 ?
M@[7>[29"E]S2M6[H\1J[''0A$S1S63>;D$6OLQHK72S68E%92/D!>(1JQH">
M9RE#:]TCJ%R2008AE(\CO03(>)5:O$K8-!"Q;+G>RGLBHPHL;04SB(TF$^GC
MV3*:>^/$W:(WD6A5Q&AL(X:R%P\"#P]]7K/S;8AQ:"PVLHT3;253EFLVI)QX
MC#K,?YET,FJVA0)AXQDDLLUX5!SY:;HMR:*:3;PKK&1#9H-'1.=*3I440:WX
M82N>YVD<I%-$-K<KS$/#(CFI$C-BZ4OPP\67 "J\9WNH=.B2%)[L[)$1SCQ1
M]8>K*O0H2-DI4[1%:LJ&^(5X_>$Z>3_>H6"'ASH+%8CEE*P2V91XU1.4FP>#
MW;A4H5:K.C*(<1"*&3J6,9H9E-/)OBMU.K'1AH1T5F.@JRVS/@'B#JXZE$(F
M*?.M;I!4F^ S/TE+)RJ1(M/?,,T))2+'W]&?HF'B$.M'2.%H[13N,[!-]D0H
M4+%E<1[U$S,KU[>%9.L'I'0"2$4WJ(XEXY[<@KD;_P!A<K6:-'(TDQY<A+BB
MK5.J$FD:XCFF)/:([8>;S1R'R&()Q-=47&9.N15L8I6$LCQ6MQ'8S='1=15,
M4R<:< JT6L1#K#R-Z139HR,J4N*5J0/K+F8B92E)[BC;6>05^O5;*AZ.@<EE
MR'.1V[(C^,U+:XKRIN)%UJ%(>+,=BV/!H_BI>^?IN%"*7%DM"/4JT7N&9.1)
MBW"6U9'S1/\ E7N/&B)I/7,BD7@%2?%8>D,GXQ^LD-R2$:#Q1OBDK89,(CQ2
M]M9&\ J<6!'.$40XLI,IJ>D,BGO"NQ&MHG19:]@A6VU_WI$<,K#9-(T[""H5
M*JQC;"HO2$3%TDBY1RDAFMV8>+5FK-1K='1:?JY17;)BM^-UJL:$WFQ8U!KU
MHG0)&%)<OCPR+!>L6)3*(:$5)*"&=B99@RKQ7>ZG:V23W*G?)1XA_P"O135Q
M.8YI2^U2.4DM%ZPJ7@3LFKDZ67&,X9/X)K8\1A5J(=8AD3<6A0*':E534RO
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M1&67-C8!EES8V 2/+FQ\ RRYL?HC++FQL RRYD;HC++F1NB,LN;&P#++FQ\
MRRYD;HC++FQL RRYL; ,LN;&P#++FQL RRYL? ,LN9&Z(RRYL; ,LN9&Z(RR
MYD;HC++FQL RRYL? ,O-CX!EES(V 99<V-@&67,C8!EES(W1&67-C8!EES(W
M1&67,C=$99<R-T1EES(W1&67,C=$)3S8^ 99<V-@&67-C8!EES8V 99<R-T1
MK"YL; ,O-CX!EES8^ 9>;&P#++FQL RRYD;HC++FQ\ RRYD;HC++FQL RRYD
M;HC++FQL RRYD;HC++FQL RRYD;HC++FQL RRYD;HC++FQ\ R\V-@&67-C8
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MR;ISI7#.P*F9%I"CD_$QFEB*2TB/T\$@AUJMUC0MCF90?=TJ22.*0["EE(O
M(L:N1"@O@FU9"<M*9$/@LSCY0CL6+.[=<0_I?R4/%(I3?/0DNF1W 52JI(13
MSRF=F4S_ * 9^,OH2?R909^U(B^CA$6JU&#KZ-)U.>B:S.(YM_SC_F(L!"*0
MVTU4Z% O5NVA C$Q?E](JNRJ<EEJDG"MP/K38>4A,QLE5([!K/9] CU>O>\.
M+029B(:^J1KNG%8<R!1='H^L9I1,C,\DK1B)&T6L3UYJ)6J,JBITH6RZ7UY]
M(1W+"_8*N1P=3I/7]O@$$S@+HC,\KVB+[I6K J\31KH*22GZY%(M&Y?,5MA0
MMH.'9]@_PW9Y.$0X!PM61EE^U9R;HJ4<X.SZ8LOVU3U<(AU*N0I*NILE.9YJ
M<S;9;K$6'6(>,\VF2.F0[B6DG#Z[/DEQ-(K1 _I*$#J[,AJ4G2'0*6PI&:H"
MJU7*0K]\PI_T S_["^ERB4(F\',B3N3TS"BZ>QQBBLT_FW$":X[=V<92\ _%
M?2?>X12W$#,BW&&I9N@G&Z;SBC;%)HH61I5EL\@E.244+83Z23:OBL7'=(=#
M@,R,[4@;4ZHVBUN_.>^9^1"L?T!\Q69A.?-=@&4?-=@&4?-=@&4?-=@&4?-=
M@&4?-=@&4?-=@&4?-=@&4?-=@&4?-=@&4?-=@"FX^:[HC*/FNP#*/FNP"<^8
M_HB<^8_HA#<?-=T1E'S78!E'S78!E'S78!E'S78!E'S78!E'S78!E'S78!E'
MS7=$3GS']$3NYC^B,H^:[ ,H^:[ ,H^:[ ,H^:[ ,H^:[ ,H^:[ ,H^:[ ,H
M^:[ )3,I?9?YVC*/FNP#*/FNP#*/FNP"=W,=T1E'S78!E'S78!.?-=@&4?,?
MT1E'S']$91\Q_1&4?-=@&4?-=@&4?-=@&4?-=@&4?-=@$[N:[HB<^:[ ,H^:
M[HB4SYK^B)SYKNB,H^:[ ,H^:[ )SYKL RCYKL RCYKL RCYKL RCYKL RCY
MKL RCYKL RCYKL RCYKL RCYKL RCYKL RCYKL /Y1TK44C(R152P03^@BI>
MTWE+RS";^":_Y5(*7*%MD)A,)@@(C(3"83";R3"8(E_R*<GDF$PF$Q<8L"B)
M; F%@(04Q,)A()K@F$U\6=XT\X0_,M[R*7JV))+B!'3[X1H0A-/O6#WQ]BW@
M@F\DWEF%B^+'DF+C\ECC\D@;7*@Y(C5E1O#.3KI GLQ8I9399.&B2^;^@F?C
M+^75B=*1N/D#_P#CH]"KI-1@6K;L:<.\=K];T"N1_NJ:RDTI&N;>(5735C2U
M>,IM,H;FVK!/6R4X9X=4'^]B2.91,J.(UQ&3C,B.27TF(Q^&5K2O@)29HS*<
M_:<]+O (/B5;K6B8^DI:,W2D=$IG+8'AE1K%8T]/2)[MK-&3:)V'8TUZZ(E;
MJE;*,Z"9$]E V2F9$1XSYI;"AOAL T)Q&KC(C0B:JF1N(SE0K<P*N^&5LJR;
MCHY!PSDD,T<\P7A4>OK68GJZ$[5*>F93".SQ>)\LRKT2,\NG2,R+%:Y205,J
MQ'IP(RFUU!Q+1G(RI*4IEN4@RH>'O2(^>'1F1A.RG&AR*>$T$7_B:T42)5Z-
M-FC,LH[#G.0YC$&M^)1] ^+20J#GS&BG1>B3&&0XQXA-*40C\3K)58ZU2T3=
M'3F.7&)UVR*S5:_6"A,@(KZ-*E2FQ6N7BO"J0ZI'TD"M4DB44R)\4W+/;,K@
M=X8SQ#_)+U= Z5"I95.B4D\H?XAXA'T,-A^Q36PN*XDG$2I0*W2)A%[S1F2R
M2XE)J6I[HK'B,.+1*$;21%6D=$Y3=YAX55H.*<0HLMK(,SL6"$:/X=6M.^K4
M=*PH1M/'D+&<[?F6Z(-:\3KFA..4GN3>3;60^SO"K0(T2@3G./)<Y3(EL6Y/
ML#?#6QJ2_<U2,)]LJ4RSB+'\+K>G= 0WMT1LGD57.EF/>$+Q6MUO0M<;O]-S
MY2>;41K[EH0ZK6FTH;Z2K)DM-Q&2'<MW@YC6Z2K,,RT>(VPA8U SGQKPK'C=
M8C?*,(R,F4#?0*SC4R5=X1/&JW6='4X:48E!SJ2N-F23J18UNV/#ZU48NEJ\
M<W(ZC1L(<CC,[(K3:O6%K1$T]'0.RUJ8QN)LVZ<?\Y6JQH6O,U+1F]$B4+#[
M=P52NG&T\%])Q8IMF)/:>?K"L>/UZ-HB:9*C3?(B>J;+5H&VJ1BK,-R8U X:
M7*)[E$7Q3Q&/\M5RH%2H:5<9)FN6="'A4#PV+1-(E!]%9,53HNW[(K[ZY6U;
M#T6D/1$2TF$DA.)$(K&^(7@_A-8TQQJ6-0-M!"I&I//&4FF<XB%X56M+%JJ4
MVZ)S<HY#I/>DA+-8$*'&K>CBUE4;HS<AL,YW$XK$RH*Q5ZS%T+*I*YQ-ITJ2
MIBD]2MR<*"#4?"(^G*.OJ&Q*)4O7.Y;(1X=1KFFCU8BILT1M1921QOH\7H!&
M92G-8F_DH-/ D24II99;8TS)'M2FV619I4(2?T S\9?RZO6:W(UIG@L4CLD(
ME=?XAHW22:",=BW(5C<8B>%E$6,9D;6T7%_J$\_528C^T>&G4XFD=!*)I&(;
M4E:F,;;AS36; @>/5"-I"?2TC:#VHC"AJKBEX"L"M?)^('67Q*-"%H3AI+C+
M$<Q)EM371X?5:E$1\'2TY'8M-S3LHLP\-KD%]+Y<HA1"1TE(J-ELLYS+P"-&
MJ\0ZQ'C.*C)%AHAK9D.\-+6<:"^1QR8LZ3$9G*&1*A&.-6:670>Q9?8<I"'_
M .P1:PD9A:K1Q#E)E"1Z$5X5VOOB?\?6(VC1]$X\A*J-HF4TG"/#XE7C::)"
MTE(Z!MGH2S)*ECA$#QZJ1Z=):3=&]IM2&4.=S?-<NBL_*U\X[GT:$+0G#265
M7FRU+8F%6;XI&T$2"I)0B/G,IC:1%ZHAUCPY])A-14,I9+!D1VQ5*OXK$.&=
M7)U)E&(=)<F5K21$FXQ7"AN.JFZAHW47Q40W+BH<]Y9!X:VJQM,^&<2D=%S9
MR;8-I6A$\6BQC=6&30J,4E=HZ*4T-MFT'1XM;.JQWGC.T9Q6G+)BDU%L!U>H
MT:K%(Z3\>4B8BT*-+*(1_#:M6](Z*YE#W41I2/:9E,Z^>\0\+C0G:3Y<HQ19
M'-HTVD13MY!&95JX=8=$R&:,X=$EQE<YLL@@G\V<.'")U*KZ)SZ9N4Y(M&24
MUO3"%XO$+1L<\W&4Z2&V1"6]Y@?BL!U."[%-R.)2*&33D-JE1/>45N'X76?F
M(D>@2:.(RB14O:(URK@J55A.TL:&<2D2.:E)ZVB(^ 0JXTE8PSDFG:96CMV
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M^Y"Z80JKVL).,G@B^4[2%RTQLL_WX7>!&U:?_N0NG@"LJR_WPBY8@;_BS_\
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M^7HC+_+@&7^7 ,K\O1&7^7 ,O\N 97Y>B,N\W ,K\N 9?$3>.89?Y>B,O\N
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M;2?$SHC:3XF= ;2?$SHC:3XF=$+\R?$SHC:3XF= ;2[B9T!M)\UG0&TGQ,Z
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M0/U"[\?N,#]1O?#]QJ_/;WP_<H'ZA=^/W&!^H7?C]R@?J%WX_<8'ZC>^'[C
M_4;WP_<8'ZC>^'[C5^>WOA^Y5?\ 4;WX_<JO^HWOQ^Y5?]1O?C]QJ_/;WP_<
M:O\ J-[X?N-7_4;WP_<:O^HWOA^Y5?\ 4;WX_<JO^HWOQ^XU?GM[X?N-7_4;
MWP_<:O\ J-[X?N57_4;WX_<JO^HWOQ^XU?\ 4;WP_<:O^HWOA^XP/U"[\?N5
M7_4;WX_<:O\ J-[X?N57_4;WX_<JO^H7?C]QJ_ZC>^'[E5_U&]^/W&K\]O?#
M]RJ_ZC>_'[E5_P!1O?C]QJ_ZC>_'[E5_U&]^/W*K_J-[\?N57_4;WX_<JO\
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MV-3\#)RLXTJQ3&)Z>DZ?(BFZ;NR8+CH*)@;7*)0,4Y1,RRW9A7-'5O+,'4E
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M4%)TI-'?S$0PK:OY%V^:\0=-01192E.M$%-9P4V%14H:OR\HRB*FJ*+9>!=
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M8[ H*9B&)>-U]J@=U5E9GFS@*7!4\M5R.7Y#T@#9 B9S/V<^O,M4U6YL?<U
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MMDFYKR%Q[,A,6'7Q6<MI#-.?=-'D:O%NFIVT)Q55@X!0BR9V9(@$L1BG$NU
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MC(%P@LHUB64>4YR[0<!E2GPXAPVIV)JJHG4S'4DR4CZ::.$6"1(EDH1F0S9
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MB8P%MDM-4_4>1C6H6DI'R>:SS-;#*5Q&N6ZR!UB41'.W!3-%2JZK5PD4$RD
MJUYKC7UA5CVM*;+2<_100T?5*,RT<4Z+XS""7*FO,(JJ-R?Z.4)B.H0"C<4P
MZ0MGCEP_S(RRFB9E1*,I359O!0F<NCOC*SQ_!VH3D<;(272I1<D453*8"B7%
M>8MLFX!>K\HJJ&!S)@ZXFZ3R1I5LUI2!80S]9R=9K+M99XB*ZFW,?9@D0PFO
M,:[5,++RA#>4#EMX+2T<(Q\2>>3;U 21<4X>+XE*MUCI%9M2EQ*;1ULAQ7(8
M,1BVEZ]:G;SD+$YPN:H1.Q71=-I..958$CB8KD44(H"J:?<3%-=K :U7YV.O
M*'@(RGI*DXAQ#TY3[E%]7CJ:8LN*&B7-..%$54DSX"Z#E()3'UL)"X[942\)
M4&1[2K4)YM)9J.\WRI2M41@-'6W7+1$*[=%,BJ4;BM%FQ2DPW*7F. VSUEH&
MHXN8I^1RCII$L[ 2#:59$!$I$'!T7,<JX#:)"4V(N+$%ULYJ?-FA1N8]0YLW
M1=/PM(21)06T>#1=JG(SK0+S-503=**K L4H@8A$M8UJ39YCYN9,YKY/M*4O
MD&68\6P:YN0DLB@=)%HTAVP+*KBF%R95BH$7T"8IU-4ULY\E&M<4[EDXEJ^<
MU#1WAW(!'M#TT:;C9"+0.]>.$RB<B4;L#E*J=0HW'PF+K6\C"&@<S:/J5IEY
M5K-M44HSF&* ,&C)DQ1-)2;)=<BS1 QFJF$S@I2W 7Z:WE14GX6Y=$3S&3IE
MY2-3U8=K/9;RZT;2+&.<Q4VNW<@W40Q@.T RQ NQEUCEPCDG0BV;.7C7D>MF
M=42SO(FCV25.9<@V3?H-I"+>MY.42<'Q2!C+-@;CB(4YC%+JE/F2MFS5^1>:
MDGR4+3*>H*'2:AF8J]<(#Q0TXA&J.@9BDL!%%1(HDB;"8IB!P;5N]JRI(*FF
MCS+]XQ;/)^68Q+=T[4D8XY6J"[]RV*<YBE,; 6X=%L[<A:EJ^(H&6KN37F*=
MJB?5(TIYP; R(=D_?@=(" 4T2!NZ'*!BK#@'$%PY.9%1U>4Y7D^TS0A:SJ:H
MZ:>HN:5I]DE4!WAR&E]KLN"X 0-CT8#F/@*);2DQ3511540H4]3C9K*0LFTE
MH\JI&/WRW;+M'#A,!*<PXP*.Z.MU[>4 C451P4"K-Y8R$;$IS$LRCU)9^=E)
MD*Q8%=K(BLJ8R@:B0&-I+JZ;1E)9JU5#4X]RIJ)Q45 2512[&';&8S\9*Q;^
M*;N'RK<#;(THN(H[O=2&WK>4OFO,2E/U;.UA6\M3U-4E$5.S2FYFEE7ZFU78
MF9N%EDV[E1\)N,E)=A;%,0VL%LU\E6%+P^1T7)PKB<A1JRMP>1CZJCD#BBK%
M[4#H,"I%H]N8Y4SW"01U>$%J95HK-.&R#SXI]X*=55!+U54$#X1L1XRBH#98
MTXV;"54IT3WMM.)(2F*4IK>3504IF9"9EU31.8$+-5IF@0K=E3T>U:H.2+J<
MM&%- ^T*Y(0YR*G+A1Q*&VNK8KJE<TGJN7XU)0QC+P5:.1I+B*:$4$J8>(R7
M%<&HIM[]&[CM/S=+3<14<.M!TRBG*PDDTE8Y51O&$3733>,U5B"8IBX3EQ:!
MMNCV^W^[=;K>;V/-M\W6M&5E1T@HPEHP^+0;[V?ME!#C$;((<%9!8MY3)'[!
MBB!P*8$UHY1-E4\6HX-4].&5O<QJ[QZNN1PV*>XRC17:]Q5[93:Q1ZCB^T\_
M#W742_VE3ZP;0'N:AZ0]54;_ 'FQWZ+5=U7UOH]JWS?-O6W=WK:.W;K:=W>T
MCV>W;K^AV=RV_P!D-W<U=ZV]N;ND;A\VVCLZ>UV=-O1'2(]<.P-@ZW:O[5IJ
M3H5\R9/)^,&&DS/XUO*%6C]J*N!)-WP38O7%MNB.B_?[([@]NUW6Q7#HMYVF
MX-.]NV[%]_G:0]*W6\R_KW;ENOV>U>-KK](=OM:;7=;T/E-W1\W9ZIAW^5[I
M:$Y$61<5%42I#*1+*(.>]PRD&YP*5P+@$S%(VOUS:VKAVA0OTC<%X[EX]11?
M:>?A[KJ);[4I]8-H#W-0](>JJ-_O-COT6J[]Q^@(]1=G3HM5<I4_'E:;H"C)
MBN9>-C52MGLT2+69MVL.D\435V!5UWQ 55PG,!,6#3AMF,[CZ/B:$JC+^";U
M?'+TY)5.]BYV&Y2;1<K#RK6JIZI3D<)$>%7:N4%$BZ!*9,;RF"G:-=YF4.M4
M4TI&'D&RAI&.8TS%2<>651DY^8D&Z3<O<U/:R9S'X'KE"EM1[I]+L:\H2L(7
M,X6#ANWFJ;=$FJ$@WJYTW,>X4:N2E(HHU<HJE-@4*<"G]<48.E(9(RTG4$PR
MB688=!5';A-';*?2E2* G.?UI2B)K4I4V3C1RO3RU2RN54P47CR0.[KNG794
M&TL4SQ982A,(J[=%(MR88-7"!@MG8WF*GAZDK#+JB2+.85@C.QYJ=J;EZ%9.
M3MY':(MY$K7C*S9;4P%-K$*;0:U0TXKF;2I:AI:DVM>3K%2*J C1I2BK>,>O
M7990&ZR8N$$9 JAF>#$-V IL0Z*'QK0&8E(5W2%93T"NY7J.E4%#TRPE"R+:
M12:??J#EDNSU$M9-31B'")K9?S<C7T%3OZSYN2IZE8YQ$S4DZY3CY1**N?J,
M2"5% RCDG=];#B#5M0M/MH6#95M/YP5=EPYG%)N6455>PG%$%&CQB*:C--N@
M98QDEVQ=JIZ[>M05+3=?-G,14M7NJ0EV[&(DX2KX>58NT&RL<]IJ7(HX;D7V
MGWL^43,ENX@O 0MF5.H9E04+1N7E2MX!:8GHF8(Z?*/2O^)H,HYJW4446VC+
M8W82@.LIH3*-FA8ZO:9&IY6&J:?AZ521?.E7$=2Y'2ZPS$NCM&T<NY39KJMF
M[CNF$H";9XPMY/+.-D/#0^9T/RE,0$\G/4]%NS&<S+/;(2T21)PV0*9F!=D7
M:JWDQ8MD?"+2J:BK"#H*'J2KIBEJ11?L9B9-)N(EP+=^NIR>D!FS%JHX00.[
M7'$)C\$V$UJEF:[JZ&HUM25=%H"334C92<<KRJS$LBW=Q:$:F K-CIFQ I>7
MN8@.FTW1DNNV<O85=%/C;$PF:/VKIHA(Q[UOM$TS "C=VBIA,%Y<8E'<MI^;
M3<(_N/F>9U$E 0"9FD2U%-:HJB4((LX1D<=V\PAM'!@*8$4"W"8Q?6E*8Q8V
MF*89%;M6CF1!T[,!3/9=ZF_704D9%6X,:QP1 .L4H%*75 O4<7VGGX>ZZB6^
MU*?6#: ]S4/2'JJC>O\ K-COT6J[JR0=J13:=@ZA@Y"E:I@'*FQ+*P$ML^.-
MV[LH&%%<HHD5;K 4V$Z88@$N(+553&75/S[ ]<H,HVI)NK)R-EY(D R>H/R0
ML.2(B85-(%E$"F=*JE6.8I *6X,5FN;2U(;=F@RCF)J?<2#99V@=A2Z5.IRC
M%^K&JIE=HF)QQF=5N8J:I"8BFPVH(YHBMZB&AVV9C3E:LZV).5#-%S#AVT</
M&GAXD"I\340-@32)LS)W%N*:\QIBJ6<89W4XT[*15'26V:E0IF:F$3L3U$9D
MLS=%740064*BEJ%O/>:\NJ%3TQ4T?&3+.47@I^G!C(.EJ5\'JWIJ3;2$//K%
M@(-@5TG@1,@Y35O,9,0 J@7&Q9LR,70U0-*FSAB19S*SNI6+J%@WSJ483<HO
M LBPJ2^Q67;''9KN#F3*8"E-HULQZN\&7*9*\RK<9;(Q_*J0JQ:QX2$B^6E%
MBLNZE_J@3; "D-W3A:+97$4IMP]_5U 9FPJHEE$F_*QLPE9 Z+A'[R4V7%>/
MZY3X\>'A%MDI'C!*&'*2IY&H7"X2) "=(]J!C- U0(#+[W,4&.RQ&VV[BP^M
MM#IOJ*X^RCLX:RS.>1[R8433?LJL<(. @P79(M%4ET!0[F\2,.MA-A+=;+!=
MK%53.)9;UVYK8DA7]5$J6JW:#M=F;P49SY(MH9%BF5J D*L58V,<1N#A',FD
MH:#ET&=>5M!U>@\E9-BZ=1@QA9'C3-9-G'1Y505/*&P&+LL)2:Q36IB++!5<
M@$#14S1KV!@:P0AJ%J!:::R312L)B!"(647D\,@03G755(8R(8 *&$"Y&5 I
M3$JXF,G&AXA=%*:9)1=01G'I9^@9NFI$K+(.+Y/"<QEED]35 M]H.EJ^IB:E
MV-(51,U)2[BGIQG$/"MJA>DD9:G9Q60B)0%6QUFB)DE$=BH2Y0 -K#=5</*P
MY492J,S$<P#OVKH.(L6R$*>#;0:+4R93FV9 )@7%3@DUB8M-IJM$8P\2G+(P
MR)8Y9VF]50Y)A8^('&Z2;,P'%Q':!JZ,5UO,WO.[/5/:WOHV2@8%,S.(9F25
MJ&HUDC'90C$3B'8VCA3"((H <#&-]*4IC@QI&D&0-6#0 .Y7.4HOI1^8I 6D
M9)?UZQ\/8 I0 I;B@ 6)U^/R_G\J.^HXOM//P]UU$M]J4^L&T![FH>D/55&!
MN_[SX[]%ZMTVW[;@^=;<'SK;@^=;<&VX/G6W!\ZVX-MP;;@^=;<&VX/G6X(V
MW!MN#YUOH?(W!\ZVX-MP?.MN#;<&VX/G6W!\ZVX-MP;;@^<-MP=_>T>G8= [
M@;UM_=NX(]J[1V[<$=&YN]>[3;1?==UC;P6W]_>ONQ#V;;AMZ[1U^V-MP;A^
MI'KV] .Q=OZ>T-MPV]O;EX^;U[;^BX-\-WL6]=O;QM.BVX;L[O7NWK;AK].Z
M'FVW[_-T^;;?ZYM ]JWKKM-X:?GVW#>I=YMMPWG6W!MN#;<&VX-MP?.MN#;<
MMN#YWR-P?D;@VW!MN#YUMP;;@^=;<&VY;<&VX/G6W!\ZVX-MP;;_ )UDH*"0
M,TB6ADEJCJ%9$3L85BH;2(B(]T<'P""*!1O,(>M(!C%8T?1K K2/:%*=TY,!
M!?RSX2E!:1DURAW18]P:0N H7%(!2% OR"7?]HRU^C=_K5[=<'4<7VGGX>ZZ
MB7^TJ?6#: ]S4/2'JJ/J:MV4D\CI*<0@FZ46R;/U@?+,9"034.F[<M2@79QR
MH8L5^(0##IM[WJO\7H?G>WO>J_Q?A^=[>]ZK_%^&YWM[WZN\7X?G:WO>J[Q?
MAN=[>]^KO%^'YVM[WZO\7X;K>[%O>]5_B_#<[V][U7^+\-SO;WOUAXO0W.]O
M>_5_B]#<[V][U7^+T-SQ;_0%7^+T-SQ;WOU=XOPW.]O>[6/B]$\\6][U8^+\
M3SQ:8.I!U>8'TJJ]2 *<A@V:9F[9,2B/+!M\HZ='J^]^L/-I^'^?,=BWO?J[
MQ?A^=K>]ZK_%^'YVM[WJO\7X?G>WO?J[Q?AN=[>]ZK^\$-SO;WOU?XOPX?\
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MR&U3#8[5GH$#ZQ=4;9$U3#J*9@R>69GX5OF$E39J6=U6REXPT.Z;1,0]V*Q
M2*[6<$(M@+M U=T36S!EXCR@\PZU=U*T<HTEERRI)"F&U+C*-3I*-YB;D*6
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M4;66<DY6N7U<TU%,H:H6,1$+S$55;=FJ9R"2#QG%2IDR"HLKK&XLH!7 ETW
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M,?6L#64GYJ1;?JQK50&[Z5?O$,9',!A-L7#A4N+Y6J_SE<_@3'J.H?SJFO\
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M0*E,4+,LVZ[S[B<YI:GI\*@C8N.!J4DA4A5CN&TQ4DDYFY=991-:Y;B_KE
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MZ,(7Q@<_B%NB^&[_ #KYT?;HPA._K[FRW1A"]_GO-ENC&%[^ON;K=&$'N_\
M;[WFRVKEA" '6Y??#I\V/L,A' 2)JB,*FG4E+JK[5U'*G#5=MQ,5(56JO\FK
M<&G5,4#?)7^TJ?6#: ]S4/2'JJM?Y_2GZ3Q-_4G:MO!O77AO#;2<A1'UIC$*
M.G<OW.M;[*0=_0</5[-KRF P#?<8IK_\;<$>M;M?.T6'3\VF^W; ?H:+:  0
MTWAUKQ$=SS;#A,4V'A"4;^P&^-@]#LVT;P: [=X[GFVPXBB;?* B)M W\&VG
MKZ=/9OW OMU]S3<._P"?;SO-]"U_! .OHN"X0M>40$!]#0-X>?V[=C<Z]^FZ
MW8'=#M;^BVY> ;_[UMSM[NC>OTV'M;OGVWNQ\_T[:=&G1\ZPE 0Q!INO+BTC
MITB%]KA.4+@$+C=CSNM:X%4Q$=PH&"_1IZXCO6T"4V\-P@-PW7[FGT+>D/;'
ML76\[1VA[-MW=W!O\W=L(:.T&B[?TVZV[YGG6O\ G_.#M6#1=NW!HZW7MH'S
M.M?IMV.M^];T]S>#K?X1^;<\VT=6%(21XN9C#@)3 -[5VB.E=A)-AU54%"A<
M9,_F7&*40+(1YTXVJHQ-$M3TN=7$YCES!AXXSQW"JS5, [)0 T< UQ@T[FBR
MWVH_UHV@/<U#TAZJK7^?TK^E$1U+Y@ZM^[YMLM\E'%.T.YI%PZG$7#UW '<5
M$8IV$S,Z9$[\4[]J0"^U^#J_56;Y*+TW0B-(1^<-.,D'#2FS(SAFT;)L72)5
MGPO%$QQ"&%;[WTEU;9B+T75N7[*;+%0TK&9>F? WGW4<SIZ'9*.E4&R0)-MJ
MX34P[0!'2!S7%. VD\ZFLQ%O(NGYHT#4=-$3=!/03Q-^DQ5XY<4$3 45DN"/
M!5#K&ME/2;FJZ;8U%FQ3[ZHV$2LWDE%J?C6<>@__ *YP@&LIM!0)@NQ&3/\
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M3  &+K%M 0LUF'ES3->U/&#+0F7DQ(N0J!ZB!3G21VJ2!T@4-A$MP8])#\+
M:[,MLI+4[1TEE8\!E4;&J5G*"95A;K.CK!)($4131*1 QQ6/JX1 W!M"U@EF
MIE8ZR^E17([KWE=1K Q*Q%>*H)J[:\[@RZUZ1 3NN,76PVI'+PYXBHY"O"M#
M4A)PSHW)<JBX5(@<3+.$R"B"0F*90YKPPZQ<5JZ?Q=<T/5TKEB@W<5]3,(M(
M%EJ?0=,E'N(W&&Y2*F*5,VHF8.";UQ<-B@4!,8XE(0I=)CJ&$0(0EP#;)S(Y
MJW;)R]*4R-65LZ30)MUZGJL1<%:NE0$!'BQ,0$'K8;,*1A8.BY*,JNL8/E1:
MHX)25D4ROG+&+7(T<A(M2IA@#$0,!M8<0VD,J*>IJ@PINH:&;<<=/*;4/.)&
MGC2L>].S>H/FI"&*F@ HCLC83:=.Y;*)E$5AE_1#MYE\R81,7-+<5DZCEL:C
ME=%C'L4L1@(F<G=3\(QL)0$Q36S=:#*PK.ILG"+JS]+*<:6?R;1LU5<E?PKI
M$A4CD4*B."_L;E]J&S&=3T-%-,Q:Q:4?3,0[1>&E':KE\=D:4Q)@!>+I';GQ
M:+]&[B,6SZBBYH99*U@C'&E(VF../R34JS*V%4RX--G>@6\V&]01W,>Y:K:L
M:5?0L]*4"@JXKJB827,]G*6XN0ZSYJ]7(&P,LBFF)SD W\F<I3&,6ZP9E3U8
M4?EK1+B2+$Q4W5[M5/EF0QG34(R;-RG'#B(:XQ_\F<W!(8UJ<RD?2<$W6JV.
M=3-,U<DHN^IV9C6K11TJNU.W+M+]4I,.'1M"&X)BFM5+6GLP<M*GJ:D'((3M
M+Q4P<'[ @KG*4[]RL!$FY\!#*'34#5N,F8=H6ZS3-&/K&BJ\H\\B$1(25(/%
MW1(R0.L+0A%E50(4Y=MW,YB\$PAJX1OM102-:T-3%4YCQ3N:HNB)=R]--S#5
MHT3D,1EVS4R21A3,4]PCJ_\ !-:6IV80XK+0<D]BI%OC X)/HYR=JX(10-TN
M(@X3;X?X1] .U:[U;1=8T?)K1LS&+ <%"W"W=-S:%V#Y =55!0+P42-N_P",
M!1 LA'X8RJ8Q),E3TPHMC<1S@^$G'&=X7JLU37BDJ&YP37&#2M]J4^M&T![F
MH>D/55:_S^E?THB.I1'?^CO6R\G:CEHV!AF#N64?2DJ[1CX]J52G)=NF=TZ7
M.DF4#'6*36'A&"R]7HST2K2OZVXV5\(22#8\-R61PT.H^X_CV>QN*/=,>&U:
M5VM75)IT8ZHHC-M5*D]'A .'O@Y23<S5&5,OLA/C:JEP%-NIB7UMLZLEYG'*
MT3F@>I)HAF8[= CF+EU%>-D.1-9,J;ELO]G-JXD$2[Y0LC6<]-QE/T53"DQ2
M,/(2CY!E#,(B$AW,<V^^EC(D("[C:J:QMU3#;RP)24K*F8Z/JT*A"EG[R9C6
MS6H@<RU5+MN1EE'"8.<1729B[+%>!R]>U9T,K4L$C6+RMT7S.ECRC4L\X9<N
MP:_&$(P#[8Q,*!SXBE$+@&WDU3B]40<K#,,IY:CJH?1#]M,'I1](MJ;V"DHC
M'\941PGC3$5*);P+>;"(%&U450PSRB:ZK><JV1<TQ2]%KM):.+#24IQH[BJ7
M(;91)4J2AA/<<H&4P%*4Q;S%7?U8*H4C5$(XIN=<((F=<0(LHBY:OEFA,9U$
M@41P'P%.?"<<(&X-JNKJN<W*-S=I@S%Z-'Y?Q"KD*A.Y=..-L^/MHJ7%8'!"
M$*W[J1)$,8J*;/<+1$Y3DUDC2U7C5IY;,='-=J%05%%1;>47<EC:)8O3"KB0
M2422:KHA<8I<1SXRC:O:Q_6'1Q*6D<I(R,CJB"I(WDI>41*V [%&2XQL]N3
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M]*OVCMLQ,MMA,=CA,A?>4Q!+JC(U]'4C3CBL@\F:AZ\8P"%-QJ]/JU),U M
M5+5*-% S58',U8M]L=$6AVZ:AA6,E?;R?7<I$,X1^[R]F'#B/CHM*"98EJND
MA3=(Q+9%HBWVY2D6V:":2>OB*!2C;(,LW0$U5#XV2<,9"1C:I=0B+9/PAJ7
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MFE&4-.4W'JN:8II[%\>7K5X1BZ=$8,7/*;38F%9NFABPJZ5+\.K:[:$T;ND
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MQMTVT3NQ6IO,*6JNF,QZKBLU(V.8U[3M'GI0IXQU+K-U8)-%RT9',DEM@"\
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M%<JB0BDM@0%)1D0A$>2C1^SV/%,!0+Q?!=O\+6L:E*GFXY*G57G*3R*@(5E
M-9-^)MMMY061<:_=2[2XQN%<;0)0&V7LURG"\H9713Z#H\W(+7 VCGS-M'NR
M/2?RYMFQ)@$VYIZ]JR>0\O&G3KZ4>3-40\I",I2 >RL@X.X>NTHITF=-(3"<
M2X2CAPX2X=%HFE:YEV$C$PDF>6C2MH9@P<I.CMG;3#MF::7<B)O!*5+#< %#
MK6C:SHV0",GXP7 -ESMTG*)T72.P6;NVJP7*)G#A!9/-).H(]E5I(@8!5>/@
MV3>,?Q.W%QQ61B@#9JZ^$^(=8! -:TY1-33$*ZIFH5$5G4<WIR/8%:@B**I2
M12C1-(4 ,HWVBG#O,<QO76R[J&7?Q2DGE9Q M'*(PZ#=%L$<Z9.FG'$2#A<8
M31R?"W;C?36DLXV\E$!7,I&\DO'AX-F,>HSV#=L!"1^@I386A-:^T]*TA-IM
M!JA1=2?BGK%O*0,J98ZQC&=1+S:IXR<8/A$HAH,)-);4O4M23C=PZHE=HZI>
M.9QK-A 13AHJBL0Z$2U333'$9NF!\=]Y2 3@V+FQ(S!&M=)JQSE"7B&B4<""
MT6U(R8G1:E!4A>Y(%*?Z;3BW;2E-3,Q"LXR?41/4/@_3<7 OJ@V& A"3+]BG
MM%RW$+C*)M;@\'1\D>WU%UK;H=O1Z6BT+DG78NWXJB+6BY]-!5RNEA!18868
MV15C"3=V+HPAAX*FK<8 #KWZ.UV>H5OM2GU@V@/<U#TAZJK7W0I/]*(K]UOT
M7;VD;7#I#>MO7@ [WT+77:+K]P.N(!:[Y]NUV?/WK=G3=H'>\ZP^I\W6M<'8
MW]ST+=O2(WZ>Q:Z[M[]NQ\_S>W:^W8\S38D;3\/+STDJ0ZI(Z&CG<I(*)($
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MI(D;2N8<JU*$U- 4#)1R:EQU(>&$1U40'[(K=B5,%X@!0*4(OM//P]UU$O\
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M3YWQ<8<\6Z4)SQ;8\[6Z3YWQ<8<\6E4QS-J!,(^2,R+?3;#7 C=%83A_6_\
MRUNE"<\6V/.UND^=\7&'/%ND^=\7&'/%NE&<\6V/.]ND^=\7&'/%NE"<\6V/
M.UND^=\7&'/%ND^=\7&'/%ND^>\7(_GBW2C.^+K+G>W2A.^+C+GBW2C.^+K+
MG>W2A.>+;'TN5[=*$YXN,N>+=*4]XML.=[=*$]XN,>>;=*,YXN,>=K=*,]XN
ML>=[2(CF;/$XE*O6'O<8#CXL8I,6F7MTH3OBVRYWMTH3WBY'\[VZ4)SQ<9<[
M6Z49WQ=9<[VZ4)SQ=9<[VZ4)WQ=9<[VZ4)V[\VV7.UNE&>\767/%NE&=\767
M/%NE">\7F?/-NE"=\76?/%NE*>\767/%NE"=\7&7.UNE&>\767.]NE&=\7&7
M/%NE&>\76/.]ND^=\7&'/%ND^>\7(_G>SE4V9T^GL)*38A?3C'6!B_6:@?3)
M^NV=NE"<\6V/.UNE"<\6V/.UNE"<\6V/.UNE"<\6V/.UNE"<\6V/.UNE"=\6
MV'/-NE&<\6V/.]NE"<\6V/.UND^=\7&'/%ND^=\7&'/%ND^>\7(_G>W2?/>+
MC#GBW2?.^+C#GBW2A.^+K/GBW2?.^+C#GBW2?.^+C#GBW2?.^+C#GBW2?/>+
MD?SO8CLV9L^F87#U##X/,?\ FCQ9M=IDO^1MTH3GBVQYVMTGSOBXPYXMTH3G
MBVQYVMTGSOBY'\\6Z3YWQ<8<\6Z3YWQ<8<\6Z4)[Q<C^=[=*$YXML>=K=)\[
MXN,.>+=*,[XML.=K=*$YXML>=K=)\[XN,.>+=)\[XN,.>+=*$[XN,.=[7?K4
MGO%IF7_Q8.O:0?1KA>HJFD>Y*U-)M46SMLP#!_5[!!-58$DQ$F)40$3*#=BU
M2E*'R(P.P[_#W7RUX;MM >9?\_Y'8_<5_M*GU@V@/<U#TAZI[%JPDX*4D863
M;OJ9*C(Q;US'OD"K5)%I+[-TT50.7$4XD-<;@F&W277OCC/\XVZ2J\\<)_G*
MW257GCA/\XVZ2*]\<*@YQMTD5YXX5!SC;I*KSQPG^<;=)%>>.%0<XVZ2J\\<
M)_G&W257WC?/<X6Z2:\\<:@YQMTDU[XX5!SC;I+KWQQG^<+=)5=^.,_SC;I*
MKWQPG^<+=)5>^-T_SC;I)KWQOG^<;*"3,>NR"LIM%1)5L[W16XI=J?\ K'=U
M0MTE5YXX3_.-NDNO/'">YPMTE5YXX3_.-NDJO?&^?YPMTDU]XX5!SC;I+KWQ
MPGN<;=)5>>.$_P XVZ2J\\<)[G&W257OCA/\XVZ2*\\<*@YQMTDUYXWU!SE;
MI)KWQPJ#G"W257OC?4'.5NDJO?&ZH.<K=)=>W?G=/C_XE;I*KWK>_&>W>^5K
M_P!95>^-U0<Y6Z2J\OZWA?4'.5C;/,>NR;14ZJ@$JZ>#:*'NQJ#_ %ANZ+=)
M=>7;_P#:ZH.<K=)5>^-T_P"@'*5NDFO?&^H.<K=)->>.%0<XVZ2:\[7AA4 ;
MG;D0MTE5[VO"ZH.<K=)5?>.$_P X6Z2J\\<*@N_*-NDJO0OW/[75!SE;I*KS
M<O\ ?=4'.5NDNO?&ZH.<K=)=>>-U0<Y6Z3*_\;Y[G"W257OC?4'.5KOUDU[X
MX3_.-NDFO?&^H.<;=)=?>-\_SG;I*K[QPG^<+"">8]=$ ZAUC 2KJ@+>JL;&
MH?3(CPAW;=)5>>.$_P Y6Z2J\\<)_G"W257GCA/\Y6Z2:^\<*@YRMTDU[XWU
M#SE;I)KSQOG^<;=)->^.%0<XVZ2J]\;Z@YRMTDUWXXS_ #C;I*KWQOJ#G*W2
M57WC?/<XVZ2J]\<)_G"W237OC?4'.-NDJO/'&H.<K=)->>-]0<XVZ2J\\<)_
MG&W237OCA4'.-NDS,#S:NJ#G"VS1S'KM,@"8UQ*NG2W&.<3G_P"L.N:W257G
MCA/\Y6Z2Z]\<)[G&W297OCA/<Y6Z2:[\<9_G&W257GCA/\Y6Z2J\\<)_G&W2
M37GCA4'.-NDJO/'"?YQMTE5YXX3_ #A;I)KWQPJ#G&W217GC?4'.-NDJO?&^
M?YPMTEU[XXS_ #C;I*KSQPG_ )TC;3F;7H]NKJAYQMTF5Z%X[@U?/]K_ +1M
MTF5[XW5!H[7]86Z2J_\ &^?YRL5)',BO$TR7X4TZNGBIE 38MP9 ;=)=?>-\
M_P"9_P!96Z3*^\;IWG&W277WC?/<XVZ3*_\ &Z>YQMTEU]?^=T]SC;I*KWS*
MOG_GR5FE0/*DGJPACW-IJGJ@G)&2;/X\YNZ\44?J.N+."[J2Y"[O" Q1,6T=
M6%'R /HQZ4-JF-Q'D:\*4HN(V3;WFV2Z6*XY-(;@E$Q#%,;]Q7^TJ?6#: ]S
M4/2'JJMOY_2?Z4174_[]MVV[\GM6Z]^@H8K[O-&V9F:LC!G<5U3DZ=E#S@2D
MPD#1MQ^";@3DM!\BU4U7RNNJW,.MV+9YYC3D(=W6-&.3$IV7"6F&H1Y 81:W
M^CF;Y!NMK.C_ &=$^[:DLU\^H.>KN6S)."U(T1!S#B%1;QAT >(O7;YHZCU1
M4%$2**7JW%!8A-F8V(ULLXSR>:F5C7-<N%BU70\RL]D7]",6S)21=OR.7("*
MP)$;*D.F9VJ.T$F!3"?1)9.3D%6+-Q"BZAI?.1S4S\4$9UDB<'!>2T7:C<1V
MB1D,18TZ>+UN'6M.QE.SJ%2P+"3<-H:H6Z:B2<O&D/M&;P43)IF QDU  Y;M
M4P#:*>1>6%0/6<U'DE(MVBK% S=QQB(J%<BZ/)[-/$5<HD25,50U^J4;AM-N
MF>6%6+(T\Y<,I;[S1360=-"8W"39!PX24<W%N->U*J X@PB-CP-%4S+5'+II
MBJLSCT0O:)D,*1U7KEPJBDB7%J8E#%UM7A6BHBLJ-FJ?D)U5-"(2?$;J(R2[
MA5-)-%J^;.G;<Q@,H4#$VMY;];"%GS;]5%3;2/225<D 8DP 59(ZQ.+'+)B5
MP?"32FW,L8-PP8A+9Q3]&TK,5!--"J"]8,VVS.QV"FQ/R@=XJT3;W&U.[G)I
MU>%: H65H"=CJHJ8RG(L8L$>/*:;-([QZ9D_XZ#,XI(HG.H7C &"ZV4[%=M,
M530,]+4O$U;4;I1G%M!FIN;6:*0[1G'ON-HD% I=8ICZQA-M"\$M;FRARPJ!
M3+6GVT,JBNT5>212*J4Y'2$H+,9J1<O7F%9<^/8 YPZ2AP<-G3&@Z4E:E<,4
MDU'G)Y$4T613AW/C;YZNU;IB/\F0REYL(X0LEEN>C9A"N5R'5;4ZYXJU<NDB
M(*KBX:N'2Z+91.Y,V%0BPE-A'":U/-YB@I]@YJR0=Q=-LSM2K.YM\P,!'B3)
MB@JJH.'A8L E,76*8Q=:R4Q75 S=.12RVP+(.@9NF1%CCJ).%XQT_!$QQOPE
M5PXO6XK,3L,K:A<)2D8258."*0X-G+!39B0X.C20)%,8%BF*B<Y5,(\$,(VJ
MYM'T1-+.J$**E8,S\2:O8),$EG &<,GCIHJ8!2;F,38E5Q 75Q7EOE,PF5/N
MUJ)AWI(Z3J';,D&;9\8S0I6P).'*3@X_?J7V)$_#"P7?-?\ (W_W/=^1N]1;
MH^?\KZ78^3O^>/J_+]O18DS#J'?P+XZ*=2TVLI<RF6A1X:8"!MBZ2Q&,BX -
M'!/>D)BC&UC1TB1_%/B 11/05Y&O4R$XS&2:%]Z:Z0GUB[X"!BXB"41_<%OM
M2GU@V@/<U#TAZJK7^?TK^E$1\IVNJ0_>MFC6M+*-T)Z%JY==@L[;%>H%.X>T
MZV,!VJEY3=S<FWK>4C*UVZCW3Z(;(1S \?&)1I ;*H,G9]H1 NDV(;\5LBW^
M5Z;6J*KR\:DIRJ*<:R,?'/& (1K6+,<S22<(@(WQZ*N(%PQ)JXRE'2!,A9BH
M*LDFF953<:89@0TE)PDI3U+QLS"NV2CU T;%,E4?OUP@D19=TY()06$,0%Q6
MJJ2J)!Y'Y*S<Q4%5&KF(J2FR.!C) JT@R2:<=0D+E-NX*FH"K$0 A##CPX3F
MJN'H.5>S5(1DHNQ@9B26;JNY!HU J9W2CAFTCT#E.KM=F=-$@&+A&[3>/D+-
M8F:EXMK(KTYQMM'/G31%Z)%J":%*\204(50 (^5+<8#:%1^FLU@.6I4L(7+.
M[D<'RX10XHA9]M3,1/LA':WFQ8<5X6\M:AJ"<I-,UI6LJH/3[%B\",FWD4DZ
M=((%CW"BB%Q2J\:3 2F+A,J&(0Q%MDW0^:RZJ68[S-^"D:=@YE[RG4$? H5+
MC4$RA5')DDRHJ<$R@W%5*EH-W,N7],DGIDE.J4*]%>!3D'1(E8RM.54\457C
MDU03->JP1/B,6_$B3K6\M>@\O%R-\U9#,&==1L='O"QDZ^A<;<B)6"QU6^B\
M'I-42W'6PF$-H2_*.D<S7JS;- :Y++Q47(2 OJDBZ<;N9/'M7*2JJB1"HKID
MP[4>&1+A$$A/)\S 9,EG.7Q'% 1*LPD\:F8\LNZB<N6B0-.,[01,BL7"KLL-
MQN%:HH(\Q*'ADZ 3(G$&?+FC$4R4M /BBFR%44@';NU%=!=U0P[]L\:5H*+D
M9:K6^=4^>?@*7DEHFHU83P@#B8MC,YB$5,CLD +@*KK 4Y<)MRWDRP=?M:6:
MU!"TQ4>R0B'<@_JAK$JPJ:;%"M7CZ2DP.OC:J&()%#AB%4PF&^U1PDSF74\(
MG3DWF$A3AF$E%E/%-HTW)",734;4<3.L$U%D+@6P- .<A5!QX@MY3O+D!4T4
M60K%U,L?#%X+Z8E2-Y2' :@V9)*2(D"JB&-,4@;IFNQ%( 8;>2B;++EI6(C6
M4$XFPB)+B)8Q\+6GU&LO)E352,""2"2X;4^(I<0DX9R@9NU8/V3B"JFF(7+6
MNE2@1=HI+O>-\334,FY1 #ME5FB*BA@' 510@@.BZ@?)RHY8J4:1Y-U[5:!E
M!7<*KR,HNI3[<[I/BI#)E%9R?9"WO#8(#BT:WS;NG_"/FZ+'EZ5=I*Q[^Y*<
M@I)%9Y$2:":EZ:YVB+R/,#E+&(I*E63NO,4PB4PE&.J^DI).08/4P*J4I=B[
MCWA4R"YCI)KC.*2Z1S:Y1$0W#%$Q#%,/RZWVI3ZP;0'N<A\_JJM?Y_2OZ41'
M5NYI[=^_V;+1"$O+HP[HV-Q%(2KU",<J7E/M'$<FY! YNY!I,0>"%G4:UEY1
MI&O_ &]'M))XA'O]'_/622R22O\ Z0I[&<0LO*P[@Y1(=>*DG<:L=.Z[9J+,
MUT3"';LL[D'3M^[7$#KO'[A9Z[<&NX2SMP=50W_"-8T/X1U#R.*8HC$<N281
M(I!?W'DX7((X/J<%K[MV[<\^S '<W-.^2<')0.Y=^Y") N "\E<8<*\7^PIC
MW+#]C+UK<M>$E0C- GL>6@FY7E<J8$P;'E,'(KX,(\'';E1K)2+:3VBJO*C:
M0=MY':KC<LKQQ-8BF)3&;&;%B&^Q)"2EY23?$N%)](R+QZ_3PCC3PNW:ZBA<
M C>36L2:4J*?/-(DV:,X>;E#2Z*>%1/9(R1G(K%)A4,3"4X:IA^FL:70EI5O
M+&.JL:8;R+U&3456*&W.>0(OMA$_KS8]:W&I:1D)9T8NS%U)OG4@Z,31W/;N
ME53W7!]-9HS&I*A,R8'35CF9YN5%HP41]KJ,F?&<")D_Y,R1"8?6V--EJ*?"
M;.38'F2SDF$NHCA(38J2?&=N)<)2EPX]PH65D(V:EXY^OBXP_CY208OEL9Q,
M?C#MHX24/C/KGQ'UC6&:+-2Y9HP@89L)1\67,<"X -RIMP6OPZG"X-N522#X
MDL+@[P90KQP62!ZI><[SCVU!7:WG'NF/%9Z@^JBI7:4BF5%^D\J"7<I2"10P
M)IODG+U4%0+ZPJF.V7+*%CI>@UJ!II:FEWD15K]16=0.G$DVRPLV,(9$O]6X
MMD)EN'PM%J=JJ7B1J9K!SK2:=0RK[B7+"K%P+H$%I!1G(W 8Y2BH(IGOT]>U
M05_(L^333)VI&L7QP'Q8QBQ:D:-&170-FF/"">DVR)B$W!MV ^3N_P"#K[:-
MRT62AV3VI$ZD?-HZ4HA':&3J%,Q\(; I04V+E+6,BZP:FG'>D)BV17404:G5
M124.V4.FHH@=1,IS(G.B=4@B41$HB4Q@ZPW?+K_:5/K!M >YR'S^JJU_G]*_
MI1$?*C\WG]4,8&FXMW,S,FKLF4<Q2!154W#4/O 1,I0QJJG$I"% 3',4H":S
M6=EXUJI!O7JL:C-P<]3M5P@R:*8JJQBTO2TM.-D7($*)@;JK$.(%$Q2W!?;0
M(#=NW#N>C8=(:-W6W+(P--,BR4HX1=N2M^.L6*2;:.:K.Y%TX?2+EFW22020
M,HJHHJ0H  WC9PR<*-3+-5U&QS,Y!B_:'524N-Q62CG3QLY)]*J@L<AO6B-M
M-P=;S-S0 WVI-]'09W32N)UU3E*JDD(LAI::8'(F[9$24?IG2PF.7NC@$4S7
MZIK.V+HH)NV+A=HX1Q%.*#ANJHBX1.HGM2ZITQ+JVD:@AV49R'$OVT7(RLS5
M5)4LQ;OWB:R[1GQBIIN&*910B!A*5/%N#8L35$8:,>JL6DDW#C+1ZT>QLBD*
M[.1C92.7=MG3=4 [FNW543'"8N+$!BVOO"X-^_S+5%4<6PXW"TFG'K5$]*[8
MH@P2E'!V;$^Q=.4U%L2B8E'8$6N]=AMI$NB_$&^41#<&QX^9CWT0_320749R
M355DY22<I$7:J*(N$TC%!4ARF3&[6*(&"V+$40WA\RQVT-'O)-T1NY>*MXQJ
MJ\7*T9)&</71TFR:P@1%,HJJFW"@ F-<6SUC2K!%^O'Q3B<?G<RL+#,V,2R!
M/CC]W(SDA'-R)DQEQ&,IOVBWTZQ;IQTT1T>*EXV8@JC@WYF2@)O$6TU3<G*-
M3*IF -HEM=H7$%X!?95&)CGDJLW:.'[A.-:KOCHL&21EGSU8B*:HE11(03*J
MCJE#6-:$K!W'BC3M1NI%C#27&F!RO',.=-*12XJDY563V8J%#$HD0HWZIC6$
M0,31V>"(7EN&S>/CFRS]^\62;-6;),7;QVX<*8$&S5LWVISG..@A"EO&RS1V
M@NT=-5CMW+9RD9%PW<HF$BS==$]QB*$,0Q#E-<("7_ WS=G]SNW>S9A P4>[
ME9>4<ILV#!DF)W+EPL;"4I T7 &Z<^X4H"8V@+%GZA(VE,RY1L!'[\I04;4^
MV5 PJ0T*H!M_1QAQPCF#"%Q NMHWOEU_M*GU@V@/<U#TAZJK7^?TK^E$1^X?
M/^8>I5O!%M3DK*N:/J]FK3-4JO2,JQBW,2J$G2S 6/=3/G:8B5L4IDA,)<&T
M"^U%3<W 5CE!3KC->CZ?J&@ZMJF3=4G6J:K98)FHF#.8;QCM#BEX('5447*D
MBH)<>(ULS#YH4=$4X:F<R:-89<*)TC%TV8KQ[6!6+VEH<T?&Q_*+ T<CM#G5
MXR4"ID5VA<>FN*?C:;H"+@\K4Z^?Q,8UH1H_.@UBVPD6?-J<C^+*SLF"CKC+
M9FY5V&(-;9I$$MLO9&,;"VE:H\GC,N3J.2DZ!IJE96;>0+2KRQ+N5I9J$TV9
MKIIMDR+$;J]U* ;<#8L-LFI!G$/YY:LZ@JI7-%K#95T?536?>)32[9>GZAJ6
M:J: 3IQN6+/M$C($03)M1<XM3"7R9H:G("G @*UK6K8N:Y3IRF)V2J"FCYB*
MQ$=%RDHX;R&T!-J?"15LK?>.(JABX;>3YR5%M6BR?E-YF0O&4FR0O%(R'FHM
M&.:.7N#:'(B7$0A5#&NTVSR?YATQ'P T[7L,VRQ?)TTP@%A?.IN1:S$'$O6[
M%F>19\0(5<ZBBKO6(57::<1LQ%YFFVU4-1S7H=,K!U)R\4F1<\!-@5SQF$7:
M+8BB/!Q7:;%GS).C"U\F:B)S**%;4I&UQ)4M'NI99G-M8FGY%]#$F'$>4[HR
M:SHQCX5MJ<%#$TS$PG0M3$J3]55&N)NJ8RA,MW-61,N]J1=&,J/]2*E32J9$
MI-N1!&3!,S=<A4RJ84RN,=O*J26BZ0,]BXS*U[&NH"&Y/:Q2LW),U71VS&25
M=J13E4%KW[,JF%(^(G!"U:R4=3#&B_ 9/*QZQ@*GHVFQ:P3YV5J7;97YE4\[
M<H5"DY Y%%F\FW7%1,5%#&Q!AM-RCIE&.&=-9/1U1Q;I]0[:HE>*GI*!27DZ
M4IAHE%ISK]-P_O;)N5#MT[C&,8$TL-I.HC4Y'.IP_DH^%BCVHJ&@X-PXJ="K
M%HMI/R5(-5I1DT?IHM4\9$S'TD[H&D2VRDJABUC4:GKK(O.49UQ'4S HJ5#(
MTR%1(0*O)3>)V.W*4@%/L$B;8H 54JA=6V="U2-I$Q!R;KE6;:,B,H:1Q*+1
M8/&Z.-@Z1:J8MPIVAP+N[*U,T%1E-)L*9R^8U_F6Z\-Q)F)-R,VI#)-E9".@
M(F.IE!^Z;(HI<GQ142$4.F*BZIBWVHQY#-EPGJN\G7,]Y+.GV7E.4O/U#)0A
MY]*%,]I!AR^BBY23*!3I('$RY0 %RFX%O)E-7,5'D3J'-#-)K5"SB-:,%99R
MT+'GBXN3.GR6;9<:,5(B!U$BEQBD7!BMEB:K:6D'LRMFW-1S-U5>5M%Y;H+P
M*=-RCB7I<U*Q523"TBV:NBH'0=+-132Q"GML5UJ K%XSI]K.0?E1P='1TFQI
MFG(WBE+34,==Y!F%O'))JHE,W3V*JQ3K)W8BJ%,(C:O%)Q%9!_X3S"92*Q:$
M0<&9'ZY6"G%&[./*.-*[NN#$IPC&&_%U+\UW578^;1;YNS:/@8"/=2TS*.DV
M4<P:$.JNZ=*B. A"AVK[QT%+K&T63J"?3;2N9LJUND) .[-Z>;K%':0T*>\;
M]VYPXNO4'07"GH_<5OM2GU@V@/<Y#Y_55:_S^E?THB.K4ET5%$54CD42614.
MDN@J37*HB=/6*8/IBV(I*R<A*'(0Y$S2+]U(G(D8;E$RG>'5.!?J;[-B/I64
M>D8@(,BO9!VY*RTE !9%766V/V,.#@W L$@D_?)R&T46Y02=N"R&T.4Q#K"]
M(J"F(04X0'W[;9>5E5U\+@NW6D7JRP$=7BZ)MU7 FN4Q#M+QUL6M9RT924BS
M:O"X'35H_>-6[PF#9X7:2"J)50PF,&N4^J-FMSQV7B0XF0%=+%XF;%C$S7NG
M<=;6U,&FR1@D'H<7<*N4OOMUB0=*WG6=-[E=10_KU0UC?36;(/9&2>(-"X63
M=Z_>.4&A< )X6J+A90I PD#@7;ECMBKK V54(LJW!94K=10@8"+'0VF$QB@<
M<)L._9LLC)2*2S @),G"+YZFLQ2[IW-DN18#(E[H.JC@X1K'E$IB61DU@4!6
M2;R;Y*26(<" <JKXCG:'X!>$?UI>M9Q>\=CQTPJ/0,Z6/QXVTQ =]W7NPXM;
MNN/6L@P=2DFZ8M<(-&+A^[<L6H 44B<6:+*JIIX2ZNJ3<LT<%F9@J\>F",>N
M$J_!6/1%/9BDS6XQB13N.;42PA911>5DUSJI*I+&7D':YE45E=LNFH=10;P.
M?7.0UY1-K<*S51O(R""C+'Q!1!\X358XQO5%DH4X"CBQB!]E@X5G"O''8*N@
M4(Z6!POM7A%]*Y7)P.!E /Z_&)[[).F;ART=(F$Z#QFNLV<(GPB03H.$5$S!
MH./!-OV(^&9F..I'5,B]&5?\;1.N%[@R#GC J 8WK\)@ONL4BSMTX(5518A%
MW"JH$77/B77 IE+@4,/#.&L-D'CN9F73QH0"-GKF5?K.VI=\C5RHY5,F'^*:
MP(E<N 1VY76P*X6*AQA/2F[V>/#M"_Y2[%V;"X?/'3]R8I2'<O'*KMP8B913
M*4ZSA50YL(=<1_=?4_P''0,#'.I68EG1&C"/:);1PY<*\ $RZ+@^G/N%* F-
MJE&Q:AJ!-K+9ERC;"_D"@"B%.M5KQ-#0JEXZ!O\ OA;=..@!P%+?^XK_ &E3
MZP;0'N<A\_JD+MVSNE*RB4YF ?*M57<<LN[;$759.4GC4QEF+IFH&$Z)3!<8
M-S3OVZ*XWOW5?/UNBN-[]U7S];HKC>_=5\_6Z*XWOW5?/UNBN-[]U7S];HKC
M>_55<_6Z*XSOU57/UNBN,[]55S];HLC>_=5\_P!NBN-[]U5S];HLC>_=5\_6
MZ*XWOW5?/UNBN-[]55S];HLC._55\_6Z*XWOW5?/UNBR-[]U7S]:H4U\L(PQ
M6<VNU;ARS508$2-FA\/^G_IE!\^W17&]^ZKY^MT5QO?JJN?K=%<;W[JOGZW1
M7&]^ZKY^MT5QO?NJ^?K=%<9WZJKGZW19&]^ZK\S_ *^MT61O?NJ^?[=%D;W[
MJOGZW19&=^JK]/E^W17&]^ZKY^MT5QO?NJ^?K=%D=W[JOGZW19&]^ZKY_MT5
MQO?NJ^?K=%D9WZJOGZW17&=^JJY^MT5QO?NJ^?K3(N,L(XW%:@DVB-\S5(7(
M(*)@0NB=MT5QO?NJ^?K=%<;W[JOGZW17&]^ZKY^MT5QO?JJ^?[=%<9W[JKGZ
MW17&]^ZKY^MT61O?NJ^?[=%D;W[JOGZW19&]OENJN?K=%<;W[JOGZW17&]^Z
MKY^MT5QG?JJN?K=%D;W[JOS/^O[=%<;W[JOGZW17&]^ZKY^MT61G?JJN?K=%
M<;W[JOGZW17&]^ZKY^L].YRQC5%$IV=:E'EBJBX4&LFZ;HD_TYO%(%NBN-[]
MU7S];HKC>_=5\_6Z*XWOW5?/UNBN-[]U7S];HKC._=5<_6Z*XWOW5?/UNBN-
M[]U5S];HKC>_=5\_6Z*XWOW5?/UNBN-[]U7S];HLC._55\_VZ*XWOW5?/UNB
MN-[]U7S];HKC._55<_6Z*XWOW5?/UNBN-[]U7S];HLC._=5\_P!NBN-[]U7S
M]8CEUEA&J*\;DTA-RQ5(:B$BZ0)P9SZ5.W17&]^ZKY^MT5QO?NJ^?K=%D;W[
MJOGZW17&]^ZKY^MT61O?NJ^?[=%<;W[JOGZW17&]^ZKY^MT5QO?NJ^?K=%D;
MW[JOGZW17&]^ZKY^MT5QO?NJ^?K=%<;W[JOGZW17&]^ZKY^MT61O?NJ^?[=%
M<;W[JOGZW17&]^ZKY^MT5QO?NJ^?K=%<;W[JOGZS!T[RNC5%E>,[17EJJ"B;
M Z53)H).!ZTH!;HLC=X?]-56'_CUNBN,[]55S];HKC>_=5\_6Z*XSOU57/MN
MBN-[]U7S]:_]5L;N?]MU6'7_ /?WSK'GZ'H2,@Y@[91ER@FO)OG*+=82[8C=
M23?/MGCPE YDP*)@"X1N_<UOM2GU@V@/<U#TAZIT;MJ5EJ+J"1IR3=Y@,8UR
M[C5MBLLP4I^HW1VQCZVKM&J9O^ %NE>K^^(^I:[]:U77=;E ?4MTK5?WP'U+
M=*]7]\1]2W2O5_? ?4MTK5?WQ'U+=*U7=KE ?4MTKU?WQ'U+=*]7]\1]2W2O
M6'?$?4MTKU?WQ'U+=*]7]\1]C;I5J[OB:W2Q5_?$?8VZ5JO[XCZENE>K^^!O
M4LJ),U*M**ZFU/\ U@;64PE)?I["=NE:K^UR@/J6Z5ZO[XC[&W2O5_?$?4MI
MS6J_OB/J6Z5*M[X#;I6J^[W0'U+=*U7=\!]C;I7J_OB/J6TYKU?=V9$?4MTK
M5=WP'V-NE:K^^(^I;I6J_OB;U MTJU=WP'U+=*U7=\/H6Z5JN[X?0MTJU=WP
M_P"+;I7J_OB/L;=*]7W>Z W>E939YJU:7:JJKG_K#A*J\(;QO]"W2M5_?#_B
MVZ5JO[X?\6W2O5_?$?4MTJU=WP^A;I6J_OB/J6#_ 'K5=WP_XMNE>KP_[Q'U
M+=*U7=\1]2W2O5_?$?8VZ5ZO[XCZENE:KNUR@/8['8M=^M:KN^'_ !;=*M7=
M\!MTK5?I_P#>(^QMTKU??[HCZENE>K^^(^QMTKUAWQ'V-NE>L.^(^I8Q4LU*
ML*4RBRIOO\;L:ISJK&T]<QQ&W2O5W?#_ (MNE>K^^(^QMTKU?WQ'V-NE>K^U
MRB/L;=*U7=\36Z5ZP[XCZENE:K[_ '0W_.MTKUAWQ'U+=*U7=\/^+;I6J_OB
M/J6T9K5?WQ'S=ZW2O5_? ?4MTK5?WP]#<MTK5=WQ-ZENE>L.^(^QMTJU=WP'
M1_%"W2M5W?#_ (MNE:K[^OR@-_UM@32S3JXA .<P%Y0'=5,90_"^J4MTKU?W
MQ'U+7_K6J_OA]"W2I5W?$UNE>K^^(^I;I5J[OB/9MTKU?WQ'U+=*]7]\3>QM
MTKU?WQ-[&W2O5_? ?4MTKU?WQ'U+=*M7=\#>I;I7J_OB/J6Z5:N[XFMTK5=W
MP'V-NE:K^^(^I;1FO5]WNB/J6Z5:N[XF]2W2M5]W6Y1^A8K=/-.K2IIW@4.4
M#"4,9CJ>N#KGLURWSCE]J]=J@E3%:/SD3,NNLI>6'G50"[$8QKFKG?\ L:FD
M"F-\IIW.M]&VC]S7^TJ?6#: ]S4/2'JJC?[S8[]%ZNT?NX6B8LYSH$DI6.CC
M+D#$=$CYZ@V.L0NF_#M<5HFAF%1/:B;R,/&RIY%Y'MF*R8R#Q=F=$J#=14HX
M-ACX7KK4!E=1$P_K*7KV!:RS95ZR;QG$UW+YZV5(L+=5T!4$B,A5.J-^$H#U
MK#E83RA6@YRILE3*4XE2JYH!.31:B]6C3RX+#K GK')M-H%PZN+5MF&_S&J9
MEEW0F5DBZB:KJU=N>1!Q(,CW&0@V_<]L&$R9L?\ RI"E*90<)5<X<I,S4\R:
M+C'Y8R>!Y"JP4Q&N@7;MSK$;G N(I!=)XP,0NJJ!BX@W=R[KC]$+7*)J)WW8
M0.0Z8F"_3I-=;:%24.GN&5*D<R6Z.G:78>SNV$Q"*&*GH.<J9S%)UL8@'9L4
MAD5@4/=@**:F)3_$+YMJ2R]?2#F$2J2168JR+=H5RY9[-DZ>XTVSA1$H^U<&
ML;?M6%$M7;J594M-+Q"<JX:\6%V5(B:FU<%3VB93=TX..S6K$<P'BV9:LP#1
MQEWR"[*V2C>.+(<>)/[#8B;8E(MLL>+7PW6.78+WD 1.78*ZMX7=T[F-V[OV
MN3(*AATW)E$X]G@!:'I>+1Q2TW),8ABBZ$Z*8/I)RBU:\;4V2HD3Q+ *A\.J
M6S?*[-NLTJ9C46;1S-U7!Q3Z:;,%7T1RB@V:MA0VCCNATVYS%2]=?AM.1-+R
MZ]203.4>M8:<,P69N9>/05,FV?J1ZB22B(J &+ 8@76!(Q%"J#?<D*9RFT"-
MXW#IL>]!8-E]DO34[E?_ )30-UM6\;QN*%V[HZUMELE=MO(X#;7K#JC<:PI@
M@H90MW<P3.94EX" #@PVRMC<N*]6JVO*[<,8Z>II]"OX9C2\H](R310&6,Q
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M\XAO[OSD?E_.4S#]?SE$_G\YY;R+CZOYSM>?G.P^??/3\O7#4GW_ #G1??\
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M>2-XO/\ V.<P'\X"9B0^SU?3IANH.C1?KCMUY)P"2E*Q(03+W=^G.&O(-2D
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M\\W?.\\W?.]\G?.\\W?.*?F[YW63N,%V_E[Y5^7Y9,4LFQ+<7K>Q@!*D[FW
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MH!89ZK>)$;$*442C4=?1QX*4[F943EV6UTU.P(=23$;1@O=X,&@G-I>).IX
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MMFYW*\ISUR@+D=4G4)._7*X0<7[1%7M6"8G <QFX0N_?JX3W+/*:G3T]_7'
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M.>I]?SGJ_7\YVGX<>I]?SG:?+USU/K^<[;\OYSU?K^<]3Z_G.T_7\YZ^%/\
M,WB<F0=Q]GP8[#R=\%W#W7[,\K\N=E\X>4X>4X3_ -LDQ]?^#ER ^#PV9]/;
M.ZW[^D/?_B_0X57?AS@QX3SX3D^'$9+DN3X3DN3DN3X2;R<$.,ATR?"&N^01
M0&ZZ]LI:JQ).R:A,QVQ_+V&3K"2^GQO&!S0[FA ]B;33JL.Z$@QDT0#<H$M]
MLH8)WPW%'=L-9 +3)B2*LE)\5TPR$^TL+,'PGYP*)>E&9[=WK@& DR@226CZ
MV'3!^R3,4/&^1A%PJ9[NH^FO3(-S2=+T$SUK^<5 NL8V,D3[<;B\CL$*E(3
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MCQX\>+'CQXH>/#+QX\4"GCPRL>/'CPRL98APB]SY/YY0TNKS[^;U_P"'_]H
M" $# P$_$/W7G^/^-$?3]GK]GV_9M?\ >-?LS1^S=_\ %-G_ #'3]F:_9FC]
MF[_XILQV_P#>-?L_X'_8-G_3(?//ASF__$U^S-'[-T?\4V?O.V%5Z8TUCV\W
M@3A'&$9S7MQ_6=,C-Y>L.Q_YZ<[_ $\)X-??/7*U^LUX1,)?GMD?QG,9$O\
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MAWR&=OIB64U34=DJ1BV&5I!K$PQPFE)$)$PZ(M)<*?WTH3!I&8) D@E@M)F
M2!*!J 2;3B92+UT6)6WF88(@H?<K(@$@,QLD#P*",U67G,'Z-$&)>=/T&1.L
MX\& _P#%1Y_.1T"?7>(@@DK 3*!-5C<- %?LC9_PQ4>("W'Y(RD_6?K^<LA&
MGH>F\&=+9:X\]9P5@0G<3V],@SHQH?I.7#4U6_?(F)7PO'?!>#O$/HAK_<V0
M^!0/%_&"61,TWQ>7$!>B?:_K&*%P>:5S?MTR/$LZ@^YC&O.)V#YYQE#4LK7?
M%2ILC<]NQA4^>C1*5WP]I) =NOG^<@)4<)P-UVP)"3"J-Q,>K L8 P)2;3#
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M:UX/4QG_ ,0:U-?7'Z_\YO3QH%(I=!LE"Z%#(GA!.6>30'0F"?V9L_>"O3]
M >%Q>'T\'>3&\G-N3F_!'G'49>O!KMXIQXS?AZ9Z\9!^ZYHB8WVK_$8;O4I$
MJ]IG(1)?(-SY><(M-7U"]17VYP*!["IR_P"/QALGPT<1TR9!E*G\#ON_C"3K
M.E@1/?C_ #%U._II#):-]WF<"\CW1W6< KC,)]!\_EQXQXFH]^V?QA.^V:&3
M-&G0WBSW#T15=O\ <;C8EMU()^?)D!(@,WU[8F$[IZE^K?3#%\B>/3(V</\
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M&.S8ZO $(>RR%_1R.[Y_K)[L'%]3GS.[GF+GG+GN^?ZR>['E+B7]G)1-_/\
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MTFL T+8P38$UD6Z9SU*4"=&71,T9, HJ*1JDNB@F=QN#DXI6K*2%MM<H8>X
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M4DABH+6+);25#) Q1%V6 04QO2C"1*'3U4%HT-"XBH=Q*$TF0X+2 ('A"L&
M!%VF PPL@U1D=3E*8:Z+52"!DB[!0X"DNLJTHQ@20S/*LG<, 4-IHP@6J4L
M08#4 D0Y!"2L5R8< ."HA04Q@$JA I)BOI4S&%J$7&T(*L"[ BB74-)06429
M.!@ MY(2C@Z-! N-$-(@4@>9:J)X7O@2?/WCW^WZ$OQ(QG+FL]/T1SFKZ_\
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M!-J9%;A*S$P<1X)31]D'_%-G[LDZ3B05^@O_ )N5*E2I$J5*E2IO$R$#[?\
M#Q4J8M^&[8]0*$+H)F:[XDLZF0,?J2I4J5*F>L3;-F:;4^!AR$U_K2I4J5*E
M3M,29=\#H<3#$]I.B^(E2M;B627)2:_2E29$B(F#$NUQ,MGBE2I!UB34J[?B
M,R"E=6"Q:4I'!Z<"X*P?^_%*ERI4J5*E2I4J5*EA:).6QLF06EC3#A'@=_\
M?)B\XZW<?)D]&2Z'TSLOG^\[#Y_O.Q]LET/IG8^V>AY>N*\9Z7U_&%:!:#2[
M8@.G3[9#(3HFL/DIL&1'D2:B<32_O_>>=X^4X$09F/?VPT*:A$1GJB1[7_,<
MS?<SRW&,/HX^,[ ?7^\F?^8IT]V/MBY]FS 4U>S[X.]<00?C%@"45(UZ!LAR
MLL\^V=A\_P!XG'-D??\ WE/T(?G!Z?E_>,8//SE_ X,B&K4HWRI]<M9]V'&?
M(_.+<Q[YI@-<7Z0&*K<E0&"C;M_1D=N#ZIZ;E)?3!U]V=A\,00@:( NZ KZZ
MR>!W"0J2A/TO#H'R?G"#"% #5% 7,=/7%?0,02/4AN^/>L)0-=7$ZO0K^#'Z
MM"'U@M(DNY^F;T(-Q*#J6#K=;YQ*0'KDED&>C%=&<P>?C SS/V,[*N_]Y+TP
MGM]7XR\A\C^<EZF3V\GKD=!\XDFGNGQ&0M#4@B10CM$&*N=K@ WN5PR$(2QR
MA\'?_%/W?-\P9'&,3XQSB'&=\CP F]9(9(AGOK<TW>: A$Y6,LL-H]4Z8P-7
M"CFD GT999WE&7B8B2*+I-(F2R"*42,$) H*H2"1$,WU&;5B8<@)#P#J9%2P
M5*D!UD*P&C4R9$$B%W ! PLFG#)MJYI*!!"EA*YYR79E5*E"044LFRYEF%0T
M%92+ 3HG(' 4U2=#N&YB8B&,.75!SHD3()A>JL+DB,CU*A;<AN5)# \\$*(I
M@)(8"(CH,D<9(01CA1&."78YU6$O5D. (4T@3S$Z5!@2TI!$;.4JC%^$)1"=
M(@D*S *(AQD,(9)I8+3E3S"S=6N<03,+1!8ZJC*0C5'5T(K0;AZ8A*&&Q#)%
M<@@W; &20= -3M:$QE-;#<<9LQ..0)'.SH3>4UKM, V I'?H.L(3&6N$#1@'
M(TT')&44@L-E6".T3"TN5P^%"I%1$@2E#7#&&@&P"[0GH$5+B^/LA9)TL!2)
MI.H,G*54J"L$3E&*9M4N3HM6)@TE&%NF %>6IA YF7DWSK>4]2\S40M4@S%@
ML(>8H28L,"-! [(#!!)=@&K1F\Q,G1B:B0R&DNR"*=PTX/0T;0HR2^@S4P7D
M#"6^@P9VBLG+,RX<K-PQ*$)4'#1FV7*>84-B%E;=,QL;<'H@96K  4J1#(Q2
MY)=QA6/I,5+K'7(\W0HYAT",K"6X:'-7<Z5K >14J9:Z6-*'  )O(BJP94$:
MR2EA8*'""DP1*!">& B$%+#' SKLI@Q%(2[L$ARZPK#A)F:2126918TF!("@
M0=J>.>]99O>'C';?Z!+Q\],%NI": 2A@HDU<BD)&(=7!*<FPV0FM##>P6:]N
MGOS._P#BFS';^Z\FZ'@SKP._A7Z-N(-?'<$1J1$U0LIHR="$H<@A!FV^UB<9
M0-";$0L%AE[$TP_$P9R&$)=E@$07$T' %10)L2QT,LSD;%0R" $U*3,M#3(B
M38CHY4R94NHBP2?L3G3"0$)*R:6B-#N!.)BPD(T 8D*O0:M,D@H:D!*>JJQ<
ML2BD(ID*)*@><1PC,DM0,  N4Q#$N-KT=>0!]:$T88R\0C+)1@FA022(LW"X
MLN(F68S+!"R%N)V,\2"2>2RY#"9Q#HV,P@-E 8AAJFLD^8DN4>C@^6D<&X@1
MYHA,K"QI@AFR:E9THI$3+HT Q,X!&<Q$B]#P<N :-3(ADBY)3U061C:LL$"-
M!AP"N^07 -JS!!0(!3+SBG&"N!0;BY@X[D%T0E!7RMK$ITHID"?B)"H.6ZM1
MBT?44@ 4P0;5V:8)F6Q0(BD$0PI)9O$Z7"7@/1#)(0,,X_\ '+GB3(E"#2=S
M(9P$P,E)6* I-U(ID)XLH$)S+:4$EBN3&P30T)"*Q:806(ZQ%KVA$@@02"P1
M!D54Y3!:9Z9@>9T,5V7W$4U"@2 0CT&%= HPEX-QMTGI9M%.% )L_01=2)B"
MVR%!QTGHG*2>):EZ:G;"!4A$R2LIC6KDBNG=%%JZ$#5X=%@:\( @+GHQF$^Z
MK8(V4!((OECG=:2$(#T! G3+)1!9X:2Q(JQN7$#@X3S*A2$I-E:OG("Z80FL
MF(4DFH%#',=5. )(."($(,C@_06$('0&P%$0-X6C1/=$.@D])B)+P%6N!8&F
M95L/X89SKQF->'/A#?+KY<CHF>F.JK"PJ+   ,Q():TP^)=YNAI$2D().I/_
M !7;^Z\FZ&&;?#F(PPZ8QX]LOQGPA_0QQ?Z?7P"A\F=0KOMU)C$!0(V<'A5_
MGCODDJ"5PU,U,<_#&2GR%3MC1IX)T+&)FD&@D!(A#$IZL U)P=0=3OUR-R*C
MG$74-Y*HD;A)*\]OK@92-('\?G(=9/H4^_=%>F'?/4MR5Q[]L10HF>7MJZYR
M:@@L([CSK!,>5<G->>T9!)13>OM_F!DGU"M!QYXZ8R(@C0/Q\_WDY&G 8V'Z
M^!?Z;\#MX)>/)QC)EQ[^/IX:\+,[Y&*S*^"AWO-;Z.WMN,')J.H[D.AV622G
M_%-F.W]U7SU9OQ')C]%?HFY_1KPU73]4G3P$M;"_6<*B0N0 BT8BD!8FIP 4
M@6 -QTT"9(LS 8=BLVUV#C$/<S$X7TZK824[LFU(CJAMI)I*(,"\RL9'1IPZ
M"R Q<"00$B":U.;4\&*UB&#J(7Y-S 09&M$2]1,3RU.#%0")U1*)(N;IBM40
M*PIN4 P @YAQ,)D/3"0VUDAPK$#$H$-227 EDFF:$T(G9CUBA&R>5(-66@&3
M< 3"3,ZD J+#/J,2E!2P:R;$!(L!D89D,&A2P;TAFT<) C8QD+I$S6H R2(@
M4259<4*Z0Y$ 80ZE&)D<C8X\=M>%>_@5AW\!SC>>GGV\&\N.F$:\6.,MKPWZ
M^-YO63-F%*LV#&PS8-$EL#BP)41Q,E]W_BFS';^Z7D/]L.9-=T_/\XB_Y')=
MOD_.2[?)^<['T9/H?&1T?4_&2[?)^<]'T/QG8^C)=OD_.2[?)^<\DF2[?)^<
MGU/G/))DNWP?C)=OD_. "ON/VST_4R7;Y/SGI^IDNWR?G.Q]&=CZ,([)?4R-
MA9YE/I!DXO$"5+T1I*0R76X199$]I3LJ-D+857(@*%4&.P##H8$V,'J9$44E
MERRO(XV3CMA*!0^T%*L*-T38BB]Z %02I4(+!A[&!Q@*!SPBMPS"X</2$H6*
M0161Y2$R5R^DJ.PP]O$237SD2Q *[ SH>E=$1.#%BI4-^XF@2(Q".'#"EE&M
M03)WJ!$+2?SNQ*JD2DPCS$8.>I(B" 9Q,$H,E;+(AMXXU6#DC'$VT8"RT(:7
MH"+4@NYK36YG3=S+B-)9F98)PQ<R0$<J(,H#4RRMK&$43'JWZ&=)]?\ ,CT^
MC)=OD_.>CZ'XSL?1GDDSL?1DNWR?G).WR]\.!\O?)=OD_.0]'N9+M\GYSROZ
M9/2_/]9YH9+M\GYSL?1GDDST_4R7;X/QG8^C)=O@_&=CZ,$)"\W_ ")^,<6!
MDCLG!@L$UIN99(<$?3C-G_C.W]T'E-@2J,*[OFLN_CPNC"FI^3'^U^7BA$<F
M)7/@6G1PKH/DQ?'@TVS"_P!S$BD^$Q$)@R1=G01O3+AH8;OY,7F^;QPP_P![
M\L,B_P!3':,AKA\O5C>?7Q$P$ZB;G4AYXQ84B*G)=+;B41/*GUPZ77FV'W2C
MR./*^<']3"-G-(>D:R CGEI")I\]N *JN-A7<@1',RO5R4CT;^Z< A7]SB.;
MNU0SR]LDB'/AIKZ,(1??9CV[PJ$$PD-0?ZS@7U$39&"L;))$M1N!Q],W'[SF
MUI>H?G/'E7?BS1C5>!11?AP_TL?Y9A(6Y;0 F!F^"QMDQ_J,O\O&+R?OG^/A
MYHR^ #1LI_<80_CPX_T#[D4P?R8A,$I LLCH)M6I'C#U'@E@#BUGO-K:^"E)
M_P 4V?NQ*/1#K*;/M<YV/SQV/RQR?>QV/RQYJQP?>QWF/8_+'-+'S5CS5CS5
MCL?G^A$,=PJ469#)5B6]$_7.\S['Y?I1C&/DK'>8^2L=YX\8^>L Y/=@J ?
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MG[_^)L_=+RY8<$:J6P6P;:XSL,D6GDYA^AZ9>'%[G)WN;N\AR1R&"'49._\
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M+[_;XQO/)CU/C((G\9%>>G?-5EUT_K*YP)/1[9?&1)B>8PA^ITSSZ=\(9<2
MNS$R^S^<2>(H-M00J#(24IK-(=C7Z%0 FU HQ'900)#;!1/]?MC7[,T?LW?_
M !39^UUK/XR'C$K(Q!L.?+E'6:_TOP*OWRYC.UUG=,@G'(&_/OE'?(N//F,@
MLQ/7\8ZN1W'Y(CSO-VXE*%&YN!,L'I 00>/=KC]G?/[._H^W[/;_ (3OXFS]
MU%SD'R(A=H H5S'K<Y_J<=C\O"YV7PSVWRQV'RSVWR\?DO\ 4X 3">>L L(\
MNRRS!G,.P/0N/(>/]3BT$$BFI=D$B<M:\*^V^6.V^6>V^&3=KA)(1\,]MCVG
MRSS3P=E\,V1'Y>'R#A\,]E\,]E\,R:'PS#P^&>D/CDG$I:2"OX.2XJ7.P^&>
MR^&>R^&9R#W/Y.=E\/"YV7PSV7PSV7PSV7P\,NT^6.R^&>R^&>!3K;'8?#/9
M?#/:?+*]AOD4;N#!%W?4YSJYO9?#/8?+/^IPCP^&>R^&>T^6*-/AGMOEEXA\
ML=E\_#+MOECMOEGL?EX9::7WXZQRH@R3&B"=O0+:K6=C\L]E\L]E\/'*7:?+
MPN=E@[+X9['Y8[3Y8\AX\A^![RGCLOAX9'1?/+H,V.0+2CH78;AO.U^.>Q^?
MA<BW]?'D/P"[+X9[+P+W;?+/^A\<JADY-J2?#]&3ZYTM-:91W"+.I/@;/W?3
MSQ^(1^L%_3'AMO(J?%*]@($XG-H:0D-ZZ/'YQJ);R)'^/?WR.^92S2?1?;^<
MGZ._;S]<BS[_ *_CSK$EZODS6(]1#2-W/?W,1#-C#I7)?,^D*LO?,NO; )K<
M&)59OK,94&[M8O*/\SK<['"NCUN=81)()HWP\\5@2WI[_&.6!ITI?EUQ:F,J
M*F?J'7XO(G,6KYX-90'$T._H^<"#((^'IBW7+M4<W7GG!%<2WR<8DT0&ONKU
M??$]P$.CS_.)%U(' QJFWI@A-"36D^C-??C4(O92>N]\>9,W2"_!(;=L$"==
M6Y2ZCNRK.U'JZN$R3N;-F]_.*1%^"HF>;WA95;K5X"MWV;_+'T[8@-@T(._/
MUR3K$OL=8/)E/DN, $N.S9VW^KO_ .)V\+F?UGA'_BS?7]<?HA-^(W"//.&8
M[HD%)10")B9V$@,1$K&HY1"O!,DQIN\N?"=O[L5VSMA."Y1D9>\XQW>>N7'A
MS^CGPUK+^<Z0)J8G?/&,V D(@-4+5='20B5 43 S+>GK)I.0B5I< .L64F$+
MN-GI/ E4:+I$$)Z5@ 6BR&!HV9=93A2,%K>1$I-4FNDF(,@JTADJ:)%N0IF(
MP@"B2 F!!;8&H2QC E )30I, 0[EWSH]($5 O(R"RKB8P&QI(@!$1<H80_6*
MQ D &0I15DJ%I07D3! KJHH06+6)@"0E,F3U'8)"VH, %MJ4W0HLRG(P0;CT
M14I%"4D68EE''$.  29L[4I\F,FW*"PBG0'(2XAPBS63BB8,()BRB56231U*
M#,3P#!B.&0H/"(BH$$42<* :PU.,V0&^D%LA;2\<IV&R5$(%]=1@?BW[$2%0
MIC>$:E)-T2P" 68DDV)Q$U#DUJA5)E I25@&I[XKE]7NS(A#FB=PPD,$[R6A
M!$@U**-18C!UAL)29%+B58&1&M (*9J) 8-<Z8(.&70L&3*+@F"00L9AAWI-
M9H.%[$;(-Z<D/BF(-1,)C9WAT.TIDB7D4$T9!ABF!\@D!$(DIJ]1F5%4M61A
M% J R:&EQ&*F]#.P>4V:VF6OCK7_ )QXQ4^)=?\ EV?_ "[\^'3],8;Z /0Z
MUY)R7*/4UO-Z!S I(* ".RHDUB',/:MUB" A*AC3Q.._W@JH[_\ K>\OG%7>
M'BT;EA7>!'OKG(^0I.K* 2G>(-6!DA M6 A8O802^M%Q8:0Y 8Q@E,P3%TFF
M# A0IM6HM!NC0980B0I0!I@I:D;7)>%BU1 @(1(WT)(@[2\BP$VV.Q/,#0M2
M5\&!&%<I,]IZQGHH##(DBM"U5P@=0DR9LX$E0B(*5@BYCDE%.PZ(T,.Y%U88
M0\A1"U"4TO(P_02H Y*&5#23P3ESA,!!D$,"&3( <7!LU]$8!D#MUB).L@#)
M(H*9I;TVGNP00(0-69B@P*Y8&:R18A'1%841=;G=,C3M8$*A-W1UA<.,Z;&1
M M*2%W/!,<1@:3U9&)%M,@9)FA:*$=9 &9O5\BAR@1@<EL/HHD@40*A$;%S$
M&0011 H;%D)&I Z;3=_ZQ@PFX$(@A*77SZ8<508F!0D2%ZF2W2\3=2.&QDNI
M!J#1=.#"=0<Y*4'=LN(O(4HG21.XZO/.JO"QE[$F!!&S)$P\V:+RF"DZ@@8@
MB:%QP,W22=6<V/=?I.2Z3 +A0=4JZE.PQ-?>$5L !(@Q)FAE85N,FK4@00FZ
M.LF]+FC(# "4>)(1$D\9^?TZ\.?">CGIX\Y?/A,,GCZ^-_KYSOX\>'KX#>/_
M (1X$ D^3U*RG(]!$$%$(>0@B=8*VT][H,2S%P5(-Q*!I./+^^?*N_T&.Y.?
M"N>WZ?MX>N3>(C>1&"C3Q?3*U!(N6AS$!CB%CI.2H#">I6R(5$>%9#+PG$D0
M,\V$:PLH423+&T5JD1.WD>RF" PTFCH-[=9!*QVN&-QWP$)IKMMIP<IEX**%
MY L.I.&O. (A(!(J"*F]MX#(,!^KRZX\R Y/17VXG)VS2@,P29"0()HGURWA
M1!-0HN@%$2W60&1:$>HEBO=8FK+)WT2OGA[>V5X$M"Q)8D:D5A.F6$SC4]1[
M[UB<TAR;=HD]/; H78"A)B8)0B^Z8U&"%(RA:BYF4L)B:'"^)@)$TX?G!=0]
M)H,D=OQ,9$-%$K)@B-VAYMJL9DLF5['EKZYI.-! @)+2!I5@TN-A.$S<()BV
M(C12IEVR41*!8#,DS()0S:QFBX21D15.P07 J;A3:LZ$C4.G(H*8E&3CI&'9
M%C'U=,FGXSQ<;[QAH74@N@ 8$TD+MF,25L[)T"CII BB<U<"+1TMF^ !;,HV
M2Q"U.#(,!&]G49+9"X+>=AUQT]L(PG O?_/_  ]?"N?#7A*]\+;_ $\> +K(
M_1///@;\)XXR\OXS><SFO"I[9?\ Z0YAP"S71:"R0L0R;$)N,H(G"7;M"3&I
M1Q$,NLX\O[P4:?#TQEWD_KAY\/MD.C]-F'+V/[Q%(;$[4DH (:6I<I@-C!@#
M-,Q079F[:?$B!Z*9(EL2B4K"@@X)(HGR2C (#T0!@$$4+->"54A*J1,E 69J
M$H4P2=F1ZDP&(GP1-&  2+@+#,K6D>A(9A 46E#IT[,,$A7ND$G:@;8V*.IE
M!$F@9>@=4DLL("6D0 7")=$1<1.&>DPI0M[!%KPA,.#2T69@([<E$$H!@C$H
M,Y:22-$+($DD;%@%9H65 F0U6BD(,GK+=*Z:29$*[2P0!QBR!V! H(%-5&7I
M@DT9%@1&8"?6SAP(T(PRAD2D2S*9MQZJAMQ8-$R!V4H@"V-I 72+OH"-9! N
M$A"3),@F+O0@V)-2";DGHBKF:K6LC^0,C,\HC9I,@3@R%J,@W (3&Y,HV0"R
M 8O9)IP!T+]"5Q[]@FJPBR$I- $,91( V4!)$*,F],2,6)"T#)25NFS@E,BQ
M4")+)2H# &:$1& (@8DR"@TA72R=SEU?(+"I"U4T@-<0I@=<+?=&)>GIJ<4
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M0"#H6LQ*(RB($.$4H#%5$0O3)J+%(UD DY:==<7",6@K4JZ6T11)"XGZA(@
M0P@DL/Z#' /(%%PL%06&M>C2(%6 2H&"36ZWE46HU,U$;&B9&FJO]$_H5=_H
M/ '">?"9\./_ $3!N?!_81+DGO3U\Q@9/$$VMEE6FUI&I5B8!(Y!A4$)$LQO
M-O!V_N9<+:ARDFO1$_+/\AG_ #&;)^DS_D<_XC/^0S37Q,_Y#/\ D<_Y#/\
MF,_Y#/\ D,_XC/\ D,_Y',Y1\$ZI$Y5\>F=?XOA*_P"0S#KX&5?P,_YC/0N[
M,\GT&;?X&;Y^@SZYZ,]5/9F3?P<];X&?\3E3?P<_YW/^"S(4]U0KK]J8[CG/
M9Z<U1=Z=Y!(H].5OP,_XW/\ A,]?X.;_ .#FK^!E_HF?\9GK_ SUT]N?\SFK
M^+FV?H,_XC+Q_!RF"7.H/J"DB@9]"V?XG/\ D,_YG/\ F,_Y#/\ D<_Y#/\
MD,_XS/\ D,_Y#/\ F,_YC/\ D<_Y#+_3,_XC/^1RH)"M#%5$%Q+>N]Y_D<_X
M3/\ D<_Y#,.O@95_$S_D,_X'/2^!G_(9_P AG_(Y_P )G_(9.HKHF?A]K+"'
M6/6<_P"I\#"!J=@=0F#KJ,_TF?\ :9_TV/\ 49_WF?\ :9_VF?\ <9_VF?\
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M!"Y<" )D$L2#&@T09*(4"@!%@2A.+U.48WD8420"(!#N9]5)0D*;(\/MO%F
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MQG*"V4$H6(/  1'VE,A+)#R1/J$9 B"-((CQSVT1?;.'BHDLKNT2)]'6LFC
M5NHI2MUN<C8J)/ Q"9HF0(M$8A3 ;:=.WT\QQEFDF4"8DI/D.25"1MP@!D!!
MM,3 .>E)EI ++8%)I66:L6))H-< DB$D1/2&4KE&(P$#4LO3J,.#1$[88!0$
M-DX'\NF"P0RLC4]"\=N&4PYMDV.7T:Y/4W'Z?MD563.;?&IRO0\;R>OCQ_Y?
M7.['P<V>%>',9>\3Z_JGG)Q<:%9^^$$I !D B$/(4[0+<-F<=)N )=1Z#%H
M0?K-G[U];XGWQAR.,MH^?#C]?WSMG;-?H(YSB'Q:RB'0NA\@<B)J4,=[%*TZ
M(48T ]3$2" H1"-;$:TT)(61O21%#H2R3 @"&,\8)*(T25$P8;+.0?2HZI)#
M38GPA,+<3Z=Q5F?Y<):8FXG5@J0L!1*1U!DE8)2:((+IKJ0I95D&)BLP:F>X
MO96,]+[/4A)+[*2*&Q>*3BA) *"E@29S,9H8TP<I,@R[&*,!PI1"2!%H5 LV
M'&TG"2B/7,H6*5@9(),3D0#2L2,H4@@GE)"K)0H. \L8#0(04$EQ' <")F5!
M1*J0.]20)*[F',+!C1A1PU(P"T\AE"DH"FB7:I[(8ENFPT@EU8HRK8*J'I17
MF@+BCE: 7* JZP8 BD!'GJX))((,- #E*I&_0AP)\7(?#G'ZYZ>$_P#A7@MW
M^MZ.&;[YV\3MA,3BRSX0Y.LYC./T3X2J>#)#R=]XJI&R!D\P*Q.T%]!"D"FS
M;8M),(]JF?\ BBBE_H[>'8\./"_"<]/&<^F<QG,^'.=OT7-88):R%(W,AKUZ
M8.&R; ""Q"? ]:9QKD9H4"Y"J2TF^FXR($N @%&R8F]/\E$CU( @)0HE,[YP
M6;] DZ , M6K/9K-,B<0MR[?W%Y%LTZ:;F!TN]&R=S/U6V/7>!KI,?.4E/S8
M]9VOWYSL/&FADE>2&:.K>*BT2@1 <'CX'FY (]YV-7AZ?;%1NS!<I"#+LG3"
MX6D0544&QKTEYA@<N"B6!@($L$W#4U5Y.GTQ%)DU2>]N-J &D,PZ;0]YR9\M
M(&PL+L[",4=^B 2TB+1&%1VG#RKI(%'9<K3%O&,0HW5+1D*)YZ<5@!,.$%-C
MT#IKM.,=$P-)1D&E>&_CP&?,9!UP?T5X&/6,UD16>N5SX J)G\Y";STSMEQ&
M'@Y->$L1X65X7Q^F_&Y_1WR9]?"P-.,<B "3"48>0JY4&##Y!]" 90EH&'ZH
ME9)C_P 39CM_<HIN#)$D%.$C,_$)^AF%D+7_ *2S###3##3#"SWN>?7)GJ._
MIP+7Z)I99YOTS#33#P^$L\N3!S_1Z869-^$LC4+KWNOC99A_83333##3###3
M33#32O9W]R$7VK\^%/-^J66:688<D+7_ )2S"S222S2S,D[/D_1A9AE_\YIA
M9IAI9AAI6W^B6825Z3!U%!MEK\922^77Z<-,+)%7+R<\(OR*>KJRQ$D5S$_\
M9K!H G1T!,1,5D-Y\Q_QY_ASRWA__P! NG/_  \SXGFUN:H_1Y^D/3[\/- R
M0FRL7O-FUG'@KE\/OPR<\GE.>OQSY\$ROY^/">Z8]*LK3)Z_@Y7/Z*.SS^3/
MQ7G[ *S03W6EW+K'AS]OA\])K/*2KZ_QG.'-S;SR@X??R8^AO/7R0]/]^&GM
MY^[R-+[_ .F;O#[^F,_;(><9!<JABI;WFUTFLDUF^3/^HY_XWGZ64YZ_+>(M
M^'W_ %<W6S;YSPOK:\/'N/PM+%_2O@Y;GCES\"2!)$,!2&L(/;OX'IL\^" \
MC3^@C\^_Y/'QY+5X^8'CGS_1\?I'T7K61C3T.QQ[9=S00"IB@H8J23S _I$\
M_P#H;/W=_+4>*RS_ .CE#YC_ #&-R$A/,+Q7IEUVJ%1##H[P-]3&[ 8 X<"Z
MNR&@T(0(@ S.)=C,2%AMPUUS4)&C1"B3)IK'X-.L 6XD$<]$+@7"$I;X9NKT
M_<R=NTI#(K8C].^##DHF"A;<<SC8!F44@_!M\9)SH]:)UZF29S<25$EXJC G
M1%VLJ2H':DD*B5IF3(@?5"%EW)C ZQ83@IW9-TN%D(];C49P))1M]!:=>^\/
MCJD+9*R+!+*/#<XQ:<BNL *9(>6"-)IDVLDQ9!X=Q)@EC9!"455VP8H0HK)&
M;;P /0&.WLU]>,882Q$'"S7@XN.^ X#V" *1T;8[][BH181,&6=$:N[D222
M&Y4FI#891V-F<A4E #:$@R(J<MX!D41]AI[X:,NR@&F_7O\ 7)NR22@1:!(@
MTDS8CEFLB].I FNX3=CO$\#2\=D!(:%))U;=A1$[4$+8[&>F1Z"H%5$E]G!_
M-0>2I,D<)[ _HP7*V1)'#6_I&;H8"2=>A>;Z;P "D5W;4_3VCOQYY+IR[E\&
M2LAJ4B;TM^W\X7UQB9@*QT7(D:5&01<Z33MS042BP!<$QM$SE$2,46%D)F2V
M)1B6H(2M4?ZP.<$B+102DXP2H$!+46;S!^,5 H9DB!?,.W,XX)(T0(<)"H3]
M+Q9"!,Z1,>O>\B,U0ZHC1*VZ#:T\5!!0BJ<=?7'/2=&0V,%Q$ X/,Q*(DHIA
M(Y1[8Z.S)%@&Q(BTGL&4<5(A$U11VE5';<X!@M042 *BI$(H)4.0!R6+ &KV
M^[UQ6,R70$5JGX]^,58(9380)@Z^G[1*,)"S5TD4B XE,<J6,1YO_P!S9^[\
MFZ'AQX<9QA'MX=\Y\'+UE>%@==Y \)^]L.>TAH*[AL%FO1<(H$$F@Y$OOKKA
MW;9*",Y- +<[D:,*O-@ $J$"$$-F.K&1Y+ 0EC4&&$VVCL.&ERLA"L3*H6&H
M"%F+HI,1R1<2.(F43&KV0:!-"R%?(&!8!-I;!-FU"R3JLM6W0 3RM"BQPMDA
MSI$K\HU K@F29@@C#$8!$@03#9(6G2%Y --0?4QUYUEJ-$C>"3-L#0U'4PMP
ME 1$!E5*1"-4Y J(% *,8F9 &Y9 R=NYB$8$@+*;5( A&&(G3 @2A(L$/1N7
M%4D8TR!5&86$@859QFJ*T.B5FM7F%18QOF)!$L!88%VC+TR--5 LE? (1NIW
M@&3M:ED1*1N&.@TXKR$0=H" [F:K;V=0R. (=MO6TQN*S6FX>)T5-YI.T7>=
M3:]J11A,^\=L2-J3!+=()")N &9</2V ZM%QQBW,SE6&"9;8$S8[' D "K"1
MPDB(W<1;+D"QHK7*$V"%YY0MD(9J63()0 K"@ G<P7B#H$LKRPZ]JP[:A(A*
M<"%-""'8>:&!3*5T1-D [[Y>7((T4G;C^8Q08M-RF1"S))< R41L:B V)( %
MY(KJY8?F$MRGCGOE&CI+*CD*M.JB.1$BI#H43Q.ZF-8B" 9VT]]\%Z#9%8'F
M,;7FUT!DTR:8>Y)H7$$JK%"$A'#%=L5 9,;EH^Q4[\,:Y.\YD[;(.<A,G!2*
M':I8Z*ZN<@*'=T)*K@P8<SLB8+&S$HPSMF'\2$A$2(^D:Z748Q,T,*( 1*>@
M$Q+DJ&XYI)%#EDA)4R:,#P"CK$4PMB"]-&&D3-(2)]F^4]*(8^,>0V3;DF1;
M2IK"1Q,A1D<@L =(((I.2"3+& 2]YE11*0N;WX67X[HR>,EX\(Y_\M8M0ITW
M[.N\DP#%)$C,H! =5=8U_P"QLQV_NO)NAAU\&JQ'7&:[YWS3FO\ PBNT#,4+
M(QZG]X L; 88@AB"41#U;P1B  [PB2*VU1)@F650X-\+ E'#?>9PN)ZK+N D
M$>X\I5"(C;I,I0Y@(IM^<#[QVI4I9=WI[) ,FV@,1%MJ*$2U4@J' HA!!=R4
M( TULPQMK@@.]Y50C/:L:=**U2%)2S)*Z"$$5V)T+!F +78ZUO(D$1)D$(H@
MLX">J8,(L5&&SS*]P34M9( *84G(3&JLE];$W% N%5IO#*U265IFRFF0S(C=
M&LKR$3*=59 @$C329&#15WDX(V5X2&%DN$@LE9G-IK' 03J1)H=F4,G@1E..
MR!,E&IQ:6IF*+3/P)[JWA!9X5:6:ZCJE6(K"$HBK18(&R*D,,-3DWHX2B*EQ
M(+*I+(QB-Z7,$": :A)G=0V/7L-*@=*VG;48<F)&8+7W<3IL[<YK'@4P.H+]
M=%Q!D*CE%.'9@JH>BMY+%E&)\40KG3)S+630B;(C*$9-*#PP7 R[ <XJS8J0
MI%ZI2PT90))@UHHP,1<$F:NA$&BP3)6U24D;BQ/*H$S*BPJN8D20Y'-\*)U)
M.A> $&]1DXUABIE@U:M1H%(Q;:BBN\'T:D@J(I)</ #S1"%(\R1,G7'!@+$S
M0).+*T7PN!^Y *E!@DW4 W;6344O2TUF2D7,R:857998DV6 <&I"L"MD<*R(
M;;"Y3I*%A6HE0JFK)#PL-@IE]0@# FYBR+NA+23!L,.D (203.X@EKC%G2D.
M2@(UR:.<6<A8,;L[;;(U(!@PF,1Z6 L2RV YBH,L\F-,A-PTH(@6A?:5C(V6
MJDD&29DB6T$DF&]-[8NS@L&)PXG+L20 )=**:5G-P\I< @A*C0L-85,I)*<B
M$TR4 . TY &,H$* 2 "=AX<""((@( F8J =NDH#P/K^KFLGY\>_A>_U+6C3[
M^?,J$:6^\1DA4UJBD/G 6R/LD,/_ "/)NA^N/&/'[9ZY(O%;8)ON#W5P9% 0
M7$$]>+\\XI-9KW.OG&IM!V5TP6.S?KT#$4'JEF^OYQB9+[KW.2(D_6'>?KC:
MM%U.O8]([8!T!5&(!/J.GGHXFH02N#KT^^ C@S0EQ*KH5Y8$BRSP0SNL"&EJ
MY;N9%].T:R#0%;2F>D:XUO(8+HMM7:_MJ=9L]LR.53WX_.)7@7-664PHDZI:
M,%N15_>XEF,0WD.D%<M!()Y(-&-="'0F:\HQIS:8X)$LGH86@[8C-4B$A2E+
M/8/T9T%):TG<3UR$S>)III>C>! K\O.L %Y'/(UQY<3:6<J=><:I@U'QL\]J
MP*:]'2F:X^G3#CB0 )U16%DB&](I6!%%Z8>)K @(.D)U[_1Q52[)KI.(IQ>J
MO\Y>(V4*DM/&N<DMS-%?U]_S@8JGH/XQ15O1_G&?+9SU:^(WK>=9$?M/VP!S
M(U_)ZXWD/,8Y%32T/I%?'JYL R+[M:]<<L?)_$8E7$QP]9Q1L!4W^7XQ]213
MV):W> 0;%@C6^=X)=R(^Y$$3]L:]]2XOU_B<4ARNK&N%?/.!!;&B'<;F3G A
M+V=CV[X(<JI@ZP*P0K+[$/3^LLP8UX<U^J,[]?!(\36>GZ$'+GZ=^N$=RDT<
MH)C9R%*$ 1[@!,-P@B&T-TMQ_P"ZRS^Z\FZ'Z:C)\)\>*_0^$5.1QXD?IKCQ
M%4U7]814:&DC!V"=&.1*PS,"%G<$&F8(A2K>)WI&423<6DS;#D-&7$8@F;L4
MAY&G7&R\H42 %5RR)0JD9W=3,$!2+),BQ.AJ&(!F6LF#6*8]3#%2%Q![ JHX
MW@Z<<FK=8"F9+580!*O:I % BPA(,1N)<A]M8R(D00FX-$%8C=1O&8D%EH9'
M7&",ND*3L#+60;BSBM]>I--W+":, L)34CL[AZ-@M74T]1T(*!8-%\FJRFN<
M1,8+<# CB)9'Z^2=6""!Z.IGH@., G1@V8< DS&\"BM&B"3) V+"WN3E73K0
M.4S<"7JDX0ZB:W +,B5Z7<K($I2?9UUZ97.)PY%>.J<"?TPQT\(EPKPCQ>NL
MB=^'/Z-?^$2X;C(V\9W\9-0!ZZGK&*$E?^XBR*"$!02 D-T@%EG81Q&)"Q!
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M_A0YTIG .+YET_\ VY6TFR8.+0K::HCNI]+^/^,#B^9=/^64KY:?U@CUIDA
M<;X 8%L)4EB:I@5=:/(@DIR&U!\F Q P/EHTPNL,,@K:!ZQGJ UDZX0,O0P'
MMD!A$_\ UW2EG XM!]8)9::,X,O1DYU!F.IDAI9")#CEE52Q<K(8&-FUBF"
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MH!64K[#$C1_)#BW,G'%5F,O.*4[#*X@NG8JUC('%6W9R**UMJBIABF)3Z?\
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M)$VD6Q P]#*#Y:L1AC>'A]";!">=^"1L-@D'F(/L,9"9,[J!=$)MA29&8!(
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M_C^L]M:[9"(BHCRY!T,@Z+VP7D'0^/  H(.A6>?XK)T,SF")GPN@& L(,&H
MDQ!*3AN *3IZ-=O^O%H!M5V;X(C\Y20PL"R#="PY42;4%E%)$DO'V3S@1/@P
M )*&+; VXMO1:0288IM@K *K=C2N3(;RL(JA!E4Q14?1#F6$V]%LX6[,H*M8
M$XPL,/W:WM:/W2WQCK=*/WDSJ>X)$^&;,[%(/NQ2YDDD=?50=)TB-T2 3;0K
M95>V(.A"B@Q(]OWL@PN&-XCP<BZ2R/01^213T$B;B%=D@;HO7TFHR=_:A@BM
M%%9N1%DND7DD*5%<N)HQWL!IIS*H91C2$%T7" +#B9O)G%]\*B>"H%'*[9E(
MIWGRGQ8F16:Z@VCAH4YM&#+U9_$D7Z//8ZN;E!TEBX6QH+WSP9U;>11])!P>
M2!1N1:%]%?FJ FA1 W0T]&U,,!5I5ME,P_,70Y6#9:8"M%H@L K>R*B>F(!"
M%<[>]42<4:@"#VEB1V&H(,CBM,W)9I!<W* I:.7+C-K%F4_3IL?B!Q>ZA;F^
M$#;G6KJB.17]&9.(C#I,P](DK8/$U('1S@XEC3Q-Y5&+PM2 K$*O=7LW)R@Q
M*(=7*YHS<[/\-^$3C#T4T3 QM)42/.W;;&04@8U;^NX5I;%ZI=,>7P"!@"#S
M[?O>/TYI:'$CI(#:)PBN><("(X<PT.#]];GG^@TUS<![K4$V=='4@6,GE6&*
MM+$WGK$UX2  "0#P4=PEQ1.29:!6-E-DGV(QC[6<0C-'VH90)K*CK."\$F0-
MP3 KPA6ZW+"!<_ [QB]5#%*4+Z<NOXO22RA'=DQ>R+BY7,$=I;"E,@(-EDME
M$\C9NC73S,1,VBQ)U+G'C$R:+FOGF@P1LLZFL0:23HW_ .KIBJKMB(!2DD)
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M'6*/WR"9Y]7 #4_+^<4VX-G5^/KK"?/;D<RH.FM;QWS>)@>$2ZF<&5Q2[3%
M$18PD[@9N[7ULG-F0V^?(2LD!D'1S7^)I(;4(YS/RB4Z,)!LMYEK%+IAGQ0D
MO$T1RH%(Q2) \SHRF'W\1*!054"_)87O1&[-LK*[LS4.FE,'3\=_M$)&# &
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MAWF4FP9(G).LM6&1T)"4SK.34X-S09HD[S9D=@M4FQI#OX]?7&>*>Y/TD_\
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M<P KLDP?><6!,.6%(@X5-ND/DP1D876[$$@-01O#0"(06J7"K58I%"+"#D9
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MUFM/%3JC($7(7=5C-CP?+A]X'(N6*ED7,R$)M@*V")4XK#LS<^-D?5YKA#K
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M1$LKHJ.#CQG1(2^[P.(?($<R2A,$#1$W5/P7X+(!B"1('9T#1"RLQG--1*L
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M[OU/_6HB.L%7'OBD@-RE8@#$I!/6<B(C]5!H4=Q-5OAS$-]>!0'#E)YWV_\
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M$JH;0PNV^9B/J=V^0'1<LX.J+@@HE3R. "> CL[ ,K/$7,S.39O]Y)OBU">
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M![].XW;7'US3IKJ<1^4YQT^Y\YWIV" [<\9^"ID] //B<).B(29HV.7:^U]
M,Z>K?2[9/1'WN'%G!%SVJQ8PA(@^0\).WAC=L](_+*I]B_T\0_ .63/!O&[L
M?GIP_P"\_=_I'X.['\9_/;]. >Q_W_E8]?V$?_'W6(^1@P"DA' /D></I7QP
F?^E\K_'Q8]_('WPR>=[XBL["+BBYYFIXP/51'T&85E2GG_A__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_02.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  M0    $  0"U
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$" 0(# @(# P,# P,# P,# P,#
M P,# P,# P,$! 0$ P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
M$0@"F@2P P$1  (1 0,1 ?_$ 6L  0  !04!               ! @<("0,$
M!08*"P$!  $% 0$!              $" P0%!@<("1    4# @('!@8! P,$
M @,  0(#! 4 !@<1"!(3$$ A,3,4"2 P4#(5%F!!(A<W&"-P.!DD-#5")38H
M)SE#)BD1   % @0"!00)# @,#PH*"P$" P0%$08 (1(',1-!42(4%6$R%@A
M\'&!D:&Q<B,0(##!T>%"4C,DMG=0DM(T-G:6%V#Q8H)#E"4UU2;6-Z*RXE-S
MD[/3U'65M6:7"7#"8\-4M$6&)QBC1'2$I,159496ICB#9*7%1[=G*'@2  $"
M @4(!0@(!@(" @(#  $ $2$",4%1$@/P87&!H;'!T1"1(C(3,$!0X?%2<M(@
M8$)BHK+"!(*2XB,STW#RHQ1#4V.#D\/C$P$  0,"! 4% 0$! 0     !$0 A
M,4%1\&%Q@1"1H;'!(#! T>'Q4&!P_]H # ,!  (0 Q    #W\
M                                           '&+=MV3K/F,?7/YKZ
MU.MGJOQE" $:IA$1  !" C(0@F(0"44IE$1(()$0"$(R@B%-4*7UA/D#]20
M                                                    .,IMVW9>
MO^8W]8_F1J6=4HMSTUR*=56((BF"(A.DHG5 121IJ=15*3)E4S)E1,F*=-3J
M*H*=-&HJ@1(I&DHBKA<H^L)\F?K&
M                     !Q<VK:<G6_,>^L?S$W$:J,0A$B D@ 0(@  )( )
M( $"(20"8!$4P1$^L!\C_K0
M                !Q5=BVZ[@?,:^L_S"UVJGI1@ 20  2020 21!,4$D021
M$ )!!,"(0"2/K ?(_P"M
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M/3/!ZJ:W<Y7M1T^6CC_2\$O>>3X^]WS&7_C?0['-CS7OU\<^J=?*@
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M\-"6JB:F=.4:)W47N2KD
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MZ'>>844O<WWO!W'8XM6>;[F/9/YA]+\Y3>
M '%S:MLR\+YCGUA^7NZMZN!$ &G,Z-R)J8C=IFMS-;KTZIC1?7+$UO(EHKA;
M+V/&9FB^FWIY-$+E$\Y3$HAAXC(O1JKA=QY:9UHIGID0!$)^L!\C_K.   !+
M2FDD (3$8D(0A"J$533 $D)H1J !!05$H51&B4(51&91$DIZ95!"$921,2:8
MEF(TS&0                           '%S:MLR]?\Q[ZO_,+<4:D  23$
M4QA"J(Q,LM.J)Z:IHF*F4F"J6:(&I3,LBJ*E$PF$(S) C D@03% ^L!\C_K0
M                                                     !Q<VK;<
MO7_,>^K?S#UXU)   !) %1L#?]IM;&AFQY-D6X6KL;F/)9N5AUW0TAVN@6DE
M:-RWK6Y$$Q0    !]8#Y'_6@
M                 #BYM6VY>%\QWZN_,#<4ZD@D@03%  )&:_S7Z%I;S_7W
ME8FVX/86KR-'T>$KO_#KN.0]/V6ZXGA\795/U715YOYN,OL_)<77>>#@0(@
M@F* ()BCZP'R/^M                                        ''TNK
MS':8G=FI4           '%S:MLR=?\Q[ZQ_,#<4:L0(@$BK0R,?4L[>6,;4I
MHEN*]ZGLJ]<_T6VJL<97&ZR;-I?2\O<3RO5T9V'+UWUO7]AP\+KF;LZ,[KC*
M/;/13L.%-[3N6XHUK:( 20($4_6 ^1_UG
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M21-15%$:Y3$+:%<SUH68EKF-N%^9+=.C+S/>F_)-G.]XSV3>._<O<L;.W\W
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M_0+=52:\+K=%=/+^'-9HO2P>I\]GL'S#JS;A*,20"2"8('U@?D?]:
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MYST?W#^ _IG=3K.IB  >*:(^;=+;)F(F6Z*<G<O*LJD -0]%4T?6XM7-[<@
M;";;'N[RA+,R@&I3$)3VHC"GV=JO,[ZC\S^H;ROZKY.JKC:Z+=<O!^8Y]7_E
M]N:=4" "2!+,RRT[U[-YYE]$=RT^US(<=[?91N.#J*S\<^_\YR/\MWM+:XO#
ML;.P*]HL@EOK\'O9>,5]Y7L[E]CC>47VWY'C3B30FB 21!,40!%)'U@/D?\
M6@         2PFD!U-&+Y&6J*IY        *6$3M_"O&W]#_ )ORY.%JXDY!
MN,]P] /E'UA67 W6E7"F\FF5,ZB$5P4ZD3IU4QB4R(4TZ,SA&])^>[!^T\:]
MP/SC^D5SFMZKD)J  Z7%/P_I6B*@('UM8BHDJ!2F("(FF:FT/0M%6_K@
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M9<93.5I%S\U        >"WZ&_,C'IV?C2S3Z'?*/LGU@>1_:H  4@  J
M  #1B/(M+YO"F@ZNJZG['T,K,U>/&:?F0Q,J92)N4?0\B/<Y$[ZJ0
M .+FU;;DX7S&?K3\NMY9UP!)  T[5^ZGDO5;N]/T?.MC97L_.Z]X/1]AHW_.
MQ5K78NGY[N<.OH?S=?CRWK]L&7R-=[.W4NUVMKQ->JYZ8LPWNMM&ZSQ+72!
MB  2GU@OD?\ 6@        ;>)\MLUT<)E65%1BQ49 8CDI8\+<Y=JV7Z0
M    A,>!OZ&_,FP;LO&)IH](7C/V_P"IKRO["             %I*//%#,N9
M.DS2T(>&F8\$Y09-5E/N&B??G,<^J         '%S:MKOX?S(/K'\O\ 7C4D
M$D  2TUZ.3:U,6[-=HT;^.B]-3>EJIFB[ML/+W%_72YEG4M4RS2HNQFLN1HI
MC33-1,4Q0($2!%,$1!]8#Y'_ %H        &WA8-,8^(5=F<LT1B#A='5-FL
M16$NM+V$S2       T)H\#WT9^7]AO3^/1S*O2'XE]G>I;RC[47
M $J$3$V](;BI&0TZ0U*@T*5-46<INSJIJQ;JW%:8A"$M20       '%5V+;<
MG!^8U]8?E]O+>M )! !,)B,()B@"$@A$!) @0)@  $D$D$D#ZP'R/^M
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M33;NUUG5]>HL6ZYW.\W?M95^=]>P^]%Y-5&WG]WP]G2+9<Y<#K.JOXU?<32
M     '%S:MMOX/S'/K/\O=S1K! B :4Q-C['3N1J9.#H8N7JW*(T9,&%J1E:
M<7YKF'!<DM-2FUIYM$V/=FMVM.F])=L:]VK2MXLK*FQZ]3*P]2:X(B  0/K
M_(_ZT       #BH><BJ]1)166FUZ1J:M]6E1;G$QJHQB15E_*CQ,T@    -&
ME2RNBIENN>6ZJ#CZ6^E-(           :=+AXJQ2]!Y34/'O8Z]]Q-:=;T55
MXSZ0K?<X3*^[1>MASN.NFU'>=5SM)0V]K*RT[_1PLVM=5_MUB]D+U7<[M
M      XN;5MV5@_,=^KOS!UHU$0$RJ8S5*R_2/X[]/56TW3]*R+EQFFZK 5Z
MAX!>E@[VV_-X^ZOD?0<L/.>N8Z=_P5JE7,YZM%ZMYG_4_"<U/GGI5NV9H.[6
MMY5#!VM:IJQ]9NFOPU'4VC[+F[/.I\VPT>F?/L]5J* ($0$_6 ^1_P!9P
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M'YCU6[^QNJ3W\+B;-JLF+MK6=[H;D.=ZS'/U7D]MW7<=:=T'G.K12 20 /K
M?(_ZT        <8CR80X"7J\.CIW"*X0ZM+%A$Y?9      2P\9J*G1&3&J?
M--$>K&I@OIG&89?3%4C([%7L8EX>9C'Q$YI(BR&8]Y4U       #3I<59IU+
M\[F*=*F-6:]M73+$:TQ-,;&MIVHWF%D29-O2O4:]NY/8;>Y.CD6>5IO;Q(
M      XN;5MV7A?,=^KOS UZ=0 3!$20T\V]"PU,_-R-^:^L=6VM^Z/E.BZA
M>P*#[33U[M9_7\"J":I8NZLRZGS2M6LVU([]JJ>MVM?+.[H]F:BW+,YNT+L/
M,H7,6%VW/;SM2BP! B0(@^L!\C_K0        /*O"E$U>H>%>)I ZBC%@9?4
M@     ;>TL]AR==%"JZ+.K-?8JJ[_J[--5RRB(OL.\T1=U*T2FJVNNY;?>M9
M.;,W97&J314      !+251,E;+B2:8Q,T2@J"6$:HDB)YF6FJ$T:4SKPF2
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M:?DZRL5-SO5N_,B:F]IU41B-6W7-=IT(IE5ZENE::5V)[TPI:N/5JWJMTK
M         @:).:@            .*KL6W9.O^8[]7?F1N*=*($0#2NWM+7V*
M]\_V^E=SZ&[3C>VW+_5K=BH^-T=,]QS.K78EJIC35I57H4Y54\'?4RKY+LF)
ML^^MI1C;Z"OVOZ>@E[GU_!U*L29) $I, DCZP'R/^M        %GJGSGVJJX
MU1Z?9G4J =/B,62<O9-(        ;*;6G9NZURG6B8&M5(
M\OL4_/X3EUF/J**@           !Q5=BVW)P?F-?6/Y>;RUKP"8$421<T(JS
M(<+[1WG6=762C'M<IO5_MI\+;XYNP\@OQT/J$]6OK51L+>,K6=.IQ+DL??=-
MS=7P&'?ZKGV*89W/])I7R:7JL;G8>66,])P$\41@( B F!]8'Y'_ %G
M   P[J<0RK)A#.C(:5+&1--*ZEK%-5ULQD?A6N9        PF]5XE@*]2^4-
M2S?TK>R]CWBWW5<-C;C42             !X.5.=F'ADE]82*M20
M   '%S:MKR,#YC7UI^7>]M:\  2T7-+/S=SK[LLT\OBW-G>NR:^[N<NYL<3'
MJ@V'#TVZF,BANUUO&+?)X]W4B[QUG&UJLJK>#?HSL=5O[F7Q.5H):XGIF>+9
M$"(20('U@?D?]:        ,$T1C5F?1!3%\=4BA1B=B,I548QX90:9Q<S.<J
M0       'G$]'^7O+#[K^?,%O1P=G]#_ .5_UYN9P>AW&12
M!\O6(^B],?,8A]7*)[!6A3,T@          .*KL6X7</YC?UE^8.O3J(D 13
M!$)0FO2B[>!R7K5UV$J+B]71>SJK:^CY++1SO>VF1;YZ[I*(7**J7,SCL;9]
MQO:^W^B;BJYLWS]5W6W@=EL[&VO<<I;5O^(U;D(B(3!$0""8H^L!\C_K0
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M>UW0[N_             Z?#S3& V:>!AZ!%5&9I\;I[AJ:LO=RG(Y34
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MD&QPL4?6^(VA;[D>MW<?GTW::'L\K7*>LURTG38%O3?!K2^D\OU(F>*   !
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MJWSAQ.=J$6(T40JB:BJ%%<M5>_NYWH.\E^FJ>7]/@E]1^;]2FQ%(!!, B*2
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M    I!4&VHBC5["[5$5!HV$\P   !Y6X6R51[/XD "S2(^=G+ZBZ0
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MZ3T+!QWG@W&96D12J21>W.IW_I?\\^D/,WZA\I0S$U&.20"2 3]8#Y'_ %G
M       EA-*6 B1D)8":0 EA-(                      6Y*?DP0]4";!
M9BS=-L<59G9IQ8'MF1Z-E0          '%5V+;<G$^8]]7?E_N*=2  ()BC2
MOWO2OY+].><3T'PGAMGRTEW)T[F//&5+".#A3Y%>G53&379,<K)EOXL6/KVH
MT5SD-/T7I3\_^B?-!ZA\L1RIC3B@  $_6 ^1_P!9P
M                  !9>IPI)B03% OO1F#IG=52          !Q<VK:[^%\
MQ[ZS_+W<T:LD@  2Q7FHX3WVRG9\=95T_FMYG,]OGS\E^M\>O=>/<2R,<O2^
M&Y(>%]]QA^G>&9+O-O;+U,3>8W>AX&[/E.UHQU7$X:O1/!84S<]S7HF4/D/3
M<#GJ?SC/=HU**020 "?K ?(_ZS@
M"2&E$Z")HG5JB@<Q6B8YJFK3A2RJG<Q54TDA(BG%2I%$P$S3>::DTU:-5/59
MCO"H       #BYM6VY>%\QSZP_+W<V]7 B D@#1O5UFYON,YO >T^<CU3YER
MC<9ZS[./$ON#$#VODU,)N6?]AY/D<\\]APS]Q\]9<N%^@.O;*SLHU.8+F_6\
M,W>^">6/V#Y.EQ[OH0\M^E,/_;^.VZ]#P8  !((^L!\C_K0
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M[5\D3+$\(2C"(21 2@C3BJ7+R?1GX]]1XB.X\;M!Z3S?=68  )( 'U@/D?\
M6@                                "7&6A;30THS.:VV38L"R>/OUT_
MH&]OSU1KXW+=RN%TN.S9<?=Q:V^VIL6Q3K*XV-Q4ZG8V4;#BN)NS<#:W%9<+
M9]^Q]M3>[K>=C(ZG?U7%6<CMM&59MM.4S Z7T>H.-M@     !Q5=BV_*P?F-
M_5WYA;FC4@ 0(A) V]V,M? ?0EP&%M,"GIGSK/;LEK41&($LM"\FB_"+$U-[
M.3Y+]*4_V^NP[=]\X3Y&1/9@@ F"(I( ^L!\C_K0
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M *8[):V>/OH/*['>EX*E^7B5&HR+V^8[K(+H/2]I@O/AZY\[4FV/%:E-4R"
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M;'V-)+NGOTU7?93]9V&XJJA3,T@   !+":0
M'%5V+;KN'\QSZS_+W<T:P$D    F"(@@1 20 "2 ($4D 0(A(('U@/D?]:
M --3Q-$V=['0=HHKLRR^9N/Q]C7;%Z"U?-U7>U7:,3-TKEJV[)U?+6*J7Y.!
MS%.9>UB[:F%['Z#%NGV3K;FL#=6N9NON;Q[E2K.[W%FW8GL>>NEHW-E%WF*K
M,[M%6;0R.=K&WES&%N;:<O226LFH"_WC&VM0)P[1<O35FL9^_G(KY:V>*O9\
M->CA;_A*\+K].3;/=T60G![+KF3A4)OZ_L5J_1ZC757R<ROV%OKF\;-FD
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MRCZOI.TXVQLVJY_(SC=O9MM.=Y.FW1.[K\LNG[6RG/T^1O2=GEOTO?:L@
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MMO=S5"[;U\>[+$C9T)8;FY5/5$E<,6=M<M;S(:RL
M   <7-JVV_@_,<^L_P OMS1K"  "2($0  $@$$D  $D$D  D$"!%/U@/D?\
M6<                                                     #BYM6
MW9FO^8U]7_F!NK>K $"(  20  ($0 $D   D@  DB!]8'Y'_ %H
M                                             XN;5MF7A?,>^K_R
M]W%&L( @1     20($0 D@$D D $ ""8H^L!\C_K0
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ME%@0:\B4*%L0:%H2O*D&D6Y$S+ !A(B4"N4=2LF J*+1^@^4 1+W#\8XJXJ
M>*N6:N PURS5RC5RCUR35RS5RCUR35RC5RCUR35RCURC5RC5R3U!H&UDHGF
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MD#<'GQ"A'422(E#SXZ(.Q0$TF8QG+H7)O?C33Q#=_M".E&5*6N:2C"4M"J4
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M=_NN+2E'?+I.0(-&>D /.D-7FRA7U,!.F^3KSA*6> F4\P!@2?)G [HI1,]
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M'ET]-.B<6-S(A$#'FWYD3<TPA#2HF"3DC+& BR0PYE#IT(:UI3@.,#:L' F
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M!/3H .KF+27^,5WW'1%=#&5+17.AB.BI417]:I^88RY3TH8 ,9?B!9P %=N
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MF3HCXJDB1(X*:T/90#0?JHH\=:4X6*V(@L#DGOP[W7@O/$^-#T!T#U69Q_\
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MLFJH(B4X\QLL9('<B!"K.>8M&%\L07O,I5^8J<BOP@W>B1NX>:J2KOF4/?\
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M@<QPB5D)TGT8/_41[?@?P29E0D7J[<]PLU'B[IVH+X),RC=1RXDAMT5".0[
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M"N?=R>W*$W+V+'M0CX_;GMCMW;>B\VD13+<%M?VS6KM:QOGG;%;V<KNS-BN
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MN"-MV%?YLQ9#XX9[C,(/K)L#-.,LJFCLVXGF+0N#<-AFTK<E<VXJB[)DMU6
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M=2!O+M:!LUKRK6O*M:\JTKRC2O*M*\HTKRK6O*-*\JTKRC6O*M:\FT !:-!
MB9"]&V?<N_Q+(PTPRG6?M^I?N85P-@XAS'*GPF&V;SNFP)O;;ZO$JRK>7FI'
M>=?\W?\ @K9WB'*_K-32KE;U<-WXR>+O6;O9FM@?=#AO<=#$-Q>T;OWKC_\
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M"9E=20W);UL3+BWIT8V+M[+"9^(:$= N0QI*\KSM*-DV>WEC<+\EN6RPMQF
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M0=*QE@S%F(97+>&,:9PM_+6U' .<U!]-G9<:HCT\=GL)+A@_%9,L99VM[?\
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MZN?Y\L?Q4G\ONAK:227)B!DMEAQA&/R"-R;S,@3#>9L>RX2]H+(45^[!ML<
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MEA^:M:Z+E<7'"[@I3"V9F]CA8&1%7%MX&R)'W/!XIFX5A;>.KOE]L=S6Y?\
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MMRYA/33K!R_I$IP,7NX0KA3"M"#7 6N$*X"UP%K@+7 6N M<!:[*$/U;G.S
M^V_;7*9AE(&"B[<C0  #W'K!?[1_10_@GV=Q?^W[T;?]TO4W"95214/&0[,
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M?*W\5)?)\.'0P\&@ 0*X2T)*X &N$*%,=0)7 %'*0*X.WA&@(:C$KE#0IB%
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M-,/-(IQU^=.51M/RKN[3\J[NT_*N[M/RKN[3\J[NT_*J-O\ 2J-I^54;3\J
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MYE!/-2F\YD&;B?HT*A4?2(*+4Z^B73Q\IF7AX676%?G[V5A3>3OBG+.O#Q=
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MG7P'T-'3?FH&FULZ&)+0>!;S K$^&;<CI^JD^/XUV^06N.T *?$%B_S?^/\
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M,'K?+BAB6N-<.>Q14\Q-T!K:8V5PT*S7]>2L3X9D?BY>0"EE)86Y!4L+T@T
MWO:4T[]DT3&(IS!?NC,7#84(AA>'5&, NS50&,(^OKBI!&\T\8Q[!(ZJM693
M'3UW5_<<QMB^5.@+%!,(0J!S:[*G5W[/9O"IF%.^U-)KVTV\D!+7/.(/1V,U
M"<O&0 4V";J6%-9XVKLO%"-$TH%-;\E(U1)%CACHKVJ%$U$:LMH1C"\ 0->7
M4II9>Y RV,VBG:[UJ65]51KS.<]BAZ7$\F>S-;+,O^O^I?\ 7_4A_1_K3Z#L
M].XGPG<C\7+R,-R?K5.Q7A6I@+=%:EMBVL:%?(M,&L4KZ^L_=4YM:.@:,R+6
M2[FRV)^'J0?3QL3Y;E=&5:WE"7?HT(-0( &+;*WVH,B3F:A1SV>F!I/!&OH!
MT<%)\,NX>G"L3X)MR.D^192SEXDT6-*>.59EB;#1UB*\/WQFU4NT:8T*Z;26
MZM-BEL+;M/MS*:D M"+T#16@;7KC"-HM5@<9VU.GBVF+]>6I3_PMK;.5XA=@
M(VU6'/2T,]>9CUMI0FK$THU$39\RG:LC>C35KW:J5V/YJ(+#O%@^)NEVFA]%
M00(],C7P1Z!I&\*3X9?RCT[/\!1TGR0P['(;4+,RO%O;JJRI0;15"@6)IF-)
M.09";9"% K]:>4"@#3GKT(2'[T81<,?LY15X  9G;:Z<L1#5U 94J:8UW=;>
MQ X5#$5,>L/K?14S!LXJYJ 8.#"F#BO3E%&;NO&$=Z+ 1:+%Z>KJ ZE=DEE&
M</QRZE()OLF8G.[6:,R &77D*5#TQUC=TZQN"E^&7\H].XGP3;D?*/)O'-44
M?#'JF5'XOZBHC;+S*HVCFO$KLR*<#\MNE=?NCBA);HY^M3RS&@60@++P4Q^S
MI'-.WY513HYISO'!T_IH:^"/1U<%+\,OY1Z=Q/AF1U[QY.*GN]^#<:4?'[U[
M-P1D-1+#/L"(G?6#3KX)B7E;.QAI4\LIHF;0*]2$H?.P)BL7PX,VH[5A%^]-
M->)K@;0C-,>S%G ;NK$EG/NZNUF97)BXHL&JI2F7WC&+BC>I)A6VNA#7Z:&O
MATA2?#+^4>G<3X3N1\H1/UNQ&Q>'AP'623_"%>>-=%/4G,SZI4PFHHH@<T/6
MB79Z6;/F":69M#)G@:K=B$U8]B=R] .K19!&4&FFBK5:AVJ**,K$')8/8SY
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M9W,;="&++*\MT!H^Z![I4^#,U(/VFA,?NA8>#=A)33'\*F< 2&6 <DCLD1[
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MY^+HRXI[+"T_8!J4TF!W&X9XTA23UN>"NS=Z JMU^Q=DQGA^**\$3.)A2&I
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MX!'KQ4W#K'XL\L!S5DTP'(!4,4FH:]&L0ZP^''9'W>.?#,.@>.*ES ,ODX8
M=79'K_I8XU^I01]M35^_@*")J]-#>4>D<:L!F/DTA[@AYN#%IVR\?)7@&5.K
M <?@^WCS?C#'FCU99^7/&HHC^#4:&$O:J7B%?Q!X8ITZ0',!#CP^7%3#EUXJ
M=9,A1X"<2E]SC]K B4<NN@A7JH(T^+%=5/=P(&$<NK50.'P\<<:A]RF.BO
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MNLV6Y3V4BA2<(.$#HG+4B_X)NFF&D3 S-^34N^KW2.C9V><N5M#91P;00L@
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MJJ8:4Z^GRXD-OMK%FX3,895M<ET+$*Z2B7I%$B!%1J2Q.69708QSJFU4J6@
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MY;"K5(51 IB4J(CPQN>]8+G2$=M;T<LWC1<Q5"&+;$BLW<-5TC%$!"FHBA1
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M>*D/0[<#!4HYTZL4&@Y .09CPZ_80_.)\F-S/U?WE^CLE@OS"_;_ &-&N0=
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M;4OR&JH"'.78/FZ$I%"H)0 .=W9\D4^@*5 :!B'G-1%YJ_&[:Y)5R0H#5%=
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MB$O2[8IU%6#;[AM)()/T!9JS[YHJ"K-DQ;'3+K;$4)J<*G3 #4TD_&Q3,:
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M:II%J8<S#2H]> K41XAQZJ#CFC:%L<T#\S7X%%:Q4J(BH)N[<:]. 3*  0O
MI:   ' H %*=08%[*VS R;PP$UNI"'8/7!N70J=5W*!S=D H7/(,+1C>"ATH
MUR<5'4<C&L4V#D3FUF%PR!'E'J8-0ZB\0KU8KZ%6IPX^C\30/>[IBOH;:O\
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M3&;N"JD$0Z*AE@'L3;<'&O-!R [81+!FX BA0(=/G-VZ9J" !4*]'5BE/C'
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MK8%9H_;E054U$;.G I*IB IB.L.%!M_<^QI '<+.H56:&.0SR$E2 7Q"!DB
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MB F&\S$*BDV69J1J+QZO(GE6 )<DSTQ3 8E/H^.'U\-O6*VY/:,<OW1]<OA
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MJ A4U=U?6>WON]NKOK9"CW:HFT47#^ 1FU<>*W[\:M'[F06<E6!NJW9J**'
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M6]8_9#<F\DK8(TNAN^<7\4Z@QO?EDSSBMPR351 KT>Z)-I5^UTI?2()'5*&
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M>!\@_+7[F/Z7U1^S4Q*V7=C4[V F"II/VB3A=HHJ1)8BR=%VQTC!VD@J%<^
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MS5:A7LJ*ZG6WEI2TI<)96YY2ZYNX9])L2;EY*4*R;@1Z=JF0FE-LQ12 N?:
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MLY'"T-XRZ2AG*A%4UDUU(TK@J"@@H@0X',0W;(4WG%"@ CN!>@I!]&0$KRN
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M=6A B92D"M S'KQMY+64B@REI<MHS<DQ9%!-,9.0GIV.>.#H)Z>R_:,#%<4
M*\L1'SZXW-F854Z,FTM9=)!=$#&7:(R3AK&.7K<"YBJW2=&43 ,Q.0..+GN=
M-FT&Y']U.85X^JFNZ:1D/%1AFL2BX !,DD!GRJ^@H@'TNKIQMS?=MG1B+N41
M?NUG;3EME@4BEVKB/FG2B8:C'3,?2F8>/+H&>6+8W FD7;9A EVWN.9;M4A4
MDD$THQFY<-4FC@S8!&A1*8#&*/6%<L;>6IM=;4W)SK=P]0T2L8@U?NSRW=4F
MC;\T._\ S1'E'7.J=0J9:F$1"AL15GED!=SEX$A[(,\44$'+ULS8@ZN*1,F
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M4%$TEGK>%G&,BLU2<+)'*0QTVQJ")?)Q'$Q<[0DW!0\FUABEMMU,K.F::[)
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M1$Z9CD,<'#<$BTYYP%YM1O#:=SVE=%L*-X^#G9R#<,N>:/*)K<GF/.!(#]W
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M>>.&,@ /K!\OVL</L_ /KLL9@ _4R"G[-C\XGR8W-_B!>GZ.R6"_-^T'U_\
M3^K[GU/>Q6@9>]]K'M^Y]=[WU?=Q\OU<\_Z.1^<3Y,;F?J_O+]')'!?FA]E<
ML[.M>=NEVS;ING3:!CEY)P@V56!!-19)L102@)AH%?=X<$7UYV+=%K,7#A-H
MW=SL2[CD%G)R*J$;)JN"% 3Z6YCT#,"EKPP 9@(@!BUR$Q1'(Q.L!XY>[CB&
M9M)1KD<WXA<\Q"G#&K*FJ@CJRKGEECWM7NEI74'W<"8_9)103&,&D*$KJX]5
M,QPSN6>LVY(: D5&R;&8E(EVSCWJCMNLX:=W<N$@*;4FU,>H= >7/5Q <BB
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M%RE62-DJF80,4<C!^Q%Z;HW,LDFRMF)7<M&YC:5)275+R8>*;U"AE'#E0B=
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M ':'Y<?W_C?[80_=8_O_ !G]LI?N\?P@C/[92_=8_O\ Q?\ MZ'[K']_XO\
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M0(E 3%$0H;2(AE4 SQ4"  ]K, S[5-6?ETA@0 H9C40#A7*G#W, 4$R@!=5
M -(!KU:J=5=7$,5IGPKT]?' B)0$1#2(T#,O07X\5TEX 6M X -0+[GDQ4I
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M-RMR(^N@4W%KVN])I*@;214)Z92,?M*#S!*BU4(()<D% S4P"29 )3,U XB
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M(+++KJF*1%%)%(555E3#D!2%*)Q'R9X75;KJEM"WEEVMNL#&$$5@*=1-6=7
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MU4S<M1*/>*)G :"50J!Q*(8NM-R]<NT^:S7#O"G-$%E3'*<Z8B.09< P =(
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M#M&$I!7*<Q1TFI(LU)E"W;<MV"=W+<\\J7O1X^%C@.!U&[0G+UB8$A-01$
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M=,>H/<-API(B[[GO")3NVXE'KAS/7@Y?6U&KRB\Z\D%Q%=94ZRBA]29 *41
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MP*@EU=F@UPZAY*,CI"(>('9/(F09MGD8]8*)G3-'.F#E)1)5N!3Z2HJ%.6@
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MU"4P5Z0P*<S;\@@6@Z7#=(S]HJ!1XD=,>>7, $:#IP!3%,01_!.!DE*U"A1
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M V8X?V#;UWP]E-[5:-V<A<#ZR)6Z92Y+C19I"_%M%Q%N3H)(*'<5)I0+D01
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M^A4$<-(]#5S)!=)JDH7M!5PJ5+47WS81:MTP30:HI-D"AP!%!)-)(O\ 6@F
M>]]02F*!BB%!*8*E$*U\WA\6(UL,3'%<2]SP$9W@K1(JQ>\O*F,0Q0+T)CTX
MD(MW;\4-QVO'.(>3*HT(9[S6:1R(OR".8D4*764P5SJ'1B[3B!!&K31HH- 4
M76 "DU4I[F+;BT0YC:T6SNY),U=297[U)>(@V>H/[(&IPL8.( 4G0;V'0?J<
M/C'[N*U^+[_L00ZPIB4WF"X'RCZ4@TX16"%D@5D1%)LDV*L1V57F:OH@-33A
M6_[:OBZ-N+J>-4VLP_M<P<N8!(I$R'D6BK@A#C0A0IP[ &$*A7$CM*-UW.X0
ME%^^/;FF'KB<FU'9W*#E90/$G2A2IB+<I2HD$"$"M S'%K[?S,E(D6L]%D$'
M=# H,YAD[9E33,]0*DMH*94$NV7AP$,PKA6\;CO6Z=P+N+%K0T=-W*9,1B6*
MZ:R2@-&A%E"ZOIS"!A'+4-.(XG;/:7%(3J4[(RTDM)OVJ#=TD>6;=W4#0BH8
MI@)746M,3&R7IA)*1DS*$EE;@-$L4GR8D-&CW4&*:Y$S /AP=K6 ]KR8V?G3
MW+(('VB0;-V38(]JHC. V233*9YJ7**1NQQ()N.6+NE$MP;S8V[>C^0E)VRX
MY5%E%O'LBY6<J*.G15#**E*9RII(8/-, >7%L;?GOVXVZ]GS;V9M^Y4VK()!
MHL\=&<D1*S,XY9B(ZB<O/^Q@.+8N%/<^]8RY8*!3MR3NA@+8DM<T8DL\6(60
M7*J42+ #Y1/FDZ,^.-T(-M<MP.H/<R/9L7398Y.\0AVO?E/$6CX55#JKF,[U
MB=0/[&%:XN+;6X+RN:[X":3B$XU.3!%%.T_!N]J-!MAN4Z_=^VXU&'6.1"A6
MF&4Y+[I;C7>C!$.A"0LC*N&,.@BND")TG[=D_-WPA1TF(50"E 2%R$ SN*YK
M?ON\+/C[Q7<.;MMB!6(WCII1X[[\^,=<%$U""JH=03#F/TI@Q+6]%3\E-1S^
M==S+1*0112\+(\(0O<&PI', E"FK4;,1&N'F]/CCPL@]MY. -;G=&W<=)6:+
M+O*;T3BH8U&I!T<NF+HN&V;_ +PV[],A,%UQ=L*D*QF>;V71E$EUJ)F4(<Y#
M&(7\.M*XV_M.(E'=O,K N0ESHF;LF[Q:9D2E*"RL@8[E -2@)AJ.4!I0 #(,
M$,<>WF(U&M<_(/MX8N:3MC<"[K$BKU=*N[JMJ!$GATJJY,X.\J99P71S3NSU
MH4: ;2% QM$G#R[V!8;12[27C6*#9%V685;/63XY7RZJZ8D,H+.ASE ?/'++
M%MW(C=D]9ES6P5PW9S=O@0'*[%V <UHY 541RUJ<LQ%"TYQ]0&KE>#TMY7/(
MM+XLJ1M"?9R?+=+/%9-(J+F=7?ZRG.N(%'272!0KB8BD+VGKJBWZS=6.CI9!
MN@V@"D=RCURE&$04-0JYY,1/7I('7BGV<?G$^3&YGZOKT_1V2P7W/MC]7/ZP
M<O<ZQX<,PQ7,2U$HFH(DU%_*!JX='Q8[(U"H!7H$3&T@&.(\#::%'SB%YAO+
M2A3='X-,%&I1 Q2J%KD E-VBFZ?BQ7(0J(<0SHFH<U _K0^' 4.7HKVR!V!/
MD(B!C?@CJQ6@?C=H0 - 5$QJA_4YX\E*U H\*:@U&Z,A ??P)C& A2Y#F U$
M<B@ 5+GB@^<'$GX7E-0*Y8'.@%'2<>@G64U2AG@<PRI4PB7+I-7[^  <JB >
M:)J":@A40#JSQJ&O9,!##I$"E5*(ZR#K*0<J98 0*;28V@FD!&IQ#5V2F *Y
M (Y5P01J43="@"0U"FTC0I](]'2&!T@)AR*&D#& # %3:NSC,: )!4U#4$]
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M@-! :"&1@R$V8#D/E ?JC0E2E* B/2&>?G"0.&8]KX< /6 #\/LKLEU:<P*
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M8?N8D%'2S4C2 &0E,34&=0$-OWUF1$9![<RZQT+^:PZ+5K&6_P"CB2<LY/R
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MSDC%4(]=XZ.23N)1XR4<-DSB9$!1*&KCGU8G[HW$NB]92UG=MW%#QR2KF7N
MB3Z4NV%>,7!(ER\<<CZ"-4*8Q*:0&AL2NW%Y7-N3;JDC?]S76D]LEO)1LNF@
M^N%[*,B$E(Y03:3E6^E*'N#3IBW>V%R7]<Q'#!P6:?[AKKK/P726#E$1>O Y
MFDJ9R@5.@^[T8VPLO<M_N,@YL*W()H7T?AG;8.^(VZPCW8'4.T= J3Z(0*(
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MZ9#"F=-$JBA!3PSNGUF_6"VU]7[8'FHOH396,W4M&/NBX6P%.(*RZ$@[9J)
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M(C42W%=)?C+,%Q'SD?L^P3DHJ09R3%9>?N9R5!\Q<@\:N"HK2YP'2J75I$!
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M^(R(35</$HI@TCV[E[R>]*I,D$VZ)E@:H-4M>E,/,(4.F@8H):4X9CET\:X
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MY5#@&'UL3:K!>1CDHQVY7BCO#QPDG(IA,,RM55T4ZZ4Y-(%/+[V*T$0SZ!X
M&H>CX<1\4:1BH8)!P"/BL^^<1<(TJ43 O(ODV3TR:79H)BH+='9SRM:\G+F*
M=0]WO[GC8<T<N]<N%5K2?I1DD[627CFY2-U3JE.S,"RHJD[6E&E!$:".D@G.
M(9Z4R=HQQRX9<<L2]Z+3MKVM;49+L[<))W.>X0+*W ];K2A(V,+;EO7"IJ*B
MV^D%5,A.V7MAGC5I/RJ5(H(:2'*81$IB*)KN4Q >BB@F_&*3A@1H(T$ KI$
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M))\PQ$S?0%UBF6IJTS$<,Z2TJ!6B/)95?O4R-&_(%NF5F(NC\M,J1=(I@!.
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M!&C6(SKQ$-4CPQGZDRE?_DD-_A/'_P"I.?\ M6%_PGC_ /4G/_:D+_A/ _\
M^DQ_[4AO<S_NEY,7&SMCU,D6%R.X&8:P#YTRAS-F4TXCW",:[7 CY8=*:QR'
M&A1'+$QN&_CRK1>VMM/9%%32"31"XY\P,8[EI%*(=A)191,N5--0X4QUCTC]
M[V./SB?)C<S]7UY_H[)8+\TOU?;T?8/Z?W< SBXV1EG9ZF!G%L7<FZ, $4,
M@@S17-GRS &6>%>=;%QI<ESW(XJ0,D4!?'(*B3*HMR574#-)+SSCYH#CO#Z&
MEF;?Q 8D'3N-D6K894#JIFBN:X0*'>0%N?4AYX:#5#(<)NI:"G(IJ?6 .I.&
MDHUJ8Q--2 L_:(@(T. A01#!I8MMW">)(@9QXJ2$DSQIT"C3FD?D:F2$!X@;
M700SKA?>)HKWN&2G#1)(-K&3"TD[1*<I3SS1PU2.DHS( G$Y_,^B-4P"&%7,
M1 SLNV;J'25<Q4))2+=(Y"\T075:M5BDJ'#73AA1PPB)5\DW719KK,(R1>D;
MN7*9C(-E5V[1<4C=D=)!$N=0#%OV"V;.F4[<%PQ]NE1>,G8+L'3MVDW<.'[0
M&QE2)M$Q.Y<ZB=A)%0PY%'#_ &2NR9=0X,8B4E"W3'1:QHR4*P@HR8<FBV\N
M+1)5OS)#DN*\S2<E*X<F=P\XE%ED5(QC*/X=^Q8OU"]\,D=NZ<-DD1,<K(34
M1.>M>K"<OZ/7 $2JB5TG*C!R?ABC54 .BY+(=T%'28I@.0PG *" X;N&%O3T
M@@^[QW1PPA9)ZBZ.R _?DFRC9JH"AT 2'G%)J$M,^.%63]F[8O6X@5=F_;+L
MW;<PD*<H+-G"29RU*H YEZ<<*4I4/O\ LK3H4-YF92"8O:$0\X.KB/\ 2P!@
M&H#F Y#7IJ @.%)RYY/PU@1=-FB"31Y)R,C(."F,VB8:%BFSYZ^>K:?H63)!
M==6G83-B5;6^[EPD8%RDWFH2?M:Z;.N*+[T#DS!R]MN\H6!?E;NP9JF9N>[\
MIP5(YT3*%(<Q>6 B)Z"?EZ:+ 0!#MF0-0]*C3S>GJSP[A7KI<\XSL^>OSP=!
MDY.Z7MNVUV3.4=H.#I)MM0+2:"1$SN"&.)ZE 2%.8MNW?'(/VT5<]OPES1Q9
M!%)-VG'3T8UE6A7J;=P[*FH0CTH*E$XZ1 :"8H:L6]&O78D?77*/(:W6Y$5E
M!DI2/A)>X7C,JJ1#D2,1G NUA%P9$OT.C5K$I3.'KIP1NT9H*N7CA4P$2;-T
M$Q5566,:E"@4*Y]&?##6Z4K7N>TV$F#=U#-KK+;Z,C+P<@U:OHBXD&D#<%P<
MAN\([#E-WQFKPAB'37:HG#3@= *CI-I-J2.G00 1R!0I*\,P+6F%%3,WS;EO
M)%H*1P;.3&+'23F-*Z*I%NI!/0OW<%DR"ISB$4 %TT52*I)CVL@$2FX" &#,
M0-2M.O$A/W+,,(2'BT!<2#Z27*T;MB:2G!-0RPE^F."A.6W_ "AQ. %*(B 8
M>QD&I<C.9CV:,BY@[RL2^=MY\8M=3D)RS:"W%MRU7:[/F%%(7:"2B15"BF)P
M. EP6@'H<NHHZ1TB7*@ZJ4#SN C7R8A"3CT6!KBGV5KPO,;.C@^GI%-VLS8)
MBDBI0QR,5C:SZ2 !,S!4*AVPS'27,!UF#5J*6G$0T#7[PXTE$:AQ+I-J* Z@
M*)RTJ4!TCIK2O17[-MV'7=$G_P QJ_4#X?AP?W.-!_%]S&V_6%C6A\/HY&?<
MQ3W_ &7(0THV1>Q<HT782#)R4#-WC)VF9!TV6)0W9.FH8H^\(8<N1B[[;BX<
M*K]W9W>L@U0YQSGY+9'NI]*9=5"EJ- #$??NVZ-UI3KB]8F"/XQ/GE6PL'J#
MY18.4=NAVOH"T]W%P7MN8WNA:9B[S=P+?P6X5XIOW)%BU<%UH%27 1JXXU#'
M[SW"_EFO_P #Q?5R1;*^RR5OV==$W'F<7@Y503?14&_?,SN$NZCJ("C<NLO2
M&6$MN]R$I@]N*6A<$X*4-)&B78.X\K<&1A= BL)R]L1,%"XR9;A>_>:YJ5"F
M0=S#WL3%O;71+MHC<$@24F9*5DC2LO(+)E6(U0</%$4M2;<J@@B% \\PCG3V
M0/SB?)C<S]7]Y?HY(X3_ -C_ '/V/R9_)C?5_M6T8/=]TUHM.!3<E;I/V]KF
M19IJK0J[L@$[R/>I7E$Y@%%<K<I] * ;&V;O>ABO'7JMOQ9)2IN$8QI)NH8D
MB4(I2008&ISC% ^H#<M4"E 3!T8>;=WL];*VA:_C,K8-N]TCB1Y[Z+%L3(/'
M.E%(%'0MY.353,]5./.$G++GJ)N#!WI8V^2D/+$)$A.[@I;2MX*UI65>@QB9
MN-(G?T<[4107<IG.#--?Z,M 3,;LC$V;<SO<^[[4);(,YNXW<7MA#[/.M<(
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M)Q&A2@!0+F->CIKY?88B'X5!IEGAINU;K8RSJ*2(PO1HW*GS/!@U"QN,I2E
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M,6]_@O'\-F_\FK<_P=C^&K?^3%O_ .#,?PU;_P F[=_P;C^&S?\ DQ;^?_\
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MZPK1_P!U<8W2_6:G^CD=]=OC^J'<C]#YC$[^K*X?^<XGZ_/ @8H" \:^WRX
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M-G-S+)J@91A%"0Q#I(AH%)PL @/'EB Y@RA89@WC(N/03;,V;1(K=NV21+I
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M..G(1X\1KF(C[HY^R!^<3Y,;F?Q O+]'I'!?FE^P_#AK&JJ:"W=9]R0:1#&
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M\DHE1Z[210F&J[2(0U(F!7EJ&637*F;/&W#NU'UQ/G%XA.K27CSR-><CPYK
M+I)LS,(F'*!0&4-^!GCCPZ>/7BOMX=7WL;>6ZFESO$+KBS*Y?DVK%8LBZ5.%
M1R C00$<0\&W4,8+7LU@V72*8PIINI,[F4(<Q IGRGA X=6.GAG\&/;UC_0?
M4>L ^' 5UC7532FH;S*B-=)1IPRKQZ*XU)G Q<PU!6E0KJ[5!X4H/4(4XA3
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MB^,36(*F\.4U\S27Z<,]606'ME>Z4<C:^Y<+-(%D9 Z961)9L[8MF\>^%>@
M5SWL0*;H&F>-FTD0*5(A[R*D"84( $1M4.!A$?-*33[_ ),<<O;[N*]7DRZ@
MQ=6Z,L (P=A0CAHF[7* ($D9(JW>E04RS1;,5A-IKIU (Y&+6];Q :HS4X]6
M:9F,(,DE3MV=->FA>6D72% H'P?T(CG2GR\*<,6%ZK["YV5MM"PD[N]>TJZ?
M,F!$#0*3R.L:'YL@5,O-=R#90R9B*$%,40.:H=D9#?N "W7.Y%@1T#:<PVGD
MG$K!^F#*]("QI@7S=@_@CG143D#J$."J-1.14-1 *!MA4MT;#VM@-L_6"DF\
M9$PT,O<KN_K6\0CTUV"D]*.'Q6AU:.$U5D4V!-(&Y0GYA,_68%P.V)8Q9:U"
M[K]RCYDDJ:#\+O@;!&R%%'1B@Y,X(0TIXCWHAR!I3(GYP_\ :"(>A=A6<>U]
M][UM=5_9D X@7ETEB[XD&A+EOARJ\DQDY-8B>MRY.1,IS'-I(4NG&REX[KV+
MMHRV%NQ>QK(7;V\^F7>Y-F^*PZ)8V4GG*TIW)T04&ZSI1%FW$Q>4"8]LP5W7
MV[]6>V=KU(?9-ZWA[ON/=%:>5/<-RNBK&\ M]K!RL0#82JLG34J[@JQ=3<3#
MD8,6Y<]N6(S6WQNW==38J)L [[7;R.Y*#M%J*[F0(1LJ+$RKANF <XIOSN@C
MECU*F.^\3MXTFF,Y?"L-,[:.9HMO3[5\%K&D62L;..G;ILYCSLT>8;F"DMWD
MM $"&QZW.Y3[;ZRH]Q8V_+FTH>+LB&5M=>^YV0C(;NKV\W9WDR5P[^E,9P[*
M!!%NV H9T#%@P>XUQ>K]=MN[A3R=OJ_S1RDZ$_MZ\DJ#%^D)9UY+DDDB#1,S
MEMW4AA&N>+^LZT8K8VU(JQ[O]'&%G;M2]QVQ?.Y#(Q&ZQ9NUIXTBQCDD5?I$
MTS@56AZ!I,.0WI=+)/4^@K.G)=J"2ZBZ9G+..550,BY,9N=3, ,3S-5.BM<6
MMO#:A82<O"Y'D5?%UR%QI2$LWE96_+@.\N%VH=)ZU7.NFGV&IEEE.4*90$#%
M*)!L#;N[-K]I'#W>6 E5[ MN$F9HCZTY9!) 5D[YN5T]436+'&=)]\[BT0 2
M+"" G,&-\]MM]F>W\+=FR2\5(3%P6,:<9VRI;TBU?.^_BUN"6E%$P2)&G,*I
MENUYYTBTSM7UTYBXV 6YZP6[-Y;52MK'E(PSRWMJ$NZ6]MA*NXLAFZR.E>SQ
M,^,<G;531/GK*.-LC[4P5NS=\O=AKJB8STM>/&MN0R#J<$7$M<AF*)'2S9'E
M5%LW4 53*D*0Q1&N/6'VUW6V]@)G>[9&SBWY%QVV:LN2$W!MYZBS<-O#6;U[
M//$#D"59"<"NUC'!;1H2,F(&9&O=_P"K]*6I+6ZXEUV>W<S/,;UL66'NHL;<
MNBW;BDW:[A3Z91-VJFDBD7EYA4<_6ZV'BBF"Q=NMT8V\+'9$J#&WFVZD>]N2
M8MB*3H (LVS@!,BB T ZRI@XX"@4#[U?8(_.)\F-S/X@7E^CLC@GS0^K[0^I
M[0^LR_I>7 5J8H^<4--#CF4QA U<P*8VGJ,(#^#BZ]BIQ9$+MLQ 0ME58<RL
MN<H[M]RB8U*%;'U,Q,(]E,Q<2,+,M%8^5B7SR.D6*Z8IJLWD>N9NZ;* :GFB
M7(>D,PRPC*P4O*P,JV(KW64AI!U$R;4%R"0XH/F1DE2#H'\;'+'=_=PQ2:*:
M]S[ZUU+E173<"9#@/X15"G#J##B3MRZ+BMJ5><XKZ3MV:D8)^_!P)5%"O)&-
M5;K*5,%1J<1KG7#ZX8R\KPB;@E"'1E)Z*NN<97!*(KJD773DIIN[3<N-:B95
M%#*JG,8Q $QJYX.W7W>W7704(9!9LMN1=ZC==-4#D53<@:6J8I@,(?;KAK$0
MFYVY4+%-$A1:Q41N!=\)&-$=0F_-&L/+1U!$1$1$1&O'$<K-;B;@S2L2\))1
M)IF^;NEE(>03UI)OH=:3F7IT%P*;\L0Q1ZA :81=75<UR74[:(BU;/+KGY*Y
M7:#4PB<S9%Q,JO3<NIC&T_\ A!P2&@=P]P(:%2YA4HF*O*>CXTA5:\TA8Q%^
M5L&JN8Z!R_!ZB/6[MRWD$'8/T9%NL<CMO(IGYJ4BV4^ET+@<*\T#&-7,  :"
M#=:ZKLNZZ562:R+->YKJG9X[(CKDB[!FK*/7"B0',W*(D0,F T#JPR;7+=ET
M7*VB043AD[CGG\RG$H'(BF=&/2>KJE1UE:DYE*ZM!<^SCIK4 IU^]ALQ8-E7
MCYX[9LF#)(AU57D@^<),V+5)$*B<ZBRY *4..>(+:=@JB-^[@$=HS1DS%%4R
M[M%)6Y'M4S& Q2(@BP*8H\,\%+D.DI RR 0T@)!IUTX_T(#3V]6# %3'TC0"
MB!1$U!H ',!J#EU>7&[^Z>]1+2W<DMP9B-]&HV9M50L?9%JP[<6,?"-DWLC(
M JIR4&_,6)R0$Y#G H"L-/65VMM#<"%MK;S?:7M*XK;MHUHN'Z.W<Q!W#"2D
MIRU/'$2O6KM"%30!MRVNG07M^<(^K3(M;P817\P4S'RSQ-W!KR0W3X?$LHP$
M$SA)M>[:A9:]1^>(5\G:GM\+,W?);ULWV[M5QN)8:EK$D'5Q-K6,[!K&,[B&
M20[NB(2"U1[J<_T@AJICUG;&/N%&@OZP^[,]N.C(C;3LR%L,YF?6F1A7#$9[
M\[,4JQDP6*=OF.K0.G/;R&W9W_?[A;/[92\/<$#MV:TV4.YD92WT=$*G<5Q-
MWRQW2+<Q  @&2$PD,<AA'4)AOO=#8??!ULZ\W2%HIN%"+VFWNF(E)!JV.T\:
MBTS2,8+9X(*&."X\S2HJH< J>F(3:N+O"?CKO@+V#=.(W8(1OZ2H[E\Y18]Q
MK-TP3*<NI0IN1J)44DAK4N-H]VMR/6+&\[RVJN(KUHU+83.&MH]ON#@$O'LX
MUG*F53=.B(-BK.CJJ@84 /RPK3'K#6!>]SFF8;?+<QUN-'OX.,-%2MC.TVL<
M6&[H=R\DRN'#5:-Y@K"4A% .9,R>D1Q;LUN!O9"7I;UI*B>'MR%VCLVT7,P4
MG9;$O&=12D%78I!02F1*W&H8N2W7?K&"?;.Z)0K]S SVW$%,7=;K4'[5^,=9
MMZ)K-%F291:%(F )&RKKUU$HL[,<&6D8AC;2%KJ]['4Y?QS:,+#B=VH4"@91
M9(NHQJ  &&O1BZ_5DD-PX:+A"WLN\VYN(D6^FEX^RD)89:-A9]@JZBQ,J3F*
M)_1JZ2@4IM1ZB7&R6\Z-UM(]KM&UGVR]NJ0[ERO/J3*38"N4),LJCW?EBCF!
MT5]79KPKCUK)^W-UXJWG?K*PULVZDL>T7[U>TH2,.\1G4%CDN9L5XH\;2"S<
MA@*W!,%![)L*[>V[;-L6K>B%KV]%Q&Z32!*I<;2X;=09=VN1X(.D3+BHLT%5
M9+G)ZN88-0:A'&W&Y\-OFA:E_;?;1!MYXY'V0202G)P'K<RLS)L)*>7(=@X:
M$.DO'FU&YABK%6 2@&-V;RN;>2=G]^-VXQG"2&[<5#M(=:VXJ*1:)1;2W8%P
MM))$ G<R<S6H.H$DR@!:#JMC>?='>IEN!+6-'3S&V6D-M]$6(Y?^-,G+#5>D
MM$NESR>@'RJE3)DH?2(>:&-P)J_IB-G]S]V-Q[COZ]I:'[P,24J\F[3M>$C#
MNF[946[1D),E"!H4543+J(4IA$!'VCC.@#_2^[C4'V<?G$^3&YO\0+T_1V1P
M3W ^0?L<%>L.90Q62X(2[(E-$I"+")7K!6N0B<"ZDC#YIRE'$;ZT>TNB1BGL
M2BO?#9B0QA/'HE5;*W&+=,#:E&AD@0DJ4Y1&XK&^C*JH4=9*',!5-(B43!J*
M!RU#.E2B4:>7KRQ]KZGWOL&6,Z!7I&G //-3,<@"HC3+IRQ)>LQNHHUBK;MJ
M+=R%I$DD# DU*F?M7:Y((]LP%#E,0XF,L82@ @4<2]XR0+M6M31MO0R@F4\!
M@6JJ@,V50H7O"@&%PZ5+4#'7TUTD ,#3AE3W. ?)_0=7$'&WG**Q2\^G)*QR
MQF;Q9CRXI$'#LSEZ@DH1+L\.92OFAF(5BKT?3RK:(G7#UM!E6CY(DE+'CW!V
M[D[&+[EW@Y"F3$ 4!/2.5!S#%RWC;\^W786NS5=RJ+P%8I^S4H<&C5VVDT$3
MI&74TII:RT$QPQ<UZ[B;JVZK"LF,B[<V(C'0C5S:[1-R@FQDG+UM&,W(H*$(
MH "Y/F;@6N&]MPUSF"3?K*(11'\9)QK>752.9$Q(UV]:-TE:F#272;/4'7B7
MM>3FGJ,]"RD=#O(WP:7.JH_E034:(1QTV2@.:E.!U.5J A<S4#/$VQDIQ\D^
M@9$T:_8EA9M1WW@AT$S*-4$H\XJI 9R <XE2<<\AQ!LR7:55:X!9]T%)C)JI
M-U)']Z(22Y60D;*#Q%-8Q! !"H9X>[8MGKDUWL81*X7+/N#TK8(M;N?+7)(B
M@5$PCW]/L@<1[7DQN)=FT-Q.V<W9LTRAEI%U "06C[Q)LU<I)MK@CEDEBB03
M4."9@SRQ9MX;@2ZQ#RT3#@94C(7$A*RSQF5PJDTC85D&LYA 1T(H%#J#%QRM
MLS2BQK89.'\M'N8V392S=L@F)P>>$NFB3@R9J4*8A!J.+AB;G-&LI]@O*2D8
MC%PTS'1H6FT7032?/I!^\DD06_. UDUICQ$"4K0+?)=O;,^\,)+>&R(6X9Y7
M2"*=P=S[L.0ZJ\SS1 WFB X8Q5V3ZC=_+( LT:1S&1E'0ME2T*\62BVSDR2>
M0T.:F11$,L;TMGUT#.VE"3)!L]LFPBF[9E#O)29,AH>,HQDY6U(HI4[PJH(:
M1KGBQ[)LV\(>SYBX)!,T_<4DT8/R6Q#*G:@W>NFTFT>I%2/K4,8YTCT*F;2
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M$=R,DJH)!J[!SKHEI$!0 .UQP8=?G4 :E* <2TJ42A7A3IP1,OF)T3 @%$@
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M^<9"W6]V@+GOZ5KN'CR#+K/]"+=9Z@S5&A0Z2XNV\_5[G[1)#W_(FE;DL._
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M*>I=)] ^[3#)G#7!<KU>3>MXYL=O8-ZG:@]=*%3334<!;XD(/TQ#'%00 I3
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MVI<IM)5,HG.PDHV%FIN*=%TF ='.BP(J)1 VD^0XV^VGW/;+,-W]J]Z[=;W
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MBX !,2E<$V=?7>K<)T+4D+2:W6YB2H+DC%@>-8PJD4:66U=S:N$FY:O!$X(
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MU%..T4Z\F?GBI6RJ0MX[*3K2C>BZS/=&E->V:.&NWPP^=F<U+1:Q'J?Y4<
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M\288SLU,TE-!O/*-^5+;B(=%,\&#,Z;T5+FQ>?E2LN1%G% JL@HVB1(G#O\
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M"/ )MX)]Q)JP-(AY=Z$B7'#5QK4J..S&I8-J>%SA@MOKFD<&&;L3[TU\F+]
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M P\A199A"+6U>L?%)*<(+"+$\W?%1T[RY^OLHK&=V#<TA0D6"S=.K@$QY/\
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M<H\_Y7+/.N4>?\KDO/\ E<H\_P"5RCS_ )7*//\ E<H\_P"5R3S_ )7+//\
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M%1QJ:M$ &ECIX#%10+NG***P!2322)O2$RG-.<: +$-*0!W*U%-2#00$&VE
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MFI>])J\#+E^ZAGB^JU@MUE3@J7J(" 0);KEV\JM6!Q=!L"4TF8296D7;TK)
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MUJ)%A)<)","SD3)=IF)":A1K<+XM95FF=,3RB;F^D?N:"HV?H7P/K PU(P(
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MX^**X[>/'6FW&M7\(M\UQWKRX[UQG_:[\=J?]TK/&OX-]*:#**?6 !(%L$#
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M:;U''^T7WXO43?I'*_:L\<;UY^=%[5GCOKQK4AQQO%3QQ%$E^..-*CG6#O\
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MQ1X(198V/.:QZ9C"4;PSY&*&A#*;!NQ*>U&8--3?6#4&<2)T>&U,SE(DM?\
M4U)XL0!4W)7TI\K$<KY2+7C<P'G46B[7>;Y:TL2<N]R@G[LOO#QY^!QQ/(:C
MC&?U46^;]\TB\?/Q7&M-_C/%J;5$X](I_F],.7''O2#Z\9H(H O1QO'@AXH/
MW,.< V2/G-]Z)Y"8&4%F)Q<C,J26(J:5;T'!3-,3[_RF58"PE")4;E[Q,9BL
M<D"D*,P!U2C?%%R!'#HT&BN./[7(KD5.IU.N14ZY%3V?*I[/E0-) ,;BD_ P
M!(+AO<A9)G*1$V>6 )ND8E+CG>+[3,?9SQSK'U?S[#8H&):7VSY8MOFF6(K
M8=X PL3=3)S!-(A<YPGHE\/3P 1.E#AVM7-Q+4_3/T-,F+[TD3\?VE(6+%NJ
M5H.FLVF]1K(K,HI,SENW&6(7%72 I%*K@B$@FQWH)4 9!8S)F(N.M28BY)P:
M3<KH01>)J55CN0&M);Y=/U*I@"5F ,Z11>ZBS%VT>;LYI>5X (F]R/-M3;6F
M:E&3%(5+M:9M,3I3C:@-P<"UB1AEE-2*<CP2.DSL^M.60_F#QUH0GMITHIYT
M'&U+QWJ>(X^/2K'I7$43QSI(H_#-7Q4).= G40W N'D/.AQ,$>:"S>D.+Z=Z
MAX9'2SR[]/.IA><L3&F.6# 64.(4! &$N2DP:$SSJ(D:)8Y9K*3VXKUR'1HY
M'*MX8C_&\(5_G4?XWA=@>V7]VL]+//#]-)2T@" )E!LPP";ZW)#00^OKVY-L
MPN$X(!(6Y>$@U9BPMIRDQ)<1B8N)-F">UH+;\##ZXPJ;<6XWK+X4:@Y1B>=<
M_P U*I,Y1QN](KF4N;Y? ES/-X ^91@Y:-J9W9]M].I9ALB62..KI6%C.-^&
MUG&W=F*FE[+*\' YNWM%I9*'+9"^1DD1QC#1,TX/LU=;Y&GV(J/ @2E$#R<<
M/7E1%  H@0)B3B'FP&@5$2 ,PQ;1RRYF^8%3Z5Y%;9L(1&#K2,W>>>6?7G4$
M"9,UQQBB@EK(H=PQ,+=+[[FD7BI^T(4;8R#:QFZ>14Y,B0W EF8IAU,IA"%.
MSM)#<QD:#C!IA+K@@6C-C73G;IV\'QCQ6?PFHC/ZQQ^J7;B])0>I\E1O_:5_
MCQQI4<<VHFFW'*-:SZ<JC]Z_N@T-N..U&.]1'&:<Q[5%[\>I0<<;\9J?[ZUF
MGCW^V&57& 1&2S9PCZTX!=<,7;I+P3.7*(I4@OW9^8VJ+;+G2//I46V=V].>
M;]IJ),>Q)Z)0M7RD]UKE/,KF'F?NN8>9^Z[_ #:[_-KN\_[4/'^5/EY'ZKF>
M2CE/,_=1,N>9?I>@,![T2(5]8_M3@ R2Z6&1M#,&^;U@28DA(8%PER8+:&#[
MY]>*(CRJUH0=/6:7M>,PG[:%:8[?.:XA^E=?R:YGI^E<ST_2N9Z?I75\FN(?
MI1N^GZ4C'LIL3;H_<BFES09B8Q.QKIRFI&R0B0HYA$==?W)</ _K'Y\4^C/T
M1YX@,3).UQ72FIK@&$P$MBYEM<V5:A= B@SA6F5MD#2:FL8UW>:WGC>D25H2
MQG]=WISIV,R+]NIJ?W.&M .?=]Z+F8GUHIP@)M1?'7/KQI5N%XNTPU( W-I-
M(Y:4^)@&"$0O8KJ68DOS@UBX(   CB;6)T>:)OHE).(8M)RR,U+<]_3Z.-O!
M1Q_?PK>$WN<<<;VXM>M'_:F*7COTYUCCG37&32N.M9IXX[4O'2II>O'2IGC_
M '_:>-*>?Q6?*ACRTI?CUZ<=ZXOUK/'1^VY @B,X[)YY-YH!>64S"<LE(Q?7
M EIIVQ0LI$0["!UJ29#KCXGE:D"70>/3PL8=Y^/O! .8OUCE1Q0V\(8")%$<
M0:JP4"(  $P!U5UN]65_ ,?7C4E.14E^P"L"8%.])<O=X=*<H/8\+IN*7-</
M/P\YKAYUP/V^!,\GFX]^(I\QD6V,2,)HP-(Q&@0Q,:Y(O0L$"W$Q90QR'0(L
M$240 ME]UE\Y\J+KSHVN.*GW7^U$_:#Z(0B$&4R=MHT34*G#(!B4$A>P"VDL
MO.F9%FP=&R[ORF,%'+^Z?3AG"PB(+FUXTSHLTUK%(@3E#H(O+0N.7G-<MKN<
M<HUJVT!-XNULO;6]+9F2%^R3RYWY4AEL'G [I/?O6!*A;KLW@XYU%R#)8FG5
M=H*WNU:.WQ:5)WXBGNFX!"Q)4.8)LL#(Q1&4#(;JXVA>X0"0LXI$6S.N=?YW
M\2L4^*S1;\$O[Z_&MN,UC]5$\<;UQKTJ#UFEGBW'KK4<=?"%L>F^:_O>H?;F
M?MA%7%Z@7<W&*YO([TSR"(G62>?=1R"]EH%MY(T!(H"6C?XQ0_QZO^9X/?\
M*4_Q/ <?XE#1FS!-1=4<A,BC8A)!(+_&BDC&W*FDESIUI4^!5VC$CD89T9R%
M&X4 "N.:5WNJ[US^^_82:,RQM02 08*Y=<BN17(KD5R*Y%<BN17(H&"ZX9;6
MOKM6"HK&#2#1F=-YG%$R@;KH:JWL33YU2+T\!N*<O%9HIJ?&,3$\W3I#FD_W
MAP:(G"V<6!IY$JZV2TPHQ+.+ZJE+5NS.-Y@(-L[:!5C&GIZ^ FI$2L= S*")
MN8NQ*E96#3;*13+#IAC**Z*)"*AO>+834VK/=G"UO+:_]J:1=$94C,7%@,0L
M4*XQL ZH33)$%C+(U-1DDA@"-%#WGRJTB(3FHL@P(UG,WG#0Z/")$%3@#J8A
M+.N]"1)$9*DU@AC!((<S493/%RQKC'7Z5GQC\(9XCI6...+4?JH@I=^&N/*F
MG^+_ ,_GY8!2-XM5VE#LHA@]J:H<14.&H<14.(J'$5#B*AQ%0XBN^BXM17+.
M?@WK"ATL(L@A9&)F&/2B;@1%]#=6>-Z6?P3CR_$F!PV>C1$'.+WO2SX7,-O
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M79[=6]*$AQWH;SH\9H8O\Q^Z@(;G4_WTIF1;UU*/! Y#37!G<,$TUD(7 B0
M3P 18RXE*$F)"Y4@$:H+[I0UJ906%VKKDWOKI%BA$L9Q-'U3/_AYL492%)FR
M04QKC)WI\ D -6R3KL:2K#2V80!<2V9HB;7F&A4A6640P9)O%K9O0;L;+FAF
M&(ES*EP+NLF7SO!FX)LQ"Y*4[@QY@:F<)*:12K9ZY@O#%[0%NM#$F!2CK2Y)
M-YM1&23/,D(CFSL.U6[X(3:(PSA@BXAF](MP9? DCAC9-:+ %NIV67PF)ND+
M;>! CF;DF!-XE>=7,P K7-$QR6C$W!R Z!,F22N!MFF1!:N,-V62W.L;""RP
M$"W;+DG3F$BM"%$791LVLP31> WD(EA+>]TF6]*X"&5UAC$-[DMIH'@G)F#+
M<Y-_:FOC)6@Y) +V/-4*HN7-"8Y 0"C.;8H84Q"&* 2XIT)3K9E(/DF^9A!L
M9S.;44<B4;,K)!TVY<_OF7;PP]>U--_HQX?-%_"-K-(>F=[I;7OV*="(4.:6
M,80%&@O:GIKP=ZS, !Z7H",&#:A"LB-;DQG0I6,LPW]+5.JF)M4Z5=0EBE&#
MI#(QRS,9<0"Z4D : > VL)/3+:U)IR+"."MY%R_4- IU(%%@IE8+PSAL8S6\
M%ER\[?SM@*S0>./IUK'W)O'A)0S4LU+:K=*EXL^"^OB!B]14121]!5M'Q0,5
M.U 5>?S6MH$ WC6L$-2&I,<3-&NXS;-%-KCDVQRI] @LZAWB=*=$P+ADX\B:
MSRJ$+C6.?,[5 A?LD0=*32L[I+BP(\W7:*AK-G8_2C\@!JAF6-L[LMJ18(Y.
MM]J-^8"I9&^W,_PJ.P86SK?CO0<2\C$PSL>5)4E9%Q@.(&=6B7)BL5BVAS6F
M3O5H=!9RT62$;.A.A%"#VFR3/6C+-:)#A*QKI/K3=TL8Y5B[?@A#U[\_;!96
M,X-*$1'JT( W(,MSD\W.>M2(N0F<!DEXW@(#13% FM2X3)<@UDF$Y[5$D3:%
M)7F,QHW,WIE-VT06NB'3,UB]68=0D->=XFDK^8F]GO380((0U:MWTLT-(4 D
MK(7(*!#8G-*$/*;M8+JHAQ!UJ21! R29W3KE=""13*>"2"20W)6BS($:4H6M
MO:[]U:Y/'&G0_$6*$R]:&4@=36IG)B3+RVCWH"0(Y\XK7#GDMW.&U%BP#KII
MTWUH@@&LIK <M=ZFA[W+GZ4N#II0B3]T_<8U8'S^*UP_7IK_ +3Y9?G% )PW
MTJ>1N^W<XOM0VO>&#OBK,$&LA4'MB)LH#;;E-J9AF-N\\/*;1)A-V+22SC--
M%7_4=\>;6KCK:]NTT$L.=]_*CKIWBLA#7C%37(^?:.4MZ9-@U73TGO$QRIS(
M?6;=&H&.188SJ4$1QHEYC..=J:%).=SR)*?!;[6_9Q&)H")K^<,5<!MQ;6C
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M;';Z?WM&;_/U<;5;S]3A^QKD5ADW6)3CO5ZN5X5-&YG![T4TA";W!QIT\%A
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MAZ^_K]G%M/N#LX9)<X[5$+B\Q:+F<&BRD.8'-1QB;%Z9HC@V8$@S6P3!P,7
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M&M9&4;,POZ&BH@7$E*2P$U)LSDS29+(L(DA4DF*-')[[S) F$OI)@UN,(*]
M2<I\4*CAD%RB)J H2U"R%R'J):"HH9*G&4\<FA"HQ(V&G))LP2(&0:>]1_\
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MOJ+@G%@WB9Z'*L]@)#FZKTK:RSF@%H!!(B@ $&@5#(0;C).##,W*C<<@*8T
MB2*A$(4J9KOQ.!/5I2P?6Z#4Z4>YD%455P$89GEE%!60*N_/-)8A"SX%<80
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M.C D:WZ+V *%5@!&/.ACI5LY,VGRGRI-^E0#FPD8  @<B'L"H=G6%\D.AJ"
MFV698--JI2WZ>E5JAN-D9<)MOER*A=C"P-TWS@Q48+BB*M) %EPN0&U:F_Y8
MCC!5I04P:RY$<A 'GZ4-W))%\AL@Q]&-#E-KI-N?T'[=.OCI!'*UC:T_6%83
M$X9W4(@V27HD>)P20J&"T/J=,7K6E=,N*NX&CM(JAM0KP:"D(A%EM"E1BVZN
M"8\NBNYMD0Q!*P.I)YR%)!@$@1=P7-P)L%)4RZV57I492]Y&I2O$Z +X^#$W
MI-^)SX<.19.(2(< _71%[U^4,"/A(;)6!F9"@B0;AHIM*]534U)0+SZ&(+2N
M%6+UBS/':!4F!Z4=^JR#+X]92#N2K>2&X(!(+0%EK^8Z/B1$T:MTNYJKM 89
MF$CE3DQ"L&EWNQRI;)[@!06L84!PLYH*0B;*F4 1$(KKBGK7J-.3F=00,?7.
MY0L0>J"'-\K>]_6E,9! +$Y7 H"8!Z#B$9P$NI ,O*K-A8CC7;2Q5O@:N?R/
MF#H4Q$5!O"9!U+^HH:H ML0P<(@LHQ3DZE[@A4S@0*T5V,>% K)E6142;WCD
M&7A,H!3I$U#+^J14E,@Z/ %,4]7FDZLS$J7=\MZW0TWTQB-C&*.!6 ,*\(5.
M>QW\60)">(131L'7OTW3BM$05BU/R##6LH!S1A3I (HRHXO/XS M2:$81*B%
M5BY30D7,#.W*A;VXFF1)-S)CAX,XY@('WG\))NK=U9F@4#T!281MV<[ N4NR
MRJS"73:T 0% E;3N%LB6+^=SJ^T)@"SQB9L4N1$"YSFWAU"@C!JWQH^8$W(M
M4XI,\>I#JV!)31I"R1NN"DM&LP=3[@XU_JFA;AK8"(D)%)V;E#ZDPP9Q/^Z)
M+_@"&W4YK ()&//&*BI^NRY"E7TQ-6$U+B]L,:Z%:57*+)33;0"H.XG**(**
MG1K4"LT><94IPV%6_P#K,Q):D=BN+TF"\XK)+0%H4$<$#$F.2+-)I$MM[L%
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MUG%,3 %5D\!).$ &XXL+4F"MB1!XB(8$A9%NF55$PQB5P3-"-P+ U]! %!B
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M24T@#7AR2#ED0Z?K0X)J1*221#O)FFY'):R2(![@7O#?O($9-"'[ ^"$T(@
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MO4/Y.6=T*1%,*42LK>/C2-60E,SS14@&K'2 "*X0'FS/5.0(!)H#^,P$ L
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MF:L3'GDN*PFT(#&@ )(8*@J118/I)_GCU"Z Q:.@D'(:[Z@W+RBU9':AC&X
M%J8H*8=P#2R! @@B)U39UV99=T7 U]0_/8?XL I.W8C4RM13=5'V#49-SW\R
M= <M:#UU[=.7$U)E:J:"2G"4@HX_Q+[CR#)(140!6.$+J](H!;%(SSV6 1[
M-479X2Q'+W+)6N!0,SKH@"A1E+'VQ2XWN9DX@*LA"Z\9NE.<S26M> XQW_7J
M"MY\)J:+  'RI(SV\H),R484G,T+7J<=2B<)@@C5FJVUF_?+)A835]?I.&6/
M>I4@H]*Z8-,\J"PR5-<VY.0J4K,O&?\ M\J?V/P4-=O5@^FZ(7,KL,7MF@LJ
M*%VERBJU 97&4$$64*)J[TZ0H)N0G:#.*(\R1.2-N_2D4W9'R=4PTA)$XLA#
M=<K2THHDQD"2TI95Z(!8\D5(O9#23+4+98 7AA$M C,-BMDDL#$3BF$EA#8-
M(Q<.HT-:0LDDWSE< R\ZBY;>4E@8I?4+Y41 A<P#">5^J@ (OD@#D#A2CH2.
M&$9K>=(M4):):I<222WYT@7 B$2XW2"+5+9BZ+(H=3$Z-=4$7+]T/*U)26)N
MS9EL#&E-<W$L1>811AR*;J)0%Q"#-G-WG4),E2UDD9<LTI&@XO\ 1&P6QII&
MWW $)^QW/J@"-/HB2PZ9/4*BT;<HB(CI1Z  /;Z! OA,,+D7I2Z%Q*#]F+0W
M[?'B3JSVCPB\ZXK5N'+X^B"9@G>"=L^$K")B;K,8RM>J #[^ L!T$5 CS0"7
MH1_W.9OHT^'QQ-=./?Z J&D,\C9N/.N1/6//;;-1,ZC9.4(TI4Y+]>[4#%L8
MGD_RF^;C*T^9YT,2=R.B7]*MC#N2QRQ6$TOK>,3!CG3%KQM?IO3LXF2\6C2,
MWOWIW.VVY;M4;3#-\1)M.].1KJUB<%$;QF=#;P8VZX+L6G-)*$VAA$Y4B;>U
M(S,VPC29OG7:-L4%@Y3,W;KD\\T&81'JL]5:(P8),(_%-\<>35BRR^I?Z1D$
MPW.]3^^//_V/)2!;BQ?/W.O+^5(Y+R))$U(L@@T$<QCX7^TC<(II24 @(814
MO(,A-E;A" &'*HH342@7JP0Z2' )I)V*)(0-QN66KJ)R6H0D!!%?0)(58BSM
M0B:^PFA (8W12X9$(<IR&!JA8UH>2G24=P4&4R3:D4'"(! [+EFW5>DC*1L5
M!0@E9*ZSX]N7S\_^[Y*(@NC?9,VV^I]6Q;6%^KYQ2F&I[D3S#O 0NC&P":07
MQP$[5A.C2O:R M=+:YJIN@U3*ZK@4HR_7?H)G0& 0:M]$0\^4T\0LBC\1:EE
MV88P-R!37XY*2+8'@S0:,$ )+4/,6B2EL$3#]Q#"@*,I<6Y?J?<4Q1-/X<D<
MK:G 6+-\8,18BW3'TP*.IC&I'T<V)XU[?^3C1 % KJPHRHO5ZB GH..4(@9H
M9.7J!@18?.9SH$ ZHM&9S^5S+RFKA&SXLPQG2<3I/T.+-F"Y)+F#:M9-R5O9
M(07>4M2"@8SM3%!I,I."6I*Z,F442"%-B1.M 0F9>D+KVJ>Z;,PMHG(S^Z=K
MF1M[##(E)(!O[V7%1XDC)<+$>WP?O?S67,>1"TNQ,F8@%L>33[O2$0H5BG4Z
MB44/>+2F  5;F"X^U8"P91$HND1ERB4ED;1:L@8QJK)&[5-!5_Y'[; ,]"*N
M\O7]-)JS$.E%TX]:AD $+<0Y$6+Q9(L$'K3SHBRV%V9OI4LA+&$#*,1:-L31
M>U,"+P8"9UJ0[FT:BTO*AD'.>>YGZ]HL'MR_\E%_6[R!+ ()%0HEG8[APUX$
M824'T@UZXZJ66(-#\3,F0*%$#A3&Y!*%3L(@$155##**.EX-N9+\KE)OU+>V
M+Q46B^V6?/Z6(O=(>^!UIP@<KV6SW\J?^ 5(6,AH  4(2M#[:>#1IL-32?4O
M(5!)35P*#PX-LB%$$J "C]JTE,(@*PE0<9L2(Q&:8)&X!K^LU+3ILQ\02M8A
MC0 *#FE0I=ZA)7\$B*(6TQ"EZEBEO,M(XLPT=N& R@A0P7EB[D[,Q&5".1[@
MQE0RYC!K#[@<6$J4*<HT<%$[C,8XI1JDK'M%O<J8)D8"C_0C>4MU.^22M09"
M4 ] P661-352@G-0 WXDJ#"\:I/%:8(*U4I,LY-'[I*B0-$"ZU&R:52)$ "Q
MU!JX,!I;!_YC<.NG*]2QF$41%$[#$"C\SA=FG'F(U+206O U$X EU[*9!4@1
M2LKW8ALLII^(#B 6#%@$,9F5<?E<DG#7Q]VWS]"VG@W6Y7/&KR\+I$)+%KB8
M2S0)2"U R., 5P=HL\O)Q:445+,JYDPD(NC]568.GO\ W!B33V<4#-G+/[>4
MJ;6)?:A/=B=V=!,=U<?1M6!K,))X+5JTTM\IHF;S:+3_ !B=.82&'>J+-:PF
M2T&@!\N@<"?8B)$%0>@AJV-'TS:E$"X$]0JB3+0Z,NHPBNR(,Y">U"=C+XD*
MHO389\!TVPB3U1FAH$9CAK20@_AN _&[3$ L8  ;_N*P<B.226 #3[&?,\UV
M1V"9KSQ^<2T.0M++]P2)N#SM(4%!2#5[,P[?@[)(DH R"=VCZ>D +[37=RNI
MM;F"-@$3'U40\ECA)Y,HP2NH @QIV5#:!.S%9OCM,$U$P)&0W2L_$ [\"I1%
MBF"W-18@^7G)$<^ EVEB<Q-L9OB$(#+'MH+$V*S*0HOZ8X&B#@(*G-HJ/D.+
MK/0^%K2E\LY,"$2N\L?U4(32B%3O98&8E%+$$U*,R"Z-*1JQFET0[%QFL.\N
M8Z.R0-NF:3D'"*./DWN'J6#P*,U"D<$ALZBD$8#H(S0F 84A!8+14NS,8QY(
M 4@8LV G379%0X#I,MRWZ5J*9AHG#L7XTA+68DU&L43,^E+PP4L86\A*-'*D
MRF &BL+/D&7.UR(NASQ<'7%,F5G*4#1UHNV6MDJ0BGD8X2;AGL%.2XPX8SS@
M :, 6#_CHF/_ '$M$*9(Z]0 TWBK1/'<  7CF"T$WQRF@,/S.W"S7X*H2DIM
MYDOEE0&^<OY'#]WA)NLZ]BU@68^CC@\4;X%L)BS)4M?4$ 0A'&Y#)1(",\DX
M(ED(0<J)C$RI$R"Y0 *(F@;@K-C4$,1+211)2I-OP9=&(8T:&(7VVO, ,6!4
MA)\B%N%)P0.DY'++M&D@$@K,>=ETA5$$&X;4LC(V];&ZP;)"E<LK)$A# 2,D
MS>]*_0811%F%2@"*/$:F@E(%\%E%1>""YWM'"!%MRT-D+Q*?!(,R*G65=4'&
MI3F]% .\WWOU$,@!S&47Q<[6P)-HB(N4*_,1&J%(SMH$#YJ_F:0K! 6 4">
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M/$DM^""E*LK(?Z7?VW,)D$56U;#=-)TN@B6@F3'O; 1T8)8!0B!/';.HL$J
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MU<E\U8L>>'I)&_AF@F=:2;-,/"YEAS Y(&LU>GVS;CEE$*T%3P$16!R"6!:
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M)&I81E1;N014E:U,W*<*,2H-M2"1&)8FL%FD)A<RW61<9$*I!@MR;VN<0K%
M5ID@:=_"2$U0-*4:O"J+M+#L<"H0BE0A9X0> \F7I@&[@,>CDGXJ;0:*+'K(
M@D?15H=G"#*V^$>@YAB#MH9=M\!K>YFL8HAD&@$X$A!02'6CSB]H<)?EM7OQ
M'MXQAO;F^I^*DXK+5<RSB$BA3 A^]""HGT(EFK#] C#^(B9,P%[WY:F3=C;
MPPFZ^(5("3"SK2Q!4>*B2   <%!(X*G !2)11(24(V1E&(T(&U"A3E+H;N2"
M=XFH$2NJ4MBWW4:LV:#LP9<A"614,>S?Z#I01+BDD@@5,%)/ BMZ&@)M^E+;
MBAN!RJ4.YO\ %X\V+P5)L%P[J7;Q@)(QTR9%\ %EA"05/[/?NWLX75,V4@ F
M]P)GYB@A"(]7/*A *SPD"C4>E%Y*LS%YL!0L#"M3)'((*Q,NM0UL)Z3KF-:
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MC#.E(!:[.>5CQSI12-P82][YOSIYT%L<[R'T>WCSXXM^*+!",(0X,ZC-.I5
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M2LZ5B$ZBP 4B245P2$"-D[T2<@YF<MW;[,^5]YML1^"M%_R(IO#0HQX*&X#
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M[_Y6-\^[R^J=-8EY:4M1DO:62X%E%XN5!) ;PHST2G<05"(^VH*)!,H!@ G
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MEZ$&+8-!E5= PGZ $72"Y%Y!UL)$Z(O$MRK"X^R5SD@)$J!$<%,E *D$Y;M
M\'S',[5A;&F_.:=<(60AA+0F&=%&,/ <0D&C2'<F$\:.P!;;3E (?3!.Z(GE
M,_1DLYBY&_.:TPWTU)YC][0O%WD0LB@6&@%- +-R+Q 4%(X(-\H+9 /)8R+J
M_M/W]4-GK?IZI @33(L^&/#^,WJ-<3OH26;33T3$T-@()>7WR.8)/.ER.&:0
MHQ]PH/ R[*UY=3_E<9W9)\"\PVE;\) 9&9@S0%GTQ'-"#1U\MI4MEXN&GQF
MQB/">P'DP,>IC1"1B@G2+94:V!!VDT]2+8D&=-'.MY'; ]F.MX$]W+Q\]'(-
M8']8X+WAX(S>2X-O[4EKFX]453,4JR- XJQC\-$D!@+)FF7[W^8_7WIWE(VS
M)LL%0OK'II9.8 "&]+LZ:9(J6R"J)%O4/ 1KEOS;_;!7GQ/ZOJZK0IAH\G&R
M[?D</W>"F%N^9[>*&9FT1$&9S/U!@O8DR70B9@WVUO3BGU&LGX.5Y9B5)>]
M+>Y90BUZI(NC]VB]! =M.4;<J$<(]&:A4! <0GS $"C"85=[;+G%-6ZK>26[
M+J0O*QO,R12<PA!Y,,)4A3=/?E.49JB"&Y!+@HB9_77+BAEL'F4^=Y#< N3"
MJRMSWX<<K"'@$$$Y7NJ\JOI"X1%P66=?+%+-FFR1X74(9G%!$MKCER0D=2&M
MFHA2)?>(!R:1!GFUR#H?3USM[[;^ C<9-R]-NW&/P"\0G<R()#E1234 &T/'
M#2AYK6'*LTS"I\^'=9$?!3-$>>MVS57HB2! 2>#(A1I;E@AK_P <<U17\":(
M2(-Q3(6B(M)DD:X<VG58PRFQ==.FN[0(N[U6)=@,T!"",DT60,.FA*42%D=_
M/(- +<P=7(OB"1*,3DDE.?\ DH7\:JNB T=V-JJ7F^9;:?2MU[-RG)6^@ ;:
MX1*9!>=CT$AZ82A8I)EG!7NG^+5%R6H49UZO;-YT@DGP/YN/1O\ \D=8?$GJ
MC!2,Q?@A'V>"5$TXI8"%60#9***8!38O<W; U.>@6V,G%Q%;=HKX-F6T@D""
M\B$2)$"81YE0RP @-\)@[DVK8,0=)'WA0TD%+T^U^ Y6U 0+!_*YF>B-]$J/
MWY?5;?7,N=$SOIX1U%3MR%Z"]+L;&1+O1<76Q"4V,+N(M5S)V+STBK)P;,9R
M&W.A(&<I+X<D3M6P[1J0+/I6B!O!:XL)M_*!'+[<MA!, R.: CEH=*0F*)<-
MRV#QZ59W*A#=51BX!&"H1RX0),$2$,ZU(.S"JW,84$50Z'Z=9Z"(T*PB!8U/
MFE(46*L&;&MO.A#N..>DI29LB;MIL@ZOE4*,@A>ZQ-JJ7'JHHB)0N"'O4DV@
MMW#%KSJX8F['.Z_Y0"'S@DZ2/A_F/U7^8_5<@VQ;73N\>1P_TK_,?KZ>4XXM
MM_SWE9<%(TKB7@BPP,%F+T3&9"K] 1E\CL5FQLVE S"9W!-O:U02XRY-=*?2
MW[KA HN%#(C!;-Q(KI>-VE='I<KZIW(PO0Z7$*%(E-6"@M?BHW7E%B15/Y"<
M/W5IZE;92RUF+3:)GZX)F+XG6-IK;7><XS8IB%19;)@26';TI2&UPG(* J8*
M1%D;**1ZNK>(1LA47S!.";^:/2H%A4(J%TA8QBEDI8D' B2Z40ZT[L@+"!8&
M!$HLN6F(NNUYTP!IDA0!, $7"4L[LT0$07(65RBV)%#B^*60 )%.)8F6$!A-
ML;40F%$K-P%F5D$C,)JU8*KBRHB15" L43E&X(F80EJ1)A85ILAEL 82UP0O
M+7K!NH('!<D0(97UCPA!2(0+H2$7M,BI1[8 5:JL0*[5'(><E_U;)A6*;3"W
M0'K&TZ46RF%8Z!_Y<_>E*8O$RG 4FE"LRZ*JJJ*R:K7M7)V\"KBGE0=JH#)$
M694=E=XA LEG):@0(" *,52\3+^4.6P"[/ZG3[*TN"!;1<C4HCZ!T^!82&0J
MQ84KH<@-U 9&)(5XH1L+A+)<S"8+U;P(LY6N&94ZWN12/SW..6DPMRQA%^R4
M30-$PP5=@[SG[?:1 6A<!N>E7EBG"(VI%>O5< $/B99PT@=-D7<,D T%F(=N
MJFLNK=,#"Z5/4VS-L<,(#%17U)[4)/*I.)-"RG[>9T<C.TO!I=4]ZP?+VS%B
MM"" MA@"9.I2,$DPL+@D3@P\J05$&N-998J F6!FDE^^3*P1V)  NA4(RY0
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MHR6A@4<3 B97DCWH18&;:B9'\'GN8CXI/?[4I<R8I7%K,JJ Q Z1M3>R;5Q
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MJ1BTFT>!DJ7-;6\<M@=%'1%HN-:GDZ0)N6JX'FRZF%!I:H"E0/$B.]Y!!8?
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M8"T\Z\!F%#%X0MY+IQ'5K4F*<L82 <Q)9+:32OD'_P!5^,(BHW&H9 N\K-L
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'0.'.?'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  N     $  0"X
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
M$0@"YP1+ P$1  (1 0,1 ?_$ 7@  0 ! P4! 0             ! @<( P0&
M"0H%"P$! 0 " P$! 0            $" P0%!@<("1    4# @((! 4# P,#
M! ,!  ,$!08! @<1"!460"$2$Q07&!D04#8)(# Q(C1!,C5@,SAP(S=")"6
M0R8GD"@Y*1$   4!! ,'"0P3"@@*" 4% 0(#! 4& !$2!R$B$S%!,A05U3=
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M    ]_             .)2<MM        '$XY90        XE'+:
M'$I.6V@       #B9RP        T3C&+EN0                    6FQ79
MR        "UB734        6I2ZR@       "U4MU;        !:DNL
M   ;-;=)=$                    %I9E=JX@       "UB734        6
MJ2ZJ@       "U:W40        6I+K        &S6W,72L
M      %I2[0        +6)=-0       !:FXW6F0        M:72
M!:DNL        ;-;=)=$                    %I<5VL@  Z@V./DO9;9U
M=QQU<U*[9%  %K$NFH        M6EU%        %K,;=/*        "U)=8
M       V:VY2Z0            .OJX\=CZ1:,YU+S@L*93EI;+#R_1.:)D96
M:$RKH6FQ79R  #Q&L;.8W/ZSKWK*!<UH]--H  M8ETUZ@9/H5R&2S"]J9;7*
M8KRY1)9E;MIBI+=&RXQQNN5QF2R%JTNHH  LHQP=,BEPDCL/RF1\R   M9C;
MIY0 =4K'YAEDO($5UWRW#,O8RKM  %J2ZP .F*2\=7QLVY=?&X$G!Z[0)+T7
M( #9Y8VZQRNB #I&3*#%<X^'E+V5A#C;+G;79=9D      /,[BXQ<>M^KYRY
M=%FER]8XO5AZ=HV-ZQ,IEN6#E]H-H%I<5VL@  ^0";-_+\\^J5   M8ETU\9
M[' "7L9+:1Z1,ITH'?RO5*O5I+U^,9F7?G<<Z#S"'=(R].U@M2EUE  '6"GC
M:3Z<O?)7Q#U#J  !:S&W3R@ \=-PP>ER)+QR_-,43)RSU6UYAX]?3( "U)=8
M 'BNF.%C+*W+&[F-X/9]N7Y=>O&3PB+^@M: -H6X+I  \/N../&;*>4?:DN2
M6$7V/)XKZ]UC(     # *3X)QHXU9S^7FT6",U;?B68%IG-6TC[>-RQRH%IL
M4'FKN/66N55<%3+DZR5^M&?MEL9>$V=U&-ZN:QQLS'EZ^T[3%]/MMK$NFN(-
MQU<;\:S"N7L^KA5F*,N.DN64EZLYC+%T,;83*9DF$J]@4F1URM5%U:  %G;,
M0Y+@5B;C>PBS(AD  !:S&W3R@ Q N/VC:'"(^<N)L7,RF5F-P$L[I9EN* %J
M2ZP ,1)C14%2X[G'4X09W2]<5O>: #9K;J+HV #$1-1-&723&BMQ%G%[%;.E
M3&^DK*@             6FQ<RL\[=6'3OV,#C=5@W&1\=;B]HV4PLQN=J<RE
MP-JZ!>RS#:WU,RVL2Z:@       "U5QNK,@       !:TND        "U)=8
M        VA;B6Z5@                    M+BNUD        %K$NFH
M    M7<+J3,        6M+I         M276        -H6XENE8
M            +3Q=B@       !:Q+IJ        +5)=50       !:TND
M     "U)=8        V:VYBZ5@                    M-BNSD
M%K$NFH        M4EU5        %K,;=/*        "U)=8        VA;@N
MD                    "TV*[.0        6J2ZJ@       "U2754
M   6LQMT\H        +4EU@       #9K;E+I         %*34R@      "(
MF@!:;%=G(        +5)=50       !:I+JJ        +68VZ>4        %
MJ2ZP       !L\L;<XY72        !@"GY/B>N0]SK(  ?EII^FM%UK0  .E
M>/.,>^&@!:;%=G(        +6)=-0       !:I+JJ        +5EU
M   6I+K        &S6W271        !U\'Y4,Q]V:^9!.9K?&S):7%.N6)U[
MKWU)RN7$"WKJ2W)$OIJN/1I+V\GG(L[$E_2"4"TN*[60        6L2Z:@
M     "U2754        6LQMT\H        +4EU@       #9K;I+H@
M  Z^#\V)C[]I?&@N(#'F=OZ&^+PW9.O.R\,O:U;R/%@Q5R#KBCGMG=&G61+D
M19EDO18?K.J!:;%=G(        +6)=-0       !:I+JJ        +5K=1
M      !:DNL        ;-;<I=(        &&">,J/>]7YJL7A+KV>PJ7PIG-
MZNR=OJ>>1>PJ7GEQPEEY;9?S&XT5F =>1DQ9[_V0%IXNQ0        M8ETU
M       %JDNJH        M5C;JY0        6I+K        &SRQMSAG=*P
M       :)T&S')9><G'C33)"VVB9I2\3LX%+D/E+('TL;,;6SXQ3;=R:?/9]
M=_'W91X?[9V3>9^N5Y!:697:N(        M8ETU        %JDNJH
M M6MU$        %J"ZX       !LUMRET@        #IPN-B)>>R8]+W IU
MKF@F9B_ KA"9OKUZX+]Y3B"VSDYQ7'US1TY='OU/\PYY^0^L=A_0?1-?*BT\
M78H        6L2Z:@       "U*764        6LENG8        +4%UP
M    #9K;E+I            TY-*8[G+,       6GB[%        "U>*ZF0
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M51%(4"I HI!,02=M_AOM'O.^"_O/YFKFW6        -FMN4ND
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MCX?VT>.^RVXYO3;O1ORLZKV.&_=>%Y1Q>=R3#L>?ZN1YU_IGYSZ[/5_)4%E
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M_H5=#B>ENL        ;-;<I=(            Z>?;_&? +^@?Y_$ @D@$@@
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M^G4>E]_?YX_H)V,=%[ZT^,NQE0      B,9.=%J2ZP       !M"W!=(
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MFQJU3NV)C.$G/CH@J!!*@@@D*002I!!*@$BA&.WM)\?]>_0W_._]!:J
M   M276        -H6XENE8           !YUOH?YZ\5'W7\. I"D I*@
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M$))!) "R%,2PDJ!!)!FWT7OOT#?SE_0?)?@^AM%,KNW$        6I+K
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MT/ED^M?D?6N"20 0143;&6-Y>N[[WG_G?^@7:AY[Z*        +4EU@
M  #:%N);I6            >=;Z'^>O%1]U_#H)"DE820%A) 4A2 %( !%47<
MQJ(RRY+HY.]QRX=OT49\*K(T[ZL[&1JSKQV:>[C3KVS(LG+7%QJ83*0 %)!)
M 4@$@@D!004U)1KV>@KYW^C/;U\._;         M276        -FMN8NE8
M          !YUOH7YY\5'W;\.@02 I() "D  A9002 I-/7MSMZ3Z1=7@=G\
M;/3?G@^@P%]#\]S8Z/VWR:V5XVZFSY>7&WDSYEQ^TQA[SQUQNK[/(WK_ &&)
M7<^)Y/=F!O?^'MWRNFJFF LH4E)(%3+!*"DDD@E822"0"#NW\/\ ?/:C^?\
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M=&?',Z9KU\.9H;>),J8ZF/*J936AEPZL=VMJY&IGA[&/A_[+],?S7]*U9
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MR1IW3\NOL8[5R(1&FPRXZ;W'M"^)?LOGG&YE>T   -H6XENE8
M         +2XKM9        !:Q+IJ        +5)=50       !:TND
M   "U)=8        VA;@ND                    "TN*[60        6L2
MZ:@       "U2754        6K6ZB        "U)=8        VA;@ND
M     ;.JXKC9Y3>RZ9IF] - DU@4&W2#<+MTWB@"TN*[60        6L2Z:@
M       "U475H        6M+I         M475        -FMNHNC8
M  !^5@ERT[[)?S^K/U^C!9?&8?IULKJ(.C5C>.7MGM'7/'B4L]!$G:4O@3K]
M1U0!:>+L4        +5)=50       !:I+JJ        +68VZ>4        %
MJBZH       !LUMRET@        #\GV+(7'/.7JB/T;%Z9CH2K]$R3\^0RZ.
MWJS+(\H!J+[F#QHRWM3U(6_G(29''ZR*U4+2XKM9        !:I+JJ
M  +4I=90       !:M;J(        +4EU@       #9K;E+I         'Y0
M#',)</I,::_0(QRZ1\G2>>X)/.HG>DN!*Y?6>,K%[PTOK+XT;>05ZRL7B;RQ
ML2?K+3+<4+2XKM9        !:Q+IJ        +4W&ZTR        %JUNH@
M      M276        -FMN8NE8        !Y1).R9,?3!3)W\XW"B3"BWTPI
MX\:[!9EE[9=PZKI,5%]3]G29+]+*=JNK+RX9:N5;L?:/AEO9M%IL5V<@
M    M8ETU        %JRZ@        +5K=1        !:DNL        ;0MP
M72         .E22T-68DR?7%\REK'J/156$<?;29E]2S<66+7<QR(Y,?6QV8
M)_0?SCUQ>Y^#^K'X/^_>87<+3Q=B@       !:Q+IJ        +5)=50
M   !:R6Z=@        M276        -FMN4ND         < 2R=<"C[-QYG+
M<C5<2\[V"U99+E1PQ-P:-M,N^8_'F6H;VMMOZ_'CL?/9N=3["I1:7%=K(
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M2QBZ^,'*L-M&>M+-HB9)92G+"6-":LV191,>_#YQ^B>QSI/=#9K;E+I
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M)"D *2"0  %(  () 4A2 "*HPVU3.\W%[CW_ /YO_H3V)]'[^VZW2L
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MY7.X/:>^K\]?OWM!\O\ 4+<V72            .GKV_QGP!?H+^?JIQ*+"2
M "%E )B!4Q3.?RKC[:INNAQ.=:_G];O=.VC=..9<+G^GMN$Y]5]_5S;P<3O+
M:<GIJ=E^/EQZM>SG^KM/K:\+/<WI_M:MW&=_%Y!CSOAY\3;QKX9;';IY#IY.
MZ;/G9Z]*3<8X+R-GGQ.=<3L;>\KKN2X\VWO*Z&"0 "9:+C4H$!2"$J6"2E*E
M @$B%3%-23        %-4WE7/X/;>^G\]?OGM#\I].IV6W$MTK
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M%^*^V>K[Y/\ J:JK5)=50     -/7:Y)VAM"W!=(            Z>O;_&?
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M6?-+K\/M/N</G<I<OR6_9_QD" %(    "DA5E$W>J'Y'^L/49\C_ %E=<
M     VA;@ND            =//M_C/@%_0/\_04D+*02I!!%7GZOT%[>'Z/@
MO(ZR\W"[GXV6/U;O^4X<X<WY^7#OMP^[ZL_8?*<A^E]'CMVWG,ZN@^@?0U.;
M:>?CKW'F-&X<HX?8<UU<[X#1<SC]QQ3+J[R:>^Q7[GR.UNKFG7]I\_;Q;<\[
M@_1T;MKNX^GKW7+XW,:]_"NPX'U=.?(='*YUKY/$]NGE_%[*T//\_M]NWD?#
MV:V4XAMT\[U<GZDY'S)A\O9Q+%=CT^5'3^GU\;;G9P>2.3P?D]5]2<OB&7 O
M7Q/0=?/I?E\E*5*(64!202   I(JF[(F?JY^.?K?UB?(?U7K\B       #:%
MN"Z0           !T]^W^,^ /] _S]!00   48\JK'#2NNK9LG'*FZZ\=L7&
M$9R=&Z-VI$7#E.OG_5UY\"W<*BX:EK'=R#3S-&\;X>[C<CT\W:W5K-?P]LAE
M&.NG;KYCP^TYIQN;9SLNCFXL>13-%<SBB-MC5&WCTLZ]&RG;IFY):YNIRT1A
M6<C'9+ R8VJXP,Y7CJ! (64$$J00202 02:>6WG7%YWNR_/7[^[E_)?5IRH
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M?%-E4M%D@BJ\;395**;%DS+4U;>S7R7UCM+\W]*%J8NM0 &G<6%U,E.-JR
M #9K;F+I6           ",)U,^O^4>&?[U^%JKE&2K'*<5&6%;/3N-<RBXF5
M&.NO+- JF6RRT;J[(DF1<JI:6,VJC%6RB2&,W*J9:5PKQSC/&J79,-XRHDFI
MLG"TY64"9$BV2AIJ;)EJMIEB8:&6.Y9T3&O+)C:<L)M8&0"<<HJ9(LFJ)*KE
M##:QO&=*$FU%,QG*K8DFJL<Z9C3G*L)&6-6.R,L$RVMPW,RISU):EA)PVY3=
M+ZWWE_GS][9'<;O0   -FMN4ND            =//N/C/@$_0/\ /V8BA,14
MQ%   (44@$Q%"**F,K"Z4W]T'C?M>A@N#U?:\4YO$OMU_H.B+Z%\#RBZ3T?Q
M=ML?V'F.7:^SO5UO>XY]IY2ZG']!V1^9^C<1PX/6#[+Y;]R9[O5E]#7SKAZN
M=:OD]-PG?P[-]AY^NZH) A4RD%.28$ 7*9B !,12%(D@4B,B)B*E9DBH$DK)
M2E2@"%E*3.OS_P!#_0._.?\ 0?(CB=[$E3(  ;0MQ+=*P           #IY]
MO\9\ OZ!_G\002"DDD !2 I  ! ) (J-7*]1?R/]2\KW<RW'(XE&G7P_D<'H
M3^B? ?35\I_3F5O5^LP[[GR?'<.-FSUGM,>N9T>-W8^7RDX/J;U\/O,?N1TU
MWN)V>!/H? 9H]![+>,^+;N'A5WWA_/)]*_.NIGQ2D+"2 4E0"D$$@   $$@*
M00HE!!(   4@ BHU\G.SHO>_H$?G#^@F1W'[U*  -H6Y+H@           '3
MS[CXQX!?T!_/X     I()4@ *0  %)I3;R75RZ<K59\MAR75R.%[^+RG7NW>
MOD_)V<:H^ICO^=NT[/#3]_#DL\/FZ\J\[L6G[K+/;SGTG"ON/!7'XG;8P=WY
M*MI%)4  %(*2H  *" I    !25 !2%A)()() (*;OAAV,>4^G_HH?G'^B7W&
M8  V:VZBZ-@           '3S[?XSX!?T#_/T 02L)(  () "D*0%( !S'A]
MGSO#M;'=AYJ3GG#[/BF_C_,V:;X]=W]G.;T%Y>#Z#BN[A6VY757%X_8VZYO7
M?=T[_A9X?=U[><:.9KS9P#D=9RG5R[<;N!]3/?I3#;9<.8 A025(!!(    4
M@  +!(2"5(4D$A2  02M*1<N4\;L_=Q^?/WCW/>1^P:ER  &S6W*72
M      .GGW'QCP"_H#^?Q2 L$I25    *0H( 6$D$&;W0?2LU?,>WW/.XOWN
M'WM[.L[.TO-ZC><C93JEGNSZ&TNWJ,Y>A^@:<SLWV_F+B==W'VKL^OQ.PW._
M# #T/S/G?"[W/?H?>8C]SX?([J_86;YO2=7WL/D&,O:>1F   4@@E2  ""2D
MJ  "P2D$J0"%D("PDJ0 L)%V4LN6<3F^[7X+^]>Z/Q?V    ;0MR71
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M8.>C\5F'T/K.N3U7SO4EG9CISB        "FJIEZN_CWZ\]7GR+]5[G=
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MK] '\^?T$[&?.?0ZLP     T3CL<HH           #SJ_1/SSXJ?NGX= !2
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M-WCRB*V-UA-]"%1%]U%!=QEQ2?LGTU[K\S7I6O9%*U"Y<4VD*U9BTSY;'O\
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MNMUOZ#K&E1UZZ5J*=0K=2H_3I*]QL0$J5!JHT?W?Z 2(S%9O ' <OKQP!>.
M. X O' %XX X#@"\< <!P!P%&%>.7W <!7C@+@. N X"X#@"X<!7CE]>. .
MX O' %XX O' ' <!7C@*\< 7C@"\< <!P!>. +QP!P' %XX O' 5XJP+AP!>
M. +QP%>. . X X#@#@. +QRZX#@+@. N HP+Q5@<!P%P' 7 <!7#@"\48' <
MO.(JP+AP!>. +QP!>. +QP!>. . X O' ' < 7C@#@.7UXX O' ' <OKQP!P
M"Q"<AK^O^@HO7_WGPZAU#J'5\-1K\*]0[VT=0UH-;1^T=J@[=!U#6@ZAU#J&
MM!K:-:#M4';H-:#J&M!K3X:T':';H-:?#M4H.W:.H=0ZJ"IE*"G9&MHNNMH*
M7:C4:T^/4*F4H-:?@ZOAK0=0UI\-1J-1J-1J%28I86XMQJ S_0,:_F_E.'6C
M06M'ACG8XI9:ZFJT+4X&IF^UWNM.M=SZJDRM(AN2N9IASDMM;RTS@9XNCX?W
M2IPKV:N=ZI.U+S2$%':I9IKI?6^-V_\ ;4/!W>GN5Q)!+OWA5'I5W"EVJ6>L
M=+D:)0X4*6(#Z):V/!MAO&33#7,PVU UJ;FYLL=5I)MKJ:8I=5-R9L2,J=4B
M4.!S<<>ZZ7G.55") XG(41SK<0M(4WNR/QMK3>B,/NM5NMR9017M5*=;42?Q
MQI: EV-[TYW,MO,>"_#%N!]J2CY6VS]NOY%*Z!2FM4VN#=>@O_T!&_YGY2PJ
MIR-%8ZD):I%)SPE0J"C4B!;>UHVJ_OFU%?8YEMMYY*/BIAKPA-7%DT<#[[4;
MHE2*FM;X=M0'DE)D"RK:E:C+C2D*M(H94BA$FHD=4!J](Y'6V(U"-$64J6M:
MUN54!S0NN;O"NRQQM;#C2DS6=0]4UJ##CDAQR"K8<:RW(W!=>B0J2U"PBBDC
ML/\ >E*:E!3DK2*2G2QM47$*&]5>V6H%-KJUI%)1CHF6J;F9&<CL/2*27(IN
M5F4J@76HR&I1>B3-IY1ZQM5''FH%UR$AJ4VHDK0IK6O8NK^1IJ->R%*8M86Y
M(*H#/G\;_F]+_0:5-LKV*W'%6G"PJB:W^T4MMM&E!K0::_"M=!KUVTI05NH*
M=@?LJ-!^G2__ %2%839;\_C7\SI5?]E=?6T^^^U*M+7'51>-\0<N4U3$I%/@
MK+CC##"5UUU_B>U9>MNI88JJ48>X*O!WJE55EZZ[Q?B[JI#%QUMABLZAA)O>
M6UZ6[.]&^V^^XV_Y_&:?^]_%K\.KX=7PZAU#J'4.H=7Y-* ]+WH\%37P.EI*
M'N08C[X&-EE;K&VG:)14+K5!2EMS?2^PQ%;?=<WTK2Q-U\-I0<,MT,0]JVB3
M6XDGNK:TK\>H=7X=1J.KX=0ZOQ]7X+::AT>*(1=74:4_T!'C*%J_'(AXY"/'
M(AXY$/'(1XY"/'(1XY"/'(1XY"/&HAXY"/'(1XY$/&HAXY$/&HAXY$/&HAXY
M$/'(1XY"/'(AXY"/&HQXY"/%I*"BU&/')!XY&/&HZCQJ.@\8D'C$FOC$NERU
M)KXQ&/%HQ1>D'C4FGC$H\8E%JY)K:N24'CT8\:C'CD(\:B'CD(\<A'CD(\<B
M'CD0\<B'C40\<B'C48\<A'C48\:B'C40\<B'CD0\:B'C48\:B'C48\<A'CD0
M\:B#D^43677777?Z!0(:K3N61RR.6!RP.61RP.6:CED<LU'+(Y8'+(Y8J.6:
MCED<LU'+ Y9'+ Y9'+(Y9J.6:CE@<LCED<LCED<LCEBHY6NI3EB\<L5'+%16
M+W#E<<L5'*]:#ED<KU'+%XY8N'+%1RR.61RS4<LCEFHY9J.61RR.61RP.6!R
MP.6!RR.6!RS4<LCED<LU'+-1RQ4<LCEFHY9J.61RQ4<L#EFHY8J.6:CE@<LC
MED<L#EFHY9'+-1RS4<L#E@<LCED<L5'+(Y8J.6!RS4<LCEBHY8T'+-1RP.61
MRQ4<LBV+5NJO8#$EOR6,W4HL_)UJ-1K^+4:W?'6OPU&M?AK\-1J*GVZV7TN&
MH[0M,I4:#J&M*CM#47&VZVFVU&HU^&M!VAVAJ*5'5\=?CK\=?PZU^.M?P=?X
M-:C4:_CUJ-:_#7\>M1K7X5KH*]=;K;:AX9[B:]7R2-?S.FW7:4;$9#D6>;RZ
MF4.AJ0DMQ-N6MBPQ*2>\U+(3N9ER@S1A3(U*A4'1<8@)ON.->$CDG3%(7"^^
M[C)U"U;C?:HM>;;TJ)><;?>\'76)SK3K?F=:]3TSU(K\CC?\WIMUNM"$KJV7
M&-2RU&ZH3%M"DZMP<$[<J*2U:5E"KT:DY\<$ZLZQN;KTZEX0'J1:D<C5I#<M
M3I4#8HL/M8E5EJ]N5F*$S6L)3(VP^Q1<S*;+4Y-"K?F?]XTH'EGJ57Y%&_YO
M0J5%:]D5TLI72VO5<*5[5@UU%>L?W5_K_6VM_;IVZ6:TL%*TJ.R/U%*5%=*"
MVEMU*?M%UNHK6@U,O%*5O&E+A2W04_?2G9&HOK993]:Z:BM-!3]/U^%*#]1_
M73Y3^@ZP\.I:4NMU;[_D,;_F_'3\_3_M.9G=(EMAAB?Q-R@ZO^WXW_W*I96T
MNBFZTPM76XPE77N*J[JJBENJJQ4?X"]2=1,6KO/.*574+/776V%'U[RU5:8I
M4=JY9?<8EJ:X:6U7U3%'*+TAZE>:3<I-5%%56ULO2K:FV(;[KD9"F_PI"^AM
MKEV[JDK>T:4LK4NBRXRXI76I='!7:6>M5%W6JKN]+5W5+3+ZF!.Y]OIVGY=:
M];P\6H[;[[S+]?D4:[55GY6M/P=7QZAK;2JDHM1;:07=<D2%$"A5*HZH"+TI
MC;VJ41?NL3%V7V(RK+/!%Z^!+UL0T!B*E:DHBRS*(BK2ZH"[K;$Y7;_94&IB
M[Z\/MU\!2H,0E&#P5EXX=2HJWTK3P/55#34E,4262@)),2)>YJ>30T7-Y??E
MH2;3? EZT2%TI>A+N+-1%F7>&TO*;J6VT0TL'@^S=33\6OQZAK^#6GX.K7\/
M5^/J^.M/CJ-*BZM]H=G4M"7>;<:9\C95A2-3QYJ''6L<=:QQQK''6L<=:QQU
MK''6L<>:QQYK''6L<>:QQYK''6L<=:QQQK''&L<=:QQQKK2Q]:Z5X\VVV7/C
M7VJOS8..-E11[:=:/;32E'ULJ..MHXZVZ<=;1QIJH.--0XZV#CC9I1];-:/C
M92VCZV#CS6.--(XTTZ<<;11^:].-M6G&VH<;:AQIJTXXUU''6VX<>:ZCCS70
M<>;*V<=;>SQUM%7UM''FT<=;!QII'&VD<:::CC334<=:QQUK''6L<=:AQUJ'
M'6L<=:QQUK''6L<=:AQYK''FL<=:AQUK''6L<=:QQYK''FL<>:QQUJ''6L<=
M:QQUK''FL<=:QQUK''6L<>:QQUK''&L<=:QQUJ''&L<=:QQUK''&L<>:QQUK
M%STTVU72,JPLR^\V[]?FO]?^A/\ 7_H3_7_J%3_0-.@?U_UK4?U_,_K^'^O^
MO*_CUNUI2ZX=CJ_Z":?"HZJVQ^WMFGF*U:>^EG;_ -==?9[=U;!K70:C4=8U
MJ-=*ZUUUJ*UK<"S*E YQ,/\ P?K\FI77YIUZ:TZ<W)*+%/*I8Y6L'*U@Y6M'
M*U@Y6M'*UHY6L'*UHY6L'*]E!2+6U'+!8Y6LJ.5[1RM:*Q>T<K6#E:T<K6CE
M>T<K6#E6T<K6CE:T<JVZ\K4'*U@Y6M'*]HY7M'*UHY7M'*UHY7H.5K:CE:T<
MK4'*UHY6M'*UHY6M'*]HY6H.5K1RO:.5[1RM:.5K1RO:.5K!RM:.5K1RM8*Q
M>T<KV#E>T<K6CE:T<KVCE>T<K6CE>T<K6#E:T<K6#E:T<K6CE:T<K6#E:T<K
M6#E8L<KVUKRM8.5K!RM:.5K1RM:.5K1RM:.5K!RO:.5K1RM:.5[1RO:.5K!R
MM0<K6CE:T<K6BL6MUY7M'*U@Y6L'*]HY7M'*UHY7M'*]@Y6L'*UHY6L'*UHY
M7M%L5IHX(#45_38]_E?PZC4:_D:_AIV:CL7VU[-]*4K4P:Z#0:=H:U%EQ5:?
MMNK6EMHZZUIK?6E>V*:U%;JVBMU12M:C6M!344MK6O[J4Z_A2EXOLJ3;;9<9
M=;6M3/W=JFO9Z^W37LZ5OK36M*TU%>H4UI\-?PZU&OQU_(U^&OXM1K4:_'6O
MXM?CJ-?PZC7X4NT"E&6KHX(#4)@I^O2H]_E.B5UNJ^H;+2TB(NU$WNMJ5)8Y
M6U56N]M2*/Q?90.U%)J!:2E+2/!"DU[67E)ZLE:&*'?NKS7@JTNKQ;8EM>+%
M"4MUM0HD[M:XK+WVSMJGFPFRQZK<:E=;%:<AZL-OM_[@:Z6*CG!MM/#(@HI(
M;7+P15SK;;95TM[_ )BL[NCV74Y4Y^'56N]EZ.U^LL"%U[\PY]+[PN_O"_F%
M::BG:H%"<E<0O;[T)G2X]_E.B?VT=[3#FP@N^QG-)-N8WFTPNSP9EC&N2FWI
MKRK^/4;U!R= L/.4.Z.Y8BO7.BBJRU8>I,2FU9'M,HN-HI5J4]R<ZU.:EOOD
M%EJQ,W&H52>EA-]'Y"4O*3ED'7J7(PXM*D2VI25'[B6*PQ.D2I3? &(:\"9R
M+S47AE7 G A3>89XA"ZVMYY+4M(-O3W%&5?U);@?:@MN+;OF5=:U5)Z+"W)N
MO;C?TZ5'?\KT2M>HT^RR\@XLRG9+I<X%%JKM;=>Q;4=5:GKTY)G?E*BZZ7FU
MONK?<;98"EB.^E.V52E-:EGDGTMTI732IEU:4H;8=74VX7=U>+E!=HZ^W4RV
MTVXXLN\\TM-9V;%I!5EA)6G5VJW"TXHT>.*LK4TJT5.L*'[M*=?S/72J@ZU+
M8YN%S@9TJ/?Y3HG_ -PO6UR4UO-H<3;9=96^\RTZ\H4.-NJ@K7M6&5L=.S4V
MZIUQ"E,?1201?<8T*;^]25,.[:8Z^AY9NMG>BM]2;SK:UM/4*2J5NH1<EI=:
MH.OO\:E[5IJW6J[7_P"4/IVS$!W9JOOK>"3#+KJ7WE!!V**R:&T5KS*WHE6M
MR3YE^@[.H//+26.CA<O,Z7'O\H-.@Z?&XFVM>XLK8814Z\LLNP5(+N+ML*[N
MVWLTJ3;6MI5E@[NVM+T]]U;";24G<66#N"^\M)+M/-3=^$Z7N+KB++Z>&+I;
M2EI=*$%%5H7;07EVW7=W;;=?92ZE"*4%"K10FVT5LI<+"RRAW1?8MLNH*I2J
MW=BVZWNK*_#3\_3\C0:=)IU@\^PBUR=#%]W5TOJ#<LJ@6<T$CF@D<TDCF@D<
MTDCF@D<TDCF@D<T$CF@D<T$CF@D<T$CFDD<T$CF@D<TDCF@D<TDCF@D<TDCF
M@D<T$CF@D<T$CFD@<TDCFDD<TDCF@D<T$CFDD<TDCF@D<T$CF@@<TDCF@D<T
MDCFDD<T$CF@D<TDCFDD<T$CF@D<T$CFDD<TDCF@D<T$#F@D<T$CF@D5E!(YH
M)'-!(YH)'-)(YH)'-!(YH)'-!(YI)'-!(YH)'-!(YH)'-!(YH)'-!(YH)'-!
M(YI('-!(YH)'-!(YH)'-)(YI)'-!(YI)'-!(YH)'-!(YH)'-!(YH)'-"4<T$
MTKS.G',R<<SIZ#F=..9TXYG3CF=..9TXYG3CF<@<SIQS.0.9TXYG(',Z<<SD
M"DHMI1Q<C5UW3*]5K0EM5K^!MXX&W#@C<.!MPX&W#@;<.!MPX$W#@;<.!MPX
M$WC@;>.!MPX&W#@;<."-PJR-]1P-N'!&X<$;AP)O' F\<#;AP-N' V\48FX<
M#;AP-OUX&WC@;>.!MPX$WC@3>.!MXX(VC@C<.!MPX(W#@3<."-PX&W#@3<.!
MMPX&WC@C<.!MPX&W4' VX<";AP)O' VX<#;AP-O' FX<$;AP-N' V\<#;QP)
MN' VZ@X&W#@3<.!MPX&W#@;<.!MPX&W#@;<. MPX&W#@;<.!-XX&WC@;>.!-
MXX$WC@;<.!-XX&WC@3>.!-PX&W#@;<.!MXX$WC@C<.!-XX&W#@;9VGADM+IT
M#KTTMITZ/?Y7\Q>KJA1-3C5=:E>C5:NKJ;8E3F&'E*C[R">WH6YKKVTHY>:5
M>C6T7IJUNNOUMNNK4JH4/'=G(W.U2I_NK=V2Q;VC!U4':TI8X'DIB3/$%F7V
M%U0+Z+@L/4%5NK;:+Z766U[50J4&DBO;[6EW=UNMNLNNLLHX+.')4ZB\VE-=
M:7E:4[8*6]^=?W9-O9J+:]Y2Z^EHKIIVNT*]8)>;KS2J74+3./C'%8K+3$67
M5N%;;J5K6EHH/UNUTNZJUTO-OZ(],M:4K33Y='O\I^8_4I1M/-N0'IDMJ=P[
MRAJ&EMJE>M+L)9:E\1<E_8[@ZZGB*I^Y9Z&'U2&J7"KLD[XXMC-[-2'!PJY]
ME8H*/I><K3HR[EQ"R\IC1)+4Y]"236XTJU*V-M3$KF@1=\WW&&*"$R4E4HO5
MJ;6= 2I1.T@MLO4$I[%B^/FVWH59-5#TJH8I6*.V<T+T]@6DVV%)%IR9"@1D
MDEH$22]Y2E6N19Y_?H'1N\ F:ZF+U[E9<8X*EEU&N\BC:Y4K_P"SLI54L:R;
M;'F1V5-1N!5J=.9V;Y F3U4%F$W4:UG_ +I8GN\*I1)+J-:.M$ZKHG74/;-2
ME?EL>_RGYBM.0I!S2D.L\$F[VUK3VEJFU$=;<U(:IE34A5WWM:&^R]L0W"UD
M14%*4[/@K*G6U,T4M2975.THTYES2B.-N1)ZJ;$*>BFU C3%IVE"EOHV(^ZN
M:4?=%LZ*RM[&A!K:FOH6WIRQPU&64F;$:&]2B3*00VI2;DB0I%91O2]\I;4:
MXRK<C,+.;TR@+&Y,J!3:B34+9D">^]L17+53.B,/.;4YA3E8<<VM:0Q(F5-B
M=8?5 CM*2M:-%?:U(Z QI17VI&Q,WW'I4RRE6I#X=.THDI]C<C+2U;TER-4@
M1J@E0(TM2D:-.44T(D]W1/U%;0^-79MIU_+(]_E/S*6VC0=FG8N[':TK6ZFO
M;Z[1UCK&M1UBM=*4[51U4%3J$$E'446_MUTMU[0I6MHH97MU,_?UBAG;%;K;
M12ZV\:Z#KJ-*4'[:@PRPL6*25(ZZ#746UMMOIIV>L?N%.T.L4IV!^Z@UNNOI
MI;;KV1K6M::CKJ/VBMM*BVFMVO;L_N']HZ[A_:*#M5TZ)3]33:64<W0Q>96F
MM/E<>_RG2G/J2&T-)+6U.[53#^R2:J-N*J>;2U1>7;:<89<O.N2EI3*H3K;C
MKCD9QU"O%*>UXA14$JU%XOH==6[]MMAQEC1?<IL,+5J+P08H.-,,4)RCSU!%
MYJM6GL5F&=I%UV?)/U&F@//L2%NKE<O,^6Q[_*Z=*-3T/H9W9A-J4GL7)";K
M+"$_;L2$]GN"KJ6)BK;C":'&7)RKK+TA%+BT1)=G@T_9HE3]GPJ:EEZ0CMZ=
M="">Q4DB\6(DY9=4B?6J1/2VA2<LRB1*64<46=6PONODM/U..H71R=+U]VE*
M_+>J@0K;T*SF<X<TG#F@X<TG#FDX<TG#F@X<TG#FDX<T'#F@X<T'#F@T<T'#
MFDX<T'#F@X<TG#F@X<T'#FDX<T'#FDX<T'#F@X<T&CFDX<T&CFDT<TFCFDT<
MT&CFDT<T&CFDX<T'#F<T<T'#F@T<T&CFDT<TG#F@T<TFCFDT<TG#FDX<TG#F
M@T<TFCFDT<TG#F@X<T'#F@Z@YI.'-)PYI.'-)PYI.'-!HYI.'-)PYH.'-!PY
MH.'-)PYH.'-1PYH.'-!PYH.'-!PYH.H.:3AS0<.:3AS0<.:#AS0<.:#1S2<.
M:#AS2<.:3AS0<.:3AS0<*2I2'%T.7?D_TKU4'5I\BNIK1ALL,<?!$#P1(\&0
M/!D#P9(\$0/!D#P1 \&0/!$#P9 \"0/!$#P9 \&0/!D#P1 \&0/!$#P1 \&G
M'@R!X(D>")'@R!X(D>#('@R!X(@>#('@B!X,D>#)'@R1X(@>#('@B!X,@>"(
M'@B!X(@>#('@R1X(@>#('@B1X,D>#)'@R!X,@>#('@R!X,D>"('@R!X(D>"(
M'@B!X,@>#3CPB<>#3CP9 \$0/!IQX,@>#('@R!X(D>#3CP1 \&G'@R1X(@>"
M)'@B1X(@>"('@B1X(@>"('@R!X(@>$3CP9 \$G'@R!X(D42)ZTM2$:^$2CPB
M4>$2CPB4>$2#PB0>$2#PB06H4=E5K0E56*DIB8SY)'?\KTC7\&E:U5*3R'I0
MM/(<;UAZY78N6IBB39 H3D]_0NKJDMNXLC+N,4D)BTZU*HIQ9#:%"M.1;1>E
M.*3O5BA.V/!-R(Y4E3V>.176%+B%%2'%(?2]W;RZ7+R+!XJRBVEOY^OR)P;;
M%Y2A.8E,&M-/D,>_RG3*_P!KDF)/>+T9*!Z3FE-#@J5'NJ(I[((:4E#+[$!=
MAU]MA5S"NNI:>5JI<";"N7E%;;#4UEBIX:3B4Z2I9?+BVM:.-ME:(C+4Z1G1
MF4JZMZA$0"T2DUG8Z7+5G7K\PZ[:N*$I=8J2WIC/D4=_RO3*=FH[%G:[([([
M(J72HNIJ*%CNB+:]V7<.Q0L5L[8MMMI:7;V;J$T'9T%UI=];B2]*E%T'=E!M
M;?!&GD=HAL2T1$_K7YCH'A(2>G[.EWR&/?Y3IAAY10L5$&_$T^VP%7=N@O4V
MEBG8J#5A)%2C:'BZ[L"X[2[7]MM_:%U:"Z\JT&*2K*%'E'"\PHL%F]Z;3]Q=
MU]!3YD:;2RCLZ7KS*=?R*._Y7ICC2G=^(4EUM[5BHJSNFFZZEQ9W_;OKWEMU
M:W4L3ZT.4V77N%:F=K4W4F^^H17& @VA399?VPH+NJ%MM]U%))I91MM+[SS#
M2S#K#"R5":O>([>R7\OTZC#+++79VN6W_(X]_E.F74U%MA5EM++;2JDVV%6T
M[L5I6\:%Z]U92G9MM&E*CNB].Z+I2I5G9K;92_L:E=GLF5*MK6ZEM:76%&BT
MKLBO=%W=Q990PNE:]G2GRZ@-.I;1X=KUU]*4MI\BUIJ2H,3F<9<AQER'&7(<
M9<AQER'&7(<9<AQER'&7(<9<AQMR'&7(<9<AQER'&7(<9<AQMP''' <9<AQE
MR'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&'$<9<AQER'&7(<9<AQMP'&W
M<9<AQER'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&7(<9<AQ
MER'&7(<<<!QQP'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&7
M(<9<AQER'&7(<;<!QQP'&7(<9<AQER'&7(<9<AQER'&7(<9<AQER'&7(<9<A
MQER'&7(<9<AQER'&7(<9<AQER%'MQN'&G.@XTZ#C3D.-.@XTXBCTY4!ZY4II
M\DTI<&!,6J5<);1PIM'"6T<*;1PEM'"6T<*;1PIM'"FT<*;1PIM'"FT<);AP
MIM'"6T<);APIN'"FX<*;1PIM'"6T<);1PIM'"FT<*;1PIM'"FT<);1PIN'"6
MT<*;1PIM'"FT<*;1PEN'"FX<*;1PIM'"FT<*;1PIM'"FT<*;1PEM'"FT<*;1
MPIM'"FT<);APEM'"6T<*;1PIM'"FT<*;APIN'"FT<);1PIM'"6T<*;1PIM'"
MFT<*;1PEM'"FT<);1PIM'"6T<*;APEM'"FT<*;A5J;APIM'"FX<);1PIM'"6
MX<*;1PIM'"FT<*;1PIM'"6T<*;1PEN'"FT<);1PEM'"6T<*;1<TMUUSNR5*%
M*U':J-;OA6@T^31KJ6_G5IUW5I2C<X%*TJ%UHI*H]'=A0\=R$3HIO577TI;U
MTKK_ -PRE;!4WMVKC[TJ1(I,4HJ''U56WTJ/]FPRZ\HJBU0I;"KZW$_H+K]+
M:UIW>I=++ZT+%5AY-]7$R]I2*+E":G]W:TONO.H7<[+B3D!AYY/[M;;NT72N
MEMVEERPX^T4K6@I:/V]ER77("%#MX<ZT\VBOM4MMK9<4*5+J.\TK?=0L:?L0
M+ZKZUI?WZ5?4U:K4*2R;7%11P5UO3I[W2].77M=W_:*V5MZ)^H>V6MHT^51O
M^;^=7]3NJUF1G')2;-6:QP)):K3N\>:N*6JM^-NL;TZ9$F.M+2'H;[:G I!2
MQW35OX.<02G:;NW<\VIB+F)94LTE"7WZ<DHBC%V>^-LM,*4^%*L8B_\ N-]E
M#NP57OBJDEW&%I2:1X]/1&5=72AUW_8I?==:XEV<:?2R[*HZ4/JE36T:+R2[
M&U?;>>M7')U3;<18:[DW5):DY5Z8^0Z7($%;6QP/TN=KTVC*KNM..17&&(FN
MZQ.JLMO4$HK[KV\NW_XXU-8B.)1)E;MWO:8[R"%+W;_V25:<F](M+MXI3O$2
MAA0VT(Z)775\9:6W?*8W_-Z 2E3)+2D2%)=:RH*WG(D2VU.V)D5322#PE:T*
M2SA* XV]$C,56HTA:HML04*+9D%+ZHR:*K6Q+:E.;$2D)D*)("V= 52]K;S0
M2WHBRJH4G@B^P391K2E&V(4UJHM F(!+2@*I>W(+Z&66F"YG:;A^@.;R5%[B
M3<H1H4?<HR4Z9,7PE 3>H;D*N^J!*?98E2EJ"T"(H@EM1HC5B1(ML4($2JA;
M<B+KPU#<E-;D2FVQN1I[$[8WI+S6AL[REI5MEK2@I2Y AO!:5*4?1L1VIS6E
M 9<4V-Y5E6Q!<FX8AJG(;4)*=,G3)[.B5J-.W1^:[$_RF.?S>@=8H+M:CKH*
M6TM'[:TIK0==1^E?UKUT&M:"VM@\632O:[8U[(K6M1UBX[L%4ZZ^((%O9J#:
MV6$4K8:/W7#KH*4N'6*?N'9NH*]0[ZVHM[0MJ-1VJTI3773X==13J^%*75,Z
MZ5IVAUZZ4J*5N'74==!_6VO5UZ:5&M=/W=GK[?Z7=$I3M!4IM2VN3@8O-K7L
M_*(Y_-Z17\%W]G:-\>53N[DU3+SR3S;KB#3.S99V$J]49XPRM;2[S3+#'(OO
M4&M:N!:@]5:Y&767V*[K*6WFWTM4&:]\>9<I-MLO\9??9X@VI&M]3&\XPRS3
M2ORBO4/U"A46B)<%]RXSY3&_YG3-*]JVVSOKTY9AG<VVG%D$EU+3EV"J2REM
MR<J^^J8NX534,NOL[\7D6WBTLNMW=VWVFI"S":6V=N].2:3W9)5YB2XR\HFR
MRVB8JA5+"J&VVV%"O7\II;6H4*[$EKBX&KS-/E-=0UJ%!!G%GL<6?!Q9\'%G
MP<6?!Q9\'%GP<6?!Q9['%GP<6?!Q9\'%GP<6?!Q9\'%GP<6?!Q9\'%GP<6>Q
MQ9\'%GL<6?!Q9\'%GL<6>QQ9\'%GL<6>QQ9Z'%GL<6>QQ9['%GL<6>QQ9['%
MGH<5>AQ9['%GL<6>QQ9['%GL<6>AQ9Z'%GL<6>QQ=['%GL<6>QQ9['%GH<6?
M!Q9\'%GP<6>QQ9\'%GP<6?!Q9\'%GP<6>QQ9\'%GP<6?!Q9\'%GP<6?!Q9['
M%GP<6?!Q9\'%GP<6?!Q9\'%GL<6?!Q9\'%GP<6?!Q9\'%GP<6?!Q9['%GL<6
M?!Q9\'%GP<6?!Q9['%GL<6>Q:ZO8<5"TZ[Y%_]H " $#  $% ?\ Z+OZ?]+Z
M?_297]/FFOS;^G_63KZ-3_\ CJK^G_T8_P!?^ANG^J*_I\EONT*4/DJ<E<8?
M:.=/C_3_ *!]6BN&WENT88;(\U_Z\K6E*?Z9T^83JZ^V-=X>.\/'>F#O3!WA
MXH<;0=Z8.\/';/':-T[P\=Y>.W>-31WAX[1@[1H[P\=LX=LT=LX=X>.\/'>&
MVCMW#MG#O#QVS=>\/'>'CO#QWAX[P\=Z>*5-H.U>.\.'>'CO#QWAX[=P[9@[
M=X[P\=Y>.W>.W<.\/';-[7>'CMG#M7CO#QWEP[PP:FCO#QVS1WIX[9H[P\=X
M>.V<.V<.\O'>&"Z\V@[9O;[PT=X>.\O':O';-[/>&Z=^:.\/'>&#MWCO#QWA
MX[9H[P\=X>.\,'>'CO#QWA@[PP?MOLB<HO9+R3K#[.AU_3I4]^F?RM= 9'2>
M5"TR@RYHCJET042J-*$F7&%E''7=P;2A=AAUEI"OM]U6XRJ:\NQ6R%%1V.QL
MAR16IKCKJ%FF'U3GVF7I57=&4[BPT@\DR.LA+H380HOM8(^>^FH$3<52P@R\
M%DWFU,(J62S-AKNODK<W-"TPF\BM$U]+8RS)G=4KC=I,@>&^B1ZN*-LK:D4U
MI85VK[4RDTZMAEAL:82W)PN(NNNTOMM+27&7DEF'ED)S5!M2K[;/#*1:56^^
MTF[Q:) O7*U$>*;WMR(**4F67%$7I3;*&6UH9'H]:ZV+$;:E;ZI#[*=S<;;;
M;?>#"5!=;;+^[M)OO+LK;?9T")RF]F-(4%*BOEL^^F?RJ5IHEI6L%N>%=\T8
ME"XEL;'%>CA[,>Y\OGE5MG*!P5.B1EHH3(B.PBD[DD<U:JRVAQ#I2^Z#QQQ4
M612Q0O;HB;VK9$V.RQ;,VAV<%@<%ZAQ@CJ2HNDZ?6]W:*."5,UW5*F,:5*E!
M:TY>V-EI=EDI3.*EYC4-4GER)"=:NF"54XN$>E+JJ0,V.?\ MN,4OM>R$%EO
M&W!18:AL1'TGS6N.;XZW*E=T1O+\6<VKG8V6--"V^+&6$*)2WK'54E;#*(X\
MV]<M*<%+K$:&$-E4)I3;:PK'-2BD!AZ=R4'+KIX56Q[,/JGNE"T\LY- "++W
MU@7O"TDCO_ /U+G5#8:2VW(DQB=Z>J&=T\T.=$I-:(&V87%5D'0-*5MBDH.9
M+R3Z*"_ED_\ IG\NKRZ52\<=:N*9[<FZ\Q[=%:5M?G9M(K(GF]<G=G5/:CDC
MZD3E2!XHI5NSLM/,ES^82:Y+STA3DM)2-ST\M-I;RX^,)<5Z=82\KR+>*+:)
M"9,^ITUKXZWGII*^HT_''>CCS Z=XAD+RV6%/+@2K)=5Z)(C//2*JN"RUR7O
MSLZE*G):N#>Y*VT-SHL:+RWE<4X.#LY.5])7(ZV5=G;PR!V7MBA2Z*U:FV6R
M$(7MW;C$+EWCPID[>2B;Y [-B5.[.1"FUU6EIDTD>T=A+HX)R&]Z=&RJ]Y=7
M.ILG>#CDKPZ%+35:DQ0KD#PL(3JCTIATKD-;*.[F84MD3P\%)I"\HR$;VXHC
MU;ZZ++U<A?%I2"0O;<2<9<H.Z!^VVSJ[&/%RZJKY9/OIG\KM4I7_ -5:W75T
MT']MMUNHTZNNME.N[M=V.L=JV^G70:TJ.WV1_<*?V:ZVZ"EMUU+++33U<</2
M.5B$VZ\E*8=;:F,."QOO2)V]G5.A9292JO5-"A*M\ =2AB'NB"6NXU31*8H)
M-:UY*/P:BRB=D<3[E".^PLU&>2::D4$V6UMK2MM:C6E!6EE!6O56ZR@_6G]-
M=3*==:_KVJT'[ZB[2HUMI7]:UOMH.SV;NJM*UNNNK=6HZNUU#]:ZT[/0+=*B
M/L1S\L:FM*TI/ED^^F>G6?MN2NB!6_-!Z,FY H2%)F,TA-:Z'6F-5'-O9BUQ
M">I+VN[PN]=;5^1JTI8:5J:P,JLFU-VRKF@U5<LDEJFRXMO<$B&]OOJW$F.'
M>(NS2I7R;2RVSJT86-4^JVMJ3-";Y;/OIGIU:]FZ[NNS96M!;7L7Z&"[M76_
M_>NN[LS3MBM*ZV_IVOW:F6U[=UX_VQI=V:U-[7;,%+ZVCK^3_P!(\PGOBQK;
M$S2E^7.BAO3IN*0@<3A(XG"1Q.$CBT('$X2.)PD<3A(XG"1Q*$CB<)'%(..)
MPD<2A(XG"1Q2$"CI!:#BL%'%(0.*0@<3A(XI"!Q2#CB4)'$X2.*0@<4@XXI"
M!Q2$#B<)'%(..)PD<3A(XI"!Q2%#BD)H.)0D<4A XE"1Q*$CBD('$X2.)PD<
M3A(XG"1Q*$CBD)'%(0.*0@<3A(XG"1Q2$#BD('%H0*.D*H.*0@<2A(XI!QQ.
M$CBD('$H2.)PD<3A(XG"1Q.$CBD('$H2.*0@<5A XI" @+B[F.!M-1P1J%&)
MIH.!M0X(UC@;4."-8X&U#@C6."-8X(UC@C6.!M0X&U#@;4.!M0X(UC@;4$Z8
MI-;\OR/;;>S?]L=HL=HL?L':+&I8U+&I8[18_8.T6-;!VBQK8.T6-2Q^RE*5
M*I=W8_:.['[1I0?MU_:/VCLT'[1^T=W<.Q4=V*:#]M*?M'[1^T?M'[1^T6]8
MIV:7?L'[17L:5J-+1I:*Z5'50?L[5*4H/U&E*UMMI2M:6CJ'[!^P:EC4L:EC
MM%C]@_8.T6-2Q^P:ECJ#6YGM)[ _)WY+_H')'^%Z!CHHHUR?ULDHV6P-1=2/
M15->\61LU6ZKHLK3&<JJ6-:N8UKK)'AA6,]&1A5NA:F+.Y*Y9#UQ"5NBAZ]#
M&XVFO>;(V>N=7.-K6VR.1-0WN[Y;J]*(0N+1-\4.<$J*)K5KFMBBA&FI#E%Y
M93'<H84,>,0J7F/J725K(LK2U718]&GQ\W)5JPQF.D#HNBZQ%5YBIS(CQ[2V
MP^UK(3S9O:TSG+9?0EY:XTE*NC2@ZQ:^/$:=5$FG=".8_P [J#:Z*FE3'WY.
M^I:_Z R/_A.@8_4I"7)W:E5K:_+DM7 EP0I9XPFHF!6]N-I(?%A%TU-<T"IU
M?FI*V$L)Z1:P-JEFC3XF\#&+&:]H(;"G1O+G+,>W,BYT>>'7%$MM\H4+$R:0
MO2!H<U;$:V6-3>:E52@F]-&6)(XIKDS5>UN$?<3D!0+>&SCCPZT2F/"MON;(
M,J)(6,"]O4H%2Q&UL\U6%G2*#JBDI$%=4W<MR]K92FQU9GAO:4K0M;ESRE+6
MO[QV95/%!1C]^=K;?9KK1M<E3,LC\@2OI'S_ "/_ (3I76*5%:Z#3KUOMK7L
MVCL=JO547VW6"M+@T.RMG,_]&MM*TK04H70?W4K3N[M:UNI2E]E/TZ5KJ(FD
M=CW/Y_D?_"=*U#(W6K+R2&IQ;EK#1*N;V-/:K2$'+E+\V(ZHZLJ,M)2,%DG(
M&.RBQ+'DZE)1E+-2$L":]SM9DUP2,=BD@MC;KE%K43>5<Q&%IG)!<W*KNKI<
M?9%3VL:6Q.SH_G^1_P#"=*TI=:UN7@+KG&U 75[M,>;I5I>U.);8J+D2SAIT
MA(.M-?:7+4+U:G-(>.[*,?J&W'2>RX\UX+O)023PB9.^T+4$.J8Q(L?+UJ1W
M<*KW.E>U3I&O9#$P*'Y6UMB=K3:UK_H#)'^&^.GPT&GQT_#I\=/R>JVM?W4K
M;=;36M+J=JVSM7=CM6675K9V?W#]1UUI=K:*ZTMK=U_NK:.\[=G;NJ.W2VM:
M5I^=I\-/R6!B4/Y[8VI6E(*]=WS]T=DK01S]'QS]'QS]'QS]'QS]'QS]'AS]
M'QS]'QS]'QS]'QSZP#GZ.CGZ/CGZ/CGR.#GR.#G]@K7GV/CGZ/CGZ/CGZ/CG
MZ/CGZ/CGV/CGN.CGN.#G^/CGV/CGZ/CGZ/CGZ/CGZ/CGZ/CGZ/BL]C]1;/F
M<_1X<_1\<_1\<_QX<_1X<_1\<^QX>8$<'/D;'/D;'/T?'/T?'/T?'/T?'/S
M.?H_4<^QX<_1T6S]A'/\?'/T?'/T?'/T?'/T?'/T?'/T?'/T?'/T?'/T?'/T
M?'/T?'/T?'/T?'/T?#2^-[S;_H+)-*59.L=H=JHUJ-:CM#6HZ_AK46]N\6HC
MKZ4K=4?O^.EXK9=:/W#2X?NH-:CK%*7BO7\+=:BZV^@[-PUJ/W#2X:U'6*4K
MK6EU!=J-:BVEUPK;?K^X=JM!2E]U:%7UI6M1I466F5%]*TIK4:W:&TNI7KUI
M;?44*O%UEUHI6M1VAVAVAK4=FX:U_'UBSM:H5JEJ4L$@2O:7_0.1_P#"?E1W
M]KZ]VS"Y>EC1;DSF1A(WKY.S)E<A41$OPUL42EMBYC=UY;I'4"1(Q-1S\YN#
M*F)25A*,A8BCO:NOC:%&Y2=F3K) HB)52+(LE3H<D7?_ #**+E6)$,:*JI/B
M5EBZL,1&*FZ)VJVQJBJ=V6)6"BYID#<8[VK8HDM35B"9&@CA*2Z0R9N/?I)?
M$TQA9<316LL406.D@73AQ2O"6.D/:=+'$5Z%(Q7,\B>(PE>7IOBY:E@4-*6*
M.:9LLDP<4J)&<W1TM0U+4IQ:97&3U[Q<R(SW=9$T=$C?&4*LA'#C%"HQE2J%
MYL.(K;32RGY':UHW.1S6='I 0_):5_T!D?\ PGY3$IL0N3O6'N2_C+:3"G-_
M27E+WQF+DKG*DU$CZXH5K-S6TDWO/*ER>)/E61U<#(XB3W/<76/#9)D%PDD@
M;UA[B]LUDF<I6F\(H=6!_:IBZIG=:6ZQ]Z;6-U8$!E[VWNKBX+(VS2)ED*+P
MJ:4-!<E,<V%MCETJ:R%;I*$Q:1IDK4D2(UUE)#S.W%RTIW8F=,^.S<LC[,YU
M:W0M;$[W<R0-1\>:GEE71KF-H)=$,@;+928[ME8C*W1"Y-T9=&Y"BF3RB>C6
MMV:SHT<]L1=MKZS&.BR6MG'W.3(?!-LE9$2$I\9[7QTE#;1W<96CJ1=?^[\B
M@_4-SBJ:%<>?TSZG^?Y'_P )TK6M*TNN':,+I^RMQ!YI1ZA5>J,L[%#.JE]U
M>JM:UNK6M*4ULJ+J:"[46VZ75TI=II376O73\S^OYU+NR(&QKSS_ )_DC_#=
M*N_=8U]UX!/:6[-1S(@+=;F6B$IA06N3BZM=KLK+1H#6PYB;2*EMW=BQ@+.I
M8V47%H&5'8Y$-20IKK'$ZEI/;6ZUX(945H*8B"Z.*2J,_P#ITJ)18]WJ2442
M5\_R-IPBM!6E1H-!I0:CJ&@_<-*#0:#LU&@T'9J-1H*C0:#0:#2@TH-!=U51
M.1J,<8NL2EOAEJRZ1'VT1.!K:F(D3@07605L2*'@X^WCA];RGP\E0F>#DY-K
M]>4<K<ZFI[I&96_F&ZIZ=_/3WF.Y_=KUMZP_M=6FHT&@_<-*#LU&E!H.R.S4
M:#2HT&EPZAI0:#2@[-1H-1I0:C2@N_8(E$[GH6VTMI7_ $!/$9BQLX&Z#@3L
M.!NHX&ZC@3L.!.XX"[#@3L.!.PX$[#@CJ.!.PX$[C@+N.".HX&Z"C,Z75X&Z
M5'!'4<#=1P-U' G8<#=1P)V' W0<"=QP)X' W@<#>+[K6-X[%&!V[5&)UK?5
M@<:"K([UNK'W6X<"=;AP)V' G<<">*UX&[4' G?LU87CL<!=!P!TMMX"\4I1
MC>*C@3L.".HX"[#@3N.!.XX&Z#@;J.!N@HRNEU.!.XX(Z#@3N.!N8X(ZC@;J
M.!N@X&ZC@CJ.!N8X(ZC@CF.!.PX"[C@;J(S"5"T\HHLDH5Z_] /[WP-)YFV#
MS-L'F;8/,VP>9M@\S;!YF%CS-L'F86/,VP>9M@\S;!YFV#S,+'F86/,PL>9Q
M8\S"QYFV#S,+'F86/,PL>9A8\S;!YF%CS-L'F86/,PL>9A8\S;!7)U@\S+*C
MS-+'F;8/,ZP>9EM1YF6#S-L'F;8/,ZP>9ME!YFV#S.L'F;8/,PL>9A8\S2QY
MF%CS,+'F;8/,VP>9M@\S;!YFV#S-M'F;8/,PL>9M@\S"QYFV#S,+'F86/,PL
M>9M@\S;!YF%CS,+'F86/,VP>9M@\S"QYFV#S,+'F;8/,PL>9A8\S;!YF%CS,
M+'F86/,PL>9M@\S;!YF%CS-L'F;8/,PL>9M@\S;!YF%CS,+'F;8/,TNH\S"Q
MYFV#S,+'F;8/,VP4R:34N/3A*^&_)<B:<(U^.HU^&OQT+^.OPU&OPTM&A?PU
M&EOQT+_$0EO-+NMK9=2EHTH+TQEE!2VZ\7$&4I6T=D%)KS :FO*&E!I0:W#2
MHI:-!V:"[2@UK\=*?#4=8U^&E/AK\>U\>U\*_#7X=H:C_M_#0:_OU_#I:/V#
M4:4^':^.HU':':^%E*5K<732E;;:1"7T4T^29(_PW3.N@)MI??)7Q1'CT-E)
MVO(BQ:E<NCJ;A,B:V]U6H8@6:J<HPG*92^\G3L]-K6W$Q]@O>;R26TB).<;6
M.BMX9T"8%PQ)<<@9$UR<Z&&D.KTS-#:25"4%E5R.]$LMZOF=O8*NA\NHHL^1
MY'_PG2_U%M-07=W5RIUC4BHFES1Q>)O:1E-5NK0VM+C(VEP>4TL9:/!#VT%1
M*.*VYO<9)($"MGA[T@:3.)QILCR^0L:MT?)0D,:+Y@W7JV>0MQ2%YD#&N>G>
M2HE3928-:FJ]7<L6:_+/T_'^@I=<5;$)=XGY'D?_  G0[:7WC2ZMM+;JCJ[/
M9OJ/ZW6U+I=I2M+-++:77C7M#2ZHLNN,I2^TNO:_96M*7UI:.NX=5P[5EHIV
M1;6ZX5I2@I2[3^^_^VMU::6_N%E:5I?;?8*7UUH+M+!9VJW]FXNM?[?U%].P
M.H:W5I^M_P HIH*4MI2)14QV4VV]FSY#D?\ PGX_T_+N_2.EV'/+.<0D7&-?
M!D>O9%6:G"6IO16&<'1DDJV=(6F7-2.Y;:T6D6&,="&Q2UH%#NE;T:JI[0B;
MT"YM)/7(V)*J-6(DMB,UK=$M&^RU$RE%D.X2,2=486Q)E 2M"%=1M8;')$B1
MM![@6S45T6L=K<8\%I[)4M;49RM4P^!I%SB$XO92DI-S.@I4YA*(4+6XCQ%[
M&B,5HF9$?2C.D-K<SI;+5K*2GN71BU,1\HMI2E(E$S'8T@@E*3\BR/6RQFUH
M-:#M6C6@UH-:#6@UH-:#6@[-1K0:T&HUO&M!K0:C6ZE6U<<WG'J:GIG5Z,<R
M_'D6+2G]?8L3R0P@&.]UQ9CM>=:<]F&W5?CJHKI$;X7CYA2M&XWI$2A\,/*J
M_J##ZOYQ9BEQ/-1ZW5"-T.1VT?SNU20GVW$O2HNRL@NH9S"H*K5^[(JZ6]FY
M[NNJH=##W92_&J"G=WHM1(UUZ9):_'\-5OAZE.<\GG-1SV<;;QLVQQ3OAY)U
MCG>6A4R$PTB]YO,/.>KSDUW[AK0:T&M!K0:T&M!K0:T&HUH/VC6@UH.S4:T&
MM!K0?^G6@UH-:#6@UH-:#6@_:/VC6@UH-:#6@UH-:#2HUH-:#6@I3M"WMZQ.
M+'/!Q)!:8KY'-&IS=V[D:4CDB4#DF5#DF4#DB4#DJ5#DB4#DB4#DB4#DB4#D
MF4#D:4CDB4#DF5#DB4#DB4BD)E&O)4I'),JTK#)36RL)E%3.2)7VZPN45OY&
ME&M(1*JCDB4VVUA$HI;=")12[DF3Z\DR?2D+E0Y+D]EM(3)ZBD,E%16%2JM;
M85**5K"I58.3)34<ERG3DJ4"Z&2D5A$GJ*PF4TK2$2>@K"9)2O)4E[7),H%(
M3*12$RJP70F57CDN45IR9**5I"Y/VJ0R3=FL+DPY)E Y*E-:5A,JUK"I52G)
M<KTY(E Y)E0Y)E0Y(E(Y(E0Y(E Y)E5!R3*1R1*!R1*AR-*1R1*!R1*KAR1*
M=.1Y4.2)0.1I2.1I2.2)0.1Y2.2)0.2I2.2)0.2)0.2)0.2)2.294.2)0.2)
M0.294.294.1Y4*0J4UIR1*1R3*AR3*AR-*1R/*1R3* R0-T4F$$E)B__ .$:
MO_0K^GSRG^GOZUOH36Q12^M/^@__ *<C*/"-22U&Q.Y=+[+/]=:4J*_NI^5_
M52F+5%HF-*CK\>OYSU_Z D#MP9K\SU \SU \SSQYFG#S/4#S/4#S//'F<>/,
MXX>9Z@>9QEP\SC17)IH\SSQYGG#S/4"F3C]?,]0/,]0/,\\>9IP\SE \S3QY
MFG#S/4#S.4#S-.'F>H'F<>/,T\>9IP\S3AYFGCS-.'F::/,\Z@\S3QYFG#S-
M.%,FGU'F:</,\\>9IP\S3AYFG#S-.'F<</,]0/,TX>9IP\S5.OF:>/,TX>9Z
M@4R<>/,Y0/,TX>9Z@>9Z@>9IP\S3AYGJ!YFGCS//'F>H'F>H'F<</,]0/,\\
M>9Z@>9QP\SU \T%(\SCZ4\SU \SU \S3AYG'#S..'F>H'F>>/,]0/,TX>9Z@
M>9Z@>9YP\SSAYGGCS/-'F:</,XX>9Z@4R>?IYFG#S/4#S//'F<</,\X>9QP\
MS3AYFJ!YGGCS//'F>I'F<</,U2+LGJ.TQOR-\)Z;/OIGHE*_O[5.S:;9K887
MI7]*WZ"M+:4_N%MUMXMNK45K2HKVA2VM1K=2E1=V:675K2RMO7KI6M>S6ZO9
M&E.U^M:::6U[5]:TI6O8K9VK.\MTJ*_IJ+=>S^[M4U'5V>UK6NHZ[OF---6U
MQ4-"B/OQ#\E%?TZ5/OIGHG9NI2&/EW$7!]/NDT@BYCF\TCRK@')ROOJ01=0I
MSC"E V/K6Y+U;G%SFY'#F9*ZN59HD-.;XJ8M;$\26J7.R&K+UJ>.*V9P6QI6
M\O+I%5#6VD0=691JB:YPI?"32R5\6<4*M9$C$B:EM.]E11"-''G]2W'3)^4-
MR^2,-CR<5%%1I=(VI,:KX$KJH-AZRB1NC)JYMOB:ZQSY#6]RYQ=0A;D\-/,H
MH(4$W_,*TLNIKK:VN*IH6L$@3/R?I<^^F>B5_P!N(7DIWY6K)K-2'%!SW#SB
MCW!*^I5<Y971$4Y$+$UL#O?&].O>6EJ2)(@]E,[B0SQA%>QG,Q+,6ZMY4LAC
MHF3'%M[0U.=KJ@L<D[@D30:^]K<WA*^MZD57)Z09[5M2MQ.5H2$D;+07NKPX
M<4<T=VADW6$GOSHX)3Y"F=2+)_*5B9.\7.*+GUA<$A2I&<VO,>XT@ND;&X)$
M[N4K*O@[:>SIZ2,TH]W^9=50WKU#>MCTC2/Z7JITJ?\ TST3]0E1G.53T9J=
M3VK3@SJW)$68=WE];J4I;IH4RKE"=0G[F\RE]PNMLH*$F'''-3H27=4VH[5Q
MERM+<E5TI33O#+*6TOT/2J;4VEM++*]D6HE)*.G9M,)37&E6(%5R=.C.76V7
MJV-8I4J5-W[KQK=;4Y.9W?!G<X$)U!AA*(\P_6HZ]?F6FM$:)4O6QJ-I6!+U
M=*GWTST2EM;3:TLOCK;99<G)4TO0:DE);B2K[E!)!-C]2TU*NM,,CZ@Q*F*+
M([Y.L2435-(J1+F8NY*]^!0=AP2EWHU2/19X>RZY,28MM0T-2WHTR4Y+=9XI
M(Y7%'$(B".&NE"U%K-6E[8G[14=;J&HFM]1&VV,9-:EK"B4QIJ<FTA_NH8W.
M%Z/P,;L\*[LMIR1[KI\RK6ZVO[:42I%*]1&XX0R$]+GWTST2SLZD*C4]*'F=
MZC<+T-EZI1>"U1Y1ABL\REYMUUA3BJ)*K==6TI6:44G<[;2E:M0L/,7+#2K5
M*JI-5BB\M,XW)CE3E>I-+4**#QROO[[S3"S5RE1>8:9=;:8;;2J@S0DVY/<<
ML.O%JM64=XM7VBS#B##%:G2BH\B\Y5>8:4X+2BZG'W@U<J,K^;^OR6EO4W(#
MG(Z-QM.QD=?3)"TWO31Y9K!Y9K!Y9K1Y9K!Y9K!Y9K!Y9K!Y9K!Y9K1Y9K!Y
M9K!Y9K!Y9K!Y9K!Y9K!Y9K1Y8JJCRQ5#RQ5CRS6#RS6#RS6#RS6#RS6CRS6C
MRS6#RS6#RS6#RR6#RS6CRS6#RS6#RS6#RS6#RR5BF,EP\LU@\LUH\LU@\LU@
M\LU@\LUH\LU@\LU@\LUH\LUH\LU@\LU@\LU@\LU@\LUH\LU@\LU@\LU@IC);
MIY9K!Y9K!Y9K!Y9K!Y9K!Y9K1Y9K!Y9K!Y9K!Y9K!Y9K!Y9K!Y9K!Y9K1Y9K
M!Y9K!Y9K!Y9K!3&2[3RS6#RS6CRS6CRS6#RS6#RS6#RS6#RS6#RS6#RS6#RS
M6#RS6#RS6CRS6"F,UNM,9JM?+56/+16*8S5UIY:*QY:JQY:*QY:*AY:JAY:J
MQY:JQY:JAY:JQY:JQY:JQY:JQY;+!Y:+-8[&4D?*Z;+EJU"Q\[R05FDFH.<9
M..=)..=9..=)..=),.=Y(.=)..=)..=I(.=9&.=9,.<9,.=9,.<9,.=9-0<[
MR<<XR8<Y28<Z28<Z28<ZR8<Z284FDF%TSDMM.<I..=9+ISI)ASK)=>=)..=I
M(.=),.=)*.=)1K6:2@<Z2<<XR8<[20<XR8<XR8<ZR8<Z28<Y2<<Z286S62WC
MG&3#G63#G23#G62CG23#G63#G63#G63"V92?3G23#G>1CG62Z\ZR76R:26\<
MZR8<ZR<<ZR8<ZR8<ZR7M\ZR<<ZR8<Z277G63#G23#G63CG61CG22#G62TISO
M)!SO)!SI)QSO)!SQ(QSK(QSO)12;26M>=)-V[II);:\[20<XR<<[R0<Z2<5F
MLE[$4FO?7?+Y]],_F,C31[<)%'> 7.,*+;FDB.(W%0K(M2+&="E<5-_9TC;!
MQ^U.PI%ESX@N:76EUEE]:]D?O[*"*U.;W>+T0HJW5TL['>5[5:V6WJ+J:T!K
M#88J5$V(E7=T,$D8[6$UL;VY6F_]-G:[=M+^VU(42PO_ +U12RMU>U=6VM2Z
M"/M9CTN<D:1*NLU/%3+2Q;;=07,ZHA%6B>EMUIMM_:LK2_LV"FG>TI9<*_MM
M/C*1$:H(*3&+H_1$SM#8L?%AY?A#>U9V*5M%.R*5K=7LUI7M65N[5->B0V8:
MBE:5I\MGWTS^9!:__DR9*3(BG-R*=X[V;.,W75:&5D-4+I$0H,9HM'C*G.R"
MRG#[7)2IEQA!!:TA#'J15:42A534FIS<Z,C!;'K^'-S@@-*9V=Q=E);(N;FZ
M^;O#RO5I3E2A-)$QSJOEK_8D4Q5[>%J:2VHDZ,]:Y49D!;0WWR]]-2.4?@M.
M]*5.QK1&9ZEI:_M+A1I@S9>A;X\D4$%RMB<O'7LBQ0O.=D"9Q6OSHN/42)X<
MC(HY*[XZH;4*=%(8X^W/RV167,C'%E-"8\VM%+I2F5J)/&;K:<3NH0T,DI4W
MJ8KC]8H(>HVK4.K@A++\O'-P-0N"95=62,1=C6Q*["W5GD#K7F-^I>[(.B4K
M?6^'3'Y=/OIG\QN7J&I>E?G%L-(=EA+=S,Z6F(I2[MY_,SM8O;Y*]-I-LG=2
M5)4@="K;IR\F75[RVMCJ=8SUKVJMTG>&JUUD[V[V%3)[3E%.RTM >[K3F]7(
MW-8J<Y4\NJ91)W<U1?+7?Q*R3O3FBYW?J53R!V(JI>G14+I0Y^/7R1Y="6]Y
M6M:=4]+5R1T=%KS6]X7&,[=)GIN(YF=+7!&\NC?5K?5K/1;)'-6:HE3VJ(LD
MCLG2)9:\-Y":0KTE[ <F)=Y&ZE.[TV25V:2>/N:=6Y2-V=D]DH=0BE3LEN=)
M O=DC8O6-RJDL=;5RV5/#BC52!U4WVR)TM<FU\=&TU?('-Q-4O3@H<G"3O"T
MGHG744NM$&E1AM?ED^^F?S/^W6ZNHTMNNK=2XZW]:_MKV]!2E*4_6MNE!^Z@
MTK05K04[(3DJ5!JE&H;KNS;6M:=F_0:=D7$W6&EV7G4OJ99>>2H3&VIS3:&%
M&$"E+:%7W=NE.SII35.F4GFJ&M:41344UL*I^RO_ &J4I2@I32E;:TM[5;AV
MM:W6VW"E;Q_:-.U2M-!=U"OZT_MN[-PT[-W76VW]/[KJ]=*?VTKH5V*6UZ)I
M^U$C,6&QF-$,Q'RR??3/2HG87Q1L\*L+8"D-QI"5M.2K438VIEY)#4C/0D57
M&HT9#:P(+UKB[I37EMN+26(W9.D-I1I1G%U;F\FJMO1HJDD(TA-MU;**B"SI
M806QFE'(&LD+DR9%8F2MYSDB;F]QJD0,:Y0RDMQH=;ZF.E?U^1Z5%- D3'+S
MXQ&BF0CY;/OIGI1"@Y*:5>=;?>[.!IMCFOL,O5J#K:.R^X%NJPF^]T6WT3J#
MT5$ZA4CI1W7&6J']8>Y'.Z^\RQP5D5,<EM]+'):FK2O;OHO44.3KCDQMCNYE
M&&.KA?7B"XHZQ4;895X<#3REZ\@*#;E-WR2M*]E"B-5G1J-$,A'RY[:K'AK\
MM2!Y8IQY9)QY8IQY8IQY8IQY9)QY8IQY8IQY9)QY9)QY8IAY:$#RR3CRQ3CR
MR3CRR('EBG'EDG'EDG'EBG'EDG'EBG'EDG'EDG'EF0/+)./+-./+)./+-./+
M)./+,@>62<>69 \LDX\LR*CRT3CRQ3CRS3CRR3CRR3CRR3CRT3CRR3CRR3CR
MR3CRR3CRR3CRS3CRR3CRR3CRR3CRR3CRR3CRR(J/+%./+%./+%./+%./+%./
M+)./+%./+%./+%,/+)./+)./+%./+)./+!*/+)./+)./+)./+)./+(BH\L4X
M\LDX\L4X\L4X\LDX\LDX\LDX\L4X\LDX\L4X\L4X\LDX\L4X\L4P\LDU;6&,
MH6+\K7Y--CKR(]QAP'&7 <9<!Q=Q'%W$<9<!Q=Q'&7 <7<1QAP'%W$<8<!QE
M>.+N0XNY#B[B.+.%!QEP'&' <9<1Q=R'%G$<8<!QEP'&' <97CB[B.+N0XPY
M#BSB.+. XNXCBSB.+N XNXCBKA0<7<1Q=Q'%W$<8<1Q9RJ.,. XNXCB[B.+N
M XNX#C"\<7<1Q5Q'%W <7<1Q=Q'%G <6<11V<=.,KQQEP'&' <7<!Q=R'%W(
M<6<1Q9Q'&7 <6<1Q=Q'%W$<8<1QA>.+N8XRX#B[B.+. XLX#C#@.,. XPX#C
M+@.,N XRX#C*\<9<!QAP'%G(<7<1Q=R'&%XXPO'%U]U:NR_3B3@.)K1Q5?2O
M%7$<4<!Q-Q'$W$<3<15Z6]EFE:YI/;7%.YIODD^^F>E_H*Z6VH&=*?%6EF1'
MQM,T-#8UW-+&[++TL)3."L@DA4GB[\I(LC3UH@;UKA>L9G-O,OBC_P!XC;5C
MD;?''HM2XPSARR01)22Z-[<L<QP9PM<5#0[)[W&/O+787%9!?0MC<U (;3C$
MOZ?GZ?(HZ_J&!0VN*5V2?(Y]],],K^L>6*6Z%)'D]YC3FB/E3&WMJ>,.BF#+
M5SVN)3IE+ZJ.3$7+#ZS=FUN3*^_:XBI7*[)VC[=Z-UM/;HC)T2TU[L5W&3EG
MM)/83U9QDC(4.CE,G=)5/%GM([JB5#P6EG$R[#2VW5M[?S#34,3\H8U3<XIW
M--\BG_TSTR^E14ZM]EI]]I91UY=YIEYU/$F]Q2Z[6XPRVVIYE;Z&F%F7''J+
MJJKZBTPZIIAAB@SQ9U;2SS;!:?>0*&G4NMNNL%3CKJN\DO=JMJI.D5/;I>[/
M'52WYAU#M"+.ZQL6VUUL^0S[Z9Z8G(5J;E34O0%ZT%:VTHC1GK;CBCB#*ZW5
M*:UJJVXO]B9K<51*Q&K;[NR"TIII&EX.LO(K2M]U"2[U5$B!4K-6-JI#0@DX
MZIR4Y*DI74$VU-K?3L=.KT.@3I[E%T5BQ+*5\BG_ -,],BMRFYV2HFPVPZT\
M\I1529([:6DJVONU*0BM4MJ-(4B,7%FFH6PPFR,W$%W%>'M)"]%;W3J53ARW
MQBA_-36%IFD_]T=NMM+:5-'&Y-::F5H""32$9%+U#2K,4!Y[^US^7?J*W!.G
M.6FQ6+E,1'R.??3(ZNETK=;=>89>94R[L6FFVUH=6V^PZZP4I6EG;KVNU>9?
M0VE+:&]W=<9VS#:W PVE:>).H+C+ZU[S0RE]+1_V^_[ZO>75I<5<:9==WIM]
M;[KC;OEU:U"5-<H,BL6*8R?DBU"F<$_)<:')<9')<:')<9')<:')<9')<9')
M<9')<9')<9')<9')<9')<9')<9')<:')L;')D:')<9')<9')<:')<:')<9')
M<9')<9')<9')<9')<:')<:')<:')L;')<9')<9')<:')49')<:')D:')<:')
M<:')<:')<9')<9')<9')<9')<9')<9')<9')<9')<9')<9')<9')<9')<9')
M<9')<9')<:')<9')<9')<:')<:')<9')<:')<9')<:')<9')<:')<9')<:')
M<9')49')49')<:')<9')<:')<9J.2XR.2XT.2XR.2XT.2XR.2XR.2XT.2XR.
M2XR.2XR.2XT.2XR.2XR.2XR.2XR.2XT.2XR.2HR.3HU2ZD)B]*\EQD<EQD<E
MQD<EQH<G1NEK='VAHN^2SAP4M[9S=(!S=(!S=(!S=(!S=(!S=(!S=(=>;I .
M;I .;I .;I .;I .<'\<W2 <W2 <WOXYN?QS=(!S=(!S=(!S=(!S>_CFV0#F
MZ0#FZ0#FZ0#FZ0#FZ0:TET@H.;W\<W2 <W2 <W2 <W2$<W2 <VR"VG-T@'-T
M@'-T@'-T@%)=(*#FZ0#FZ0#F^0:\W2 <W2 <W2 <W2 <X/XYOD&G-T@'-T@'
M-T@'-T@%);(*#FZ0CFZ0CFZ0CFZ0:\WOXYND YND YND YND YND YND YND
M YND YO?QS;(1272 <W2 <W2 6RY_'-T@'-T@'.#^.;I .<'\<W2 <W2 <W2
M <W2 <W2 <X/XYND YP?QS=(!S=(!S=(!S@_CFZ0#FJ2WVQ.:7*/EF1_\)^=
M0$6=HR1LEC*Z/,4O;%_*#9<K0Q.T\+HR46U_J76ZV@K30NA=IE+:TON96V]W
M<G=!8VN%Z9#P>^E:F%V7UJD),4'*&+A[PN(2EK;NS89:76HI2VHUTK0LRIM[
M6F/!49.I(7A"6V.%+[:5[%U]A=A5YY44CRM.X)FTJZW_ +EEUM;+*_LKI;?:
MRID+F??;;WM=:F7:=J-LI+XL01:RY(J2-13;2RZH[)E+NS6^FM:4NMN(MI2W
ML22/49*4MU"]@HC8VDA.I4GL%M8ZD3D'*28V8X']CMB^EQ=]-.ST.G[1#)AW
MEGRK(_\ A/SJ=01W=H^6.K<D<59]ELO5L+BZ2B]$85#;8XIHSP-*68[N#HO>
M&Y4N7(96WVIVB]2^+#8>XV$\X)UQZZ3TI7DDUU6VS!G2J6VCXH,3.2Q4J/G]
M_P#[4A96Y<PU<SKI@IMO*7F]Q<J4ET;#_&')TIJI:;.T:Q2YK4]+ZJ4%FJT^
MRTNYENMK#(0IM7!=_P#%5>UYRV5D+UZJ2,QY"!I:TBA))['16SPMP;T2F3.*
MI$O:\>:\<?B^9&!'?2Z+<7563-E).:T3L421))#XAP8[KD;6K>BDY3RHI;1^
M1N)CXF.=5K+%C$]A4Z+7K4D&I9:H5-RY7QAH,.L8#NPO9YZ[G&K^B6774K#9
MCWGRK(_^$_/+O[-5[NL=%"YU<72_G.0&DH'AS;CG1^=G6U$L/17+I(\.=J>7
MOA2=([KTQ?%EO#+Y$\GFF3!\.+M?'$M$;(GBUV129V1A=('9Q!LJ>%1R60O:
M-:M?G1P/K(72B^Z^VXRCVXU:53XZ+&U2\.)Q:F6/*I44_/"=5:8<5?2:R4HN
M^XWO$[LO1ML=5)D+X[.YBQ]<'!4Y*CI?(#4[=(WIN(+D;H4?>[.)S4ID+PI.
M7RMX6DMKDO:#6Y[=&=5>_NQB7CSS:YHY,\)*G29X4'N$@>W,A/*G],1=_OF2
MEZN6)WUY3 ]V<5B6LF=KUB23O+:D.D3RJ6E25[1K"9 \(E:I[=5REP7*')9T
M2W2RW2MML'E!JNORC(_^$_.I34::#]HTTMUI6OZ"VEME/VBZM+16HIV1I32M
MU-::"REEX2M"U2GK3LBE:U']]>U0L$IS#[].R*(%_9IV=""*JU!R<\@^[LWW
M::5K^RM=+!K;VK>U?=6VVX52G5*LKV!V3:5_N'5KKH;KH-=!K6H[-U:5K0:_
M]RE:"ZMHIV=*UH+J:#]MM*:5*Z[;JZUIK:-=:]5*4[';[-+;^JG1?T#8W*79
M5'X^F84_RC(_^$Z9U]JGAKF=6<6J*<["R$;BWM%I:Y(W^)5]RI?VUL)J$7;J
MK1)$E4<8NNY@KW!"%2D;&\IA3H-3FU,<ZFEMR8CP+872]*UIBD2,OP]Z%*;9
M1N0FJZWD7() G+3.?_J^4:=BG_I;&Y2[JV"/IF$CY3D?_"],UI0=\;V4ZU2@
MK8I.[DU<N-3W+C3!Q)5=0MR5EDVKU=I=KG2QN),J2<C6GHJ>(476)5)R0Q$\
M7(G.AAEI=KBI*,-5J3C$+U<A*/6J+RJN;@8;14HK;>:;>9;;7L_*/UJV-AKN
MIC["G84ORJ1(D*U+RM#QRO#ARM#1RM#ARM#1RM#ARO#1RM#ARQ#QRO#ARM#1
MRM#ARM#ARO#ARM#!RM#1RM#1RO#ARM#ARM#ARO#1RQ#QRM#ARO#1RM#1RQ#Q
MRM#1RM$!RO$1RQ$ARM$!RM$-.5H@.5H@.5HB.5HB.6(D.6(D.5H@.5HB.5HB
M.5H@.5H@.5H@.6(B.5HB.5H@.5HCKRM$1RM$1RO$!RQ$ARM#1RM#ARM#ARQ#
MQRO#1RO#ARM#1RM#1RM#ARQ#QRO#1RM#1RM#ARM#1RO#1RM#ARM$ARM#1RM#
MARM#1RK#ARO#ARM#1RQ#QRM#ARM#ARM#ARK#QRM#ARM#ARM#1RQ#QRM$!RM#
MARM#!RM#ARO#ARQ#QRM$ARM$09%HE6L>0M*$GY%__]H " $!  $% >E-KIQ
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M)8]QW-I-L\V_S"1079;@6 2EWV)8&=Y8T8?B3-BN+_;RV\0HC\"C^/"OI/\
M!C?">/\ $SU/L*8_R5+<D81Q[EE^QG@_'N)7>0[+]O$L7X\V<X-QM+[]@6WZ
MCTG@3A$L7.>VW=/FN8]-C/\ +=FM ^-4 Q/O"VU1G(6P:6V;2L;8%PYBLS+&
M!)[,MY>9<#SV<[L\>[![I)CE1M6D+'NPIM1W=Q;9OB%-NHQM',3_ &T<?NV+
ML18>S0R;*,*8.G,"V4L.RS)"';M,<&[C=U#Q!MN4H0;L-L6Q.1;9]UXBW]O0
MHC_"Z%#?\%T*$?2_03_]B$_27RJ,_P SH46_MZ%$OX70H;_@NA0CZ7Z"?_L0
MGZ2^51G^7T*+?V]"B/\ "Z%#?\%T*$?2_05'\>$_27RJ,_S.A1;^WH41_A="
MAO\ @NA0CZ7Z"?\ [$)^DOE49_F="BO]O0HC_"Z%#?\ !="A'TOT%1_'A/TE
MT/6G0M:5_#&?Y?0HK_;T*)?P^A0W_!="A'TOT%1_L0GZ2Z%NI4*$FVW;1C3.
MFZ7(NV7[<^ZS$6=?Q?=:EDK9MXT&K=?"OQ_</6K6[9K]E.22"0.'X(S_ "^A
M1;^WH41_A="AG^"Z%"/I?H*C^/"OI/H6['_C)L>W+,&U/-&"_NMXRSCD.*9=
MW<_<5W"XMW.;F-F>['[H>Y+/.+=T&V/(V_&63W#,:W_[V\C;'=V^X&#[LONW
M?\TON?9DRMB#%JK-66[?M'[*]P.;YKM.V@Y7WZ[F'W >ZS>]$\PY-S9O-V5[
ME_N2;BMRD309SQMO4VPX1D>X60;E_M/?;ZQCN:RPW_;GW:9U9]S?QC/\SH46
M_MZ%$?X70H;_ (+H4(^E^@J/]B%?2?0MV/\ QD^U;CJ!9/W-92VS8'QWB?[+
M1A5NX?[C.IV_[[N]+Z;LI/DE%@K:?MH?M[OW!)MMRC*^%?<J^[=_S3^\13_]
M0J:5]DC8#_PJ^R-_YAP37_\ ZC_=YK__ '&^XQO;ROAN_=MMIW&PS:]@C_\
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MG:'1!DV,.<;G&;5D\B^6)X5DJ>]*P3@J6YTE^+\6Q3$$2AG^"Z%"/I?H)_\
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MDV/8M6[DJ9,BL/B4CQ?M\9Y/C#(3*8C@,KVVR#(N4#<(,\ERG*]JD7LBN/\
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MA^X?N'[AUC2HTN'6-+AUC]PTJ.L=?PVF[4'#,SFT-#:Q-L,_P70H1]+]!/\
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MZV&1Y]K=3M=Y9I6MG:K6EH[5H[=M:TOL_)T_'U_AV=;Q?""EU:B$?2_03_\
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M\S@W=MF\V<S'<YEJ=Q4S>UN!-6,^=\F,J229MG\L:W'<CEQQR5D;<+E'*C+
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M?I\BKJ&)B=Y([[5-J[1@UH_)4?QX5])](NTI6;0B+Y%CGHUVT#T:[:!Z-=M
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M^/4[GZ@]3N?AZG<_@C<OGHBSU/[@!ZGL_P"OJ=S\/4]N 'J=S\/4]N 'J>W
M#U/;@!ZGMP ]3^X >IW/P]3^X >IW/P]3N?QZGMP ]3V?QZGL_CU/9_!&Y?/
M1!.T?>>I=%M*Z_@[.HI2E/RU'\>$_272?N4=>&OSJ5_:RH*.KQN,P:@P9D?,
M6UM= \H$[0,6'R;'VU1V?%N1MM\8;,8:"\LPNMI1U;+2[KZ5(/MNP[C\G)^3
MLKP6S'&13HGCFW$]4ZC6RR\P1R/NDGD+MA)! ,QRQK9FR45+,M,[@\4ZZ]T;
MV^Y.NN7XOACFC9=M+CZA,C1&V#3O70=V;4IA2M:Y\8]INWZ2PG)\;@4<D5"S
M;K;BCK*5*.I9:4:<,2Q+'4N>KDYFM]M]E;RS"QMNPPASMD.%;:6Q=%7R)8R3
M8R\.HTLLO,K?;=;=>4<4*%&]W733<-@)'A.ZXHZVV?8&20W!F+(U!I1*W/ 3
M(1@"$LT>>I>P[>5.0I+:69?6ZPRTRI9MG0ZBG4-G&\2E;::TK^<H_CPGZ2Z3
M]R?_ ,,_G?TA_7+=WF3<5Q'+<L?6E!O:E6 \H9$W*J(8[IME)6WJ>^4&Q2+Q
MF3YUGV1LM9=897+IM!=S4 ):L8I)1FZ<W;1IXD0'[JXG.)K.]T21(F0;27K*
MTE2;T<7L#] UN7W5=$<JS>53-PWY(N]@\/E9QT]Q93)\A4[T)5_^'Y,=+VRV
M:2Y&FQJ\G3&1Q.,2&5S)UW\Q";/&5)BWISUZW'R-WI/Y&C);I%@:O_\ 1[92
M_I9)6:FUQ29FV;7S3=9'II.)9NCPW((Q!L8XCB$NAV["S)DGQ/L@FD%A\VW4
MY(E$4G.,?MYZ^?N=4WJ-P''JU]+Y63I&JWH8=;)! 8CE=K8&7<CN"2O>2,.K
MU<.Q=+,OM["U90._Y(1*>O.7XG(<J3'$NT@UB:6G?HAFLO@6SYSLME3OCN=3
M"S(^%GZ3H=O\H/53K$^_'*\@NG_1*5K2NSK>-6^OYRC^/"?I+I/W)_\ PS^>
MC5GMZO(>4IQE9_G>6I_DIWNW?[C+V" 96R%BYWR9G?*V7RXU)7Z(/>1MPF7<
ML-K1NOW ,<<C67\@Q./J<K3I;CA=N#RVXR-SW;[@G9L29>R BA2C<)EI3DN*
M[D,RPM;.<YY3R08\;J\[/[O&\^9:B$LE^<<HSN2V;A<LEY-=718].EV;<F78
MRD.;<GRC'KQF/(C^T/&Z[.[X^,.=,H1F0%&WD7I]Y6X]*%ZU0YKF'+4^C$%P
M%*8S!LO95R\Y33-TQR#+I[+G;=?N >XYCW<%ES%K.QY\RS'I@YY6G3OCN1YT
MRI*WF=;E,TY)8,<Y.F>)I%!,U9+QG(%&=<GJ&.S<)ELO)T/W&9D@EK]N'S%)
MI#D'<%E[*+2P[J,]QF-J3CU9]VYS-5TEC^;,E1:Y\RS/))"#MSF:E,[C.YG-
M<.97W<%EV339AW!Y=C$Y9=PF7X[,IAG#*4^DL\GLHR9)NB4&O9KL<W1/LG/M
MK2[\T_\ V(3])=)^Y1_X:Z!U?']1;^FGPZQ3X:_%GQ5DR0MIA5Y!O=G=WUU'
MZ!MCD@>E.M-+(;+C3-0UM3D^N+LT.K"XUI\*]FE16H_4?U,8GHEF^/Z_'4:]
M7Z_#7K%1^T5KH*C]!_05&OPTZJ:='J(! )1DV4[>-O,6P)%_S;[>W8RMU&EK
MZ3]R?_PUTBGZ?@=3X0WXPDKRSN:'(R)FB>)9Q!L7HULX9(5S)+#4TCSCC2!1
M96Q1^G_Y!$(3!7V*;7'>]+G9+<T,>+YI%<=XJC&%4$5,2N6+F>1R]U0XU9V!
M5 <=)RE<?QC'6:%11N6(ET/C-4A4%A,AERURC).+L\Q]CC63/S/Z#04_%IT3
MK^&/L?2G)\IV];>8M@2+_*?N4=6&OR=?RM1K^1J%3P[+D,?G$SB1"2425"U.
M$]G#JTG2N3J5!L^G)X;\D9":6FR82PLPB>*4F-6IV=&-PCDVF,0%SZ]F-T>E
M,EB:R&9.>HE.R'IZ2H$DZFB!Q63"5N%\'RRU0]"Y364NJIRR/D!X<[GUZO;W
M-V=7I5TK7\[]?AC_ !_*,FRG;QM[B^!HK^[M?*=SF/,:9(A?I-V:Z>DW9H/2
M;LS'I-V:#TF[,QZ3=F@])NS0>DW9F/2=LU'I-V:#TF[,QZ3=F8])NS,>DW9H
M/2;LT'I-V9CTF[,QZ3=F@])NS,>DW9F/2;LT'I.V:CTF[-!Z3=F@])NS,>D[
M9H/2;LS'I-V:CTF[-1Z3MFPKM-V;#TF[-AZ3=FH])NS0>DW9J/2;LU'I.V;#
MTG;-AZ3=FH])NS4>DW9J/2;LU'I-V:CTF[-1Z3MFP])NS4>DW9J/2;LU'I-V
M:CTF[-1Z3=FP])VS8>DW9F/2;LS'I-V:#TG;-1Z3=F@])NS0>DW9H/2;LS'I
M-V9CTG;-1Z3=F@])NS0>DW9F/2;LS'I-V:#TF[-!Z3=FP])NS,>DW9H/2;LS
M'I-V9#TF[-!Z3=F8])VS0>DW9F/2;LS'I-V9CTF;-!Z3=F@])NS,>DW9F/2=
MLT'I-V:CTF[,QZ3=F@])NS,>DW9H/2=LU'I-V:CTF[-1Z3MG VTX\P+CI#\B
M_]H " $" @8_ ?\ \)TG_P IK]&3ZXD^NE^K5^DK_')_2$OU6G_]JN5$$5>A
M4#/UE<97C"HA6".?E/\ ^"+9AC8T\-,%@A3W<G]>H7T&7Z'+]#E^AR_SY!+]
M8,8Z[>(Q]O\ ,^W^.;^0O\<W\7VC[1]OE^T?;Y)OXIO+-_(^WR_;_!]H3^.;
M^+[?)**<,T/==$OU<H8=QWY3_ETB$6!8(O,5P*H;5S:IOF"ND,8STX#&GL;B
M&C*<P1&>\*5'?%(^ 43/?G#ZM[*;IA#JL,I7;K08VLY6ZT'4<D:2P6_Y$;.8
MWA!?";K%LVDN"@XA3>4IW;HA.J[<5RK+A(>]D,N'D&D9,8H+.*;B5+OVC3UL
MIYMQ#00I=UT:)LY#2PRGWL ?6_\ 4A3\)[R!D6-)27E.T-.1WN"8%'7%.SZ
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MG8W$8.+'W<7U<S>=^4_J"4&5N?@&_/Y%MBFT42L BM"B$MA3L^8**0H!!O\
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M80;_ )%%,;XQK(WI@5WS!1O"83! MOZL4:"%.>ZT#>[ZB/>P_1*17 ^C.U!
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M:?=C9G\T^[&S/YI]V-F?S3[L;,_FGW8V:)S3[L;,_FGW8V9_-/NPGR\3F'T
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ME'S78!E'S78!E'S78!E'S7=$3GS']$3NYC^B,H^:[ ,H^:[ ,H^:[ ,H^:[
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M!'3[X1H0A-/O6#WQ]BW@@F\DWEF%B^+'DF+C\ECC\D@;7*@Y(C5E1O#.3KI
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M=IU!LG:=0;)VG4&R=IU!LG:=0;)VG4!_XO:?#(;)VG4&R=IU!LG:=02U1/\
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M%MMYD17W-$OB,#]1O?C]QJ_ZC>^'[E5_U&]^/W&K_J-[X?N57_4;WX_<:O\
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M*81ZUG5#0,C/T[7S1F:3&@\PZ5G:"JYW$@4%!EHZ$J1DS4<(7:1,EC$"@)A
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M*JJ?,S,"$I*"J^A<K@IN3?\ 'EV\MM(:)D2\5%@R=C]A7(IKX=!@MGOY6#&
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MSIERBFI'+[CI04M.%*R&<=#3Q)RB%8N1E5':*2A7[+DA%564C9",,&U1=H;
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M31GVQ>FS?R,\H*) *Q%+%&9C4 ]10:4K52#H^L98Q4-DL?\ C-!C=W*L4O\
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M;"D1#6$VIQG_ )2V2TE4--R<94*^7%122RM6P\5#.:EFXHC$("</$M)!UA<
M59ZILE"$,44PT:FKY8*69J<WR?$LJ@;4TK+1G)B3,.*U&56-AS<72-Q<K=NS
M4PE,<NOBX1Q,;R<7-'5%6-*FJ5ZSDYQSE[0;2M7%75 <^T=P=0JJ"@*)3*"H
MW*)C!JI8> 2V<DC#TV]I5=WE##RDQ"RK9B@J,SQP=J\7;L7;Y'[X3!(Q];3K
M8BZ=;/.7S"?ISSZFZK'D)P,?'LPBR-@IQ\V0;)LVR0 "1GRI2#AO!,<.+#;R
M?:9HF7KI"F%J61<-Z+HC+V/GJ;KQ%TU(+U6>J=RY:%;JB4^V.<YPPX]J8VM;
MRWJEI&#)&)4Y+H3D53TPV:&0C99"GW#]1%PS:.':0[-Y>;"14P: #5X(9YYS
M5#6C"F8Z9=M8RJ,P*?HE6;S/.]9,F":+.E6L _AF[1%)-ZCB.9$VLIBT&#$7
MR/ZCBYN=0GZD;P5+U14#]KR#/U+".'U**.&U4,2Z$SK#K.4#". PB7>M1L9+
M*5%X#MG"*U,MWB+XM/ _<T.H$J:)552!$Z@&'NNS,;#K;EO+"\G9<R:\N:M*
MDJVB"NE"D*W?\N*"N0BY^ 7C+-#3ZW;*#ZX;>3OY/;M9D\I#*:!(W<MEBH*,
M7U9G@%9!J#I$VT*90ZK!KC2,'"5^JMY3%.U.MF7F% MHZ6+R5,Y=1-/4WEXY
M8MGO):T+-NI)H+DA=FF=,R0*',5,%+M;2S/,H-'CF*I2>EJ>:O"D'',I<20(
ML@0XW"HDBNN=/Z7A<(M]O*M3S,+-*1<9'5 A%<LQPLBQ;SB]3 YA(L3MDKT4
MD$FYMD4QP+>0W\;B-Y"SIC2AJY<,ZA?/$Z43<QS-:3XK!SQU3M59ATS;[9 M
M[I$JIR7F1"V>\]2F:%=,(NF7:LA7&56:5(QBR$8^8&XV#&E*C78',T3+L+F2
M;%P<HF ,2FOB-Y-$'1DW7473SVGF;[P7H/+QE4L-7[AVR8J2"513RJ[8C=0V
M(YSB8X:%!4,;5T>5/6%#<G97T7$I(H5+*NZ1/468--NWL#RC)M:+C8&H-BB;
MC"ZR^+$N0I\&J&SN+Y&]2I1,SF?405+LDAJEC'TY55;,>+-Y%)M-(RBQ4TUS
M<4(HD5PL8M^M?KFOSX7I7,NO:9\'XX7U>929G4G$2$&RX@@#A-E3$Z=JZ39)
MX6QP;*1SD^,X ?:&*..WDNM:-GZV@&$VPCY=['Y?Y?-:L;5Y.O&\<M)QE2RJ
MBJ&Q'&LNG>8X:+SF'N1<-<*0< [I=!RK&.WD&^29-UVDJ[BFJTF8R;!T_1[J
MJ?:ZJGK][J$.MZ=]^BP1$L9U+Y;S#DJDM%%':+Q#A2XAIR$*<-4^^N@&A8 ^
MF*4;4]-0KY&1BY!LLZ9O6QL::Z2CUR(#]28."<IM8I@$IM8.HEOM2GU@V@/<
MY#Y_55:_R^E?THB/W.^T#1J56/DZ8I>7;3\!#E;1@(Q<RT76=-7R*W$!5-A4
M<J'P*JG+K\&WZSS5I(FS XF##PGXI#\:!GQ0(\&^PY,XMAV6I]A_A6G:BI*M
M)6%F*F75<S[ML2/6)*KKKJ.3K.FSUDX0Q[18QL1$B78APX2VGJ5D:N?/*>JJ
M:-4-0Q:R$9LI6=4<H.U'ZJI&(*$-M6B9\"1R$U>#9S3=&U[.4]"/%E%U8YEQ
M,Z15URB5=5L9ZU=G;F-NB+<R>G6X6M:-KL]>2AZPB8E6"CIU1I$*/&T4N&)P
MT, QADC@<1OQ*E.;ZH;5DA"U4^CT\P=J-:%2;QAN7Q6%Z<_&N,L5\-XR2_M?
M9?9![%FM)4WF14433K#VC&-569@:%!<7&Q;.W#!9<B=]W<RJ[/=+APFPV>YA
MM*\FFM923=-G)3;4L>W4?-6Z0((I/&*3(K-4I"%N3Q-S8=WA6BZIJ:MIV7J"
M#4V\'**N0;*0ZY3$-M8QNR*V2;FO(7'LR$Q8=?%9RVD,TY]TT>1J\6Z:G;0G
M%56#@%"+)G9DB 2Q&*<2[4";2[UUH3+V2J%TZHRFW1GT'3ZB#$&D:Y.5R3:H
M.$FA%C:KI70HJIPQM4%$0M1.F-*54)35##IHQIVTH9,""4RZZ[-5<O +]B53
MW+.T*!KB:IMJ_'&Z:,Q:N6BJIM47(,I%!VF500_C"E(;LV_62G6,L:NR[02U
M&[%J\?%(JCQ8Z*:3MNLB">SU2I@CA !U0+9YF%"5,\CZS?N)5V]GTFK!1TX6
MEU3J2ACH.&:R [<5!Q]RW]&&U9%AJJ>QX9ABH-:;)M''\(!6.].L+KC#);#>
M,HXTH;'[*-B9:C4+D:%)(<JDIOB[#B@/]HHOM]N#+C/".)L.VPW^MM'4Q$9G
M5,R@HDS48YBBNT,#0K)9-5JW*[5:J+F1**8=P.J9*X,.##HM5\T2LWY)2OV(
M1M9/2L88%)QF#91J#=TGR;@)<FJ8N) J1M;A69TG3F9-0Q-/1^#B$<W,Q,5F
MF1;;)HMG2[%9<$P,'V+:;/UN'".&RV9:%92J%>.4MDYJ-J1@@Z<(\7(T!%=J
MBR1;*)[-,"X#(X=4-^U4R#FNY-=Y6T2G!50X,SA;YF)0;N&J+-8.3+DBE3>*
M$O;[(V$PZUE(2B*^G*?B%5-KR8D+-VS24,-XG:I23)[L1,(ZVSPXM^TC7,#6
M,LRK"6(X1DZ@4%K(R+Q-R<IEB+C)M791Q"F'K-6X,-JJIB&J1['P%:B<:KCD
MF[!1*9!4ADU.,J.&:RI=502]S.3=M'U+34@K$3D0OQB-DD44%%6RN%1+&1)V
MDNF;5.8+C$-97,+PDE$:U7?#**5(S5(R?G?' 4SKWLT4B%Q$'"<A2X3%U<.&
MR$37==S=1Q;=<CE*/<\1:,N,@7""RC6)91Y3G+M!P&5*?#B'#:G8FJJB=3,=
M23)2/IIHX18)$B62A&9#-D#LVS8QBW,40O5,<>YA9S,T-/N:;DW;$\8Z>-$&
M"QUF*ABJ*(&3D&[LF$3)D&_" Z.%9>>H2I'U,R[MHJP6>,DF1Q79KJD7,V72
M=M729@QI$-P-4=RS_,1A6DRQK:4'^DY]F9JBL_ Y"%.1XS(U!NH3N91!(4<.
MJ&K9B_KNKY:I7<:0Q8X[Q1%!*/$3%,91FTCT6:1#FV90,J!<0X2ZVK:*2)FQ
M5 IPI13CRG-%J7!L#M;WH+1BO&KR#_SS;:=;AZUJHI/PG>!3M:2BDU5,7Q:-
M*C,RBCA%THZ54XGM"B*C=,V%(Y"ZO!LZ>4#5TM3"SX@)O",#HJ(O,(")>,LG
MB3Q YB <V QDL1;QPFLA5%657,3=0M-D#.5=N=DZ8%:J JVY.!GQ,K? IK$V
M)2:1Q<+6LR4_6O4@FC4E46@"2&,%RJ2:9N,)\F87!L*>A1QM3%TX37F$;2[V
MBJXF:?<3KE1]+\4XFLV?O%U3*JO%6;YL[0VUZ@]T*D0WK>#:$KS.2>K2;(5T
M4\A.0DNLRJ6/%(BG)KR)7; C@2;*83<62V13 8^$MXCBS80CL[*RSMG:_AC4
MW2T3+4J]IYE1T6=!\D'*#EY%PR#A4H2P[9PDF=5;BZ1#!ZX%(2AJ^FZ?B%%C
MK<G-^)NVB:Y])E44)5E(E1,;U^SP8C#B&^T[5D'6DLSJ6J$54*AF%N+2+Z61
M6,4V%TO*-GEUV$,& "8<( 6XI;K3E 151.V='5*ZX[/0)&[ S:4=8&J>T6<*
ML5ERZ&:7V)4O LE2E.9DU'%T^BB=!K')'9N.)H' <23)T]8.UD"A=J%25(!?
M6X;593\15,BTAJZ!4*P:X6CKE[;D537.^=OF[Q?$;;'QF*J0QKQ#%:02H"LY
M6F4982&D6S(K-PT=*-[RIK':R#9TF50"AAVA2$-AU<5H :OK.9GE:84.O .7
M8M2OHQ8YDU%%D)%NW36,;$@F;$HJ<Q<(8;4]-2>8LR\E*676=4^_6:0)EHU=
MRUXDY6O")PJF.B; 85"'L_S"A:KD(^M)8[]63GT$H\7#Q664VK\5FJK-1N(*
M'#$)=EA^E MG%82,S(.*J=R))9:=*MQ:0-))&(<CXBS/B^S.39%P['!APAAL
M:F*JS$GYJ!."6VC5^(-47140U2/E(]@S47+JE'"L<Y3&#$;6LRG:>DWD-,QC
M@'+"18+F;.F:NN3&DL40T83&*<HZIBG,0UY1L_2?YGU Y0DHT\,];&;Q'%%X
MY<J@+(<43C 3(8X+&*99,J:@AHQ!A"U(TV>KY<D-03@CRCFC?BK,U/N$RG3(
MNQ?-&R;B_"H;AK&W;<@5GF#/3T)C2.I&+<3:-5S(G*H@9X2,8M-OA,B4Y=OM
M+C% W"L6F:6S%J"(@4RJ$1C4N(N4VJ:HB)DV1W[%XH@4+[P*@<@%];=:6FJ/
MK2;A92>.*DV[340?'E5U%%%C.GY)5M(E.KC6$VV,4%-8^MIM$(U37D[-<@RG
M+4,NX.U2>QLKN \:R+)JU<X@O' &VN)HP@6X+>#56YBU!,P)]GMXQ06;5LZ(
MCL\";Y2/9-%%R7IE/A74/K!BX5AIVB\PZ@@H/$H9.-2XB[;-]M?MN(ED6+H6
M^(QA-W$2:VMNV>2LH]=2,B_<K.GSU^J9R[=NEQQ.'#I<^DQS#NB;=^7T?+_.
M^3H^:ZV&[=ON[>[8U&4\P5GLNG0\H501XL9%A2XG*($EH]T9%4 75,4"\5+]
MG^IV>,.MZ/4*_P!I4^L&T![FH>D/55:_R^E?THB/W,-_L^;HMN>COV'T!O\
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MAA.8=[1:J:5K&IX1I2\;G&3-#+.N%W[7D6*DH^3:OYN*4EQ/L@92[-KW,V+
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M46#8Z+BH*@<$/R=!1MX@8ZJ@B&-8^ 00;@.(YOI2@<Q6-(T@R!NT;W*R#U4
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MA,76MY&$- YFT?4K3+RK6;:HI1G,,4 8-&3)BB:2DV2ZY%FB!C-5,)G!2EN
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M?1LE P*9F<0S,DK4-1K)&.RA&(G$.QM'"F$010 X&,;Z4I3'!C2-(,@:L&@
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M40X42373;RC!U'+'04OP*D0=HHF$NH.L 7:+?1[78MP?1&W!^;S[<'T?HVW
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M;2FIO7X3ZVZ31JFD)B[OJ]W_ )MSJ.+[3S\/==1+_:5/K!M >YJ'I#U51O\
M>='?HM5W[GEY4L^YXE#0-70DI*.@0<.>+L&3Y-5RKL&:;A4^$I=Q(IS?4VE:
M^D/*&JJ$=2R$>@LPC\OJG59I!&LB-4E$U'-)BIK%3Q#IM663["I57E4K9DKR
M4"P6AYA!62IU"?9.6LHN\&+1:)BJW:;4Z9E2J%X&'%JV\D=*!EU)F4RB\&75
M9Q:<7*LE(]2(:4^#IN@M(,6J#@P&CE2E.@J8OU6&U%^450U7R]7NW*@1-84J
M--245R+!^#:T&=['.YAC'E<./OH3;(JARXB[N'3;,92'\H3,3,-]5[5ZQI2A
MV]'MJ4C:9;2Z2Z3EK.R[^F4.-I)$7,'<U3F$" 6[6V@>3S1=-S(R%24+$2+>
MJH_DV69\FKKLV"*).-.V;1%7$9 WV!5:WDLS<)(.*@_5[1\Y368$<TC)5HZC
M"3<13\:91J>4:,4W*B1F!Q+Q=10IL&[I+:LY^BZNJFO,P:MJ5U+02/),U34/
M2#-^^3?.FTB248M2O<('63(9,RF(1#@W8A/-U,@Z7IBH8%_2T\JQ3!5XP;/%
MVKA&021 !,ILE&08R%UL"AL)3& "V@YS*FJ*DS(S&:5RQJ9"7>1TS34!%QL?
M,IRJ$6ZC)5DT%53"@5+:I ?=$V,N$I;4]Y2DK7%5P]40L2U,[RL)2THY7=34
M6P=LFFQJ%-J#/!<Z_P ^3'@+BV=YBVSRJFIID,H\T,P)]24I"ORTBXKE6G88
MR*"#>)9(MV,B8JQ-@H98<!"J;4-/<RE#R<I>G*OE*X?9;3C23JYQ*0+N'FWH
MQSJ&7,^6*JRC61EG/)QSX6RIBEQAP;4/Y1="U?+U8_443BJNI(U-24;R+ ^#
MKJ"7>LW4LPCBJNOOX>Y H<N(O"PZ;9BN8?RA<P\P7U7-GC2DZ#0I!O2S"F$I
M9)PDLWG)>0I='C**6V$+TU3F$J8 0-;:%R>;9CUO4-!U7E(P;Q+^$C*6D)T*
MK8-$&3<>1WB"*C9N=<(Y+9F<K([,QSD.42E*:U/SN7TN:7A6-#1L*JJ>.E8T
MS=ZE(2BYFATY=BP5'"D[+K%*8OU5LGZ8SCJV?H:6RF1Y-D(^/@9F4)6,6DP3
MCT"1\E$,9 &QE2M41.*@$,4V/"&'">V<2$9(R65LI,+)IY69ASE-KU]*4]$%
M9$:*H@W9LI Q%E5]JN8!)APJE(=03)%Q>2/#4S7,E6\_2E>&2J5_+T\_@I-X
M8S C0DN[($:R:!QA1N)MDW.;"!@Q &M;,'-V8K6HEZYB&1FB>6R5,2)P>SK^
MFXUKQ]C49$EFFP5;*E!,KA5$Q%!.8UY0"^;F76<589+5[+5Z_JN=2&"DJ]H6
MI8Z1E';OB#6GVD<[(U6V)DT%EOO8PBB&L8IL))[, D:]A:!J.C$:0D9YO$&+
M(/9%LN+M2J'\0VQJX5#=SU2K*[-(AC%OU"YU92T)F3.55,U<J$A%.Y>D)R)1
MEG*RD<<C*/-R:)$]@FRPF.[XMB4X.K;R6JBA7[BHT\NJ(G*8KUBVBY5H[B.7
M(BGXXYFPRC1BFY.D9B<W<%#E'!NZQ;9A-(;R@<P,S92LDY..IRE"4HWI&)IB
M*F"+(N&<\^?TLS%V1)-T*5Z*N(V "Z+Q4M1[AOG/7$3 P]/KLZGR5J2EY2M2
M2KW8A>G3E4'8G1:(BH [%,76S!/UB=YK0F8RC)&E*0)F:C51F*#915.#ABS(
MO-BFTCFJ@FV9/6($/]26U2YNQ1G539?U#$I4T]>,F;YB\%@O'0Z:[YNQF&T>
MM>@XBB7IG(3$4#83;ELXW>5M=3V9%5YK-'$5'Q;REY6GF-+L)%2065-(.95B
MQVXI\?->=+'BV1"W!B,:WD]T' S(OZIH5%\2J(L8R4;<G&69\7*(OG;)%LMK
M?YA56U+Y@,VW'>07JG&F.,J0O8UZU78R;0BI@$"F,BN?9CIU@"TGGK*5-5$L
M_D5G\ZXR?E:+</&BT_)-C)NA.Y6BU&*NNJ=4B2CW9E,/"T%*&=]*E!C2545O
MF&UGJ9H.+A9 K!G"-I*G#()IO&$<DP2$J,4<YQVJ.)0!.4NM9[Y/F;%0RM %
MCZA4J.FZRCX1Y4+2]5^>2.T>QL6V=JE,*BRI.#A,4_" Q=;R::(I:6DW.6>2
M4JW?R]<RL4_1=RKCB2C-5PA"H-E' )%V@F&YOBQ'PE#"%YLY,SI2IS-J)JNF
M'T? S/(51+ \=JFI;9(\GMXA5VE>,:OK+H$+J=D+3.6"<X)JX<YE/)Y&$Y,E
MPQ0ZM1<>([Y1&.XH'<]; 9QM-%V&WD]T]2<T,I+4+1S>(JEMR9+L^3'P0L$T
M40V\@Q:IK=T9*%Q-SK!HX5JH:2&:E:Y-5RZ>H.HRIX^-?U;2$E'-Q:"5C-4<
MT92 *+E$'!2K[$FHIJJE,7"-/R%&IF?\A4\G%3=9*0Y:?7K"3,H01>\E#<HF
MDF"?<=OK%VIBX0* 8I+(3-*JY'+MQ&U'X2TY5;. D:C8.<;KC?%7#&&:NUL1
M3+JE/B*0HE,!BJ8BX;>2I3U'5=).XO*2MVCNHE):GIQK(LX=JP7:C)NDB1JB
M9S***8MBS.X,!3\'5MG94T=FS6>6KZJGL*YHS,&$B9J7IEVR80L2U<LZ@H1S
M$JK*J LT6*D=5J3"4XF*HGJXLH:[A4%:M3H:%E(.N*[1I\*=?5>6?9IQRKF.
MAG(H* 1L":BJ*:^'2N8I,)=)LQ4X?R@LPLRI.LT'\=2U')4DVI*-I=A+(K).
M6T[(R%*M>.$1*Z%/N:IC#LRAOF4+D^A3N9$EE82F4V@YD4+$9>.)9[6\F0J+
M=R\DZF)%O$M@*J9W!S)N#*BD:XH%.!2VSIJU'-*LLOU:K.R4H;,NF8^;<0Y"
M$CR).6M1T2YBE%G(;5,-CM6>@0/K%U1MD35,.HIF#)Y9F?A6^825-FI9W5;*
M7C#0[IM$Q#W8K$!(KM9P0BV NT#5W1-;,&7B/*#S#K5W4K1RC267+*DD*8;4
MN,HU.DHWF)N0I8"ND$Q5 EZ:QS82ZN,P[0NYN77C< Z=\!O_ '"^WS?-OVZW
M7T6BJQI"15C)N*6 R2A?L#MN;0NP>M^"JW4"X#I&T#_E763%DJBPJV)4<'JB
MG!4':LU7KQ=5-^R!364:*[7N:F\.J;6X7447VGGX>ZZB6^U*?6#: ]S4/2'J
MJC?[S8[]%ZNZKT;_ ,ZWH>=IW;!?N7=8>MV[?.&_ZK>\VS*;@W[F*F(Q<CN.
MD6BFQ=,G10T+(J;P^99Y4%2RSV<G) Z!G\I(K;=X[%L@FT;F55^H313*'U)0
MMVOH&W+ &Y?N!PK[M%M.CKZVY;S\/GVZ_9ZV\-UNO\\0Z]NM=I[=]^&UW7'2
M'6OO"P>> ]?SK!YOU/8WK=?3HW- WW!;SA#0'H6NW+!Z/5-]_P WF_(W;QTZ
M+MWYKK1>:Z<A)4I1]/N#@1\V-LG-5JE'"YAVY%=4[*\,+M4Q3ET82=UUD^HH
MOM//P]UU$O\ :5/K!M >YJ'I#U51H_\ ^3HX/_I>K@#JO=T7>G?;-O,V2BV,
M])T"TI)C343+I ]ATY>L95W'$G'\8H.S=%9D8F,1LN0Z1CG#:%, 7#-2\S&0
M</4](5[04&E4-+TW#4R64@ZV?N(]U'2</3K2+8*JM3D*NV6XN4^'$4QC%NN7
MRTA:NKJ<Y"4J1M4+AK17&I:5E(0BJK2"HV(C%) ZJRXDXOMWFQ2*-ZI[D[5J
M+V-D'2,SY.4U7<3$5U!-6U44E+$F$XTY7"& R::Z2C50S9RC@-@.&J6T1$R(
M*%IV-3=U35ZY2FO:TK3B!Y.:-===>J1'8$^K5+;)^K,OZ?BZ(B,Z%CTRXAFL
M?R;%4I5D(\.QD419()(@0#L]B[PA]D-M,-LQVM,N9N0?M<R,M*3&7J:"A4I-
MDSD9Z1CG4G3KIHHL9)%Q@-MFRIB#JDQF-;. "UE73@<E)5@UJ W(4$4*G;RL
MHK"((0 \= [5<KK9%.=SB3PXS%+P2VK48IZQGH"6\GEQF93SBJJ8CY"6:LY$
MS4$VPH YV31^@<BI2/FQCX0X)=(6RJI96JZH3JS-JAQJF(42BHL]/03_ (K+
M*M6,RH9QQE9%12+P[1OK$ 1Q%-;R=*><2,% >&-+U<[.]CX:&B)>1>Q4O*)M
M8=>7>O6R3]^]&/*V9*/#HE*97#P0M3=,U<QKURSG:'JF><4I4\,I34[!RT+&
MS9R)R+O^CT7J!@CMNS=1RIB":XJN^%G69\Q4]8L$W57S5(TS3[2'B'[QXJR8
M,7[%S+O>-M4TBE*L/&=F4V+4*D7A#:1JQ%W7_P#0U!HUW(U&M21X[+]^*3UN
M64I2#F))LFNJ\326$".<)D#JE,!;R:]DH&C(D&S8^0;BK'S2KXF/JF,.\6R_
M)/INF39V] Y'J@B)E%\6%%0;T2X-6V5T95=45#&53FXS)(P(1,2T=P5/,9)^
MO$4XK4@N'2+E<7*[8YEBMB]S2N-K&-AM12M<U#53>9K#,:I\NE(^FXZ(<MXI
M]3LVSAE)<[J0<I[5'$\+C0)A,;UIM6U2THY<$>.*:GY>!6<HD,5)VI%OUV1G
M213ZQ0-LL5PCHOMVOE_FN_<.M^Z(5?5R#F.RUCW08M4R3FK'"!M9A'*".JV(
M8,+E<O9(G>?$8D?$Q;1!A'QRT@Q8,6J>R;M&K62=HH(HD =!2E3#J.,_Z9^4
M'742_P!I4^L&T![FH>D/55&_WG1_F7TM5@C;<]&VYZ-MST;;G\(+;G\(+<$/
M0]2VYZ/T+;@>?;<]+U+;@?O@]2VYZ(>I;<_A6W/1#U+;G\*WF?36W/X06W/2
M]2VYZ(6W/1MN!^^"VYZ-MS^%;<_A6W/X06W/1#U+:0O\WZ%M%_6W_4M.-D&<
M=-P%41AH:J*9ER*GC)MACVJ)%SM%6RZ*R!P!1%R@J11,W!'6&T1 4Q3<'2--
M1M3Q=8.H2-6F) 9^>B#?T<XFI:;D9!V=-$I3$10*L1,F,QBEQ#BM7=:N(:&?
M?K'95'%U/!'4E&S%:-JA8CE\VCY!B]:O&V%1%,Q%$U\5P"4UY1$#'91]*TU$
M1I<L9'*9JQ9#+JI,Z:>RBLPDX!9Y(*J*.TE%C%VJAS[3=, FTVJR)IFZ*?UB
MA&,GE5,W4DPJ.,C8M^G)GCXA\S>I[(KE5 @N38;S%)AON,:QHYS+N:D=-:HI
M^L:?FZI?RL]*TO.P1E2[2)6D'JI11=HK&0<H*D.42B.#"8;[3$-3^7]'TRUG
MJNIVMI@6#BHW:KJ8IN24D6::!Y.:=[%J853EXLG@*4IM7#;-W:QL0E^N-]&/
MYX4P>XHU6-G?"! D1B7X)U37'VVUU>SIL"01,*)?U1)9. (@^Q<@D5VH2@_?
M@_?>G[7_ ,G;+&J48F$.\RJIMO3$*U4!_P 7D6B"<FF5Q)@1WBVG]+*?8CIE
MU0U=ZU M75-TM,QU P<_3B,?+L%G;2<C:D=.W4BG)IJ. $BI1?#L5FPIG)<4
M0-B+?:@)"*IR CX/+>"J&GJ=I7C$T_8<EU21X$\1Y*O))9^8R_'1PB#@NSV9
M2IW%LA0"$/'1=/-:NEJO9)-E))T[:KS#)%B>.XV_>.C'23(W#"<XX]&L8;3J
MCBC:7&?JB@6V7,[4H+U"5VO3[)BTCVIF<:$L#)HJ4L>B8W%FY"FN'$72-HZI
MR4Y EGFF7:^6KU[M9HQ):'/3O@VB]79'?BDBY30"\O%RHD$=)@&U'E?TK3-2
M3&7(+IT)/S RY7=/MS+G>M&RS./D6K5^DV<B9RV*_26PB82Z2Z+4.R?(,':E
M#5C,ULU?K<:.ZEYB>EF4P^)*#M\.SVC H%V8$-AOT[MJ@JI\B@W>U'-24XZ;
M--KQ5%S)NUGKA)N"JAS;,HK"!,1CC=O[UM_SQMN?PK;GH_0MN!YX6X/I>I;<
M#SPMN?PK;G\+Z%MST0MI#^%;<_A6W/1^A;Z/T+?\8+;GS>=;Z/T+;G\.V]Y]
MMS^%;_C6W/X0>I;<]'Z%MS^$%MST?H6W/X5OG7[GH62JVKD7,?EK'.;Q$<3=
MU5;A$V$T<P/>42MRF#[Y7+]J+K8C)LHB'9-HV,CFR+-BP9($;M6C9  *D@@B
MGA I0L3W1F?RL]ZCB^T\_#W742WVI3ZP;0'N<A\_JJE&5+P$U4CY#,1D[<,H
M&+>R[M)J2F:G0.Y4:L4'1P(!UR$$V'#><H;]NBG,CL?U'J71V_Z.MT69D>(U
M2<V6TY59C^(]1C_X5;HJS)\1ZCYKMT5YC^(U2<V6Z*\R/$>I.:[=%>8_B-4G
M-ENBS,CQ&J3FRW17F/XC5)S9;HJS(W_]AZDYLM=^JG,CQ(J+FNW17F1XC5)S
M9;HJS(\2*DYKMT5YD>)%2<UV'^RG,;L?U'J;FRW15F-XC5+S?8Y4\K\Q3BD?
M9K8**J0=BK=C AOZ."X=<-%NBK,CQ&J3FJW13F/XCU-S=;HIS(\1ZC^?%6Z*
MLR/$>H^:[=%>8_B-4G-ENBG,CQ'J/FNW15F1XCU'S9;HJS(\1JDYJMIRJS(\
M1ZDYKMT4YD^(]2<UV'^RK,CQ(J;FNUP959DCV/ :I!W[_P#LJVC*G,?L@%#5
M-O?]UVTY59D[NYX#U+U_<JP?V59DZ/\ <>IA[7_5=A_LIS'\VAZDO]"+M=^J
MG,F_\QZFTZ!O_P"J[=%.9/8_J/4F\%W_ &5939Y79B*8%#(JX*)J4<*Q>&D<
M0C0N$N^%A_LIS)#<N#P'J7FL;=%.9 _^1ZDYKMT4YDW:-RB*EN"X;PW(JW13
MF1UO>-4V@-S_ +*NMT4YD]OP&J7>ZW]%VZ*<R-%_^PU37;GN98?[*<R1[5#U
M+U^S%VN_53F1IW;Z(J6\=X=R+"W15F1XC5-S7;HIS(\RAZFYMMT5YD>(U2\V
M6Z*LQO$:IN;;=%>9'B/4GI<F6Z*\Q[_S&J7FRW17F/XCU+S7;HJS'\1JEYOM
MT59D^(]1\U6Z*LQ_$:IN;K7I979B* 4YTCB2B:C.!54!V:I!_HX-)3!<8+=%
M68_B/4G-ENBK,?M^ U2\W6Z*LQ_$>I>:[=%68_B-4OF?]76Z*<Q_$>I?/_U;
M;HHS'\1ZEYNMT5YD>(]1\U6Z*LR/$>H^:[=%.8WB-4W-MNBG,C>W*'J7FVW1
M3F/XD5+=^3+=%>8_B+4W-UNBO,?Q&J7FRW17F1XCU)S7;3E3F3XCU'S78LSF
M9"3=)45#.4Q<Q\NR=Q$Q43A/ IR>U:.RH*)M[_L[G#N:J6MB,FRB(EDVCHV-
M;),F+%FB5!JT:HEV:2*"1+@*4H!=<':^0G[H3'Y5>]1Q?:>?A[KJ)?[2I]8-
MH#W.0^?U5$56YIM>I4Y2HVE/ S0DBQ9DC.8^6D2N=NJQ?WW<EX<&$/LE]^@;
M=$$CXYMO@W;H@DO'-M\&[=$,EXYM;OT;MT02/CFV^#=NB"1\<VOP;MT02/CF
MV^#=NB*2\<FOP<MT02/CFV^#=NB&2\<FOP;MT027CFU^#=NB&1\<VOP;MT02
M7CHU^#=NB*2\<VWP9MT0R7CDU^#ENB&3\<VOP:MT12?CDU^#5I53]4TFIRC)
M&?::Q;%V>-%!'![V_P#DK=$,EXYM?@W;H@D?'-M\&[=$,EXYM?@U;HAD_'-K
M\&K=$,GXY-?@Y;HAD_')K\&QMT02/CFV^#=NB&2\<VOP;MT02/CFV^#=NB&2
M#_SFT^#=NB&3\<VOP;MT0R7CFU^#=NB"1\=&NYXMVZ(9/QR;7?HT%NB"2\<F
M_P &;!_9#)>.;7X-VZ(9+QS:?!JW1!)^.;?X,VD/[)917C\N\DO?DV[F+LQ3
M C[VO6X;=$$EXYMO@S;H@DO'-O\ !FW0_(^.C7X-6Z(I+QS:?!JW1!)>.;?X
M,VZ()+QS;_!FVC*&2\<VGP:MT02/CHU^#=NB&3\<FOP:MT0R7CDT^#ENB&3\
M<VGP;MT0R7CDU^#=NB*3\<FOP<MT02/CHV^#5NB"1\<VOP;MT027;\-&M_Z-
M6Z()+QS;?!NW1!(^.;;X-V<I?JGDE>,RDE(::R:A=R@\7>;.\:;];M+K=$$C
MXYM?@W;HAD_'-K\&[=$,D'_G1K\&K=$,EXY-?@Y;H@D?'1K\&K=$,EXYM?@W
M;HAD_')K\&[=$,GXY-?@Y;HADO'-I\&K=$$CV/ZYMO@W;HAD_')K\'+=$4GX
MY-/@W;HAD_'-K\&[=$,EXYM/@U;H@D?'-M\&[=$4EXYM/@W;HADO'-I\&K=$
M4GXXM?@Y8C/]4TFKA</5L?ABW+I=/%G6_38?YZW1#)^.37X-VZ(9/QS:_!NW
M1!)>.3;X-VZ(I+QR:_!RW1#)^.;7X-6Z(9+QS:_!NW1#)>.37X.6Z()+QR;?
M!RW1#)>.;7X-6Z(9/QS:_!JW1!)>.C7X-VZ(9+QS:?!JW1#)^.37X-VZ(9+Q
MS:_!JW1!(^.;;X-VZ(9+QR:_!RW1#)^.;7X-VZ(I+QS:_!JS6/\ U32:O%@5
M[H-7MBW[1PLL.J--_56Z(9/QR:_!NW1#)>.;;3_]-VZ(9/QR:_!NW1#)>.;7
MX-6Z()'QS:_!NW1!);FYX9MANWP_V:"P4=)P2U!R;T"%@E9*91D6<P\'2I'@
MY*P8;)8=&Q((&VFDM^+"4U_6L.CZ/[BM]J4^L&T![G(?/ZITZ;4AI_\ U*C/
M, *7J_3?;@AY]N#Z-N#Z/T;&T>CNV^B:VYZ-N!Z-MST1]6W!#S[;UKK@\ZW!
M#SQMN:.W;<#SQMNCZ-MST?HVX/H_1MN>B-O\=N#_  K<$//MN^G;@^C]&W!]
M$?D<'^%;<#]\-N#Z-MP//'L6W.M9=:GZ8J2>1;FP.5H.#E9A! XDV@$75CF3
MHI!PZVFQTEB*(JI',FHBLF=)1-5,<*B:A%  0,&^6VYZ-MS^%9L6<A)F%,]1
M!RP++Q;Z+,];?^T-.4&K?:$^K+B"U^]:[YKK,'4M"R\6UE$N,13B3BW\>A(H
M:H\8CUGC=$JZ>N762$P:P#OVNN^;SK7W!Y]G4VTA)AS"QQL,C,MXQ^XB8\]Q
M#8'DFDV412'7+]D.7A!U[-1G(.:A>4$>,L!F8I_&<?;!LQXPSX^V0VJ>N&LG
MB#3;<]&VYN]FWT;=CK7A;K;N_;<].VYYE_S[;GHW6X/HCZMMST?HVX/\+Z-O
M\?J6X/HVW1]&W!]&WT36W+?X[<'T;;_GCZMN#Z-N#Z-MWT_5MP?1MP?X5O\
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MFN\<KN" 4OTI0W<.&T<M2%=5/(3HOG+*>HFNJ(DZ3J>&*GM.+/ 'BYVADSX
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M@!B,4QC$+7E,UZU?GHG,VGPI^9D8E,7#Z%40))-VSXK4 .8Z>SEERF*7&8!
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M7XL1;97PE/FJ"*0J[.:H865EI9G!.ZNC4&5#C)(-F\NU8M4EVJAD"JE3,D3
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MND=7K32SREZ0)5531,=!U'7*;"05J298QZ2"=QDG4HY8-G"Y62(.7C1FW54
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MA)9R1#+9P<S-P9JY :CHXNS<%(FILPQ5 %^A0.#;HP<^,M&?".W1>XNNOO\
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MZ(VN4623'K'4(4?.$?E+U%")@.B\Y@*'HVQ$.4Y>N40,'GA\D1,8"@ :3#<
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MMV3I$CE(Y]:[ L @826\FZ78TE$.).I\VZR854$'3[1-)XCX34JNVB)-!JV
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MM^)V]_5'?O)7\2M[^J.O^UROXE;175'?<Y7\2L\%*NZ-'B;]TP4N1EPN5:G
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MPG$N$HX<.$N'1:)I6N9=A(Q,))GEHTK:&8,'*3H[9VTP[9FFEW(B;P2E2PW
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MU",<J7E/M'$<FY! YNY!I,0>"%G4:UEY1I&O_;T>TDGB$>_T?\]9)+))*_\
MI"GL9Q"R\K#N#E$AUXJ2=QJQT[KMFHLS71,(=NRSN0=.W[M<0.N\?N%GKMP:
M[A+.W!U5#?\ "-8T/X1U#R.*8HC$<N281(I!?W'DX7((X/J<%K[MV[<\^S '
M<W-.^2<')0.Y=^Y") N "\E<8<*\7^PICW+#]C+UK<M>$E0C- GL>6@FY7E<
MJ8$P;'E,'(KX,(\'';E1K)2+:3VBJO*C:0=MY':KC<LKQQ-8BF)3&;&;%B&^
MQ)"2EY23?$N%)](R+QZ_3PCC3PNW:ZBA< C>36L2:4J*?/-(DV:,X>;E#2Z*
M>%1/9(R1G(K%)A4,3"4X:IA^FL:70EI5O+&.JL:8;R+U&3456*&W.>0(OMA$
M_KS8]:W&I:1D)9T8NS%U)OG4@Z,31W/;NE53W7!]-9HS&I*A,R8'35CF9YN5
M%HP41]KJ,F?&<")D_P"+,D0F'UMC39:BGPFSDV!YDLY)A+J(X2$V*DGQG;B7
M"4I<./<*%E9"-FI>.?KXN,/X^4D&+Y;&<3'XP[:.$E#XSZY\1]8UAFBS4N6:
M,(&&;"4?%ES' N #<J;<%K\.IPN#;E4D@^)+"X.\&4*\<%D@>J7G.\X]M05V
MMYQ[ICQ6>H/JHJ5VE(IE1?I/*@EW*4@D4,":;Y)R]5!4"^L*ICMERRA8Z7H-
M:@::6II=Y$5:_45G4#IQ)-LL+-C"&1+_ $;BV0F6X?"T6IVJI>)&IFL'.M)I
MU#*ON)<L*L7 N@06D%&<C<!CE**@BF>_3U[5!7\BSY--,G:D:Q?' ?%C&+%J
M1HT9%= V:8\()Z3;(F(3<&W8#Y.[_@Z^VC<M%DH=D]J1.I'S:.E*(1VADZA3
M,?"&P*4%-BY2UC(NL&IIQWI"8MD5U$%&IU44E#ME#IJ*('43*<R)SHG5((E$
M1*(E,8.L-WRZ_P!I4^L&T![G(?/ZJK7^7TK^E$1\J/S>?U0Q@:;BW<S,R:NR
M91S%(%%53<-0^\!$RE#&JJ<2D(4!,<Q2@)K-9V7C6JD&]>JQJ,W!SU.U7"#)
MHIBJK&+2]+2TXV1<@0HF!NJL0X@43%+<%]M @-V[<.YZ-ATAHW=;<LC TTR+
M)2CA%VY*WXZQ8I)MHYJL[D73A](N6;=))!) RBJBBI"@ #>-G#)PHU,LU74;
M',SD&+]H=5)2XW%9*.=/&SDGTJJ"QR&]:(VTW!UO,W- #?:DWT=!G=-*XG75
M.4JJ20BR&EII@<B;MD1)1^F=+"8Y>Z. 13-?JFL[8NB@F[8N%VCA'$4XH.&Z
MJB+A$ZB>U+JG3$NK:1J"'91G(<2_;1<C*S-54E2S%N_>)K+M&?&*FFX8IE%"
M(&$I4\6X-BQ-41AHQZJQ:23<.,M'K1[&R*0KLY&-E(Y=VV=-U0#N:[=51,<)
MBXL0&+:^\+@W[_,M451Q;#C<+2:<>M43TKMBB#!*4<'9L3[%TY346Q*)B4=@
M1:[UV&VD2Z+\0;Y1$-P;'CYF/?1#]-)!=1G)-563E))RD1=JHHBX32,4%2'*
M9,;M8H@8+8L11#>'S+';0T>\DW1&[EXJWC&JKQ<K1DD9P]='2;)K"!$4RBJJ
M;<* "8UQ;/6-*L$7Z\?%.)Q^=S*PL,S8Q+($^./W<C.2$<W(F3&7$8RF_:+?
M3K%NG'31'1XJ7C9B"J.#?F9* F\1;35-R<HU,JF8 VB6UVA<07@%]E48F.>2
MJS=HX?N$XUJN^.BP9)&6?/5B(IJB5%$A!,JJ.J4-8UH2L'<>*-.U&ZD6,-)<
M:8'*\<PYTTI%+BJ3E59/9BH4,2B1"C?JF-81 Q-'9X(A>6X;-X^.;+/W[Q9)
MLU9LDQ=O';API@0;-6S?:G.<XZ"$*6\;+-':"[1TU6.W<MG*1D7#=RB82+-U
MT3W&(H0Q#$.4UP@)?\#?-V?W.[=[-F$#!1[N5EY1RFS8,&28G<N7"QL)2D#1
M< ;IS[A2@)C: L6?J$C:4S+E&P$?ORE!1M3[94#"I#0J@&W]'&''".8,(7$"
MZVC>^77^TJ?6#: ]S4/2'JJM?Y?2OZ41'[A\_P"8>I5O!%M3DK*N:/J]FK3-
M4JO2,JQBW,2J$G2S 6/=3/G:8B5L4IDA,)<&T"^U%3<W 5CE!3KC->CZ?J&@
MZMJF3=4G6J:K98)FHF#.8;QCM#BEX('5447*DBH)<>(ULS#YH4=$4X:F<R:-
M89<*)TC%TV8KQ[6!6+VEH<T?&Q_*+ T<CM#G5XR4"ID5VA<>FN*?C:;H"+@\
MK4Z^?Q,8UH1H_.@UBVPD6?-J<C^+*SLF"CKC+9FY5V&(-;9I$$MLO9&,;"VE
M:H\GC,N3J.2DZ!IJE96;>0+2KRQ+N5I9J$TV9KIIMDR+$;J]U* ;<#8L-LFI
M!G$/YY:LZ@JI7-%K#95T?536?>)32[9>GZAJ6:J: 3IQN6+/M$C($03)M1<X
MM3"7R9H:G("G @*UK6K8N:Y3IRF)V2J"FCYB*Q$=%RDHX;R&T!-J?"15LK?>
M.(JABX;>3YR5%M6BR?E-YF0O&4FR0O%(R'FHM&.:.7N#:'(B7$0A5#&NTVSR
M?YATQ'P T[7L,VRQ?)TTP@%A?.IN1:S$'$O6[%F>19\0(5<ZBBKO6(57::<1
MLQ%YFFVU4-1S7H=,K!U)R\4F1<\!-@5SQF$7:+8BB/!Q7:;%GS).C"U\F:B)
MS**%;4I&UQ)4M'NI99G-M8FGY%]#$F'$>4[HR:SHQCX5MJ<%#$TS$PG0M3$J
M3]55&N)NJ8RA,MW-61,N]J1=&,J/]2*E32J9$I-N1!&3!,S=<A4RJ84RN,=O
M*J26BZ0,]BXS*U[&NH"&Y/:Q2LW),U71VS&25=J13E4%KW[,JF%(^(G!"U:R
M4=3#&B_ 9/*QZQ@*GHVFQ:P3YV5J7;97YE4\[<H5"DY Y%%F\FW7%1,5%#&Q
M!AM-RCIE&.&=-9/1U1Q;I]0[:HE>*GI*!27DZ4IAHE%ISK]-P_O;)N5#MT[C
M&,8$TL-I.HC4Y'.IP_DH^%BCVHJ&@X-PXJ="K%HMI/R5(-5I1DT?IHM4\9$S
M'TD[H&D2VRDJABUC4:GKK(O.49UQ'4S HJ5#(TR%1(0*O)3>)V.W*4@%/L$B
M;8H 54JA=6V="U2-I$Q!R;KE6;:,B,H:1Q*+18/&Z.-@Z1:J8MPIVAP+N[*U
M,T%1E-)L*9R^8U_F6Z\-Q)F)-R,VI#)-E9".@(F.IE!^Z;(HI<GQ142$4.F*
MBZIBWVHQY#-EPGJN\G7,]Y+.GV7E.4O/U#)0AY]*%,]I!AR^BBY23*!3I('$
MRY0 %RFX%O)E-7,5'D3J'-#-)K5"SB-:,%99RT+'GBXN3.GR6;9<:,5(B!U$
MBEQBD7!BMEB:K:6D'LRMFW-1S-U5>5M%Y;H+P*=-RCB7I<U*Q523"TBV:NBH
M'0=+-132Q"GML5UJ K%XSI]K.0?E1P='1TFQIFG(WBE+34,==Y!F%O'))JHE
M,W3V*JQ3K)W8BJ%,(C:O%)Q%9!_X3S"92*Q:$0<&9'ZY6"G%&[./*.-*[NN#
M$IPC&&_%U+\UW578^;1;YNS:/@8"/=2TS*.DV4<P:$.JNZ=*B. A"AVK[QT%
M+K&T63J"?3;2N9LJUND) .[-Z>;K%':0T*>\;]VYPXNO4'07"GH_<5OM2GU@
MV@/<Y#Y_55:_R^E?THB.K4ET5%$54CD42614.DN@J37*HB=/6*8/IBV(I*R<
MA*'(0Y$S2+]U(G(D8;E$RG>'5.!?J;[-B/I64>D8@(,BO9!VY*RTE !9%766
MV/V,.#@W L$@D_?)R&T46Y02=N"R&T.4Q#K"](J"F(04X0'W[;9>5E5U\+@N
MW6D7JRP$=7BZ)MU7 FN4Q#M+QUL6M9RT924BS:O"X'35H_>-6[PF#9X7:2"J
M)50PF,&N4^J-FMSQV7B0XF0%=+%XF;%C$S7NG<=;6U,&FR1@D'H<7<*N4OOM
MUB0=*WG6=-[E=10_KU0UC?36;(/9&2>(-"X63=Z_>.4&A< )X6J+A90I PD#
M@7;ECMBKK V54(LJW!94K=10@8"+'0VF$QB@<<)L._9LLC)2*2S @),G"+YZ
MFLQ2[IW-DN18#(E[H.JC@X1K'E$IB61DU@4!62;R;Y*26(<" <JKXCG:'X!>
M$?UI>M9Q>\=CQTPJ/0,Z6/QXVTQ =]W7NPXM;NN/6L@P=2DFZ8M<(-&+A^[<
ML6H 44B<6:+*JIIX2ZNJ3<LT<%F9@J\>F",>N$J_!6/1%/9BDS6XQB13N.;4
M2PA911>5DUSJI*I+&7D':YE45E=LNFH=10;P.?7.0UY1-K<*S51O(R""C+'Q
M!1!\X358XQO5%DH4X"CBQB!]E@X5G"O''8*N@4(Z6!POM7A%]*Y7)P.!E /Z
M_&)[[).F;ART=(F$Z#QFNLV<(GPB03H.$5$S!H./!-OV(^&9F..I'5,B]&5?
M\;1.N%[@R#GC J 8WK\)@ONL4BSMTX(5518A%W"JH$77/B77 IE+@4,/#.&L
M-D'CN9F73QH0"-GKF5?K.VI=\C5RHY5,F'^2:P(E<N 1VY76P*X6*AQA/2F[
MV>/#M"_YR[%V;"X?/'3]R8I2'<O'*KMP8B913*4ZSA50YL(=<1_=?4_P''0,
M#'.I68EG1&C"/:);1PY<*\ $RZ+@^G/N%* F-JE&Q:AJ!-K+9ERC;"_D"@"B
M%.M5KQ-#0JEXZ!O^^%MTXZ ' 4M_[BO]I4^L&T![G(?/ZI"[=L[I2LHE.9@'
MRK55W'++NVQ%U63E)XU,99BZ9J!A.B4P7&#<T[]NBN-[]U7S];HKC>_=5\_6
MZ*XWOW5?/UNBN-[]U7S];HKC>_=5\_6Z*XWOU57/UNBN,[]55S];HKC._55<
M_6Z+(WOW5?/]NBN-[]U5S];HLC>_=5\_6Z*XWOW5?/UNBN-[]55S];HLC._5
M5\_6Z*XWOW5?/UNBR-[]U7S]:H4U\L(PQ6<VNU;ARS508$2-FA\/^O\ Z90?
M/MT5QO?NJ^?K=%<;WZJKGZW17&]^ZKY^MT5QO?NJ^?K=%<;W[JOGZW17&=^J
MJY^MT61O?NJ_,_Z^MT61O?NJ^?[=%D;W[JOGZW19&=^JK]/E^W17&]^ZKY^M
MT5QO?NJ^?K=%D=W[JOGZW19&]^ZKY_MT5QO?NJ^?K=%D9WZJOGZW17&=^JJY
M^MT5QO?NJ^?K3(N,L(XW%:@DVB-\S5(7((*)@0NB=MT5QO?NJ^?K=%<;W[JO
MGZW17&]^ZKY^MT5QO?JJ^?[=%<9W[JKGZW17&]^ZKY^MT61O?NJ^?[=%D;W[
MJOGZW19&]OENJN?K=%<;W[JOGZW17&]^ZKY^MT5QG?JJN?K=%D;W[JOS/^O[
M=%<;W[JOGZW17&]^ZKY^MT61G?JJN?K=%<;W[JOGZW17&]^ZKY^L].YRQC5%
M$IV=:E'EBJBX4&LFZ;HD_P!>;Q2!;HKC>_=5\_6Z*XWOW5?/UNBN-[]U7S];
MHKC>_=5\_6Z*XSOW57/UNBN-[]U7S];HKC>_=5<_6Z*XWOW5?/UNBN-[]U7S
M];HKC>_=5\_6Z+(SOU5?/]NBN-[]U7S];HKC>_=5\_6Z*XSOU57/UNBN-[]U
M7S];HKC>_=5\_6Z+(SOW5?/]NBN-[]U7S]8CEUEA&J*\;DTA-RQ5(:B$BZ0)
MP9SZ5.W17&]^ZKY^MT5QO?NJ^?K=%D;W[JOGZW17&]^ZKY^MT61O?NJ^?[=%
M<;W[JOGZW17&]^ZKY^MT5QO?NJ^?K=%D;W[JOGZW17&]^ZKY^MT5QO?NJ^?K
M=%<;W[JOGZW17&]^ZKY^MT61O?NJ^?[=%<;W[JOGZW17&]^ZKY^MT5QO?NJ^
M?K=%<;W[JOGZS!T[RNC5%E>,[17EJJ"B; Z53)H).!ZTH!;HLC=X?]=56'_C
MUNBN,[]55S];HKC>_=5\_6Z*XSOU57/MNBN-[]U7S]:_]5L;N?\ ;=5AU_\
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M^GL)VZ5JO[7* ^I;I7J_OB/L;=*]7]\1]2VG-:K^^(^I;I4JWO@-NE:K[O=
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MVZ[. :5/+IQC-XS>L'#-F9RH8K11E($371%.\Q034(00NX-O)A#?_4W6@?\
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MS$MPW9QO(N@Z5JIY$9L0=*0)JH3=2O@LTG*16D).-[F]3%P=FL)TB&7$]RA
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M !C1_P LV_\ 9X/?[O\ QC1_RS;_ -GEZ_\ R)M_V>7K_P!N'I^QD=?I-O\
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M2BXGG <M:]M-A+#3])PKB$!IZ&]@W]XPF'T&HY06W+!IR&15-#3-K#4Z-8$
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MSN-AZFC^6$SFS3QB+IT[98$$1U1+/<SUK7)(K0%GUI\NL83DK\/N],L+K^Y
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MIAJ-*FRGF,F$,A9->)7UYSGQ<- 5:.K3],A@O0XNB+>Q<]<B&2=ML0<WH_S
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MR1Y.N(AK)J7MTSW!/XO)O9N/YZX&[^#2XDG;3Z#O.HM_'M&-,]0Q&<WU>V;
M;\F0^AP-A$/K>,D>^,$+A]5V3$'?*8-PAUKI[<X2>O@O2F?>L00WR'OK?KGU
M._1R5+VYG)^C$@%[/; F6H_G!)'2<>W_ "  !B[->3)$2<'0[HZ3\_;G 5=<
MQ.O^%]2^V(<AR')>,.0NO"'PA\(?"%UD.1<9(FECG4Y>B[/6=;WAO2?,'*7$
MP\\OIDQ)V-&H4ZZ:.F<OJ?8Q;HC,FN90REI1KTRJ5CC4M$,5O<59K GQ0KM#
M$2CNWO59-:!F,,66@SJ[/?.*4:K*#>HS/L\WACK\/$[:3N4T/H.)? 20UJ5
M<A/WA'.60VI22-=-^^+)$EU%0^7SD2!(US!+30.B9.F"\MV68+4HL1H-4:UT
M+")ZQ/+Y+C@Q*CF.2J].VM:],G)4;.IZ,9PQ18[%&JNR+HU22$B!*4">"BVG
ME K2+-PVV*P](]Y2XRR:4-:9-2[]:^#10Q]030/;K,\9")PM$JAJ5.^I]<8(
M6*:V]H=3[W1!DUIOGN'<>K]><%)E+P2#":.F*:U+UH[>WP9(#P\,(G9PW^<
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M/?[O_:ARNOA"UX\Q^FOT<QE[_6;?\8T?L^#W^[_QC1^UF,-SX;[>O\Y%1O\
M3/'OS&5Q?C*:S6LX[]#^,V^>_P"HV_\ 9Y>O_:-9Q@1JYSC+G.W'@&R9W\=,
M!-,GH^_AZ8\NISN8]=_Q]L>,(*,]<:PF,&2?$V_[/![_ '?^W$8L<YL^^.OH
M_P ?I3IX<96%F*2SQ7S>.SP-_0_G(&G.<"O$V_XW'[,U\_=_XQH_::N/Y^LY
MOZ0X)YK"W_7/3$DUOV^<.?\ <>N@S6$SZ=M5B@R"?62<ZQ7O.2:/\QAI//7)
MCU^,?K_G.;%WUB3S[Y"I;DI_DQ95#KOIC$S\^)M?^SP>_P!W_M*/IA7&O/\
M&%>9]L]?/UR8+^?)DFIU7-=L7S/'MA9.17GER.G$=..OQC5%7[[P"HKSVR08
MZ]NG2,GSVRGG8QSCNX_KIDH(_G%4#,]8]KT^_;#CH)TE"Q3QUB&$)UC+>2$&
M2I6-;F 5BXF:#$U?M-K?OXFW_LFO^T6_;!GWR0PK?]YLZ?QWQE,-KV89Q 22
M)"/3=?;.)<1LPZ8B/KA,;K7K'7)K;,\=.[@B2"+UKWP06J(<DN=<]NN*@G<+
MJ*B_I&%B;J3C*-T_2?\ <Y)@(@BO7XQ637;7U\^F$41*Z> X&X['UG=OC/!]
M/S^S%]8_9HF?-O[,5)6?V=IT_P#:G4_&*/[UO%)@1>.$GD]?IGFCPV\EX[#Y
M_H&6OM?GGL/GX#-CX9:*/O?XX&0S^/\ #(3;ZOQZ4@)ZN?;WYW/Z%:]^2\43
M+PQ\.+0C\\RL0^?@$EP^>4[?J^#_ &&77^KCDGD/_=EA3V4_X\^,XL?EO"3C
M>#%9,?GCSWD_U\UQMFR1C[3YX[3+H^"'S:^O')BF]6<+<O#LO?U3S],GL7R_
M2VI>^T_])>A+N-:S#%Y+RTPKK_CQF%V'S_0&-W;_ #_7%M:]:[7YY[+YX[#Y
M^(:[)]6"NRSNOGX3>2_TM:'OS5CR7XEF[#YXCZLTI"^@'UAD?+)&NO,+\>L=
M/WT4>V"7)<FYR7)R77)9+)<EF?T#&2Y+QG/3G!LKZ/-^F,/:.:XWR]<+?(SP
M&F_/]8S#[>/4Q0A[8*GK?VC\XNNB$/6=^EX'/"4=R(WB!4]N$^V" Y>I$?&\
M$YEW?$'%<9&D680(8ZF&-V.W/Q],0J$!W,DB:^V$PL(OW/?G!0<=74V?G.%D
M^DWSC+BV8UDD2HBO7MB T"J+U/?-EV<?'\82+OKC37WP<+J"=03PQKS.+BA!
M+#<<$]>^2>F/0[=<03H_FI^F2'P/3I64SHO!F1TZ>FL98]?F(P08D(AD,ZD'
M8^^+2S.WK?3)+O\ K[X AX\N15^9^F2R7)<ER7P)9*Y+DL%,EXR762^,N2R7
M)9+DN2Y+$8JTY+KG<R7A+X$N2Y+XB,E<ER6LE@IK)7-Y+DLEDN$Y._7%NX3M
MWTA+_IF;QB,M82&6>00>6X@\(T?\[FZC#6I5PKC :J,:&D.XVEQK'<*Q%0IX
M*?3 9)DJ"9[L\[A]9F ^9"AM ]IDV]MX[!M%.9Z5..]])P!=OM3M$($:U<,5
MB% 2&R"A!0Z]?4$9+%HY(@@=.[64-C>QCA!B.C&^<<>TT,,E0FKQ9[<V2B78
M[E0&10'I%%1, NV!8YPAI9-N4#<H&9@FLD%%8#39B.X>8:O*0C0:;L!(==+K
MC>#\]0QT)67<?&\28PA7)!.@/2^<<PSPB(DII!V36"]DE9TAN75],"B ;22'
M ANIY0W6)3DCU7<#B]/UPLKVC%M]DI(41O&@>9/LAN8R=26"+03@)5%UJ,B6
M2\$V ,P:]&?1Q,I 5(-B&"<&Q_C+1,%S!)CE57'/ 3CCTYO%A#Y1_N'<(@FD
M-=S,E-<U;$@F9>"(%?QGYG)&10*0MTG4=AVROT9!-=%'DCC E@@/*4 ?=T]S
M>/)$HK0@H\!(NF*K(:)19*!8/ .>W.&0+&!KH)9@90GY(P'4CYF_^@,.:/!A
MLX81QD2+;ZT]GWQW=.U7S<+>O7YATX:_YW.^,VQS?VP39+#VG%I]\6T(S*VK
MN>CP^N6*.E%+:5C7?-IVD(,D5?OTO D0. 9T84UA!M,22JDM]O7VQ83=M;XB
M]^F0ZY)*2238Q4A5DNC0!]9KZ8R<$*Y5C=(CT9G67; =C%@>SK?4Q!9"$.K2
MB2JU,&HG+E])R0D00".^2/IJ/<[]VMY!DB,S]; K1S>\45F.NF)GRZ9&HP+K
M98T:@[?7%8P3)J<E8U'FIC23B31>QS^,#C7$JXD*_;(_KH*I1Z 4^F%?691#
M10?9DQ 4UR]43OJ5>(Y.[ZL-_P"_&)$VQ[_&1QI./4B&^,3)DXS%J!+\[C&(
M0%'D4@#3HZZZP.;89[H*2?2(]9G$!OZGL+GI_>6R$P];G?$<?ZD\-J<0DRM-
M\;[8A9E$&0(G2;7'N>T)A5F*,-.A9GG4DGR&("&812"("CTI>34X44/0&Y<+
MU[]/^C/&;<V#\??%THF1^#DNJN99RV%B$3GJ2>>Y]<D$M<^_[KZ']H>V%&>=
MX<,S/7B^E[ZXZ%#UYKU[80TJC'T-WO-Y*HLN\TD]>E8Z2@/=K<FW"&12[\WK
MVQ*J5[^F4$L&)*)BP7$!QLLR5#9T802&Q\'!@W;HYN)RD'C:HW$2W,ZR-F_6
M)G@CIS@LI[#LZ)XC%[G:\S&122J%H&;)@N374P</+%OIQVZY.P3V#7DP/(2O
M4WK+AY>T[1OU<_S@HW)==8VWQP8UM^MVPU/<R:H7B^L\#K(G345ZF*Z[[4T=
MOX:O!A@;@EZDP<PIVLGC-<6O?%Q4F103$.]#+=.Q\U@9P$VI:O-[?)62:9-_
M7AZY1?;8[_S).0.S7,T0_.#,A(2&N DMSA&MS&]:F0^]=<27! 2]R#3O3F=8
MS1R/IQ&*1"A7I_N1_P!"'P63VY2P69J(NF_MB^IF#J'>&O27F[P8O_G\ST2-
M=,.V 14P[%/T<5C/X1J;1]$?;BV:I)+;,!1WRS21HJL;FXB0S9XC3/Q?<%2,
M$SS'J?KDJJ@V,K+%$T[GIUP[S>%S$<K+OD\]LT8"'LHB]831#^!!%;GE)$A2
M$C>,2DM37?3,WS],0+=O6!DPB V+GG)4[[B?H.O;&'VH04J/M,$K#J<6XQ(%
M4H#5E3M7+5; 2D@T-0.")>0ZY,U3!.I"A/:HBN,7:*52J A)N(9EO&6:@C&L
M,-NVN>D5@'G0.3%&&=LPK]"(P2VE[EZER+1TJ\DO@O>H+&?5U'><GZNU)PA1
M]X,[8H"+J?CO.0(R$O6:&.^Z],8>8N:B?N>D\#BU(0CZH?6&?3IFF0JFV+-@
M\5)-QC0ML&- &3A1'.NRXB+Z&I13HB)K[*9,PA!8:(%P,FI+(E>7GI453#UE
MD3N?KE5?=.V8F?,Y$9'DBN_L\^N$4M];3?;7KWQLB9/9PB.M"_UG$_\ 1BXP
M 1ACH+3+9]A<=,I@2G6]UT*,=/[SG#DO"' 760Y#D9#D.0Y#O(<AR'(?&7@B
MJO77^XPY?37O].^(T8'9+Z+[9&^(S]@=3ID.+E%O,K7F<8PBSWTR<P?3WQP,
M)09ZO4[=HR<$RA=^OTGM>+W[B=$=>V7L?)]-3YG(6$=5^JI#U^F5I#2+?5JN
M4F]7&-Y7O>TRJ^\W[Y,V'K\;?/;.ABY."/0UUD](Q@-PV72:F" ]6+R"P$*)
MW $D&I+]2*<!Y%%*>%2**KWR"=]:)ADK\1.$&1M2\I*F*[8]B:%MP,?SK_ P
M;\VMG:^=861?4:Z\YRR4[;4(^.W\X0MOR:J'G[XQ1<8W4@3HUU#&B%9.T77E
MUQ2*.4=W?MWR+3/221<[&_K77"K57>HOIJ_=YQ>$[;MB=SOK6+-+R+:)(;#C
ME=UQAE!@<ZU5],4Z8[>_.^F.^ND\>Z<@FX9_MG^<"<ED.0NLAR'(?"'(R'(<
MAR&)R'60XHR+R'(<AR,1-Y#O)9+(?"%\(9C$C]ESA*G.0,@EE0T3Q!E@))@Y
M8]B_Q@(@U[^!H_<L)7&.(I1T4&S[QG??+/??+/=_+/??+,NW\L]]\L]S\L]]
M\L]]\L]]\L]]\L]]\L]]\L]W\L]]\L]]\LPA)\ND=&=]\L]S\L]]\LR;?RS?
M,OEF-D7RSW_RSWWRSP3^6>&?RSRR^6>Y^6>FOEGGG\LH&_RSW/RSW_RRL;_+
M# "M=5?1YUAHG\L]]\L\L_EF!D?RS7O\L]]\LG5_+-,3^6>^^6>^^6>_^6>@
M_ED#G\L]_P#+*W+Y9[_Y9[_Y9[[Y9"TWW5]'GMG?_+/??+/??+/<_+/??+/?
M?+/??+/??+/=_+/??+/??+/??+/??+/??+/??+/?_+/?_+/??+*"BIO;^>Z/
MZSOOEGO_ )9[[Y9[[Y9DV_EGN_EGOOEGNOEGOOEGOOEGOOEGOOEGO_EGOOEE
MAY'1?;S^<!N<Y^G7]O +_8XF0J>L=:D?7Q""[SY_HA!!?[7P!?[7P!?[7P!/
M"OEB.H/H<R*;9-O6X#T_0:/W(DJPWI&2=E1LZ1O)^&230Q6ZX>*.'L\'8X.Q
MPR<,O9X#H\'9> YZI\!+V> :\7A%5=78]F=+P77ML';8>N,,3$,%4PPKL'S+
M*&*Y:EAFYV=7,,$>;TS>$70P=$>!YJG3#(>QTHUCL<#T?@?;<46M<J-)P]CX
M![M,*50O)RHY8N."6*7X%5X@N'L,/;> =:F_K7V<U3'#'PP''G25%PMA$Y6:
M(8*ICAZYP7ZX:*,G9X>F<//BT9R6QA['P"+P'*JS#WGSV6#LL'8X.RQ=M@1P
M>TPQ7#)3A1<#LL7;X>RQ=OAF!\'HX&0@,T& ZC[?%X(Z\&&BS_V4*2?/OC>?
MWW617ZS)X5XF'_,P]:.0<O&2U+R&JK#Z)W[N'BV',Z/J,FHHMTD7''6G4^DF
MDY 0^H!]L[.\.R20X,^T8U>0K/6N7=<\X$M:#0XE:GIKODYL$(V*H8(:N>NL
MF&W0>**%$>G6S(IK1YX#S6,KJDELS6][OVP*5RG1$55=O; 3@1I:I7^_VQ8W
MD8MI@AH+(;@EG.#2_1%>^*(P;;>WY,O\'HQ/QTZ9,ZP-MFZXCKECNF"(UQ+D
M#HB[HCK;6(WZ9&)V$14NXR=1)=C9@:3(.0BP0_R9)DZ<8)<)+OM/OE1<@NI[
MN0(D:D)C>YC A.29VQZ8_:Y(PI,@S'"IQ*0(34??WQ83A[''O@FVH:FY'88#
MXTMZ#NWZ88R1!.B1,O4Y)PMQ+(HZ"#H8BICU#/:-0C=N$=M*N9[,?6</;N*T
MHUS/TP*1:SHW4!JZ^6.9RUX6%CI+SQA6>%<^KOB>GVS<&2..?;I],4I)7P(+
M'CODTM'IV%M_.(A2=IZ=#ZX0P45Q76G((JP0VA-NUZUD5$K4[60K2/>>V0'S
M#:>1$.G5SEQ4464+08A>C[;Q6&%KNUVR <<22^MZK+7OG3N/SD$.]&^+WQBL
M230B=$X%)[Q[H?Y,AJ)/HXK@\_SE5)[3I$2A^C^J7QDZ9Z_JKS_OZ;8C8*]P
M93[?QCOH/^WS1M%J^9'[XJAA1Z#D+DZ<^N-A8,<RTY>KSI=DC 7T@$QI]LT6
M%)9GF))6IWC7:"(BD&WK#=XZ:!%0@32WC:Q/MA,AC3$$1UG5VM,[G",YM/1#
MJM>9P!8B&6(@6X"'ED)^P[RV@B?)D)Z"2DVZ> V]-XFKC,"0;D@Q6>F73F1'
M"!9Z(D,(==0*2TX&B'\Y#,9H#20DH!89ZK>)$;$*442C4=?1QX*4[F943EV6
MUTU.P(=23$;1@O=X,&@G-I>).IX ^<?1-%#0H?N/MD_@Q!*4%)5T<1R]<W$<
MQ7A3[EW]LDXJVC ,O #Z?SEIIB:((-0X#UCOCN]1(W'0U#MDA372&3R**-[Y
MWCB092Y]XW7;C+@(E+>VO=)XBHQJB<"A<FZ:3KS\$Y?4FR<$_P!XL01U6D<A
MZS/QBPJJI%0E"V.S!,8RJT0J(610DE2J;IQ\1Y RJ&[J][7TPF DIPW"R=>#
MIQD%J8E+B)J0OBW!8Q3(T$46".H"^V5O L[LEN6UV]LEN32D@B02$^AZQD/8
M<O4$2O2/Q.IG E62:$A/HJ]9,D0.4),P6EJ>CWQS%[$HF$R(Q)))PF0*VD2@
M-$+(9!'T;R/LA(9!(68G=]\$-@=B=%V],@'ID)MHD'HE]G&T J6RK%LUJ9OZ
M8<DN5R?Y"=/.IR589DR35+7KCK%URQLF6RXUBN-UM.&(D$.Q^N!M#/.[ZC'W
M??$(<"*D4(20V88GOC4?M(BT;,-KS%=\):B32EUH=R+ZFK:$$L5>J7Q,1/;]
MJ20V]E$U\[^,6E5@JXN.1\G_ &N=912A#=-3H??WPRY9)Y7'#^<9MN(]*E>A
MTZWSFF65[G+S3WQ8P22AFIABGG>'8L=Q#!JE^N6%*3-2N0^?KS/Q+W#H'K,?
M3%X!B;71OI/G*(1-W2]]_/,MSGT;Y)R8949$T,(B0V%_PXQ%.]9'3ZCEV=[^
M,93&(GM:MUYZ9'9RIZ<R!)>X]^,8= /<&Z.^CFS@A-"#L\=,F$(S+&Z9%5[_
M -\+(W6DY@.M;R>Y4MW9MZXBF/?(<ZQ' S-*WX[];2NI$[U7V'>,":MMV9VY
M>D_$Y(J@\$0&:/&KG"&+6'0#!?*>(]UP8$]1<2R;4V273&G+JH0*UD1+['QZ
M9*A,E)Y)N :)P1NKY08IX3T)^N;DMFYW*\ISUR@+D=4G4)._7*X0<7[1%7M6
M"8G <QFX0N_?JX3W+/*:G3T]_7' G*YEH;!P:^<;MU,]#&WWY*PX5$1TSOGP
MO&"C4>JL'EC";JQ4V(!\]XF'J.AF'#4='"'E0Q4,J%?O]\AS.:Y-U"\S<Y16
MP$D5B.3I..BK--)69A7UWOOEER(V6.=ASV]W!DSOM6:GU]ND8(2-5B(<@?7C
MT,0[F)>DUI=?.G=PKD<5^0>V1!.'EZYI>^K.V6AP)N9)%SU)P[PG/4R-RN .
M,K@D197O,4-&+F1Z1LQ$\J>?NR\_&6Y3$,Z=S*)ZM?0-->+K7$N/)S^T%-9\
MIR<I6&VQ>X:$?0<?7:!!?]3_ -GFGAQ,R/KA,&E.O4_&3<GN<AEO'VZ8G*4_
MC KDCW.?G #,^N0.LGZ:P(4:B/YR S.]:RA&_P#,A0N*?+Z/\9$L=*>7B/.N
MN64PPP:?2#X_.1*6VZ[5>2 T]?O^<H1LYSAH_P ]<<R>NIZ37GXQ2J7CM-<^
M=XD]CA\+YG'$2N5>ATZ=*O$@4=:7SSD4FF((=^?3XR993QQSDT,GYP>7HCM/
MKE76.'C!(425]6+J?[<0EK-$S%,W!Z763I5Z^V4P7[=#KCQMD5?2>CUR-C,0
M=K_TSGN_S!FM3[9,MD=PJOY<)# /:N<$==]5\X('E,M<1BQ0'XQI_([[>N#%
M;'<F%0KI.;8Z/[Q ")C=](P%U^[_ #B%[/7&;B/3MBV]OSVQ50V]/3MDH_F]
ML4/)]<%IYO:<34#F.U]L-XIX@_:L XR6"6^ ZO %MY%5 ])8]ST*ZW4+%QS^
MR-'_ "^?'B*>';PE\'*5R?N:/:]=LBY$,LU,C,G,:U?-"LTD$T'@JS_<4P!E
M#]'HYGE^PT""?MGVX3OE^NMZ0&BX.#&?4O"V]5[_ %RUNJ2!NNG>NW?'=R ;
M;DX!$/-1J-XT""9R6 S@ML;Z,8(5G,CA$>KJ#UPOK7?% UZ:COA,%@-$K<A3
M'W. PW7HY35%[D44<BFKBWR3@]'KVXPEA^DB_;OEX"S4=>=\;RM6X:K9=/GX
M6PY(:Q-J*[31?49*]1;2U@-;LZ%P9ZS=7!I%UP'U<WP7:@"6>O,X711B*(0S
M)UZ]RC."-9F)2:I9U<>[6=2FK%._-5A+^3?S]\FHQ>GB0;OPEB,=R>$O_@(-
M_L^C.M6)E!W)/5>K9BHI*.L,3,'CKZ[_ &AH_=])9#X0NL2/TQ^O?A#O#]6X
MRJ.,]:8,3-)Z_!AV"+K<:TSLZV8M;L91]%UQA*#-I7,F@6=9R=QI-N8B6]N9
M^,CU+V%*EO?GZ81E(>K<S&^>N3U*-LNXCK=?2L 77ZT@CKM5S1AUBI933M&N
M*GO7,Z>TWI4A]3-SPN3W!,IZIH7U[^F%;#FX*=26]WK<X"65R+:5B7,O-3AI
M!3%DY>>OU;C$D<:7P',-;KTP(#\>W]80DW"X995/,\]><ZIV),K!W,S/KVJ<
M6UR!/(NY.WKGK'L7%>Z?\O)*E-N%FJ7\1O)AVD!7%BE%E?W%M;)-.B)9O^^F
M#"$!B)U,[GL9!EUTUV"_U0^._P!&O_#MD=/T0^,?KB\8!QBH LJ0$&V* ,CK
MI0;YVT8K4?U!(O\ :#1^Y@8XPDZ1XL>\/>"/"GR!GS1CR!GR!GR!GS1CR!CR
M!GS1CS1CS1X.?-&/(&?-&-&A\U8\@9\T8\T8\@9\T8\@9\T8\T8AX?#':^$P
MA:S*9VR<O@@O8> ![7(;'LUQT\'S1X$Z\WJXLF_#$>PKS.#2YG89.UR3;S!=
MPP[?!%I,SS1CS1A^<^+MGR!GR!GR!GR!GR!GR!X,?(&?-&/-&/-&/(&/-'@4
M\T8\T8\T8\T8Z8/YNF?(&?-&/(&?-&/-&/-'@9Y SYHQY SY SYHQY QYHP!
M\OW<(R8Y"7N;^@<WZ>'$A':?Y_5+HP$&F34\9R&C_P C1^YH3> ;,.LNK5YZ
MWPX]7Z_G.T^7KGJ_7\YY+_.=I^''J_7\YZGU_.>K]?SGJ?7\YZOU_.>I\/YS
MU/K^<]7Z_G/5^OYSO/UP+H[W/QO.T^7KGJ?7\YVOIAZGU_/@'J_&'J_7\YVG
MR]<]7Z_G/5^OYSU/K^<?+./+/Y9W7Y_+//+^<\E_G//+^<\B<D>>MR1]<L_W
M(O\ 7\YR=>[^<HJ?+USGE]?RSBX]7\Y/R_7"'KZ?EG0'Y<]7Y?SE]_=_.>OC
MM5Y=<XK^OYSI+]?SGJ?7!RGU?SGEAP]-YW+_ #GJ?#CM/P_G/4^OYSO/UQZG
MU_.=M^7\YVOHX]7Z_G/4^OYSU/KCU/KCU?K^<]3Z_G/4^''J?7\X<X_#^<]3
MZXZ ^7YR3?\ +]W/5^''J?#CMOU_.>I]?SGJ_7\YVGX<>I]?SG:?+USU/K^<
M[;\OYSU?K^<]3Z_G.T_7\YZ^%/\ ,WB<F0=Q]GP8[#R=\%W#W7[,\K\N=E\X
M>4X>4X3_ -LDQ]?^#ER ^#PV9]/;.ZW[^D/?_B_0X57?AS@QX3SX3D^'$9+D
MN3X3DN3DN3X2;R<$.,ATR?"&N^010&ZZ]LI:JQ).R:A,QVQ_+V&3K"2^GQO&
M!S0[FA ]B;33JL.Z$@QDT0#<H$M]LH8)WPW%'=L-9 +3)B2*LE)\5TPR$^TL
M+,'PGYP*)>E&9[=WK@& DR@226CZV'3!^R3,4/&^1A%PJ9[NH^FO3(-S2=+T
M$SUK^<5 NL8V,D3[<;B\CL$*E(3 R!/MTZF1?B/,T7!JZY^EB^7?UH1^#6:'
M2V/$4C/WP"@FEI!VHG4\:P:JM4*FN+KOOC)=4SUG>T]_X3!@K)=*.EM_C%2>
MD\K#=KOUP23S%]<J,G)<4X\)J/T2=,GG)<G)<AR9.3.2ZR<F?"?"?T*.O"1X
MP8X\)R>/';T_\=4^+LHZB9.-R'WQN=FGAAXA8]-^N\N.V;+K?_@:/^MS[8I:
MIJ]_3-?,B^I#9N(GWP9HICDF!,FQT^^5B!,5 #;NO;G%W/%A*(\TT6GKUR1<
M$6>Q((&TWK)C@2(628KIZ8H12ZTR2^(B-<Y)$TM]#HJNS @"&'T-VVG3?KAA
MTQ8Y01R3(W%:UD7RBX>@S%<M\=\8R9-'@OL^GYP/R9 J3 6$.Y/ZR3[*I;TU
M$_%9O&98LY;7P].QEH?C%,!D1LG3G@<D02(7S02MR&N^&E@D[$)7E,97@-9)
MP3+TXR($SZ"KV.^G^<C-$Y%4,W//1OIFJ( $ E&ZVQQJ'$XGI]/^A;>5/6'4
M][R-Q'&2I)%$GGC'I<R=[WSUZXQQ_P +Z']Z9<K]$Q&A>V1?SWQ$STX:CX7(
M._/UP 1[0<8B+Z>W3(,+U,D>F$4(G1?/J[Q$OTO^LN.VIV4GKFDKZ?'-=-YU
M5?FLEA5;>/+@+_G^XP+@UORSA@3?=Z#7VK1E.P]TW'=]<3A*]6SI@]/6;1%U
MU]\1)+I/H@5)&6:*'<,4I)IL/K>1IPCO;+4O6O\ $]W_ *,*0<XDM,1"0DY$
M<T^DSZ8RQ(*3Y\_?_P #1_U^=$[\MP^>V,19;))<1-'.&\1YRSM$$]92(W*K
M!NX(9,&!]7/$51'YQ0TS'\[WB3* )5X$VR>N&!/5XF:*K)9D[/AW5=\:S2>8
MKF-<\]=8&8X$]/H\'XRL=ZZ7??#UO^2\!4;R%EZ3/+7UK[99W;Y5QW\F.//4
M$S'K&$,H/>;B-=9U[5M8E._-R3VR=S"A?5_LP+!ZP1T.YA2TQW?_ $!AG%;$
M+EB +EGYO'E)HLAB+L,=H]9Q0 _X7T/[T@G)U"0H-O9"TE6(Y)0&% :B!.5F
M=G;&!.+=N)&Y<E;*FVVL)4! J%]W)3E52J2B8.7GK73'#A"2+7*8B6^?ATZF
M11$Z0V_R9I^H.TJM7]>,<6F/:7#B;^?<,(>@? 1&;GO_ !@D3K01!P#V>*]A
M(RCJ99'S<P^AUPPU$2+%CSNHKK6\DW.<AHV(TA.<NPDTNQ50QK<EUO'IZ!:A
M"&O?WCC#$]=G5[OHYWE9>PC''"DGUQ%F9%#0ESU>(?7$"">XFY)CZIAU593[
M)N/L#GI?1(,,'B,,LHF%Z2[/3(B]Z"\/U7L[81DB05,S[W^*QW_S@FC&,G1C
MAMK6CGBN_?-?5HHG0.C#5?S_ / \P4QUR>R+YQX4D2V2I(OGMB8[R+:*DC6L
M4KQ1L];WUWD@="F]R5KVU@H7%MU;T-1VS0'KOVPA+JF>'4_U\85%]G$^><'F
MS7WK&3&VU=R;3UO?9PH%<K"V67?>^\8.!.FTF+?2-\3CR+NE)B/37MK%7HOG
MBU/DRL@C3.I]\+J:9V!JB!^V(NEY8J.^"#:H(37T^<0R'>W%&VMS6 4?6/1
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M'9>7OG;^(8$.P\%0J#+NM0<X$8Y#(-074MGJ<].J=GQG=>?;/(3P!>V +/\
MC  <+[?^YKY(NN/K:D=Q=@Z=\!:<97FQH>VSGUR+:QH'@L)[.9[$8SM+2H@O
M3MW72\:R4DE"T 'MS.(EE3.N9*^E8&GS8Z!V2?7MFST(OL8T(B>^X]_ODD>U
M]X.A@\ZHDY3:+7N,,ZI#(M+@'\>F;DE$SJB!/2Y]<LS6O\;[8C"0%/I'KPF_
MXQ=0)9DU7$O35YUPU39J)")MUZY%4A29!Y)ID(40PFYW!Q.\AD0FZN'I[80+
M1M^:[\XW[O8>IQO;@AN]#<%N4;/G$OM4*+8*W\]3"XV&)+",&+QT_.$M$)L5
MI3!+LU],A8B, >"\WW11?TR5Q"K$^Z.*BO"&0D\M=^E..I<H3E-D<<QVR53P
MMZZ:P_G$'V]>IFI5W>IK>_SCAU=CZEE?7$)D/1K$NBK?:,@0[BXUUR2KT'GT
MRQN=RZCIBE\=NHA0X/8V4&@+6,S'&HO(R2. H*B%]5@B]TB/EAW<WC ,.C7J
M[>F.H,05EY:JN<0J15"]0Z=NV!GH3+)*:/5_G *4(>3H_P 9$QJ1<1'T)B.>
MV63,5"IJV2PJ, @BS &NZZ]<NI 2=D<RUE.0.H<%1ZIF.MYM'!((E.0FOC)B
M#!K3,6HTG2-.(V 2Z$:Z7@*F B)NX];P4#SN0HO7[,GC$T<&L#,*]TE,]JGI
M.R5"$^G_ "OJ7_LC.3IC\GIEA?NQTW[@?UC!$&?J$Z+F>-UBG+@$E48!B=/3
MVEQ2],VT!9 3,R-<U48[LP;[";$G;'/7G&@1D-0(&DJK_O&$T=;.K(G\'2=J
M759MM#8KP1'3"-C2JP'$=9JZP9+A.);*5Y[,UL<XH0Q=]6YO ^U))419(;F@
MCKDN4 LUJE#XCWR?,#3.VZ.A6OC)_9F+Q*8%41"3WO))PT<$W0C2+GZSAXE#
M 60&U4H4A^]9 /))L402#$!S<]L)B&>5JB;$_ P-%&E9":XF&VPOK.%9V.'I
M[5^,1=(C5 L^C['\9 W;YX&*(#IJ4>N:*!SY6<=SOVP6)*ERP-IXW&6UFGJB
MD*=A17-92(D$=T7QXCZX(_64ZD"HE='1Z416D"?NM9,JDKWDO#7TC$L"[V='
M=J=#[29+@^&0^2&S^<GH3,++ ,0G;L6>><L92(E4FZ5Z"5[5&_84>G2)Z]XC
M%N!1)2:['\N\$BRB6YL2)YK#FY(ZZM,\+)45Z(I.KLF:CIK19ECIC8<1UUB>
M\Q! P)+!N+]<0'RC@I8Z'Z8$P&-O#YD-=+WUQUD![#U".DEU$<X+).B$M= Z
MD[:Q7P&*("*J2%2V&GAM9$\:Z80=/-9J#A 00M3!,3O=8#6)]EWZ]KG+K&%4
MD Y=-3O\03-&RL+I.AS_ $1%D"&FTZ%\[K62).$6T]DMWO%QHC=+;N:-Q-^^
M'TN%V(6FHT/NRT>&S,W%71O<,872A)3"$+=I>4Q469,7)*]!6%O0Z3?7]J'>
M]A1)B<I)([EK:N>.?7]@:/W7U;]@MN/2MIQDA4F=^IVK;UQ^LDF57<[CGH8'
MD!D '71'Z<85K[-<1V<'7GOD6HZTR['\C6 1R-6L)$121YYQ8W/-@;@ETQB4
M0MH0,/8]=I/QDP7JOO.0TO'YR"VL3>G6G^48>Y"7JDOX^;S2TY YFHU^;Q="
M 640#@7#C\Y8O"'3"=7PS]E:SUW10Q ].<56[L?3:]ZR<BA-4B64WJ>^&:37
M:J1O-;WG&!K4RQ,V[!SH@<Y=N8W7NZ=>>AA@M .60/=R'\P;VACN/H=)S7,
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M!ALR*R4U@\&<>)H_6Z<N+R6;SG'7_@Z/T\YR],\V973.:QW6?SGOG$OGZ?\
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M0R$@"T"O)WFT 8](! 1&-CUI$U:G0-+7 /<8E-K+Q$'<H0FY$(C0L5* ES(
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M,#UE ]:<U&7J/6SJ<XQPCJ>7ID:R\O3(TEY>F1U/+TR.IY>F03(=6Q\^T8.
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MKU$@LDXG16+$Y44\B:U,-[@PC55Z-3SU_P#@/)NAGKG<O]&W.:S>=/U\QA,
M,A 8T,$S,S-[Q147"Z02JR&HB+DD0@QB$P 9%,[[A:1AV K AL:9)+:.BV6K
M8KJ(0!"0I2]> $&(X%A8;*B';J8F@"2:!&"[A8.PH%B"@1/A!$ M R.I<%/!
M 63(PY/0@XQ:B*<(E 1(&TZ61$PR,8,@-\$QW.C(=4QEE,"D @*T"7'-(P'
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MNGQ&0M#4@B10CM$&*N=K@ WN5PR$(2QRA\'?_%/W?-\P9'&,3XQSB'&=\CP
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MW]<KI^7\Y'*O]OYQ\C^62_V_G(\IRNA\XAT^7X9"T5UF6L\T_EE=/R_G(?\
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MH501R32YB</PW$"*9 92(-@X,&&;<#)Z5,=&%(&:* PT",23:(IS4A0%X0A
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M:(->A)$!,3:2MH0.D$:HQ2E4(DZB,;<R!&*)/2P4/SESE64(!HE=@),6(Z9
M@]22CF[,"RFABC@!!R J(.>%L04T(#52A#(!$Z3H6VR  !YR334;3-A2+LB<
M3"*> H4"IE#M"VA<GJNQI*A3*#5+$I"SCY2D0YJ)-K)2" *\I8B5V<=ES,$
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MXU&!QB9VS7F?#G'?CS+G;SS^B,O-8;O]P:_9FC]FZ/\ BFS]KY?&09,F>:\
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MPG O?_/_  ]?"N?#7A*]\+;_ $\> +K(_1///@;\)XXR\OXS><SFO"I[9?\
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M(UD DY:==<7",6@K4JZ6T11)"XGZA(@ 0P@DL/Z#' /(%%PL%06&M>C2(%6
M2H&"36ZWE46HU,U$;&B9&FJO]$_H5=_H/ '">?"9\./_ $3!N?!_81+DGO3U
M\Q@9/$$VMEE6FUI&I5B8!(Y!A4$)$LQO-O!V_N9<+:ARDFO1$_+/\AG_ #&;
M)^DS_D<_XC/^0S37Q,_Y#/\ D<_Y#/\ F,_Y#/\ D,_XC/\ D,_Y',Y1\$ZI
M$Y5\>F=?XOA*_P"0S#KX&5?P,_YC/0N[,\GT&;?X&;Y^@SZYZ,]5/9F3?P<]
M;X&?\3E3?P<_YW/^"S(4]U0KK]J8[CG/9Z<U1=Z=Y!(H].5OP,_XW/\ A,]?
MX.;_ .#FK^!E_HF?\9GK_ SUT]N?\SFK^+FV?H,_XC+Q_!RF"7.H/J"DB@9]
M"V?XG/\ D,_YG/\ F,_Y#/\ D<_Y#/\ D,_XS/\ D,_Y#/\ F,_YC/\ D<_Y
M#+_3,_XC/^1RH)"M#%5$%Q+>N]Y_D<_X3/\ D<_Y#,.O@95_$S_D,_X'/2^!
MG_(9_P AG_(Y_P )G_(9.HKHF?A]K+"'6/6<_P"I\#"!J=@=0F#KJ,_TF?\
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M5((4RLRC/1B(*((2#+00(<Z*S4+0T4N@;@;KC3%;LC<+W624,C000J@*:R)
M&4\P$+FI<EC=8%CLPM3@= ,54$END*)(T-\NG*.LF1!$ILDD!$*(R4<<A"04
M#0:%MSW48<0:P41A!'!<G)GV2,S)J+IUN>3KLGJ_HW[>,>,,3D<Y#@1G;?\
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M&A22=6W841.U!"V.QGID>@J!51)?9P?S4'DJ3)'">P/Z,%RMD21PUOZ1FZ&
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MYBR+NA+23!L,.D (203.X@EKC%G2D.2@(UR:.<6<A8,;L[;;(U(!@PF,1Z6
ML2RV YBH,L\F-,A-PTH(@6A?:5C(V6JDD&29DB6T$DF&]-[8NS@L&)PXG+L2
M0 )=**:5G-P\I< @A*C0L-85,I)*<B$TR4 . TY &,H$* 2 "=AX<""((@(
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M_/Z-?^/?)_2L_JY_1K]7$?I2:<))EO\ =L8W@D1%$;6>*\-*K"O"=I0&3L.
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M]>,-T3(<Z"O2+.D=CCA(L=BMQ+ T&U?&EX"O.5===*!A:3+J!(Y.O#U8/<=
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M$Z"X\K_(%PT%J/2DR_(+Z_</OBV<"H\1FFUFT*-F44WKD%4)97+,=1@TI2-
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M-[:K;KB$7^[%304YXK+H:TN66'TBQ6F+Z9"">>\[Y)392+'!-I 3+(9&(35
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M6[&1D'0^,K[?UD'0^#(.A\9!T/C*_C^L]M:[9"(BHCRY!T,@Z+VP7D'0^/
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MKQ[^ $O7>^_3W_8 @%): 1 @\\8B[B1HIW#N+Q,O82+?,N!(N,@E()7&M>$
M=2C_ *0.+0#0&@(U4;OP)@G?,:GF,(@C45'3CQ4+6#O08L1N^@OS&22$WN.V
MOY_1.-B?>SW/#5*CLQ'0?XQ2Y8Z:GBPOKXI)?4^1'^,GB=_[_'A-A-*2#I%S
M/?IXTS+IV(@%C?IO%"#< 2*@E,,2<8T*39#-"PW>BS@;34Q3RQ))M^F1"'
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MN5(# IOT?^\*Y"N0KERY<A0H4*Y8";51;- ^7&RB7N?9S[-@#^V!Q?,NG[H
M+838@&L2UUYC!-#)Z&Z+KE-H]3^V?9=>=9-BZ>IW[=\X9?6_=6<LH]?LRB;C
MTSO]6O5R=L[FGHG:6OOD_P!+-OY,?&=S[YWG37X8I3%S %/MSY7;EG^0R/1V
MRT^PZ]\6AEHHA*5_CG"4W#3M]UDF-#@!^@'7/NORPIN.9Y3OFQ.&M4=Y/B7)
MB2*:8S6QFD1#LWWTP050KHQ?3(.\QJ7YQ?Z0?P9/1)CJ03V[YY.S+$+%=+[7
MG='ZA^<32%"7+0EAZ_3#C1LM.H(Y[XEU.D$9AT\OMDP@TBBGIQD/M\ID/-_C
M%7%=</QB!*C$EQ3V#]&+SM8.)V$[;Q#=,$:+CC(F*EPJO>%)R<@!E9H2C(JN
MN2@?<CU7&[Y</TR_47=U[/5D0"1DV6Y)C&6ZLVDL4-7A,[1ZV@:GCIA!%(!
M@0W*_7 A+F(H C</KATJ)'<(J5C*!#IR2*@Q:LG; U5B9OE7IZ)J(R/[&(']
MS[YA(%C@VK@G(8MO4R]/7KGD+\9WOH_C)/.UB%][A]'/#]S]\AY8NX7,;R1'
M5Z!/I$L4[LV;_C)WTLMFNFWI@:_"V\NJ]NML4+8G*!-U/I'417'!TVM&$;>?
M3]ALI]]_] '=H=)'']6NN\@?; #//JY#IU/9G\X :\QB2;3N;R.*B=1Q\]<@
M[_+^< 6?=P :WZY!TR"9\_&6+/+I'6*/WR"9Y]7 #4_+^<4VX-G5^/KK"?/;
MD<RH.FM;QWS>)@>$2ZF<&5Q2[3% $18PD[@9N[7ULG-F0V^?(2LD!D'1S7^)
MI(;4(YS/RB4Z,)!LMYEK%+IAGQ0DO$T1RH%(Q2) \SHRF'W\1*!054"_)87O
M1&[-LK*[LS4.FE,'3\=_M$)&# &  ,V(;E*3,<>1OI2SV1?7N \#K#%>PTU$
MA@+;V+AA,D[+ [&.X&GAH^@?Y]27)-CMCC1)P%U89PC=]6T*%8R611FS@+!0
M:(D@95,">Z,G$Z+0$#.3VK6(822.0(95"+-H<]^5EOWQ4(L121]2%)IVBW2G
M.(3-@A:1*] .LHS7E[0<$$9&,6-P*HN:UJQ%^4X"X.A1?(HP*%9& 5H(QA.*
MB'11B<WX&G$KLXBJ5+(H>;"[*+CNYG)G@?L+)7[FI64L8L"6)A"4+H,!\:C@
M4L?TDRX33@KZ)9#L.[,<]SM"9M+HXUA(H"L:8U$=*:ADY"$-/PNH)153IP8<
M3ID^B5ESQ'UUB"WOUZ=O?(/*Y$#ERP=LA,QZ;_.0>?C(]?GN/\9!N,"C5="#
MV,0=Y[&[XZ=LAT/\Q>I(S,7DA!8+)S1LR,SWR(9IJL4PNX5' ,.HV]!1ET/J
M%SF=@,AT.S,/5_\   [M#K9Y<=;X+='?G.)+YKD[?JW77O'UR-<QR_$_K=Q<
M^Y4]<A>M&F07!3MJ)DRKZK=KF;X%<J)7'CE!=1ZF#G$B5.PQ4GMZX9+XZ>>0
M=MN85YU(DRQV) \,.>ZN,I<DB>-4E([<^2I:JK"H#0@Q:*\2HQ8HXPMES?I0
M7 W7!M$6IZ,,#W_ -HP9ATXBX0,PJX8K@45;D?\ <SE:R3P:QN@8RZ6?>C["
MY'^&0&QEHBLZAA,E '"(E54I4.<#^,PRF>:Y7T6-(@O!3"!N",(%T, @]YOE
M-R<H1>@FP0/)"B1B5.BS_@MET%Z0K:68NYS,9[5>LL(AA)1G0$CB*MLG/@97
M*"K"#@L0Z.TR9('8A]BN94 )X#RMV6QK2>P\B8MFJV^&6-)1%.SJW<S4?;FI
MYJ,P50 DE9#$ ,<P5B\(EO&Q0:Q0 :] 3'&!4AFL)+_!QR*2&DTL !*]<^>Q
M\A,2"I;7$Q1; &$%\V PXRE,B3)XAWF4FP9(G).LM6&1T)"4SK.34X-S09HD
M[S9D=@M4FQI#OX]?7&>*>Y/TD_\ #^<2?/\ 9A$24>4&TR6Z(#\8(P)G;;0R
MF.,2[Y-!38C4F\BIJL8YJH"6[3HG_P  #BT(4SW=S;A,7]Y^L'_BS#$3%3U^
M'_P>^N7I%R_&-%Q!U[:M=SSC\=^GCVO6X_J/T$FQCJQVF EU^N+8-KU;DG&B
M)3+0$Q%F$CJS@02)HL)9"E,S*,F53#?2NE0X[??);Z"&1H" VJK[8#CIB;M/
M$WF[<VG)E%HM  \C(@)@F(("70ER<?.-5V"%1BZ4LLW,\XL=*,ALQQ.$]\9=
MR"*86#8KW<YJ0@N F%;94]8O7;!MDXBI(3*'XSB$T&2)D2$<=63TA)1<D4$#
M5.\,P4B XRH(8BU.,.* 914,,)$63TR8,$E8LD@H'?O\8(9%NSH2RQAY_&&B
MHHKIVXUE[A2=7K<T^GBS<1,5/7O^F)(;Z_IZ_6]5^CG7O_'Z4'Z=M,FL -?=
M> Y7IA((:)L]%4(:XOYQ$<4])083#D&(E!0:!+%1/3_O@[M#I8X8CHU^H^.W
M3X\50[S44)J0O7C]_G\?J?6-].CU^<0>BED@QT>.F:B-?$';]=HX5%<P=3TQ
M"0;[/U'?9T/ Q#)K42E"W(9<KF/?S]1+FL#C[R]]"LDF5@J>R<!8D50-! .4
MI44%"S@Y;-5D059*2>+6&RS@PS=XA9E@X"X),[#";X$6KA[GP6F\SLE)Q1:.
M )M"&[RER4(L0,RLH4(/-#D$OM+F!DU&)9"&1##&(/181684-08B3*[DP+7:
M5\1  PC-A,L(!7 Q'UB\G];9GR%P>\BR "5%FH6* KKVXUAKW?O^NXI)ZQ7Q
M/\Y<N_Y)>)F<+L9/T03/.IBX_P#3UW\_P8Q/+GT&NI.*ES0E602$H;E:AH_[
MX.[0Y;.SSR?Q/CO=\?I8AFR'IT[^'6GUJ_2_%U5/#T[_ *:6&)W'/K'_ (-B
M;XC^,8HB0OI0HSCLLQMIS[4=8R7U==9E*[!.Q'6\("F+A,@98KI]K%MSN092
M"V;"+5Y7K<<@&#&Y7=T;(:Y-(U=>A*OTCLYPW043#.WN,7'I%)LF343NEQW-
MP9ZZ1:?M@@VMK<WDH"#C)[;_ +&&,*A8I"+V46&@314@R9&N(;"'MYC8BY*1
M4O=?> 520A=4!>*X2@VC5<,U%L#1,S8VPCUL<8!]/3J"$'M,S0WP7KK_ ,^=
M]:ZZOQ8ADDZ1/T_\Y$28A7%CB#!K)&@$$ U2$!5<9+Y%7B1NE6@<^$,]2CIS
M(?\ P .[0ZDG8A\SVP(B%$;&=;7/]AG^@?I&?[C\9[!NG/\ <?C/]Q^,_P !
MS_ ?3/\ <?C/\!],_/2RGEZ1?WCZY=-B'#HF/OG^X_&<$,UR^V O?Z$]I<_W
M'XS_ "'\9_N/QG^ Y[AJF\_W'XSD^!/V,_P'SSGL&Z:Q['S"=-ZZY;(!8E(E
MB9'3$-*.2VD%(=.,EM-2*TED0-]'7))F4P0&^8G''?!H@("30&K-RZQG(S1$
MPE@)$3.N8[5DR; 1(, (T-QSC$A*,R\!!9@A=7,1<8C(3*LA8E:4D.S&X @M
MV41,6TZQB@@1(F10@""93F<0;4)""NU6);GMD5M5!5BAJGQE IK!59T68H.%
M_ X:F6"%M$1&-1,&(":0*24C462WKQOG)@80FR5J+8$ >^"B8EG4LE2"O6IR
M6998(%#,G(,UG^ Y_@.&H3Y?JSUSZ!P\Y_N/QFJ$]ESN/A]<.3V%W_&&H-?S
MK/:.S^,[#\.0;^!R#8>SG^PS_(?QFKBLM7%5WS_ <[CX>-Y_@.?[C\9H^X^F
M?X#ZY_@.:Z-FMNUF07-C8@8@/IA<,D&^NB3M@@4P6'*^JLM8(D:_^ !Q:%/X
MEINMGB(2F^,J]?'),U==X\RZO,?#Z?Q8ECU_IY\I/DK/HG!Z1(\+CHF]/N1R
M;?L<?MS8AX:GV09\_'=Z8ZGE>W.@GIB^I^WB*CL8>:6'2Y!&(>?A$D]+-> ?
MHY/;]<NF7TG^QX\$':/B^#,A$9V=]#ET$>W1CL^F2;#Q(W45E('ZV\Z_)D-P
MMZ39P=N?:>L?PS?^1K4>K/Y^ZI./6SC#[;YS/\;[VAPRAG[-CVR!K;1CH:RR
M5$B,?7_O^%W&40YTZX'!F;=Q&D]GNZ8<0^QGZHU==2/ UYQWO'K$_P!L]N0W
M7UH^N8@XJ*R?<Z80_'L][?3(_LNLW[6=>'P*0ZD?WL'FOV.8Z.F2,LDU<ZC>
M=YZWH/Y9:/FB24GR!L:XSAAYC+7P_P W3+95QLGV,>2[],VQ=TR53R^#8)?Y
MK/G(O\F1VH/I?1GVG'YW\ZS[6_@S'LO#OQ@6@KLPA! 9A985X21IX3VZ?_ H
M0=V@3!.\$ -<(@32)#V9'KJ>,>^)\I/2\GN]99^^35A\TZGG/6^<^=^?/>\O
M3(^N>K[X0S >SW[.^,AJR=3W,],?,8X=.$PDWG)--R-X'4<C[5?_ '+#:",C
M9!7,JI@(E=L43(3!2/23%I,NI!].AB(:ELEJFI\GIAM%.7I&.(H0Z.8&S;K+
MQW<LU2.))KJX(+:NE(CS 8WB!PM]E/3)T@TIP2]W'&2.MSR(4U6 I(.3$G1U
MEC0>@YNZZY("&&P-  B7%D(-L"QU;)[Y&AZU9]&N)T^U$UV]<09B%W,L'MB/
M]GS6/NWH/-+VR"& Z>QT3 E&1HB6&8U??"UG<Q)&.)6K.@4R^XK[C*.243A4
MUI[G!1<U!O8B/5<X#*XJX6R1Z/3$-HB>J.\(_?!$@*6)6OKUR16*' E[QBL[
M&%JX7!Z.+1%$8E]2;_&1\RXSGN^7-P ]WF=R3(KIA2N5FG?3OT>=5$S8WR[:
MK&C2(SB&7P%U/7# 3!:^>')@S.10)1J5=E1@R@.H!3K3&!"_*89@V64&IC(*
M2!8]R?%(YN1"=2I9GIZ]<(=%,4E>L,F3#:>G\G"[4/4)(*3&<+EU?8\#K@!I
M.\OE1D':-)I\IC\CZ^,57Y3L8%B*>N]Y'I^YW<A5]&G7$?WV(]'RPA*)0&EB
M28]^G$:*BGU,/LF0'#@QS :&696R@_\ CB3!^7OLYYET_=*$D30]IS;SWYQ
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M19L7%$^V0FA8!0E$R8*</9C$.6UC?<Z":043EINP.PXMO@@2$J@J%+1:0DN
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M[HT(3DLZQI+0#ALGP1_QI8L4\ARUD<5?AO\ 0#[8+B#"J0&A@T()A'*-7$<
MB3]9&*C+N.=A8*>."96 6>FJCN1LB<('(+0WANG/$@LU9@\(+8NDC T2<W15
M#KYLMUD1.8"(DB;B$@1E,2_7*88N.=9%L\C>ISOSBTOG +4HW<3EX>0A#FGF
M\/=F7I&LL#1O]AK2-T*!J,Z8N\-_EB%:Q/YF)HQ LR%H&)J\19>LR5AJ>"B0
M1,O1-E"6.N 1PB=K._Z4.>I[QI/KG3=>;Q!V#ZD_J@F8O4\QTG(J-_76MSB3
MOSQ?B@])-*##U)_53#24COT3P0LW-1VC;]+O^F#44S7KOQHKB%G@B-KZY0=
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MO!F$\=Y>QDC3)?#3"V]%&2TZV"P)@)_DP-B]7+;$?CE"Q=)CJZL7@"9JFPL
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M)<>W[V+0C,Z ]9I^QB ZT<@PH:WK._U0/J%L"\R]?X^!;;^-].>?S?\ !R\
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M-Q]7I&0Z:YG^\0Q,L?6G<>N <>=_G-9!=%[R'3^?KD.F^>?G(.F_CXQ-JI=
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M<=0 ;#,O2!PR](<MY(N1*5CT$JR:83O4^5N_225A2?-@D&X*L$_7PGBP 1P
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M%/E#!C%Z#S4:)*4&N<(+VSC@8:$LDZYPB 5PP.,D6W:,RAW!SD,+M,S2#2%
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M:QBA\>.2T\FC@VZ_;I.-N/2/@Q_1N](@GO(^R,#JO8+X@!4=;\2$B-HA]-(
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MUBNQF!0C(S!R@S9$A#?QAJ-DAA-IM&XQ&2P T!(+;!-++;D"BU#48[3$2B9
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_03.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  I0    $  0"E
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
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M1.69C.J</HN$PE#,4QW">GB,)3-U&=Y8)I8\E*"%WS(
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M$QC#DOM/1<D                     "A4          I,5B0  *%0
M"DQ6)   %)BL2       !28K$@
M
M
M
M
M                                        8LNZ_P#!(%$\X@4328I!
M,D5.4 3R*UJ5*BE2H !6DJ4     *@H    5*%2@@M,DT9'VKP
M                        ^.NC4+O> R1@=#QJCE2XU/TI(JXUD4TES5<:
M:>45?E734YTK2E(6,>]I4I5D*%0)(5EQA42K#B5D@  * J !*D$.53C "LJ0
MP'GZ?+EO,FAH^V                                  'SU-:NQY/-.M
M[3C*M%?*E2J*Q/&FI716)4U+EJD5D*:JS3CNJ)<TX^5*H
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M*HE]%5H(N8Z,D00_+IE/>(B\F-Q,0L,V?S'H55 "-V=SF.MEKIK<_P!H
M!J1BGSOQ,BI7BF44T^C%4   !H2BG5DFQ869,_<C9Q$P.JIMJ)SH;#4;]IJ
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M"CNHGH9B"\IYP^*)CV1JJC.29=1%X2S[%0   C=L.<QUL-=-;G^T   &CQ3
MF*KTF(^F<T8?B<D2[>&"S*$Q(Z)]%<R !J4F([PCE#M89 E&E&34V(6G$_#,
M=A+:^C;TJ  PO-/G,IFTCJR4Y&^9O^$9IC/",4I]&DQ,F*@ !I[B-3J):)L.
M8Z*FJWYBVCN"P8;MZFS](^6IK6V?)]]J.V\@M=N2]-C13,;6:9U"2]!,UW5+
MZ(G15#+BW@TV$37*)'JMOW\;64OJ<;*DR   /&\C5/#L9B5,3 PE'$TJCT%1
M.K-$!(1NEDV4DCLHF0IJK1)DD?,ZJ8B6YO(/37,@  "-^QYS'.?KIK<_V@
M                                ^>IK5V/+95U?9XJKIBVC,T+6AF>4
M-I98B?L1\Q]B<KD3)IS90EW->.)B7E.-E29   'RP_,^.8^L'1G<2^^F;=JB
M"Z/LB9Z)ZR8[2)ZR8^XK#\$\$?C,?8GM8D   1QS]%CG8Z*:G/\ =  1O1C
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MTW<CP/IU]8]SB7J])K[X;SGZZ,G7)H^ SOM>E]4_K/N_RW;N-[,R[G&RI,@
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MK#Z5V8     \RG@G)8\\_P!YBCT'P&X/,?KWUA?9/(7'$@    :P=-S6G?Y
MZ>!_HGR7/?S;[0W-?7GGNR7?](J #Y:FMC9\KF?2]QSKQ>5NWQEQKKPAC87F
MP^8;L6=_X+)?A/?]POT[S&TSHNG4JU.-*F9>QQ0EU39RI(     #6AO_ !WI
M+V-A+F?:]3,Q,Z$VBWY0#A'1/H(N6H;]?\S;0>:]PDWA=<     (Y9VDQQLM
M!-3G^Z     LF:/!KX3^L>QWLOG+!FNZFT,;H_<+Z[^<     &"+5OR#_/OR
MS,'M?0L0:_0<J*O87[+]"@    ?*>0SR#P/.]W*LRF[AO3\_ZNO=/HS,:0
M  /-KYUY7]O-S!&OEI^YN]O3=[#?UWWIX 'SU-:^RY;,VI[7DL<K-JIQNUZ?
MN;XBP^'U>H#!X'=WT'J4:IY#T,>B>QTE4X0KF7L<6IETQ\J3(     'Q13XY
M.@\GVV:#UG=VFH .E4>8S(UF0<OEO21JN^_2J0    !'#/T>.=EH)J\]W8
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ME<[[#W\;3;9UGS#MWZ3QT    #'L4>8_QSY[AIK.9GA?W^=NM[?T+^A^K@
M  ==,>6_QSPS)VPR:X>!BY'I^]=][N60    &C/A_-LDX^-YZ?._)]^?HWJ^
M2MMTVUSJ.M  ^6IK6V'+9JU7:U6.5JU6IQO5Z<.1\^R!8L:%?/O,_0;Z)ZI$
M+!U>^KN/4:@'#(OXYF)=TV,IS(     Z='DGF/7A%2EK:Z;RKS,^K_+D"-MS
M>7M5U.TWF/4?6%Y5]0]JGHZJ?)K1/KFF0    !'+.TF.-EH)J<_W0
M      QWCX]DQ%F6<:3^9L/NKJ     $9-;@ZO.6X'YZ:=HW6^@2@V&<
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MLHNCS$H]$,QD6*OTF/LB1$Q38B>H1<B<"TSM;J".6=H\;[+0S5Y_N@
M                           !\M36SLN6S-I>XY7+2Y3Q*II3/)2.*H<E
M(5!1..HB7-.-E69     &'ICSOTO4#,T0EY@?2_FVS^B\<AIDO1WY3]=;/\
MGN\ \C<1ZX)G]     ".&?HL<[+0S5Y[NP   !:9IK1?DL44SF>8R[#8.GL)
M    #C#2*C-!!R6PE&RY4     -2*+G1$Z$I$YDE/!(    & 8C7/+XJ7['?
M&W^J0 /EJ:V-ERV9]1VU;MNM,<5540&FG,<-=$Q+>:I4Q.3843RI<;E*FK'<
M1+N<;*8     !Y&HCU'S&5E0^93 ??\ G&4<'JY8:K?+@:WT0&AZ&9D
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MY-SU.2<7RT#4Q$N_I]A'7?.N^SB?J'Z:J@    !'+.TF-]GS\U>>[L
M      "PXCRKRUZP[,F%+=-,;<XJ     X&A!&G.$(S^B',]N     #"41X)
MR<,3M[F-],R !\M36SL^5S-I^VY33QJ*G*FG%DM)ZG7S"W)GV94W/QB/GN7/
MU6U,<[D8XM3+IC95D     .EFUY_N^^4][?!?4-[T;#4XC4K%>#=OY[?^M[7
M*EK*WCUIU1$1-KPD MUY9N\Y#Z0     $<<_1XWV.BFMS_<@
M#%:(<(AC*](;@4WHD     8P1;!WE+(4NXF0    !\YBA%M(O")RI,@ ?+4U
ML;+ELTZ?M5RWQ5<E-*:TQ!2:<(S3@]5O)36(XU55I@5JC'$)=4XV59D    #
MA;:ONC\6FWI_3,SX^]Y2 U9]3X'/_F_9LFVML!28@MM?.;RQ=C+;#[7DD
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M;[+035Y_N@  !\:(40QI*6L,:I^U'0'<%NG;DEDWE(
M       0^V_)3!U'6@               ##Z,2)LY$[$@       1RSM)CC9
M:":G/]T   !K_18Y:Y=$/U(LRRL=D70;"8G($@
M  !#W;<I,+4]6    *4Q5/Y3'ZS-)@5B0  %)4'"'*50  #BCDD   )A$@
M!,1RS=+C;9\_-;GN[                                   A_M^4F!J
M.K    & \K2Q?V_)YYUG1RAU_1QVS]!(G!W_ "D!@#.TN?\ !W04L+Y6KR!:
MS[HHN]#39P)GZ:3.%OP !%_,T$D</>?>K L6[B6_7CY:Q=FJ#JIM8:O:[/5C
M;  ".>7HI%X>]CCL-'CC9:&:W/=T
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MOY9])>7WU;Y?VI\UZCMGX/UORD^P?+.RSF.^L[(MX@SM/M]XGUK5YU'G$?\
M:\Y?5.1EO7]+++3[NQZ\3">=K=2G<>.[A^']GP]F::,FVYC93R_HWHZ\R^C8
MX[/18XV>AFMSW=@                                  0^V_*3!U'5@
M    ?,4F/D/WLU?+?L<J*^L6^<U=W;N_'=M]K1<UI]3YEL5Y'TKKK]'<VKWR
M7K?X*>=N[^-RWV--?**?OJJZ>NCL;=S\;=/6Y%KMZ+WS33^=%W[J*/AN1RHG
M]*X_,^NI^-$]=<?HM?137U]<+;MYJ[!7&W8<[CO8:V:W/]H
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MH\>K&:\;=]9.OZ>J_P#K9LW/7E>KCR'ZQCCLN<QUL-=-;G^T
M                       A[MN4F%J>K      &&<K5=7%NT+V!FK!W^$,_
M2=Q%S'61K9C:3L8B[OC\CXN?\"OE51<EK*^6NST%S&N*QG8[R=9D3&VENW,;
M[[=SZRT[^#>MK/M.YC_<C+6!NM GH?@F\+A/;K2N8'8KF/<G6YCP^@X1C6!D
M8URTW_FIJ[BB;$R\*&N\XG<%Q7L$;MISF.MAKIK<_P!H
M                  !#[;<I,'4]6 !;%>+C2]@])5:UY=9Y?L+Y'U'GD4WS
MC9W4UX_3S9O3%V747+-MW,'/>#OH\[+0ZG.R\FQME:K99R/J$C<'H+RL[&EN
MS:E[&O\ Q\_Y*G6UV_UA95_"NRSE:F^U\=VY\/[/T%RSWMJ]J>['R/8OR?H^
M5L7<6)L-==-C,_:BJU;UCM[:-NUYK.6%OKPPLN,NWT67;&QN3&OZ_.CX3,^%
MLI?Z?L<DXF?'+9<YCO9ZZ:W/]H
M!#_;\E,#4=: *(T%^A?/\--UQ\<MIRW=W(SUHNRBMN^+R]@[3*6!T^/]AR]P
M8NQOK&W\0>@X+U@>._6?BW]T^)YZ\_WU\8FT^I.&=AS\N]+V,9,S3=)G:[/>
MFZ&8.K[+$%_4PMZ#@87[OBMH?->J7OA95HYF/AV_HKWQMW #I_.)]Z#O.@E\
M-6OXTW<@V-S@'9<KZ0/+OIOS*^G?,%P7(^Z;N4M;O[!R=3MGY#US3KV'CWVW
M:,V:SH/59Y)]51QV?.8XV6NFMS_:
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M5B>,N4 .,N4.,N4 !QERAQ.1QE'S-YK][UJ:VB[8
M              <)IU[[#G.DKQ.5Q4H4MN5P@F*)J4.-MSN*G$XVW.XK#\Z
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MY+=9[KMU[+KK?>K=?V'U<TIZQ^?\1K=9VK==;]W/W<O5R6Z_ ?+X*5]/^?\
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MD&E$\6S%'%2S!?$JH"W23F8ME8]B)CG89.R4"X089<V$ "C6$,F>J]M]7ZO
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MVUML$:V\V+TY> EO3_GMMT>!6VW7X1;K.U;9[N7R^"%#%RXE_P#EEX"6]/\
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MF9$3TLX4-V4$)&&'+7"R"YN=]UL$$D0N!B8N*!?/A1E9)2R]+BSBG8E1B^.
MUP4H54;!(0NEIQ%/+\J#ZG>KT+<2V">DX*>0I0RGFR9TD?"S,"H)X'*PH"H<
MX$LF%,U/-:-%\02K>%-@MP8<BK[O-Y+]?V,H^I_LNQ;;H46P*VWD&O)1>1SA
M91?:29[L;X SI9KVM@A$8^!%0BB=(':F'>YTUNW6E<PNG^;>ULK-=PD5Q)49
M+"C]=<SF,KP"<@E3!%'.")XA4M=R'EXCW8HDG.[$8_'1T-]E7@O GQ.<*%Y]
M#O3$.BCA71;&L0%E0R2!&P(960BY#)NB*QE",AIH)1Y!&,"2V5.7QQMCSS2\
M72L3#W43!A26L%%/Q:)JX3>61C-*PPZZ+<F,DJ*@Y2."F75T_,:YPTH9\J#Z
MG>KT);'(# 8RWCBNJEL30AA)-! HZB?IOJ)LS3B-!F["%5XGDM A$"I8\ 73
MV[AF;,^7P61,_,;1#U+P%2]3_9=DDK)]%, &V@[,<+(C4;*X\V\0;22]6RX\
M'2WCRKEBJ-]GV550RKG.=NM7E6D8W@=)J!!5*%S0[<,@F.^U9%604X(,UFLJ
MYM8$51$LK9-)7KJYY]-!4@44]DGBKH!8"C2R4.I8 WGG#:YB( 71BI<IW5BH
MJA8H 4PY^>& E*1,)'5#94BKA(2L,!2N:MQ*,H%2Y (+)?/+9)/!I);9/$"V
M-L<>5"]5\EZMNO0H((^"H1[H5AR!%0P0CEP\U,\ 64VYF"&3/8YKIU13BQ(H
MWF]<<E@&&&7JW@LD?#!#U+P%2]2_9=IYN/GVRMEG>^[+B!K[.]K7L<1"9N^+
M.QL< !  N:3B)NO=!+\X$J&!LU!- 4<1FJ?R$!9A0&CR&5.  (:RG& TH\;N
M3)%R6&QSPMG8VV!@<2C/-7R(H !<!8:PY48MWQEB01,0,N:A>J^6_+GV(@8S
M?-%!$]N*QH5-;MB.2@V#*=28=/X471#)P2W9!X<GDVO1O,*9(H8\G,DGX8(>
MI<S//$+$@HE%(#9J7J7[+M&FTDD(B?3VPZ")OY?M:[X:)9(#V>ZE%6+IUTQW
M8*!D9WE;"%381L/:9Y6PQLN(XN1@\2(Y!&,#&.U,'"A6UC),U@6.E#.>_?ST
M+U6]7Y=]JM0N8> .X3?AF'E>^6=Z\OG;N6W5MG*W 5TLU'(,8&Y=W3(H=\VT
M0Z25^CEO>UK+2B:=IM.3BR87V:EZE^R[.W7(9$_<@U"N+91'^AFSIDD7&"C[
M9Y9>9:+#Z'?!\V)75HYR10%!P+*9F\]H""$ON&3&2WT2R(F8J)]S-MN,A+VB
MJ>Q(D6A%V+M(*"8$24 XV;Y9GI9RQPISD+U3RY<N[>(9,V*@,YG"O\TJ$CK=
M,H\4\0VDHYF9 YENJ_5MG6VN^@&FY[JMN=CNQ#W^;9>6CB^H(R.51"FT4?4_
MV79WONI""+$F?)A%3%+QV5-E4202X)YM[/+#S[%5.R.*AE.\J/=HT\D+#%85
M]H**,F+@YH9?-&;"H1U<S,*I[:/$,7-**NVZ<E"I _!!.,41*:N&6*;SD+U3
M*K\MK[J</_%*3'*"E$N#,JH"6OV&*-BX8HO,MU5;;;[TX&GBIG.=NWV4P<SY
M)O-W!NDMJI>I?LNSPR\W)_"#*B*R3ADVFR@;$+'2-S!)A;,]EG8NV$P 1-#S
M]UE-)2.]<DL+NQ>VA\/)QJY3 1KC*8XZWF,0&:QC:.@^(2(EVR:)!W<H?=^3
M</',6X:XA.YR#ZGY+\MOO+JAP"<725*Y4JNELDT9/&4*:AWBL>9Y/ M]O!5+
MU/\ 9=HSWM9'+*[X;B4F9OYJ*A9W.<5?,[.]O.L(&.V#1TS9SGB+E#+%6^5S
M&RVAC+%#6U@^&9 ;1LB6)WM9QJVT<Y2PQ @K$QD_,P#BLJZOAB"C$;$B?.0O
M5:ORV^\XB?&IZ0J!#%<Q< 3QPZ6)D&L5RP+\WR^ N!Q"HV(TIG!*N^CHMRTB
M&L F\\%)=&\ 4?4_V7PS,/$2P86(=7*A7SZMJ.7"-@D6NG$!S[7*'S!8L"4!
MVFZUZ4FP04;FT$D:)IK>(IE^>A>J7J_-4&J"<KW:)V2B33X?/"V-L/ ]_+?J
M%=2<7&<\?I#I .1^[$L9MQTY5DYQ;?92:V7(8<ZMR88V[7:*7J7[+]N]==>Q
M0O5?)>MU>;6ZO-K+'?C_ -K8VJ]\\ZW5NK=6[:F1>%+?,7'B/F+;<4D/$<3E
MD1"!%PS4UA!/M%P8.HD]WR*@%R'$JQUB(X*<D\AT>Y<O\QK5\QK4B._ODQL5
M'U/]E\1T+U6_/W<S_M7DVNZW.4B6)\LYT?(&H/%$L;>0 J@\F6@Y*!_''S;;
M=1]3_9?$="]4KHV'3S;^"/QL8J)6)2]@55Y(6&;M0$;!&)> *7J7[+LK?;J%
MZK>_-WUOYODWW\&O;?11O $580C@(9\!4?4_V7Q'0?4\N9Y>;U<OD\GE^QE+
MU+]E\1T+U6^QZ.3R>3P$<<$J#CQ+^5.;;IK'_GBH$L#Z<WU8=M'-JH^I_LOB
M.@^J<F_8>6_5RWVV66ZPPH[_ %$L6 * \F._&SF6[(B46S[4/'HRW[K>5P()
M5?(-E=,)QG:*7J7[+XCH7JN6QW<G1X$ZTI57*3R!=**\R2/A@AZES'&WP%\J
M@8*89#9J/J?[+XCH7JNP\G@GDKIYDD?#!#U+P%2]2_9=G;[<0O5.=OK?R[[5
MOYGE\#DG*^#=3_4O 5'U/]E^P/+]C(7JEZOS=UJW6Y=U;N3=X,X4;%<3P<.R
M!\!4?4_V7Q'1/5M_1TUNYF^MW+NY=U;K_9"CZG^R^(Z+ZKTUT\WIKIKIKIKI
MY>FNG[(4?4_V7:V^VD;U7["\G@:CZG^R[3I^VT;U7[64?4_V7Q'2/5OM91]3
M_9?$=']5V1P^6(XV=:%>^*H3$,U90!R,<PR>!+<PT;#*8XY>=:LQ,0L"BD5/
M9\XRIE"@ELM^/**+B%B6,AF@^7/*P>)4X&;Y]E '(S2EZE^R^(Z1ZMLCA0N:
MP::<0'7L%(+!SJCK5TI0*JH8KG/N55+YJKL$)IR:X# JH==2F5OW>26!AG2>
MR,E3'$A#N<]=47E/%;:?>!U/1"#E.'1D\^LF$ENJG<S=3G(H<:&ZU RJW=B@
M(9L]#UPSQW$B2Q>"@!F=$.CO,X:LGD@':H7P670;(JAU>4@:LN]^MUD8=FW%
M9940#A1T"F4'!VJ& RBOG.\XZ#[-+6UTTGJ**X#)T>[K4P<UAQ&0#)9PC9I!
M9R*P"H3M;WZI1]3_ &7Q'2/5ME?J: )@-PXE\@7LGGQ,W 4"N,\C 9@Q<^5%
M&2@ A,7:.7-#%$2XMTI:RPL92\C6:?BH<.Y,TXP&QEBQH-.0"60;D2<AP$K-
M-.B-$L9%6%=N@"!.(@6&"N;*&149>+9G4:XQA1*9%APWFMD[G4VPXIU+%)#X
MO9>XNSC1RAD%%90.0#?6;##+R83.8-LX6,V+&,A$IT,$N*637" 8%=:86-@+
M9DED835[  7('-PXM0$K^H%0;V?-*7J7[+XCH_JNVMOM;S<-^ZO/PRSRRQMR
M7QQO>B+>Q*+=L;7Q[3#.]6QOYULL,ZW5<2WG;JW6O7DMC:UZRRMCCAV>=;JW
M6O??>]Z\VU6MCC;=OMECCG6ZO+EECC5K895>V-6SM?'#+'.VZUKTJ^I?LWB.
MC>J[9362256#U11+%%PJHI:></ J+W,BE5!+<J<ICXO!-S,8YXY89O%*P&4E
M]/3,$ _D,XK/5([(@Y$T^HH!A(+9^^Z/?%5S3++IYU)9$9PO#A"YAW)!2QIS
MI92PKJ)]W%U\JKH5E=.245+<I!2R$>R1C18R&:+YO5(PP-+Z<53R;J3S8;7=
M6:P+B\TK(PHN5-33HCO(YI)==+K#:LL)R6C)CA(*63<'-9$FXLETAO#+A(%1
MO2KZG^S>(Z1ZMMGU;M#.&%O?,B<L6:2@06PFXMJ()H F(4-O'(P730NUOD0,
MF\5% 5<\+J!(4N(NB8A>YHV%_?!"OGD'?'S&6M;_ 'I6;D"ZDN'\3:0NW &=
M3B.VP7&]A:]%C (S#6L;=RX& #CS)XXW2&K:X:"F&2I8H<QM[MX9E%!WMO+M
M"10((P@G0\,78G88"98F S# 43N8"2A9Y>^36N%F42B_%L)G"CK:E2KZG^S>
M(Z1ZMMC1$L=KNXK8S9%3,0<PL!0<TE/RP+)9,IEB@)(8M\=]KH*51A+(&P T
MLB%?)*3\@+D"F0P2:2!QNCIURPB>3%$,(B6:,B$"@Q?%((8V-)A _F73")2X
M:(E@A")I$8L42$\E?%(3PP0  P F\V<PCPI F*7)(Z>GYAI) $S[O)';9$2N
M0X:81!JR,F8 C)A$P7 3217(-.)@ACE,"R<S489%3*5?4_V;Q'2/5N:**&!@
M74"AJA5,D%=X+)U-*%3Y8Q0RD1!&$- !6!4"A@012) B"F000RQTL;Q[U(=M
M?HJZJG8C.EP&21HPX3N3A)64L%/-0*8C&!PBV)8T ;M=2)6,<0#VH1@$?(P;
M*EJ#-@"A65"-[CFRY6FHM'E,^*;+@7R.E<02YD$V&ZG!<DFE#N-RP9@ 7.RD
M2N*.; +6!-%Q@@3Y,>YPV&1+H:\56B(2B2&R#.%A15(;,5/+"7 )%SA<Y@4/
M"$@$QPD% KD8!Q$I4]4_9O$=&]5YL@CC )B60/ +8),J/91RS%:9<N&1>RA?
M(0-7WC(*>#P+S1$Y/5TYU]OF&ED#A9>#!L0-F1[!I:>4/&D)P%+9G;$BGOR@
M9"8+Z$F)ZDWU_@<143,P6445,*GT)P#8IBHS"^.8+B%+"K[:S%# ,!8AM8Z%
MQ;F88> 1Y[!8C+#F R)+264.D309/#W+5<K67TX6Q901T=,.(+BN:,.=%3#H
M0*5@&0-KX88B47[4JP#13%-&?66*:IJ!8L R%O*^2(62$Y*6$0 $TDEDT,PQ
M40R.X5BE7U/]F\1T;U7FJR6"K%TYJEB1L-M%,*S:Q/-.N@EKJ8C,(B4,V"0I
M,)"+!*1ACIHPI]MDCQ9,;10D."S"@0]@0L0KL@AE8ZW"AP6Z 5[[)H)8H>%9
M!$6E)M$U"D]ME2!B[((^<_2WZ*B%+$4M2;Q90.I[7))X.;2)B)B@W"QXTCM\
MLC#J"$64CJRWRJM=(;A1+KW((WP46N4/YI;:)IE\&20#NJMPJHCDVR3+EB;/
M)@"B@ACA%&H1+ET]G%2ID-N$K*.#6*V3C+<)'""4VRR:<36X33L"Z*7;J5'B
M<*63Z5?4_P!F\1T?U;G^3GVYOEYN6&.57OR>39>397M;*L<<<>14]3_9O$;J
MI-' #"X@"N(!KB :X@&N(!KB :X@*N(!KB :X@*N(!KB JX@&N(!KB :X@&N
M(!KB :X@*N(!KB :X@&N(!KB :X@&N(!KB :X@&N(!KB :X@&N(!KB :X@&N
M(!KB :X@*N(!KB :X@&N(!KB :X@&N(!KB :X@&N(!KB :X@&N(!KB :X@&N
M(!KB :4C &96UK=S^(U^J_=M?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM
M?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM
M?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM?HM
M?HM?HM?I5?A^P__:  @! 0 !!0&G$Z6XT4UJOUE/@J?GJ&$H^F*B<LD<I:C+
M%S4I*:>CDFO+49/8ZX9IB9J'TMX-=:11M1D$EQ$UR("TCH,O1@Z5?WH;UE]1
MGV%$@X3E:-CZ2N.)$;2:TY&8;\IP.ULM6U(SN;+A..>6HR9:B&IIXJ>AKZ*Y
MD\LZ&Z:6W;*$=L,9+5DU;(.R2&"PJ*NULGT%'6$M>3E)33T<DU)2CA]&!G2W
M2RZO.-!:Q"YXI8D@.1 =)$@Z&XJJM+*XD-U/(*1%2((KE0')B>>#83%3ZAX,
ML(G33$RP1<LFQ\S0VK+<9O@XX7,WVDG-)_LI^%G3+49LDVV'HTGJ4 >#6-'A
MM14$EA 'RSS#=:LK1L^3"TYV^VZ"=3<,+BZYV\V K7M>SKE"/&*-=VMFR"F*
M:>L$,G0WL5U#=#><P8KI;I9=1G.WW%FM3!%K<6 A0S 2<Z6XKJB@Z&ZDJ=.A
MYM-EE&Q+<8O0VZY 9+%P2IYAA<.H+B0701,N]KDU@QJ(@LH,%)4?CIU.U_,M
MAE6ZYV\[DU;G"(&RH%G<USB B+R*Y4XV[6R07%>=X903Z;+,:+"("<*F2BA+
M49I29EJ+@G$-%7$AQIWV*UFJ%KBU4M+1='\2R;HPTWQ+.F<1(:UIZU;:MH%C
MF \$1Z-5EM'_ $.R>+L8FGDGH&?D@H[>@-SZV8>$3DI\Z8#^B_*&]2%\W0['
M)_G'!PR<4R'!_P!/]/YK2H"M:N&_'2#!CA;YC5WK&1-"\9L23/\ 6%%6G*U6
MUK35FKI<TBN5[Z=F'IOT1QW)T50&=<D.R9H4F21=-"2GNN[0UN:4]+K3U)L:
M-E4UHSU-:4-.*!JG;+DTS(&G&$] 0F8FD;4)WQJ9U>ZHM)S+T_Q]J'6I6F6>
M-3.HE.U(:%-3,FBL32[H?)J>FR6-)V0E]<=:\1C\QKFB!\#91U!$I2MIWD9X
MJB0^=?VO/3'#C"5M<$%1M"&E+65[DWFDP4A=7U3V;V.MG6#J6BE"T0.)T1VR
MYM_T6G.+T[1!*L?8#!ZH=,*OHPM"VMMGGT:.--I#0>]9,_T=S%P&U  S&2UX
M:NIP;NH73?+#YO&<3:4-)[/G^-)DT[ING+2GHYOEEI:4A!__ -/],\DRIIR=
MSG7"#J_T3:$Q+T*09%?^=T/*,7(2"GZ1=.\!>]D#RMJOR$OK7K_4--++B=J7
MT11DS8MU(R>CR^UX$1]%;RD+2 H'H/G:'0C4SO73&J:./E)K%0V@W6@(/B7*
M:;HL2M;SL.M##1!JK8+0TX+^JB,S826W?\\II5X#0F ZY E7_06-U/3(#*^H
MA#B(IH0T:SB^X\+Z(HG9\Q1]$.EZ%U_6ZSF>@L-O?8LC1;->FJ=8QDC5K,LF
M04ZM1VF)5@B"YU=<D2T>UOS#&*?HLC)S1E*9:8M/C1>K%E+59*+#TJ$WOJW>
M<.-AK07IRD:=H$B&<HED^<VR<U!:WI++$8ND0/7_ *&8.7V>4UZQ4]7XUIHA
MZ9H@F]DRSK#FB2-=4:2!(:FY-%$>N'4Y%&GMUN*1H[?>KO2NWH$T\2DF8Z5]
M-8B[HQTD:3I9C6<H\-ZH=%&.GF!)1?$K,I/U*:&5%.PU72_%FG>=M1L(PS+D
M<32LN*15+55K1(G('=K9UF_Z Z(WHXSTKZ?WOJ/GN8M(CFAF0DE0G> -5$"S
M9(LKCM73 [M1.HAG:<'MIIU::,X,7D=K0EH\E6"=;^O&,'_(Q_7_ !^\I+TV
MZHV-+:/+$D%=0&JMYRK%LT:?9^6&EJ"UO/J5TZ9HBUK8,+4-K%EQC1%)I/4)
MIOD.=8"B%]S-JA+LY7C63M3\WZYXR?LAW9L6R 2U_P"KW0Y(";)[C:Z8\6G'
MQ[5-HI+N%#U82_IQA/47J*BN)D%ER4YM;^B:"7"E1E#>D.7X1UO1#I5<CXCQ
MH3-K3A1LSHP]6\PPO/O^=C?^4,XDM02NX(^U330\'G_HNP9(>"%*L@:O]4C:
MU.0&^8S,1IJ/E%R/G7S"TM*:LR(/M%>E73@_YTT^Q5JU*S/,D8M?5E."^X$E
MI3_HED*-8MG#49/4.:2TQW:B)IB!(1],*;HH G#2P_H-=*7JEC)9F[3M(DX'
MI;U*:5I;TL@3CIQ_S8BZ58JB^'8ND!"UQ?\ QV&7FT2@WOXRJ]_&57OXRJ]_
M&77OXR:]_&37OXR:]_&57OZRJ]_&77OXRZ]_&57OXR:]_&37OXR:L^V5>O?I
MEU[],NO?IEU[],NO?IEU[]LJO?IEU[],NO?IEU[],NO?IEU[],NO?IEU[],N
MO?IEU[],NO?IEU[],NO?IEU[],NO?IEU[],NO?IEU[],NO?IEU[],NO?IEU[
M],NO?IEU[],NO?IEU[],NO?IEU[],NO?ME5[],NO?IEU[],NK/AG97[4+L_$
M;.__ (FRQ6>OA_*^.*^5\=5\KXYKY7QS7ROCBOE='-?*^.J^5\<5\KXYKY71
MS7ROCBOE='-?+".:^6$<U\KXXIRQU'::WT"'XT44SY(QE7R1C.ODC&=?)&,Z
M^2,95\D8SKY(QG7R1C*ODC&=?)*,J^2,95\DHSKY(QE7R2C.ODC&5?)&,J^2
M,9U\D8SKY(QG7R1C*ODE&=?)&,J^2,95\D8RKY(QG7R1C.ODC&=?)&,Z^2,9
M5\D8SKY(QE7R1C*ODC&5?)&,J^2,9U\D8RKY(QG4CQ&P$MH6''^27B,+Z)A^
MS:\FTM3V^$F;[!^Q9:^ _P""?$8?T+#]F\G75K7O7FY;]U[6Y+[ZZZZ>:]_A
M)F^P.8^Y6CF+RK(D5C22ETYG8V68FEQP38/(O.!$:R3@YV]F@MR3X[=Z,W',
MWW<E<CE>#69Q6PF&0;4D1BOD5:6DEO)R*M)3D2Z2WXRUQP**B12"+7=;:>J-
MEECC;D7%Y%;*4A+Z*Z$KG2U\!_P3LU-23T8BWIUBQT$E>=8O1L$#4Y"CGP9C
M[:L@).Q<CG06@CI$WQ@O)@<ALT0ZWY'8[F:B!/,4N8LHR<QTIOG9,8J><^HJ
M'/=,A-<8J+1:#S;+\1M@XY,9#2< TLQ\ L+,P1R@+;HEF/V8H.2<(N:2EC*;
M"N\FR[&^\"/.O*C#LAK<WQ<W'&I2U'J31W51!Z:IE)PB\XM)$RQVM&09JC8R
MW )+9!EY-IXMQW4DR0REYVO5]M2/$81^-$%1=4ALQE'2KR;IQS#^A8?L[+EU
ML2F]8;@C'5W*GTGQW.TD.'5_JJGA>@Q$B'58K99PSK:>+L:D7:M)E]_6)JBF
MA?U79=%ZZ*M3W^$F;[ YB&BI4[_Z0NUYFM*&K<+4KJ?"T[S9J2>$Z:8':]E.
M/=-L3:X);$>J#K:U-)[2GB?9MU%Z?0!.P_SL@H?Z6(TAF;)'C#3 -KWF9<@)
M9U8RAG"4U:A'/J"TTZMY9M#6EK1PYF'!6I&9)UGJ?XMTX3O/Y\JF:XM31Z)W
M[JX<<:NWZI9W1WXU-94JM:*9-D+4>])[C#4OJ7D:<D#6_-F$LQR[=0@!2.M3
MTKR".)_H',JTCZ7=0LLNR<.9+7P'_!.SUI-%Y/2$7FW@Y74]$\?*<>JFGQAM
M2-X0_P ^&RL(C;V.N%I.M;39&14J3TU9:TM--SE(GFQKQBJGO?EQPX*R=0NE
M(I"S\^DV9\F"\64CV;1ES_Y^MI9;D<[#51#BA+&H)H)$J*@F,9*&HI9$:TCR
MS#.*26CVS4@.5VHN?YYEUJT <[*&99&A/)!P:3>,PK,+5D61(S:COU1R@B$W
M1J*NRV*XW7'2(%&4,)J!.>$N:=IA3HK/Q:SI[C.5]4;+G*>1";[<[;<\Z$95
MU6/"+7,:?T]C^A8?LWDZZUQQH]I;@C6)I4E]QG473Q)!O57.>E-^IS);>C9_
M3LXV;HEFA2/Q5"NH%^28Z(PD!5UY7Z<N5[_"3,]@\R;](+>E)[-?0:P4=FR5
MHJ9$AQB:_P [H\44.68":<P0XT] S40ULQH6C@Q&3F_SQ9BUE>$V[>$75HBC
M!X:=2O\ G2PT3-.T((;5CO'_ #2BM.3O_P ](Y&:$W:;6G/!>2M$L(OJG#_G
MNS5<[$VB]@1$_2F@V-R<-.O_ #ZC%UYNG1RPW4\!O\_4--8BM_GY&^*+'.DY
MFQ^=8W^=;-9QU5T'-4T[U_02UL"Z7H%BA'(,?3<TV)./,EKX#_@G83UJR9FG
MYZNC6C';8F QJC9I:/$77TR#@B=K18F2LR-;46O-.0M<4?NF-UO7E&S99"9J
M-8ZJ[F;K:CY[0Q"6I]%E]Q<V9)N;4-IIC66F7;9?7BFBH*3J*21WB[=4+<;3
MA%UI1A9*D#6&3B]83M6C%/Q0P=9D8OQXMC77%[E@]S:LFN@1Q!\V($XMCFS7
M+B7"3'DK58RHY.BZSF@>=JSK(CM%./V=T!@NY3UZ(#8=#YU-L9EBW_T B?'3
MW(.L6.XR0):UAMV,GJP7JD2*S.9V0>[(N!GGJ*U:%=.ZLQ]9Z<\F4BZ\X\-%
MW?J'9S(09'U<MA =BEJH82%'[5UQ1*YV8>UP1T0T\R3JV:K&(Q!)[9FQEAA!
M V+-U$)*@_H6%[-/&RZ<10]:NGMSK+RU=:>V$X'CJ&AY@L6-]4L)2LX[S]$V
M,J'I78B5)KSEABL!PNV6&(Q7<TM2<-OZ1C.I6&"4GO:?(FCE]RQ.T90?473U
M%4S"T]_A%F^PMAJ9U]OF"=0>LG7JOZ?S";JCB1/;R_,D6-4W".LLD_%]TS_#
M3) E#6]!L5R%J'U!-B 8D6=5FK**VV/J?@(H26)UAYO IDR18L-%M3S#CR1)
MDUXZ=X@;31FV+7SD-/,- $'OJ(;RE&3:UXQ I2+%NH(09AD)MB9393"D]@2>
MG["6O@/^"=AJ3TXN699$9NBB3BYEJZ<]0"JA!_Y_O@%A"Z;=0+G9A;0?)62X
MS=*,TQ42)Z0)-<*V;T<:CDQ^K.B>4VLFZ9=/<I,.4N;J5AEXOQ69$"RBJJTF
M:8)=4HH<L0ZBPG?E"\^Y.XGHUE=D1TE1-J7+3:GZ79]3D=7T12O8=,T.RR*Y
M5#2)-J W-(L//F(FOS9 9:5(;*8.DB8RL4/32Y/:N;=VC^=<DUU1EJ8>SH:V
MF6<UB.,].^H22+&/\_Y(,%EO15*4E!.K2M/RLK0$R'%&T0<[6%";TF]IQEIE
MGAL10=T6%$: ST.ZD9 :++@W42H.A,TPZ@'$@A:()*R6$#1A+JXF'](TY);>
MTH18]HBC/D']"P_9KZO;W T5H^HXS >AE2A8I JL$K Z2\E15CS6";>=L,7.
M^FDL?Z'ZVUUN9S3J;6FZ^=:R8/C&C]:J:6-:F9E?*9,KIU*27E*J=IE4329K
M:I\?"C-]A;"7X>7)5UHA1[+[VT\3&8>#C(1O%RT_)U<\42<1E[4(FJ2EJ"=<
M;DHQRU^Q6[)HTYS7J&^I&#XRRCR&=0301%&()26(SE)<0'B0,RA(,JZ>P$K_
M #M-O9)8>II+83S<;!GZ-'0@RDUVZW(JU;81[*Y:/B,9MM0A;_/Q=>Z@:V$L
M_ G\$^(POHF'[./$P%$C'D>-&*6\\=)VGU^N)U0?%3U;4HZ>8BFHT8CACFX]
M<>CK3R[2Z?IQAA.C^,=/$.0V?#TYPU@WU'3W$*KBRXR8<>LE3T@:>UAMQE D
M2PX-3W^$V;["V'8A=KPP%P\TXB(/B6+X7N6+;CB(DJ 9DF4.AVMCCB CI14V
MRM-<>,667IIR8+ZF+AP+ DTM-3RV1<#(&Z6G7!X,I614ME<8@2,7%3R Y;!+
M30210F4(%]A+/P%_!/-=<KLEE'_J'BNOJ'BNOJ'BNOJ&BNOJ'BNOJ'BNOJ'B
MROJ'BNOJ'BNOJ'BNOJ'BNOJ'BNOJ'BROJ'BROJ'BNOJ'BNOJ'BROJ'BJOJ'B
MROJ'BNOJ'BJOJ'BNOJ&BNOJ'BNOJ&BROJ'BNOJ'BNOJ'BO?]0\65]0\5U]0\
M65]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U]0T5U]0T5U]0\65]0\65]0\65]0\
M5U]0\5U]0\5U]0\55]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U]0\
M5U]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U]0\5U;4/%5?4/%=9:A8LR#9TV1N2
M(?/F+J^?$7U\^8PKY\Q?7SYBZOGU%]?/J+Z^?,7U\^8OKY\1?7SYB^OGS%]?
M/F+Z^?$7U\^8OH\]FV]66S?87V++'P'_  3S1B)(QEW2E5W2E5W2E5W2E5W4
ME7KNE*KNE*KNE*KNA*KNE*JR2E;NZ$JNZ4JNZDNNZ4JNZ4JNZ4JNZDNNZ4JN
MZ4JNZ4JNZ4NNZDNNZ4JNZDNNZDNNZDNNZ4JNZ4JNZ4JNZ4JNZ4JNZ4JNZ4JN
MZDNNZ4JNZ4JNZDNNZDNNZ4JNZDNNZ4JNZ4JNZ4JNZ4JNZ4JNZDNNZ4JNZ4JN
MZ4JNZ4JNZ4JNZ4JNZ4JNZDNNZ4JNZ4JNZDNNZ4JNZDNNZ4JNZDNNZ4JNZ4JA
MDI+L$Q"9"Z;P*?7!)]<"GUP*?NN13[UP*?7!)M<"G5P*?:N!3JN13ZX%/O7
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MA9^.+5 V],FJ%PQ^F$L$U.Y\L_ 7\%;,0,,7 LFD"%.67)LCG4YHI>3P?NJ
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M7'=%\9MR)VOM)8^ _P""MFXS9 B@E6@]W2\M*2TCQK(,V)Q%\2Q$22I1W/\
MLY+;A9VL6.I]<L9$XFC[/5<HBOF0=,CBB0P:U%3ELQL+B MZ0$^%)H>$DJ6H
MM70\5/1T[YWF5NS1>/T(9L,O9ZTL3J.\/J5C<NT#D6267+XZIV"::>AS R>)
M<T7T3#]F=7-UKW-X1JW9981)DN(H\I#5FA*C)76GIK-!*VH[FOCX29OL+:YY
M6PMJFD;"3YQTXZ+6/#H5K6M;F'B151*:B=$PZ:=T$RZQ%E%\VU]K+7P%_!6S
MD5$NY&+H_-(Z4/KN2DA*;.DANH.+4G@V17YMV>J-06$N%].4;-YS-"4#2]IF
M>T+0I9XI;<0\6'JCV:F9X%-0VE?4+(5D)=TFO-=-KNKMV2M$H4*&F*NB.=H;
M/6NX0U<87298%LBZHG<Z&;GI*)CMO0\XE+-G\T?T+#]F\W6,[[IS,QTM&CC5
MCO4HVF9"B?IV<BRG:(U0LWE?F>5[;O=%F^P=KKAU!*49M+2'IJ3(#8]7RM;E
MW[ZORZU(#5FPJZ>)G2)VC#:2U\!?P3M)MTRK1]RB0+J!GLXGP]J?C8UI_P!.
M.<?J>S<R 0=2"WUYVZ8'1J#D [,><>ZF$%H,?3RP7,_I!V9HO@;+(HF>G*;]
M6TE-Q<B[2>^VHWF%(ZV9U&2>CI95%2]GK(8JB<3(^FMIK;#C!>0QY^F&=VXW
MV)I,CA09,?<T?T+#]G<ODK60S3*LV(MD=KK#$4PD$[J5=LBM5 8NCIKGE!P<
MU[]+39N[N':'CI=-)Z=$O/4IJPY)LFY>BH!YZZ)\7!S.H/4J**W]8.IEM80;
MJBU03$Y"6)C I2B0*JA#3R*<TUZN]I+'P'_!/AC@:Z ZB;6C1CLRODO&-U0(
M($N'M)(BMH2LBM;0^UDQPN30XUCK@C:)F;%:3M#)8 Z7>VBEN+:^N:'8^%;L
M9Z06@S52UK8VYH_H6'[.Y;<ATD24R;ZT@KI,V/H6Q[C9&DER'3:0DIC>2^7R
M4]_A)F^P,L\<,0AP3&(8P(V.(X(F=CA3(3M,*QRQSM@9+YX9# X7Y=5;SR8L
M": 6@ V-.M&LQL"Z)J_B96<,AZ<XOE@HNZ:E]!.,;2<M/)5[QB33<SX%G->U
M 2YC]VO] $\TRI$3#6!Y-YBFK):,6 =S5,E3Z\B)>0JZB !D7FT%,[R2S\!?
MP5]F==O ,[[K>=:U6OOYX_H6'[-YN_F]%;[<Q[_";-]@ZX%U:;>EN/574GDT
MHVFDW&S>4Q)#A2/FY(3],/5KS:\6W#T/2E+1W2B-)1]N0]+3LD8)<CUV B0_
MCK&M>K:PPK6UAZA_F/"&G$H"1@WD_P!%HG"0'5#TFN%N&(Q?.$B)TN368:!*
M5Y 4EDQH!CD=I1-:UK<G^E)7 >%6=JU[L:GUB85&NH>\C.+DU.BEWMJM,(S)
M?K$=[S)ZHV@ZGI,"PUC+9:#'T])P@XQ"I9^ OX)\1A_0L/V;L/+R?]:\M/?X
M39OL&9XK2IIC9\P(T)!B9@Z+F.VE!F:%F:V'%CHJ8P<>8_Y[Q>8$6- $)G%;
M'00S5-#=.@]H+A]D,M C]J<&4KA"M:[FW=;TU:/'%@YM._).L9$Y:C)%"566
MY-%JKDJBZE'$8(/F%8P5M0$LHJ,00$OD_P!+UG 1G-)&+IC8X0K6  &%^258
M5C>:$N*].<30X6:^F.&&9'JQIYBI>3&CHPT^LMW<DL? 7\$^(P_H6'[-Y=UN
M=T<VU/?X29GL+:/]MAO!E?YVO$VB!<NMW2\<<>7^>"IQQK7JVE?*;=+<!)<%
ML#EDTV#J!UV8X^9CLY9^ OX*V2X>S2T>(]8#<4X'<FMN#DYA1W*VK XY7?K1
MAAD/MUZJ8,93D+&2YTOLKWW6B#5B5<"82UEP KI30U":IGJ2=NJV(&5*NTDV
M?' R]1)[61IT3G [=2DGO^1$S4(>:,30KJ$CN=R>SE%U&6/'3)U>,8I!\@:V
M(K1&!%DBZG+O7+6Q"(,C<T?T+#]F\VTY _4H5FF'#QY[:N'!=_LS4*U%F*V<
M\6W(#<KR\KW^$F;[ VNJUOK.FR?&8[T-^-KDSQP$P:L%H;&DY>B=M..0N74_
M.J- T7:!H<6FNTMI+'P'_!.R<Q8<VWR$+2='3%:T;G]3D@28?U5RT;DLO.\N
M3+.42ZDI%J"TY:2(=V5^FSH@*4B3"[L^HG5<]DS56<@.=&C(X<FIYG,\0V<]
MQ8_';J==^2O'>FQGLN5].;E:]]9D809HG8^;4*[.;$93<,2IL<2!#ZE$D6NJ
M9D)S&]3$ES&83IKEJ>>:/Z%A^S>7IKR:@VG(3FU8/3"&P8=93T/:0G@G/?-\
M:?/\[7XG.#3]5N3RT]_A)F^P-J_F0@2.TX^>;ZT"22@.!'="35[VM6/5:VZV
M^W)+<P,J%VI%+"?NMR7"Y<$J#M)9^ OX)V<I0XP9B2(RB)@1 C;9\/9NQTUI
MK?L#JD&0-$D-,5NR*_$6,F2Q7BE2"TMH-V?8QQ%&D1Y.>(IMCR;4@E.T;J$M
M;74(@Z=7<XTU[0%IY=<O3"Q8.:#?7$YS(G-']"P_9O+;JIQHZ:NH"/HY8/>F
M:J@*R?A(,2GS. !4#D\OEWVY'Q\),WV#M5=73D)-4$E3UKN@^PM2^AU=AW7;
M"DH8IJNE+)?HMR.%YM1I@R]_H6RT@VQ=(TNZBEB(7^LP:[<<<-K+'P'_  5X
M6X6XB.U&UJ*6*R]L9OD(KIK?V2:WG^:DW*,(KT<)[E%BS9WM;*VK@\V(!@73
M _S>FZ4$5_/YJ.LB< /D]HY&2S%Q1F)Z/.3W]J;D@/4DM: )0-O&*.:/Z%A^
MS>3=RO=J%7TT-2"BF:6]*L+/E/3-/>CB/VZND1-UA.7=5J>_PDS/8.T.G2R<
M47%1PZN7JVVZCM1'%""&#EG1;!<M7-:")G8EW@W=>D4(9*&]?[S*)7^<RZYS
M<6Z<8?AXONZ9@B5NRZUH0EMPLMQ[26?@+^"?# 66U2SDF>"PGRW]/FCG&.'=
M.>D_&16@WD4HVT':+K.:SH,O"-F%(%SK):*@UB1(HFE-H*$&,$C,-FMY!:,5
M1RP32.RVHWU7FC^A8?LWG2- +5E:2'SI"CAV/%C:+U^/Q_)73S'O?_ZFS?86
MS_ZZ@(_DB4AV0S&_'[=MNW<NL+_TPRO@_F3="J-,#?API(1%D=5ME+'P'_!7
MB,/Z%A>S>K8>7FVI[V_^I,WV!L^NO,QY.G?RZPO_ $RRO@[F[]VTEKX"_@K8
MSP[EIBQ<T9C'2 7CJ$=I5P,Z;4AXJ!+4V^4I3CC4FM91^7U#M,Z6+:J6AVT3
M2J0E9*V$ON]R(IQRRC*$8JY[420+YHNJ!.,G">K1L'D.^H(<DHZG)Q?<>,^$
MI.*2>SMA)R^>:L>I>J8\=6W#J-041'0M2I0VN?5*W; @3YWK0FKQ,(E)"U''
M $Y*'S-)FP?NH=:9;O0M0*;=H*>IOA%A:U1-E&3S.I))#7AM0^:&:2-6+16$
M^&) <+]"Y1?1,3V;R3Q+SFCUXMN3T/(-Y:@E$FH)DWL0VU9;EO&,U% U(-U4
M?+FEUCL_ OJJB8Q3KFR/V6;7=0,;MQQXY8"!<CW^$F;[!YVJ.=EN#$>=IM6H
ML?,R:O7=';Q):_I.02;WU).!JN6'M7$N2L].=K"_]-,CX/YZTL$D!(-ZZ8,
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MH$699@KJ;Q\RR[OJ0.#SH-"B]O,AJUZ4YF(&L-)Z"K[Q19E%7FMYNM&6UM7
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M>34^0P5YINSY>PZGC$(@4PK1\"\8U<7*HX?[(A5I\R">!WF??:I/V1S>9?-
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MVR/JM3_#<%)WA![S6U"-3F=*Q&&E2?T+L3>%O\G25*Q!D08Z/;%G\B.,F#8
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MW)&>*E_&:TB!@-4=G136O$I3Y5UCQ+NB\#:Z-,8J4QU!B^C^<JYXA+O2[!>
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MU4N',0G?#LNWX1I<:JJRC)E2H-->L_I<A@WL]V+(NX:XQ4<.R!X7=)*?(:R
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M:A7Q!.&'=&'#Q5P4[%^(SKS60L'X05\7?NTG/U!,E..LZ,-/D/$LN]ZD<?G
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M8787878787878787878787878787878787878787878787878785ESD7_]H
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M^>&'O^/&RW?GAA[_ (\;+=^>&'O^/&RW?GAA[_CQLMWYX8>_X\;+=^>&'O\
MCQLMWYX8>_X\;+=^>&'O^/&RW?GAA[_CQLMWYX8>_P"/&RW?GAA[_CQLMWYX
M8>_X\;+=^>&'O^/&RW?GAA[_ (\;+=^>&'O^/&RW?GAA[_CQLMWYX8>_X\;+
M=^>&'O\ CQLMWYX8>_X\;+=^>&'O^/&RW?GAA[_CQLMWYX8>_P"/&RW?GAA[
M_CQLMWYX8>_X\;+=^>&'O^/&RW?GAA[_ (\;+=^>&'O^/&RW?GAA[_BB$W5
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MF[>$0KZ\ -94JQI"P(W.ER:ADI6-80Y<RD]\IR[,&@ W=%UDP,$2-0=9'1)
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M1U$+8I=-0,HM$PT8/^I"S$J5)Q"S*[K M#;XL-E9-K/F'7XD"SMW\D]8K(9
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MX5=G\7FIR8*T,S;%:'IE,W6 :@EIV>(C9LKZ^/!@F#,<=P^%U%+<5&O#KW'
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ML?+E?Y@_Q?'RYS?_ $YOBV/ES_[<WQ;'RXKX.X^+X^7%?S#CXOC;X;K\'/\
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M+<LEJ2\;E&LH3"CZUJT9&37+L,18Z)5]RK#:\DVU"JMY=.*[ IIL< 3TLO\
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MEY1,&;EX1-*\Z6X5G5M]3)A_=.ILZV9047)N&<#&.#96[5@$A.";)[)22;^
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M%-PN>J >OD <&H ^Q*JI2O;@D),:E)U2L,&E[&\KHE9>&CK:?6O+'"]*=FU
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MA\2FW$/I]: 5.F"'HG%PRH4\1I&LFJ^-7C&138E2E RY%^RPQB6:<C5@V$V
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M+2NG64@,<)UH^UV*IYO/C]CZMGF%_P 4:?MX:^O^UZ*[D':Z":LFY71R>P"
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M<*F?H5;G7E&XZB*B6M=I?9Y5(V?8P@(1I$(::)&,:<J$IIS40FGHJH6ZX_K
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M2L'+LH!\ ?L<K;SE=8-/F6>?C0_^HXELC8J39C55?60H'MS$VDWMWL;=N+N
M6O#< 0FA1$ID,%25!0I)1]BO:Q"1MOM2.']\A"W8A&BM>(Y2,#//N<N5*B[^
M&<>H2"W5+"$^N204FG'4Y<#05;+-3N1KJKU_.639+(:W=MZ3#2_GU([Z)$DC
MKP%T7W//LPE%.9*:)IZW)3T2=]R'_2IQ^9G_ $_H<G(C31:V3([E"*\U:A0I
M>S[&&>L>LCUE987=VW';3<(@G=E=5BI]S#L^JL6"712*7P$UW4]G%VWM;EPT
MNDMIMXBKB# V>,)%;RX'B8^(9J2_;!RU68E$+]CBS'U\:41Z;&OLR<S=G(13
M*8L1J=!#(<3"B/<SK*E*?:4?QE,#L2>D)5J;PRRMYW-%AY0,.RFI+OC)DMZ1
MEPU573NDKR\F&=J7)>=(^6>48*#FB9A;&E)7A^#L\BAC4-.+Q*9-_LX"Z:E&
MX;.!I, PZT6@@U4VI6FM/0ZU[%*;:^MC6VXM3JL;1MS2R[&<&&0K3-UP#IHY
M<<@@<92R=XW$HIFKVL3,A!WHB0<0T(\GB19(Z6CGQFK5H5Z-*$/V(=G%2/<V
M[>?EQ;VJ\!H\P>:2W2Y XC;=7*P[6Z:6V[Y6LT22<O1IWN)[5PMO)BT-%9N;
M(C4.\G+)FQA0MG)T-W#RHTB$9^@%0[=JO9^BZ0Z0L8ENXAM0%+I)R1-G$8I&
M&1+M0JJT_P#E*=C#^VG6H+9$G%OD1SI=(V6(PH^7T6HI-#%0%J])*ZXG].?)
MHMF/N'Z$1T9*73>4R1MX&6J<8J>Q,4Q;."-5\0M!+3G['==K";YUVM5]8<\W
ME'4*6"85^DI95VTH#\<8?1]#]*!E43=HKFV8F269('K(VV]\&W%"OFQVLA#O
M<B2\%P,P0]R1->;NO1+TNYD!+EY;=M3$PU;+Z!31[$SE"%<O;'C2S4_5^5;6
ME):BQC9PUBFK1Y)NC.3MJNE);L8P+PE4I3SKR[,.KJT^>UU$F3W&VLJ$MZ-X
MS%V]NV1:*=,(TG7P"RU4FF;EI3$5$ZKZ=1*K4N.*<3"+BA'T<S7:?# @PXV4
M9*>E*X(K/ES#3W%< T\=RDE'.7DLY@&4W(1$HRB7DVR5PW<>$[AD--<JMB:+
MS[*[?/&]R)][7$Y^54__ 'TOF?M>9L\PWD\KAJCJWMDUR&N=;@26J @C42"T
M+0O>IT\.8UKJ-!%?LG'5'3=)4;$.L_!X(B\7*3>IW.+BTZT'TDE=896R%*3>
M<DS?L8^/BG *IXS%"I'A)43*2BMU?9P3534%FXTF9,2%;3$;<A*$<-G85G0M
M(>&,/$V\"OM25X8W?:$DF8MV34NC&2&-0TN.'LS[$+Y>Z\SZO3\RGU=C'U_V
M<%_Q9E^WAI]U_P /HUI^5':+4E;9E7 HF_635*^"E).\K>.4_;5=55B(NRW'
M@WT/-LQ/6AA+2KO94TKE7EKR5IV:>;5"J46E:5(52O+125=*F)34&U*#C 7"
MQ(WFX@2,C0KI9!JZZV&BJ:)KL%2G[6+9U$D@=8EK58OV<8@E**"A3ZH\QLNV
MF\G@TR5\Y-7*\.A4X];FC;:C$JV.GTHZ1U<*P([/#42B\3.KM\#6J_-6'9)Q
MRMPCOS>*>J$[ &M24S)WJ5]%G/<A_P!*G'YE_P!1Z',M&R*E<.(YV( Z<ZR+
M$JB$T]>N/)YNVX;.\+RM@:@W\61TGDJ?]TE&<_?*Y%E/1;7B!&H@ [%(XJ^[
MICRMVUM6^*PKAHWL&>@8IR-0P^&8.ZCS)V<KP*E3QB]5H)?"Y,U<:3.(K2_5
M/3R[K6D6K&_7C,3$-E2;!L@Y#.8VO63'RJ4NFS-@,%JUHGJ23R?[0F[?DX"!
ML>/CLEX33)HW7X8NXD@YWDB-Q4]Z4C=5C4BV3Z;WBH#E%JN].6\"V;_0H$/#
MJ6=$5-K<+ZSUP0J(%WK=XF--HNXV#B*G8^SH5K+1SGE<,GP&8T';F]-*J;*T
M]#K3TJXU+DY:WNI5C_*&L#4"(MJ;2H;6_HF \(F<QK5""4XA"YZ#0E2D)WL7
M+;1+#-IF]F-(F85LC!0%PQD6ML/_  3X2ZF0H^K\;9DR[V7;BU-$8S2[4F$U
M*TM7%1D/?]F#9IL^X6+);5GUU9'CGCY5#&NNZE&/)[N6W] +QN>=L*XK<N/4
M.\XMDS(6<3'_ -J;(.1R+OF_W2>YPS>$:N&)';5NY6R=)HERT4<22*;.$TYE
MHK7*KTZ>B:,73!P[Y5K0S)V":N5NG\6A*D:3"*$.3>R^WI[GLX9Z.3FF3&2>
M0VK(U,-36@:EBKE<.W\LZ"Y9'ZSUE3Q/6^&C,C+N5Q<;^V].[EU,TSUIL2T*
M*59XD&NZT)YI;A&AUNZ.RM0)2HTC5:.GS8O4<-I[=MXW[,W[-_0QO=0!.I:U
M;3.9KU1YD;DRI-P>)DZ:<R<7C)W#8>I<1J-=<EX:OB]=16\6-Q<TPH0 JZBN
M+)EX>45.DA/0]$U%@X5H5_+2MGS[".9!IM*Z=NHYP  $>FI2Z4QY+5^SUCJO
M!Y:FGD;;%PZ:J0@EPVVZ8P[T9YADU<$"#>J?*O,I6[2N-;[[TU@F,%>6GGE'
M1>H=M6L09DQ;\T5;"$#A.&/C9JK49715EQI9?$'IKJ[8$?$+9HU)C)84<*W9
M$C%35!T120.2DX9$C7TNW3'ASR@]"-2CZ<V7>KZNF5I6A'1J;44+KG :75<7
M6W'&410QH.M0U])'1\\;W(GWM<3GY53_ /?2XI^WYO8\S5)M8+:0!+O]&9L,
M?+@3PQ.?_2&0T:$W\H7=2C[;&A$! :62UI:KP%P1L5?UP.A<%P2>_P"VL95S
M(G&])Q,YEUR94XUYTYU)MZ[FL-JQ/$N^P]2K5;!(8JG4:Q8@9H=/.+W[,%2N
MAEQKJ3RG(*];Y!%2*(_2-K<;4-9MO(23-\2*=J0TJT3NFX:LR,^&%E"BI>(F
M++?O#2;:5%4*: D#(0UZM_!\S]CS/6\PO^*LOV\-/NO^'T:;LRY68WT1-M"-
M7 24S42NM*\(Z:=M"MBO6P?2_42CZ9T-N*0J:V+DWB)A4F7E1G6O(FF5*-].
M&4[ /P2<3(A2=H]:KX@CC7LK2J54KYG+7'/MIC9YKVZ[TDP,F[<:^J-*EHEW
M).<JJC;-45YU*R_8PWUMU59NHC2"U'JU61:YZ+H&2(W7WDW )Q$](*%&P)LV
M$@+<"$B"(=*)&(:$Y4H2FG8IL]%G?<1_TB<?F7_4>B!A;\B32C-L3C-ZMI*0
MBW("^R&XCG+97V<+@;!@00S$IE'<KXQWKYT95=M5NG[U9BD^Z77T>9O.ZWJ8
MV @FU7<F]75.QN"A*(SUHM:.RNG9P6^-4'G7=*9#JKE+YLX*V(4BZ..K+;'9
MO6BLVXO9E+AE<VDT+P&%XQ<;+AF';YY+23R-=-TNF*%O9!P[72E$'INT5R5Q
M<%^7!UBL);K,;Y_U1'&<5 MP!JG@H[JN9PG$'>4'0](F>:4>,Z.D5">@:K4.
MG%'R[%;GHI>+[5PU\3;[#+7-]C%PZDV;'!EI.R9OB31W4]+.XB(F <1W0U(L
M\D9LE2>&I70Q*2^G<K6390DN^@7J5C& @'L:Z.S,GAH(7<S-U9%=FFRN)/1)
MI-4)?L1$-IMY'Y$\&C1VLZ$(0?B<I*=7KM3E]&L*S=9*$K<5SOSLK02TF)&*
M<D=H;+.5%21[YK79D0KI(7BP_)\B$MK8GKT EQ;$("G'+(46Y6S2MR\<'J8B
MZJ17E7GKA=\:C2O@>WAR3&+4[HA*Z];D25&U'1*RBYZTY>7$3<407K,7-QS.
M4CST_CF;X"#MR4]5)*5]?SQO<B?>UQ.?E5/_ -])YGI><F8F3(&/:R;!PU=R
MZ4#$^:-RB6-9J/J<(FZE=>[Q;MQW9J,\U MRS7"I*WHUU&L8V+:KR=[<OI1@
M3B&RI1168^?HXI,+<VY+P@DI*.9,AA(Q8!CW,R'S@14T2G X\%Z:8OWISI$&
M,$\A'!W+FFX-"&O#WE]RC%>JL8]EFZ?4F+9EG_?]6$+;YGK8^KTO-)_BC/\
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M(O7B5F4QX05Y%H:&[M7VN%=2MLB'%"2#,J%T-Q$N0G4%L5JBOMB.3,OV.&D
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MA#DMT#U,@"*4!=60GR>1+E(>)LHJFVO/B'FWEN1SF6@AC%#OB(6H[ 0JHH-
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M^EBX[AEH\C.1F)Q86?&%PS5BT-V^3;RU[*?,F_<Q_?TQ^9G]3_L1=7Y>7/\
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M<GU$Y/J)T#_)_@3ESH#^S_ G^!/\"?X$_P "= ?V<N?X$_P)_@3_  )_@3_
MG^!/\"?X$_P)_@3ESES_  )_@3_ G^!/\"?X$_P)_@3_  )RY_@3ES_ G/\
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MEJ:L3O 1KI"-3Y=="(>%S'W$.^P_,,T;/]@Z&XB Q[QC05M4TA&@FM><0=5
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MG#H&"(U!U:151 1D15V17VTJ 7(&I!!9D7V[+,T8J,N%')C/$)?B0 8$&1<
M9'[@XJD H&WHD.@^\*>ABA)."2+#YH.#79)EY($FM!.&O*66 #O99U/RC]1
M"7/L"FX"@"65E6'F&@$), 0(,@%H0FWJH4 @>21X%A# Z0V,"/(+%A$;"HD5
ML6VQ2AC0PA (J2 *_B(3K;$(HR0M4%V0L[/:",GUX&$9U%. H3, "@L+=<7!
M"H&]@-2WR!XX^XGR?F-4J:.M:_@_F$2LR&,%7K]83" W():.H%<[Q'<'4_4
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MNG^ZW "2A'F,'+K2:_< H04V)W6VU&$ AUB.=/HZ5L9G^D Y"2$!!P890TP
MSO-<U]Q X_<9@6&:.MF:)ZN'!F0PLUFGZ1FD.0MZ&4]C&5@"\:=@T/-&ON'$
MY=,1!+8"80AD1C-MV+6%=SY14,DBM)].@RNP;P"MV"'7I]VA,I>:'E#9K<!'
M/5:=8#8MX/&' Y'6 $R&QF_(K;:$HR9@Q?VP*U0H&MCLT!@3K[*%UXY-CO0
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M@R$ MP-2,/%0<MJCE2+J$M&^?Q"#JX>UO!LJFE"E6?7>8-7X.NNT+=@__+"
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M0A4U9A418!Z/0B*77Q-*FM?9*N'CYUA;NH"@)K7I&-H1.?Y_9[?W[)&\LF%
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M".4@[#7IO-X,B*>-1R0/KC,:&#XXV+\Q ,I9V#?F:.1M02IT*ZJ$.5?V\]5
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M1AZT7R )OTGU30].?>&G;VQJF@>G>650+14)#+T]68 "E$\ [P#S[/\ 7I,
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M*(8$<''H0QO3HC]5- (( .Q[M=.)32<XOFZ<( &3GS?G_P").DY/U'T;M)A
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M/<'Y_P#B3KN3]*IP@$(P@ (;H$P&A_$0D\3N$<92C$CH$".8YA)=^) !5].
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M/+LH2(%@-\%!2%<@.$",\XBV".,;!."()@L+3&04EIN3^:2+'45Z)G. L2Z
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M U6D*) S6D$V1L+(C/W!M4\JP&I#DZ">V83H %I((*\2[]#<+8/+8"2CT-X
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MD X !-W<>A(E@]2L@TTYYC:);D ^A"P"L/87V^X(LF$=G6'L)JLP_08%-<$
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M(3=8UZ[0B6P=Y@/?VAZF@+[A[#>99L+SG!0@H90"906@A&PP8)A0JQ*U%B
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M@$0 03 @&>M(U<S1PZ08'UJW"M)C7K28_4HYZKPQCZ>() S!!U Z;.\U^]@
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MV2!7P(?&1BT:U@#P1HN94F"Y(# =#WC-I!!EAS;!X#G& (;9T4*6!WAP5BP
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MHN3V,7A2F"T*UGR<*S"0*$PR!@N^P'0D !-%BT+!\AB.E*)V\1>HUC754?\
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M,,@ZZ0S(  ABQE!&\@%*-=KV8 ,@PC8\,C02R9HR@V3T"OU#@C-J\M^T928
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MH=$Q-C = U &#7&0)4P"YJ[B*YM/V-@>;LK_ '?FP!&Q+9^L3-;(D&1PHSG
MR3:0 (@"!FCZ3<_PSPSN-KGNC\F_G@V25!9Z$$WFPH.-.%^% NY .ZQ(^,VH
MQ=V("1 D9Z,+%4&*<D8VVW7%-DT+<N4F[M"X$-OL$06,'.P,'_6QA$!5^4YE
MG'Y4C$8SU8$/W+B\##KBZ/>$^5RUR@<KN[N@S$?L\XQSPY*\V'0KS@QY?E B
M\GP1'>)\,?W-,X(A*(GJC4A[@O405AQ$\4EI+4H1X8QCT;KFVU>>J-W!G)QR
M> <>CD\D#]!TLQ-^QZQ0;+,??5Q,-2_SPQF$YQD@_GPSN'O?LYKAX\[N"]^O
M\9['\/I$E*/_ 'S*2"*D"BQFJDT8T Q-$;"+[0$B71',$-. 6:CV>8%(:(-Z
M(6N<"AI!R#)@J-1=5CI%T=@& ,0X0N: 'L%@%2;#N'&C3'@)7(8,Q!%'2,N)
M0#42OB,,Y@5D7;KT9 J!Q-;I(&A!G,H'9"QYP)F&D&CAM!MP[:4[K$:B@W"8
M"H49$D%"("]8%#Y]CB4D@(H$!"61.6*]0?'4P?&21V'2!BT4"(,9@-$YR^0H
M?AX@*@%BHY-2GGUHH$=5I6&T" 6/I1*D E*HP15BQ@J90(+#3'>1;!IRXH
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MD R=!U;%$A8F)69MB/+A98.Y 0=<FVS,L-L,>",GW7J)@6!YMV[^D$:N] D
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MOU42=)L7[2_T3D[: IK8)!;[13,_O\Y:6SN*14C J7JEA4$!7V0?$7N_U_\
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M+8.&$L%8+9*@\ZQG/+(F[4BR+9+#*,,"RX#M6&. M;J8J:C?#2WKJ\B"X9J
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M9/.1LJ@# TP+0AV,!?OH"6LS XB1*@+.MU&U?R+,C <B<&Q849>[DE8E(&U
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MOFB/:&'.;(6WIC\JC";A!TD8<$A8])L[@MA @-* U0(*?@$III]-C7EI"?L
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M8 J$[35'SC1C>PP=@9ML#]UY,,0$3=A"L 40Q0XV_E&!G0E*QAT.JR<3"32
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MS#TM?2!?6WW#<+N&%$/C.[L0.?<AI/WN *N8A9B86P KWJ;0SRD.!"(@ 44
M'%Y@+@_; O;!0MGZZ&!K;N]>'D,OH4_#VW#6IWB"]Q_2&(2_0>R9]HZ,B!95
M1@L!0A#B>D5?:F^#-0QT.IT-ED8XN4%8A%2!I'.9G%YW0,F+%<&$($W=7=N_
MB<=4]G-Q7-;'@>!_ ]@IUS:.C[?>+:,A4!!4 " (TVB%M)!)5Z+S3,8< H3$
M15JZ%6: @    0 & !](/HZ%P!43G+?$(U@.]#YT!.%;S"EARAP7B<R)!UN$
M-D1/( ]GWCX9]</N!>>4QN0C'68-XTI,#M >LD;8@/0)K#P#/FPW8A]ZTK#
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M#-P,?U<4=@(<@+FXA^NL8MCDU1V8237Q-N%;$G0B#"AC-&8L$$$+[8#&038
MXF!M5F>L1!UM%H['T]RAZ)@!L$+7PP\ YC<#$149B+-2ZXXP@ ""G3/W0<''
M>/DP/M;#J9;6'R2C&"U\P.\+J(D4N<C#00'">,=0YB-$B0J5_P"*"5S&[ T
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M8,#5Z^\IO,.F6&1/DC""U+^ ':XU?=+&Y4BF*0%V(<,0L"Q!."M5Q=KW2AR
M1)(EZ0#9:ADRMM9;::XKQ'0![SYPB2L"F4'A4%*A7B.-A)!IZT:D:A%*M0=_
M(6'L(-8\XEH0301$_KWJ!$IW3_L5+MR[']ITW;ZS?B+JD() HYC3AA6H;3@,
MX>K!3,O6$XI*2V)L5&!P,9DC,B94C\X?RG*((C1(BUIYD@>,@5";KZRXR"]2
MU/:7)L'8_F?8,FF"9EUD&+5 6H>:NW0,@0T3P2RZVI7!:8"03100:%R &:<9
MU20S]BZ,^N'VL1/N(ZK#A[1Y,AI>%$YFKS+E/4>X?4W!"HR3)?6[!@A5P*Q
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M'7!.H*C(Z9!Q)JDM\1[,XK\FK;X8#<XZC$J-4X^2@( $V9)>>I"0 I0D:H:
MZ)^P&QO"#<[9;0T:/08\P<%$;!S 1&OV$VC ')1BC>? *TL@ 'R(/AUPX-09
M9I14P8(K$=WIH!GE?_%SD,50(";A?6LP4L$W.9_"C;LP8 )/3L\".A[?S\)$
M;+YF;BC\>O?PD_\ .C_0#TCHG'A(^[0AZK6F>H[YW=798._)!"ZX:  N(^42
M&T[E1!]/^*XV$^8/J $64MS#QC,Q$HBE$"N83F!8_+'<$[9_XFHS]E2#$VB
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M OV#H^0!,=9WB8@SACED!L$#I&X<Y2+& 864068?4%(IA39Q-E4#"X2*_"
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M%I)PB>;%LJ<$JU/IDW)4^VY(O+-0M)=:&%<R89NO-]L]"JT@1QI.3@84F0(
M* -M+%  =/=+J@M$IBQF)IR_T#.$41)U&X:IKL 0@(-%AFXXF%_@<6TT\T5)
MLAW@M!%(3"W!'MC &!;U6RK:5-(:$9-@(7=8@;W",2U@0R3)IHP3"O,A>EM^
MI\H1.$$%9 YL+Y!@G3\![=@2-[((@. =R)D8(8T09#(&-+N,HX79*&,62PF
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9B\"=_KDU^$U$FD!L7W"F#Y3;"]<O2G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_04.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  K@    $  0"N
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
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M    ^_@
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MU-@,5
M
M
M
M
M
M                          "F:;/S1>M?'GS[^B^%8Z96#EMJNQ^H'R/Z
MTWL<)[/R5J*RK7"BA]AJ*/VW/3V,K*/F.T      'A5X_B5X\\3&$I,    "
M24Q&         DE/     0E& $)1@(51QH]:B_4=&4
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MKVKXQ_07^;OTBNO1F  #!_=8.J/K-;YB/EW^F/+/'O4_3;X#Z)]0'B'9S9,
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MP5B<ZY> 9 GU13(                 A,1B0   !!$4C@FB%1"$(R)
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MQ:U&<9]);+.L\$R!V7':3^"^J\]NC\BS6W?E.E'A_JO*[:^>; NE\6
M 'G56_&IIFN6^*B8(5Q-3<Y:J9HF!Q3!.%_,^LX8\][)N2[GY9L'JNNUT\[[
MYM:ZSYVZ--S5GR_T-L<Z?Y_O+L>;T^\+]/Y2;WR_%[1^H9R[[R#-+?\ EVDC
M@?K/*W;>8[$>G\5T[>?_ $W</:ZG:'UWSMJPX+Z5IK+JVM=O\PU%;R>14
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MAXM'--N*9I)%[9)6O3EG$@  <5N:4R]?6%C/ %F=QI?G3^A/"M#OOOAG'%0
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M&SSZU^/\O_7?$N<RS^O?CO'WJ-%TOG/Z+IGRWU'BL5Q.QDVZH]J\8G]W\)R
M\>]3Q*^=OHX8/^%_0.N7YE^KE,B::JTZ#E]XWWA^>\(IR6]1\LR[]E\25/D4
M18-&7$34DSYR/G:A^E!4J&)  '':4;F:^MK&P %HMKJOEZ^F?F_35[5Y)
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MTE>3?8,9D      0F*&NZ^NK.Q  A#75WW!_*M]3_->(/7\C/D45#K<[Z ?
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MZ=&X%#7L"N+6=&)  %OHC&\HZ;$S(D8\608\I%D3DK'F3QK\Q,5G0R2J5W(
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M8ZJGM1-^XJL1,8]PVG58\Q*#D7,NZ:[AU3*C%O:\?8O9\?Q)@1($Q $3F!P
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M9$6.7HJH,?Y_:<C5LA+8\8S2MW3.2DOIVE$BQY2!.7$HR,O*P
M                  $J*&RM=7>+L@         !CMO-%KE]#X.MK&10^7B\
M==%V=9LO/F*3RK-Q]-G9T<5V-W=5M(5*(O:JM*-GR*@!;*F<2ZL:!,2$X9$K
M'1DQG&,B 8\Q*3!D*:I:L69<RZIN7&J
M <*FB+V!7MG8@         =:(P/[GC\9NBYV>]1[V-D>A3/!<HIB[;V[>0^F
MVFVFMUE>D\'<O"S-B?FG=_.'ZO\ 'FV[B??]BG,^I3@ L33&.M5!;,@QY2 9
M$;=R:YAP9$&/*R)K=R:JE53*Q^1<R0IN7NJ
M      4%D:ZO<?8@        #';=:'!CM^3S$Y#JJ\PLNQNXU.+?7\I?_FNB
MQOZCFLA^5Z/P\BUL4X+MN[%6%74\UFAS71V^OZW6'U?BV ?4>67+P^AW%\#[
M[E9J>VYT(6YJC&Q%,55&/*&1!CP(@G9$"--2JF58J^+N2*;@I\!%#(I8\:F>
M"JCGIK]BJ*H37434$HR                         '%9BBLW7UU8V(
M      M;DX5R,/+[5526+O0<]365CYC\GU.-F]TF-O2<WD]S/3ZV?2//-N7D
M_I]=XF8J4+DZZM,7/FHJM+FZ73GWOS_BWM.'R;UG9;B^ ^A[T8^YXT6TI6F+
M?GD4W9+F'*R(L>!,3+OKT5W%E=M%8S-D(BS,T49$JK014BI3<$+EB<K*+EZD
MWO5>G(                        2PHR]KZUM;    <*FWNQU].;375EI-
MM7&!F1B5X    -4_J?FVS3S+T&I+.1+#5]Z9YYL<\V[OLU7>U;GU%0H2_@5M
M9S>6*@!BWL^.TV^@_/\ :K.Y_/CE?4-LG%>\579R.E3/EW:?#IJ\B8XHGE/7
M*B3[DQ,631B_%/F56@IK54!;R%5M5;"FXJMJ:X54^Q3<R@5WIJ
M              <-N:0RM?6MG/  %#9>!BYW'%6$Z_FO,R\'ELW.#)L7#Y[?
M9B^<^A7DTVZ    ZIIR]>\GW+^.^L+@60VFI\^[%_P#3;< 4'FZ:NL+<3) '
M!:<M<]>FC 'J?,-3W;>#^=71M'XKW/9'ROJOH3<   QJIIQTJM$03%$$QMWX
M56XU6P MY"JTJH6\A5:54Y(4WLD*I                       $EN:2R==
M6%K8 #C4XF]KQF*'HGG\E^@  2VZLP_,O1\IN0ZZ*0,2YIM+#8<J&+*+X7[%
MA<3(]2[&3D2!B[2C5&4*10&7IZ[P]OR3(   'BU6M5_9^(ZY^G\FK:SG[?.#
M^@;K:_=WMP.A[MT+:1&%,VHJ5O(5V?D87;*&_J*O=1Y9W48P)R!*V1C6JS^4
MY@*""55.;--ZX]0                      "2B:,OZ^MK>>!!&#/HOG%@>
MVY!,><J]"NF60 $;%6R'Q7V.XV!LP/EX,<HBSTK-PL3,;YJ*]"%5O??,]2)]
MB6-AKZAL"F+]1/T\3-OLS35_B;>:*@    )86SR-=IE[OYX^;/V#XO\ MY^<
M/TYR[UG7C$*(LY%M50IK54: J;^C>60ID66<1E6JMBC&>)W32U+3'T-TSGW5
MCA;R%S'O7%S+6;@                      "RHK(P*UISP,2NUXSYHO=O'
M]#_>\U]2'EO7_%'[7P'UO>2]OM\Y?=*HL5B9.H'%V?23MUR==L'Y'ILZ/./1
M@,#5-@#P:9\*J*5B<^##&J,E:&/Z;CR\.7C0NB4N;7)FA<C55UC[4      <
M9-":0&%M$6QKL+>0N8ZFYI?BY1$Q::7ORK2&N8W:F+,5>DC"&8V"0W7U6%%Y
M79%TJ;V9U50                      "PH7-UE=6=F.**=7OM7C>CCT'D=
M#_=\]]>?DG>?-!Z9QWT%>>]/=S"O>QK\[X)=%V-J+>5+%5?SC??#G\WOO\:]
M?   E1X%VW[=NYS1(   HB_@UO8S@        ,::8QU4*;BYCC7A3?T7RS<A
MA%5%T2H(G9(:Q(JJB::\AT9?1A-@"%-S)&:\D)D
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MTQQHBQ4NG59C;OKF.IN*K8 4W%5M3<[U2^\5Y%R]!(
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M3KCL4T\%574FCN%48F12&79Z=_&R\X_JZMQ\B@<O4UMB;3L*@
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M(C1=++:)VUHPN3JF,FY?8C%5[9B)M"AZL@            !+;4=DZ^L[6P
M_.$1XD3N7B/:3LMFG@EJVB:N-R:-H\U #";L.5\^NU56-D^)=LPF.1?^=3Z'
M^=]=OI'"<<V.6JOU,?+^O?Y"^I_6HRLD>=W=X=/MA0>1KJUQ\_G5
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M/<Q\CN2HO-L6DVNGN/K\ZO-;G<-VGDB<T^/ZOU+5T4;D:RL,39S5@
M             ,=U.,R8$2) 1*J$($P($38?%7HS              DFFB[^
MMK?'V@        $L*9R,;W[=[%_H-!0NSPO'R;/#:=Z)Y#VL;)I_)Q\Q^1ZB
MKL3+ H>_KJVQ=A-7(                        TD]Y\Y[FN$^@_<C)
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ME!,YIC)F)]4MT4S+T86KB:24W\JFD*5W9?<I,BW^1J*\L;;DB0
M       !U:J/ NXDU,2S2 1R47):J8)2)L/?TE[,;;]R:P51FB$23":!-%0D
ME[=K*[\70         !+2I&]KZPM[            ##E3F,J%A*J<<J)V$3(
M M_?U5>6-IR)                  %LLC3X:;_S>,Q*D$345?+SK^MSIR]=
MX2WG3&-CQ&36M<U"L6QIKJI%M9N7.C'UOT;7Z0<CFERDD0(Q&5FG] O9@="
M         )+,T?E:^L[>>                * RM17^)MT@
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MBO;>]1D6NV&AM)L^9KG7;O OK?)-@_*^Q?1/Y9]6BB[^#5N)G<]P
M                                  )+"B,_7UUC[ 6SKUVCCT+YVK.U
MD7YU_98V;7BKJZ_/N38W_O4W<3MQRNY3@?>-2_<^'66S^4S'TGHF&F[XB\NL
MWOJUY'7JU]/S:Z-W'V%<I[#0U_2XU;KD[W:GH^A,4??U==4[&S&9S7?HV--W
M]?D9J.OV;\UZL*)R-;66%L>2[(
M        XE-%WL&M,;/G(UHQ,E5,4S43),<=*4FF()YY1F9$0.2S,LI*DT1/
M1,)<=VDF,I8<MN5*6Y FMRJ1NH%O+VFKRSN>P
M                   #CJHH>O7\TU0E(JXJ[/'%,L)IB:,CLQ3/%::)(JDJ
M<->/+37!,Z.U1>XYCF1)%2;74FN6+7&IY*I[5-R>+DTT<<S,JZRSQQ1"4:%P
M+>UY8K
M                                                  '_V@ ( 0(
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M<?PF^IL8>[,.IV8_AH],.VG&O>,^VGAQ[QL8>^]R>&ZD#_BI]]!?J3^AT/X
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M_KM[]>(]4G^OAOW*C]5RAV7#^O:?JC5='U4T#1O='Y50W[7<'[;!Z^63X_\
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M)E?1^H#PZB5^&K^D2%0#4P!]0_RJBU:4GY?-"'XN&HA3IPFS1<+BX4T#2?\
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M^)XS2/X9+G&BB) <MEW $:+J4HV!2@8%UTY!2<B  L T*P!2CK6HA/O7''4
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MSTZ^@Y.@1#X.^U\.&NG!HH5,Z3HH%3=M^9-VW*1-T@ '=-]!=MQ,#Q#F([0
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MC6@UH-:#6@UH-:#6@ZB URFK0:Y1K0U<HUH-:&K0U:&J/C7,@XB8EO%-^/W
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M69_RA^AE^CRY_'/G9_7;.1?X;2'_ (A#LQ%_&KE_CM89_+'LG?WK$'\@J_\
MKNS&/\MR%_+<8_S&LL?RRT?Y/69?W%I^J#LS)^TI_G1SDK6V7CDSIR4IBGD+
M .HYM^ 1@$9V :SR<98S5DY-S:P[XS!_D@P*6E\\??P^^/XB/;B3^+RO[96&
M/T@]DE^Y8?\ W+WS,OY=6[^P9>_CH5CW^'9*_A@=F(_XS=G\:JR?X::L,_IU
M?RZP_P#OM78J=6Y,8_S&LEJ'4N^ROY-[EF ?^9AOWBLT?D_XLOT>7?XU5B*F
M6M+(O\-I#_Q!6(OXU<W\=^6&/H'LD%3+/\0?R"KR5,K=&,?Y9D+^68R_F598
M_EEI?RBLR?KVG4[#LS+^UI_G2"XI6;-OE8V(,JH=6V'KB5A9Z\9+QUHW$YF*
MNZ<<PS1I=$XT706(X1NY05+ ^>/_ .'WS_$A[<2_Q>5_;*PQ^D'LD@_Y+$'[
ME[@X<(-DVTM&OB,YB*D#(S40Z<#-1/BEYJ)9K.YB*84ZEXMD526C$6H2T:=F
MWEHQTBRF(V1K+$BPD"]=6[UP&7-?3NE8\-_VCDDP!9]8E, 6W=I@+;56:]9H
MVO6'3 5%<X%1,'7B$0+-B(:7*/-<&-#%3N\! 0R*8#W?:*J2%PN96/9%ZM?<
M,O@/G$3U2NH<N8C<R.@C4>8#,,N#_P!N?/'VGI#(G\-IN'_ZCK$8_P#;ESB'
MI^L."!2"8H Z_48CT]0#V77_ "7&0?\ =N0OY;C8Q27@7LRH.MU6H(!<H:5F
M+09)M^H 0$N7^N-2_-F#@6U'+=%VW-CQYWT:T1BFL]:<FC(6; /(L]SP2DXT
M:V3.K+)IIH)73UX_K'XZVC? _P#:M8F, VQ+ 7RSY8;'_I3U(?N&'P_Y#AN"
MSEDVQ=X^VG?-FZ>WB6+FC>5E?:1CW+.[\FRW9M?V:LE#C#<]O=W"FWAY#WIX
M4R+DK)VYC!F5,3[X,VDWZ[<]U^0I7;C]N[=)GS*&0-C6=<HYFNO@^%=2808M
M&Q6\>Q:F)',$E1CF K*1S%PJM'LW=+1[-R!V+11$K!F#=)BS030CVC4,BQK!
M--*+;IGA;QD(9O/3;JX%"Q3<IH>?D(2IF>?SM&ATN>&E'<">6N>3F$58A(Y[
M7C69+14BVZAXEVO"K2=X2\HW7CD%S1PFC%'5\3CM!VP2="P;A''-?<Z9!TW*
M]-:<<U3F9MO&+LANI'F]6$KU6G7JI.O52=>JTZ"ZTJ8RC=\1RZ2;)'NMN!AN
MQ.O5:=>JDZ]5IUZK3KU8E4?--7]9,03<2#>/0;GCK\DF3::?KSZR4:W1/#7G
M(1#>>F7-PJ$AT2G@KE>019ZY'DZGY.ESH)D+C@8=(30$TYMX\W=[Z8;JQ21S
M0;Y> 6E;XDG[1U&I.#PYE(5=UD"1<-7C$CPV/&*;6?OI@F[N&.;>6JER'(D;
MR9!E56;!-H=KD"31;S2ZT\LWBTD#Q5[OXYO.R;BX56T0B1>?'_MWY=5".E /
M#4*"@ZZERE4L<(=$#P-R/($D]=#Z=3/$("> F75NFF;Q?2K=:*144@WZ]OJR
M5]2#]JXC4G!\8MDFKKANGA9I[O\ F^%;ZN+".TF&N</MB6W;\\3[/FPZ[=MD
M7$99=WAE5_\ <+@KOEI_>M"S$CNTDL&7;D""LO\ M6<V.#BW/6VW>GM%S];N
MW#*/!R\62F.DHLFW3DLA1[<ZE]W(K1;XN8@L<C(B>_'S5^VXW+>=O6J60SB\
M.=GG&5(I;&0[<NI:M:'MMG^&\7;MHP;S6:HAJK_=]Q<\+FF$>&;N6SQ#A;0?
M\W<:YS/]1UZ4,X.B]NAT<5ND-,USH+W_ -<A0]8U<^0;<M0SS.,L=6/SD[*>
MV[Q@+J3X!VHZ_P!>=84 \)*3CXAG+9O9IF3S=<!3P68K>DU ,4Q1&NNK&'_N
M"\/Y!J-:T4!$;ARQ;,(=7.$\8\9G HFA9V)N!II7;2?YMP?Q[AIK7;79P^?S
ME-?174'&;GX:W&DGG(>9+.$X52W,J6S/J" @(\,<?K?<%WG=2?1D9!M%M925
MD;F7GKFM6S&4ONUL)BLGO#M,36OGO%5Z*OHU5N"9P,%9"O(+1BG#A=VM796N
M@XMOA>X$>%M?PVA[5%$T4[YO5W=\AQL"^7%IR :"%6Q^]7!^[?/I1WZVY^IY
MTR=M^_K^&4+W4MMH)C&&@"FSE=DXL"[0N^%[:[:2_P#'==E2#]K%L;LNJ1NV
M3ZN.,;[5A'P_AX6/_(+O_D/#+-\+'<\8*=DK<DH";:7'#Z#2?YEP?QW@FBHJ
M(M%RUX-P-'(=,:^<G_":ZJN2?:VQ"S4U)7!(\/EB6^%W*E&ZZQU^NX?<HGH6
M/W+;I)7'=N; \,7;$([D++QNCD;[8T;B]I8OVRY_=%$9#BLBW!B9UOHO:3\F
MWU;J)R:8;^=^][Y/NW<#O<R2[N.:X&YJ<.&R<KT;KDSS<MFO-4=C*-N&XYZ[
M)$=-:TUK#VX*X,?.0=1LDR_QR?+#*WI\^-NRRL%.G*!35;7\.H:R[*GC;/Z.
M+)492RPJV?WF?_=.AH% '"-_671^MZ9/JO[]</8F45#W;+J3MRZ]#$TGY=>E
M!VI?^/.&;90[:%Z-ERIIFTZL?^07A_(JE9+R:*.<ZI^/96#I00<:TG^9/_Q[
M3K562:"J[<K5H/!-\Y1!-1)T !4E_"NWAFZ5%24X]M-G2K%PU=IR#6L=?KN&
M\7%.?I?<KNPL'=-NOVMW-:RSC%V*]M.9[;^VA,[?LLNOMGY*VMYPN&PD;%W<
MX6W@[A,<[K;BW%W7C+<QF+<-8/VZ;ZR39\_MIWANL X,O'-=YP=& VK@S$LK
MT)YYY?$73=+.P[*FIJ2N:8Z'RVO9%592C0>4;K2,C='0Y1. $,0M6SU6;PSB
M0QH.OGQPFF<EJ5;/[U/_ +I0F(2N^;UWJ%=\WKO41$:C@_ZVZ/UM&.0E=\C7
M?-Z[U&@41'@7MOW7QIJ0ZUEB&25Z%AI'6O6OFE_X[X9U2/XSCVUV5BA(Z5A5
M8_\ (+O_ )#\[Y(9:R>';P[:PJF8UW .E)_F7!_'FOYVNHZUU<4#G(LX I5Y
M3^%<,QIF)?%#IT+4(9*U/GCG]=PO&^;*Q[$?W5B'T-:>XC E]O;3OVR;]MVR
MK_LC)$*\SMA2/O#IF,):71:FE>A?1Q) ;OIQ5M; ]*(DUX66;KD=5F6 .RGJ
MZN.-K>-<%U"83#5L?PWA?,">Y;7[./91"'4-:D$:VK<JVOWNX/W4.UZ<PN-:
MU&M: 1IH(G:QOZRZ.MXF&IU%3'-J-:C6HT!AI(1.B3ZK_P#UW;6N@Y1M\T'=
M6G0PK J+RM?-+_QY1:RE *3UJ=!DR=23R*C48:,JQ_W^[PTN"CD263N&$<VY
M,=O0PU *1T$':G^9<'\= PE,LR[^A*)1X$3.J9!MX.OG)B/HKAFN".X95\N%
MNP;BY)O1,O#''ZOAO.B([(&^[>/MDL7;GM&P PN,N)?M@_\ T$^T* FV=CC&
MQ-O[^,[GRWI&$ !PS*I,="]T.^M[>";G=])7K+9Z:B=M3,0PGHV[<?SMJ*\+
M:M"=NI>U;8CK2BN%IM3GM,X<HUK60L8JRKA=!=JM39NN]7QWC-2"6KY6HD9>
M=GRZ2G^3O]4%#IP#L8_HXPNKVYRCXM+\P>BA^F2*)CW^F8KCA=%N,+IB;FLZ
M<M1>AJT<>S=U*1<8QA8ZOF@@?T!7;1=0&_,5N4US%,0U1T:_EW6/<=DM0.KA
M8A!-/7D023]=57W8S:\6DQ"2L [X63BR0E5$R%3)U4G]=S)G2@OE0N5#!_T8
MU_T@4*Z@EH*D4CFLJAIRU0>H7MCN3M94.$;&2$P\L&Q$;.::<,<D'Q/#<[M9
ME<V70Z^W'<,MA?&&#]TD#";;MH&YS;]";:-F>YC;M'I_;$OXEHQD<UB(WI:_
MA69F4EN@_:$?LMUUKN7-G=*U8)>Y[F;-/#H=TH- FL O;"M.2.UQW9K-0J!R
M$[I2NY4J'M>1E%6+%%DVN:S'"BPPLJ%>2RHUY1)U)VB$T3^H+6 T=:GDZ?E$
MG7E$K2$!+KJ6Q;)89*[6J"+4(5]S.+-G55_1-P5Z(N&O1%PUZ)N *0MR5;MH
M.!.W-,0X/T2P4B"OHF?$?1%PUZ'N"O1%PT%DW %%M^221B+?6*I.PB<RP?PD
MC'*=TI7=*49$YBNL>6:]486':D8<R:YA[E2NY5&H&TG\DLFW2(VG[2=L5>X5
M >Y/7=JU*VY#S=)XRL<AV<6VC4>Y4KNE-6L8^>'MBW2PK>Z;:\Z3<1[UJ;N5
M*[E2G#(CQ!7&ED+&BK3@(0PI*C7<J41LX.:V;37%:5CTY!F_AWK!7NCUW8UW
M1Z[DPUW)J[H]0UNNWZW@VXM)RTWT:IW"E=VI0$5"I+&]H2ID<060B>/AV44A
MW*E=RI3"$DI!2!ADH9E\O;:AHZ0<J3'0TT#*%E-K@C<@V+*8]N3Y\1'0()*\
M<<PW]_[L:_O_ '8U_?\ NPK^_MV%?W_NQK^_]V-?W_NQK^_=V-?W]NQ"O_8#
M=C7]_;L=/_8#=A0;@-V%?W_NRH,_;LJ_O[=A7]_;LJ_O_=A7]_[L*_OW=>-!
MG[=B%/,][IU$ S]NQ"O[^W7U_?\ NQK^_MV-?W]NQH<_;L:_O_=A7]^[L0K^
M_MV(U_?V["O[_P!V%?W[NOK^_MV-?W]NPK^_MU]?W]NQ"O[^W8U_[ ;L:+N
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MZA#JTKF"N:@$M<W6!BB/#FKFX"( '-^$!U#AK^$1T#6@#CKU .H="X6*TG&
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M*+%7X3"="RJ/"$W>*FXAEZ%=:(#AP*]XE6'4JNXQ?W(7[/V=T@'1&AOJK_\
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M,,R+&"!RX#@W\B$MMLSFX8[1;*O8J-I5T1;P1V?6Q+D[YA373:H^&'N-HAP
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MW5G\(-UUK=W.JM6X_6A,] )F\BV3&/E!;XYQJ/9ZFG$FMW:;VEL1=(1=,L?
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M2B;:K6K<W?".MN =L5;4;F-SH?1CCC%;QO4W=_=_B%CVE[GU 0S,L%D%\1F
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MF21 G.3RE=NUNUI/)%>\%NWI/)&"[::W:TD<A5R<(@9SS%1FB,,Y'(5V<P1
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MTA+_ &@91],K,;-+,6(*F_<Y>YC$(O157F(H0[J(CVLG./&S/&7$5/&1._\
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M 6L<O,X'BDY$3T)+RS6($K)=Y)/-R?>/B%/NBD4PF%4BF(F$V0^4'1OCV/\
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M:O\ +I]5%04?#Y2DJJM<KV\@_4IJ>I]M,5.-4RCN&(=1!-P@R9;PLB"6-'<
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MRX&H-R*-_'GW'!XMYQ%[SFZNF<Q9MTFC-E0-"LVC5NF5%!JV:L:*11;I))E
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M44#':LS."-".EBEV4!<G26 @&'1BPC99DVH*/H"-,.!M*G*G5(N '9 R$N
MTQ>TW.*U]3Y@50^*!A,5!-T$>@CX6 $(Y)H4MXC[&Q5V]45,DNF;&10DW)")
M3$YO^R+$;Q^9E3<.3R:#XC&2(&GE"18NS6:UCFU6 1](CXV)@#4]#(3%1!A
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M)*LII5FNZ5=PR+!59TF=@HH7=FX\N&_3LC80$APNUWE'1ZEO)*=G9-?ZUL&
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M]?1JL)U'&X2.-Q0WB:)1]J43'+?ZMKU#'Q=G18R@+ B4FDRIS@DF0-=YE#Z
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MW>M"'-KX4Q ]RDLHD7[BTU[AG?\ _B#2P6<W=<G^F&W4=?K=Q^BLK3GZI?\
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MGSSB(]LUKP4-@]C=ZF*U[ P%+<!3HG#&DH!0N#$71ITZ[ W<"FDWOO,DB4P
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MFK(.4$E"(E\6;:4,7FCUK?WD4G#0,VRKB@.DG'YR96/1BG*#A])T?*UN^7/
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M2M>JW9'+U@24*/OL0V(G*LE&G(99,^^)VS%P$'WM]H=PT73<(CQURB1\07_
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M"PB*?(13CG!OQG$I?<V DW3^$H_[)B79[R^V.R>@I?\ 8KEMQL.]3>)%$H+
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M*.X?(DT82J8!Q%Y#@/@X;=_KZ[!Z>O93^;_TBA:ZW+Z;[.Y%\?=,V+=1PX,
M:<!? 3]L81 I.R(64?/3&(V(82QT>!L2#!MX)2>R4-_#*ZS#V+@] C!2:QCP
M;]4J2)E!$0BG:QQW:J8 &A(YCX52ZM.\\':N$-H!N$.L/+8>S9G_ +I_0W=I
M'W9?6MZO?['45I*)6,DW;[$VY3-<+ISA 31I#E"_ EC\;ITGV>:73;UNHE*1
M:XHKIC<=,1\0[0O'&U=$\(AO\&FS.89 )47A38T3#B4:.438'#10WLB&\+P@
M$!Y;>GLV)[HOW5H;\T0U_@D/J]31:Y-,ZG7PE,:[O6VBD(/6.L@0?ME MLD
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M>@S62*N3"^$EQ\1=)NN/5T:N6T8V41Q.'"$D=NL%WBR(&9 N0!U[>_)[WT7
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MI>N(VBH13!Q#5$YWHDYHR#I0[AWI\+"90$\0\B86[]F'YPE^5)9U[HOW!;K
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M5F\-<X"[=J#H!6[D'3K]?JB<V@ "\;&:M3&*U(-QC7W"L.OWMK_W$?3]+T!
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M6V!A*LG*G\4FL7>]K=#<;U/W5C3C0V/S<5),4P'7*2QDTRB'9*0Q/?C9A')
M )LFB#0EWL442D#UNI=:/K"**)$9!05UDB;*:CM'=A(MC>U<H[7NDQ-9I(M!
MQ-7B"3E ]]XF37(4Q!O^RMP\DQ:/T!&_<O$$W"=_N%"F"R35H@DV;($!-%!
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MH.IXEN8P 9RQ?QLON_=H'\W&][8[ZB*B:2VX*07<>.)G+L,?*]BE]TN4-//
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MMI C5*\MQTEQ9<4.J_9W:?+RZA^@_-C8]VK?B'+BY+^YU[82\GW77LJIO%#
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MCPX-KV-LHE<KG<]_;NZZ-SY:J$*(,S6I1S)< L>4<YFX$U% F"R0?!MZ<O\
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MGYLC^3+]'1+HAA!H@UE2N2WA=O5N X79UCY,^GZ$.I<&-$Q3$'MB!1Y/3HM
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M'W<TLL_G,EJSD_[1.RIT?QSX"#!_U EL?@;J[_#4QX*&:4D>(:?]1,4V\/\
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MZ<<FWZ./?\0>V2[IN8>6M!PRA-N6=%20D AUU+L<M;]:=TT+V?5O6E+J1ZJ
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MCC/@S1D6<FV_LTU!.!UO3=[4 B)&&#*,M=UOC6@$9EG4;9MH_5(48HLQ/(#
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M2/=9]6KQ)/F+<Q$TL)M3@$2$:KKZ?-"1(VN]#LEOBK#);#(/FR.E%RUGL4(
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M1Q>O7O>L/7[E,-*-SA8J5-AA:I396A4A#/%O#.(;E*;N?Q3GH^&@';0@N"/
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M=R'1] ]"G68QR6TEEZ.L$$$ ]%ZT&1N$'2HN8^<>)&:>7'O46ORK7CE5\/\
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M:,_-(9(+G-?N?"ZJ)MSGL1<QVJ<P*K 6S !%S$+A;@2R((EQ'$);P;BR&V-
M 5/(=]ZNH5J&4)4$,I)EA2Q"5F:!(IX-R.I[14:)Q!\_P[Z2FVCN P(G<L@#
M1@)L2+:Q1$!Y)XQ#,<I5MJW9<F$A2:DM(O-LMUM%W-<,T@(<TH>X^JS2%$<[
M?RH:;!@CEU50(/+5M$KU4LV<1\ H7);>L53 Q9\UX.;U@_H1@889&UKD(I>6
MC8C%Y;@(QAO89(9&R^ L,M6,MBPKN )[%96MQ*K)@QH$P[P'@KM=M= GW/&
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M,>\+*WI%1D[K:<,;3X!C6HP[/)7JB@&V7I=<'C3PUPKJ\>#2<2MY-Z#*I1C
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MG1QBIH9Q5^."NU%^]"UXU*O46QXZ^1M"/:']HK@40@0(E<R@@" DL$\$B\S
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M8[*. 8=+Z)7@)N"5A2(9F89,J*[8[DFT%$0H_7RB5O=B*:L%BY/ BZY"9 7
MLE##).02"HCHV\"!BTMVAPD]99UJ+ :(FO0JI' H247!L1LA++#>3>K%&12
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MJN]&Y-SJQ6/JM$'14V#ME-K4$IK^8V:Z'$[J*Q("1"NF\)ICSTDDFJ-94&
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M?M?O\*=R/4GGE0&%H+';+ *6)8673$Y\^]%X@J @9CE;9O\ PD!"24.B;-6
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M\3,7C7K%6[(=.VTP0B;PPOX37)S=2<$B.$F"BNR"%I.V"9Y)+5F&-(H--2E
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M)XDM+9UR5R$.'0F7X%\'QVZ-D'-<L%=$KP_0[N6*B6!3*V:]93(3*E8XB?\
MS$I1%#1P>2A<K( );J8=6?)*(1?3!Q5L%$E9#M;A6OD[^P(8H>2P%5#6+E<G
MS1DJ5"JCJTXXE1 );1BGK+$FCXUK05!<YZ,^)=>TPE-E]V:X3J!!PTK,K.-Q
M'P!,7>%,C"%,\48G_P!S("@"%%D;14*1@  :0 _!4NE6BR77\2Q30SAX"N'6
M!YU@=/\ [0S34UZT00%P8^TV,FI8S2*]]$MN:42,Q$0WF-,!+3!]S _P&G-$
M9 9!-8)FEGIL<Y<B;;N/<Y60A:.B@&@A?)JWA F(#B9E9J=L*RSL$<O_ !'
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MJ2%[)9C6BUQZB3=<]*F&E0U"1F2WO^S\([[CQ(X"]#M.  @_BX9_$]Q[T:?
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M)>:9<2J-  2BW"PS2OA66P5:X%"63UB6(EXF,TC:LKV^I_K5M;LCYY_UDDH
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B6]M%BA<<L-"A'E:,!S,$H2S,@W$T3P@);-(O>?\ ZG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_05.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  I0    $  0"E
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
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MHK+B8W.SPV2$9:6V@E.#1%1%57#"Q$96)V>7&!(  0($ @4&" H( P8% @<
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M(D@          :T$;5$@
M
M                         6,K%IX7FLMS,?'*<PJE/QPMY*EY9V1(
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M=_6VN'J_O/LR1F_SSJ2=9=%L:[7Z2LQM'(:ZS:6\6]<2RKYMU[6^Y::-8
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MK=2+<@E$UI&$TB9S:)Q%A!"39,,\IF%%*_*GZ$5NL.F%LIK4436&.><H
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ML/G1]I\MH^VMOC1],Q\D3R3J9       $,)2B*SOA\L(CME'#[YD
M         0H^"*RBNI^>MYBQ_+>D%,W*.%?JJE3+]^3'Q@CORU^2<O15WJVN
MP\AM;MO)<L][ZUGJJX                              "#'&I?EG5^S'
MB_95=,X                  $*(L<\985GFJ#)6/':&TQ3$*.""'<E) ?/5
MVQ'.5S!CG"S>>)Y8[3RFHXNDD                            -!_.^B?
M#[WUX8V^<*[L]W70'NFO(U                            $)KDWOK_\
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M>7HE1TWU',8A#,$Q12*9ZJS[ O/7OOU#<+[K          &FN(T62]91DZD
M8 0I!&RZ9  &'B,6X;9YD    #P_=X^*=4O+.J,[N!]WT+N>U79T>NH[-IOF
MPS;C<-BKO#N&2VQ<RUZ<AZQU^]C=(^VWS3]&/0]QGLP           #P=1&W
M2)T/3'I-F+')U^GM82,75=:T3O+F1XMXC?FFE5=.*?8;,@  #QO]S^./,[VG
MY>BJ&>7$>W=@G"^\*4S[#C-O?#L$>5=8VVW?B/-XZJY/8+Y[][^H3A/=@
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M+O>W;J7U=1N;0_5:ERL6JZ&BLY?6?!K^)Z@NTO,44W]M/FOZ+>A[C':
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MP-Y=U+L>X?VU.+RL                              $F8OKI?[KV
M                        ZYKQ->-+?NS2L
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M&&'1OPH0"E[@A;44\DA,E>^W%[18YR6X1ON[@" 4XAKD6@#6LH/J5W>_+O\
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M76%G.F%FB;LN9F:"Q=X[F'4_$ZUYUJ%M*']F2",XB98K,G15-9*\AN,A*T
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MV7SCGNNR'BF60K.N-)K%DLMC*Y-F;<O)HIE^>Y8@6."\?92AN36:Y24%@G"
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M=O1J9M/G!JRW,"6^'R.324MM<E4C=Y"9>T,$DD 8R5\AD;=FUW??]$+1&W*
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M^.>GUFCC6C6I7%+V#IHD0HT7:B?F1S7R&31R(MK%(F"4MG9==:7:S32(R,U
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MQ;AC;9"<&84F7XY=D>%(QL5P]M@Q$P=X:W\X9R5D60?8/+85]@<N5]@,M4&
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MXWZA/_ENV=,9GC_$WKFI(]$W=*>RVEKEYI<\9;,9QG?+;*ZLNK;2: =XU#-
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M/X&\-ZUTAO-,+H.B4"]9*.&!E!NW9N=B9>!!#VV!0Q].RM75GBX$XQE>=_\
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MRP2'9==DZ):UQAN9KVFX%&Z<9)!L5;)T(-:XP,Q7MMP*#3+!([L#LG0@UKC
MS-6TW2@U<T;@.V>8:U@9DNVAI0<V"1N0[9YAK75'>:MKF'-JCN]6R.0:UCO%
M6US#FP2!EUV6Z):UC?U;7,/H@6*MD<VM8[P';6M&PVQ5LM70-:ZH-^K:/(/4
MD-M+LMPPUK!O5;3M*#Z(;:63<.F<.NU;3L9#1T0RVLF*DAIF8=<6;L9#1T0R
MV'29U9#3CHA[BY2]%D-'1#+:R8J826>J'N#IO19"&,JE;6F0DN.B'E4K1<)I
MT0P+U%IPDN,.),[G6PFF$,"^[5,-.,77D]8M7#0OE#T>H? 5A(7QUB7A6)>%
M83P)"PD+"'P)XN/A=/3]/B+X0[1&U"I*$\%S]W[H\@GAGX)0OD4A83Q)PL)X
MTO*2B[SCY_$6*(7P(Z43\+NCU#XS=S_3%UPEAZQ#2S!LM$UZ.6&Y>YUM/5G*
MK5#2=*_5^B.SQEJU\T&TGW=2ZH;?I2X>4:TU)&XL[;Q[6R/0D9B\#151+'#E
M2 RYIPY?1 B[T?='QE>YV_/XF7=;FM<M<M</)%.&J6')#;CG*+2K(2JP]<',
MDJZ_U1(8.YN6*<Q-SL='J\1W1ZA\2)Y=W/%+I@XP7%N'*8:ZVV>M3#K+V]3E
M=)8I8.OA-VJ"XM])CN3ALLZPVO:F)P+#K<AHJ,I\\545=)^F ^B8TJ?I\%SG
M'J'PZ7P2]SM^?Q&O>)MP.I>33!+QV;\3/1+#'$)!RPGO,6[4TFBQ9OTZZ9F6
MN*M<)X3T>H?&937 2'AN*166[0,IC#SP]UD8D:1R\L6W"UU 1UM:"&MMMF5T
MM^F'=G-Z:1).F*0W:^LHU:HL/+$.U5,2U:?5X;@Y1ZA\974UM^?Q ##5;+ZJ
MM^MK6#9NV:G#!U:8\D;AX6TR;3+3,Z5Y(0>%!!^6CXE7RQ;<^?Z#&/WOPQC]
M[\,8_>_#'^]^&/\ /\,?Y_AC_>_#'6^]^&,?0[\,8_>_#&SC^]^&'7V?*71\
M4FWEVUD<H'K(BG,MI)YCZB?')BXRYI(U_08Q]#OHC'[WX8Q^]]$8_?\ PPB_
M>_#&/H?^&,?O?AC'[WT1C][Z(Q^]]$(#][\,&Y:/1/\ 1\)3P8^!/(M:^3=<
M,RC;-9>"CJD73A!MV75C6B3_ , 7+%\TEHV'3DJK(?/ :#7<O=8SDF$O)81A
MXN$8>!?B2?@E"0P#&TM.'M8Z(/\ @#9E"N^.S_AG_]H " $# @8_ ?"G@4^%
M(32?#.$\ ,3\"PFF)Q*-F#R1.7Q,&-Q,/>;9IM)69;*X>>&FU;+MXJ833&*<
MQEG,YR(#6S)CN6[.]^JHU+ZIQW)MHF[]73@OJA]TVB&V^L5&RN$'.,MDVVXN
M4:T@9LM.[=@=>B 6Y9VUA,3],.?EK1>&=9-'R2#W.R;B8HDHN!UHC=)7ALKA
MYX[RYJ6R471!;8;41\M,/N6+9<VWUN18#[#"X.D#K@=\M&VN"P79&T;M.K])
MC^HL%G.D!V=LFT'8*DX[SF,NYEL^U+Z8?F,M:+V,Q(T1OLK9+VZY15F[)M@:
M21#<W<MD6W]5VO1!?D;)NIBB01E,NZY3C@$CNM!W@E1IC=9NV;;CH,-OWK1:
MRYU2=/R6#F;F6<+8Q<H1(&=N62++L'Z#-/7*#G&6BZRW%^C5ASR@7LKEW7&'
M2"$AS\O:+Q;ZR>S\D^'<2S5J_P!V<'VNTH%Q-H#J$354Z5T1F>!<1O\ >LIF
M&M+\Q3NMU0"YIH:BJY&_:P!7/--O8X*UARMHE?>L5SEQ]D%'*FA#&3=Q:S50
M;O\ 4R;+=W-FAK1I 'IUQ:9Q*^>*Y>T7]B+1L;O!#6QM3L!YN6&YV]='%LE9
M=-&BPZUM-%* 5%9=$TB]9R%X9[*VS;[(L%HY6<MH@.>73Y0GGXW^7;3=L]U=
M8$_9#7W/D3IE%C@5HT&S;)NNQ0D!S>?H.GDBUO<]WU*O]$6J<-0"K\T<*:S.
M]RK%Y3NA=J1^$Q)%Z8I;E]^.*U[Q];6H+5=.RLU.I(S?!#<1F44-%+,2[%4)
M\Y,97/9]V\N5XH&Z]#0!Z(XIP+BIJR[-T6%!V1D?90E>4GU@MREOB6Y5K>Q[
MN':<:T]$7,KQ7-AV2>UM.5H-6(7M&BI%"SYHRGY:X0P,R>#K>.\KQ5[@7!%U
M^B49O(96Y_;[CC;+,Q2ZZ"$4MH*C21BOFCBU^^P6\QV!#@6NJ5\W(B"1CA5^
MLW79HWM\$8-YN[@I'4V4PV4Y8S&3X'<#LN&,7(N92;(0*EZX YRN5W(H ("0
MT?"9^4RG_$$<0O9IM5FX^TV\W6*&!LPI]I91DN&9@^[WJ.UAU1PT1G&\/OO?
M4V=8U'3Z4Y(=G;QW=O+BJLX D&GU:BD<+_,^;OB[F+POMN.:U K+98U @T+[
M(Y=<6?ST/]39T]:>7)]7LZ.F+_!\V$'$7-:_DW;3<;@FG41&<_*C6=KEQ;KF
M)FZ_>8\VH_1%_P#*UK,M?9R[0;-JE'UEU95TI*5FXZDCB+G7C5;?:I/U5NVY
M".%6.#$[D@FV0FV327JL],UUQQ87LSW:KN^_>&.?3M,W>R-<NKK4QD[&:.]R
MF992]QQNB@ %R!=DIRE3K,6_R[E2N6R(V=9-T-N.QGB=?T1_>+=T6'YEX"N
M=4QCB"DG3ZV@:UCC=UFW;;W5SAK%Q5^LDWF,B++^RO.NNLG%6[MQ=)2?:2<<
M?LYTE^5;1,I*;T32BC#".(OS5PV[=3%("GK !.F+7=KKKEL7"E00XE?ETQQ:
MQPRXZZ]K[%=82F:BE=" T]$9^[E,QO,T&6OZ:DAI%+9UD4R$^E,8X1D^#./=
M=K<HFTKAO,?G.G5!RV6<ELMVV)+W%6GE0J/IAG]X>;C!=TK]<)ARQQ*W9;V;
M:=ZT[I&LIV9NUM^KC%]V;S!R[!<6H-+O;:G5UF49C.W;YR=@/8%#77*B'C4
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MP?JL<G\33%[)[S8S!:7R;M4.J;-%"'5%C?7%[LN[V6R5.2>&E8=G,R:G/Q*
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M^F*KU@CI:?48I>$,#+Y9M;W8#_.!WIHL,UU6WIT"Y\\3XA/_ ( _GQ5P]PS
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M@7(@02$\4B_PO\O6]W;N^\N+5O /U7VU;S@B$'P+9"Q=XWG3_5%JN=.063
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M[NY<].[_ $Z(,'/Y]]%D8E''D]D$^B*6"C*6SL,D5,E<32TSU'#X+F+Y"TL
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MI35&J-4=YXCF*!^P_P#V6F,UFK#:<E80;S&M0?9+0\)%^U8>=T7'I"E)1R?
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M.A/\ TNF(0?^"G__V@ ( 0$!!C\!^R.8AQRX? &"\0U=P!D/ ?3C+PAGVAF
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MLV3Q<_+3*8#'/ED "&>)& J&X=)M$W$Z@E(BO6>&EY%CRQT*&<,V+Q=0H /
MPY9 /;QQ#(VBSP5>5L,B2(@4YJ59QIIB35T\N/C@=K)<Y8=09)IZAXAPXXC#
M6JR05<":DD(:(&;E&49YG+.L^1',.K53YJQ\O"F3,1Q"PLK-Q,=+V-9RW@(Q
M](-FK^;68H=4\3BF:RI#KF23#F* F4P@'$<2%=;RT<M/Q3-A(R4*D];GDV$?
M*J.TXUX[9$,91-)P:/7!(YBY&%(V0\!Q-1C*7C'4E75&R,^P;O6ZKN%5>M"/
MV1)1 BAC("J@<%B H :B#J#AA_7ZCN'2;/.Q0&-(P]?M$/+R3(A3BF=19FQ>
M+J 4#>$3:<@'AZL2,U VB F8B&=2+*6E(R78O6,8\B<QDVCUR@LH1)1OD/.*
MH)1*';A*ZO[/ L:@X9QC]O:'4JR;P"S.:4:(1#PDLJL5$Q'1WR!&Y@.('%4@
M%$=08@D)^QPD,M9I-"'KB<K*,F)YZ7<EU-XV(!PJGU"YPXE32U&'N#LPUKBL
MM'I3[^/>2S*%.[0+*.HN.6:-7\@W8B?F&114?()J* 724RI0$0$P8GJZRW*H
MKZ>K#9X[L4*TM4(ZE89M&IG5DEI*/1>G52*W*F85Q.0.7I\>6#W=U98)M3B1
MA)H]I6EV25?"(43*LE)#+G6*AR#%. @IKR'/AA-5(Q3I*D*H0Y>)3D.744P?
M" _<=KXI2F2&XC9Q5;(8]18V,*NJ_,B#I0KKS521B2$Z<2<P0,J74 9<1QM]
MN)6*V_VMOM4LJK6"V^=3JMO>61.9DSM'M=<NF4C+]0#I 3N2Z%#"0HB0-)](
M8V[<M[2^&1]X;=!JGN19XYTJS>-FZ"CL?8UCGH4:)M^+8"@*9A'6/$#@&-S6
M-,M+Z.+)0%><J[:C8UI(K;DVB$1"T-4)*0>/T=8'%$YP,"9N=D;B!!+:U*YM
MNXV+GY>$B(^.M5DW59.VUDZM^T4?5UBX-9),63AXDD)2*"1 W'3J)Q$)Z"9M
M;C[OUTD]O9M!"*M%A&7HDM)($$@6I.T/'DL1)PB8P9*D, %  '@8V2M'+:*_
M>Z!;I)I(1Y[2WL9KA1]V7CV+4.F9\_\ ,I1(@+<WG(<HH"45?%HTD,3W<MUS
M*N>A4G[?M];SJN5#(%B[!<[ WC'3K48X_P W5$3:^X"Y=^0W'<IPU>2K6T;R
MU2DUJ-2?&8A)5FK.EV"[9D[Y[<$@>NA.05<RES+JS]%A41V>E-J%G9X],R4E
M=4;D,TFW*X,4Z*C:=F2H@ES<A^)JU]^7#>I-WM%+[K)LI*I@D,=>4ZF$"16L
MP^LPI+3D2*W,^-DF!\M'9QQ(*L[,G7%=BZ_5_8VNF?KG-,699VUD9N-,9/G@
ML5%K'HME-9LQ. <1*81QMMN-'1:PO;_=*,D^D234VF$A!2\>JJ=H9HE)$03$
M2D(!C(IIF 2]N>-R(2ILU(F,9TFWN&Z)7\B^5266C7"BJA'<D\>+YB(9A\H.
M7=C97<FE.I2%MDS,U&.GVR4S+NV=M;3@\IZW>QL@]>(YE*<QB<I,F6K/+@7*
M>D7VR4U<N3NG:$AO:6X:4,RBTVTZNHF56O'L;(ZI6VG,0*W,!^SQ#P%!_0ZA
M;/;QGNC,++[F)SSAE7$(2.E16=L7+5:3T*ARRBF9(K41,(Y!JSRQ<=U+G,S:
MMV5D[8M'S:4Y-,#4]."%3RYI&L&D@W;I%2!$#&*=(?7W9;9V.S1#W=V':4,W
MM'0X&X^06AH_%\X8-+PI#-)"/7<E<)I$,4Y!/F(\ [\;%P324M4]73J;HUR5
M8VY5RRGH\OE^:U<D56JR2A@;@L (J\PQM)@TF#( #>QIT1(MK0FM;D:H\D+'
M8",:X]7CG;E21766F?E$P50*J?J16*&CLRX8HTU>XJ[5VP/+0B*>]E:MBETI
M][+(OEC-F\@0)%XBFU<%,1+3TY#>'4)?C8]UOEKJD!7WG:$FH":AT@53&,L0
MF25*0P 8O#/2;AP[,>Z;#2FUSC>F,>S.[QW6VK=]6F03IV]*8G;.SC<)ROQH
M]((\\.I=$[!T9FX8:4R'V^C_ '5)#>?<%GMDPAYZR4./;5UG9'::=SO3VPUB
MRST6@1&$:/5TSF?$,50$2B!3"4!W:V"A+I%;AP&S/O!;45"OS499F-H;6/9V
M[;@5:7JO63T2]<D=:$W[V)>>,<A:"F;+'NXO]E(P*,PW<N]AVXW"H,"[?)5&
MRPI:9-61A9?97JE&;=_$N8,FE\V11,*3HZ2PF*8A0OFY4K2*^_OL62AQD=;%
MV8!.,V*VXE88*M6[\IB'(0Z,BLB8"B&951*/ <L4?W;VM8CJKLF7:2>WJE]N
MJRL\K4'N+>S66,J*!K6G$NV2D@UC6K8JW0JG.B<ZY3+IG  #&X^Q]$.Y9[5.
M-GJMNBUIQI*0DXJC6U[:I*N.VU=2D7;L8]I)MT <= B)$"G;&.F0@"./?*3.
MJJ8B-_VN*B0ZAS$2(;:2NG,")#&$" (FS$  ,Q_#BZ[[M%9!578[W\KZXG 3
M7<G*;;.[MJI3;LT.B*F@4DBR+=YD8HZ.FU%R[_>-W,58/+' 5[<'9#W>Z; H
M/BHHS3:%W&KLYN8T9=4[9-BGD9&12C3K**D()6FDQP* XW(/#^Z2^V)-*739
M!@_C"RVU3ASN7'+;K5E)S6&ZM#OEA(ESBJ&;B#]5FD;J0U'T@<2S<33]KYOW
M98I'9@)"R;13+V)7;;ENWEH(SA[Y",Z78+9 )EAP:+,W"Z#Y-V<SXI%$>6 '
MQ[\[-5P[Z138?8-N=%%XNW$B+^V3#5X9L<APY1S$4$-9,A[,4/W9[I+2+^Q;
M3>\Q[MCZAV61=*IR&XVQUCOK8*G+&5.9,SEQ$B16 EQ+KS49%4/GSM6-QK!,
M>ZP]W*E&/O3[D$3WS6E=L1;5DL=;$U&0BPLMVCYP21/A$4VT8KG_ +R50<5Q
MV\<G5TVW=HZSITN=0W+2W3N0:U5' B8  I?RA#( [ Q6O>2#=JJ.#[B[URON
M^+[9DOL,K+06R6HM1V_LSNCDDU'3916S0RLRZ7.EX&\SJ,)4RAENON/-S#QK
M0=V=T=\=NKHH_=*&B(.U;21<=?J+)I<Y0Y4A=Q#J<:Z":0,9L7OQ[TDU=7<P
MC*;^4GW6]S+1'&?O45J[&[K^\"*3"N,2BL M^@A%F;(2%TCFB(&S'/$=[K\S
M,27M;4[!NYMYNF]0=*$EU:)[NT%)VIG(KN$LE2EFVHU<H+@8-99(P (YCCW4
M/=QM6[,!M5'3_N^1F[ETM4_>8VD+H+P52BXK:B,:3$N]: N=S8GH2*R"9C*"
ME"F$0TGSQ,;_ -EJ=6L&YE=V2M,6O8Q00>/ZU>JJS=1]C&#DFZQQ33\R8J.V
MATSCJ353.!A*;,?=8D=L:1"UQ61VOWRMDO&5]H9B2SS<5M;77C(\DD@8!74%
M0,BB;4;Y01[\%]Y&Q3,R[WXFMII7>%7?0MMG6UI@;HG!/K"S)!O494C=E%QZ
MR96989ND1D*2/+40.(GS4][1D$T]LU$]W_W8+;NYM\PYG16G;+<2HS#_ '4:
MMX8H"4LC"+%3GV DTF-Y<JWR-S (/O6S,5)$EX:4]XA.1A'Z#@7#-S$R&R^T
M#YHNR,)A#EG*OK#3E\8>_A]SM_>'LO/@(#D(" 1CCAD8![AQM1'PF:5JB_=R
M:6.GN2&T*MK- VN4D(L4S*'*7QG(*61\RY*<0RX8WNMS)%$AIJ']W/K&*Q#%
M3:3+:SN6TG&."*DU_)KIB4P"&>D0X8HJEBJ&W%9.INM02M%J*@=-=ZG_ #XY
MQEU%8UCGEP.GI$W:;/+'LK'KO%Y._P PUJI&\(T/,2XQ2QNJL2K./:$5.J8K
M1!3-/(-0#EC?7;9E&3<)"L+!2K95(*RQ3V'DTZ[-V>!:RB!64D'-%)%REES.
M("5<O9QP[]VY8%0C:C=+/=';8.9R@V[;5]6\0""AU"#S$U7TPF4X%/VCZN-2
MN#!,YY?;?9O;^[L03 #**(Q-YD EFQ>/Q5&JZA#Y_D]F*%O$Y5_HNU[@71.$
M?.$Q("5,HL T8-7!!4_WI0XN'(>$!R/ZL5?>EY$VY&3M&X\H2R3C^LR;>KFV
M[LW*KE?:I3YD@;*)M4D6[@AB\1TE)^2&=(BPJ]=*P=[=6-^[:!!QAFCM[UZ^
M3M=H+<Z9E.&6L0$<;Z/-R8V$?3K.X6*)F"3R#4R\)5HXJB4$VCP7XMVA$4P%
M R.@,BER'+++8DJ58B;TNG6-TF\'$VM\@BT=UUI95$HU91Z]:R.H$2@H5N(E
M-F0"@ Z,AQN;*1Q25Z\TG<J8N;2(;)E1BJ38:VV;NSQD0HD<Y56SAH4-:F1
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MK*;A$6YC0[3S!(H'*0=*2B_.,3+,!#!]H3[H5):L&,Z4376W J@RZ"[F<5L
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MY $^L32 )4"B!^6': CA]+S-SVR?2$E .:N]<JW>"UN8!V)1<1I]$R0-!A(
MCP <!*0L]M2S?)M56B#OVWA'"S=!=,4EDVIG$VKRM1#B4=&D<A'CB.I8VK;#
MV8B7;9_&1(7J$*@R=LW!G+9PW.69 X&(<XB ZL'GK#/;1R<FKR^J<K6^ND.]
M!#1R@? E+IE7 ND/SA3=F$JS-W;:Y[ (*,SHQ)KE746B(QYP.RY)$)1+2!-
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M,RH(3J1?"5, #@'8';QPC(2<QM&Z=HMV+05U;I!"+AO'E*#-)^4LT0'&@"Y
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M\7"=,=7BL-K8K+Q\ G7%I=FE+FFY2*>3T;$@R,KKZA=G'KN4DLM1DTC&* @
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M\?'Z2A_+)?Q\?I*'\LE_'Q^E(?RJ?\;'Z4A_*I_QL?I2'\JG_&Q^E(?RJ?\
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M@YTNMEV>-&"DEBCEGZ28W,CN< ,7VXEC?JH@BF83N6TO)MT#Z] GX)K"7(!
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M\,;;P@=CV;G)<Y [S1D>V8H&[![II3]>656>+PLC$,[+6(Z88*2+YB_\TUD
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ME4A64#E"!=0&#QERSP=O&@$G8GJ0$F+,Y;D2>/NPXMFQ"F5Y#<#%\*0&-F(
M)A,/' ]W'&>.W\6.W\6.W\6._'?CM_%CO^X9YB ?@X>C,!P\G(\A*7?E054)
M9(UF55M)N1X@%AB@4;E7 >("J0R:H9YZQR$HU>(O$*=NW7B;2$7/L#"\@)8
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MS"OACIANP>MG2T5( F1864BD@H<45=)RFY:FD<C9Y<0_4)U53E333*8ZBAS
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M-I^BD*BD4C?PB7- H$R)P,(>'+MP<_2M]2@G%0W)2S.*A 34$XZ>.HI0 ?2
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MGAH\K1T3H=9S"L70 I%4#/L'%/KWM2R\YO\ &^=T]CRGW,G(LB0*F=-3])H
M-/854R9AX\!XXM]E+=(X82@2YH&X2(-I/E0DP5Z$>=@X)T(G.;G#H^1*H&8_
M&Q4:L%I9C/WR(//U*-Y;X%)R((V4>&>M5!:E(4O*2,?)0Y#<.S%IM'MM'>04
MJ9\@L\CTTF*41+\TJ(L5TP8\PXZC9:DR'+Z\5:HI6AB>QW:%]HZO%<MZ*TQ!
M],L[Z]N;IM!2<IN<P <Y!$"]F+#<!O$:%;J<RG7[!*]+)F1BY@ZQ&Y62Z?0
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M3%D>=TW*T9(G'+FZN'9V81O8WJ.]D5YP*VC-]+*@V--F,8H1_*&/YFH<NT2
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M-.7SA=M4->I1/243<P@"&7?AS*^TL)Y8R=]"[D/,V?1M7HB0O1KN.;I*IF<
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M&97QV7,Y@(Y!^<RT^OAAO.>UM=\F=/ CV\J$PP\O</Q,)"L4'G/Y9EM1<N6
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M% @$*  4F0 ' ,6!I[)P(M+2NBXLC<8QKR)U=%4RJ2THF*62QBF.8V9\^W$
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MF2'0 :,\O5V89P 4ZN!"Q[\95A%!%M>A:R0F,8S]!MH$I5<S?G X\>W#^>&
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M&K#/S3<-@$7<78*O-<VR*D9'D. ZG( TFRS3 @_M4:&-4& QNV[\9.EM^<^
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MQDN9@U<<_G.5#&U9;5QP;DH,:'MYO-O1-.ZH>O6GH9&IV5ZNIMI(Q,:WKCI
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M)%52";&\/N^S53CVVZ5NLDZ_@H(EHKKEL[9/?9?IES3*$DHS2U>5K9%46 >
M9Y9ACWDMEK34H]CN'N$K(C48A*T5YXVD2N8J.:IBM*LY!PV0S.W.'RRA>S'O
M$;(;@Q,13KG=+15+;0S*62&F(Q[(U1(CA)M).H!S*<A)8Y3-Q,(")1.!](@7
M(=PO=7?56CT+;MT-@E$IN2G*[+6BRJ.A3?&ID$XA[&^01:OW+<FMX]10%,BA
MP _Y(>\WL?8J/',[_N%,U][3(PEOJSI"60;N891]SI)I*JMFXI!'GR!PJGJ'
M++&YFU--I%)E(S=YY)1MFK1K+6E[?7&;B/;1;Z;@)0;(TC5$Y%H4S51,ZJJR
M7+U%3 1U!9PW'!@WW W!G&DI*1$<\2D4(")B&:K6(BEY%JHJBLOJ<N%EA0,<
M@<PI0.;2(_<X^^5Z0A48QC4(VOJ,WII L@=VRE)M^91,C9FX+R],D4 S$.(#
MZLQ\<1_!D>_X8X<?&B_ATR/]78_.17_Q3^KPQGS(O\$E_5N/C1?#L^L_QCY?
M^#'YV+_!)_L]!C+FQ8?>D_VH[';$_!ID<OP>7XXFBO\ XE_5V,^9%YA_RC_5
MV.!XGL[PDLNS_D\,,X.:2 KB/;&0452*H""AC.G*^:0K$(80R6#M# !^J8?>
M^X6>_1]PCB5D&$5"RM>:0JP4UUUK,PLWM=?N#ZA, +Y+]GQ=/?5;!N#*W2$E
M*G%R,.R<4^0AV/6L9!TF[!.0"5@YG6**A#BGHY>7-/JSX8KGNOOI"TQ&WU9:
MUALQ=0KV+1L1RU4Y5FRSEV\BGJ!CKGS4<B#8-0G$2Z<*;3T>3LDG7E9::F3N
M[*\8.I;J9U-%)T0J\?&1:6@H-@Y8<H1])AQ8K_09^_2LQ98-> ?M[3)0;R/2
M:N91M+**-DXVOQ2@'ULR  F4.&GNSXXA?>%LEAOS*Y0;NH/&L?#2D(WKQU:4
MX17C <-G-?>+B4XMP!8 <E$>X2XDMN]T:^E8JU(F(N"0KN&;V.?M\^CE(N09
MG150<(B;,ARFR',2G*9,QB&9NYBT;M6J 8.3+MZG+66*;1AP,<HF;NW,- QS
MC0;+(XMU&QA_?!B;V4*U4K=&F:>M1R,JT#:/4B($[(&!$8<%$'*:9DT@ ""*
M9PX<0'%MA=N9JX3#2Y2<;*R1K>^B7RR#B+:+,T",S14+# 4@@N8QM13CF/;E
MPPMN-(#:J%?7QTU)FPT.3:L GUT4.21W)QDBPD4>HT@ "X;@@<^CY03CQP\L
ME*8SEAO$BU68.+O<I!*3F4&#E0%7+*+09M(YJU(H)0!0Z:'-/ITG4,7ABN[A
MWVPWZ)F:U"-H%DVJTG!LX]5JSDW4H0[E.1K\HH*G,=G 1(J3AZ!P?:2[25AC
M:XI(0DF+RN.6+66Y\$83M"@L^CI%+2;5XPY/P987V'JLI9I&IN$K6D>0G7C!
MQ/%);CNSO]#IC%QZ :.L,"/R'#(-6KOFF-OW&W2@92T$;GB+(:6,\L<8V:"Z
M3D64<SK%3!-PU> [*5XB];K@/)(*8IF 1&RM/=^L$Q<I27-'JW"VV)G)H3"R
M28N?*HS2\A(1!NB05%3D;I)ZQ$=:@GR+I^VX=O=BDSU-K@S$5"5^092;HLG#
MM#-W*\B1PFCTK^0:J'U%XYIE.'#TXXU!SV]GF$+P]'_YCC_-!?\ YPAOA_\
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M==9HYQ)P]_/C+-4]O!FNLT.M?\X^G.:X->WZXN^?Y^GY4W<<D\E??=]G%WU
MG- (:TW!B%,%! [$0H@H["(CWE3EH5)7J5)O;.G"";QJ-,"4591.;<$B:VW4
M[:VU:[DW4*-394<#:A?!'8,<1I(A-<TT5W#J=H/6RH35$V(6E)-[<M*Z%K@
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MZ"<4KJ5%2""\"W>)-2]CPA0PIIKJ8W/2M$) 3/<URUPO'WH*UG*_[XR5B"?
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M@1CXQ<DZ01*-#9R/1M@OYT+R?0HU336Q3$S1N.6UAH!!V.UP/RB)00?5V%E
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M?#-.7\X0Q\"Y]FA!_4X:A#Q^E1Q4@N1Y,6V@ 0W[H#W4/+E2]MICR1OV??6
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MWG=Y0;3(!$#26;#@KG9Y_CX:Z;?&4][ERIS_ &ROD#L\4&K^X7-N2*HT78G
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MS/4V=M]?IE@:&%PX#>#B"SN=\^,X#[0JN5>)\!OQ,5:B@"ZZ.M%H^QH88U?
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M(1G.0 'L(*(V<C2.FJG3H_7(V'W?ZQR+C!16R%'Z8V]*)>0(6H\*[XQ*(>%
MT2MS=+<T/Z/AY//^!SI]YX ZGZ(XI2#QT)2@B<MBK6#IBBB0J@JL :'( )K)
MA0 J$2PT',XQ:VQK (!<(-4V6M++(+K0S;4(#22;R#)R"G%I):J\"%8U;KE[
M&NYXQ<C8&W=HC>MU-\Z28OM '@!#Z!9G' ZGWS@N*4!68D=HPI04ZV8CR *%
M4=D&B##ITEL*41I)11<_" >7 'UXCCKPZ]L"$P*AF\[#?;KV+CDWD+3[?WQP
M-'K\?5C:/L22=.3KE,TT8.FG9'<!WPLHG51UBJU_(K,LG@V#CC?_ $RQ\X6.
MDQ0'*@7]&8R!>(WJ3*IL B5V@^$:\GZ?"LGYJ6I'D#@"3:I:^] 5.$)#QA >
MBQN@UA=W.SW_ "W)O4#=?,'+S[W&&1CBFB1KTT[Q((&($8Z^L#[G%J<O0SZ?
MIV01I,*!P0:VS],$-=9MZ?!$YQG7XD'G)$,G0 6KZBSQ,6.-W?8D&CNL+I16
M7[4WU4_C_;/R05AG24A_4G9RGLY!29RI:K0@0@@3:H\[-J:2(;!'R0=8!S5!
M1XV#6EY'KE<7M^^EGU6=92Q\O?GTQ $/57A/ZTP ' 8J>N7KK%K?\"['!L?7
M.YK<U,%!T2IHB"N5AD\Q+EFM:ME*%T9V1&P,1&NUDV;B(#[Z"%HEL\',WC V
M]";$V6G%U]=81LYWB(4,/*'*YS%E(BI6VZ=0F2Q.%&".Q4!=#?#GES?@",)4
M, +$ #E70>^&-AIM4!.C+F!2.U0V.@K=@ 1!?@V+7+VE?'7F^F+?,O'KD%D'
M2@PVE4+Y5T*4>8=!/2%\A[!4Q2N!"&'N.(/.>#\BIK+NSIP2H"&FSV X<>-0
MX=M_2F;(H40*3%B!8^F[#\\TW)05':'J*$^^SSF@.5=,M&T"=>#";3\%BCWY
M25>7\I!=Y4N>M-@$M41B3C>;K@Q94!]UH>AYS;N_X QQ1J!"=C;3K<_5KB^:
M*H5SL]R5G4C^2H&[FP$N2,:-]\6" PL=@RD! 3N4S@/0U,\(X- !.,=H[,4@
M8Q+=YS@Y4C<9-?X4F$!R%=76AK0LH6&]X>='5I$+'>^@'=HZ%*I!7!P!H#@P
M!L^# >7(/)BEU,?B,=;P;UM#X3AQTT@3J'<\9X0)DF<>/I^"7GO-;Y'1Z4#R
M[25UVXNZZTCL;HGN/'UQ'6DV#DI>#1?$-8>'!^<U )&,3C2(^R(\(F0%,$::
MX+\=#[8JM;?R#7X/;X<ZS?X#D >3U/CSQGMCY_!Z8/\ @\8/SU\#7&+Q%C3T
M]L=;W[XNOR.Q.L5>?\I"Z*HD:U%YE;++UD#?@3!T4@.56 >^ S<3I !K2B<+
MSA/OVQ8UB<^F#(=<GOB.HA6<5AUYU@^W5QJQ%'9I"A!N'_8E!B-H6J *Z70+
M@0=?MF]>/EQ@6B"6V:C<0>@%E0!15!%)'G+=ID"=G1,P!T/=0]<J1H2J2\'R
M:9YR1#0Y?&2QMXP,O?.'.:QKEK!$U_D#QQ\^V?+\W$./GT_?/366OOK*3Y^V
M'KG5?]9WYSU<9*SC]\WEQ_;/G]L.,X*X^<H?+D7YYSH<Z^??_ /3-_/_ #)K
M7S\_/.2YSV/SZ8SK7/\ >=3'R^G_ (QA6D/>9D0[4L.NT,.0 -X0MQY) P#5
MPN2,!]:I#:$MJ:@%*J9QY8<*)*@WAF> D.2&BZ%9)P:,K=P%LI4+J( B[L>T
M4"90 -!J+1F$*&A:R:JDD$2<"8%LA->(WM ;@+G9RB%U2CE!67(B@7-JKRC!
M$X:1G:F,K= &@/;M0$;I#5/( P]X<K=Y;B@07"5L(^$RX:1$]EP!!#Y+#:Z
MI7('*!%A#)YJV]/)6 *=0ASQ[7C"!T)*W1*(M:/'^.$XR:S4GTS6>OC./GY\
MY8USK(_/\F']?IGMG_3.><XX^?&/SZ?#K/3/3#],O^_7_#ZF;N'&&B'P^?\
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M=M7BD._2@=CZNL']:@YT;M3H9RS%PU.(0[]"(=CTKK* &[J4^5KX&=S$4Z7
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MLS)$1M!FBN(A25UYMUNJB1P,NZ (*OH\Q6J8Q5M>*$ J50A5#.,@!0Q4%>5
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MD6T/-V^AZ9=^6A5]Q6>8HF17E@O>'=BWJO.)-5Y*(<<OIA0'040),6.&WQK
M)'U1T,4@%4,#2Y:F0  %+H^)4!!:KSN1:+?B_,Q0-( D>-]%JTUDJ#<XO*;+
MZ8)B,]@?5?#SCO'O-7OI>,B0< TGD!FV]W"C88=OLN<JMG&@Z8_"5U!4*CA>
MD%,1 08$$TZQ/,#E68]0 ]L'U"0"K'NTP&KO>*,9L##%*)'%4KY<;&65LW-1
MD:Q'$L* WN)7+:%-I!TV21O)MU6:XU@!I O@@P)&^M<9UJQC>(T(F":DRX#J
M@A VZ <!QG(N!!%'E1WZ9#-5#<5V=;]\790AJPUO?"=,;E? P#0!%QWP# W2
M@=RH*XNQ_0E[$1/OCN.LE,8,H290Q-T#M4G5$0"N2.O$JZ#0+[8X#>?E!JFQ
M/62-1&$A0^ 0*XE._:J@//1@*2F1O4[X4] TJ*HHM< T/1;.R=7$M0CQS="/
MGTP@A- ^^OW,TRH11*.1CTGC]CDX'D%!80N_1D-\N-A0J9LKC@/+IW/*\9J"
MM<>SL\;EV^E:L\8LY#KV\SZ\B>(!NG->^Y[>,#=^"0U9QZ\[ W]8U]$Q X1P
M."&N-3.#X]G"=8(Q_@ _SY,,+)S1M>6S<53)'@X?KO ZV,,IJ!D'(.&5 KHH
MKDS@S[(5C2.TTMB0C65"*AI-:<!MJ[3:<&RKR&54I$A]QQCBU#!+^BO2N703
MHT0:731:34"$, @IJ,33[/?$#$!#1W1'?&NL6O<OM'\Y0JSG_CG_ #']_A"6
MC^0H2[8W;>.$]G*^/0_CX-T^TVOT/;&K(37B^;$;UW,EU(E642 PQ/EC5F*-
MGMPY&<M/.!JCCV*@1U0#G#PO=G9)%:,$0(@0/.M!P9CH8+@H;&,3 6=KR[U,
MJ!)S=NI^WC!$@'/JNMOX.)-)+Q9HQC;N&BAA-\,F//JC]B?"-XM3ABR\4_3)
M#&7:ALM()!J'*8]")F#$ARZ3FI,-YJ(*XT'\F)P.H/3;W/6_"T#^4WX_&
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M?0E:K)LD)>I\"OTW5JB*1&MYEXPH$8=#H)HZOA!:N"7V^&I:WW>,!V$;*FF
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M8JW:4R0FE3RYHI&,=K6G0FTCD7)TE$80','1RP%>(M%ZPD)&O*F.\I/:G,#
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E7I_[7+W?3USCQ[G/'&.?]5P__ /'O<\</GZ8<''!QQQU_C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>linechart.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 linechart.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$! 0$" 0$" P(" @,# P,# P,#
M P,# P,# P,# P,# P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
M$0@"4P0! P$1  (1 0,1 ?_$ 5<  0 " P$! 0$! 0         ("08'"@4$
M P(!"P$!  (# 0$!              0% @,&!P$($   ! 4 !@@% P0#  ,
M   " P0%  $&!P@0(!$2$Q4P0%!@%#46&#(S%S<)(3$B<",T."0V&8!$.1$
M 00! P("! <)" H-"08' @$#! 4&$1(' !,A%#$BE!5!TS75%C<($" P8%$R
M(W:W0%!A0K4VEA=Q@=(SDR0T)94X4F)#L[34=:7EIK;6=W"1H=%R<W27>&-$
MA8:GYX"R@V3%)A@2  $# 00#"@H'!08$!04   $ $0(#(3$2!$%1,A @87&!
MD:&Q(A,P0%!@T7*S%#0%\,%"4J(C,W#A@K+2\6*2<R05PN)#HX!C@Y/S\E/#
M=#43 0$  @$# 08' 0$! 0$   $1 "$Q05%A<1 @\(&1T3!08*&QP?% X7"
MD/_:  P# 0 "$ ,0    [^       "JGL(EJW'RP     ("=+KX9OT=SURG
MRNM#Q"ZS#3]
M      JI["):MQ\L     #%]RIWM46;F!0%ZC4=R_P";^ADM5;0
M                                            !53V$2U;CY8
M PW>K=ZM CIHM#?IE)=+Y].N5\_GSAY[?ZF/T
M                             "JGL(EJW'RP      !'FT0.Z/';4'11
M9Z?60OOM':%^>[_?U;L
M           %5/81+5N/E@       04Z-%ZX6M\6KGZJ)2/Z' CM;:K=.(F=
M"WEEF                                                   *J>P
MB6K<?+        &F)ZL[K4V>?2_HWB[/G*A[33Q^M-?4)XW;3&HMX
M                                           JI["):MQ\L
M #X\E4':+ N8;I@!4IVT/G#]<J/T?>MKPN[F30[P
M                            !53V$2U;CY8         UE+0"Z9O6N35
MY\! 3IH_+5[33=R'YPZ$
M         54]A$M6X^6         !Y&:IWM$TJ!*>G <]'J597#U4;LU\#O
M                                        !"Z^T5X]3&%EO)RI94FX
M?%]<W7K-7O2LV7O><6%-O>0H'=-&VS!SL4Y638MRLJJGL(EJW'RP
M  *;.[3GYU)RH>AB'$'^C.>LYXV9>7YI9;U@9_V
M                   "M;K(M=O51K3^+ESLYV0-*3L*Y>PB:#G8= /F=C'^
MSUUU=5&VC!S@YT<>VKAYE-O=0ND_RNS           P62B9=/+S35Y]EFEX^
M:J;M(5978Q(MW6FT;C9G0#Y?9?V
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MGT:NVM#S$8[G5?=Y=9W<^>S_ -_@
M  "+UOJT+8ZX=W^BRWDY4LJ3<    !53V$2U;CY8             QO:K:ZQ
MFD=-3GVP8P  #0=AAQ5_HKGIG\_O]''[?QY;9SXYF2
M                *\>GC0PO]%DW*RI;T>X    "JGL(EJW'RP
M   /E^M!6;0UDL YD   /.R^>=]1UM-?"%^E^<[%_!;VU+BY8
M                      %='4QH5]!HM\X>9N^NV     54]A$M6X^6
M          !4]VBP#F6X8(    ?P<27Z%HMJP<^M+Q"YRG4R##Z
M                       .=GU.LD-6;+!^7DR9I]P    %5/81+5N/E@
M            :3L%??3)L\^D?5/H^    !1EZ+7UO=;%JK[F#;9PD[K6\/N@
M                               *SNLBUZ=3&MLXF9-"@W@    54]A$
MM6X^6               ,<VH5] BQ<+..1;<A/JQ     <EGMU-L:+E=?YY/
M&Y(&S?5;L                              TS8:] V>N(-YINBX"<
M !53V$2U;CY8                U1-0HZ!C^Q9UR+U,     %<?61:Y^NB"
M@_TJNL*Y>39;QLRXG@IVY(68                           &$2,8[V>N
MA?TJNZ0?*;3<T#,    "JGL(EJW'RP                !KZ4@WT+P-J9M
MWO7      ,?S^<T7K]535WT'I1\CM;9.(F;=A9@
M     51]K#B)=Z;%.6E1 O=%X7G<\    "JGL(EJW'RP
M !K>4@%TK.XZ8U$V)%      0OOM%&WH\".]IJ[(?!KL
M          #_  CO::M[UNW!9.&S(F8    %5/81+5N/E@
M    #3,]"V_3:Y]MZ"      \G)QB^_45J?&RK_?,;,
M         5M]5&P&7A*:HV[XK-NQ(F0    %5/81+5N/E@
M     8))0-Z-BV]85R[9$5^GP     ..WWNBA9T4>=7,2NMGPVZR+7]
M                    UW*QJ*[:'_&7RTKCI>\J[8    !53V$2U;CY8
M                 &D[!"7H'L:VSHB<'/     !X6:GSNH5(WH<#M9_/]X
M                        *,_0X&W(F7^_%M_$30//R?;B_L _#Z_(^SXJ
MI["):MQ\L                      00Z-]?Q-CGWV8@    !Q5?H"CWY7Y
M7J>:V4^.:D?;\                        5S=5&@_T,>RSDY4S:#>/'S^
M<T7KM5MVOV=#'E]ERS>RU%V_GD^K/LHFMI>/3OY!:U4]A$M6X^6
M             ! 'IFA+)-"@91I;<@LEU    !2#Z' H"]1K.W+\Y]#LF/\
M0                       -4S,-K0\P!IF;A6YV,30T[#H"\SL:Q^MBP Z
MB-L>+EYOU:+QLNFWNH72?Y79@                      #!I#!)+4LU&&X
M25J6\ZUN."_T   %.7=PJD>WA_M\ 5F=A$ZI?&;:X/A)P
M      B1=Z>?/TZNWE7Y]$_EEGE6G[_)0'Z;6S&H)&=QLH^6NK)-/W!)./RY
M+H> G54]A$M6X^6                        !\F3 Y"MOK&7:%DO)O8P
M    #25CKYI?7JG2-AK\#8[._P _WOLX?0                   *CNUA[G
MA9R<I]NXX&SZ_@    54]A$M6X^6                          (\6B(%
MZL6Y5F&@     !Y.3B5_1%!;5PD[:L3(7$\)-SB-D                 !Y
M>3F ]=JIR<]OEE3[9^\S)     JI["):MQ\L
M  "/EHKUZ=:?QK/HP     "/EGKB==:1 /J8M#?IM;=#Y]/Z(/*;3:</,
M             "+UOJT+8ZX=W^BRWDY4LJ3<    !53V$2U;CY8
M                  CU9HEWC']B<'/-U5[[<7]      &H9V%3O;PJP.NB_
M5C]K*[&'WR?F7I-C1_H               A=?:*\>IC"RWDY4LJ3<    !53
MV$2U;CY8                            _#ZK]Z=\.3$-S]_B3-0D%6,D
MU      !3EW<*I'MX?[?  K/Z^)U%^/6H L YB3)JGW          "+UOJT+
M8ZX=W^BRWDY4LJ3<    !53V$2U;CY8
M UU*1>N$-[U95R:0E8         ACT&B*MYH BS<Z?)V_.C3R6U
M  IY[J%'^TU3JYR18YRDH    "JGL(EJW'RP
M      !I*P5U]2G?S:254          $=+75P]?H_G?^@A^6^G $,[_179U,
M:ZWSZ=XV38\?+!=WSU<7[_%!?I=?<AP,[9L7[DNK+&MOR/\ 9:H"=/'M;XJ9
MMF)D(77VBC3T6!)ZHVR?J-MK_%3     *J>PB6K<?+
M              Q#>AQ>M<RV=1DCJIZV#;T$        !R6>WTVC+#7VC> 7
MH&BK'70KZ773?YR1Y.:/-GKC#>Q[*^-F5R];%^KX_P!U_=$66NQ3EY."RL?S
M^_-P5^S8,7+ZRY/@IPK6ZR+7;U4:T_BY<[.=D     54]A$M6X^6
M                        !^'U&"W"+5RR;2F90MLP@        XQ_T%07
M@><V(MFX6='FSU5$=U"VU#SU[(QV[7[,SP0TN].0Z<MRP\O-^MLP\\"D8S#H
M=]6W:PY$T^W6,S"9E#OLAY24*Q.LBQ<N],@JS9:YQ<P    "JGL(EJW'RP
M                                ,+WJ]NH^6&\O]S#0        K_Z>
M-&6XTT&^G5O:'^>N@V3'^@        54=G#BA=Z;'>4E3IYR0    !53V$2U
M;CY8                                   \#8K5ZU93R;(-0
M <P_L%3&.UU^_K^@  "U3BYET/!30   (77VB@7TNNF;1;]UP,[D^"G
M54]A$M6X^6                                   !KV2KAZM)>I
M  "7M&^S$           (1=#HKAZR)<UP$_<,',    "JGL(EJW'RP
M                             /R^M92P      A7T"P;EV0:P
M    H[]"@VS<3,JF[>%=OYY/     JI["):MQ\L
M                      1$O&F)[]_C-HR<O/          !6CUD72-GKMY
MX6;D>KZ!'^SU[-AY9GHRT38Z\\C98!+P_+ZW]5[:J>PB6K<?+
M                                  JR[%-GGVXH+TL          J2[
M:'HFQUV8\G*EE2;AC&WYSX^HUGU8?>BORRS@?T<>KCLXGC9?+D.#G3 H]U5/
M81+5N/E@                                            1?MT;K9-
M_GFTH8        "%/0Z*C>VA63\G*LAY24!J67C5[VL+3DS&_P#\SL:V^KB^
MYK^[C@;*)?2*Z\+SFPIM[J%TG^5V8
M              AM?-[UK:4,        !!#IHT ^CT:#M-5VOGL^65)N I"]
M#@3%H=_Y$%.FC2WH]WCY/ER^6I\9,JI["):MQ\L
M                        :/L44KE@$E-OGT@:P               *J>P
MB6K<?+                                              $:K9]^*0
MU6               %5/81+5N/E@
M             #3TY#2_>C@ _+ZS:.G5S@            "JGL(EJW'RP
M                                             /@R0"Z989RX
M        "JGL(EJW'RP
M       /@R4^=TD-5@ ![6M/+FP         JI["):MQ\L
M                                   ?!D   _T^[$         *J>PB
M6K<?+ J5[B%N"OV6%<O)$/+W3%"[T6Y</-CK::JXNLBVK<7,J+[F%=!Y_/K9
MZR+:7QTL                                       ?)]4?^C5]EW(2
M]'S]=AO,20 ,9V?(?7^B<_.2          *J>PB6K<?+ H0])KM53<+*^3EZ
M$LM>G9^O+]7VX'@IU)_H4"<7.R*+?1J_J&\<MJ<^_@ZSEX=''E-H
M                               ,;V?*0?1(&M)F&SH6>\:S;G.G[$BY
MTS)HM\:;75*2FW4M>AU]J?&3-72\?\+N?/IP        JI["):MQ\L#EU]CJ
M+_\ S"S@MT4?R]GR.-MJSF/E:)Q<RHKNX,NJ+?5)VD._+S.QB#?Z([6NJ_CS
M*R^SX                                       QO9\Y;/9ZCI]\<MJ
M0/0H&K9^##[N:%EZN'W]]64NZ/=!CJ(OA9O[Q^_I]^=!?F%D        *J>P
MB6K<?+ T19:][UNP?/\ 6@[/7'ZTU;RK=FP8N4&NDCV'\K*K*[")9;R$JK?M
M8<[N9DR*J=H                                      'S_ %IBPU[O
MKMFB++7$.\TS$H-\3[W1+ZAWU\=5%L.Y.5!?I8\W>=D:$L]64Z<I;T>X
M    54]A$M6X^6
M                 *J>PB6K<?+
M                              %5/81+5N/E@
M                                           "JGL(EJW'RP
M                                                    /Y*:.^@S
M_P"8DR:J-M3_ &L.1=5MU1-PR+5]L*Y>353V$2U;CY8
M                                         $#.DC_!G\KUZ>->1YS8
M5(]W"U++P];#[Y.?R_GS.QJA[&):?Q\L
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ME/4;0 (J7&F5=/N  $0[[1+RAW@ 14N-,JZ?<  (L6^J4]1M  BI<:95T^X
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M>21=3MF#1;_T^
M
M
M                                                  *+_1J^]#SF
MPIY[R#:EQ4W--'T :"L=<,[_ $6D\?+  QO;\T?8824JM@  TI8:ZB>YA66<
MC+EK2;@ *M>QB6E<=+  QO;\T?8824JM@&@K'7]!DVG+9\3(
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MC$M6XJ9%>WU9OK>!FN[\\G@
M #!)./\ )]WQ[VG*,=QIE+3;L5WX_D:WEX[$BY?I\?E]8;OQW=7[(O7&J2%3
MMU]+PS>-EX>SYJ^9ANRNV1KM]4F:C;^7U^7UC^WYJ^7AN*#L^++Y^GQ@LG'(
M-7W)=.6I9VO9\//W]7WX\G@;?GP9_-*V.O;-?L_/ZR_1]PZ1CLV'G&ZVU2EI
MMV*[\?R,WCY
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M$" ( NF8G<MH-]2M$X]2L\>I6>/4K/'J5GAN/;WE/Z8>X],/<>F'N/3#W"U
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M!*HLXQ9_D]@,7F/=Y%_D+?\ )[ 8O,>[R8P)1LU:,4_$HH\2BCQ**/$(H<
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MYKRU:-2A-U1-JT"34  9@_3CSPIRF&>H20<H,.IUX(+U0A$,2YL6MVJC0*W
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M-F)0H$=S5S@I2I3C&J4F3*--(&-4J,.$,8QB<7 1?[0:::>,1QHP?TB__]H
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M?!_0 [X/Z '?!I$?((@&A'/0,802D>&<X$,()<<.V<Y!EX@,2GMCC W^Z,E
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MI0) +G,1>H"9P8)$/BZJF0>'+]M1-*4@!V24ZI7\QZI09'!+V@-U!@".1Q8
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M9]\L_P#CGO:54]!=T+W4WD*N7$98W#MS.WERJ&NM3O1YG_8?K3LAYHU)@+*
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M.%0S'RB$ZDID:SV#$EVYE\//_"4Q\I3H9FGWM"JV*-UUQ!UA=X(UY-]DX6/
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MJD3HP")YW(7^EG5,\%1L48@?IRU2/E%HR(6TA&9L=8Q)K%80NWX*I4J0,\8
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M%WF:IM'6X(Z"=WN\I S/0.,FQ&$KQ8A" <FP*/OD,.-VM!NON)U[R4\M RC
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M*-29>1M)-[ZUW,J\S&YL19N=.%WE:1G(Z27/.5&G.1,8;()+![V&C]D?_]H
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M4B*$<'GC<%@%&U;304+:F@CZ/0G4]UNK&3[Q&.VOF^^P@>65XDV*@^.O>_\
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MF/&$ET%9#S;*$J>*H*N$.O0F!(8&B$)"J$)"2:H0JGI1?O"=><!IL$U-QPA
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M(D30J3:D0%IZPKU(_JL^U_Y3W?KVN&N1M.1!+37M5S(T<6?)K&M&]@EY&/\
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MC-2\>KX;#;;<9ER=4W,?N=IM!%-[EBTBEH&JZ=0K!GQ9G1(\MK_V)#0.C_\
MS_A8TW->/\)R^;#86+#EY1BE%D$J+%5PG5C1G[:!+(&]Q*6P51-5UZRS(:;D
M^EQJHOLEO;FJQR%@2C#Q^MM+25.@TD08N1PVD:BM/BPVC;30Z FT!3P2TM5Y
MEKWTK*Z;8*PF#26U>2%&=DJTCGTJ/;N[>FNBZ?DZY*A\B9G6XM)N+O'Y-8U/
M:GN++8BP;%J0XVL.')3U2=%%U5/3U M:Y\95?9PHMA D@AB$B'-8"3%?$7!
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M0,(GY*UB>;C39A"PB:F+4,$FXWO*ON@&KV*_*U!(V[Q\%T_A=:;YTXGBFX!
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M*QF/4K$A--"2@_'DO=U4U7O[?0*?A+7]<^,?VB8U^_[4FXK&IS[+78:<<<D
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MMU'^Q=ULQJ4[&[B[D5^-O[>\NTT)*I=8[QO]H?B^UP/*<CN(&-X[FN,@Y?\
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MV)]QN2R8,H3G'^U72$U0==J^G\G7<C/LR&]5'N,.@Z&Y--1W-J2:^/XH6O\
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MTVS)28$5(FW;^D0$]'7$<7(^][Q6@F3&DD$1.#2V-];V.-!ZZ"J"-;*B" _
M*(GP?>]S/X%#.QZ@DM9*Z63#$6DK7Z=MYYNVFK8*C C'$C<WO>J.FY?1JD7C
M#C*=C/*W)-W?4(X74\?R*K+IM#Y2Q8.SLCDTAS @LK%!V*:FXUX2-5_1H2IB
ME-;R?.6U1C5%66<O?W/-6$"KBQ9LGN:)NWN-$6OPZ_>XK]EO%9K\9G(6V<OY
MFMX!F+U#QM6RF2"F5YHV]CUN_L91-55 4=X$TZO7VS*:HAQZZJJLMX^KJV!%
M;1J-"@PASZ/%BQVQ\!  ;013\B?>\&V=H\W'K*[GK$9UB^Z*FTQ!B5]Q(EO.
M (FJB+;9*J(B^CJ/18IGV!V-Y)< (-<O9KILU\M5!FN;LXL)7W?4U[;.\OAT
M^]<>=) ;: G'#7T" "I&2_V$3KD3[1O-6:XY Y"Y!S"X^C46T$KC)L:P"K4(
M-3!K::GCV<E@24'(ZFTS^D"('KGZW4K(N.\EQ_*.PC$.QEU9![RB"2$]&C6<
M=]IB4RB^L38O "+H6GH7[UI;.KKK%6-Z,K/A1IG:[FWN=KS#3FW78FNGITZX
MR^S=A-32PLLYDR>$=S+A5, )=+@U%)&?8V.]D&C;W.1.\BIJAM0)(+Z>J;&Z
M6,$.GH*J!35<0$1!C5]9%:APV4T1/S6V13[WF'C#GJ6UA6>6F>W>;Q<XR.,$
M"HSS'I4:(TR]6WFU0<_2Q7Y;3*GXE.)L$[XNMISMS[08],Q/BSD?W'!PB'.K
MBIG<H*OC15LLRCU2@VHQY;[+LIIXT17%G'_&1S[W[)F*YIY=S )-ED]F<&QD
M;*>RR:.U'2J:GQG!%IU1D-PFFP<)S=YHFMJ"X7<RVYDMQH=UA!4N08K<"TT$
MZKGQ;JNCFQ7R4)DV^^P\XSHV::*HGH2@B=<:Y=.)"L,EP3%+NQ5-=/>-C1PI
M-AIN1/#O.'HOP_=,$,VU,"%'&]N]M214WAO$TU3TIJB]<<6E,S87N:7W/^#?
M2?D+*YKEWFF1&Y0Y8;Z3KB1X@R9Q&S\LPC36K8DHJ2;NK^^($<&DI;6W(%UT
M,:V"_,4%V^/CV=/#H^5+1D+#..5\FRN]R3)9;;#EG8C#R&RIVXQ/B**+*.P'
MWNTFU-[YKIHJ=91C.--,U&/\K<5!E5E206D9KSR.),=-9XQVVT$'%6KFO+IH
MFZ8ZOI+3[A@AFVI@0HXWMWMJ2*F\-XFFJ>E-47KCBTIF;"]S2^Y_P;Z3\A97
M-<N\TR(W*'+#?2=<2/$&3.(V?EF$::U;$E%23=]SG/DY\+/+.0[VQQJ4.79=
M-6XLZ&NG\GXZK&/XP+@ U7PX\><40!C-@2M>H9*/JIQW^HN)?R!7_=O:!FXM
M<?=NJBPJV[VB?&+=5!SHKL9+&JDFVZC<AGN;VCVKM)$5/'K[%E3@U(, K'/\
MUE7MS+><L,BR2<+^#.I.O[J4IO27$*8Z0(1; [I(V((NG4VLL& E0+&))@3H
MSFO;D1)C)QY+![5%=#!Q1714]/5KC\G%<4J>/X=).&WJO=4"+2-TK,)_SYRV
MA: =.RKBN.%ZWBI*NJZ]2Y$@9K=%:\BY;8X6U//>\UBW:J((!X(@I_CT&<I;
M=44U(D]/W:G-L]"SRR/CU='BT.$W$U7\#KK%M^P<DY >-H M29CP31:,I7>'
M:P'JZHFC?Z]91_O=7U7<B<@2,&Q^TB,?1VHR[,IU+5%$;?<>L/==99W;[ -F
MXK9N*+1(9("ZZH/AP5<\+>4R,>.7)UER?R/B[;,K'0K$<9>KZ&9D\,#8DN]M
MJ2R#8.NZI8:#X=S;]SG/DY\+/+.0[VQQJ4.79=-6XLZ&NG\GXZK&/XP+@ U7
MPX\><40!C-@2M>H9*/JIQW^HN)?R!7]8K]EO%9K\9G(6V<OYFMX!F+U#QM6R
MF2"F5YHV]CUN_L91-55 4=X$TZO7VS*:HAQZZJJLMX^KJV!%;1J-"@PASZ/%
MBQVQ\!  ;013\B?=,$,VU,"%'&]N]M214WAO$TU3TIJB]<<6E,S87N:7W/\
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MO\J<>U?)G(K[U?1XW8Y?3]_C[CZ%(0:K'FF79NK+C_EP=?'05T$"-!=<?3K
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M@(B*)HB=3F,:Q^DQUBTLY5W9LT53 J6K&YFBT$VVG-P&(Z.R74C@CK[B$9(
M[B71.F;/-..\+RJR8;1EJPOL;J;.<+*:;6/-RHKCB@FG@"DJ)^3J-5U$"%55
ML)I&(==716(,&(R.NUF-$C TVV*:_FB*)T]>7?$G'%M;R31V583\-Q^5)F.C
MZ'9INP"[Q? I.[E5$1%\$3IBOK8<2N@101J+"@QV8D2,TFJHVQ&8!L 'Q] H
MG4VIN*^%:U5E%?@V-9916)U?/A26R9DPYL*4#K;K3@DHFV8D)(NBIU#IZ2MK
MZ:HKF BU]750X]?70(K::-QH<&(VRTTV/P  HB=6F50,:Q^#E%XRQ'NLDATU
M=&OK>/&!EJ,Q:7#,8)$@&QC-B NN&@HV*)^:G29A9<:X+/RE'PE_2"7BM+(M
MBEM*JM3')KL,C-X574725231-%\$TM9=/25%3*OIY6EY)K*V' D7-F0"T5C:
MO166BD/J((*O/*9:(B:]6#>,X[18ZW;6,BXM6Z*HKZ@+*WEH RK2P&OCQT>D
MN(V*./N;C+:FJ^'3V6MX_2-Y7(K$I'\G"I@#D+],C[4I*EZZ%A))1NXP#G85
MQ0W A;=43J(N<X/BF7'7[D@NY#0UML]#%S^^-QGYD=TP$O20BJ(JZ*J:HG6.
M3(V(8O&EX?'F1,2E,4%2S)Q:)81UB6$7''VX@E";?:7MO!&5I#'U214ZDTN1
MTU7?T\T.W+JKJOB6E=*#_8R(4UIYLT_]H5Z=L<*X\PS%;%]I6'K"AQRJK)[C
M"Z*3!3(L5MS8NFJANT_@Z=I,KQ^DR>F><9>>J,AJ8%U6.NQS1UAUV!9,26B(
M"3<"J.J+XIU*J9\&'.JYT-^OFULR,S)KYE?)9*-)@RH;P&VXRXV:MFV8J)"J
MHJ:=0Z6@JJVCIZ]KL0*FG@Q:RL@L;B/LPX$)IEIL=25=H"B>/5K#H<8QZDB7
MLV797<6HI:VMCW%C/ 6IUA:L0XS(R'GA!!===0R-$T)5Z<PJ%A^+0\->9E1W
ML2BX_4Q\9=8G/.2)K#E"U$"*H/..D;HJUH1$JEJJ]?4CQ#_\M<,^9>H5#E>%
MXOD5+6HTE95W-%6V$&M1D ::2NCR8S@L;0;$$[2!ZJ;?1X=4$6IP;$*Z/BLF
M1-QEJ'C=/'''YTMKL3)U-VX8^6?>#U7GF=AFGYRKU(H<JHJC)*67M\S57E=$
MM*]Y07<V9Q)K3P;A7Q M-17Q147J9A=/@^)UV(62R%LL8B8_5-4-D4L&VY16
M-4,7L/JX+(":N@>Y %%\$3J)35U?!@4\""Q60:J%$8BUL*MBL#%BU\2"PV#3
M;#;0(V#0"@B*(*)IT.1P^)N.HMXW*\\U:,8=0-2VIV[N>=9<" FQW=ZW<'0M
M?'77IUA]IM]A]LV7F7@%QIYIP5!QIULT5"$D545%314ZCT6+45-C5)$5XHE/
M05<*GJHQ27W),@H]?7,1V@5QQTG#V@FI$I+XKU=7=3C])5W.2N1'LCMZZI@0
MK._=@ \U!=NI\9AIV43(R'!:5\C4$,D'35?_ "1__]H " $" P$_$/\ M)A'
M,!\2FZ;/&'4A$1L,X#,4 RCNH("/GCCY8"8.P13O$/U\3[;1<N+ Z%.YS.N+
M) ;>HA(:IV.3L,@R6"B^JQZNT,..R Z[?KXF+4%%!2SHS"*:U-M$[ACK,A>L
M$@%MF'"E> A(%B$>7ISG](]S:GE/&!R"]"#&H8[@3]>DP:PRE UQTU,1P%+0
M%#QUBCWN"EA%.2/'L]&41YYZ^7:)W$8ZO1M+2#//Z])D -#D' <!TYQ*6Q**
M3KQK'2W262S'Q($#8BU/!Z+C\:;51?5<I>>XW(<'0ZHWW%B^U1@2]B*'&EZ]
M?UX3M<V)9U&\/;.G(@12G'3OA,XN=.V>G7V/P>(*(FQ$X3!+,B5F"!?LYUO+
MB*KVP4^H[/?!> SH4\GJOUV3!.B<)I,1&RZO(5^6#I#<ZXL.OMC6CE@946D.
M@XU,(L$63"Q".5N7 _QC6H+K<N<HT+9;-[AI;K?ZZ)NIAI:7C'*IB1CT<?+'
MTY*B<J.%O4]QQ@@!$0(TLTB/G!\BX&M+D615G81OZZ)IE$IZF7"/"M;M.W8Q
M_P#1-DX]PO8['8='+E>F\<#%"PKHFA9>!]?TJ;"IR Z$36[GC8/&P5@95H0-
MCP WS.GM0-BZ,;E4 I4"P#?(E**K)-J]".F$-GD<BN*QD L 4NUE7JYQ,7C
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MUN)B(T$WZO=!U'3R&'&#G::5=1H<Z(+R^P5&A,)#"UN(6D^;Q":JY@9M/3O
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MAI)LH"VZ,*- (@0 VP5M5[OY03.H#H:Y\F\LD@+TH#^<A38H@SWK,UMY@!-
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M6F_/F-5 KJ>!P?HTF^N)/E\\,M+F@N^TQIHH+T5G;*\@+QR:ZO:9Y?U/OB5
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M-=%.,2@ 6[H&W(8CPB!V*([IHWKE;92*\P;Z'0X.GZ1_='\X;.,8+>Q,%'I
MW LXT$=->F?ML#^T-0.J*(>57L9PZB^:R$%U^^&56HPI2B>O3TU9:[P1>%B
M;.AG(Y3W_=DA3FUE;.^5L$#XG5_3*48IA%\70-CB5!  '+N9'5!'0U #NA.H
M[0$"1<E!UPO(8/KO#_K524@HO#1[<(?\XG0,ESHLZ3EXF"'996JYX ^092V
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M>Z/B2#J='@'2F7X)2Q!W0B>B]O=XHIA77+X#JNCKBY>JXQ:&!.60ZONM=!6
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M2*AP<OS_ %3\9X?\Z"1V.39)VAOD=X"(\31YO&,N,9^I_C/#_IWG S1;-;Q
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M7  DO7TP1*?E6P5BPY9.OC.%+W=OU<MW8H^IR?B?&>'Z'=ZPXXK.5Z/?"$>
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MVAZ(#Y7C-L.&N@]#V?&>'_P'XSP_^ _&>'_P'XSP_P#@/QGA_P# ?C/#_P"
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MDO@-=._.:E I(SS@#=O"5>O.(F$$/"D>3OBPTE>4/!YPU\\$;/"&(DCI'U3
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MBQ.?5)BXI+#C\T.W<RR4!_7@9O-*+X0T@A(V4]<JL6*COLA)$BIEQ^#8O&3
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M\4;X"1XP&A<39X)04.IQ@B-2E!!RL+)I:R]I 'PT=5_0B'&%7&H)*6EI+2!
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M.>?B4#E,)D_-[6)@:Z(>'KK*A&[O A#;&Z#7_)$/\-.'U)Y*T$F_H >V&0'
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M<\<Z%R=7BU@(F)-894MFL64I>R(ZCF/VV /A9#LZ3@ ]9((3!.!.79]=OW^
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MKNRB "X">\G3ITZ=.B@$!728-I(T >ZG3ITZ<B)ND, &@(FW;]].G3ITZ?\
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M@)2-!'JU,@?="\KD 7/%,?"&<'"7R")HYUZ8I[JU[K\[Z[QT"&#\=B G +*
M 1OW"(V?H5+#0F\#V)P)0I%I_P /Z/ (]S7*\U?2()@0#EE^VQK ((@1]U,_
M(3:!CE%Q$&70@G;Y.A3J!#W.KSTIJ0"1;1%B$8FFMP1RB"> SU%=(KC11J0]
MG5YZ4U(!(MHBR_)EQV7%=6ZV(Y2,$'<>,A$(>U>\C'RT\Z *3@DK1,*,W=8
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MYJL9&,63@!3LQ$?@   "'_ZTH]V6%AG9-R7LP@:+[DCQ-*@0BJ1S@#K@0*D
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=Y)C>0B(XR$>VADQU%\17-\B?E[8V(!/_ ,B__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_06.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      !  K@    $  0"N
M 0 !_^X )D%D;V)E &0      0, $ ,#!@D                %  ))1/_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M 0(" @(" @(# P," P,# P,# P,# P$! 0$" 0(# @(# P,# P,# P,# P,#
M P,# P,# P,$! 0$ P,#! 0$! 0#! 0$! 0$! 0$! 0$! 0$! 0$! 0$_\(
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MKX^5R       .FAS2[,                    Q2(RN9      Q6)RJ8
M #$89=(     #$N>LMZY                        #$^4YG*9@
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MZ;Q_8;%Q6?RO4U5YNR_/T/@KJ0  :$D :$G0$QD<-N@-$70-#1%TT"$Z:$D
M:$EH20    "3E)!)I/FT79ORKKIH26A)!H27592:)NS=2D@T)+0 4F+LB2
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M&ZM<<&K![T,O<0JMX_K:OR:+[_0>$=R     -"3H"8R..MN(          :
M26A)!H20 ).8NFA)I/FTW8ORG4M  D@ .NVDT1=FVI)DYBZ!H20I.B["0:$E
MH!)!H([HEFONCNR]YQR=;2FK#NN\C99X]'6>CC[VO4H5LR-Y[J,B=XQQUK[+
MIY_2R=5YFC;>V>&G(ITY%6KUQ;N'31SZ.8Y7>VS*)<*QTW;LU>?]]6GOJ8>@
ME;3\_7/P<SVZ:L^3ZFKL.J_/T7@1ZD&A)!H!HBZ:$FOTQDL3MP
M!H!):$D&A) ).0BZ"D^?3=B[*^B2 -#1%T$JNZ2INS;4D@  T)-)W-V4I(-
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M)(-  DM"2 -"2T)(!2C-INO?D.NFA)   "ONE$3=>VN3F+H&A):$FE"+KI
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M*+9(CS5-<IY2:L^3ZFKL&B_'T?A'0 !) &@ $5^GK)(C;HD@#0DA)S%TT)(
M -"2T)+0D@T)( T)( %)\VF[-^1==  -"2T)+JLI.BZ]O#0D@T)(!2=Q=AV
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MM68K[[?0>'+N$D   !H!HK],Y'$[<&@$EH20!H $EH!):$D "3F+H DYBZ
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MB^=JN/"Q5;'U1HC8&6Q;:\ \[?K7T<>9X(VOIJ5&KH=]'?9B35KR?5T5AO\
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M20JWX_JZLQ7WY^D\&,]X#5?HW,Y/0IV!E]/BT>/O+F[ ,G70ZJ^^JTY]HRZ
MF,BYZV_/"2DM  DM"2T-"2DM"2T D@#0D@#0D@$G*2DTGS:;LWY%UT$G,70-
M"2!392>5V+:P  :(V=*A2COB[+H    &@NJ\[O.WVFNH^!WVFIF:.TZXP#'?
MW4<ZZ:,BN\SNJ-V@^*]D33D?/HG&3+[XP1/>W=X/QCXK].QHSZ_QZ,\W4=#5
M9DQV#53JJBV?5>/G3WVF#G+-S),U.4W] $G(1=58\GU-78M-^?H?!?4)*2
M  T)-?Y9)$;<2   -"2T D@T)( T)(   T D@  T4FSZKL79#KIH20   KZI
M*ZNU96 - )+0DTG1=A(    2<IH_//Y?NWSV^=3O!NV1ZGR_WT>K\O.S4OH9
M[6YJ=%47_%W5ZN^AY7G[X/O=)[M&NZ=-VO,S^;>;T[A_1^!3##]19NWY?M,^
MKUV]/ LL@#0DM )+0DR<Q=   T)-6O)]/16#5Z-_1^"NIDYBZ!H!) &@*_RR
M*)VZ  -"2  T)( #0"2      T DM"32?/INQ=E?1)  !H29564D3=FVJ3D(
MNFA)!HI,79$D&A):$D&A+/.BCJQ%KCCKG[Y[C-IQ2W.NZ./G5C>:O)]FG->_
M)UIYOH9AONQ-YFQ\OI]'U249](V>MO7T_)^#/HLC96JZP!H!)  !H!) ).8N
M@JUY/JZLQ:+]?0^#'J0:$D DYBZ  T!,9'S.W)  -"2    #0D@    T)+0D
MM#1%T#127+KNSHR'4@   -!592:.KLW4I(   T4FE=B)  DY26A)277H_.WF
M]#<]6;8NVK[?.OTA]'Q9OR5A_0\RH/@?1:N^E\S?'CVX99U:#;Y=O/!]3Q"^
M@XL_AS_)GOROU\WT>7Z-2=F;<?=^R_*C4/HY\P[CYO)OQKZ+#ZE_,;?&K9DR
M+?Z&W,>#AL[Q_#J[;V,>.T6^O76&;H2T),G-6?(];5>/3?CZ#PCL#0"2   !
M7^620VX-"2#0D@ -  "2T-"2D@    T-$70- 4GS:+KWYY=1%T#0  DRJ[I'
M,7:LY!H!)  I/,79@DM"2#0DM#0<7^+&6_>W5NL-=&L/-NCZL8_XM^ZO;\R[
M6'9C.G/JG!M^W;DWUQ1\O.G0F;K#-%.R:[MR>MFPWS-6&::,]CN6?O66NO;A
MK'/<58[?ZHK?S/7Z?0I%APV]NG4/G:]S>QDVS1=;#O& 2<Q=2<U9\CUM58]-
M^OH?!74M"2     5_F,CCK;J&A):$EH20  :$EH!)!H26A)   &A)DYBZ:*2
MYM%V;\[Z DM"2T DNNRD\1=>W@ !H20"E"+KI  :$D !U7^/>;7]4QMJ^KL]
M'/8Y=..6Y^^BG3?6CUEKP^4<>[@&?S/0#TL])O.]W=NSP<.ZU[)CO%ZZLQEI
M'M=F,V^;^75T#0DR<Q=-"2#0D@T)( T)-6O(]/5F/3?CZ#PSL$G,70  2<Q=
M2<U]=9&G;J :&B+H  &A):   20  : 26AHBZ:$D&BD^;5=>_(^I26@$D&@"
MNZDL1=FVL   : I*792    T))3?XNY]FT9C,KJ-;:8V;DT_5=%5(NW35B]$
M]>.B/G[]JW\=GWW67B<NNI[Z-.O>N>]IIX>=?0SAN'=19F_ET]   #0  D@#
M0DM"2T59\GU=$8M'H[]#X2ZD  ).4E)  K_,4B\O=MK5QFDU]!HI[RG5TBGO
M(]&7/E:\G3R.L[[RN?0QFIV3)V4ZIW9#BSI\T?!NC)?.LGZ?/0UY,B;(1VLN
M+'._0YN<W>6URZ[QY/3<^CF'7E5 IV7(NRQD<ID2%L#J=<P0^+J=3-Q^\SB$
M[B)+F'S)*GG,W!XZG;61(@F%Q,.9=W)'7-7;Y@]-@8^]R[JK*1PY "A*3GF,
M=/J'Q,)* +OOFBJ,=.>3GHZYXX[:! F0IA<R="($M"2B2%$@Y5MQZMV^;KOQ
M]#X2ZD   !H!)"OTO)?)]!JF,&#Z[M\::]M>);HOK+<CW/)P?Q/HMC[\=7]>
M_;7C^5C>[O=7G^C0/W*/7+Q,%<K?1T=FQZ?S>OFOL?/9?/H4,G?Z+4^3C'7H
M7=H\3S;W:/J\;W]B_6^']OR?J=+[6/I)C&)]KVVR? Z!GV;M7YEFTQF-*RR\
M^JRG*YCZ+( KNI-*[%"K*+4:JE,X)%N=(DI$TFHLNQ'2T4R-09K_ +SI>G<3
M.T;L["K9XH8[=GS1VVWCU)[HDYBZ8  "(S,XY 2T13*9C$,!3*B)H(Y4]@@)
M1!))0P$,"K/D^IJOS=E^?H/".P-  #0D@DA7^84QGIAD7Y&GAB>OF.PLK,=F
M>:9UMDOY]\?3FHZ.OK)K^LHRQJ_71G5KKL4XS,YC/&M]$Y77H^F^O-\5.'Z+
MOAB,DO87Y_61ZLWQI[FN_ +*M29;KKWYE7=J[)M\3^XLU9W7OU='ME?\?G7F
M^HDNJRDT+B8-GACZT]SYNC =4Z\]#-8CRJ^:[-[>7<TG5W92DM'DIY/L5@]:
MC;.?BW^SRKY5WI+J[I#U-W>ZP: 20  :$EH26A):$D  &A):$D&@$D&A)!H2
M0DYBZJUY'J:LQZ;\?0^"=2#0D@   !7Y.2&W42CE23H)<RN[)5T^)WA^GJ#Z
M)Z%V>75[P_7I\GU/];Q*OX?HM&[N=D8L6Y>^^DR<U@WZK<ZZ,@QY/5S;04<,
M4R<P3T#LYC1II/3U=B_,[)Q?+9IK3IV=7@^SK=E=OE<]>D)564DF+L3QT5\X
M11WW.B=><3L"NVBJKTHFJE$\78=- 5@XZV1S=A.;K)?2R[GKF3DJNI#,W<LJ
M  :$D : 26A)$"0:$D&A)  :$D   "3F+IH20"K/D^GJW%JOQ]!X3[@&A)!)
M   - 2R*N=NQ#MY4RDSYY4RI2ZYT#Y^_CUY\)YZW#1WC&[/E%-U>\3.O2LZG
M%FZ^VS[9GZ:.OEVSUD9[F()Y(1F6A)<0IF4127/LNSHQ$] 1"F91R$9Z(@YU
MTFCF[?>53) "9(@"5):]=V)2ZR T1GJ?/$9Z1)!S;2*JJ[EO9T;I#J)#NY"'
M5L^*U'<HB%&@U53IB*';R*QTDK/+OF58OT1IQJ;W%*B3OF2%9+IE=G,*B\F2
M[.T5;\WT]#>;K]'?H/"7<@T)(  -"2T5_E5>KO:L%8)-!$HE+BRV3BUZJB!Q
M6XU+CA3#[Z.<YW:)4R^(C=5*9?/"!*'!2!E/<^JX>G(D@X*2"#DH'.FGL+A]
MY@4CE*>22=.%/>--P.N9=9U$M"2I$I04(\6>8U>S8&:[;N[QK,5>A2I%F.N*
MQIW5SWJ2&;:,UF9YHMYOH[3WX,MHM-4:<Q:]W;L/R9+ZJ3HL/?Y&0-DZ*9T>
MUK+T/'W/5=@,<=_.?N\^K8<Q47T,VY//=7U9C6F+.9KJJ3.5]U2GGZ[N-YPK
M?@W;M\O9?CZ'PEU(  -"2#0DM%?99+#;HN9C>JWQHM2I@IEUJQU&1<9N@C1W
MRD0N>WW6NM?1U1&OC(.XZ'0[VJ@:QV].;'Z;,@ZY54JB'?P"2%)\NJ[&C)+O
MJ/,Z5L[RO%3T7H7;'XI[;@DNJRDR+K4=5:W1:?J@RL$MLSF(E?<ZZ*3Q%UW0
M!J'GOL:KL$<=SHJW?$ XCQ2I]39<4_!93<ZB^BG'&K]>GY6?<'/K5_C!KZ;/
M>B[Y>F./U:>>9[VSOH/GM5^1[7P?18]K^;A]!,-]5/2]'7,^=]K?IW+F].%U
M4&>H&_79*JO0>/)LOKOUXGGQ1]&[?GGS5.JRSGJ4>B>3/YC<^A6JFKLJ+MM_
M2X?=S'AJWX?M:LQ:;]_0>%'M)S%TT)(- )(!7^8R7F=MREWQ\'D[/*F^:^;?
M3R?'YNKXT[,T5UVP;=G^MGRK%3V6?7Z%^YXGBAG]BS^+!8[;NHOY].S=,2US
MQ8-^;;O!RSQ?=T/I\K(KM?38>=0[=F_^_&]Q+*(N@:*3YM-U[\S[G5WF^CXE
MQHLY?13755[%[?,M/CN!U64FGFXGGZ_##W>L@\[9KS2U[;CL1YO7)OR>WRBD
MO$78= 'DMY'H5?\ 6OMMDS;L]3R;SY] 2CFD-%]W-M#HOEMR<?GZ.2RTC-%R
M<=1[LEV*;GJH5G$?,/5VX%D%O4:T\G*Z[--:XE\]OBSH8J[VR%!(>F"J"F]Z
M,ZYZZ'K1W^:M=U.9JSY7K:JPZ+^?1>#'J6AHBZ &A)  K],Y+#;B 3GH)ZUO
MRS/J.MSVXK?5\4SW[GXT\W%FQI:2=['F9=UXZ1JX^6YE&352373Z )K-Y^W&
MO5\RTN%A?5^87SL&N@ "D^;3=B_+*YC&*_2VFC9R.@H;.V3V-4A*KNDDS=FR
MCH9ZP9=W:==PV#,42KGTMZFD\Y[KI *O9-&S-W/P<4[/F.V@#JLI!TN_W5%T
M -"2     -"2#0D@T)(  - )( T)+0D@T)-6O)]75N*^^_T'AG8&@ 20:$D
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MZ\XG8%=M$YJ]*YJI1/%UW30DUBXG9'-O63UWS/LJP$JK*0=1=[NM)!H20
M : !):&B+IH20:$D).8NF@$D  &A)!HJQY/JZNQ:+\?0^$=$EH!)    K_/.
M15V;>CE7&"&F(XAH261F7$ T"8S,H@$AB2R$RPB)!$+J2"F7$4GSZKL:<B=
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M,9+$[< DYBZ:$D :,#HZYMW.;57X^YR#B[H7'?7XUA:UTZNUIHS9T;:3/:
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M@LD0ZZ8KR0   T)(-"2T)(-"2  #0D@ - )(!5SR?5U7BOOQ]!X9W )(  -
M-$76@)C(NKMOSFAFF4VK5P0,LROY.;HVT8C1JZ]Q@%'6<>JZO(Z?#&1^O1\G
MC^EG>S'K*BG[MUWT43M77S/SK5-1;PKK'FJ+=A&$KM4TTFKVW7NRN;L$\S=^
M?;=?<C)53?T'L)N^?N#BU),JK*2EQO)V_FF]^+P9;\.OXTCJOM%X^#O-?'K;
M'G4E[ONRD \7/-]C47K\/S--D_<^<];,-H.JRD747<[X   ).4E):$D
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MUI+0"2 !2=%V$M )+0"2 .KJD<]7;LK      :$D).8N@!H!) &@$D :$D
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M4PYA1(.)   'URN>@ %,.)#7E?'IR[RNJ%*$S.(!<'V %P?9<.EZGZ;8[.0
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MB\W'<+!WF/F^Q2OV_"UO5LU3ZN6SV5K4LA$[7\S52?VL]H*-N+SYV&SJ]9/
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M?;?"^KWY=^K\L;01,@  3($;:Z_1B[SJS=.?:=$ @1)(!(@3$0&(8R)(0Q"
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M>'V445]'P\KQ[<0VX\:YZ[OF;7<]5&NR0YT<]%N^->6P7G>G1;K!>RKU*_\
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M+ !C @0[QT7ZQWOJ]B)(" $211+9XU[L?HIH"9 !$A"[QT3[QWOI]AD1$R
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M    #D= C*4 C*4$,.0'0Y'2,I0C*CNC-[CQ.5<#D!<     .CXGZ#M.X
M                 Q*N<ML@     #$N9RWJ     PZOK,;.0     ,2KG+;
M(                        "@!=6&52       .FAS2[,
M       Q5&5)      Q:&4R    #$N66]      ,2YZRWKD
M           //XNM#*Y       '3PYI=D                    8HYRMT
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MUR                        &)\IS.4S       !TT.:79@
M        &*HRI(     &+0RF0    8ESUEO7(     &)<]9;UR
M              &*<I3.4S       !TT.:79@                   &*HR
MI(     &+0RF0    8E#+9      8ESUEO7(
M8GRE+*I       '3PY9=F                    8JC*D@     8J94
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M/LY  /@NP<G'6A,M^1<U[9TU'/7Y^/GOL<5CKZ>K_MW89>=QAF77Z_?1?+^
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M_9^P:8TQ@,!I#3#I8AHL E& 4V#7B,F;;#HRI8;P6YO)LL WN#N\*WA.X$C
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M*'/*F'+*I>]LE8N->5R'+*TPK!2#]W@$HS$;A)!M$@9S0Z^V1+).1HD8(;/
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M4&[R[<,O36EP&L//$N)CUZL1K_Z\4^9PT0_F5$1&=&/?)_#=]EWB^YD$+_\
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MU!N0I!$LBP,*VP_LHXCPV>.S?LA^'<.<?#N/&'X#=]BP[WQV8[5_CPWM_P"
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M<;PH28BY:?Y41+*6'HM<7$OO,1JVWOS5]MF9S-Y).NND]"1L0:8J</,M%CA
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MSJ/0R<X:+$.$3"76R<BV&->$AVC0Q@,H2H*479\5!??X95--ZZ<,XSYQ@-3
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M/SZ?O( ^9-:-$1R<L*YN7L7L;W$T]E,F\R\^=V&/%32L$[$!0X EX!#N 4K
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ME&4-)Q#J,!@,!IC2&48#*,HRC*0RC*-,:8RD,H2> 0[A#'[P%[H/?BJ/SX#
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M"]B0L0RLHB3S!4*3(0T3@(]8.-Z8>">R]P,O*V1:SK9&O8D+^Y_%07Q[QYO
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MT\P46X^O6:?/)"*,TNI,TMI(([*_Q(;VO\>Z\8D-)Q"U8"$;,0F*PT]B'7L
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MJ$[I7LP_$CQ!;Q[((]4&,P</$U<'./AW!GB2$9F,NJWI9&VFM$DL\N>*0:,
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MW">+_P!SI_ =]D_;[I A@KBG[?&>T7#N$\7^'<,\"X]PGB_]SI_ >]@_;[I
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M3U=4]?1=MJ]D=:2"TMW)1++5RJX% 57>2EY[5<@E5O[DP5Q8FWEVY#01=/\
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MJY%6%-4#CNA2_P#Z-_L/_: +9F40P+81C>.(PQ'B+O?*>W?R]& QQV$,!B.
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MCKRAWYC.9#1DS8N+TW2.G[7V:OM*94]>.L(&DIW3%"K;MS1U:VYH"F:RZ=Y
MS9^97LI:=5A;R.KNO:PKZW]MKK0S<;;F'G4DO?0U,4L)_3,T.F>FB+BI!:6^
M=*UG.*XK.DY',;9TQ1]8TU!2^V=01R:AM.BFYCTXIDM$27BL;A"_R+_L/_:!
M@P0/9@. X;-YF,1=XO\ U1;OY>#?LW'L,C!8[#]K@,"V8;>)#>1 QQ-6(\1X
M#>>WS#=CTP?QP4$@P8,C&[9OV>'3+\@/:' MN_#B1BO?G>HAX#' <1_EQV;B
MV6#JF12>@3Q#U=TTQ4*N$=&P\LA)7,:=K205)5,AI""!XC' 1\3+&)D*IJ62
MT93B7$*;,&> AJID<94[D'"O1--53(JN@*VM_3%PX&!LM;F7PR:8DB:HCF8)
M^#^*M _I8E9B/<0G5D[9U#5C==TBIVG9I(JI@N)C'$R+8["0K[_$%@-Y"%Q]
M1?\ 8=^T HL!ALX;2!XD.&P^-WOE/;OY?>!XD1;AY1@1C@.*O\O' Q@8\ 7$
MN&8&,,1@. XCQ!@\"&..W<8Q&X=,'\<#X[-YC$R(]Q#<1EAB7#IF^0!\>)\=
MI[,17WSO,'N' ACB6S'9XP;\1"TG#Q]Q:6I>4U!3,#<6D+HJF?4%44UETWH.
M%<J)=M+H3R"F=4R6M9BNL:;F-RZ6I.EZKGT;;>@KBQ\8.GRZ:)M>'J4B8:,Z
M:ZMK%4AO['5(U)+9PMQ:XCK>69J"8P5P+A7.I:V$%&5I*Y;0DON%"36GZXNO
M513VB8BI&*F1-97.I'9**GMK:8@*TCW;CQ,YJN36HO!<N?PM%4'4T)/:>J>F
M*^G-R+JW:I2JXNK:[FTFN5,)_,YY6\RK2M)Q+.GZKH2*I<%@#&[9"_R+_L._
M:![RXC# RQ+9AB#W#B-XX# &>^[WRGMS\O;Z5=.Z*MBS0JK5&?4A4LJD\=U&
M7+E2H_J.J*!FTAZ@YS,YA"=29U90E.7<KE0A^I"<"U-[*DKV?5[?*>4I/>GZ
M95?4]8M]15PHV.G_ %03.1T/.NHJ]DZIZXW5? 6LG5O[G3NOZINO7\5;6CCZ
MA[@2R8+ZO)?.:HIN[5['XV-ZG9E%2>ZE[*NJ*!HN_<55MT[@W(J605%:NNZC
MNY?:;WV_+!2W4#$5#=2S?593-W:QP'CTP?QP/ 8=H@0\.F;Y _Y5K<:<T/=,
MNI1_X94O?)ZHHFI.LR1T_([M7XJ>I*1H":Q]35F0KWYWG[(\H/$%B-XPP!\>
M(P%B:HI>F[7153TW+YY-)K+)'!*-"TRR5P$E@II,Y;)(!)D98B25;2M30]/5
M+3E72C@$QDEG[<'!PTOA"]HJJIDZE@:GIR9SB:RJ!GD!N&8-,4"BYG!4QF<N
MDL!"5';FF*(;=;>;P!#$PS*I?#S+\-)JQ&&!_G\B*>2V;2N;MQ<IE\PB2P"A
MQ&\<1"?R+_L/_:!XCQX;<=A@@>.S?C=[Y3VZ/_U]5=+R6M*?EM@9#S<#TW4P
MQ 3BS-+3D4ST]Q495DBZ?*8DDY5TVT['-IL'3:9C"]-U)0T?3=JZ?IB=UO8B
MGJXGU'T-)Z*5+[,TO+A&],=,.1[72_1C$JC;)0\5,&[>1-/05:T;*:[DDXLK
M2TY.3V8EDEG-(V%IVDD1O3!1L1*J@Z<Z7G\YAK*RQ%<5Y:V%KJ:T':&DK<3.
MH>GJG:@J=NRLL76M*V?504+*&)E#2@ATP_QN2>\A4GZA_()K<FZ-#1;MPKFR
MV9PE2W%G5M;/U'.ZMM?N+87#IE^0!%OJ"U<GG\_E]BH25P!=-M-PLO@^G2GY
M3*ZPZ=J;JV,H^D9;14GPWU[\[U8C' >%<SF[5(UK25R+LQ\YIFM*YHNO.GVM
MJXKF3<08,36FU510\NKB77%N]5ETZ_GDEN%>*O)/7DDN-<2.GOQCNC3]'W'O
M+7<GK][$FJ.F[E$R.E*EKND:,JB\]T)9#Q5QKCQU:S6HZSF%1V8JZ:5_::Y$
MPE]%]2E,SZI:/FL56]V?UC2MQ;GU=$R&]UVJLMS3-=SZ3W1M!=VO9W>#J1,_
M@#<=<,]:R;W+N% OP%;W?F$51E4W(I^SDTNC?*=R:?WBO/%5W,KJW,5&T;5]
MVJHDMD*PG%>6LKR0QT1U(4O=6JXZ332]%[8>0V,K:>7%DG U#<,<!"_R,_L/
M_:!C'L;P6X&-V'!7FP%W?E/;GY?\-GAXGQ/@QU24DIY/4O*(B5+O]((N/BKY
MTS!U93M\I34\=;BZS-R45Q?BGZ$GEDZYK2O*X<ZGI*J8'?Z$BZ9C>K.B6&8^
M^5+P4+:V^E?O4VQU'4_-VJ=Z@H]R;3[J$IR3S6"ZC9)!-3SJDHB6R*61[,TE
MG$'AAB#,>.!8],.'IP2/&M95/I[2DBL!4\-;'T_5#$2Z3VHN)1\@H*CI=;VC
MQX;LO3,?_H&,=4B&IN^$;&4*W?JG2J:F^J*BY^(_J*F\764'U'TQ&5/(.HFF
MZ@JHC%>_/ ^&&R16@N9);D2SI\J>3S.C^G>:RVE[1V8E5HW 1@N'3U)Y3,+8
MP]%4; HEUF;0R=J*M1:^-G]%6UB*>JR6VHM?)FXJU-K(VH:?IN54RVW1E(LK
MG%L;;5%)GZ-HY\XNV=N9A(YI:JV4\I]%+2AFI9C2-*3A,72%)Q[<FH"@Z<@+
MGV3.M)=3UC;:2FE/TC2AS&!LW:F4-LTQ(6:8BJ-H^,>B[>4%,JB12=+,B+M%
M:B.IY^D*3B$1MOJ#F<^B>G9R<75G-MK=U#3S5'R)B?)E,J3,YE;&VDZDITI3
M#CDIDTGD$O' ;R'$0O\ (S^P_P#:![-^)#QX;<"& P!B[WRGMYOMYXC?LW&%
MEB5#6)KJLJ8FMB:B;AI78BHJ(CSZ8I(W=*3=/DR@;HVFL)$6ZK6O[&SNKI_;
MRW;- G*[(%+A5725$5&4LZ7/RVB)QT]5#&U+4?2;$3V6TOT[UC;R%G5@9['E
M35@9Q+:GI*P/Z6G5S[959;NE9% JE4CW8[#+ AQ'3#_'$]F&SQW[#!$/\>F7
MY 1"-9FV=%';JA8#I=D$#<QOILEST@BNFFKI\Y\ F^3MM35:1-TL"%>_.]1;
MB'';X@CW\01D(:'HEWIXCIO,>F>2W1ZD+@TM)I7<2>TE#TSU"7JKJ$N3=NX]
MUK1R3'\DD+KM#UW;>Z\XI&C*VK:Z] 4E;6_=U;@SAOJOK>1QTUO7>BA:QJ:]
M]603E@;C3RZ5NKU26=Q_4+2-T9G$51+;TWHJV>PO555,V;C;^7%;NK;R\-3U
MU,.I(\.GZDK:P3L^FM^ZWJ9,ANY4LVMF_=BZ#=Q:4NC="G;%P?4I>6I:7DD>
MN:R6.I6D:BO/+F[P6CGT^K)=4UU3-U[L3J4EU!WAJ" IV\=PY[,9AU27"B9/
M4][;C22J$J-0-.^%_D9_8?\ M N!#BG9@-XX#B"X;QXW>^4]N_EX#/9N&) P
M>S>%'NQ!<,=Y9C!@]X\,=Y<>(X RW8^8]P\>(,QP' L1X],'\<5;]GC@#S8
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MW3<ZI*LK8Z(O-6M/U+"]2L6A*+U7'9KRS-T8BZTBG%_J@@YQT_SVJH*S$5U
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M'$US7-R:$JVM*GCJ[@7IJLI]!3V1W>@*^K>C*5F2+D4S#].]51$QG)<.F;Y
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MT>.. M!6<TI^1W'OC4U%QUIZRK:JXZ]E<3.W%K:/O/%3V+>NY4C5IS4DA W
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M2%@-^S@,-I#?AX MD+CZB_[#_P!H'P]D88@R,MN\&>(,<-GC=T__ %/;KY?
MK<W&I>IK=V2KFGXF3V5GL&;]J;QRBF9O;^\DF.WMH;NTI 1UH[H04C:LO6<.
MBW="W(D-TNH*F[K3Z?RRP%PV;>3ZV%R&YG<VCII5520UD*O:E,MZ?[K.4+6=
MIZVK1F>6PN*_/I-:^X\'.[#T5<BF*RO-;NOII4=HJ,J*DX^DK7W 1,*0LO<F
M3W&?LE?ZJY;5]N:QK>-K^Q->S=FEK+UBNHK;VUN'15P<"&!$?3#_ !PP&XP8
MW L!X>48#<"WIZ9B_P#0.)#$<!NPX=BO?GAX;MF)#RC*G QY1N&!8=-ORD/
M8%@0\@-)$,",;AN(%L(L-AX$6[;N,>48$/*0QW;C&X;B&X>!93'EV%@-PW#
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M4SR2RVO[@W3A)]9:M7:@J^_]4SVB[/4K5<8Z[$7(K-%EC<RJI^*O1="04]U
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M;#CV"V<01;"VGN!#B/\ ' >*<-N&!)'$8;(7^1?]A_[0(]Q#@. QW<1P+9X
MQ=[Y3VZP^'WCN!\<=FX8$#XD8P!8C$P>PS/,7&<UC25/S!21X[QB#"3/#>,0
M?LIX[-X/V.F'^.!C@,2,&D\1QV^8%AATS?($MBN/'8?F33UFX.3U3N,J]^=Y
M[,<2!<5'Y> +9B.F[Y2_XQD$Q'P<)#0\%#8Y@:@195#@-Y[.'9XC >(PV<.Q
MX;>(W;>*?$QO!;Q"_P B_P"P_P#:&SP"MF\8CQ"O9\;OX_"BW?R\X[,!AO\
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MXC'9OV^'3G\C.UO&8A6WSC\-GCV?&B*JK24TA)+J3"G(Z(OI;"'ED3?RUD)
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MF6+1U$[+Y-8FY,1$P%E;BS*03JV=T:EFE&V>J:#J6SC,?1-(;)7\[_['2/\
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MQ]0+I"'U >D(?4!Z0A]0+I#'U ^D,?4"Z0A]0+I"'U ^D(?4!Z0A]0+I#'U
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MQ]0+I"'U >D(?4"Z0Q]0+I#'U >D(?4"Z0Q]0+I#'U >D(?4"Z0A]0+I#'U
M>D(?4#Z0A]0+I"'U >D(?4"Z0\/J!](8^H#TA#Z@72&/J!=(0^H#TACZ@72$
M/J!=(0^H%TACZ@72$/J!=(0^H%TACZ@/2$8D?6=TR1-Q9S_P>\F'_ @\>5^W
MR(C_ ";9O[6(Q,23'\H[B)Q*:88=QB,3$E+&7_<V/_YJ<_\ ![R8_P#7P?\
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MVMI9J:1TZM9O!8@QTY_(V,,TP=&3$YU;MKJ@D'Q DG4O-'H2<78KEJKX:_\
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M%^^/Z.)_?Q?OC^CB?W\7[X_HXO\ ?Q?OC^CB?W\7[X[>'C?WL7J4/Z6*TO\
MC8OWPSAXK?\ G8GW@W@8C5?\?%D[X)?"Q6I=^?B2O>H-/!Q6^M^=B,^NP?\
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MO[P;PL7/^=B??L#.%BL_YR_O!)\'%;&PN-B?>##P,0F>MQ\5O_<Z@S].L_\
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M=IO0V<+J"*^H-9:&!'>"^Z"7/U1#$1/=AI&&CXK:YP:H.">\%=W*8.CJ^QA
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MSY@98L4T"%TZ@T7_ "$_(R3+M!84L#"<[= 5F8*-0;!PXB';<X[&]"<$J#V
MBIL'"4^%([0(IP2(."U46A)_%:.*ET)QQ$/E@8/$G9:P8>'/>L:+PNQY@LZ
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MBD)FD)*0VZ M- 25/)A.(3CW@SUH5!)TA)4^83'3Y,FL)KZQ=AO!D-X&J#F
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M!P=I&[IYAPW=(=IR.&WD.#@[2':<FT.&W)M&W+MY>T;<CN9VY=N3;R' Z?\
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MKI"+Y$VZJ.*;,,51;Q7&N@X8)D7;6UI5D6<1A- 6GQ4(O=J"_P!,II2OB_U
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MA$.T4<)AVT]FG,,->\V_[OJ,ZPK#(KC6%[0N,TB^R6$X^(BA*#]Z&<&HL_U
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MJ0HQ(XXH,77!7G7'&A+RTF<+&*X&[8=XB2L?Y4'#^4OM=B 5QMSD@Z+\.[N
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MLVW +T%\_3S1Q@;GC])K[]W7NVW+^[?;<O[M]MS^BMX-_P#/6\&_^>MX-_\
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M'H0^!K':-LS10*D?2"IVB:2VLV.NRAO@4]8%):8M/<I8)2N7$-J-,.XH.DM
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M_7O_ .%C7V]-F9J+=NDG*Y9(Q+PQR&Q7I,5]%('@#,22I>UY1S]72-($R5$
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MG%\0:J &5-.G#>V578(KMRMAAQ#P:UN5(7V8*VMU-C\<;D^>6N**,S$Z9+X
M2^)QP6IDNNE*<YT?J 50FSX("!AQJ9/'$,<YJ=#49*'D=G/5J.0++*('X!@!
MX++B@UPD%P[Z'_A9SPPFF&8DD"3GC[1-_P"Q#+ T&;('-3J"U*[ZA<3RF../
M2RXO:G-F;URK+#@+SSDQ9IV5;I##ADTI[%FHN0Q\+B"9TY?9F:,[\'[%FJ2E
M[95"!)R2<'ULQ.I\$0\?H+0*-T^;)4Q(XY2 B9 ''5%(.9W)84Z.23]F#A61
M[9<AAP-./[1F%*B *!\<& %JIFHGMWC4NF$\INW($T':(?*I$ZN"RG30XK&:
M*FS)T3,!(S )1F;>X&&I0  +PS!@M#(V=4"0MX/&6K:9X<3F:E"J6NK?!%[<
M4U-;J;&FJ5L.=ZK$6K,9LH _K9@!\>U(QFS%A*<I-3FI[T_*7XIF1,PGB-E)
M.:71Z-1H4^S)$YYPMKV;*XF+,L]1>=2.9N3\7'6>3%H)8V4G.2WI')6<CO>8
M?)J0K=G.:S1E"V5.YIBUH,.,PSC?,R/\1C1^^<.W1S_CB4)_3Y':_JW_ )Y4
MSV 3#[W7.T(]B$;_ %G1_P"0?I?.^KM?,4+_ !14]^]-HMWO)^C\U??V;4MN
M_P"*"#>ZYWSFA?Z'4_[W&WYUVK_-LR/0VYO$\$/U5$"=T,1I3'$IN654E)RM
M 6XY.8 @P90!FEYF#B!LE>72,1]T>&^Y.% [KV9K7.*3)5E.1.RN)Y&8#+.2
M$GE99GA@"/T%EN?'&11SFO2.;CFM* >W.:.XK9'17=D7YQQ>4#*4&<H# &SL
MUR&&11];7]20M?6UZCC,ZH7I8CR=D5.J1:B4EJ!EY(<DPS,P80V2 1QE@1@;
MV8R.( IF9L( @CYN3FL*3))XB$S92O4Y?)\0/$XEE;,X0*&+FA>W-;2N:%<7
M8E+8K;&#.YC;%3><BRQDHLT6R$#*P$8AY>"S.G9(K'XZC8WEO?D:.-LK,S)M
MO:"LIO,-+1HOK8.3Y/*X@<OTOB63.YC<WF.Z1*H0(W0:-*-Q2)%9I)RM*E<-
MGO,  P:4K-++-P#R0_46/ODT3C,A$I;#V)3>^L+8\;0R+#4BQ6S';:B4XTHQ
MI"C#4_@#&4#B<6QT/'36 CB*E2G6*8L.'QP4=4+$9:0E(J-9.:L@8RP("2RC
M,OB9(?J 6C810J)8(<08EB ;XZSX(LG-2[&:EC/J&_8P&$\3+3Y7$Y.R9$*)
MQF]&CCY\21(Q,#5LB.,*RTA*N,)"=BRP-I@&]/FHR^0'DAXG$!9;'&*"1**-
MB\M.D6$12,1Q@QIDCISP4ETHFO+P9V(S\@,P1@,!G*6;5+@V-Z\YG6<XM"A8
MC2JCFIPO2JV[;FXTXB[)/R59J?,+X^ X9?HQV3M\XB$6F2%&>8J3(I9'V>1)
M4R@U,<D,4E)'E"I  S)-$7C+] (0+/;;&Z8T^CS?)T/-4E0,,+C+2AD+7>4:
M3L+VD;6M,!43@5FEY:C-!RPOJK,K6P0R*,3;'%RQTC;<S1QF:T+"Z*REB-6O
M94B-$G F/,+<%!9IB?*,&!0;]6.QLQ0P.&HI>=<LS)2BBS$ED@[G(1RI>6>\
MD(=K]4#/&8;?F<<8Q8[. &REE.6PMX+7$NI:"#QA$!R*=RB274E?DM7+EJ %
M!+59GIA8.4M/SZGHX74HN;2AK?;F9P@B N-,R1A86Z.1] 2RO[K+0''IR4@C
M#5F:5C&<++ 07Q+$',T1B[2<E*<"4IK8PM:$:9.\&I#78HHU$A3X *#&\DQ6
M7Z/)#F>""S<\-38C:AM$<\56Q U(T+<W(6/:B5A*!*D1H4V LL90<H&9@!@Y
M, ,8\93K.:8T]F;J0F+1D.,KA<>D:XE&2::<4E*5O+6H& &,X0\'Y,5F^&/<
M"A;O#V<22]IBKG%F-QC37S<4:D0<WLJQ$J3D[. X99667Q #L]MS"7'XT]O#
M.C81/*B&L4C2G,;:I--*CCXRNA"<"UJ, K4)S4>:5Q%)NSC),'CLYJ5Z2$N+
MNY2$B1IRXK $$%B4<6(V(F-H/$^*7.DB,0&;*4+-/VXP8QG&\<!8\%G-P:J<
MP-L<'L*\+RN01".H53OSQDDNW.JLE#F';1E VK,S,> &986F.L?'9_%\6)I0
M<>/\M]HO2/L3EA>I_ XXN)9R>6Q(4B4NB-L;C24Q"5(D)1LY>2WE%%(B$WI8
M#OKF;^=^E@ "RA^E=)J9R=]4%E@4O,A@43>G54627E%7&N#BUJ% \L%WYYO6
M90R:%1*1ACAP%$="_1MG> ,)Q67<4I9.<T2G9A^I0<=/E> &SBAD,(B#^B>%
M:-:\(GJ-L[HF<UB)-LC:J7)5B%0 XPH)0 %&#\ '$LD.8H?%V4YOO6<WC:8^
MV-QB.YQRN<-E.1H4V#:,H&;E^'A#98^LM/X2SOCB8L.<'EKBS$W.JT]RO)*<
M#%+@B1)U!PU.6&\W,,X^&S]'H_"(I$VR37YCX3%8TQ,ESF=G7W[2O)1-=Q9I
M_$],,*,'8A,2'"2G*+(*_0R2\HK3P?,2/\1K/^^<.W1S_CB4*_3Y';JZ_P \
MJ9[ )A][KC:$^Q"-_K,C_F!0O\45//O4:/G7=M2SV((/Z]\YH7^A5/\ O<;?
MG75W[4X84QL">E/X3JCN@J95'>#&>,U*2-M1IJ<K9U6QM4C&/9@>K,OFU<#D
M>4+R[/J1OIV=2FY))HA?/*<7JFQUI\SM#\J<F@J8TI5Q+9RR25(R2C'#;$*
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ML+:<VM[6C8 &J>:VT#<7E9B1*<N4IP&&>E^IRB_!]'\Q(_Q&-%_[IP[='/\
MCB4)_3Y':[JW^'YY4SV S#[W7&T(]B$;_69'\P?,TQ*@];3VF""8D 2AQGG)
MVV97<XI<GT8#"#1\3^IVF=1(F0H#,)Q1QTFQ%XQ*4IZ5&Y3=$25E&;"I4)@%
MMQ69F;,8,C&(S!Q+,3M(*@(G*G;%62FZE"Z1JOM6*CMT=,77'$/>WU<>62!C
M.!BRK]DVE=L)@\'(XL-G29,4LE1:I=TG2XV6V)9,Y!BRAD=TK<2X)5,?)6[
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M2]1-C(G(8UXX(%JQK!'VM&S..V*DQ*,P]5F.38 '%RS#L=H3(@NCVB 7/:4
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MH!PQI9%ZR1$NB4I<B4M117+)36\Z^XL[,]+V?T8QA!:7U9!,H*]/:8REBTV
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M>5]BEXQV3RE3*Y[*I"GFI50U3@_N,=&<ZR,J$K*?7YI;9'&1.23L*OTA(6F
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M91&+DD=7Q9P;5AE-&L54F0N-FE+#H[%*K(GIM,1L[@>6+;T:QM<QC K6 +/
M6<#)833YHE6M49K!,:K,J$N+&)G ),P13 IPCJ]U\8E!9V6JF1IY2PM,FXA(
M2\CZ]9K0WRR+NC8CD]2Y$JC\_IH7/8DJ-J-*#I(4X%1E9,&Y.!X:BS34[>X*
M-N!RQOJ3C#!:&T\*6H'J)16')VH;US26V.*IX2*\M+EI27Q2  ,CTT&S<0>'
M+,X^ M]FM26&*5'N6-S.SQADET/8GM#$&MM*/.5EH.>2'+&>L5*S3S5!917)
MY9?UK&-K1P>H<,8*;1^4.<MC5+WZE3D_QYJ='(XI6E*.O9ZI0W.);E1QZAO1
MY11!&:'D!F$D# T2J0+*6NLJ!&B(O(W"4T5039L&C1JEBLES@K+)9>X\QK<;
MBHXZPQ\('R680=D\>J3(AE?-0ZD.D7<T2PF.(!^+!D5:XXW%%%-Q*],G4YGB
M_C]*2@!G8, \''<%LGJ/&WZ3.CU'E;DG<*9&&TU>&"--BMM01-_@'C[GK$V8
MJYP-S'S!M0 CP!+  %G5T3NRE_O:V&KZ5NC$%I0J*VQ?5*Y(:D0-4:AAKELQ
M"<]+EDY:;   ^4,!@QV:7A[DT;(,$B@:M.5):8)Y7-X6=%B6DTYAA\O<Y4F+
M;4*DY",:I.G;"C\9P^7\/&P%WRC-O8ZM/E4L7,F#:>=^??M#]U.)E\]_9'*X
M\'I?'L<&3EHDSH>:X%?:\C((V/,-);S#2N=''CX,.;ZI,LSTQ?*G0YQINVJ6
M\2I"V4I=VB7N;>VN9+NF0G25;5>1) >J"2\Q06Q\< !98 8[*IHWET\+1*G]
M9*!&K*11UUJ4%W<DQI1J4JI[FM4F ;LPW,*(3MI:H&@( *LO'C8(XIF<7=&I
MHAZN*B)FE+$LW*;#U:]8K\:(0E<Y@G(:73 J"6:H,3.?$)#EX+3B-W2_EY6F
MA8$;D7'\'-#A"D#:C;U)K?SYZI 88WA,-3YB7B#$7C]':>\]U"B;X\S]9'E3
ML6X4D0.$!4IV%L(;N9W6"/4P>S%*%1DXS;RW=*> P <L^S!%618SNJ R0NKE
M(]E8/%YB:&]SOSKVR%,)$A4<VI2QW^I4F8Y^BX]I)^(QH_?.%;HY_P <6A/>
M/D=NKK_/*F>P&8?>ZY6A'L0C?ZS(_P#)FOYBA?XHJ>?>HT?.K^W:EWL/0?U[
MYGJ[/S%"_P!!J?\ >XV?.O/U=?<M3R)1%*@.ET\GE5VUI7O:54L8&%.VU!GC
MDZOKJ@1K6XQ2662E'E)"U*;.,PEYY/AVDBRMU[ 6V,RAK"RS6&LKP0AEESQR
M1+6@I^2]SUW XEGX2\@!B[:LX.S\IC!9*XW/SYZL?W"+D-'B!47QM\86ULYX
M5,YL*\5>> *MDY0H!B+&/ZWCLP/XGYV7H9*F=%S24QPB=21WV-@.-2/:E?&&
M&+N#@C)1GD[.J&L3)@$&<0S 99Q>(V\A?']1"2YE&BR(Q,7]@YO<2OV/+I,Z
MQ]JR&PA8.[**YP7(,>$67X [(HJ[/:Y._GJH\T*C2(C+U480O\D**.:6%TFJ
M-D/:$:I1M0,I(L<BQ\L5]6"U]]^X'C>5W;.4\I\U0M1$VV0N[.U0-[;',N9S
M5'&WHYB=G1)-CI<RM[2-2<D4<W)U#0N!@)*,,.!G8"9I"Y@J+9G%IJ(BAS!L
ML?E![< #C&(LYM*:5R9$0YMB-:L5.JA.E H4H-JR<"< S CLB"^RP]Y<7(V9
MFH01*G%15:E2W0F3G1Q[RX^S-4K5_:XPT*=4H]+'@-5E@ G\!N6N4G5'H7.-
MM\R+<&&*364-Z&)N7W/D<@71J.O1#4A4<?*4.AB8 \!OYR/ 686*XTLP-XRC
M "Q@& [ZZ5:KH86[TN1H:<2OQ=:8W(8)*UKG(QDPB*RG*5S1#4]M(1WJ!R :
M?,+95.0 (3,L[TNT'D+XN7L0IM&6>3C0\QR%^!$D3P>0BS)L^,#6XHV9*6K.
M$GV]T,0)1C)-X_(CRS8:J?W #VCDS1$%]X(E,3F1KD;\E:%<>9G65$QU0V(S
M%@'I.6DVA<6 \8\!>,P P 5LZF1.NV(WYTBAHR(//U3<=,&?;=JAS<](XLH2
M*GLSFX6RM"=2:M5\3((.S@8V607/+XM2R)3($K8W-,$J(]2F\^(*S44LV^%,
M\6<G='S<>7D. UB%, @8RP&8!G QNJF&NXI%(Q4M65/C9*:,2QT8SF0QB?7>
M/.<@=6UJR$2508R&E^K%* P8P9'V0( +<T)%NW25L8V5QDR=M;'@;.T*W= C
M<BVPYZR5* "[ J"HV#;=J 0:6,P& 01C4REG7QAI6!D,*9C'F9IE2N-,S?)9
M<S,+@\.B0E[C>,E&0X#/^SDH.+QQVD$LEE>*+U%C;.>R-RE11^)/&T-+H_K[
MF]M3.ES75&JYAPUIQI1:1.6F3#Q_5V1,R]X?D*U<9'"#A*J?5#3M[*OF%Y/B
MPUS!U.B^R,:Y1M964WO!B _E2KS  Q L1%6Z0+S7A0]/D;3&&128I&4Z2QTQ
MSY[CA,I61U,V&+DW,Z@S9-MSA@!GE@$#CV5HFN1GW7)&YT>;G%UC\ECL>=&=
MF.R'9XC<J?F5M;75$GS09JQK4J20 &$P9F6,%G$J+N+@:H:KDPUR!ZCDFB;J
M6G6%7FM[F6TRQD9%!R)0#%LJY.682/"++&/ .R^17-ICNM"J:VMF9P*MAYU?
M'YS2,[(@.5Y"G) 8>K#FJ,LW #$/ /!@LP"EM].Y='WC:"'KQ/CKQ#'2%&;+
MM:1>:ID\]EI;REQE9!NSID)X!C"9EC+$/)D18)(H++B[2X/[BK61V6-[6L8V
M<TTEV>8TZ+60A.\I4XRN54,YBX ,0?JP61JECQ)B[E[2HD"0C\&=3QN(F!&J
M.2*Y&<U%0ZX\EN*&E%FN!A99  81X\L8!C?UR>5&A21MJ1O:Y2KC<L1DK&AR
M57HVETC)JUD2\\DJ#RLA(8S;> \?$+QF7V.<3']Z3;._IHL:UK8#4-MDI;\N
M:C'EO:_%!PBQ+MC4$%YB7U%@'Q<&/&&S2DC[VI/6O9#R>WI%\?D;(K_8VJ)1
MO:14DD#4VF)E2(9H"SDBC*/!B\"USQ'EW.#:,]8E*6;,J2@-,1F&HS;RML(2
MWC!F$^F%\0?UNRF&3V80&%1X<);Y"VN$KD#;&E2UT.>')&J3)E3RZ)DYH"P)
M &999=P^-Z99=*']Y;W! KGDPC,0'3UED4Y.DC/&UQI13HWM4,)EBM: LC -
M6K3E9 ,?H+(35$I5+"W%@(E*4QBB<VDI8(V8J-2<\*[XU'G'9DI8R1[4-1E9
M&#E\%BDKW)CRKS$C4O-6-\;ECXT-I#_E<R<]O;,R.21 -;FAV0"Q2F&/%Q 6
M+.*OQE&E%FE7X?#+-Y4JW7NWK2+\1C3=^Z>.W1S_ (XM"?T^1V\RW5VOG=3/
M8#,/O=<K0CV(1O\ 69'_ # H5^**GGWJ-%N[V/G/=T6I;[$$']>^<T+_ $*I
M_P![C;\[IU+80L:2)A I]5=Q;4$B/7)6&0(W*=SQG=F%U<6PEQ4)LPA6/*5E
MIE.09A,R!^!9_,426)L#BY.L?"A@D:D\A:VA%&FY5G2!#?6%'"&U_)7.I9@R
M]K1-!>RX09 ,SCV9GY]71\PI)4613=0DNF<ZG+BF1O%/38JD0>,TX0J%[@>G
M/P&;0H,*XGI8 <0FS'%6M^8U#(2*HYKFUHJG5.IH60\2J6N+PR2/G: ,B=>[
M 3)' 8#6A0I0D#,'X8\ !V>89&E=/'"Z:TKC$#DJ]_?9.BYA=(J@<FTM>R)4
M<6<><"%@'$7$4&(!D#!CY;'EV(5KWYB6,37,H1(&)2=5"I[6D1Q^)FL*PV)F
M4D9FM,P''F'I%!Y3NL,7G\J & &  P.8G5F&SWIG9P;D8<]4?SDW$Y.4Z:#D
M388#,S!\GE^@XA@R\ [/4#@3I 2(FYR!W=V.?O+@\&3.#HY4\JWUV0%P0^,.
M+>\GISW!1S>H4/:$''"6H('D\M+0@<60T]^KO *GIU*@]4$\;!$+Z>W."9PR
M&3+ N,\4U>4667<1RH>.#&/ VNB]=&SBD,<KHT>IE2\9VV5.J6CF#&83G-:7
MB%I"A%J_J!CRR\\OCV9J=DR2/J&-%1F+P!+EU0JE"6V-R=N:EK;)W0V-0=J3
MIY2E<?4A9);XI* 2 D7J4>:< :YE<F<*),PHV!*C=BE2I00\*#6S[8Y1*UJ;
ML&SC*R\PLPT \8? ,Q@!5GQ/:J7*FJI,M+D37*)!.I:D=HUFPF*149JN%(J:
MN)#@8G''AJ"B/&!!G8@ S"?#LU-L<.321F44KC%)Y%XR5/JM3PD!$<,=[O&)
MQC5+3VXB3%K"Y,K,5-#@N; <3 6J !0=@G1"15'B?&2N])JG-F,]TY&,4^_!
M7SB@5Z&I09M1GB.KV4OE <L5C/!C'@8,2UDOYKZ1,HJXHPJE_'CC]XX;*@)^
MU7V=^R K-+]+X@^7'Z,U&S/;2=''2<U8E#FQHJGU)I8<%3-I&D<H@^GR:G#%
MSHMYN2FK2U3#M2!*>-2$>U<B 9<KCRYPBZAP>>CA$*-(%:58[C(\8(XFJ&2J
M7JC%32$8$)GC8D'N&'<0W,+X@!C?$<7;6Z21,YH8G9!&^>WWGA'/#=D;I8E;
MC?%U[QMSCE\Z;0H,S +CE(Q\FIQDMS,TFMZ56EF].Y*:-R-4@*V2(3=@D;@4
M2<2B4\N80T&EE<E@QC!C&#P[(V%L-;RCT\QI_(#1.8C0)!M\5FS#)' KD42K
MCF$-)I91>7EY@PY@P%\>SNIN?F@^,>-4#?8N-74VIT=3LC'%7.-O#A&%=*8P
MUIV!R/4*F]4H*>'12O&#.*!D R0#)B"!4N8P!9ZTU,J&\F)%J\!QS!-BZCDM
MR9N-YJ^S2P2Q/FYF6 O ++,'@!C744E"F -L%3T\>("BE# ND3W+7W.0W,[2
M\JF5:UQQ&TY9'**T9:UXSACY,\G!C')I>X1EM<9&%@C\<;$">KU9:J.;PD:%
MRPZ\PZ0U$(4\V$#,=1&%-B-H- 0/$88J&6/D54?$N,8UYIK.[-+F61MUS/(6
M!S1O#2O-2W'ILXLM6E#FD9A>8#$#&#'CM")7.(?1*,.,.<KG%?/HH:ZR>H$N
M A9W)G1,Y1KE"H48S(A\XC4&E\Y/''"6#T..S_&S.8S[D4 FL*ATE=:K5EEB
MA<9*DI*(E4=!WD_F",D9:0K:T[6F><?$R\DLG -P4I5;&20JH@HIJG+&>N+P
M/9W.7JK*):OL7U4'E/#\+D[(U$,D3 TO2*ET?@VT"<WAN,4+&U^YR>TR1V1,
MBD]&2H2FB3E+TY9IY QY@",P !V)D3TKCP"!5.CDX,;SZAU(J2XHVYGA#C&S
M$/C345%MZP_.-"8489LP,'@ )P !9$F3/T>)JH^5AEKM3E F<3><75OGCFL)
M=4J5O.)3'G;&E< N"HLLHT -C#RF#CVC$#;&(OF!!&N5>23#2"T:U&825LVR
M<UX![3QQ_9./^I^CLYST1[?>SK8(UQ<I.$U3SB!P1O+BY&FFE9.7D8%8/KN/
M'BY.R:8Q:^$/<@;YK4MV(9']]?61G6,%05))Q1IKTCBTB/3+DVR!SBRVPP \
M6#/!@S+/J(;M'%BIYHRX00"@(G!, J1N3F\.2HTHK85&!#]L0EYA?'XGI%I=
M2UHDM/7!]G1%+RU\9>W*1HI[<O;N8FT[\'\5.BZDA_2F ;A*-H3J4NRX19@.
M)9$G'J&2E3E"[!19!/D2/\1C1^^</S[='/\ CB4)_3Y';JX;_F.KM_.*F>P"
M7_>XY6A'L0C?ZS(_Y@4+_%%3S[U&CYUW;4M]B"#RSOG-#/T*I_WN-OSKJTVI
MA'3T(#")G-*T)3',U=LH&<MBF-0GXU2:5>0HS@&<WY?II6#'F6?Y>M);(W3)
ML#FM<[?W],W)7XA)F[>^[*L(3$)6O_2B]0NY?C&8"R,!@T,L45*@),7=+U%S
M;)3IC' ,+C>C+.-5\WO-SKD'98$HAFY9G$P"LS2%VJ%!6V/R0PLN.OCA+6%"
MS/PS2S#2BV5P/67)U0S %"^QS3/!LG<6I:B<F]85M"->WJBER)2G_/4BH@_
M,'%^MVF<8DBAGC#=$FZ%K+I(]OR!N0KSY@I?DB9#E+2$Y9(RQL@2RO5)N/.\
M O!Q[IU^$J ^)(E6QW3*^8QWQ6VS,N)V7QAO=-DQXS0%Y>;Z8*P7,N^)MC09
M?.\L8IJ4M=5+?"I1XMDOS<W\U)@'-J@'+FK-IP$#.*+Y?.Q@5J8'-XA-DJ P
MHE>IB,D9Y*0A./*SB2U1K,M4%@&9DCT8_J+,SES7SISO,H7$LG;=AV;QOE#;
M&]OSKT2G'L_..T9?H\&7F \.SK#D,ZARV7,A!BI[BJ23LQ\C:$A!91QJIU8R
M%NT$@P*RN4,+*\,/U=KGY55FF29CO<N90/!\\BA36)ZN2E.=[1S@:ZWD;5D&
MA4;/F8\ L?@6C)+M.(@U'381!4,(<9(SHCI8-6)'LA<:*.6I^<,SG!/E;'F^
MG!^K!:HC3S9L'B!,RXEM&V;7SKG1&*RK;\K8DN1^V;(R^5])S,SCX 0L+LG3
MA:92]OC8XO2QT*:DL;0,4#E4U5O*O.)O+&#!$Q@Y0U, &=F8^)@'$ZGK9_$H
MM$IFE3FM*V72>,,EQ;@:E/6'1Q6H.>\CG)-DF@5I"U)@P#)-!Z"SG#SE;,E;
M4\9IQ(&&4&2!#L4I45(7S!&U,[25D7EC&8")YB39U1F?M')@XG'7-29P0'.;
M84C,<FXE:E&N0EN.;S>:X)2CLPD"G91Y5YGAX19?@6/4X<>0G-/P8\&+)+SM
M[L6IS+YK+(;3=54F,M$A:&&53-B;CS!.*1(M.0H#7DYE,6;,-P"#-+*N\(/$
M!BLBBSM/8:UR5R4EH6R..,I8D+\X+S@(C2$"%I.7)SS3S .)0\L!>/":'ZL%
MCH,&?PD<V3W#VB&AE+#XTE!*2;8<8;']LN6 Y"[,]+]+Y2REIB<]ADH=D:-.
MN6-L=E+"^."1 K+).2KE21L7*1@)& X&4,PO /,M+YK<@YU\4XZ\2#F[:MAV
M[F= 8KV7:MG59./*R\S+-_*6:8G%V4#XO"C0.TW6"=M@:H.WN*#:V](K5DH7
M(:IU4YP1E(,LKD.74&$ &FSW] DJ=3Q4OBI"U;*4!$SCAZR-(VTVXIR4OZ4E
MUS$0$P^3-&HRL'URSNMCU5:;/R5B0WN;XH99S&G1.RMG*Z5[H>D=%.S$790N
M4499>JT9=X0^1FH;5(9L@A)KG%)4V.;>V+%J58L-..5LO.)8QE[*'D.3\/TR
MS,S+9/#"V!:CF%[Y,E,T84+/%76+JF)&:S.IAWJ<!Y@WO+P&J2C #!EX!X[,
MGC!/84Q>,UX QN]YE3"U^,@SLG* P;:N3;9F9X/L?,\,-JAQTF3LZ9;2\T@,
MM-7O;$0C0D&H27$Y>9>2ZJ#"DB;-$G.,4%)<L9)H/06,DZ&J-.EL:*6F-ADA
M23:,JF0#@2F.6&(>=BG39\_(*&9>7F9F  C+)GR,OC3(654&^](\,+DA=VI4
M&[3I,3+VTY2 77P#MV+M7T;:>KS+:>K7;J[7DR/\1;1^^>.W1S_CB4)_3Y';
MM>;\[W_HVJ9[ 9A][KC:$^Q"-_K.C_R+VO,^=T+_ !14\^]1H^==WJW[4M]A
M[?\ U_R-7S="_P!"J?\ >ZV?.K[483N2!P70]GJ!7!1++V]]-8Q[ LD]2&U*
MF5F(US:K.(4'G +-+3^@%RG)V-@M\:/FK#3R<1"8P-P,>8X2=+X@PO*1Q.@B
MLEZ>DY@'1$ D0$BA9LJ4\&5F'@, /''YR\PGQ?;556I1.U4<7N<75.$91FTZ
M.BK0O=>9GMQ2#7*5I03,MO4K@ +&49C\/ W'N<,0RY<.$5L;#H,1)Z?I7ED;
M)'4%9)"99LC_ ")N+/:C$II1;@8C-,/!G%EY ^."U+XI>VJ$Z@BEL;?MI(V4
MQG+3JR2BBT))NW;1CY4&5F)BP#!Z6,> =I*YDQPMQ8'60='M: 9RYF"$]OA,
MR?G>5F&I3ER8SU.0K*'EF%<IBY/&99PGB2$J)4B;:X/DT3Q)N=(FE<7YC?J8
M-$0*D35XP.K>D J1JLT>SK%R > )HR^4P &X+TM-8[<XF02OZ-'%'Y=%W6.#
M=)Y4MGDD9CK@D)79!Q:E*6+^H<3 H&"U1*CSZ/SXYJ=8C3]@:?&E10_QP/4,
M[J_%*T/--)N96<DDOGT(TA>8N.&#B9XS,!((TA8$6WJ4%2J:2!87M*5)DM$<
MF["\.RG.6'I\>6D2'&99?''AY, S+&D-</>6B$E/E27Q<GDKM2F50HHZ4MCM
MDO%+GLI"GF2-U<5SL UP3N>4B( I7IR#!E[+CH1%X]#G)*=&J3&1N2NL*_ J
M?-(_)S6R-HSF!2]U7*>4!+ M&6K,=1LR9<J,&D(RP#+],C; M;IZJ2O]!H12
MN0L$)?J((&YF=8LI?N</&][J+'I8>2W*.>PF$K(DF5*B]F$9L@S );5'/?6=
MR-2S^L+&"-*$JQG7G*&]93J!QSGEQ)YT3#R"U<>5EF\GG\3:,C+X]J/+F5"%
M2DC$WD#J^J+U*4@#<WN-*ZA1M(JRCC\9WJY\2%Y:<LT?+8\&6 8[4'CJ2GDA
M:7"%TX<X1(G2+'T!<ITU/B1OCC$WE$O=1U$J;"8L\ ;U"IP,;DRIQ]3),Q*#
M ,D;^VRAN(C"ULZ/-$61C>37-G5)FJI=('JH,D)57\VJAWY")4<V*,_   P#
MY._B# !!5!]8W(M[KM+6B0&(4YB<]2S-;Z@1ML)3KR5RU)?EHV9I2;46CS,!
M@CS, R\8[-8XC C:@L"UKD*%];&1SCS7*4#N:!%=&5R-7,93$T V[[+ X S#
M518QD&%@&6 ZR"FC#&CEX2^CPQTV%(H**C*<A[D"1"\(W6.U&>ZHMB]X R)N
M2,:2XZB*'C6'F&'D8P#)KO &NF=SJY2U%1MB734URAY"*&&,\3C:N]2_[6Z$
M+SN;AXEC5S6G<\:K%F;,7RQD94KHBYH&*-U;E$H5$-8J'-5-SV=R9Y@SM,FC
MY38B42]2\+0.I"A[,=5R$&><;EIS@8,BA#HY1<M"FIU0R;LDP+3+XYGI)(Y&
M0)RV HWG7+.&I&R+3-H+-R,8..,&.TV01ML5B=IC3Q\2L[4N&@0KN<'=A.*2
MH%AIR[9R1XS0%\H;@!]79@4TY:G*11>5I2T=2X^Z27;7%JEFS9R6HQ3A*'SE
MLP?(.R=.8:,8 $#3E\08!Q>=#I:^+U<)A,[;DD&YTZ/<5A:62/QK&:WLU."H
MGLZ\EC,&W"Y=]<C57$]( 9QQS<1M'Y,HJO(U# Z21YJ 91EX3R(9#PD.5)80
MTI*E31 FYF(*$-D1NNS)0'@*,,&<9G8Y/=)$<Y0!EE687(A/;Q(*3H9X5%VV
M$G,3LJ5G4S1-K6E5ECOV?+1%&#P#S"SSC.7M2HE\A#<G;:51RI$83O*.^,$-
M:XQRYB1QJ1M3(A79B4:Q*4HSBS$Q0R!YH#.3& P<";X_")$3,$U,R86Y+620
M4C>(P8<4N.5DQ>J,3J*0J3C9"QK!FF+(T:I6C ::7@XA-JU)6RG;8^J):* .
MS(JQ01='%G-K-&VA\0-+))G1,6!R1C:S5#?SJF*0XP$9@_06 _RJ,R)4A4U>
MA\Q,4S9QI'XQ7,C!!%K/MKLDI<4S-@#DZK*!LZ(M2/P.6.XX[.#$^L2Q.HFM
M49^Z--Z$]F5$$M;DZ+'AN6N.0Z7#  P!OULLT8,?*%@MP_-2/\1K1^^:.W1S
M_CBT(_U1(K=KYY4SV S#[W7*T(]B$;_6='\SU;OSS1\_H5^**GOWJ,_SKN^;
M:EOL00?U[YS0S]"J?][C;\ZZMW5?:GD85D.!B^:3.KZ-K-3E)3$J8QHFT\=U
M?.)QQZ8P ,M(+*RRS>/9\3,B%V/;&)5S:*4&$)@QQT="3#BG! R';=M"D:,9
M66K4;-D8\0"SQF & '6L@!.(1$)D%K.O4-@)7&F>1 ;C_P#3*#GE"HR1\)A=
MBRR@7  6'"$L <!98-\NW9W[1QD<ENS.<L7+&^/I;DJH_;EB-K5NZLK-(3J"
MR<M*WFF>J#"@<7!X=MSK6W;2:=/:=P6-449'!]7HV@I,>ZJ4;:E-6&%H"EBU
MM+$/D>2S#2OT2S;69Q;92>P.9#>:ECZ% A,EH%"PV\A4@.;SG1,G >BRC3%?
MJ_  "<T>,>"P#+OK@0##IL,=P1&"N#C"67E8Q?U,K.LB5J&U6T*%25.><TKQ
M(#%K<8:5<>8@5&M:YR1C/+\ W9E*D'$Y,8R^/;JZWD5-:WV+[9&Z?2=XCTL:
MJCQ]B7,CCXH+CLV1I&\Y:]D'-^U-2C*,490\:07$!@!9JG4>:WUE:G!4[H2F
MR3(T+<\(U+$[N+$L*5I&U<Y%@Y=O%E<IX&''@\"S] 2B'"YYCL=C<F6J3"TO
M-Q[?*7"1MS<4E.N/S!G '&5&;F%%@XY66,?'P3:.HB' M; W=K9G8Q44F D4
M*'B.,\I)-;C2#U(Q@R7PHL[,++XX1?6^.-P<$S>A2KW0:<UT7)T:8E6Y#2)2
MD:0UP5$$9APRR"0@*S/  '+MN?2U=BQQXPBO 24,P6CPN2+N-\VS55-L1R2Y
MB=) QQOFM6W)4LA0N;](FV.(^<&\YUO+ #,<25&,M2;C)&$9>/&#&,X=_)EA
MS17Z-')]?SK0AN9!KW,FH48>)9''8",Q*W"9V@UH).,5E.>S+"!F7OA647LW
MH!9F"W#?N;MKG]V(7J4?.S S9;84E.5;1)'A(Q)#<HXY.7@+/<0YO*>!B\/P
M+77V[-C(#D.'/!,:3RH2C*37MUZ!8Z*VTHK-SLS/QMP_K6#!AX]O+\JS YR=
M.\'))#*&R*IS&="4MV-8Y7&WEKG K.38$I>4/-,+S<'AY>791!R"U@W-/&4$
MIVS"FYK.;')>K;4I91FWYF9F)!:LK+P8>/;J\_YF2?B-:/WSQ6Z.?\<6A/Z?
M([=SS;;GT+;_ %76O[%UKM_3O=BW8MU;NJUWG[EKMWO6T=RUUNKS+5+]@,P^
M]YRM"/8A&_UF1_,:_G?FVZOH6T7>1U>;;R[>=]+YCJX/FZ%?BBIY]ZC1Y/5=
M;Z?G^1V?F.[:EOL/;_+.MU=:RR @(<+GA#'$$H-/$6EYM$WN2]8VDEE&Y^9G
M8VX?UO!X/*6\KM6\WS--M_1U=FSA*'8A<I;VT:,!Y+<6E4+A<Y+D3<5E$G*$
MY?AJ@_7;+XPD(6C5M;4@=%RK+2["GYR^Q$!IV=F9^#CX,O!@]';JX;K4,_0J
MG_>ZV_,;MNKO?,]77M0QJ0.$J8VO\(%=RI!(8HD+VIK:UC]4A&<48X'(G,M'
MM&=L^T>'Q^3Y2SQ W*/+$<EH0M:Y;3F3IX^J2QJ4L<<5;8R&I'9$B3HR5N04
M)O<$91N/^R,&6;Q*5S]\BBI[:ZC3N03=S2/3-SJUMD;)@;PC@B:0(SD*E. C
MDBE!1:CZ\KP>F6I9'))3R0(ZE.M3Z@IZA3-PB;RW-<I9UC/,%#7FS!:BV1](
MV+9=D1IURG90%8,!.#!:3'SB /=3FN@$9=*5)8:DB9DTNFKRY&D$E&E,%Z)R
M&I'S(4W@--RC2_5Y_P!1:?<SP:5L\HE*N+N\W21;HY3"+LB5,E<2E"2+M].Y
M-$:<CD3 B"4,#LC;RC%SB2,WZX<2 NC#\]442$L$2K/*.;3F"C\R9$13.\0]
M84TR=!2F372MWB:'GBY/FD&91 #T85_$SL=FF3-=)UT97W3JI-TL5I*/U+*E
M?-BV.REG:E4EKA()&I1O[<XCN3J$K>W-IJ5$ 9!&,&2#'2E_*A3G&21=&Q6*
MI+B1&70E:NE"153TY(EEFQH<]2XIP;:6E3J,P\  &EE@P P6J&7&D:Y\.?X
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M@LKJDGZ,,P&T+4[&"#HF:7MK^JE;FY&JR' :S8V%-S2UHC$?+/#@467@& >
M%ND A;V1TI!4ZF),>$L'$JDMLN3D)W9^1$!,:9W#-@+SM)1I9I!?@:,&/3IL
M_P!(%4<,O/A5,8E,3Y6<_F*CWHQ\92%IJ8UJ.:N1&7B^R-I-Q_G=J5OK-1%S
M?W:J<RFT-;XPSSE"8L2K(BH,2E*2E3E&V\@X"@8,9N9LH" 8C,8\%I$\.71M
ME20-.9.7':MCOGD94-4(SE9*(DQN<"4&8['Z3<S9R$Q0 <7E]%B5C!15ZE\3
M(CC9)7F<2"9,E,HX0E>"BEB=NC"^2H%0'I< !N@U&B,Q@'Q-%NCI+*3,<ZF3
M-4&DSN^I*4H94&,MKNX*W _+4R':E@D -G 2/U8H*-P<6TK1.T,<Z>3N!/QD
M=F4,<W%,\&-:_+S?4CTC(3%J2,'H\HJU3.M 9A][KAO6A'L0C?ZS(_F#VA\=
MG,*I !.)Y4L\0F4F9XX6L^Q#97((S''M T@,],^VJE+Q.4]+L2I3&@/3*"P*
M"%"<TLX@Y.<7<:484:3X0# >1U:_)N;3%NQ.!J]8W(D+LE7LZIT4-J7;%?,B
M5S)3&+RRP<IM"/-!Q!<IQ1V N3%KBB3!*"@@<FQT9U7)&FE&YK<](FT\ ,97
M)#RN.#"87C+& ?D^=90L4#RTR4@P\\S 8/ G)*SC3N1LU2)C5;:S/:$AQ:UF
M0J2;2D5E9Q1N4M(3& XE_@&%%C\CZ%HZC _MZPV5N;FR1\3:(QT3+GAA2N2M
MV0WN#62H3DC3@:E6;F&%<<D1?IG$MW+/$ED"S8&1B;ECL[+MG5*]F;TA6<L4
M[(C(4&#RRRO2RRS!V*4DBQDJ"P'E&8<O$6<5G%&VZNYN6C48<U+E>_2XU6%B
M;VN/R)_&<6W&I"7%>O-C[4XEHDB<;BGS5:PQ*0#.#F#X_P XH7^**GGWJ-%N
MWY"UT=%A#>UM:-0O<7!8862F0(4A9QJI2J-.X@   6(PTS\C:1.9$B5-R:*-
M1#Z]ER>+3&'N)+&MSN;GE(U2UD95BQ*H,*$!*>C*-">,&66,8^)95-0/:\#,
MC>?%]4F4Q:5HI2!_VK8RF'Q$6,B=[&M,&8'*2%MN<, P&%@&7Q['U1\8"28*
ME:U#LM?%2-T2C2)$>$I66J:EJ%,K)/+&5EFI!IL\ ^3R\SB6(6)A9B9206>0
M/ :#&0<5G%&<MY-_;M2[V((/Z]Y%2C#F6:*&%RHY&VS;HHQ<\'J#T<L>%BM"
M2D6')RW &##S@UEF9YZ48@%EXS@6DK,JIRK9(NFG[,O:KHC0&:M<6D9!*&[:
ME4FZ+\GDBEW$U%GFB+5I&K*&I/ %6 O+QCM2.3N--) S1]G-JBP!;8+3^?W@
M3D/G-WBTZ%TU.\8W=@1+-E%Z@4<1%X \DNU,B9%'5Q+.73I4@9V]VH1-*M2"
M+3LU]6+"E[4U1J410<==,DU/E.[B;DAP!QF P#M+ 32G<TJ%/EB:F=]-IBDI
M^\/9S6V-IK'S\FO?V7GI&TGEG%'#<"#%Q>=X?+%\>TEDSXE6(G24R$\\I&X)
M52)4C9&THIM9$AJ1:2F, /(*_.K:NKC6H7^A5/\ O<;?F+H0H?E);Y>XD,8S
M_%V3#C)3X<7G%L1LV)8^9 .)G_L\Q=G:_ LZQ1!([AN[,0X'++SVE]0M!Q;/
MK=>:I*M:DS6M&CT^JRT:E281]<P6=@-+\N")F:%#^?<Z1:81W;V HW(-?H_<
M_LC=SLB_]+:]J)'C#Q^."QKG'BI.!$7L^$Z2P2=PG; +"LXI4WESB/QP:D@P
M'U]/F@_)^3Y=HB3)3'Z]2_S.J:%G01V&2^;.BY0CJ--5:LHEJ@\=D:O 606(
M>9EX.)9\82E4D.1MZQ.CD;(>742E$I2&:"5J5*[-2PF%.X$J@'ULPO)/!B+X
MX,=B$*1,4E1)""TR5,066$E*G)+N)*2E%:.( L')Y=UC9(VLKFG<QFO"I(6.
M73!4SLBQ_P WGQ?%(VLD2E U*E&:;FJ&M,F&/--Y3CCLNIS%AJB7)O3@E#FF
M7K)$^.B@#ZJ-)YY=9-(#W-0M.,,2#+S%"XT_ 2$OTL ++FEL4N"]8V2%1&''
M9F%].2MKXD9B7XU(XN'-6SDE[*J*]4&&%DC&,)!9F9Q+=JW5UK22"IAJW-SC
MQ "I*G,C3Z-A3[8F1F\U&R8YJYL.5#(<"C.;RU)IV >88#+L;,KGL!461.3A
M'PJ -SIGG.[0\FQ8UF:6,E#>L4JMN2#1I4Z9,8,\>'(+'C!8HT%P[@&E@,#<
M:480?@.+^NDG$9@!_P!3,Y2WEVNNNMU^UY5E$3<KIHXOZ-J;WI8WQ&EU4J@;
M"UO*IR1MRI>I@\0D9!.T#:E&4 PPHSD160RB%J4:U@?]H<R%:-,:BVE0::=S
MCS@E/)3GDJBSRAEJTZ@HL\!P1 4  8 8+=KZ.FWE=^PU"8MP+*+5N",5SDUN
MC,=M#:J.1FFE)'1"F,&1F$BRCRRLL\& Q.,98P#'8^32A4K1M)*MJ07F(6=]
MD"TU8\N"1G:4*5E8$3@K4G*%2LHLHM.F,'C%96F:&^<HC$90#SA2VF%3( 0,
MLT[(]2JY]$HZ6I,Y+TL@PP8+%ID29.C3%<0I.F(*((#^AE$V<#V)=MI+2]N\
M<7F7)E:7*>&%>:W.R;U:0GQY9Z49>,ODQX.3,';R]VURQV<F]J1B/2(PJG)8
ME1)+E;BI*1MZ;...3EXU!QH0$E^C&()=G%*26X ,;%!:928J:W1$E-&<F*68
MV]6L1)DZT&6<'E$9AH #Q QY@!@\C@NLWMSV>]*75T(4*D;-%89-IX]B1HS2
M2CEQK)!X[(E9"4 S0EYYA90,?$QV9G"-KE3NWOY"M2@<$;.]; 'FXT@E6E=5
M6PW%MZHLPW!L;CLQ^, @8.(/ 7<K3IU-Q1I:@L*@@L_*4$^E&%9^G /^J6W>
MKM^1VN#L>1]'K6?9"WIEHWN2&%C=W!T>WY\/& GTE W\].KAL24&G[$1[*1C
MY3!;(1ITZ4FX0Q924@HD&8=Z:;DDVD?XBVG]\\5NCG_'$H3^GR.W:M!ZVIUS
M &*1JFKK#%R!0J7@D1SFO=U3D4I2)26O9QDX%'AF*2A_D+-C4RO9$;EL3E#)
M.(:]*TG.#<GD+(8<8F*=$M]PL:8RX^_,O+N^I\/TL<HJ+7644P430%*9/32G
MS'3@B3IH>W>,2!:2:^O2R0)[EF<8,_7LY1H  $+P^("U*Z.-TCAH913Y5'5S
ML@=CY"?3R8\Q@.O,9W0UN0MZ\248^4^QM(_J 7\I:O;4)30QG55>8(0E:6^#
MHI%%HK''-B<"EK@AN;^87 RY+^=*,PX\\SE#  QV.J31F7TO;S973F/P*:IY
MVW2=:-!>Q(2&TMXC1+,1ZI%^=%J#$H/SP [='8AXD,#5J*2U"GLNE)R!>^W@
M<4DH-$>D)9"SHLEQG\?E0*-F #T QVZ3L52/$( ZUJJ,5+XLH4+GT"5"UDJ6
MY1LL@-)CJDPD_P!3"Y,@I4#\G9]?4#M1>0MLD@#/$]HJ4S2B2/D!5-#/L693
M](0&] ',/*NT*U''+QX]GS \>@$DI_*Z1-4EH[3%1"7,E\%+'"/OK@:J/.V8
MM,BCC>?L1@#@YRC,3'@&#P!VJ#,*F2%@D-2:I27QEDE\4(="HLUY)64F;&6]
MSNN/&27E^F&%%#M4OK0&8:^#3'7&T(]B$;_69'Y'9\BKT5JFO;F=_>)S(WU#
M&WF\H]TJ4R/Q913<3$&MSNS'K,^Q]G3YF ?)CP6D #)%,J9R5O8Z?&4'IFC?
MUT2YPVO)YU;"J?Q]S3('P\L?J=6C4)G,"7\A:8R$R?U*:79%6F+Q5&E9Y](T
M+(ULCP4C)=6M)'B5O-X\S.'RBA,:,CPR!DV2Q"456GL9IXV5L>&1<^+ZF2Q$
MZ%1PZ,DJ^97JH"UTYS AS_KYBTH9&X6>79*3/ZKSE@IX4PSQ5265&S^1Q1;-
M'9(ZDDQ4"N3(W-D4/AV1>;LB18I7[4  1F .\.T$<Y5,WDZ2J8E C[H CJ1-
M:53LMW6&E<X+HI "HXXL$U.6YWJM K+]2X,OB8[1)[F4ID*1,TURJ''F=0OG
M$F9&M&89!6T]D8;BT;TW)+LQ4;EE$#+Y3&(O ,L8R[16^IU3Y=$HX;&ZJ+&!
M[*J#(H:-]GS=.W)&RM"N0MKVWGN!Q20H6RM!BDP!P >D#PVJ!+'^;5&:9+"Z
M:4@?&YM02R3QI"CDCDF<CG!>[1AL7-J,X:G*]5HUJ8TG'Z#B L8N<7-Z9R'!
MSC[6)S:)==3PA,:Y.!)69()^4A<SV=MY;U6O1E9Q(,0R./:-111/9>5&558I
MHB!=&*QU#E-RR+DTP.>$B!OJ>YDQ-Z<$.U%#4)59F5_4!\0 [11OJG4N9QR'
M@C-6T4>?"I_)XTND\S89NX-$=9W:0MJU.H=E1;>2+9$"Q4IVK"(9A!Q@;-2]
MK<'!N<$U%F]0C<T1YJ%Q1J.82;BU20TG9S"3@6J,!'4BL%P8]16+U%;+AU5F
MJ@8)L=SMM;R::<]9@B3,KE6C,YK_ /0>*# 2D62YG8)$=*(8GCS&KJY4!J<W
MNGCFS,YSUS302,PIZ;'<E0-6YE^,!BTHQ*,K,,/3%H\RU&X>URF3D'HZ_P!;
MTDJ CJ!)U$E:#"&NII_-G.A[XH<&D:A#<49F(S$IYF<)669GBS[09%5:J<OB
M<$3H:Y(&^4"J)(88J=Y?$*AGL4*9WN>-KVR+%BHII)4;(D6+C-M&2(P\!Q@,
MRTF+K7-YA%9,9T=HVXT^8+I,^0LN:R18V/ITQ5+X>V7-J1Y78RD1;@WJ$R\"
M(L[,RR<8QVCZ(R;.;ZXKG^G;:W0QFJC-HG+8^T.36W(U995"%K&XL$J8.5-<
M'"1EFEG$ &J 6,)B &"FQ4BE#I":;N<X,15$DS7)7.$["UE1A]6,25PFK*M9
M3VE*I=4J).:>6N38QC"GQY9PP#I;)7)\F3V6C@M=@Q%X<9E+\+["V*JL5;80
MYN"?GI.0YD*&YP!ZL4%JN<0 2JU SC $C!T@FE?.E\87O%!8\OI:@\8%[:I7
MR-&;4DF0*82E).QC7%YK>8KV+EP  089R8 #LVICINZ/K@X2RGC>U0IFJ=-8
MA-&!L<D")&XDI:%+F-Q8)>P&#-4.#K)+C2CTI(UA8#@*&X& I&[2MG0R$%1:
MCMLLAA]5Y^_OIU.DA3[XH&?@&(A2EDCA%R=(RK4DC+<4VU9W*'G'N6S?,T*_
M%#3W[U&GR94_3ZYO'#6ID7K)$2YI"UZ%2UE%\JE.;SN3.S?2]G]&,006F%60
M3&"O+VE-I8L-@$$F#'+#J>4?A]1F>5J_&5*P+G'/<<%ZM8XF%<@#)R$^/)SS
MEU9T;NW'4B2](>)N"J:%*"AQC8$E'3H&KD7.GI&Q)W@T",U?F8 #]'Q+5!5H
M:>R>6TF?5%;ZC-;ZP., )9U7/#](SH<YN#=+9?'5@VY,0=SP48WIE^<,X@PL
M&83QXPM5M+BQ*#V1#>8U.IC0<X)?4Q/)JCF!S>4G\XI,\GM>9:EOL00^6=89
M@[]   Q"%^0LB/+7S)*U.*PM&CDKO26KK!"SCSE6QI/V:O,(;F@ #!\0H9BW
M ,8P@+'Q[78;]-U^D0;[MSJUV[/5U[7QQ4I<#7NYK3O?-;:POSPKYK5NES,4
MJ**96IRQ@SM.;]06',,P%\?R.[;AZM%J&?H54/O<;?F+Z=M\SIE#(W$YJ6N=
MV[QKC#',JB5'1WYB5*TL!*Y.HV4L>#:E9A>-4,.67X&.U.HR\JV\;E2=?6!X
MJXSK %G'QQ@5ENV4.2I3_ (6<XE96T<0[,M-)>*JD&BI94&,CD0BT'<&>>OE
M/H :N2'+'Z5PZ-+5/JHS90>I\K(0D<0S'Q\$J:&F? JO F(N/E1FH)1D*4E*
ME9J4Z]VCI2^G[&R-AP$>65R9:;/!CY08^)\QT="HF[L+(^7U*KWLJZ1QY=)F
M<L'/53,THUF;91#% \POT>VDX/R?@6JX8^.3:CK+XQP=%4/FUV<Z;Q8BD93F
M:D22V,2!'XV/#2W&)'!7SB\>KCDIP!9>#  8X-?*ZNFME.W"M*]J!*H55N=/
MJ2Z%>+QZPUE<JW/\=AB]R0EJ\[[;EF<AZ7MP!IL8-HD=2WPNGCI%*MM5+)!*
MY.O,+E8TCS&S8Q>E=G)1<-S6X+W II6&&*E1Y)6,L8\>.R![EM39?%YHJZ,]
M-W&(F()G(F1UE$W. K/2%F)D:U.8_KC##?N0LVX!^8(9B0>'& -Z92L3R1WK
M!*Q/S0E/4HD3J]D]&]N<MA<&\G06,!:XH!A0#"S< P!^HLT#:ZK3695#5PU.
MMJ7%7.9R*7M[%)KS4E[MSXU.5SB1%ER=6>I3E-B?F8!A>9ZD.R<9,](>*@2J
M&OC53Z/N-"&)CE3Q'BY=-SG%]YT3-\;;'1N(E*[/2MB<UH6)G0L #@\AZI':
MOKB8-\YS651R7!.X2J3/2(H\VG\)<S=F0O+FX$$CSW TO, 669D@*(^QR20
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MK&!U#%6N7NK$Y-T6YX^Z&P*T<=;EZDP8"@@QNBUS,  /)X+=N_LVH9^A5/\
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M1>X&)T)6U#.VA1C,X]FP,D1+[U+&J-6LKNQ2&10^1,YYZ8Y&KYIE<2=&9>E
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M9^7R%FEZ(EDP@T@9FQ]8RGR&G1\M:JC\DYMYZ8U1,LCLJ2#),&TI%&,M,6<
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M(8+-R>ICI+W:XDF4I4T#='F.GQJ/>-6U(W!<UJX^UIUXSC"3>2VAS5 (S!Y
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M4%2VJ,VHE'4B6+$P"0(Z=,;W29W->$V2:Z5%J \4[E2=O,YT.V,U(8[QW+(
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M%*T2U-3* *TBI(>1GEJ$:HAE$ 81@XUYA>K3N:;M=M= J)7[O_-5!O6.VC\
M5$K[MWW*X-HX=&CF.VFZ@=$^S^"V#W</_N.RAR<J(T*1-Z0D]0M7*Z:0!*B2
M$$>F'JE9[* L  _5F=O19&M6T:H(C2.2Q B0JE5.J=D)5RIR/(3MY"8X]F"
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MQ487EC/Q"S,>.S2:VQYC;C6%H,C[(8B:4"4;/'CMDS&%JR2/4J4SFDCU.7E
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MK5J9PUFA#G,&E;+GX+W$*DL,RI;&)&K88\XN3<G=#9I$;C%K<4<E"HQHFUS
M/ 'B#M!PG]&]5/6./4UGZ(5-0$T]GP8>YL\W9R78QB.JA)XZG.2X\8$NQ\?
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M:G#J[T4I"Z.BZ,(#UCDY4UARU:K/.SLPU6K6,B@P9G]4,M[@5$_>M@GK';W
MJ)^]9!/66WN!43]ZR">LEO<"HG[UD%]9+>X%13WK8)ZRV]P*BGO607UEM[@5
M$_>L@GK);W J)W_]EL$]9+49;4U%:1)4#H74?G1 GIO#R$+EL;$W').<4A+)
MEG98S1C*S/2[>X%13WK(+ZQV]P.BGO6P7UDM[@5%/>L@OK);W J*>]9!?66W
MN!43]ZR"^LEO<"HI[UL%\KF2WN!43]ZN#=W[B]ZWN T3]ZV";G!]Q+>X%1/W
MK(+ZR6]P.BMW_9;!?6.U+V5UZ/\ 2)^6SN85<:1/B^!0XY6W)XW)IXL2>G1U
M28<7D-(491>87@+"'ZC!:?MIG1AHNL/AQ4#*;AF0B MR1Z=)VJ<FUO2N"L^'
MX&\@L]O#FK#-IX@\S!Q..LC4[Z(5"HPJ+:N=VM\B41C,ZAB\C:2DBML5R!RI
M; C$KB7FA'L9B*_&#$86/BCM>(R@E%L 08A7_@M@N]_N):8HS.C91R-DQLXP
M]H5N-.H -/)(N4O<V@Z3DYT739  *V506:7RN %Y!F/EL $YA-*>CL8%>RF2
M5#>"#4V&!9'R<K-?DGVKXZ$N]45ZL+XG*AY3CV;9<7".C&^QQSEC1"RGJ.1F
MC+JUDO;NH**O+5N/J5.66F+.VQ7RF8 @ C,%GA"L@_1;1JXZW&/#^C51JDY*
MIE:"=CS71U).17#3)2]J*]4*,H'*A^KM /$VC71MG3).9!((_=)F&,TQ6LC6
MI8HD^RDTPYP;(X] %]R@)S2\PK!G9GH, XJ;,X'T3(POE[:B7M"4]LI3L+SG
MEI<PZ*.+FQLACFDQJ@Y2@M,5CQAX@,6"WN!T4X/<K@OK':7-5+>B-0*<AIZ>
M0@F2UY88?#[S'LYK1OOBY#BB:9ROG!:6E5)S#=M-;" #6$%YX^7R8LKEU,.C
MU3I5,&U.X,T>J+ J90B2&9Q:3,0J&-_1IS]J3C4@(-+!FX!BP63PY5 ^C&GE
MRQ88VI(L?%Z3DR-2X%)$BPQ E9#D5Z@9^0O3J,!9>/ <$?HP6/@26 ]&%1.B
M,P2J%D1.E!TM3WE)=K.N,C1*&Y6# 0:!1Z5X L=FNG<7I%T:Y28<RSMRE#DQ
M1FEKB.'+X2OBR,UF?&]"QJ<HXSQB.^R#4HP;&+DQ^@6G0.G_ $99NG:S"2W
MZ(1*ELE)0"6YQJ8M<:SHU.2(S)'E9GU%ELH=NCY2-:$M2UM;:U-E*( -U>Y
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MJ;M?]CYED3$XPCHM('MR-3D-[*MC-)TCJN/6%[4D*2-YZ+/.&8 X R@%E\<
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M0:4N-5E1RJ$4J40I3G,I8U8C3%D:-4K1@--!@XA-JY+FN%Q]X?9:Y4_$SH3
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MHE=&2+1TT]\;DRAE1L4K>1NC"^K&)44:TK*)PQ.$@PQN.,*4;<:/+P<3ZCW
MJ*>]7!?6.WN T2]ZR"^LEO<!HE[UD$]9+>X!1/WK(+ZR6]P"B?O5P7UDM[@%
M$_>L@OK+;W **>]7!?62WN 43]ZR"^LMO< HG[U<$]9;>X!1/WJX+ZQV]P&B
M?O603UDM[@%$_>L@OK);W :)]C\%D$]9+>X#1/WJX+ZR6]P&B?O5P7UDM[@%
M$_>K@OK);W :)^]9!?62WN T3]ZR"^LEO<!HG[UD%]9+>X#1/WK(+ZR6]P&B
M?O603UDM[@-$_>K@OK);W **>]9!?62WN 43]ZN"=;_W);W *)^]9!?62WN
M43]ZN"^:R6]P"B?O607UDM[@-$_>K@OK);W :)^]9!/62WN 43]ZN"^LEO<
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MDQ%Z>3]47WC=$A9?'Q[89]1:H[W'W*GM7J*CF\O=)K").AD-/:B-#N2OSGM
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M\K:$QIP ?7Q^'9/)%$[7N#0979_IT5!2V"' :3X^B*<SBKC7 F.I7/;0#2@
M48!RO!QN. 6L=J,.3A5'G-!553-#7BGYC%#B4S"!A!?LB6/JVQDYP !./B&[
M8N5#&/T?H+;W?M0O]"J?][K;\P?#X QA2,\9J"1/:D3T8S5=PYNC**/21V/&
M.9Z@PY<9Q=K,+Y!*#D_3!X+42&NO9PKPOU:_'X2\24'VK^V_.WC-MO)Y'I.;
MM'$\&TW4JDS-)8JKH?\ L'+@:<J*M;)&"9&SY*!U5D^-I"P!@\H\I87LQ&0'
M++2<?':JB5]51MXE 6ZGY[I((61S7&%B UK<;FI,5'CCW$9"HL&/-/,7*L\
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M5&P>1IKZ2U(J(Q+6.FU7(HP)'&%&M'-R%NFDS6IDDO;E ';[J,Q2$ \ 3"P
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M#TI2@U&MVHG."$>#,X]I W$Q=2)OD<<>8@I;U<IF#@W-<4?CLYUB\/;ULC4
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M=']-K['[.+%KFOHH]-IU1"5NA85K50]$O1&*"7162K)+5%3C!B3G%C(-!=X
MP"!Z&WQ.^G?O?\P";M?[]K:^A[T[/D_I_;O;3_ ^Z=7R?T^[_=S:_P#[G?3M
MTWZ/_#^GWO\ EO;7T/>G;[P)%W>NF]OB>=.Z_1PT"3=_]F]OB>].V[_L!3^W
MNWQ.^G=\GY-=Y<XM===T/.G;=HX>C^G#V[M$YM??_ \Z=O;Z/Y&B[^_F^WQ/
M.G:'LT 3=Z_QWMJZ'?3M_,T 3B[WCO;3_ \Z=W8_@_I]?!_OX\NUU]_0[Z=_
M8_ "GU:O9KYM]M?0ZZ=W!KH G]O%]OB>=.Z__L 3>WBZPKKNB!TZ 7ZM?X "
M+\.CZD/CKKTV#?\ P0.G-BX?P %:1:]&B^ZZ:>=UK?$ZZ>'O )O;Q;XG73P[
M5 $_MVNM\3[IV:+N&@":[=Z_CS;3_ ^Z==VCAZ/Y._\ \N;:/X'G3MT<%] $
MVGN^.]M%W0\Z=G:H G]O%UOB=].[W@4F]N_[^;?$[Z=_R?R/;S:Z_P#@?].J
M^^[7JH 1=WO'B^U__<]Z=NO_ .W\F[1_?SY5OB>].SW@4OMWM\3[IV>\"G]O
M%OB=].ZZ_@OH GW>&[]F]]K_ /N=]/#Y/Y'MXO\ *MI_@>].S5_]OZ?N_MX#
M;1_ ^Z=5W_X_$7>7-[K?$]Z=OO!I?;Q;XGG3M]X--[=[?$]Z=GO!I?;O;XGO
M3L]X-+[=[/I)W1SZ838^L\:;G5'#UE!7(V421$L?PM1JAH1-CFY)RB$V:(1I
M[F>W$7Y0BB3#E%X2!=&O=^.70O3V<Z3:-WL6U[O8T^1N]_@M]/R/HV\_3;=Z
M^[W[?3MNZ>W;=[>FVB[JUZ[50_%Y,_O=<;075_O/C&__ .Y4=MSR.SV>U:^W
MT;7^=?WK;O?M]&WT_(\Z_P B[S[7^?;K]NWT[?3UVW>_;JX+>9KT=SR.KS?)
M\RV]W;=NV]W?(^C;Z=J"Z/\ H<IM=?\ W',^_;AOU\-UOHVZM%MW>['E6^CN
M]^W=\CJ\_P C5IZ_8NT6I/UH:V=SE?/\G=\OR=WL;MMWJ[=O*M0/]"JMWXNV
MVZ^K>T>7Y&];Z=NOV]=NYO\ S'6OTVH.PMR[9FF5U%KVC?TFRH#]O3MTEJ:X
MI"LTXA4,G+/2!,]3F%>#:MC/#!N2^^+,E+U32D9(\@?W]B2ORJ1DRM^C[)>B
MN,<EQ9#>!0D;S-JQC*" LL>/ .0LR"M!]36EO:\3M&ZBQMK@5:H2_D*D>5SA
M"FVGE,3 M2DA7CS'!H+'C '+,&6,>"HLICCDH9WQDC2]>W.29"E=%2-027H*
M4IF]<B<4YPR]/I9B8W']0.UR]15?I/2@IO9W!T6L%0^CVGI_%%9:-":8=<=)
M3^C'3' ,OTPDLMW*QC 'P_2[-TF5-<L$A=*4+*QDEIT+6:K+C"/F*XU :7<]
M?9W[(2N3+,P<07+_ %8AN-.:FE!:HZDELXRTT&5WTXC#DL5HVIWE>Q3U3<?M
M!:!0I*(8N>%0""18R &<G:0-!T.J*M98DZQ]KET[0,[&.&1WQK*;C6I>J.-D
M2=>J(P. ,[F]M7F)0!$-0 DL8!C21<MAE2-L=WJ01F,3Y6D8_$N52>*EJN>X
MZU'(Y"I<P'D<WKN4<&U"2>-O-R#Q\3,=528>6>E;EB@@> L> PE,<<6;E']B
MU,'I]K/TH%[](&Z+.SRU*.CJA;:>+7!8E1K'!#XZE=%=O3 :C3#!@VLN0%<A
MR@%6GE+1166WR2XJ73.>0-MN,1MF84[T]*FQSVJ<?MI=@2F>)*O9#"\P8\96
M8 &,>".3*.48K(^()@E4NC"D0MD! H/CJ-K1.-TF4KU]0F]L1$F;6!.D1K5Q
M+@<, LA",L QVC)L3A52)L6_0.-5+<;HRS1XQ?$H?*E1R1I7/+(Y2=F7K!XV
MU5FHV)$\'>I!<3CDYU0"6A@JE4-TC]2&R$7QIE8X>8:B<'&$1N593(X&JXJD
M3,X$KMGF+Y$XIA[6,Q. P>-$2.Z3-;8^LF4\R"/N;')4R%*],KW%7USC;TV.
M!38N>4@AEJF\W08G4JB1@PC ,=F6-P9P+:Y]425M$)B3B8B2+;FC;,UWDTBV
M182H3CYK9VEP<"@'EF &>246, \> ="$S(GE3;)Y;4)U@55'6 @IDK<(Y(*?
ML4ONFS"VI*F+=C!>8Y1HU028:A,]0IC<O K-2EG1Z8N":I4-BCG32<5#0>,3
M=!!,[Y#XKXE&JY.L*C[I)'<!Y?C$ AO2%[+G^JLQ(9ZB'9_>7"D%96%6R(6=
MP0QM;&H^Z/<G(?SMB:B8V=$I3(V_/N/*P*TZM:A&A!ZH< )B!YUI6A%%I;#'
MZ$/:=AD4:F)4?YT2*UC.VOJ!42JBDBE2 XA0E=BC"C$ZTWT69@L_R!N+ H?@
M$)VF*HC@8P.$P?513%%$!V_@,7+T^=]0#$9Z"SFUO4B3F53I_5RGD"EKP2V,
MP.>&B53R*$I'F]IV'9P<ZL<A*S<M,5@.&;L^#""S8RBB,^-8WF=*:;M-0R6V
M.^)+C+VPIPYU0E&^-%SF M.-K5%[8H;BR3!DCV<9WIEG5V71Z:M+$GB$EG<6
M?7!#'Q-]1HQ%;[C7ITA^R2=Q/!@+.3F;.\)F@\8%)1@"_#N _+Q1&L!2U!!(
MW*TM/>98.\+U;>_/K\SLBIC*C#Z]'[:M$W8S2UKD4E((RC#-FP*L$J;!Q.6P
MF0PMT1M$@CLQ)CW."<QQ:D+PWJB5<5D4K;SB#"' H>86M,_J@ 6D,C1A+4/!
M*8M!'49@;A@7RAW5$M$?1':KN(8N6%9O]3Q6E@ZOG+Y)-*9R9KC4ENCC8U@=
M'@N4N#:3%'A*U$',J?U20^$&&Y>4#'FY9=H@S1^EDT3NJNJ:" 31ADA<&"Z,
MJ1SBYLD2K4BIMJ7>@'M!&4>486I57  2: P #\L ]C:V:I=0Y&OF,X9T<<0-
MT#"_%$0]SV20*2C#7.*(.:D9A@"T@U*K;3P##Q#AX[.L@0-$O(2,U/#*EJ2G
M!K:TJWF,E<[MQJ$HF][O]78V,WDS,H'&#Q[(EI].JJ.48-(BQ[G-VUDCH8NR
M73 U(2U 4F/,O;5:W+&Y$[9S.B<P$8\ QY@1@M*I<T.B)G6HD:,2-R5FMA9A
M(%2](4J-:2WK0G.6Y!QO-Z<RXS&?A+P&>EC#)WE^<)8S.;NO40B3OC9'&22O
M43SOM>I?VJ)(FY(4=X7)EITP^)RA #+:=?5UK7]:[@O\KR-WOV=_Q#-V]_UC
MG6Z-7\<JA/Z9);;GH=SM]>W5NZ=&_BMNZNOKU6\_=UZ]ZVCS=VZW;W]-^JVY
M?HW-.O3U[:-0NUO;]MS1N[_6X;;FGN:]^WT<7;ONMU=7>M4_\7DT^]QQM!O8
M;%OUG1ZK;FKS--^];3=?=KX=6YJMIT:;N'@NZUK[K^#7N;UM6OLW:-'E6#QK
M;VG1=?V>&W8[G5QK;XMWL=RVC5P77Z+:M/8W+;G#QMS7PZK7:=_>\V^^VG1O
M]F_@ONMHT7\'5U:K>;O<&G5:[7=P:.MX.JU_8U:]-W:TVNW>'LZK:[^]I\NW
M5Q=%NT/R[:='6U=6Y;=U;^C1JTVW/J<6G3;1P;NKN7ZK7>9JW]&_:_J]#?AM
M?V;_ *K3WK=G5N[M^YOVZNSINNM03\3E-OO/9MRW7^CP6[&YU^+O6T>9O[OD
M=N_\KIZ]O!MW?H]7T[=6OM_1M=KTZ_I[MK][>W.&_1:E&Y^T]MZ^^;;3NZ=7
MTK=;#QL.BV[IZ^K=W>U;C"ZMZ\-OIWZ;]%N#B]G1KZ]O,T=W3;7?^9M03]"J
MM][#;:[MZ=WAMV>K#AMK[>_JW^[;5_F;[^&UVC@[';M_EM_=MUM>GKW[]L7E
M\-]^B_5;?OX-6_KNW[=;RO*M W>.2$J*3"%U"JF\1IY6LOC,T9BNHD[;W%"^
M,A+HRF*DJDA6,LT"=<@'QLP!@+2]W=:J.2:I\K<8\X^.4,83(DQM7BAFFQYF
M20]9(I(-4WXU1O."-Q<E.U9H@8RR\&!;4252R*RV=-<5<XW#B(S %T*CR0MP
M-2+%=SLWN52Y6L6F&#;R='VW0D !BXF9QP/<)7N21@>9/&N;5KF0W'.Z%N<S
MDA&UFDM_.K<,XD!^+B;25Q+_ $RUS?+ZATN>(Z>D4(7%#':/3"+NRE.<E.(]
M2.CI7F6$$#_1&XWMV,8)!5=L<42"DKW1Z,7H*;FM*AM8'%<PG('1ZS9LX[:N
M3@CP2S!E[  ['CP$^CDZI@J 3%&>HD59H74-O51 Q^<%S.T&N-Z55$'4F4,I
M;2MR'M60:>L1/ ..5R'$X]8XZ?(/%>E#[)8.4YLBF#JCG.4L[/&&$D\J*3$]
MZ;TZ8E3LHDC@88VN?$!ZGV4S&.QTX;":;[&2^2B2MII=&XP&J)CI*KE9JM(\
MU:6NCDH4(BSW=08E+1(6PX  E$#5C( ,!]R267($3^O1N"5=S<1@1$YQBPI(
M:4EYT<>/D91AI>TF\IBX]H=#B:J4I<HQ$6=CCP"S:'3%,^KF5H2)T> YTNZ0
MR@@"HPDG4?L1H,SE,CT-F0XRI" Z%12H%0:@QN-EP0PEZ*65';)LB=FQYE7C
M@H+4D)CYNH4)<#:E'@!@'G>F%TCB Y7%'=IIE O$=8T5!I:EJ!%GI1>WL+:3
M-VN)K9>WI$;VG TG%H%2SG@!(%YP,@>,>.G]/#9M&E3-!8:W1!([/U)&=VF4
M>$W&DWWS&DTI)D3(HC3TI)()S5!G.Y #$:4PA*3@&6=)[T\O8SR9/59OJ2X1
MN=0(V<P%Z3I*:L\ (C$SBA$OCG.Q)9[&2[I!F*4P *B2.0'DXQQN",2]C>8M
M?)9\^R!:1%4,2+;R9(N6/K4VQ]J9WV\A, A:X9!2<M$87D!^L8.6:Y545NCL
MZCD>BJQDC\"E<49WYD;GQX="ECW+#N>N<BSE1I#0A2)/4Q>0 !_*#VCB-[K#
M')HAD(131//DE.6.(ID3.AD9M-)?3=[-:C43VW$)25A#VA6&D)T/IZ TSC[7
MC)@D->Y4H6M</H5)Z)+1HV8I N=2Y(5"2;Y0D-.7.):,Y,.&@,*3F%J@8S0\
M?B<=_B4OK*T+E#F5%TR"YEI?S!$N;V%T*<79%*H^;/7MP=2WH!0D#LG ^-J4
M:4> !!.,X9S_ 'Q11!58YQ.V!^?FB-4Y0T[B,?:RF=O8GHJ-1]LE2G)Y-I">
M48,Q<=C$+:,[&,X$-+E]S8\0R,.+H]ND%>H\B>VB6NYK6:VLICK>YGJ09#>!
M6K,O(,3&XSQE#Q@R>/>IIJ&,4G85XX0ID\6BL&0HV=^<X'/6F;LCS<D9G5E3
MDJL"16@-4;,<,8%)0_['P#AU/XX5.T\$C-=9+/7&-O=(GMA0MS>K;Y<L5N?X
M:N>U# ZMRA<^!YI;$993@ "GU7RB4S!,6-J54Y:43Q")/!F)Y8*(1AHGP4<D
M+R+G.H$[YZ4K'Q4F 2'[#YB >/&8H </+R9.-!.1,I[_  . 0C09'S7%$-/"
MI&XORLM[2$R)M&L;G4MW&WN#>6:EQD#$7G\>TE.B:F JSYQ+X\[/#1%Z:(:;
MQ!@;D;8D:':Z/1]MEZG)S )0F%&&&KCL8N/G8\P$132WFYVA<==U;X\PAV84
M+VT2QPV U&R\Z\Y'7EY"/:E!EY TQN,8RC.)D\8:JF@(S2AG="HP7)XY%8*V
M(VM]50^9-TJ9'/969UCB<E5ZF4)#3]F-&,!P?SG -PF+--DS4[J*FQ>HK>4O
MBQKRWIKV*&^)*IG5I")2R#.V@C-,*4%F)<@8P<0[!QV*4L#Q++Y*ID]37'QG
MCU#Y!5EF;VR=N13\ICKY"X=(N=P#S"0<WN:?D C *Y6#C@!9AN%."X._RBEB
MN S]')H3XTN!J1R<'9R*5H-BET>+0+2QO1V:686M!@XF !@,5KEJZ:196G+*
MA7-BR24H0RB91<40YOQ-\+E[G+DQ;2A6C;Q*%1"=MSL9P_57U4;"TR,$<DD.
M?FV2QUX5LWC"S\YHTQR/+>H]SHSF*2# *S>33KDPR^+@/^KEL[!+VQT.GB;-
MDC$@A*:.LJ!ZYP.6&*82#Q@>5#8B,&<(9R!0H<\P\8C\_,';@\[OVT=?L=O<
M\CZ>]V;.WXAVW@_Z2#[=&K^.70G]-DUK^KZJWEWW=;SK;O&W/H6NWNMO:;K;
MFKS>K5;>TW:O/TW<%MR_3Y6CKVT[FJ_5P"[%NSV=6KC6\J[5IZUM[K]?1U[=
MV_NW;G>M4_\ %W--/]SCE:#>PZ+Z.SS.DM?V-SMW[]UM=^K5K[/!IMH_);E^
MC<T6NX-&[=Y5M?F=6[;7J[_E_E;<.G7=JOONW==KN-VM-]N'S[^O?;=NNZOR
M6BU_6U:MW5U[:=[M[FY?;?[/7W-'@VU[_:W]RVB_@WMVVO=\[>TV[.[].[S[
M7=T/EZ+7[FB[LZ=VVCAOWO,\JW:T]C5OWVWM5^OR]V^VGAU=7:MW;]_>P[]N
MOW+MW1?;\U^2W;<-_;WK:K^&_P RU_U/#IM?=??N=?K;UOJM_=T:[4$_$W37
M[SVBW:\O=MU;F*VK>NX-&O@M=VKK^MJNOMU]&O=[EO"\W7:Z_3_EK"X=5K^]
M=JU;^C1=;?W>UP6I3[#VWRS;>?P[^[;7AU:NYP6[?9_S5K[K_HV[NOS-=M_K
M=;AOUVZVC1HW?\K;3W+[M>YJM03]#JOP:/VL-MKNK@T6Z^_U^OIMIX-W1=KT
MVT]F[^ATVT:=&[U]5_#;=OO_ "N];<W]V^[KVONNT<&YHW;7>%W?+OMU=F^U
M)$**;4QITWRZHU:&UUF=5VY4X1UJ3-TWJ*[I2[RB9W3HO.4&)@)^47>C\ =I
M\OF,]IK.HI#5$;)15)I&U/!S(].,DN5E>*::*-DHJ<K4NA8TI.@M&M4C.VD)
M8" &>&C5E/D@$:ODJF&I62ZG=2+I9XT(D-[DK9E4)\3^=R3BTW+^J$)?$Y2S
MNS2MQYGD""6S1A3943FR*.J2(XJ5G%(2I6M:U+6<Z["ESSF].NVK+X^0 NS>
MX&RE.G1.D'/J8C6*D+HE('"$?-NU/AIIR)/DY?.Q'J<S*/XWI?$%:?C6JE39
M H?&(.YD*G6!U$8)DH>)@YOR,E!XJ/3(F<U6T;*DYO(1M.,\9O$S\=G%QB2]
M>J)9WA0R/*%XCLAB;XSO!*5&L-0.S!+&QF7IAY"HHSU0F*Q@'R=G^4DHPN3B
MA2Y;$SWBO 8]O[B:2C968N_ZM2K5E)RLOZNQDKJP:DC;[&Y*9 9HD8VQ^=4I
M4OYT*;F\II:6LA[6# X <$2Q(7=M0\"PH!A@[)FETD#R@5J#(^E-$I@50"D+
M2Z2C8[V".R%T\5LAL=% %91G-#B8E6@ :',3@Q66PLI]4\^(KW0&,V/29*PK
MUC EN5OC8R3 YD3-#DN1%XAJD#>M5'DY)N, ,D[!*)E%%3[+5##!%$_:&CQ,
MJ(P%RQC*V0G;V!W=(3EJ$H#W1.0X+$A:DM#FZ5F3@'9T=)'*@M+(F8:;N-[,
MO@$[:I$RFU'>7ABCYKYMB?,'SBJ1A3E).;4QZ4:8TQ9R9Q> Z2W/3[<F(E1<
M',9102H*><WR\YO)="HX33:^,^,(U6R&!6993=]B\OZ0''9+*8BXF.;*L4+T
M835#<YLZU,O:%ZMH=4+@RO2%M5HE2=4E.(,3J$Q8P#!Z79/?$D3:Y3N4R%BA
M<&;G<*DUN4O[\JN*VYP2(UC:><E;D12MT5%EFECR$!O'!X=J:/+L+F-[J.I/
M8$L?O(7JAHYXT-CZY2R)&JRB%)8!MPXRYEFFJ,H QH_#QC!C1.!CR].(%[Q,
M65*CCT(G\K>SE<$=#V&8&>+45B[TX;*WJTNSJE^S;* 8RN6Y4G'-&$\+D3%H
M=2V-U8/GY+++%T:71M]*?5III2Y'%]CN++2M1*@HTM:9M0SCTY8,Q&J !"YN
M[S*4B58SJ)*.ZZEE4U2MKC"1<<W>-$E;T<(4*&EK&8E-V5>ZEIDIP"1C3F"+
M ,RTBC:YXC;4WH:L-T$B^7'WYU52Q&LHXW5(V4IP1OF0B58U9ZC;S"LC)2Y&
M1GG /L7%HP_.*IW6('1U:KU\1FK"SR-L9UZ)N=7*'R:01YN:WDDLY65I4-2E
M4#E0CU%BQVJ!,VHE">ZQ*&R20-Q3F68>W'+&9K6+$I+@40>F&,C&7RN686/\
MG:GS&CK-T=:Q^.3B>A>HU2MO-9)5$T9+"Y/!DF5&7ULJ: Y*G&W@2'$&(DO'
M6!&6?Q, W$HF5+R2VUAD$G$XN$+G36RNL?BAI1,A>(I('*,)T#R2FS@Y@V=2
MN\,)A?#9O3+#7DF".T \;DCI^#.J@G_&C?7)N<')>U$QVY0F9"R$H%!KHI0E
MI0 &$S:\ P6(97*3*A*5(XZ28O;(M+WZ--A\J-))C"5_ES!'G)H;1K-I*RBW
M!:F&,!Q1G@#!IA\&B:SG1W=:EDP>1'+(K,;XZG 0RO;D[I66:7(6UH.<$YZ
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M=UYR.GK Y+)'($;+))7%Y0Z/[<DV>(%('6*+68\@A,J.&X&F%KBAYZ1.# ,
MAW@5>(;G<9"Y'**7S65))[-YU+WZ^3TVFS$Y&.#>ZRNZ5K#ML9T@B,"AR*
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M[.ECE+F:JM3:G-G.J-2?>L>&I\GT=O6,Q:@!H2R6E&F4I2=F 9CXPQ@5L<<
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M$!EG-Y>ZB4M;(\0[GMS<]D5&8E+<J D8D;\JYU5+"&TA*K+(,-/-1EFJL"0
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M,(R[0Y-$I;3Y6HF'/4)YV9O4;4RK *UAZ56H*,1\NJP"&G,'X=JIOR^*!A4
M5QF ;(;%Z!5$HG%ECHC5/R-P5$P62NDL7C5%[626J<%!:88P83# 98<X;6OC
M;-?)'2&SF#SKQ<)V6Y:]HXK)VYW<$#3>M4)@;480D'LF89X>&U3HG :8S\;8
M?320#/?9C%I33E<;(SDV4TQ*/1:<1UE7N9Y@,X9JLLLM*1@"#,&8=@!6=^04
MUJJLCSM'>CH@);%U/IA%Y"_7QN<217)T#0RO*)F7XTY"H&;R9?AA,QY8P#M)
M4L<HH[)**2.I\:.C$;E-$ZFOT2B8V>%N9S[+%/1JB=\4=UK<M6E)492-8F3)
M0+OMD/'AQCC4)E;2ZQ=Z<)?4\,=CZJ'OL61)F@J3OKZ@3(&I8ND9;8EV$T)B
M!O,<C< .(68/ .U.7N7ME8C(HCIS4=O-=Z1)J\"6IW]QDE/#6U Z.% R>< %
MJ"6]69EK#<D>3]6 %J>%HHI62<4>8*D'K:HQ6HL(Z0<SDCF0LB;N5'52J*U>
M:W%^?6I$ZG-R@Y&C3N9!8P!/R.1,,!2Z51>EU4F*G=U-ZT0AH8$L$E3V\,+A
M*)="'F-%+XHVE/2QC:UH&16-N+<"T)*(&40>6WX $ @L4/HRM4S)AZ*T*:V!
MR?Z-5)JD^72P]F5[?'8>N9Y#'&B O;4>UE'JW=PTJE0SDH"RSMC 09)EDHI=
M,Y359SJQ0&04^GB2G\G>;F>EC0[TLYU;?',I$J3MA*(YO>S'5H4*$IXS#A+S
M$HRQYX&@TFGTK25@35JJN]5&J49$'M(W/M'G))/_ !3;#:G'-EZ!U;S$CC&T
M[?'D[DI/1'I"O4I.P#P49BRJ.&1*7S&*,ZY]1FQI<W.SI,TD2;EDA,E:LEKX
MCB6!)E_;$TH\P"; 7CR<!=*WJ4ME8#HD@@=4&Y6\4?1UR&YHWMR>J;'-*!U<
M:%D7.8"5!#>J'EGF9 \GZL +0=.T1:M4TI*Q5-"X55BM1H;TB)?(WIM61AY(
M8SO%FKS6XOSVUHG4QN4&H$:9<0 8 *,CD1F NK1!XL[H ,]8*U4W1Q1>B5IG
M8<;G<P6-L)9E3>?=<H2WII&TM*<I&H^Q25A^/!@'9K@TXI_*JJB1='$"=K+9
M(<_38\=0G&2RHXZ1&I6!$X%MCBM5K%!B5_4%I0(AC,]5)<[CUE<:@Q)8R2D_
MQ"?7Z;(X&[K$LC1W4_AR1\5%2]L9%);@,#P6YJ%:<M0:< PTU68 &:,=E"6+
M)0.CPU/L0F#:SF*"D0'\R(RAGD?,^UK%"<LDQ2!O&648I-*  8@Y@P X]H,.
MFPZYM20YQQ5#B,OI2V0VGD=CY+&XE*Q^-4^IJRKUBXQQ.291;!(', P -'@R
M./:7WMQ;DSU0,I741EEZMBHM+*=&RR<./W%7RJM4FJ&H02AQVC:3&EX9T1P
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MRN=2FR(QS:B$^;F9"DU5M6,19G)@!C3/#C3HE%")$.:I80^DS*Y2].BZ$)7
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M[/D_8IOB[MF0HV4.U%F*C? Y/!89ADHG2YA3^,XHW#EB^/>+\-63$I42]KF
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MDT8%F2#DT;:EP8>0R;1E!%9U4:(JHXPF1<^0,#C&>?Y''#EQSES0\N+Q$'@
M+\]6:84K;RD*H&/DSP<2SH;XXU%CS?( 1\,I9&)X:1MTI518U*:U.;TK?X\^
M+\\ $H '#3K4H#_KY8S./>%E;#E:DG;5:\]8OO2B7K%JT[-5J%1J)$VEX]7Y
MWO6W>K@NM03]#JO][#9;K=6];<N^EO:[=K<W=S5INT6CJS\((%:B3SU.TQ^C
MK,R1A:SKZ?DE?;9]<'!9'D[V!<G!C4&J .6Q$\7D!VADB'*TKHW5;75$9&2$
MN32SH8Y$%<6YR\7EJ5V;&3G,_,&W?;#;%*_'C]3@!9[99G4514AI8X!=))^9
MS%%42"!2TU45<WQY@7QJ/QT_)6@-%LJ1T+7*L  F#/\ #M.UT]V<AT:ZC/C0
MWM:5.40%D8RD#0K;VLXW8DQ@SBP+.5,,Y3,&(&/  %K]6_V>YV[=G?U:^S;A
MZKK4&;R;[KEQ%0^D.[M)V5C&F=V=XJBXMRDHK\\+&5:F-==K+1M0%DDB[,I-
M(VLEG3L]*WU]EAN63=F#]7*P)S4_IF-N$"TTC3U*9O(HS*:&O\X1#FL?HLPD
MK <_,Q+*_P %::;.KD[HFM20XBRB)1FJ<&'CC,".R,^)S>:*(XDJE *=+T:>
M,4614R0GO!C-<]QM>KDSKXXN#OD.P5&ULY124&,H&#B'#LUTY/D20B8126S)
M5/7QQ1LZ4"N",27G>/+S22&O9R0+/&!L2&J$Y27P3S"\!@+5 &^3N1F3.ZDS
MO/8V->R45?X0KO;71(C.E-*I/3L^\P;)]M2@%))2B-6C <49F<0_&G61:;S%
M<P(:J4XI^YH"(Q1MMI<G6/ZI@\8(L\JI*Z^.J]T,2O>T;8Q%%)2,98,'$4CL
M;JTWX>]V[K2:)-A^P./2.E%1V"/J$X,L::8(JWR.+.KH7]6<6UR8"_+_ #AG
M$/T-H%2^EJ.:M+<-SZ2#L2MIR11\;PG!"JLN+.U,QOX<71O: -Q8'89BO9_5
MOJ8.7@+SAVI\I'+V)M,J?3R)K)B)K+C#^R4*&L7LZ-PJHWO;6AD:-8U+.=AD
M$@<5JY+G$EGEG\WDN!P%U-2I\XL"5SK[^#U)/"&>%'/K+'V>AC#4+FMJ)<HZ
M>V#6NKCF^J%C:OT .- 6 '(9,#IFUUXN+*,BM6)$\52C#%3<]\?72GTC8F%'
M&'!*\,LK9"#T()";SWL:)*,9Z#D"T9>,@%.IL^ 1%O$HAT?>W*]O*-(;CECD
M@).,5-Y1YZD8"5'IY(##<> 8;2.L#D:2C1TZAU"$TC7FAXB:$3N45FA[^-2;
MHNPD)CUZ)T-,\  &[E+52G3:K#&Y96&-]&%Z=G]>D2JCH>FK56RIS"2O.2JR
M5) U3$QOB1O2;06:3C0$9X#D^, T-)$%5',VY)T@PT[5U%%'8"9*UL7<>C^Y
M535M:U*5$+V4#HWKC 92A.TE@P 3 /).]4YL-@CC5-;$3BA=(M8YU((CT!Y[
ME%U&ZG^(;(V*DCQ'5#027L*OG![V-L3#,R0[.-&#'95+CJJDQMT@'1N9*S&G
MH8U#S&FI$A<G">7&^,!+S'7 PED+\34Z;9V8;8J]6&\MF9.!Y-3*N9$LVZ23
M,WRY&8F3'XF?^".T2DQ"::<2I,)RU3(G,QIC"A\CEYF6,8!P5H73&92J&U%I
M_.9FA/ED:HW&6)V2-SS%O%F1TT9(.ZN<J1-PR'4T&7+<T\8,/'V@!V"LPO\
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ME]9FN+5DB]*XTX(RHZ9SIXX%15&WJ%91$W<E&,LZ0A4'&;,EP)3BN(8L">0
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MIA3U7%;W4Q],C*N%1A5'1OAIAQIKR8R'->S[48)4/U1EX] A<?CV6 .C$<-
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M$BM>*E]2B8@U.C)&&:2DN\%2RQ^7>*Q>R)GE@=?&!E1H%2@LT>U[8VO!''S
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M!X\O:-II-5RJB5]-*>5;1='60BG1ZA0Q[0-N%E+W3:B"\X)> >$8[,6WM35
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M\2P#$,9=!WIH^\1%$%RG,^>B6N+R-*6E=8S'RWF4.($#>8 H.4D1[,2#PRP
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M=E&X(5.# #!J""S\J,=E[B6].&V)T:I0N/2M!=Y>3>E;REBY5@!Z/++R@?D
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M.$=>^<HZXJ >I5:;[:(TR%4#^QU0#!G8PJT+U,&6*F/40DCG35K6,8(*]O\
M DC0DBCPON5QY2[DC3EQYL]3HW=*E/V K/(,Q'8VR/MD@E3*X,<WD]0XW,&Q
M1'CI/')'+WJ2.[X-!SQ'7!M&087+%S?D+&U2#93>/B,  ^T00H)A('AH:AR
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M"TK$SE4VJBIP/ACM&W"-QE0=*%3FG;%@D\C67WGG%JRS">;[EI&6<$S,"G$
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M8JS#I(H [M0>99+,4[$4V77G-RAP$8$P20T9QB0"@ ,&]Q+K3M2Z-TM<%IL
M@L1;6BH3C1]M<'!?$I*)[4JH@=1<32AP$%98V<<C5%F7G@N N!LUXPBERF=M
M[@C-=GM,>RJ):DI<745<A(:D2,1\Z44;*YE4C+,)&!((@1IFRA*VCCVNZ^GS
M;[=R[B^7?;7O=C1IW[:[OH]VW;[MVFVN[=W-_7O6TWW;NY==N7]FZSK?_P!1
M#=^^.HMT; )7!"I,_ABT)%@)5)U!F7GR'E,HD[7;Z&O<OMP]76MIZ_?X-5UM
M>_HX=[M6^G;3INX+MWA^C:_MZN_:[O\ ;[-KM_JTVU=N_M6U7=;KZ=S7:Z_R
M^MHM4_5=[GDT^]URM#4BNO-&$JI+%8X0J3**HP8@Y,H)9TA)R0TD]\O& PL=
MW@6U=(&B?OKP"[_YAM\8&BGOK4_]L%OC 44]]: W?_,5OC T4W/^E: ^V*WQ
M@:*>^K ?;%;5T@**>^M ?;%=;XP-%/?6@/MBM\8"BOOK0'VPV^,!13WUH#[8
MK?&!HKOZOPK0'1]\5OC T4]]: ]O1^R*WQ@**7\&FJT!]L=UO=_HG[Z\!W]S
M_?';XP-%-[_G5@/MBM\8"BOOK0'VQ6^,!13WUX#[8K?&!HI[ZT!W?[H;?& H
MIVZK0'1]\5OC 44]]:!>V*UVCI T4[=5H#[8K?&!HKN?]*\ W?[HK?& HKUO
M\*T!['_"*WQ@:*>^M ?+\8K?& HI[Z\!]L5OC 44]]: ^9(K?& HI[ZT!]L=
MOC T4]]: ^V*WQ@**>^M ?;%;XP%%/?6@7MCM\8.B?OK4_\ ;%;XP%$_?6I]
M[8K439WFN%'FEW::3P%N=&IRJ5"V]Q;G!'$V@I4B<$"Q\3&$G%F$B+-+,+Q@
M&"VKI!44]]6G_MAM\8"BGOKP'3V?VQV^,!13=_Z5H#YLBM\8&BG7_P *T!]L
M5OC T4]]: ^V*WQ@:*^^M .#V16^,!13WUX#[8;?& HI[Z\!T_?';XP%$_?7
M@'MCMKZ05$].K3_A6I_[8;4R:7BN%(&MU;XJ@(7MKG4R%HG%&H*SKC4RM*L>
MTY@!_P!3';XP-%.#W58%[8[:^D!13WUX#J_OCM\8&BOOK0#?_P"4-OC 44]]
M: ^V*UW_ '@*)[O_ $K0'VQV]W^BGOL0'VQV^,!1/WUX#=_\QVO_ .\#12_L
M56@.K^^.U$7-+6^D"AM:BZEW.2\BI<+.1-O.,>;2D'."LE[N+)V@90RRLSP\
M%KK_ .$#12[5_P!*T O_ /F&VKI T4]]6 >V&ZWQ@:*77_C6@-__ ,PVU=(&
MBN[_ -*T!]L5OC 44]]: Z_[X[?& HG[ZT"O_P#F.WQ@:*>^O ?;%;3_  @*
M*>^O -'?D-O=_HI[Z\"]L5OC!43]]: >V*S<WNM;J/M:TN35'/&B7U*A2)46
MG65*F#BE,V1:])S,!I"HH\H?UP PC]%;XP5$_?6I_P .K_?#;XP5%/?6I_[8
M;?&!HI[ZT ]L-OC 43[/X5H%VO\ ?':]CFU5>C=,67/*/O:)7.*6R%K$H)Y4
MI3L#PYJ 9A>YF9=D+.RUNH&SM+6E(1MS6UU*IVB;D",@O)*2I$:-[3ED@+!J
M*++*M\8&BOOK0'VQ6^,!13WUX#[8+>[_ $3T?C6@6G[XK?& HK[Z\!]L5OC
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M9B;DSP%'^F$@&"/E.E5*H^-D<,?P-E1D%].&J8W-$E27HGN.G%-E-D[*-*8
MI/?]R<\!B8H99X!@QVC[8WO$OA[0T0])3MS:HJY,Y"68P!&J)5)8I*C'ED>5
M R?32]H;C4*K+6* 9_+6/>Q2*9M#,Y.L6>Y) V9>QI8A*GR$WH_%IU>LV/'N
M8#".:4.<6WN2$@_8"L\L?'S'N]Y=+G$A4\J5+&3EI0<U,]Y2<LILO.1M;;CX
MY(C.4S1\?!F#P8[/#\TU@J@>1(Y0OEDB8'!#1Y4U/K@XX2C2W!V_!,G?!DE@
MPD)0%NY6202466/ #+LY'J'6621F/87^*L40DBYG.C,*C$J5G+) PQDIM9&U
M7D*.2+QN*Y<8 "8HLLP)8+2-,"H%3G-X?VAF84TR<'UC22J-,,;-SH\T1]4P
M1]F3Y*<XT9GJQ,N$IS30+!J0#&79\&!ZD$G?9(Z\\R:3RPUH&^O*_9RD:0:D
MI@98X@)+3D)2DY1:-$F  L >);L[FN^U)_8>V=KTZUVCN;MF*2KEKVD<6!GD
M[(DYG<^:M">5$HR7!3M2,FY8 \'-X=E4)U)8RQVD;@X5'JH_R9^8VV.$31P?
MF-KE4>8V=2<XM*-K5Q2+QPL>6><(S,<$RX9V(1:@9Q?$LX[5.*B*I>ZRMHFA
ME2!GPLB9%/["AYG:5*1*CA1##EEI31I\OF2\(P>F8S./9*4TSJH37)D<FD$H
M33\A7#U4PN7RHVXZ0I;RGB$.#0,A1E!Y,;1Q, <O!9* N=U-8UOBJHA+Z^-<
MA;%KY,HVLSCC$4F<)-'I%RF-4,91Z/83P8\&9@XEF6.H#51J)C;DC6E-5FE'
M*AIT9.22:K-))38Q\E^=VWNWY5J!_H55_O7;KMVSPQ\Z.;(%W;3VX3LR&I2'
MA"!67DF*F\U8B<2P'?G1AA1N[993U94:?RJ#J6,QC2QQ\04J;TC87FWFE.C>
MJA%+86LVHL?'S%"E5C'RA@!V5L2ZH]45R]TD#&_O$M5FT\6OSW?'"-GCS0ZI
M7.GI[0<B3;NS\T\?TPP8QV2M"JMM70.B1:>J3RI$;3-K>KR#B=B-:532STU;
MV12EPZR]I:33P&<H6>6/C6BC#&'(Q)#&!L<$JYK6"2JUSPX+#;CBG14K.:]H
MS\\X1YQA:DHL>/TBS+4!+4NH<,?8ZTK&EI*C"6F3DVHP..GG%4C2SZFTSR51
M@.(:>6:6/+Y/P+)'=XF4]$88W,[7,D2-3%$+=4A(PJ]L;O'!(3$.)ECQ?<8Q
MFY,8B_ L%X<YM/75@+D!$H)I^[.4=<8<G?T=Q5S>L2&+(LI>B0)S"@F%-Y;T
M4BQA](XP\?C>D?Y>O3HUCXZ1N&N:QG.B$0<Y3^V!='RD4=3+\9^:;]F+5H 9
MYN6 ./R(E<<[OT9>H[/ZG/,:E,94("7YC=":GSLDY2D*>&MZ0'%F$F#+.(6H
M5) P#%C!:0-L@D$SD\@DCLSR!;4)T<VQ%,DKW';[SHRM8SHRR1M CYN'RB0M
M&VE$8Q"S &8QXW.2'U"FTWG0F)8Q1Z237Q&3#C*=9DFF@:4$-IW'6OE#"R1F
MJ%#:J/Y/+QY>, W* RAU7A#(8]S,\O;)L"5QSSDQ12Q>@VQL7IP#O,N$85F)
MS0?D+$&NM<:I2YJ!<82ICDA9Z(DM#DF-)O)R59D4HW'E_P#_  ZXNT;+.F]0
MWN(0UW+>X?3EY7QD40CR](:<:TY:IMB*![6$(AG9B-.Z.RX@G 5Q.1)P.MS\
MZ7.QBA\<%37R:4O86<Z\K96PTY$UMV/+T#Y0PO'Q\!@QX<=G] 5,JC,T#EKJ
MH>9?3%H=H\3") N6&7&O6<K5Q=4_(R' R[[8I&I[0$GZ1<3,..QO2,*I\3)7
MNI43J>H*2GM@ (WR'W14EI:V\KFOB(?V&I,TOE1\<S+&#B8$SH@<9&<H2-=3
M&DLM8M:QD[/529%3:0&&WDM:;CEJD@2TGU!'IF<9Q[<R(YW4YB95E,XU2>1-
MK,Z10@,HB\.3.2-EYT<%D*<%:4[0[&YO-:EM =B]4%C+XEG4M:]&.+!LS&BC
MB XM!M3<!N0[&X'&G(FMNQ[0.X!F688JP8198P%CR"Y^J1J70TVH\A\97NY2
M:E&6G771=ABN4U9*%-@)R8\29RF:/&,7*8,  -,=0RVH3&S)Z;QZDLJ1-#C&
M0?A&@$;*6%-+/,#5D7<1DF8'!<7MC&-G58%YO+^DX),3M;^03)ZEP>J2P"=2
MV@"GD%/?$KF- W?:KB(C/$-%G%F9HQ8S<!X,8,$-&".3Z,P2$5CF-4+TCE-J
M;O=)[BWAGEY.W05*SITDMYQ=%LJ"X&H'LLIO18UY:08R\G.8*A''+[GJ.1B4
M15 E+-3<U'-\J=(HY.!BLG8,P9Q8XHGRLLPL& 1N8 SB8%Q3'*IM%KOP@CJ;
M$ L*J,Y=-9<XI7%')5,+2O$6>2-E=2WM:-P;W4MS2XUAIB<@@P=F%W1NDH7.
MK(SU%:SW!T7M9ZF0+ZI2-GE4QD3UDMB<&VJ%K( PK8RTJ4G-&660 O  %]/*
M4L-3CT"^B2"D5\NC<]I<WMSVD;"W9N9&^K[1,6E K)1(P.HS^<XEF+3RU2I.
M,C  @ U"):Z@5,"5GCC6Q-8 )OM<>TM>QNJK.O0IE&!2/#R:A2J\#,Q@QX !
MD8I#,EK4FDDIF3/ U:]D!#&.73 I41(9"U&HX\G=\\_G1=R"QV4I2=O-V<@'
M)Y:HI@F-1I4XQJE\]@-.XY(G.%$L;6V2EF*1EM!13/#X[FF8V]/I7N"DQ3_I
MA4,NR)#-YE4AVD@(Y#VAM<E[M#SUT#(BKRW2M&V1J]'%A(U("W%O*&:>\%/!
MZH!(2U!YQ806(DRZ95 E,A+F:"?*W61N,=&-P?VZ&K(45G)&:+LR<E+L2O[$
M1EI@ & &7@+X@W)M:3W!02ZR642I0)R-3'G%KY2\+'YP**O)1)^0*/<!EE>C
MR\.88/P[=B[7?OVUWW:>QPVT7WW7W;F[:^_K;^CAW-%M&O?WN'5;1Q>OX5K_
M ,SY^_:_7HU?1\^VK<T;MO!W[]7:NMV+]?<N\ZU^_P!V[3IW;;M_8W^#>L[?
MB';?WR%%NC5_'+H3^FR:V_N]ZZZ_AMJOT<.C1]"U%JD7RCF7\#[U('CF7F7G
M'QCO?6Y,W;-SASLW;'E[/CS-F4X_R%I?7*"]*#Q)?Y25>W)R%]$8Q/E##' 9
M(2(VU.$KE*@!*<.0#,V=.ES- <>_:GM3$W2MYIJ=!XDZ1%9,OP%P];S^G<GA
M:Y7*?%HR1)T";DU8$^ M,;Z3F8^/:?TSZ0E=%-:FN:)4R=$XHJ9Q.FR^,B)&
M6>0K1\P'.@#S,XD \:CZC!:!S&K_ $@'^L;?2@I653>-*X-'X>0RF+$W-URE
M[<&9>I&YC+(T QJ+B[/<&I<?$:!CEBY&;-GZ&4Q8MME3<C&<<%F=;V9UB9@R
MQGG9AN88;:1TAJA7A/4RESM$@19DBC/1N%TP#%[R;]*-T;G"/K7$PX9>2#B*
M/J+%5)J%5UYJ[(V&*EP2#C715IB"2*Q+.O,V$932N<MM/'E!S%9N6/B>#?9\
MK]XTYG/4(00WQ4YDO#LVR&:W3GOG7CYGYUL/YNWG>5:IWXO)I][CEO6@WL.B
M_P"LZ2VYK\W3?;1?O;NYO;UMSN]B[3;7=IZM6];L?FK7Z;]>YW;;VN[AN[MM
MWO=ZVF_7U:+7ZK[NOPZK<%WFZ+K7=KRM-^NUVCL>?U:;<-_G=>VG?WOH6ZV]
MYEM&GZK_ "MN_H\K@MUN'L</!;1N=;R[:-.O?Z_EVW>'N:K:K^'>N_RUM-MS
M@OMJ]%O>;;7?P>5K\NUW>W[=J[<OW-.O1:[1HW>OP:M5NOZ+AZ^COVH%K_YF
MZ:WWW;G^\YFW[=ON;EL6[=P=BUVY?]'KV\WL:>'<MW>[^1MIOMIX>Y=HT>=;
M1V=&YO;E_>M?HW=-N'L[F[KU6I1[#VW^O6Z_%[VNZ[3:[AOTWZK<-NK5;3?N
M<.Y?PZ-VUU]^GLZ=RVKSK7Z]6CKB[-]J!_H55NW^Q=M[-NK7W[=;>[MK^SUM
MZW6W;K_IVWNMPZ[7W]O@W[:;N&W9[%MV_1=V/*T6OLU>RJJ?[ZLUMINT=7T[
M=6Y:Z[AX-[>NMP=6NUPM/!O=VVGS-W5;L]6]Y]MV_3P]5]O![^YW;;FC@UWW
M[MNK5KX+M'#P6U:+KM-^JUW5=N;UKM&[P]?P=RUW6U;GTK;O!JU;W;MW^UIT
M6Z^NU_7T6T=C<Z^G1Y=O-[?T+=:Z[1Y?9MU7;VCZFVB_N_0M=WK;W;OZNO;O
M[VC5?N:;<&O=ZUM>COZM7#?;=[/5UN&W5]5UK:>YU8M%K]'!P\&K3IMKW.[H
MWM5]KN"[5W+]%]]UKNWO]GJTV[=VY;?NW;N[OZ;.WXB&[]\=1;HV7&-BY&'^
M&)0N[-4&-HP>G2#B>HUZDSN6[OEAMH[>[HTW]FVY?P]?3;M<.F_5KUZ>Q;OZ
M]R_AT:;;VC7=P:=/9MN;N]J#?=;M7<&F^W^6^G;@U:-5K^O?=H\_O6NU^9HM
M4[\7LT^]QRM#20='&M"PHF*QLLM8G?>CR60H+*9TOJDK;>D E,P&:,SE"RQ_
MG@ 6^+16K]7^C?JNX?C#V^+16S=_]N]&SROX0UM71IK9O_[/=&S?X/\ O#6N
M_P"[76O3?_[]Z-G!O_\ >%O[UM'\&JMG7NY^Z-?7_P#N'\JU]UW1GK9^K_1O
M\WI"W?4V^+/6W>_V?Z-?\H:_@M\6FM-UUV_S_P!&O7IT;FCI#=>VF_HUUKU:
MM'/W1JT]S^$-;XM5:[_]WNC7=V=7\(2ZWQ:JU[VG[>]&S3UMWI#>;;XM5;->
M[]O^C9JT?_D/;7T::V:MS[?]&O7IU?\ U#>7;XM5:O[H.C5_*%M\6NM>_P#[
M.]&OL?\ U#6^+56N_LOW1J[OQAK?%KK7^KW1K_E#V^+56KK_ &_Z-FC=_C#V
M^+76KK?;[HU]S7TAK7?]VJM?ZO=&N_\ _>&OM\6NM?7^W_1KT[G\8:VB[HT5
MLT;_ .R#HU7=OC=(>ZWQ:*U=CG_HU[F]=\86WQ9JV]:^^0=&GS>D-;XM-;.O
M]ONC7?\ _O#W6^+76K]7^C7=_P#O"VN_[M=:OU?Z-G\H:WQ::V?J[T:_-Z0U
MOBTUM_5_HU[^G_[A;:?X--;=6_<_=&OM?^(:WQ:ZU_W0=&KS>D-:B:!+T>JO
M/"5'2F )27EM>:!DMSH05$VDHMS;RGBN3*K 2H!=F%[2F2G8!\H6 SBV^+76
MO]7^C7_*'M\6JM-W^[_1M_E#6^+56K=T?=[HV;ORAK?%JK5^KW1I_E#V^+56
MK]7>C5_*&M=_W:ZT_J]T;/Y0UOBUUJ_5_HV?RAK?%KK3^K_1LN__ 'AK?%KK
M3^KW1L_E#V^+76N^_@Y^Z-?\H>U,T:7H]U?=TR:*H"RG1L>J!DMR\-V;ZH1E
M/-<F97@U_P!D)BA_D+?%JK7^K_1L[OQAK?%KK5^K_1L_E#V^+76K]7^C;=_^
M\-?;XM5:OU?Z-G\H:VKHV5J_5[HV:O\ &&M\6NM/9Y]Z-?E_PAK?%JK3H_V_
MZ-GE_P (6WQ:ZU;W^SW1K_E#6HBK,Z/=7DRA&74K(;%#UT?AKG7.CC<2=S>:
MDKDH3AV?PS=I4I?#Y/&/B6^+96OA^[W1LX?XPUOBUUJ_5[HU;^_\8>WQ:ZU?
MJ]T:OY1%OBU5I_5[HU_RAK?%JK3^KW1K_E#6^+76K]7^C9_*'M\6NM/ZN]&S
M^4-;XM5:?U>Z-?\ *&M\6JM/ZO=&O^4-;3_!JK7V.?NC5_*(LWIDW1[K \$E
MRBHQ@5[<]4# E$8?4N8FG)\EYKBW*,:<9HDYO)X,9(LL8R\ Q_%KK5^K_1K_
M )0MM71JK3N?^W^C9_*&M\6JM7ZO]&WM?^(:WQ:ZU]?2_=&OM?\ B%M\6JM?
MZO\ 1J_E#76^+56O]7NC5_*&M\6JM7ZO=&K^4-;XM5:OU=Z-7\H>WQ:JT_J]
MT:_Y0UOBV5JT<%S]T:_Y0]OBUUJW_P#9_HV=K_Q#V^+56K^Z#HV?RA;?%LK5
M^KO1K_E#V^+56K]7^C9_*%M\6JM?]T/1L_E"V^+76K]7NC;_ "B+:/X-=;/U
M?Z-O\H:WQ;*UW:?^,'1MW?E#V^+56GK?;[HU=O3_ -X:VKHU5I_5[HU_RAK?
M%KK5NZ+_ +?=&OR_X0MOBUUJ_5[HV:>'_P"H:WQ:ZU?J]T:OY1%OBUUJ_5[H
MU?RA[?%KK7VI!T;.#^,/;XM=:[_]WNC7_*&M\6JM?ZN]&S^4+;XM5:?U?Z-G
M;_\ $-;XME:OU>Z-?#_&&M\6JM7ZO]&W<^4-;XME:OU>Z-?\H:WQ:JU;G_M_
MHV;ORAK?%KK5^KW1L_E#6^+76KK?;_HV=WXPMOBU5I_5_HV?RA[?%JK3^K_1
ML[OQAK?%JK5I_P!O^C9_*&M\6RM/ZO=&S^4-9P77='FL E(Z,(D@V;GV@7.1
M::ZH1Y]SE>??7*Y-DWCY+4=>?F?6,OE+=&K^.70G].DUM_=[>_;JX.WNV[^F
M[7KOOT6[&KK:>W;=T]?1=YMM'=OT_5:]^VCSORMNK3U]RU_:W^WJ\RVC>W;:
MN#<[.Y==WK=K<T6J?^+N9_>XY6HNZ$2>1)8:R4=@E\EC1#PO)C*E/(U1+1<\
M.++G9 SDXRBBRE!A6,&/P[5<JA(Y&]+:?@@-SA%HT?(%1,7(2-LN-C;<\DI#
MS]D1;8/[+697$  0^/@P6BR2GA5,CWA+5B*1B7#BE5DLZABYAD;>L5I$K5,&
MRGBG$<8 GU6#84)Y P! 6,>/':3(9%'#WB(.-=7N#$2MPFJE0Z,ZM844<WH6
M6-',:DL;4FRA%FC,<D(P8N32CLB?I+ RV2GLE(F)\/D:277.CZM\3P&G&@DL
M:-CK<G0;;LH]ER'=SW0YF"PI;(8.I;&0NB*J8L<-C,]7RQ*_$'/B+95SLDNB
MS*6C6EDFAVK+3+\D&++/.P6<'8PB"8$*TM,4X4YJ:V56BZS/*SS"BWE$S1Q0
M2J3^EJB%C:FP#]+&.SKL%/T"Z"M<W+IN*5*IJ:A=[Y<<27EG7Q4F(N1?-99Y
MI19JOG;/!QC"TH[2>I$S+5.+\L72]^.(-J7,9FB4DL3D\% 2MY$F:V].S%E[
M+L^SMZ>\&66 PSE.)9"J*A#@X#5T9_"Y<B;70U<MOTJ6TGF$LHADX_W1S#5?
MU!0N0LZS]U3TN$!,^LT>:G&)5O8973A4YOUQ)24I_J!XNLRAFV89OJ_;63D=
MTO.LZ/Z'F"Y0P/2]A>!1"5IIU$SE:,HI7M49EZ)&W%N"4PM6'C[,E'CQ%F X
MEFI>PM8YE-*NS>7IXK')/+%\0C4?8(@8Y(CLU>0RRPQ*3ELAI_J9N4C/.4A
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M!HI[ZT T??%;W?Z*>^O O;%;XP%%-_\ YUX#J_O@M\8&BMW_ &K0#1]\-OC
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MAPTA:TU6"5&DKKN;QE@2'9NV9.#*%]0.R"9"J9 ;H@[&KB6N67S..^+3D:T
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MZ2,^FZ],@=)"=5YH;S4-4WU4=.8 \QYNYG0HULGV I_YR4DN&THS"  VO+'
MYE*66,22*1"'3]E,:9 DO<3O&"5.D(-:G-*W'HE*<99:6.KBS3##2A@&<'+
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MUN]VK$SD%/U<R(::HU/>0Q-J>X>2]+&>:H$B-J?6HV22%G0<GDCS2U"U,>
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MF\E@/!>(U7S.B4JL8 VJ,U*H:G\8GFD-*(:S%B=HN,:M?%2G*Y[0%*R77+
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M.JWE;NYN;^FW<NW>U;1IWM78ZM5M%]UVKJU>=;1YVGAT6UWZ.MY]MVU)]'_
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MON_6N_\ _)?I(7?_ +5K?M@K;\ICI(:.U_A7M]W:V?*8Z1_PL6^[U;+_ /\
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M(41()7DG*,S&J/V[EAX.("RZX,\)(IVY3Y/4I=$O%0P<@%)R;BO494T\9[R
M-9AB4!AJ3F0T[PO55CJ;*78QS3GD2=,>Y@1<WCRY&X.*PS+2;<I]+YPP>F\?
M!8:ETJPW+U3?30^E\;-:J9(6\+:S[<D6)5[TF?Y3*T[@=@2A3JB\M* [&+
MFTLC;HX0(1TB?HS)4K)':4)H[2!K=HI=FI#%5)3)>\%J=L$9]M?MD5M6 /I.
M&RB/E%PPH:]R6N2PJ T[8:8Q,HQ6243E-4693W(P!> GTQ8N7GC&(?+9>  &
MM"RNX8?,Z23F7GQ.12.'J91&WZ-S QR6'%&-14ABABD&6]&D>HW),80-,''R
M?$&S2!OJJ@+G8(L^PZ3O[W3Q*YM#VRORTIR, U1IFE$4YO/3&)0 0'F+5^
M/5 5)G'M(V)ME"@E$^4LC],TYBQJ*5*4A;%<M^WRLTE<V@.&HVO&:6 I+Q_K
MEG12W3OQ?<%;! &9&K\5P.NP*8(\\[E+MD.?$Y9VT>!D>@^K'8$QE50TCQ+E
M#V\.SNL:X3S R&IUD)=X2T-3*RG2A[4)B40'PY9ZH6KAF#$/TO'Q&)H;JB.+
M(M8*'KZ.)7IK9LA5F+/%O]E!>2]\3]K_ -AEF\?.]/!@L_+626T]B[V[N%-W
MA&G@U$TT1A#8ZTWD1SZW'FQ1%.%"A3MF;EJS%#OGC\//++P%V6RN/SQN:IO^
M$T^I+.YKX8J=X\B$XP1M@;NPNL?*E[,H6DF$I31E&%N2$8!B*\/)X[>\G3$Q
MU<PQ*I#(]GC8BDH'5\J;*&B5NK\D*YT4[,0G.;A)TJ S:AY @YBH9@,8[J&#
MD!@+@TU3T_\ &<MLY32C826;GCF3;OZCCV?:?R&/T=JGDOLX;S'FI]+HO3IQ
M<FN(&MK<W*XWXU9K\D:3Y2Y&#+4>,_V(8IXF3Z>/'Q%%0T]U.QENC_&Y2\G2
M.C\9F%1B7>-M[<W%E1"HD@=%/-*%0!D29I'-*HXL>T&)%24PX!A#)"T\O8%2
M9IJ1-)^N;)K #)E Y8GE[[,'TJ/2^"DR^.[8!O/DY2A*,Q;@VI 4?D?6P49C
M%.I*V)@L/X<W<V5**4;3"&L$V<V%X+CKA%8S(8J0E!ZK- @+1N2'['#Q!EA&
M0.5Q]=);GDF31F (1F/\80NJ91,(%/)A4@V4R5IVU,G<$+JZRP1C@T9:4O(
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MWS+1$E%\^&(L#CA"L+&<6=GCZ^_V=%J!Z/\ H;IMI[</:+:;N'RK[7VE;]4
M* V%M+$X+Y*0Z(DK@B4M!27U6D,;CN(?F>E[/Z,8PEVFU7R9M 7U^1BI2O'3
MNG\S8I@=3FCD(J6T3%9XUI8RM<LYRP7K5;B,OD"\G9T^/)SSZ]2788]/::2&
M:1]9'59Y"%_BSZX1"GT;:%;HWW>J$BT"=Q;S2\_E2\Y/^> M1.&I1;-?4E%
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M]2E_.V[^U2O\K\Y9_P#='_4Y?SLO^V'#]<%7\QSOQ )OWQ55NMM[3^NJ+R/
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M;H35^(OI*I%@V^'ML#IV8%K4$J\>8L;2AXP!RQC ,>!6N5&!)2HTYZD\P7@
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M# Z'MS\GY0TT'VK3;.#E1C'%#"4;\4&7S.9P=OS4R&[9G>"7R[G92X7$NBC
ME,\256RF%YAAF,K, #&/!,:APVG4Q. UPAPF<,=) @C5\7D[>C-R2G("QGG-
MPTQ)>:!8:@<S6EQ&1BV=*,P RP&QDZ!U O>6V#H)[)@HD$<=/%ML=T[YL#>J
M2LTI<3UBXPYA-2%)&<IRQC&7Z#&,%S2W1F;4TES?,:%"7MDV;X>J/70ZIM3F
MR+*C4IC#(9FDY0E*M1F@,,*5$C] $S .R9<QQ*K%2CEDIJ2U86UH@Q*YO+@D
ML=V-UN<%ZEZA;02E+/2Y#2 Q3MRHD 1X#C *1AC,U8MIN9Y.RHGUN"M)N3+
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M#.L^SR/J(PI>":G,\[C;,[N;PV-CBW$T[;(&[-CTN1,CB8C/QE&J$AZ=.Y^
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MO!RP?JK,<1C#M')2@<X],'IPD,?D[8Z)&)7%3HAF-C@6V[27C,)E83^44E8
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MD'J2P&8#>5P&&_E[_(A\0GT50RY%.)+>R-K8\,31(64AS2,[Q(RU3@E>+[P
M  ME-RQEEF#QB#^7LD:F= B:6IO3$(VYK;$R5"WH4A)624F2I$128!("P>E
M+M?I[5_:L4_.Q"Y2E4/<:C]P$!2<\_;)3(FR--YM^T')R\!9[L$PWE/  ++
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MTOT8 BNMTKG[HK,3FW4U>8!&FML!'X^Y1EID#XWF%FR1+'&8Y"S83<D)^82
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MR<U@;D2DSD31F Y48P4YD$?AR]DG#C/*[@D$D,8E:5R):',JHQL:3R!?D)S
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MIHLW:..,\7*6K*[AB-5T$;>*743:BS#J:OB5U7*X[,)XY/Z$V#2PJ.JGE$G
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M>);&;"VFCQCS]D6"+%C%ANOQ7Z*?UH:EW1Y+GD8A#C$WIO7&5,!$##5[TX+
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M8S.3TS-SM):*I4L=:USFD2+Y"H;IZ:ZN"5E0*!%F*A)TJ,U2<$@H> L QBT
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MY/=M^9_S-NWV[>7W?(ZN[98\.3*S.+M&J+)54<=5S6E5KX^I<9Z:U."IE7J
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M [)/[6(_2@?S :/]K$/^IB_G;?\ VJ5Y7SEG_P!T/]3@^=E_VPX?K@J_F/\
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M=5NS:_7YO>MNV\+J[MMVV[U=VV[;=MX75W;:.#=\O=LU]:3U(_?)F&_;=O\
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MBS.\1ITBM_,Y["SDDFH&-S(3&$D8RAY1>45@\#+!X%F6K84<ME3@B?9FTR"
M+&0HQU:H([S=W5F*H&TDM=ZS:B^2</KHUP.3^HM'II(*;O+HW$UWDS@D<EE/
M7IU<&]O?:=,Y3&[WI#F-2L3)><B2N7-** 0>3QQ@,!Q+U#9!G(\*MWFITDE<
MDI?)X/-&=.K+..2\]U;1/BB/S)"8?DD-Z!.4:>E)$4,S 8F':-5)41U^?HH?
M"WR&/"F*QUWE;]'EBQX9WAO7G,$91."]2E,YN&G-V-.9@&,(S.)C&"&/TRI/
M+%-)6^>.'.L661EYD[W(F#Q<<D<?D<FI6B93UX$_.II0RD"A$J.!DE*S $>@
MILWS:GJ]RBK>Q5C/:(_*V14M1,C,Y2(I7 V=[:5A"E.2,M+>28WMZTO&EP%%
MX &)N(UNZ6'O+,XN71WJ0VU"=C6]U)='!>D3,][(@F#HMY<:HL"40&_;#,8
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MAXU@/3#"K19#(:8UYIXVS1:E;H_+)]3PMFB:]<X:T"<MZ)>G#'<?<:'*RRC
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M.IO"SSU)QS6D..,-.-9>.,PR_P /KV]PVC_O90OUDM[AU(/>QA?K+;W#Z/\
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M[*%^LEO<-H_[V4,]9+>X;2#WLH7ZRV]PZC_O90OUEM[AM'_>RA?K);W#:/\
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M'1"2OLSNB+(%ZJBD0TU5W<S&203\X5%61A.H1I=E;U"?*4,!1PUI " $#+.
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MX=G**R%'>O9G='L:TC--('E_GI2LGE #+],)&"R4<KG=0IZ0V-ZM Q(I<HB
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M02 8)[$EKQ)W=34\AU+F\R=5C89+GM0Y-M[/M5QR-K(0)MF2E%)TA"1M+2D
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M1@0,0$P2& 0@A= 3.?8$=7[ JHN+:-N5I?:MUHW3Z?X]'OI_CT/I?;Z'H)?
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MF0VD@-@-T4UUN48,VLD_;-2C!9N,Z*"0 .*9M#I\X=@AU(F0  4 )_[7K,$
M(\L#P\* F, DQJ3)TBU\KG0A-UP#@& %CL%" 8'3O0))1Q9@+ T!+203LZY
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M* 7;9U3NB8!X69J%E-D])F!S$TP$F#'</N"J.;G$ELLR2]Z%FE$1/-H9V!>
M"!5AR&*>J<P"YHAB'D*5)K$ RX@))"( DY.N4WUDP(7M%-ALFI#4I[_S?9DR
M-GC!< Y,,&(;(,HQ&04C [L+CB!L!"$%IFT_+^G2)?\ GA9HV0$RG:PT=G(1
MQ!<H%HA^RZ!)\#.[K5V&#HIAPL.Y:8HLJ<)$0L J;"_13N+$+8, ?MBY0 .
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MP@3<@AWEP(DG/BC19>U&W=$1Q0H3K$O8'<>4RV3"2E*EEH'*,CT:J@(IQ4@
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MBMVD5<.*!T8N9^'WAIT3;F5I+\)&>=T<7<LM0.?A#&@3(F\[F/195-:VH$F
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M!KM4/:UB$TD*LW9M93@-V?KT13DW&T5.2B3TXUPX&&TZ T*=I<BJ=WV\($.
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MBF^]4#W^)'"FZC+%IQU5V\(:'QAZ[(86XGO(QG)7%-V?;';U-.K*0\U5+6%
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MB #V/&B]=,L(&V7#;&LTV5%7.O":7>![*1"S>Q]>Z$2Y^!NF OVA-NU5/O\
MF:=65'E4M8_L%?\ P;>/A4GD^_\ 3\C[_P#(+CZ#S]+A>Z$T:8Z@Z_4RYD>S
M<K0[%+]'.R9CMYOLR<GS\$Y0WM-5AC_5$_'8=<(H"*QIH[*,#\9GIA/V[&K]
M,C#N>B!(@ #22)^IMMZH(E<0Y/-!RS/LCU16*,;BG'5"N ?-D09N9G>(0=(6
MQG9%<CK9F/\ 4'=,!V6$&O@B^QUJ?^,TZLJ//UE4M8_L'_@V\?"B#S\_T_95
M_P#',@;M[IPFQWTZ%-GZ)R?OY5<M>;G\!E!KW\,(GXNA52EO.3ODX^@V-_GD
M;ISZP3\Z9'CJ]WZ84DC5OA1^G]T^UU-GNC-X;WC!RGNZ'46R-TT:B%A2U@VW
M":0P#"QP6K;+]*H*H1 _26SA$]A'L9!L5<!>-50@C\V+5)H=W/<II,_'_&:=
M65'E4M8_L%4?_ LU8JD\GW_I^_NKN/\ CT[H*B_1[3:4T/GMX03XD5C9/#S8
M#+?I, 6%&-WD(73[XIU51YQ*KTPYK?H>$+N F3B+$;A  722 RP#Q)-R+ "@
M%71*(?YX8FB@,3,Y)8PU BFM$LI<WLUA\+S+&)-!&1)KRG ]M^KBJPJ4R[\3
M7LCPMHN=O(QNB)\.\, -_9'+#SH751!HL3O>\-NJ-N3[L66>9PH#MD68?*Z'
M)?\ P]^JI.'/B80VU4"G #/0SO<[(GD\\J(#M?4ZL@@<!JQ W&#IDW..GL"U
M_B8AL6Z#@0B[8GN_8IQO;HIO"FX:TW,FGV?^='K[*CR%K=/[!7_P:0J3R??^
MG[?\BB/$0.IXY0*0[G;9$ %&  J=-<(T%)Y>7(XQNHXN)%<DZ@H#A$##OW77
MR)W\0@ * ((J386 !&_E0MQ=R[+JHY0<2RPG3=KEY(Q^2G"3\O@!,'XAP\5K
M5$+7)-B*O6HH1]JW[&:D"PILN/\ BYY(+6P:)IFW00\_>_10B!/T_NW5 (6[
MN'MGJCGW0+R2PWPA5V GBF6<!>W=OG/BI'6BJ>?K>&,(?#T/[)H.^'DWR5"O
M8!U88'L4T7'STP@]HZD:"(C8BM1P'5915)*P4-K*\^RA&]\]35&Z[WX(5WO&
M@>R>CGH_N>W\Z/7V5/D*EK']@K_X-(5)Y/O_ $V*O_C-A-OC]*O@YZLE7B?K
MA#&U*:@IM;1P&=)/1%\\%Y/9A28U'"^AX^T"[N]IS5L!O*-@3\'W^>GH'@FG
M3X*V>/K=0-H?@HL(QD \%\"A3&@P-AVOII4Q2+>0,EZO/PJ11(&=Q!;N_P!*
MY?#AE&WE.DM'N:YWPZ$ 4VB$[0C$-+Q_C_CH]?94>5/5C^S['O\ ^#2%2>3[
M_P!/R/NJ_P#C/-M=K]R!R!T_TF]N>D<IG[ZD((*T"1AJ/TB9Y*:@_EE?;X\J
M$=?"$ GB^M&%6N]R<LF1JY^C;,81DJQ<<;EO97!_OD)O]NV%HO\ %@0R>^^,
MY=*)KV#23<.,LT9[KJUF,-82)M5$E"+G+NP1%'-.$:BZ*NYSF6Z*B0[>0&_V
M@TUVX5JY3,)!XR[?\9IU94N;*EJP_L%4$DA$DBX#(#:9W1 H 9F!+-FHS2Z$
M0YHX L[E"+X#F[9+K\)^H_!G9OU#E \'P@ Q]E2]=AQW1"F+_3HU0VO\0H@#
M;5Z)@1M3XH 5M^L)B\MN^RCAB/"9!';=D17#=N800)L7ESUN7*&7 .:V?90<
MTF6W>WVFH:T]!R_*(3U* .T< /!3Y&%&$VX]T3!']MD) .UN6&1L@-NY03+,
M4R-D!0!C)_TJ.CQ;KRN^&LO(OX0B)  :#-Z+<(1($=#6%"-@@'&T<+2$S [?
MJ9MV_4S [?JV_?[6P.Q^TS;LF;=OU#PTVZ"9B-N4RT=DR##LF;=OU,&.WZF;
M=OU-P.Q^TS;LF''9,-AYURFX"9MV3-NRCCM^INW;]3<!,P.R9LF;=D,UTW:'
M= .8_P _$2'6 4+\<\N3-NWZF;=D1/X_4S'8?M,V[)F.P_:;LB&W;T,V[?J9
MMV3-NR;MV3$;LF?X/VF[)NW9-V7 =DS;M^IFW;]3=NQ^TS;LF[=C]IFW;]1V
MCLF;=OU,QV'[3-NR9_C]3,=A^TS;LF;=DS;LF;=D  TO[/A4^0J>L?V"J86P
M.PT0CC9)LV'R&CH.=<7L6C<4#1%O](2Z]E4?MA26FUU3[@\:&KK<]\=GT40,
M\/?.R=#N>*]$#SBQ/@]4X0W\"4P^9"/#I$H07PWV_>J8M_UUPBC"N7 80:5!
M_=RW!"94(!O]T;&89[:U1 2:<6=GY5HH=RP^+V3AT!LL -6"%B@+>X' 0D&A
MQ02Y$8.7&@L-SNTU">)+A %QJ2J("*,: 5+ $Y1,K&[%_CN@?,(M5QIQ?NF-
M6KT!EW,*S:_A<?)1?;ROHJ^ZE*!X]N-2M7/5,QY_$S'G\5!MY[)UW[]T2&A1
M4)Y[)F//XFX\IK:^%G&NB9CS^)F//XFIF==DS'G\3,>?Q::JM)CJF(!GA,QY
M_$S'G\3.[#O/1.G:H_41HZ8ATXS:HPZ9CS^)F//XF8\_B9CS^)F//XF8\_B9
MCS^)F//XF8\_B;CRF8\_B9CS^)F//XF8\_B9CS^)N/*9CS^)F//XF8\_B;CR
MF8\_B9CS^>AF//XF8\_B9CS^)F//YZ&8\_B9CS^)F//XF8\_B9CS^)F//XF8
M\_B9CS^*#R3X4!Y6MT_L"UGX6L*/OE1JJ %=57C7XG$:>5)W8]-.NK7%W"V%
M<=R&H1  YGJ-9SPG!S#54XT###@$\43U]!] % @=7UMGX0\4&\A@6R%$"V$R
MT"CH\^L[VY'&?I"D(-_(D@;S'>JOQ<Y( /N?]3A\/U[H;^KOTEE,_5NI@2F?
MT\GY3ERA!OV]D'J\<)[K;="47:JM&BA1ITVV"I"I//RIC5C\*+S];(FQ,L[$
M2>+W:7=;[NAAM=P(LP-OV01CC2F_K]E=P@8\E[M2L%,YKT9W4$^.6P17:G1(
MA&!F I2@XX'ZF7+OHW'E$?->:," 36:[\*X<Q/@7?.?XU"VO**4VU\K#PR*&
MH-77,KR1^<GU^RK[?^/1Z^RD/*H:Q_9]CW]6'\#H7C5<HL.*QJ^5ML[N'^5M
M4SRC:['WIX?ZG\.@6AM[P6/Y3W!#(!V]I=1Y?*BF'=0;/LC QZ!F% J7"88]
MHJ1.XN,HPXQ2Y#54'U0'\EV![E!?AM<-GL@9%O8<%- 'L?:OE%U#R%H.W^43
MH4K+I*:OOZT)_P JGSK94A4GD^Z@"N@R=HHY[ ;A&7K):X*!J/MO"^SSM[IN
MZH/PVWLFZEFV]?MZ'SM^@<J!>[NX M\(HL._=DY='N'V<&UE:4F37@K<GVE_
M/* >J.#AYL]!%T8JQ-*#>T>?X@#AG_4)M61L7-\59N,?MD630-%)8>OW_P#(
M&G5E(>5K=/[!7UN7C\3L^/Q.SX_%S7+Q^)V?'XAKHAVL?M>V_,853K&Z*_-+
M&6/=>P=:#]1P+SF[YC5T=DP6)H<<[IC[;)S??9 -;[H3;.G3<>/A&R*L!M<=
M5S\+GX3Q?Q^+EX_$[/C\3L^/Q.SX_%R\?B=GQ^+EX_$U7%=!.1WTR=GQ^)V?
M'XN7C\3L^/Q<O'XN7C\3L^/Q<O'XF>?:FR<U6NRY>/Q.SX_%R\?B?E.SX_%R
M\?BY>/Q.SX_%Q\H;%R\?BY>/Q<O'XG9\?BYKEX_%R\?BY>/Q [_UA.^J,@&1
MH/1$B7PJA_%>[O7HH&[*/3ES\)N3V0R\,![@'YRLC,'<@?."MF4 "D[<IR-S
M^T1.]_*)=-SX4[^$4&U[Y5S%=:PB"B8R"AHIY_%U>-#=5FK<)WKO MO9L*YX
M ^!U]T#V=!]]$<6\OKJ_H0R<G+EX_%R\?BH<E' $I\?V!5$*,.R;H+1'VN'I
M:M%:M'T 0J!V'VB6'8(A8.-$H-HTW"!FPLQEWU*"I&%L-JR*P6S'VB>;%)\H
M!LW 0(POCZ1P?P;[HQQV ^4!FP\?8308#L(URN(UU3?\/M:M%21ILIIHA:M%
M:M%:M% JU[(0#CV]#@AL4TX+5HJ*:(^T,X?BM-T*X[,<K5HK5H^A+_'I<%P4
M/\?:9MV"XNWZN'K6B/M</4M$?:(_%'Z@4!>V$(VCL$,9 TZ@ !VX0*@*[:N@
M4\,9^4(>.4"R8+#LN#PB*H'@&%H-]H1L#H7-CX'5!BF?X=6??8.@)9VO#! N
M/&K^4$HLQMY?V41;)M@\I@E@@.![_"V!_G">-!3A"&:9M_F$0; I(P?*A8=#
M^(@(86QM]*A3%/U<7@()R _^\:"%8+-'X45!&H'FN>B(!!)BT0OH!W!0G" $
MW:K 8)#1>1NZ"P%OOU?HF&/"8;#Q\IFW8:A$!_B9@>+/K>5P0&CG&["I\A4M
M8_L'J+!W?E-W;R$ &>2]Z:JI1P/;[3ANH!0W9S\Y^5%TIW9T(<XSE'6K=!AA
M-/#I@;FV^\X31!7\-K*8:GZ[UV0/,S_M=2L.!C[:<)QV^%6)W32-B??A,;XW
M>3(A4F,9X7.1S<HPR9@KW'XF(W?+:A$! EA^]$_87;HW"['W4-A3^-FK%4GD
M^Z T:A,-91E@>;&T4-QNA(>'N;?483@(?YVHGH]O5]E6K%3#4HPSLUK(@(KC
MUL_9*!G !'=ADY3&RW9AJ%-F 'ZSKNF'B?,#4(NHI+^/1>[&< +/0=T"YL]F
M*:TIITPU:^X&-\(5[#2)J2VH^_4,ZG\\I]X]DP%4O,CG?**T2+>@/1ZT;PF;
M;VL"<'RC@KU. ?*%LEG&T4 _TZ'4W/VZ)%-*HNA/<U#WRB>_<XYM3]*FK/X"
M/C'&4VA@_*X&4QPOVF"30S^[&$ 9<[8'.NCL-/T!W.47'?#,M0IO3=8PL4A&
M,L6LP2-['/9/,7>3?J*)2CN 2R/*(%J,?<-0B!:UJ(+C>L=HP?8,J9?7@OMC
M(0@D!F:P]@4QA9NHA-?\BB(^M]T19+Y:&L:Y1.K\.%7=C;L"]NCX1PKN2747
M.+;H]67(LX$!_P!Z)L!=]G=8;[)]WY5 TZ(*='*XQ+HQUE<I^_X'*<^T_"-.
MK*GR%XWU_8$?0ATPJ=M\(@-VQMRKBM[IEJE;6 X^4 D=&/RQKPFP\>R9UJ.4
M$#M;?E'TKOI7NV1C,SI4,VDWX1B@HIR %6.<(H"VS,SSJT;NG$(R*7F/FV_A
MA!%R3G[O#)H;/$\;NGY-2UJL4&Y[JL)@^TT46K?ZG)+GW_%5L%F4P<%4 <66
M;DGXZO3$ H!)$"!6@;&LFZ&6L94,UUP3( D'L3_&D*D\_*I:LHW?X"&?O\_"
MD$6\IO)Q,0##Q9CW'LF8:R-)U3U^WHBQQ(.^3T=2>6=$$918V.LPWK](L0X>
M&C:Q^$WG>8>QE;*CS IB[!CR+!U78QVHZ90 UM_&3%FW?56I%BJEI2.TS? ^
M5SJWL/QE.#\;_?/J_P .E_Q3>#])T*-)>V3T3>\?S+Y_U$'<C0]7$4I'E,L%
M>_1Y\H7;;%;9DU*RZWT?8U&46%<(^ =2C 68S8NN3?Z"J==<)P#S1+;BA1;Y
M<<MQ39 _6J!]*3Y'N6WR@X_0=\JF&K>)0WS_ *QMA/!:3[YV0-T&='7")TW^
M"#WNAO= #MC[/G?Y56=/V5%CY7+QT1T;J#U=\(M._E&R$UZ.@BX5WO5!\P.P
M(N?A]->Z+VM"'/\ ?E V-M9@_+">Z/W/PPB9KKP@!^D:=65/E4M8_L%49_@.
MD_"%[GJF=76O* :BHF3?X$$@<7I8JV![;95GZA60'JA9K;A" ^3KA -*LAP
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MGY7+Q^+EX_%R\?B=GQ^)V?'XN7C\7+Q^+FG9\?BY>/Q.SX_%R\?B9KMJB?\
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M^4?Z5]80J/Z=/55?TE>;_!;LA7(M1^5DZ^R1 1JPYL<*3-8Y\(&<=4^*!$=
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M ;+"*?=^?M&$2YX$$@W<8GP@"4%NMS0\C#FR.>[N14(\A\*' 5JAG"D&PE-
M#:*:U&PR:JZ\]R#\Y3P  D-)W#/(H?F>6"#.5R.=TX^ ,\MPFIBY29I!7 CI
M $AKO8^R! +]Q)Y*_'2J,C&(ZCKA#=0*)>(K ^R":NWOH?" RH<!SN'-W0""
M@%"!4!<6.R#X!FX=ZZ[H9R0[K0XW/1#QHNDQ@')O8\K"EIFSV<8S&Z  F0O8
M^Z\PE3K\?UWZPJE5K 0_BTFP*(<MG1R!I]EH/NFRNX]GVMT']@!=/&6$%*YN
M_2>.Z-PW/PG3;GVG.$8=NYNQVPA&\4IM0*5&IZ(Q[9;;KPC,-GS/C<(S?O;A
M1=OD!%P?3]9&2%U'_P!=3B^_>EGMM_/YOA'^D4-N/A.?+ 'N%M!5R>!\JR^_
MX@'_ +^H#!M=D0U*J-8117J==55Y6CO_ $G%.3\;#"B5250_2[M2M;7*,"!,
MV82]@&0AZ.[L+0#T.\V[(OGC7!R'0V\IK7 !VG L$_9N+86CV58V?P-ET)F-
M'B7$WRA;O95@T8]$=K)L KL U^ IQO.\1L<8(8J  :4;<#ONY='>YO06 I 6
M=JL@#:J" P)+F'7-Z6BAY)X)J0(>@!%8<4;0Q'A[9S9NK(=P3'0&HEI!@49S
M PCU TSLQS0$(B4 R@4"Q_UB3U1<98M<W=J2?"<$Q2+-BX @&C/9!.-&?"VX
M-DWC@,U+XL&G1!F; (#OT;W37P0XM>,%."B.'-ZL3Y9.XHD LXP0&I6MX4\W
MQ\ ?:;&9?Q@(O\GO70YS\)E:+[;:2BOY9['Q\H*0_3,?Y5 RU L(A\-:OVB
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M@QQ!"#M]'7NH(W ,G88@:](0_F>!N) E0"*"OVC2Z^/5KD(008\AP8\,HCS
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MZ7^5 ^#[E7Y^OZ[^GPA<!T\H@K8;H)[EF0&N S\(KEZ50:/PU 05;VU)SK9
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M9;WLM[V7%V'VM[V6J%IC[6NW7F$J<_']=1Z*OHA&[_[5#C7P@OMQ#X,R#JF
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MVSX^T+7N?BJF[GVC'!!.P@/A2?<0P9S-RQ-4 H !BU0$7 PUK(F,&2+28O\
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M"F<Q$$,2;"IAO-$,:M#MN@;^+5:J=N<1#BV7P9XY0 -?2>%SMLXX":,DFUW
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MCM^]U81Q<FJ)DG*8E]YJV]U&@(('ML;$*D <B2Y8,,L#BWNH>TB8!;N.R-3
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MP( Q!<+C$ 7,-4U0)QVCV9@VQD(B<&9>849S-RS"CT";3"@N,-DH,(/)W)*
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M1LHJ#>TY$!S,_CZ0.!C#M2P[,UK9"9[+F,$@F6H]B^@J_LC=%4R'%Z2( P)
MZ/M9$# 8B%J2-&W1:?<WWC?U\#V5.78^QJ,"XEH#A)IS >UTW@(0P$N7%"&Y
M_P 3'DEW([A< H,WRA//A#;/LIR#4**@6(>$#9Q$6=0UD3&?A&D&(N,,[$FI
M I[[H_: O-0!6B.2ZKX@;8PJ-0&A0>;0O!-Q;BH1ZD!!V.D9(,HV@ %Y9Q]I
MVJFC!Y?A'VZ:#X!08\H2 R0(.##(#A\<90==L?:!K?7&=D&]O#1I"&/+<?*Y
MO\3(M13#YX5/[Y&9OT7T*==]+(<?Q,:/I! ^UF,7V0)7Q:-EBZ8H@D ;PX$2
M;.1TAPJ,2">S[G:%16^PT!P1C4HL?C4"H>Y.2BX6+VRWOLC?#XC;VLM,:\H>
M+.M9V49!6X:'C)<!PIN@%M,X6+-J;(O3;%F947V0X="U&>0!GX1!&<YB;FC
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MG@ 2+ 4%2UXMA,0YHU33&RFVR.&Y"<K14@ GA+M? AI1 .N9-@X4X,A$ N6
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ML%3$=S7OF716*1 @P@@ 0+R1:J+" #F6 0 ,,X C>]$Q0&(DSF%6'D3W1F2
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MW 3,#LF8'8+@$VC>$W&N_P##-QKNM)'VF8'9,QX"TD_:$GI'AMT/A])NB4W
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M$ D@"NQ_U"),!@=G^>S\50(;D;B7#U#9W"N$8@!S4&X)03/(.;,^+Q,;V3C
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M"/+"9EV))-PP+M>Y0!YR\T %-MCT1C9L+(Z $CE!LF7=0 ");<!KN$5-I#0
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MX)W^"</P3O\ !.?\$_\ R3M7TG/^'T@Q3J:NWI)PUX6P[$Y_P^EH:I_Q3O\
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M;Z1'PA)!NY^"THK= %; D.#<F3C?8@DB"ZU3N&!\M*>=G!+$$C*3&1#73O\
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MI#PJ(D&Z#<2U,&,UCFHS%F:B 8X"*$%W6 +CP4"TQ&$3+V1$&"'Z(%& G#,
M,(8GW-AA( <-$O#00^>\H< #"+T<2Q]VK9D0#T6,H)B&OR":(>4 (N!/!69V
MS5S8' 4)2Q%P $#5FTS#HB$  !.#!V,%Q4" R!"WJ$D"X&T--:D$PC7 !.H
M'00) :YXX031$&A) *PB2+(!!F D8>MA#H"\)CE,<ICE,<ICE,<ICE,<ICE,
M<K0%JD;'B('R@".Q$%<],_2J&/$0@.#1H^55<!TINA  @A# Q%G!:H8$)@AH
M9Q6BXYW[0SD;;BL),F47:0XBV78H93B>X6<P(($R;!#V(+$S#AC)N!&0G"P
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M3C!H!N)1 7->J5A1 MZ35T M.?9"#L:59I9]0$V26)$BX"1,?M(JF# ,!P0
M\B9$DN&BDS!K4"0+@,L,,O7X!%NH&]H (Q("F-U2%!\<7!@&"QER,)&')".A
M"! *$ !HD)@@\=Z!.8*3[F001!R23>"T0"&.0J:%I7&%S4 $+UDQ4^Z>604+
MKEC$C$$ZZ])NXH"<'!M) +$!=G(W:#1 6 RP$*2'@V=YQ* 679D,#Q71 ,N6
M<W0T@.'!3#G+ ,+FI$L B0 7F6!$PX&$:]CN!,,1%0S,)VY<Z\@W$_A9!$1
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M%&!1(W':Z'7WK+"&'8]$Y@'E+FIE+#RPAAJ_+>QX^T-_5!+D.:;M4JP!8W<
M; " \],JFCC6K!@*!94NY "+%< ;"Z!K_%,XU1,(I]<@?G57.[\F=U;/;N<)
MOSVMLBAK2Z -#(P[*-V'@<(O5ZNQ,J->$-FNRB"S;88MQ391.WU:M*;>?4>S
MZ5*J:Q_4/2Z-N/GT8@";4_:;4_:?3)^4_034P=OUKJ48CSZ?B :H@G1<5 ]
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M3NI&.X0,W#=P?+H@#.+1"!Y'<)VW<?: 02S4KG*-BC>.[HIT[9!KP=K(D?<
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MM5PV%I*YV0"0?\[("\#S/17*C6%4UCUG^FX1_@?XTK_ _P!P7'\*OZE/;Y5
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MJEPP8X]$!F#-J</[++PV;\GWW=  XSEK$H,9-FUJYCLB1>P=_A@@I?87_P
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MVV^URG]!Z#HA[/I4=_8JH\_7_./0>M5LF_H*K_!DZ^7TA3^+_P *#T]D?]@
M'J?7OY7P?*-<]I'"U#._T@#G<2*"P::^R&:5[RU!0=*N1U1$Y"+@,2,P-[J7
MY&(8"_ VW51ZTV^T(H',-\WQ^R.SQLT6:_X1X4CV).!C*C^N@+;=+JE*O.7#
M</%YLFFW/,/O"S+'LSV?3+8+YG >_E.+>_B?RS^/*ZC95!42,![9X3XW+V\Q
M[(E12WC96'UV0(:GV0>?7A?.NW&$6EQ=-EV]E2:]D!=U1J;AZ@_X@ZVWKG>%
MW:3&[8&K*%WJ_0.4['K@^41NW.KO_"#Z,A[/I4=_8JIK'I;^L^C_ ,*_RV_H
M?^G6G]&52H_A3T='TK=/<JC^DZ[?Q ;^+9'CY1$\L.E4HP)1Q3;OW1,_OW?A
M"LSFVC:R-&EY;'5/^W>4WI+\=M;(P%OI7=.3<#9\W='\Y[FVV4[?X]_8@.%*
M6-WV8T:M:JWY<G;W3BJWN -G[* T^I:I&%?^WKR<K@ .&I6H[0A&)WCIL^5(
MV9#0=4_C3^;?S'M4!K"J//U_8/OV*/\ !W_EQ_%U7^J/Y5]_A"W]/U5/7^=E
M1'^@!O1U?3;*EYJ&:T5]!.]'ULCGVX/T=T$?XM#=??HA);YVV&RQD[GZ*=I7
M<U_%/;F.B!'(+@]F#0[&!\H=^K9F#[YV3Q86U?W53)MY(QDCW+^K%M_9/^4\
M,ZSXS^ZI>#SGJN)GW/@)FPCFW 3JW&WR%QID>&O;HKW_  /KKZ90]GTB)?Y5
M36/Z1/K='"YFLYF'#-DXP&.T.SLCO15?4$=Y&8E&KZND6(VU1'OT8,,=B=UW
M%3N-D[C("%1&!3Z')J?&Y&BY^II6_9%.-%?\1V;B34S#$T>7G8H#.)YUA7TY
M=V/=&53?YA;IM^41ZJ^5(% 9EFNG#AQ7FJKLQ?BA,H5V,P]6!K"/=W?>FC*N
M9F[X0*.#E]T($F,,^S)IPW<0B9I<R((#]=0B@G 9P!8=C(F^IV1VF^]>$45_
M/(BF/\12RAJ[EEN>B=NW*<NOO^+K[_BZ^_XM6@N771.W\?2?OX^D'93QG79.
M-'3A5T_?Q])YSX^D_?Q])^_CZ3]_'TGC/CZ76N*/W\?2?OX^D[!UT3_])Z?O
MW'TN;PG[^/I '&<8R^0/E-X"">9([!?"$A-1'RB5!I9H>7GLG[^/I/W\?2!6
M?Q])V_CZ3]_'TG;^/I.TR=OX^ES>$_?Q])^_CZ3]_'TG;^/I.T4[3)^_CZ3M
M,G;^/I.TRY/'TG;^/I/W\?2?OX^D_?Q])^_CZ3]_'TG;^/I/W\?2=OX^D_?Q
M])V_CZ3M_'TG[^/I/W\?2=OX^D_?Q]('/[SRJ-851UC^BO\ $!2JQU==43V_
M-MF0]_I'#;NPS"=?N.&X1$[M,PC'.$>^?@&#8HL[729LQL=66UA8UW7 TR".
M;^>$R32=&*9G+AYH.GRJ'M[%8\>K\HCF;S&$:3))W:Q1&C%_+?17<'RRI&-"
MV>OTFPZ,'^4&R+/[D8/.K-T %A/'G*"2B##\WZ)][DNH(&5$]9)>#WI](1&<
MGWV9#,(ZK1P_Q"/5T)YSLFPD&L^?&=!$]-!SH2X3AKE586D#[4A!\?JC,ZZJ
M%?$_*#M9UA$ &GE-34S=%R&M1T]N4U-73KJG9UW34U;"?C7=-34(^-2R[^GI
M/FFIJ!MX>6Z-SD+?R\QA@W&&>OTNH"]SI5;;R(W'#V/1-3-?XFIJ:FIJ:FIJ
M8FIJ8FIJ:FIJ:FII3=#TM34WTL34U-]+4U-0K&P'E4=_8JH\_7\6])5/X73L
MAC]1=\<50-M;)@OO?Z1'.M%&QU2%[ ^#_B?#?YHHYV\-]H*JL7VHVR)GEU8Z
ME6LF,N* ;'KNG>&>FQZG/B%$G#<P^Z?R;AN_6B3WQ@O9.J!;;)V.4\<Q\&1[
MY^D:*_WC1CT5)\O%40 [9M4'92>GA4?*D%&@]+WZ?J</]$H'34=$9)C/U54F
M/9=+S\!'UWYV7S/P@M9NFW:ILC;;/\K\*=:/[AJ$X@H^.2($;PZ>JGM\KY(;
M\^Z#U_Q533\$G\#YYRFBV"VLNC"S2-PF[<:N<IS V1G6RKZ@YZ[XV0.Y;&[[
MAE<W--@VQZT'I[*@<?V#T;^IV]1_ 4]>/4'T'L^E1K"J:Q_8$?4SUU. @B<@
M?",H.</F!HH ?<13E!V-_?\ WJG9^?/1 W08M4W?=^*;IFW-^N$*+8FN&1E#
MIK$%""^<[*!8[L&'Q@+?J^Q!W]T  Y@[HV^Z$)NP;*@FY_ HAGVA1;N?S!\(
M B"8%-*$(SZ+M55U/P@GB$3I;?11)$M\OJ^Z*;J"/,81@!J"\=<IE&_M/K3V
M^52FD;F)CCNKO[?0RB?^?NTI]P\ P0<IUDNWO:B#G#8ZE&HZ^CQZ$ !X)[TV
MU5&<U4%.Q5#[/G5 @)5(OD,3S3[]'5/;Y7P?TT_H'_$+7_@/:J._L54>?KT=
M?/\ 2ZAK;U'T:F01"/A6Q^K>P5=^GONC(-JQVPJG\"+3\OMLLWQ]+2X0V?ZK
M/>F9X6LWT@>"/;K9/?03_.6!VYPF:?[6FG0";^##T8)CW0]3#T9-MZ,$!<ID
MW'HP3:?T8)AZF&4P3!-MZF"8)MD9!LE'F42DI9#T^MX.FMD!SY=/U @G+GKO
MZ :?*/GLBZ'1$RRJ"V?Q$RGI&J;IP-?]?9.0=?*UZ9!=73TY9.Z_4=.I[H4$
MP )BJDT",(.S(/S^D)[H!_0(&_E,RF"9"KI[E&[^\T[JH\^K?TFR8N<^_P!I
M^2MQY^EN//TH*O*W'GZ6X\_2WCY1 Y\_2W@[H002/GV4"23KKE#&I3ERFX/<
MH@;'N?I F?OF+A",Y!,S-C=$30'N?I,%0>Y &KZ_PULFTS6DZ>%R/E/R>Y6X
M\_2.1Y3LE;AUT6X\_2W'GZ6X\_2W'GZ1/)\H9'<K<.NBWCY6\?*W#KHMQY^E
MN//TMPZZ+<>?I A4GN@>??\ ,+<>?I;CS]+>/E;CS]+=>5N'71;AUT6X\_2=
MI_E<G?\ 5O'71;CS]+<>?I;CS]+<>?I;AUT6X==%N//TB@<6+9V1!@2#%+TW
M1,HW/VGT$M&=DYCDY'DYW"(T7P^RD@7R5LG"^Q-'K==3W-TY$3O)'R@1SY;1
M3\GNJ]RU&G[1*G^KILFY<W1SGSJW@JO?:_VB$Q>]R-83P23?YX4JF+G .Z.W
M\B">B-436LG[W5X+6<G;G/PBB27C61KNK4DY=OW*-IX1) +$Y=SLLP^;;H#(
M$UGF-T1K)P)??7">%XW-D#,N>_[IT8 Y+ST;[1KB_-41&3Q+[^?A6#^;LK4U
MR=]=$".8$S2WNH*G_6UV6\?*!/F_SKHJ54UC^0]8;TMC^!%H*!S]T8!@VXM>
MGE% V?AU*O"@K[!$P85UL,(#J&2D\TFJ*ZEHB[@R(Q58POV9D;#?,C4(FKHF
M@ 4ANW"JF,=CDA'X7J.FRD$$9];=T<;!"W">:GD[SMW3KN'\D'QRMAP=P!LB
MFTHF]7RF(MMMT3B?4(&?+Z?+?Z1+,ZMU5W\0J_P^WN$%!AU1;FA,)!9F!Z-C
M*%Q]]\K=%(Y;P$;%YM%4WI3V^53U6GUR5Q.GZGE@HOOKX0:W= CO48*FMOX:
MAH'S^\HCMY]/U1>'RIXP]UQZG82 \![A$^P3.)L,=;2K;]]D1TUUD()+G[UU
MU3N$03]:A:RPZ*!K$VU"SK"WX @\",;)EHSW38,@^Z=AFD<'!U*?B=,V'PJ9
M,;S+C0GW93.1 CDZV:@QVJ7G7.X^ZJF/^.VVZ8SO;/+JQVFU1QK=7P\#I1"*
M7>-X[@S*+/ GW/V'*BQ;Y .R&T9NN-_=DY6D$"UPQEA7MY<UOT_%O4'5$]#\
MW3'^53G6F16M;X.P]]E\WD]=!#.J]D/6MD -+5\M97.;]%>;]XV0=7["*)CS
MN/AD?2:VUWVP?9&""_[U]TYD:WZ'[0]GTJ._L54>?KTG7/H_J%Q_"Z GO[>D
M>MD IS](@%AJ'-10:-P:[,F0 &GY93V38_.R=QIFY"-=4TN3;414H 0F7(>"
MHP9G-B=/]((0 3$.14+DH9"'O]NR=P2[?!VX3*??QQ-=*H'9B.S1N?=[H #%
MQ:^YOE95!\AU14W&&.BKN89IRAF!3X#G=; D1N0"" 60T=-U*_D,45**_P"9
M* *SBU3KNO<?J^6IO]*,9^:EV:13??\ C]OA"B@6KI]._P H0_?ILGHVH9-4
M<7Y\[(Z&H]:.WRJ$?S\*R?:+:]T(0@]VN4!KPZ_:9%NFZ_=U'VA?")D=?X/D
M.0V$ 9;X70;>K;_?HCYW[?'JP-\2?!#X1#9$'P[XV4$##F_"DF1KKE/ <W43
M_P!05/J/5Q])Y&AW?HI?2#Q6/Q.[ FC^>>J9>OH!J$35:GFN_A.@R++:JB.
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M>]]X]NWK1V]E2-7_ +JK?U[?O\7]7UOZM_*O\![/I4JH\_7K\?TU*^OGT/\
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MHS2)]B!1J[H'(/WEGON%(3>B/56*I<_!4^#_ %JN1]BA8#K\+V/<K]OG_O\
M:"(=^3_3[_RJ_'S_ $Q/GX"&AQ_,>CY^WMTP@<#0BV1&^=50!(Y.IV<2^>$4
M(/2XU8M8XX:64B@R>7(]E/?*(LI.O06 5S,+I6\V%BVC0IAU;R*[CK,4J@9$
M9 , (;H4?W,+S0:AGJ:")%"4[7&IW#M3<8NC( 9BTEW$M1@]F3*8@.9V-IG>
MJ"]TG(AG)>#[VA I!G<V9!?N.<,Y4(;EY%"Q.,_"&- G87F,A%LV#8.D\R"\
M;'JV)DW1EP!A$Y <#9J=G3R=YR=_C"D&Z':''.5ST<7C"L@;#D)J*?F^6-L0
MR#K4@=<T(;RBS&>X<NT;$UZ2F4F]*R9SQ](+K,$[,W^WLH ]TNTL/4';G*CO
M>!U]F-B43C;GZ'9[K7/:,^7L$0E8]Q6_LX=- 3+$.].E4/@:F""<]W<W>B:K
MS:AL*?/E&1D<22!:3(N,0)[&1<UBD_49A +R ;:M&RA.D&.M^O:> $4XK&KK
MS"\BJ7/P4^ ^_P#7YA]BK>OPJG"7/_?3T5SS_373QA_36Y^ O /]) SPWLF%
ML@@= COTP@ 0V!I:S/2B*!R\I#^T0[)J $ $8-HR\MVDW56DL8,>UNS.+H 1
M()QF+#W4ZX=Z/(Y9^D-,H/2>I)OE/2ZYG,1V'V=$W*/GWY;A,- >(EQ<N+N?
M]32P 8'  12P)80+3.CFF'D!@:(](,Y%QDX?5ZHC+;V-.Z(,):PB':.BUNBC
MCFCTACTIN6L+ [X,"8F(> ,8K<U0J8410PI(/$#9/JH>[:$9?IQ%4#>1>I]N
MBJKP/)NP$Z 39&3<&!?<^\(XVSO 'L_VJ(_B*Y*EU7?H=CCSA @S] =AY^45
MQ$#8VVNZ<I^M%(I_N46 UG>O^<BB@P[.PL</F[5LA%39R!MA_CA"+]6)S:.R
M;2"6B;%RV0?J$'A"A(>@R/KW0XJ5?N$YJ0HF+.NX: 34$ELR,RA)/;8^.E4)
M$:V7D%Y*CR/8J7!]Q_6?;]JD=?A$Q\(#)Z?R?_I]A'W#^=/2NGM_TU.?I#P#
MV'],6\#V1# [ AJ3SB?BB$[&Z;#?'PA.ZR$ E_%![&B>0V#\Q"'MPP$!Q9XF
M-T(<*,.'(RQOQX3T5R8I=K@D7R@CHEGK6C.!/$!MD(@Q[PZ8!)(AU+(VAS)'
M3JBVBHV:O(LJ6KR81G",H"P3&=N<HLM_G8-]0G#-CW,9RHAD\VCCPA&@$DL:
M[AG,[S4\LJ>8-N-M:'I(@@1KJG"^2'I6OGC*:,X?AM=451YK[_#J 93]?:Z
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MH0W4C9">;7A.64#-7P@ S:\H461#B^T,DXF50^.W""&=?J"Y3VUE,9:-TP@
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MG.(J=XML4*)L)?%<>40MS5S?5(>6)38)>N7D'V:,LCH8!(/9P,"J@["J"$]
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MI6Z@^!SCY0%]7Z^4!."9:NQ0>UG.WP4!\G<6'PF#(+<'J^G50Z^RI'7X7M!
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MV_/2*BW/X@DV[=U!W$Q$!)V;]%-_**3NS?HINA@"Z?:F=4?ZB^:(6D0::TZ
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M"*[\>'1 PQNC$Q]X3- IJ;'P4V/@I]J9H%<GE,T"J(UZJ1P<TKZ"UOE1NH]
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MDK(W%308$UW:U:(NSM8?J, H&'A#;ULHB1@A-!?)Z<H(&00D$R^0DBAG>$0
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MO].5NN_V6\TY6Z[_ &3=W?[+>:<K==_LMUW^RT7V6^[_ &6X[IHOLM%]EO\
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M^0@ !!H]2-2=1GUK\_ 3OP? ]6Z %T</LFH(UT]0<'5@C(>VB@XLB/I %$U
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M-*33N4P<9#FC+XV&4RLQOPV!<(.)E66 XQ\7EG1/&L^C5YOLJ)K3T_B=._\
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M:-OC)5-^.NB)GCK/#"'T:^RBH<C+ 7X9,W1XI1@)I-PT]!W^XP@#)?'A]L%
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M':[""71M+&=%/LT?JD[KDR_9OW549SD1$]?YLN+,;;O;=-'-"ENGRB?\Y5(
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M<$R;/9P AF8M4%*8"&0K&JOKHC)$[^NLVJNM/1,OR/ %,$9))):#7 %KM.$
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M1@$BA3U;_P V&47)AV>FVR^'SZC!O[*!SX0UZ*!6W]-2JUNK>JI.K^E*9?\
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M,AX%!423N$N(F>A=2B!X@ &+GW)''ZQ! SB (R*%1@^>-#U Z%TW331@&(
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M:%9TTZX]-&@$F L<5H(P%DB7;BH':6B4< 2U^M=@PP4A$,5:] ^RPQT*(+@
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M6S"$)N+XN\#('M T2QB!I]M0$/J+AF@1&$(78P8;[#, <*5I*RMK*=0CGIN
MX@H1TZ# J./&A @$6BF%P9A0S ONMTHV8UT3;>Q&_P  MTHV6CA-EHX6Z4W2
MFZ4(4@@S 0-A!)F>MFUV&UI*^N@0]D \[=?7/3 *-4K\C@PA%+Q#,Q,6@H9
M,>';@6Y 6E-MJ 0*F9N.;9N$A5:"#K(CHWSI"4 VS 37*3VLXMV]$+!G@1"
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M+(XPQ#0; AAPA\ S @$9! (T%N2""6)<#B D82+LRF4X: "0(@0Q,D0#"M9
M.JAW:1AQNX)N:;H* ,)H#DQCNLW^EE+;QK%#"^Q*'8=7I2&)L6\6(1#IDP<M
M@-&J\.0_A!Q92X&(WH_5D+]05$[ 29OQ!8R( HD2,UH+ERGGE\GL!$LD4X$@
M<(0,. :J26 1B;B!,3P27LX8C,T0<37@)@]L?RI8<8$ S56B!8 @\A7DQB8Y
MP.&,!FY#N^Y+(O",JAL<EF5/I_ FU=?V)$]KCY37EDO<-OGZ+1OR]!7AL?"U
M._.C:> ) YP"<2+<S1%GG08CAPA&\^,HC*%XY"Q0['(3*&"I200904=")@:*
M77&#TSBPZ)LF#*9"07AJA$@SGB9F9,DQ*QA!QLD:4RS'".H;*:@8ANF@! <>
M)V0QRLY F.UPNR!D%#)( Y/F3@P#&CH<6*818!(L?63*)J^ ),DP288%P5"K
M@HAQ:TFYY17/("E86ZDFNTLR+W7@C+B@A2;#J1')C!8&F2$50P"!SI@A<-7
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M#*4TLR.&N?UHHSA*+;=V4CG+CN4X78-:!<"@.L7XIX4GEK*09699EQ8HJD
M$(2NZZT$'!,VJA<= B?N3&[Z?]_X58D-@P +"%/Y;&)[6*Y^_63/GTAKG"HF
MW+CV%[]F+K]WLH]YSCUH>#[*=,W';TZ4K^J*M]$[^G?>W3Q_"]6WZX'I361^
M_P!1CF#QLR/7KBRI&_MZ7]*[3KV3Q6*OFL^GQ7V].XM]/5QO7N,'TX30.[LL
M2?>6NW?]]6V.>G;T8X-6ZX5?BO854[_E%63%Z\)7MR'P/Y4BDONII-:;\>C%
MKV(JS FG#**8'Z0Y>$9$O%!O,T^>RF@X\IP$@, =D =,L=D7*ZC0/RWJ8ZB
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M)[^R[J0"7E&VXKIM!P@2"CN'<T<[(7+&L.00>G0V1)H.\ \&8D]'6&=TC@*
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ME]XLMRD5#>K2,:BS 'M$$)71+T.! %Q!VKMC?;J^H^C?_O9;+FCW&A[CE4"
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M)J+@D^I<526@.>J=\(XW$]T"GDR>KX$,^0WIT_DDBGC"QFM064<+AK_=-L>
M20"**C'HPA@76LF:SG7!$]_:J 85FA!N#A ;XZ*1!AC)R[NNX*Y0X*%O7QW4
M5/B/$:>>-KD!+(O UFG!@<$H36%$%+V!<8,$!OI8EUCX8THI#9N0-/A*7I;4
M-*C$A!*OD1(MOSKO6O%.%8D0C_90EZY9MG7L6-B)Q)_5_P!:DY'>3QA3;0%.
M:Z<14C"VD!T#,**(K0HZUBMY+.2PH@ASB 09(=Y%SH"SN#4P4*.AH $-=7/X
MPAETQVH@@!P>(F:;E/C0(WIHLY9)"M>Y(LPK^D$L-QFY151"$D/4X(#);!(
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M8_@*BM;5Z*:[>/YH"+ZJ96]HP6K<_@V.\LR&" #L&VSDZ2/D0?>,R.&:QYC
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MAC6'?]#XM5MV?T#4L), -U *YQ6?P(*7NWZ,<YDP<5V.%B2A"AC4(]<AU3T
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MAP.J= #DAR" $LY81X<A,O+;0C$S(O30P%ME;PU )@2&(7 ?Q$@JQ+N\6+R
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M',:YF+=J>Z.I-D9,2C"]%F"!C2W$@)B/6@AG5%T'FR+HC/(8E7/J4&):!H)
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M@VOLAE48[18^G6U 3I? J !P11</ETQ)T0;.QHD$TGGL$(*9<PDD?"T[0\U
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MS\J-N9X_?YH;L^QRZ%_'+A8!VR?[^?@'F%;>H@("_?M#%Z7#R[ -[>$4LAE
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M8T*FZX6E(TRC<7):&&Z?<X;\"+(53;LBMMI$7!G4'P1CX,U$'_P9]J)' RK
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ME'_>,R?JPD,,_$+3UV+&60$G5+WMCOL2%67OD/$D9/CLNDWFMMWE!R=5J!#
M:(8Y:JOA$9P.<ZY"T-S61<20\3E/D$ $.!O\4*5&9;6?^J"DI#$^E<]$T>CF
M2MMU5L4?U'F#D' [#T;I_K:AM =-"$ S!@9YX+.2Q-OX&M^M?4"_:7T9LL<A
MI=\L4*/?@T-BA,JN*>?Z8HR0Y9OM,G,:L-N\$.!MD9X%<QG(DH-/(<@CFD8!
MTNX; *:,@LK !G' 3BV"?< Q ""1DCUFI#B;TBJ<2Q31!V&*PL!0AR@I,?GN
MR2>[@NB>6<]O2U=?\P\>$S$.,'IZ6I2_VM$90#W Y_ST?+EJ<VKZ9_#Y0Z]
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M5.Y/OZ-[TY#A!ZXX^?2Q7LR!)7'OEOXFOR/X=]'T7_B2YG^+P8(9\'<%(0G
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MOJ_UZ$7=Y;Z]#O#B#YB4+B4.[=6:E?UM#[XV_L%:'K'8*Y*?CL]2;&1EF8/
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M $FGC=1,[RC?KAH0"O+81?<(&2[(1MQ>$T]W0)6=EX#D,IGKN[#T;1M+(N"
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ML&A;OL'YW1UN-"W'H^%V&$^^MO83M3LE&,W#B8*M0&9ER$T1L,=\2FR"Y$R
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M=X5TGC(%[37,H)S<#=F>LHCJ[%6IEX.+9U4K6)S.7>59Y<HH?*WY-M*O+2'
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M<]SALH!$92XD5"(_ 'X3AZFC5)\A1#7:\#-O*!G&>M*#\!$AB1,"^QK'= @
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MUENGQ+8%9#-&S%,N@HL;"GA #O39*_0FG(O*_>Q2HHO&IO->I=.ZJ';OUS6
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M]Z&OI<'?:VP;U=S-'?O7^6^])_C1QO[+NT/_  +K7Q3>^/10#SD YPMI./\
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MV5$XB@9 1<#X$6PX0D(902A%B6/$)W#.3L' (+*</1H7YV TW*B L^!Y*YP
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MLK+%A$%@-<L#8= P#</@J+MJ"JY<';/594Y/!#BL$^Z<->@<)UJ$=4 09W%
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M2_,QG/-?8,Q"L$F^E.=C6 A'(&,D(R*X1F1*$&]_K'+76 LN0Q;'ZH7OR9F
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M ,B .]TXBXDLA+$,N4#N"H15U4G%BV)$CEST.'8S%_!.16#-#AH+3'E!!0V
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MF)6$IHF<*8\X90I^TE!=SX W-L!;% ,B+'3^C)TF%NDNB:2SYR1#D%T0LG!
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M^AV#H+QTT\#)(@RW 8$ PR,,07["2#E5 +V:H;F;!;28+Q4Y3*( %=0:ZHP
M2@>.QV8!A?EBL<W89*2$&&?.%CK5.0$/<)$EHL\)>2!Y%F&J+O6B9L""<X0#
M"MR7&E4.^9]DX%(N;P<"^EN$YNG>(W(FFR&G<'(ZW<E0O<+"6A6#0P5Y%",
M8</=S!!!N31 #MJ,PY/5 #,N\A#,<UE5S(EV9QOQ%:(3@67.<E]B O(H%>8(
M<5/R@2_-KR M$5346+7!.BI" T95+# ,-QG?)%7"- H !G#2NC8$U@7+E@27
MW*.()M;-,7DFJ&O(X!;TMJR-&VIR[15^40]^WYBP$8&548&52 +^+V,IW <
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M!%RPZU1<( ]7!P)8&U!=00"*2\L26)S%2KDO,.6#5Y*O9"'@P -0DL!+$;H
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M5*S@M .@]_JTB(P @0@%1Z!!:AFM\Q2W/UYQ(WXA"4BAV!Y5YH=L(8R_0D)
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M84OFPHB"C%Q-ST&..J(.!R3J&@E2)_-YX%CMLDZ;8Q:?/4*X;,)("T2R^V"
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M% +&Z?=@H!H,;34E:#X3S#GS,L0X-4"UBY,#4!J (F[(CE+!D,DQNG=$DL,
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MT&H&(9+C)2K(2'H=A0YN#)8 U1D*F:(-1VH@1LZ3PJGM-7*H!-V0(J;</ ,
M$OU5"D2 L0 "7PQQ=-78?RD@_"-!R'+N&8-LZW\6D!B0NC9.XT? $O4DV5\1
MQH&2$E]X7V/O[/\ 5"A]AA$CTS8CWHN&^M.87.[V43QZ4V,"8U*50[4,9%=I
M5DU<YF)4J>] W J%FUBX=D1: +$PQKLF$F=@G;-#R$1W"]U.&3OO4"1 , *F
M,(Y[/@]CUMO^2F,)+;GSY\(]7$- .9@#%RST5<@JAYPK^<N+DR ;NX20@CPG
M!@P+."O4R>3D[U(@@CH0I,#TD@'D23U2#?85:CNS)F> <!STD,4RNS\GTHP;
M['#BEW#!R$'8DA%AJ 2A2"8H-@M@(>%LS*@'"[Y+\"C4*!AR7",B$5L)S:(X
MS)81.XRA1BP9(!%2U[IZBAIV@'J'E#9U&Y[A&[:+/'5PK/A/V@[@:\A(6]EZ
M&NY6=IB4V*=F9VM=UX!YB!7":8CS&K*YTF)G _Q2L D!CZ!85,!@JPF+$ *H
M&J+'[!#RD' 7'U8(1U0TP)F)I(J4L#,$TD@B2^Q!Y6H1@1,3J '0;QU=_?ZY
MHOH].,CY[!GJ6*D:^[ @YSQ'LT5(- QF_=2$F4PD+RFR#8U!T-/2.ZP7/)UE
M5*W91H0B<_Q9-JNLL(2\Z[WN[KH7X+1Z1K4A>/*UOJ,@WRHQ'!-69[=@+X\*
MEUL:3Y%_-43;0BB$[IGSOS6Q8NTJWESK=43T7@[,0<0=\P*W? '$H82&$7)H
MV&P#N,:J0K,O4F^HY//?>#LYL)#741M=^"6P"CQ1FUB*(W=.J"@,'26'&&2:
M1!#<-4=1*.=#;!@9=J ]N.0H(!R-Y@960#>L-4GXN.#RZ9ROJ122 X:%3M5E
ME[ @!,C;:<% \<L+BM68>B:ZS;O7:%6!P27$")B#&U4\RY 1N[@'H37B=#I<
MZ93=) $%C+%\&4 U428&# +D]IR&IO/<Z#0"8C<1J\$)CRD,;C?I%YX'+K!;
M3HE70#F8. \0RF"\Y<O 0*E<+-?8.%A$6QY3PAEB"'>0#/\ 54&$R9NPDF X
M+!!W":B \&2&0G#@V#"BM8WXHG/AONBCDRC=H((+V#1)( )*>58,Z C/*-E4
M0VXG.$J.VCU.?OT0 BTW  D!@9[[+0*&O]0 P(@1)%[RZK9Y ZZ44R(A<) C
M0$Y5A #)!B0"P=K,B9W&:W@.6&5I]J=*J B:$C(X3-(6$,Y%$LN:! R1> X+
M("Y_A"Z*@7 [E!L.Z(,NQU)3J@=B4U5%)!<0#%S"(!CKVP+L7>")X4LPF3D,
MI+=:NIVZ5>/*>\@[*F*?D"=XJ%,'%W?6J 8B<\A+F'L@2#(%9#.8.A@ZELM"
M.RHT9J7A,,7+.YC.?ET9!JUAU6%,HC=$!RQ)&-G,4HB;MIOD )QV9$.P+#9"
M3@@ \IR "XX4SOV1!@$ULX/>4 RXCTF/GE.<,. $&6,;YPAVLQ.'N 1ET!9S
MD5CAGBL9#8LH=R<296'H0K8%08A[$>DL@2'*B]'!$F'7T2QW"4/0LYJG$N.*
MTQJ'96#U-ERSS-/#[O%:'PE(V*5HB[2B(;+T:A1!!=@ ,8 :N@NZ8!,FCH)C
M8D$8WW$&;X1ESL:A)))8-LLZ!>9X$!R\X";IP]22-U.]%0N,!N S!O5.)9<(
M 688:CHR4_W2AV 0P1M9 E00'I,\!&;A IXQBR^A7 0I&VM3FJ-WKOT!8(02
M*DL-%^*H8X (2)UNDSC<BF(?\2WNV?16."+%K%OG4 'JT'J;1@<,<HZ""S C
M #',Q\LF651SHY>IF4I74N-O$-<0.R<X%O=Z.5Y0DT1]Q'C1?&=+V?+6HV%2
M"*IXA6QVB^;P?"1G:A60C7P@SU S,Y*W!Y=8)@_C,T8KIE=FA/GN+!&T -4W
MZ8/+U]=>@4&4+E":D$FI@[UP58#C=]3V]H49B;3J+P2H%= BB(-(&G$\L*/Q
M@"UC9.2)7YJU3X?H+G46FMULOK!"QLT &N&#@.Q"=.,A((8=;[X-EC;F_/\
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M>5*R'+E4XZU=-OJ6V=C"Y(U<9T*_RB7 0$COVQ6YV>;KI08<]VA*,'V_$'+
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M#H- R0&ROE,*EV8,8"@<)@[$$L$DFFB7.Z!P"HV3=&#U2P4#F8D^RH !!<$
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M*8:$. UG >V5! 6_,^[0A5/ADR"01XQ8XV T-6(JA&+E"FA^?""01,.@:UK
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ML3H.R)R2"(:E9!()GHF$#   EWDT(%J8]T)!8@&$&VJLH64I$7(ER[*EMC[
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M8(J;%@!#R .&KI0(#($7$"9WW*8(DQ+@D5<HEI#(0),FK0!<,P)@T 3')F,
MX2)-%8(07W "P=0A/002&/0!S. 7R<(D%CI#-1C 5(P@P8K@U<LX( M2@"'K
M.&K%7H^V<H,'<H #@!@'!4C@#! NY)G=G(U&+W .0U@AARI" @B!(S1DH378
M$;,*)Z#O#KZ^PBTKPS5!(('?K9 ,%I+J M#@/5  %I8/KFX]40& >2"Q@72
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M109=Y/>B!+F@1> I<,-Y3MKJ.[*'F-="]Y;%MD21K/10H+O9T@#/'331NAL
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MJN2,QCHC3&1!S)EF'PF(<XK@SEFG0-C!?+]I8V=!,*F34!V&#G&ZW*1B=O\
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MR8(@-_5J09N,\9!HL/U?XGU8'@6&-,JH:!5P ,+[?NP(T[IEX5.BQZ2R]*1
M!U&I\B1]*LFL\M5[&!!JK]^:M&T47-%W"VI$. 0(YFIJ$-$170<5::*O)5E,
MZZDEX,&A'55<12)CF\20WFMNF/TS.  %TLE=S6ID) D),35(J!.,D$CQX36#
M !QM"%S+J &-@P@0DYLT1(+H.Z0=\ *KPK=7J;7!-EBUEL7 A[Q HPT4R@)@
M$AEQ4<*30#N P(:O8L<K5YHOH(1G 6J280(<@ G;*S$1)>%L&'8&3UDZAYS6
M3)Z'V''S7)#DD@)#T527@QC6W1%68L ([$;V4Q>#GK4.^G1&]">!8E@80;)S
MV0N>WG-JH9"0#!&JT:$J9@M9#96K1$2S5<D]"T%$R':3#0!<R@Y <,+T,.!/
MLSHTM<<"7R1['*!@S$X,FT!T\'R/N1G*CL F')4Q(%F+D@("9Q6)=B; \Y]'
M]PGL!X&IHB!*P<P Y-#M0C#<@[ GJJ@R#1A&S2P:I !@X#9A<R3<A$)G( ,\
M06/0!@(X$N,;JB.00(9I:$U]F$2Q+J!,!#C@L%<@I0G=5U#/BK9)9WIY+B25
M$1W%S,SL,8GQWDXM2>#7 #$$!1'AH !@"\R+X6$8))-MIRT1_9,D-,.@C/2G
MV;KAIC^J([\8(9<R8!0>U$ 7L?8(\S1$(9.Q;2%90"SP7.NY1K9" LVQ#ML@
M$'<B1Q 6AT-P7G;PA*X@#"GKR33E>Q8 S M\)A"/!FG !R[&!W+*N;?0%+:Z
MO?Z^AV5_?.I +9?%?GGQV)L  [A>M.-,AU84&-RY":"U.3+*/MHS'D?% =>I
M[00FN.#7%)+MT!.Y:M 0^\$2V"6H<")K<4*F 1P 7[TR&0.<D$-82Z?Y<Y];
M*;$.>%G)LLF%'5KEO1 )G+5R1D1#!((26;!RCDL'RC$>PPYV$^:=<BBNMN[$
M#272UGL*('?=$%C6:HA2,&>(Q;4)$\+,, 2"0-FW49?6YSR3.36R1U15P'V*
M<_TXV^R'!<.RE@L\:6RS!RY%DL<T>7EFKLA&8Q/^D &SIH$K%Y"CS65[6[G5
M[K4#J,[T3,,X4!=I*\K-VKJ*.YP3)AB@P#%PC#.J(S8!T\IMP;5YJ&"H&[C%
MV+;8#) A)>3R[,]E)RP\X*4'W'A/-=%1"]8$M3O]JJR8L&O,Y>%M75]C7(7.
M; ->J)B0,2:Q:E^FH*D:)_#HA5_I>$J< H!I)5E",]TW<R?M^2O73";8.7L=
M6 '0@:&HN/E@<H!#$I:21OP*4&9>.!=U$0#4SB6$T)2'KENR=ZD')- < +$5
M@=E.++O0L#3Y1<E &6);# \JI$]7<$9J0UB8\*-T3NPI.YGC84X[=H]BR[.[
MB&S.Q</LM>*:Q61^<\W]A7MC-6L7C[L?T1!'>V #UI= W,.^*A.^S+O9FX9
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M!E,PO+,D)L05%@(T38-+B&3=0D,216NRDA(: JQD!29HAT0<!PAA%V8I Y8
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MP-Z[T_=K.L)!,_(*0-6!\4/9Y4=&C 3O1SV%+=Y<1HBG&%<@H;C;,+ 8X^0
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MUP,0 U%.N?=1B'W-.KH4)@?EAG"E\BY[4RS:9"HXY5@RRMKH;C8"L#,ADX,
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M_LK>Z;A",[#RZ T(.>;BNT@\Q]DT-%!7L#T5$';@8R )F1@+]:BU>?<-@PC
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MZ1L&ZA<?O5.)4,$!0D4<X*=P 7[&EMNWLGDP['+*OA..)NF(H:N++S23 QW
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M7D@7+ B9,(94*E@D.;,$?45Q#C!7&<2#4#RB=BX/@&EOQ1 6=+ '@>V39.<
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M@$$'@C9"("8G9EA0<431EX'CE@SWGQ*1$#,!L=(B'$E0X*SES6J.-C 4!AE
M6J'D(@[>+FZI 77&]]]I%Q4 +&0-((CL%!SD8@S['*PPC(%X$59MNB6AQ6 (
M : @ "G$S46N:+8>XV57,V+%&H,J:JF6&5IV!@UD1BESAP' )56PB XAQP<
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MOY]/&>KSUV^J+4LW=M8-5RF[P1)H-1*4?J>4\C;K)740D\'I@M286>GL"VH
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MZ]_TN'I*?3G#95;I[A;'J[B3+1K*>CE\LFU8MF5FSNC.SLPAP*?A!E)F;"_
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MW4MF;:GN4YJWU5)9C>&#?#"M]@MOZ:O-94Z.2FCZ!_1G)D WEB80<\CQZ$$
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M@3BW"0$8P*]I! '+4P/ZDH$UV>%S9" ) BZ(3M'8;*S 4T$D$W$@_>BQ .6
MBG#$R; CC.JR'ZCVE]1DUZ7^$)=FTB/)0SX7@!4G,Q;UD,AP4A%C4;B!#M;,
MP$$)O1<+9 1)P[!DV0V&$$4  W51>.<P*_:GE(#Y@(-&93!9WY?#+>KO6/G=
M8C]E9UV=9MWY 5#T]Q^H-29O^+5U6T^>PHEPT19;]8EL70TSS1);11DU8,;>
MZ8_Y^R?<[UFB)<O^^ZT_2BN5EW+;)&O*X'S-4UR0.EVV"KHU5-XJ*.<$7M%@
MD+EW0C#Q!/U7W+Y(S"2I8W9Z %EEW=_]=3)#@/1TOO".7W/FZJE[O/R[,CL:
M7O(<.N/\=%7?W%NN$#LJ[8*M"5H>*)SA]CA&]*4K>B<UST!H  CB?FH;BCK7
MW,H3M05K;LA\C:V_RIM3V?I:Z!ULZ)>MZ_*-#K4O,207AV4:]![!3H86=UL;
M(/P4'H\>R]RMOB:>FU+/3N@@EN0S4ZQ/NA%\7< ]5GP!5&@3(;%&7!S5"&>Q
MK76-VNWG:'H >V:"&M/"I:2Y$Z/)P/P)I(.(9R!:V;N2XA?PS<L0VZJ%QT6D
M@X3TV5<5@>$5#A)S?(A-)IN1-:UD(#%*& 1Z1JJ.#K1:$L&J T)LFO[6( P#
ME+(<A6"<RRZ3?>82T4 G.5,QH[C9Z)0ZP'1,N:+8$"V(3'BF<5++>RQY6E'F
M[.,P5"64+VPOVLF +9JN*0>,=L0AOSN=A0CGYZ0 >"()5DJ)2XU=+0 U(21
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M* 4#-A99@U\-T75@#CNKW9Y?@R#O=^#(/8 -PE^>$[[\0OE[E>+LTF#S"WO
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MGU+#^GP/_2BL?WP^/-A3K6/_ "TYN6OO5_T^#_Z45W<?_:O'E:GU+#^GP/\
MZR*YUSK4Y.=0!!]OZ? _]*9+N/\ [5:\K4^I8?T^!_Z45W<?>BTGC1N:M"H
MQ;P'5D)OE-\IOE-\IOE-]Z1AOE-\IO9HH&YZ1=U!C)!& 2P 2)008%-%8P&P
M.\]?1%[UM93?*0._\G3?*5K54""IJ15OB)^5WBF^4WRF\4WGI&&^4WRFZ4]Z
MVLIOE-\IOE-\I[UM93?*;Y3?*;Y3?*;Q3WK:RF\48'>8+@P-V+3?U^D-\IOE
M-\IO%-\IOE-XI[CM90:1AVC=@37=ZO\ N^4WRF\4WRF^4WRA%50>H:CH]QHG
MID+LP91AYL%3?*>];64WRF\4WRF^4WBF^4O[WOO8A,QBAPJ4KA)V@+?*;Y3?
M*;Y3>*;[TC#?*;STA#>+;Q3?*;Y3WK:RF^4WRF^4WWI&&\4WWI&&^4WOU53?
M*;[TC#>S12\]E-]Z1AOE-\I%6^(GY7?*35MF9^%WRAA^"0#*0@[I%739#W*F
M@-+*D5"0AN*WTK,PKI-KDQZL;/4Q*L<9R#)EN3!F& &N#I+L[/##M52^3'$/
M=@!A2U,%J"-O*DRYVH1LQ1SF\('U>B:Y)$CBIL3F4X7W6]0,'ZL4JY+" R8
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MIY0F=5?0B7#4U TR>6BPT$H_HVR6!\%P:B8T4P9(=\=_K1!6S:UJN/2!+>S
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MRQE$D ^V]!C*I2PWZ*;EWE\H 0/G@Q1D$$.;,7(J'9@?4,XF[5RVS)@;%R+
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M)Q!(!/T ]-,XH^J$[\ZD[NZ!#(#!N4'C.<$PJ"=,W@@;L(9VZ#K[(0^4B<G
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M<4FB9W %A&6#W;T,TFZ+3A>:$&]K-@NUT_U+[.3",(>W%SRO*G16GIJZH8B
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MGPOB"0?9._[(VV8(5$CTBPS1G* 61932 KC$!P7<D2[6U58$-UA/HF)!K+N
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MW>7LN[.7*^&-9K*_WGC0H::!X0Z>.;LP?T'-!$9'1J[KVM8.$W:GW[^A+L>
MEI::)SF_,>A GK</EP&5!F^5" 97F<N#C$NJ=[(>D@B,G 5HR@07*#<!L0#>
M& $X/O6<.+RJ;A\J>C0Z>);<!G"0]CS7)CLY/BV:+[+=AWPP8<J:[BAMLMM<
M5$8JC?W%C2) U#@GCQ0]\84=B$91@=59<^MD2B ZD ,- #!?=,;HEWTG&8TJ
MP$(+ *P7#?[PJA)TH0E.D*X8 +!C:J@U:NH#03)83\5,O9!#J!1_[3NPC+>%
M/L$/G(Y(9KH_.Q?!D>@CBR?A'\RR &H'2J>4"4C=&31H%33XJWA%.C$RO%%
MFS _@8Q=03 #T#+X"[P+[T6V3GK-VFNN"W@V$F5B;&/ 8::U/3"44TS\!-=6
M*]Z&+A?T(SU'MI!I'"&'\[Y'IV]S=1<@.\#U=V)C3":@(L 0[@>23[H/ 6A&
ME&_.'$(VD!T;W?V%_$PD\M!7#6+3V:X-Q(8WDTP\'24*B#2,U3MQK"UPGJ <
M.'[./1%2CQ,1JIG S8D3""R>W[,299TF+U_A-,>)@<HYS^Q.UU6!6)4P\Q,C
M5)T2@.B(1@0%6$V[:ARV$P!!M=DD<S<06 LQ).TM%-U/8<5HPI##4/%3E>0W
M==S9H^4!1DJ@=><:15(*(\T#U%!'YFD@@)$KJHCX=)C,2=QK4J$F%G&U(5[R
MU6ZK[G$%UU_7:%$>Q'=EIXA W#U@R_(=8LO-NY5A%Z)K)$)CX.")9\=5O>!]
M*IR2>I/H\[K>)]:#O.+^FVT1Z. !W)8SBH)-!CA2HBH"5@E=@5F*P8.!.4P,
M#3P+RZ \,35_D!6/SP)P  6Y0O8.P8- BCD^'5 O%X=X9^?0&E1< ;K45H+8
M8/X7:6K#F0;*/8,:1@'T#?=*[LIN&^J@IWF^1\T1BN6ZT9!X=6HGS 0%I6#.
M:)N.?94_3\HDG<FKS90=F4Z(]9VR@ +"!!9YN*-!AB@=R-,O-/>JX:G^>D,&
M #<S#7*H,$GEB?1J@Q[EQ56F<BN_I;?0-"$D8I>+^%5CR/P+?>-5 ?->'-79
M<5^+KWL,FP"]^!,-)1S4YO7*<!*8=]@3;F$XS=NN$6G':%=P3%#([AT-J+H.
MC'-+LU$',W]T*>=WI6+62;D0OXM"DEOM*A=NU.=I\Y4SF)+T64T8M( C%0%0
M>!'HYC971-"9='I-0MAC(Y2029!<, 8&S(?QUPJ7J8&&'H+5DV$R;",^L&,=
M_"D,7W%(;_$=&2-]8L#"A 5,0M5;?X]/]_%5\?[/=-(84>E@V$U^C]V]'V%&
M9HHSLF.X7&%'!IV0:G@71]J_Q[[S&T=4:M43;WJGQXD"$X#0#KPK9<!!J$G1
M6BPU7J\5M$>L4Z-\+7N\,HYC8Q^J/GUI5&IM])E3B-OXUW\?"I)<0]Z5HIT5
MJJV'<U'KWCGT+$E]S,]SU3ZV1VGQS?T88'9<O'[ZT:^?VGA5NGL%$J85<=&3
MN7,F[D^4##!JN6)K00NU9YAE248@27+S#IZ%V\STA&F8[HM- :]+5QRK3S&Q
M=7-R9^!67;L]A!0(<S?[11L9HF'$85B,E[VZ[J;AH![SZ$,2XI&QBT]_3:\C
M[34D9O9\.G _W:>,,(Z&)!3M\OA4"E!M8L_)7M=HIY1R^20Z"C>RX171D-EZ
M1/8H1LC(')EH/8!U2A-"'!-,KQO'ZNP/Q4H'!H>S<(H.X.P K+>+:1NOQCH.
M!8 EPU1#/#LF+SPQ%P3/HU*B_>;C='CH/:5JJU=$PE@19[MRBXD01<5%X].
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<";M*3[YEIML9YIZ)Y+W4HAAC!#&<RF1R;P__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
